10004|9c983da1-a8e0-479e-8816-5d5668ea242e| Pantoprazole sodium delayed release tablets are indicated for <br> <br> <div> Short Term Treatment of <annotation cui="C0267055">Erosive Esophagitis</annotation> Associated With <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> (<annotation cui="C0017168">GERD</annotation>) </div> Pantoprazole sodium delayed release tablets are indicated in adults for the short term treatment (up to 8 weeks) in the healing and symptomatic relief of <annotation cui="C0267055">Erosive Esophagitis</annotation>. For those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed release tablets may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. <br> <br> Pediatric indication and usage information in pediatric patients ages five years and older with <annotation cui="C0267055">Erosive Esophagitis</annotation> associated with <annotation cui="C0017168">GERD</annotation> is approved for Wyeth Pharmaceuticals Inc. s pantoprazole sodium delayed release tablets. However, due to Wyeth Pharmaceuticals Inc. s marketing exclusivity rights, this drug product is not labeled with that pediatric information. <br> <br> <div> Maintenance of Healing of <annotation cui="C0267055">Erosive Esophagitis</annotation> </div> Pantoprazole sodium delayed release tablets are indicated for maintenance of healing of <annotation cui="C0267055">Erosive Esophagitis</annotation> and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with <annotation cui="C0017168">GERD</annotation>. Controlled studies did not extend beyond 12 months. <br> <br> <div> Pathological Hypersecretory Conditions Including <annotation cui="C0043515">Zollinger Ellison Syndrome</annotation> </div> Pantoprazole sodium delayed release tablets are indicated for the long term treatment of pathological hypersecretory conditions, including <annotation cui="C0043515">Zollinger Ellison Syndrome</annotation>. <br> <br> |08098cb2-c048-4640-f387-6beec4a38936;189b7b6a-9717-44eb-b87b-fd3e985b2268;18f7b809-b270-4d44-8065-685bac30efc0;2b872b24-4a06-482e-8716-93d616ccded2;3a8352f0-569d-4d7e-b42a-392feb9e31a5;4b21af6c-486c-4b45-8adb-ae67f7e77ac6;4c8a0544-5e03-47e3-9236-c9646a841e9b;564709e8-358f-c185-4ecb-b3849c3fe59c;56ad5b97-8e5f-48a5-b2ba-a5484b43d018;5e99755f-e72d-4865-a272-a4eb1e940107;6814cd6d-fbb7-4504-8c01-45b31df7b566;6faf465b-c3a3-4ae7-9e16-1ba758f6962a;72f82e7c-fdfb-4d54-8161-944ba00b700e;742ca9f4-9fba-44d4-29a8-1fe3a04f1af6;7969d44b-7776-9a88-c544-eb51496b2b26;7c958802-daad-4c7e-88eb-73be7d2261d8;83c20b13-f3ee-4724-8c8b-18a42460680f;903a60c9-d464-4665-8575-553218f97186;9c983da1-a8e0-479e-8816-5d5668ea242e;a55aea68-42d5-44fc-8916-22b978af5a59;a81dc60e-af42-4d5a-ba21-865fec74ce05;b19238be-9962-478c-bd29-0f5f8d0abef3;b341ddf9-a539-4e29-b72c-e8f5cc247172;c9d84177-bf6b-4df4-9a71-5ea414b0fb99;cfeacb5c-8b1b-48f6-9acf-00044a8179b4;e6238767-90da-4176-8ac6-d71c2025dcb5;e747c09b-98b4-4958-b860-7318b71895ec;e7705bf6-e473-4b9c-bb5d-57e26ffe7b97;ee114ab9-db51-4a71-90b9-cd9865e4fced;f9be6294-9a16-4de1-b346-af0d09a97482;
10008|634e3ab5-1c6c-423c-9346-9b127cf9646e| <div> <annotation cui="C0003469">Anxiety Disorders</annotation> </div> Alprazolam tablets are indicated for the management of <annotation cui="C0003469">anxiety disorder</annotation> (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM III R] diagnosis of generalized anxiety disorder) or the short term relief of symptoms of <annotation cui="C0003469">Anxiety</annotation>. <annotation cui="C0003469">Anxiety</annotation> or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <br> Generalized anxiety disorder is characterized by unrealistic or excessive <annotation cui="C0003469">Anxiety</annotation> and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients <i> Motor Tension </i> (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); <i> Autonomic Hyperactivity </i> (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or lump in throat ); <i> Vigilance and Scanning </i> (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or mind going blank because of <annotation cui="C0003469">Anxiety</annotation>; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. <br> <br> <annotation cui="C0338908">Anxiety associated with depression</annotation> is responsive to alprazolam. <br> <br> <div> <annotation cui="C0030319">Panic Disorder</annotation> </div> Alprazolam is also indicated for the treatment of <annotation cui="C0030319">Panic Disorder</annotation>, with or without <annotation cui="C0001818">agoraphobia</annotation>. <br> <br> Studies supporting this claim were conducted in patients whose diagnoses corresponded closely to the DSM III R IV criteria for <annotation cui="C0030319">Panic Disorder</annotation> (see <b> CLINICAL STUDIES </b> ). <br> <br> <annotation cui="C0030319">Panic Disorder</annotation> (DSM IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. <br> <br> Demonstrations of the effectiveness of alprazolam by systematic clinical study are limited to 4 months duration for <annotation cui="C0003469">anxiety disorder</annotation> and 4 to 10 weeks duration for <annotation cui="C0030319">Panic Disorder</annotation>; however, patients with <annotation cui="C0030319">Panic Disorder</annotation> have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient. <br> <br> |039c413c-acd2-4e8c-a619-2f48c58ae3c2;041ae7f6-7e42-4803-a015-f3bfcce277ba;082A3791-20C6-4FFA-A113-B60128344381;0b25b6b5-d97d-40a8-8926-7e90a97a5ede;0b781118-9a91-4855-ab7c-669ed73068e9;0bde1207-1433-4861-b6e0-1d723404b44c;0d97256b-77f5-405e-b5be-cded19653180;1338d1c9-7c75-42ed-95f3-9eb1b6fc51d3;13930c94-d83a-414f-be35-b1fef35f738d;175cad46-c9ac-4dd6-a31a-65591b85f899;1e828836-7a09-4b1c-97a8-e88ba9e886ad;2238E083-08F2-0AA8-59B7-16B6D68DBD48;238050FD-5221-4B93-BFCD-31793C9088A7;259387c1-e374-4bc2-9510-5f7f2c60d1a5;263d7c02-ca81-4035-9b3e-5104e8aff086;26ec6e6d-10bc-4ce9-b602-64077d7eaa40;3122efd5-0650-458c-adc9-5c1cfdecef7e;326fa31a-5420-429b-9f7f-170cb38f64bd;3292a8ff-0664-c0a4-42a6-9827ddb93665;366500a0-6e91-4aaf-802a-8966b1c5a3e5;388e249d-b9b6-44c3-9f8f-880eced0239f;3a30a94e-3bd4-45c1-96ad-b8553defda4e;3d621379-9ae9-4874-b9f2-e57a7cf93f29;435f8884-04dd-4609-90a7-4f17425f4222;4440015d-5a5c-4f2e-8993-13a94035d70a;46feeb48-589a-45e3-905c-e2779740fb58;48d8b759-2300-4267-8ab3-b57a087b5bb2;4f6c075f-e2b7-41fa-82c7-eba85cbe27a3;50710e43-bb70-4a2c-a95c-803c3302370d;5abbc5cd-7c71-467e-ab9b-74ff29778420;5bffe9a4-9b4b-4c74-b7ed-ebca90c9c9a1;5c921bf0-0a5a-4408-a3d7-b02f907aa321;5ceed721-2e65-4c81-bd84-f110b1ac9d2e;5fa2dc50-3589-49f7-8fcc-0f7c0e91b3b7;634e3ab5-1c6c-423c-9346-9b127cf9646e;676b8fd6-b611-4df1-a52c-2f08b0f4d031;69eee61c-81d7-49e0-ba99-1c6d0d409e5a;747d1977-945d-4f51-b493-757c584fee02;7538d0d0-346e-4c3e-8f7a-c1cac8ec8ed3;7cee4c3b-1ee0-42c6-9b3a-cf9d0dd7957b;7d4f450f-ec2b-4770-80f4-382d935aacce;86d1eec6-fb4d-42da-86f4-16ecd9f6a0df;8789eaa5-a568-4453-813b-06fc680e8ba0;8895a5a9-ea0a-406a-8c92-e03bbc3d0bd8;8d0575c8-5556-41ce-9b94-8c013ff69066;92a66ec4-ccca-44bb-8217-41cbcea66270;92efa23c-3fef-4828-8f90-d1c37e8051b5;968291f5-13ce-4a8d-bc1c-657cab5f3229;98c12507-3579-41d5-8b38-2d298daceea6;98cc444a-2c39-4410-8020-aded0a8deb81;9fdaf4dd-2b1c-4193-bae0-9930f8533f1e;a23063c0-099a-4256-b95f-3a857bbf704b;a64496be-bf43-4ba9-a4b1-bd632965c1a0;aa58fff3-c297-49be-838b-599c32ad9835;b19c23b3-d88d-41c3-bea2-789f0898aa86;b5e516a0-d0f4-4613-ab56-b1bb440fcb78;b945ac6f-796e-41ef-85e9-61007e4a4e9a;bb6708c0-0446-40a9-8b68-a8785c7ab061;c4520457-0b0e-493f-805c-c04a788268ee;d0c453e2-1126-4754-be8b-677efde03ffa;d15217da-4445-428f-9430-581bcb567c57;d229aac0-eba9-4d8c-b1e7-d303fea8d7db;d5282c4c-32b4-4f53-9954-0aebdf20038f;d6cbcdd1-ef4e-487f-83a5-176789b449f5;d7a54ceb-2d80-4879-950f-cad362324086;d9b0e228-17cf-40d7-b62e-5050311c571c;db1291e9-ba65-4b6b-83fa-6b6187b17f41;dd915df8-c47e-4bfb-9900-7fe3937e79c1;df6d7793-02ec-4789-ad0e-667956871e55;e10f867c-a6c3-43d1-89da-d82d1def8487;ea350660-9be8-40b2-98f9-af759a8f7864;f025900e-5d16-4614-93ad-7fe08a865458;f3380741-6778-4295-bcb2-2cf66be50b2c;f7736203-7ddb-4461-91da-1924145b2f86;feab3ae1-39a3-4195-8ea3-4a381c0bc454;ff593501-48f7-4ac3-9830-6e9d8d77ce42;
10012|d45418b5-ba22-40b0-e29f-842d11bb09ae| Amiodarone hydrochloride injection is indicated for initiation of treatment and prophylaxis of frequently recurring <annotation cui="C0042510">ventricular fibrillation</annotation> and hemodynamically unstable <annotation cui="C0042514">ventricular tachycardia</annotation> in patients refractory to other therapy. Intravenous amiodarone also can be used to treat patients with <annotation cui="C0042514">VT</annotation> <annotation cui="C0042510">VF</annotation> for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with intravenous amiodarone, patients may be transferred to oral amiodarone therapy (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> Intravenous amiodarone should be used for acute treatment until the patient s ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but intravenous amiodarone may be safely administered for longer periods if necessary. <br> <br> |01C3122F-E791-40A5-B52E-963CB6685F71;0c40521f-99e3-4546-a71b-64749c3e8c16;1EFECA40-3DF8-4B89-950C-EC8CAC6B7780;304d0be4-0c13-4dbb-8ffb-b2e7caa7fb1e;42a5ed18-0ea9-4fb0-87b7-62b3af79f85c;51772745-9ea9-42cd-97e6-7266f41ae3ca;9fd7a181-ab26-4e68-8404-20ce339b0844;FE8909BF-9106-43D7-B89E-1DC4874CB864;b7e2af06-1fe4-4b45-ae5d-bc6279ca47f3;cdd50dc7-f712-4248-b0e3-ba247cf08cee;d45418b5-ba22-40b0-e29f-842d11bb09ae;d8d04647-8e25-4127-8ecf-360ce1991c2f;e9108958-b8d7-4fba-87c3-9a32990de551;f446e1b0-2c46-4763-8eb0-b3a6be956f69;fcc8658c-761a-443f-8c32-1499d86028ec;
10016|943d8700-e136-4c71-ac88-5fb323af95a1| Clobetasol propionate foam, 0.05% is a super potent topical corticosteroid indicated for short term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid  responsive <annotation cui="C0037274">dermatoses</annotation> of the scalp, and for short term topical treatment of mild to moderate <annotation cui="C0406317">plaque type psoriasis</annotation> on non scalp regions excluding the face and intertriginous areas. <br> <br> Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic pituitary adrenal (HPA) axis. In a controlled pharmacokinetic study, some subjects experienced reversible suppression of the adrenals following 14 days of clobetasol propionate foam, 0.05% therapy (See <b> ADVERSE REACTIONS </b> ). <br> <br> Use in children under 12 years of age is not recommended. <br> <br> |11054e55-9dd4-493f-8d1b-d6da7dad7ba2;3f75880b-9ead-4c6e-b999-3bd7e1643ce5;704dcc0f-a20d-4d92-b338-cc478d5ae895;797805f2-5a08-4ed3-8057-6b0b1bb08113;8e913e0c-24c8-4e4b-9212-8d7bd6aabdb4;943d8700-e136-4c71-ac88-5fb323af95a1;
10017|0aff6dda-b9fd-4f01-85b2-eb3097b760b0| Metaxalone tablets are indicated as an adjunct to rest, physical therapy and other measures for the relief of discomforts associated with <annotation cui="C0184567">acute, painful</annotation> musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man. <br> <br> |0485d087-a215-4f61-8687-4161b9a55f06;0755d115-dbf4-44ac-a02f-4d8a013902e3;0aff6dda-b9fd-4f01-85b2-eb3097b760b0;1c410d74-2c12-4a6b-854e-8a03b5bf2fbf;21618014-77c1-4a35-acca-cd5678d7bb89;24da58e8-86e8-4206-9ad3-4ebb27522cc8;43671e90-7df9-8e45-f741-35ca6a8f3b65;5c489585-7839-4701-8b26-bb84f0e970c1;5e1ec092-4748-47c6-9b72-1b826da0ce02;7a4163f2-c553-4d14-7e98-d14c5c7f772a;83cfbe48-4b69-445a-9c13-742ea345830e;8605de17-f114-4d53-8192-744f0161e9ab;8e1493da-6e00-441b-a785-416c123e3c1a;ac32ec3b-29f3-4008-8995-9c468bbd4318;b28a2d3c-69ca-4c97-915b-41135b9b5bc0;bcf9b39a-aa68-4f07-accb-9e9287c63068;c3ad15a2-c518-45f3-a322-9ddcfe4bae77;cb28abf4-608f-4dcb-b179-9dcf71274dbb;cb47d76e-a7e3-4bac-8074-8d7e95c6a6eb;d8684144-6c2d-4664-943a-2d3d2b46b1fc;da237968-1c52-47c3-986b-4f878bd6b173;edc1656d-26f0-95c2-ee8f-50518fd5affd;f001063b-6577-4b48-899c-b05684b5e2b1;
1001|741ec35f-42fc-434b-9ccc-69aecc06dfea| <div> <annotation cui="C0020538">Hypertension</annotation> </div> Metoprolol tartrate tablets, USP are indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. They may be used alone or in combination with other antihypertensive agents. <br> <br> <div> <annotation cui="C0002962">Angina Pectoris</annotation> </div> Metoprolol tartrate tablets, USP are indicated in the long term treatment of <annotation cui="C0002962">Angina Pectoris</annotation>. <br> <br> <div> <annotation cui="C0027051">Myocardial Infarction</annotation> </div>  Metoprolol tartrate tablets, USP are indicated in the treatment of hemodynamically stable patients with definite or suspected <annotation cui="C0155626">acute myocardial infarction</annotation> to reduce cardiovascular mortality. Treatment with intravenous metoprolol can be initiated as soon as the patient?s clinical condition allows (see <b> DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , </b> and <b> WARNINGS ). </b> Alternatively, treatment can begin within 3 to 10 days of the acute event (see <b> DOSAGE AND ADMINISTRATION ). </b> <br> <br>    |011ee828-5c2a-49b9-bf8e-07f5eb5fc635;0a3ccfd4-8b65-4c7e-b0ba-27ff40d5b5e8;0d451179-d5de-4832-95a1-baf02ed34b3e;0d739f0c-a206-4d70-9f63-af1c87005d83;17ed5d5c-074f-4a59-bde6-209b3df87221;1fa5ecbc-4e00-4083-af02-b0ee6d3ee56a;20cc66c0-a00b-4643-9819-6e0daed51e5f;2a2ede6b-ad06-428a-ad65-4055e1cdc7b2;2b705cb6-cb75-4c2a-907a-4bd45d18bc2c;337805dd-74ab-4c41-a49d-914b2552fcbc;34dddfc8-badd-4371-86a5-e9ee31a66531;353beb86-4b8a-4a4a-b2c3-8ca7c8d23401;38635b1c-3a32-4164-8717-a58dda73dd66;40515bfc-dd64-49e4-af76-0ef302e85225;4230787f-d42a-4ec1-8ea1-e6f7afcecf2a;4335bf92-07c8-4a78-bcb7-1028fc13273b;4f64f091-6bd5-4584-8c1a-8eca3aca159e;55136184-33b7-4230-b1bd-291a86168eca;56803c6d-444a-4c1f-a936-790720b27b22;5842af6d-9607-42be-8195-cc0122106244;59019362-b71d-479b-ba90-7c4923a8a044;6399f2c3-7799-4f8b-b8b7-8d2137b1f852;6ae551f6-b6cc-46df-b3d7-eb2963295e0a;741ec35f-42fc-434b-9ccc-69aecc06dfea;7fd5b896-1dc6-48af-ab4d-a717fdfc9d12;809c6386-0039-42ff-a03e-e42733e229b8;8fd17a7c-1d95-425a-b5a9-59e812225443;8ff18a70-965a-4d3e-ae3e-b599c4e6763c;925a7336-965f-4d95-9718-eb1048cff0ff;961248d5-d53c-408d-8f8f-d31885054f96;a4d07b57-09e1-4732-a135-559febcab3ef;ab44f4c5-9497-4c92-8545-e4718ddb8f08;bb05420c-fd24-4672-9f62-fdd313819287;bd6632b2-bd80-43b4-a4ba-fa0ac794dfc3;be59c773-1d4f-4843-a326-1eca9a494d2c;c30b8c70-4d7e-4960-a7cf-5257a1a89bf1;c9a87c39-4baf-43e2-b6bc-3634f1eb77cf;d0f4d3f2-af08-447a-848f-cfd7bddd2034;d1043177-2247-47e9-8501-119c10a731c2;d27ca215-001c-411b-893e-a8a6200f364e;d2fbe47f-2f30-4442-857d-c6b517a2c5e4;d62307f8-7110-410d-b4fb-80572b547b9c;de9410c2-e443-42fe-a166-3805074d97e8;deb70186-796e-4e52-a7e8-afd8c17e637c;ea81055a-8dff-4ca3-955a-dffc6518d136;eedb209a-a587-44a7-b7a5-19dbf9efd280;ef8ecfce-482f-44cf-9a96-5370f6d5d92a;f3d1a381-d0ec-4e8a-a4c3-c06585877a06;
10140|725b405d-a6e5-4ad6-820f-4fdebcbfe9fe| Bupropion hydrochloride tablets are indicated for the treatment of <annotation cui="C1269683">major depressive disorder</annotation>. A physician considering bupropion hydrochloride tablets for the management of a patient s first episode of depression should be aware that the drug may cause generalized seizures in a dose dependent manner with an approximate incidence of 0.4% (4 1,000). This incidence of seizures may exceed that of other marketed antidepressants by as much as 4 fold. This relative risk is only an approximate estimate because no direct comparative studies have been conducted (see <b> WARNINGS </b> ). <br> <br> The efficacy of bupropion hydrochloride tablets has been established in 3 placebo controlled trials, including 2 of approximately 3 weeks duration in depressed inpatients and one of approximately 6 weeks duration in depressed outpatients. The depressive disorder of the patients studied corresponds most closely to the <annotation cui="C1269683">Major Depression</annotation> category of the APA Diagnostic and Statistical Manual III. <br> <br> <annotation cui="C1269683">Major Depression</annotation> implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts. <br> <br> Effectiveness of bupropion hydrochloride tablets in long term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use bupropion hydrochloride tablets for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient. <br> <br> |0a7eb657-e991-4243-8165-58e506180a9e;0d1715b2-4193-43d6-9a23-0469d6338ea4;14b11c03-6410-4192-95e0-2f4145509933;24e1efd1-d6b5-49e8-83a9-e9d2a4843835;28fa8921-7546-4681-89ab-9ec32695e701;424efa0f-b2e6-40fc-80be-4ea2ad267720;4d3191de-685a-45ee-bb98-ea76e0e8ab99;5f69a06c-7f8b-45ba-9820-9b58bc477640;60525754-0d2b-4ba4-918a-1c9d3eff89b2;6e636f4a-e649-426d-ae34-e599e3f9c926;725b405d-a6e5-4ad6-820f-4fdebcbfe9fe;753dc2b2-8297-4b5f-a130-e76b00f93734;753ef4af-e31b-40f0-b757-b088e5bbf1b6;85ab3b32-c02a-49db-9aa8-3b8c263dbf2c;86530199-999b-9f92-b1bc-b8515ec829f3;8e9b33e3-beb8-4970-bba5-78fbde261ce5;9251cc4c-33c5-e05c-9b8d-647855c53dbb;92f0c82c-8b9b-4bad-9de2-6e1b81588000;9ac9a12c-25a1-4547-8a79-a79f83854dc5;a6f7f0e4-87ea-4508-b899-91c8ba819ab7;bde35cdf-41e6-43be-a144-398e1928060b;c46845ee-ed1c-4788-882c-b9a84ff88bab;c6251001-4563-6b55-3043-d7cd221f4dfd;ce024abb-c5d5-45c8-bc3c-afe18b1bebe9;d06963c7-f6de-484e-a212-34d865939e8e;d705cacb-5c5e-4f6a-becb-bace1a5a0a0b;df777f28-cf31-4b73-b4ab-249479619566;e2eaf21d-0589-484e-9dba-82b3cd2299ac;f117f33d-b112-4ecc-a908-6ef3d2823294;f676f4fc-7802-49c2-89de-513343105302;
10146|a5416154-8490-4e84-bb6f-4ff0cc605214| Temazepam capsules are indicated for the short term treatment of <annotation cui="C0917801">insomnia</annotation> (generally 7 to 10 days). <br> <br> For patients with short term <annotation cui="C0917801">insomnia</annotation>, instructions in the prescription should indicate that temazepam capsules should be used for short periods of time (7 to 10 days). <br> <br> The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. <br> <br> |09abc9b1-50fc-4c60-a6a1-9772e35b057a;19e1d930-20b3-81e3-0c6d-3e4979460444;1c08d30d-7c27-a09a-5240-7050771d5cc7;2b673d8e-d16e-4a73-b7e3-0f1cc1f058df;2ed81194-be24-45a0-8dde-fbc6ad3d7abe;30dadf97-4e8c-4630-b362-940313a8852e;3e4a35f8-77e5-4c9a-aad2-b0aeb98edd66;43fc3559-6482-4ff2-bd6a-40d881b3adb2;55f28be9-7d69-467c-b5de-6e281ca9c498;62379cd5-a314-43eb-a1ee-33997623bfa3;68e2c1d8-9d6a-44a0-86f0-ba63a3263d22;6979644e-0587-4040-b754-5dce5eda87a4;85327378-86a3-4448-9185-e20bb20ebf45;89394e35-f134-4e47-91a5-0cbf14dbe793;8f54731f-c5b7-492c-acb0-444c5fbb7029;a2a65116-b351-4833-8813-c975161dad6a;a2e1a7d2-aaba-45c7-9987-61f91e96f92c;a3f06243-fa03-4cbd-951a-144ec43dcdfd;a4a2e4e3-6213-4d72-bbdc-7c1447283e2b;a4ee3907-45d4-41b9-af8a-39a9966cd533;a5416154-8490-4e84-bb6f-4ff0cc605214;b9d4ff6b-4e36-4530-8b67-4403ed2d357e;bc56f7fd-1aaf-48ff-8aa7-d467e59e1015;bcfd6a3d-66eb-4844-bede-6ec671985b2c;c9bc61b4-a579-4003-98da-b6f6e381c150;ce2748a3-72ab-407a-ac63-86ce1a126e18;d640e6c6-4f89-4440-a2d9-1d2a51cc7345;f0f4184e-e7e1-49e6-9b93-ac599ac524c6;fe3a8ab5-8603-4d8e-922c-7a41fbb815a5;
10153|42226ef6-7467-4fe8-8f07-4911c0b916af| For symptomatic relief of <annotation cui="C0003469">anxiety</annotation> and <annotation cui="C0233494">tension</annotation> associated with <annotation cui="C0027932">psychoneurosis</annotation> and as an adjunct in organic disease states in which <annotation cui="C0003469">anxiety</annotation> is manifested. <br> <br> Useful in the management of <annotation cui="C0033774">pruritus</annotation> due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine mediated <annotation cui="C0033774">pruritus</annotation>. <br> <br> As a sedative when used as a premedication and following general anesthesia, <b> hydrOXYzine may potentiate meperidine and barbiturates, </b> so their use in pre anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. HydrOXYzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. <br> <br> The effectiveness of hydrOXYzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. <br> <br> |06068fff-2e79-4721-bcc7-b0938aa20e7a;06555ff6-ddfb-4373-9853-9860557e376e;06decaee-0c9e-41e5-ad0a-a19a67990f31;07d01d5a-7243-4389-8548-01846df24cdb;0a20041f-7d0e-c82d-ef08-abbcc13f8b46;0a67ed27-fba5-446a-ab54-6c6e7551b07d;117aeccc-1a78-46d8-ad8d-4035870ad910;266bac10-f40d-4982-a0dc-3e268bdb6fb2;2bbcabc3-657f-4b2e-a473-774adfeba78e;2f8cbb68-0784-4b67-a15e-7810a0e44952;34bd2df3-5f54-4818-8172-085885de3d1a;367f5dab-95c0-4025-b578-c40e79a7c4f6;3abfe605-4b41-4a71-9ea7-2dae28c597fc;42226ef6-7467-4fe8-8f07-4911c0b916af;48b10c63-5d7a-4841-9faa-17ac3d4873d1;59b53047-03a1-4ed2-aa6b-fff75796c65c;5fea3e0d-aea8-436d-a094-aa9462d2cc22;63a3b10a-4d87-4d61-8e8e-8cab01a63094;6f31f4c7-fc46-4c06-8ea3-d6bc715e23fb;71933574-d1fb-4952-acc9-fc345f324756;740fad03-94a7-4da6-86e2-a1622d907f27;77207fda-cf1f-46cf-991e-1599c6a6d400;79c93c3a-167b-4394-841f-ee491b8815a2;7bcab9cd-2ed9-48c1-b2f5-953ec522e4fc;7d4593dd-6cf6-45c2-9823-739bee485bb8;7e5df0ab-3d66-43c8-80a6-f1ad8a95b43c;7fff369e-efd8-45c7-bc2b-ca8b623fe716;80309ec1-e5d5-4454-b8ce-67d7e6805e44;80833d7f-8a36-470a-b7ba-6343549e2273;81f9d88f-c50b-4c6a-a25b-46fa162a503e;84065605-11a6-465c-a86c-ce0d7829091c;8d5805fb-d8a0-4197-8341-26f438b08b8a;8e5fce17-936e-46ea-a969-518c952c2091;92b5435b-eab1-4e4e-a689-18dbc84b9984;950ba94e-a7af-4034-943f-e0df5679d998;989107f5-e3df-4519-98bc-3b6ed290758f;A6EDD742-30B1-4427-BCA8-A81F7EBB2BC6;a04da66a-f4d8-4d52-aedc-15dcc928d76b;a3673d64-500b-4541-9538-c366f67ff687;a49c7e1a-ed02-439a-9b02-bef7d86ed464;aaf38269-f4e2-4bb4-916b-7e4185816d9b;aba7d887-5921-e9d8-0f40-c7f7a80d1d4b;adc4cb73-77c6-48ff-aaf2-b3568d53de1f;ae49a5a2-2393-45c1-8ee0-ce45458495a4;af6f0641-7030-4d25-aca2-bd50c3827643;b0919f40-ed4f-47ce-98bc-9898b4a84862;b1836032-29b4-43ae-a110-14ac2f9f1d3e;b23963af-653f-43cb-bb42-e09df8c06998;b66b967c-c3c6-47cf-bda6-471086368a1f;ba531426-cc51-4d32-88d1-1824d014d0e9;bda79d58-1043-4cbf-b197-0d46cd40a2e8;be1723df-6677-4670-89f7-721578897380;be909eb2-ad4c-424e-9ef0-8bbb220f8fc4;beefb4ba-ee88-4923-96b0-72050466847b;c1b478ba-9e46-48fd-b76d-7f9a74f18d95;c2e7bdf9-8d24-41b9-89d0-44dbd511051b;c848b1ae-2216-48f0-8646-165ecf7ed39b;d689b73d-1bf1-41c7-b7a3-593c6d6812dd;d794dece-8d16-4c53-a23b-d2006dc6e833;e213bcc5-b945-4cd7-b61f-58f5fb863fd1;e330f833-97a7-4f7c-9717-468e7a3b0f9f;ea6372e9-c886-4d66-a7e2-f6d0414341e8;eb509c97-5315-4f69-abb9-c84e1ea63527;f5c09c07-a839-482b-ad66-f3f119994414;ffff4bb7-30c3-4880-8fcc-a1a2a09ce16d;
10157|44c336d2-01d1-4f13-bad9-549cdc3505ec| <div> <annotation cui="C0030567">Parkinson's disease</annotation> </div> Pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of <annotation cui="C0030567">idiopathic Parkinson's disease</annotation>. <br> <br> The effectiveness of pramipexole dihydrochloride tablets was demonstrated in randomized, controlled trials in patients with early <annotation cui="C0030567">Parkinson's disease</annotation> who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see <b> CLINICAL STUDIES). </b> <br> <br> |04bf2b80-5371-4641-bbf5-e19587c0e9cf;0ac104bc-8ee9-4602-b1b3-38521342f97c;1a5ed33b-03fa-4b20-87c3-c4d52a7604a5;1c828c7b-d459-4bb1-b87e-cc6a5e4d1e87;21236d13-111c-49e4-8aa2-5939a106a678;22b48150-67fa-4e0e-89af-a4c15a98c002;2cfedf7a-8ec2-4060-a4cf-305c06e03192;35dc1239-62de-41bc-81bd-806af681fa21;3db51472-c0de-4cfe-80f6-53f5840b91fc;44c336d2-01d1-4f13-bad9-549cdc3505ec;5ce35518-5319-43f8-ab1a-31e3c612631e;60167d7c-469f-455a-a113-561841af5e59;8f7a9391-3de0-45cb-a6be-87a6383da27d;badf360f-7b93-479b-8f69-cae960a505cf;bf5df133-af56-4804-bae2-75a1bddcffa4;c8b8c294-57b1-4285-b230-fb5ba1cfcfac;cb41bba5-6ba4-1a1f-1bc3-3a395aab42fb;d441add2-b30c-414d-a645-8b40a13b67fc;e2e8155f-0e05-40cd-bfb7-26441ebaf17d;
10173|a8b38ef8-67eb-466c-95d4-acb6e4eb0145| Levetiracetam is indicated as adjunctive therapy in the treatment of <annotation cui="C0751495">partial onset seizures</annotation> in adults and children 4 years of age and older with <annotation cui="C0014544">epilepsy</annotation>. <br> <br> Levetiracetam is indicated as adjunctive therapy in the treatment of <annotation cui="C0014550">myoclonic seizures</annotation> in adults and adolescents 12 years of age and older with <annotation cui="C0270853">juvenile myoclonic epilepsy</annotation>. <br> <br> Levetiracetam is indicated as adjunctive therapy in the treatment of primary <annotation cui="C0494475">generalized tonic clonic seizures</annotation> in adults and children 6 years of age and older with <annotation cui="C0270850">idiopathic generalized epilepsy</annotation>. <br> <br> |08e1bfea-7f3f-42d9-823d-f75080e664ff;0a987d59-560f-4650-96ec-31aec81953b5;158d03d1-5c7c-460a-acb0-624069e231ee;1982fbca-fb5f-4e14-b837-e0c59028dad7;19fc5f11-e83f-4ff2-b92f-33e9c3f6a7cb;1f3c04d9-cccb-06a3-a0f3-f7c9228ee743;22de2626-eef5-47a0-a254-10837e5296a3;2471ee03-d747-4113-86d0-1aa93c8f3eba;24f815ef-58e6-42b9-8137-adcd6c382aa6;28972d09-9ee7-4027-a9cd-433b5b16b978;28c0e61e-1af9-410a-9fa9-b71bf99a776b;2f078cef-a889-4d8d-b244-37ee13547a67;334d7b8a-a10d-4312-805d-20ace80baa38;3ca9df05-a506-4ec8-a4fe-320f1219ab21;3edcaae5-81bb-4a18-8bfd-834835187b13;4797366a-fb71-4366-a766-79d95c5dcd3c;47eaa54d-acb4-4b8e-baf6-14b5b576b298;483a42b9-c8f3-4f8b-98be-fcac5ab23c7c;4fe5abcd-4d9c-486c-9ac5-32c27845eae8;5267d7fe-2ad2-5007-7080-cb7cabda6c16;528c67d0-129d-463f-a160-41f370dead6b;5ac8a774-e9e9-497e-9b2a-5166a3b41888;5c4877cc-52bc-4f98-a995-0aa9439da742;5cb4a1db-f32d-44af-8985-0a94ca506468;63b36274-89f0-42d8-9f09-f9e78e179af4;64ca3fc5-857d-4e94-9c8d-3e67cbc96ce8;656756de-2404-4845-a8a7-c0ffa2d61c90;6ab24168-058d-496e-9023-da8ee6353eb3;6d71e14f-8092-444c-afa1-2b79d69d81e6;70e52e89-3844-4cd9-a406-b29e9520a12c;746aa1a9-4605-4991-bb80-62685284bb0b;76c7e13d-37a0-4131-a1f1-fd5af0f60d3e;7967f8f4-eba8-4849-a176-944fffa2ee53;7b1d9124-5fde-4f57-9fca-ee061750fcc3;7d060be3-1429-46c7-b312-d5727064eaaa;8968facc-7fab-4f8e-b7ff-339f5acd2317;8bf7c1ce-dfc4-457f-8a8b-365f82aa8512;8d767545-1eb9-45a5-bd16-e8a66e628fea;8e26d49b-f0ba-4fd1-b863-4bd68e65ee88;90b553fe-4e94-4cce-b5df-ea3e6487930d;90f90650-709f-4d2a-bf94-26aad80e0805;925d34bb-235a-4655-b5bf-d1c3d93f5daa;92cdf763-8aea-4f3a-be05-e515f3cd4317;930601ae-c7bb-4ae1-8268-b87eee2bbe22;94a972db-11b3-419e-9410-8d923c9f1489;97d9d2b7-745b-413e-a7ba-8ebe207a463f;98bae5bb-729b-4a36-b429-5ee25aa80411;98dc2482-ec98-48dc-9449-93ac202e5679;9EAD5896-CF5F-7F3A-BD8D-BA6A7AEE930A;FA122B5A-DDC3-A1B7-0DE3-FD0001FC8213;a70be430-21fa-49a4-84c1-134621ee2f4f;a8b38ef8-67eb-466c-95d4-acb6e4eb0145;ab7226ce-ffda-42fa-abde-7c92ed676686;b155a027-a5b3-480a-8c07-fa39af3a18fe;b18a36bc-1697-4b3c-a1bd-d76d2a543d8c;b1918b4e-2238-4cbd-81be-61cae5481c88;b2eb10c8-9d8c-41e6-a045-01e425c3f8a7;b4678d25-f888-84f9-be8e-7f61107a8dc9;bf412e94-ca36-4da9-83d7-fb0f1323cf21;c33d82ae-7991-443f-8e48-5832c02ea450;c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e;cb8aed34-2f3b-48b1-86ea-84b0d9e2b618;d1329893-a8bc-4f31-a31b-76690d111035;d293d765-e418-4bdf-9955-76a4bdba129b;d618a40c-d8c3-488a-9519-fdf11c1ca30d;d7932a2c-a3b7-46df-a306-1f17716160a0;db0a1e4b-90b1-4754-9a6d-17042e54ce05;df661166-325d-4071-9bc1-f7bf992996d2;dffeca56-ca22-4b62-9537-277caf7edbab;e196c127-c081-43a7-8f0d-be3e2b434b50;e1b14939-7262-40dc-a334-2b3b72c88d47;e77eabc9-9f65-4d4b-8135-0290291e6ee8;eb02779c-acdc-48ed-9d23-ca39ba152d0d;ed1b74a8-2a9b-4315-b051-673c7941cb13;ee03507b-cb35-4fe9-ae7b-85ea89f876f0;f102e5ad-8cd0-4cc9-85c5-d196f7f15800;f44e0069-84cf-40e2-a4e8-57494131c65d;f65ec19d-b90e-452e-b761-c68b1cf2c892;fc0cbcd4-5400-4b71-a239-39e451b4c7b3;fe7e0c86-8007-4af5-965c-184c6dbce17d;
1024|4c5557cd-c4cf-11df-851a-0800200c9a66| <div> Indication </div> SKLICE Lotion is indicated for the topical treatment of <annotation cui="C0030757">head lice infestations</annotation> in patients 6 months of age and older. <br> <br> <div> Adjunctive Measures </div> SKLICE Lotion should be used in the context of an overall lice management program <br> <br> <ol><li> Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels. </li><li> Wash personal care items such as combs, brushes and hair clips in hot water. </li><li> A fine tooth comb or special nit comb may be used to remove dead lice and nits. </li></ol> |4c5557cd-c4cf-11df-851a-0800200c9a66;
10263|0799b639-1d06-4ad4-8bcd-4922db100717| Before instituting treatment with ceftriaxone sodium, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of ceftriaxone and other antibacterial drugs, ceftriaxone should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> Ceftriaxone is indicated for the treatment of the following infections when caused by susceptible organisms <br> <br> <i> <annotation cui="C0149725">LOWER RESPIRATORY TRACT INFECTIONS</annotation> </i> caused by <i> Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis </i> or <i> Serratia marcescens. </i> <br> <br> <i> <annotation cui="C0271429">ACUTE BACTERIAL OTITIS MEDIA</annotation> </i> caused by <i> Streptococcus pneumoniae, Haemophilus influenzae </i> (including beta lactamase producing strains) or <i> Moraxella catarrhalis </i> (including beta lactamase producing strains). <br> <br> NOTE In one study lower clinical cure rates were observed with a single dose of ceftriaxone compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see <b> CLINICAL STUDIES </b> ). <br> <br> <i> <annotation cui="C0037278">SKIN AND SKIN STRUCTURE INFECTIONS</annotation> </i> caused by <i> Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, </i> Viridans group streptococci, <i> Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii,* Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* </i> or <i> Peptostreptococcus </i> species. <br> <br> <i> <annotation cui="C0042029">URINARY TRACT INFECTIONS</annotation> (complicated and uncomplicated) </i> caused by <i> Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii </i> or <i> Klebsiella pneumoniae. </i> <br> <br> <i> UNCOMPLICATED <annotation cui="C0018081">GONORRHEA</annotation> (cervical urethral and rectal) </i> caused by <i> Neisseria gonorrhoeae, </i> including both penicillinase  and nonpenicillinase producing strains, and pharyngeal <annotation cui="C0018081">GONORRHEA</annotation> caused by nonpenicillinase producing strains of <i> Neisseria gonorrhoeae. </i> <br> <br> <i> <annotation cui="C0242172">PELVIC INFLAMMATORY DISEASE</annotation> </i> caused by <i> Neisseria gonorrhoeae. </i> Ceftriaxone sodium, like other cephalosporins, has no activity against <i> Chlamydia trachomatis. </i> Therefore, when cephalosporins are used in the treatment of patients with <annotation cui="C0242172">PELVIC INFLAMMATORY DISEASE</annotation> and <i> Chlamydia trachomatis </i> is one of the suspected pathogens, appropriate antichlamydial coverage should be added. <br> <br> <i> <annotation cui="C0684256">BACTERIAL SEPTICEMIA</annotation> </i> caused by <i> Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae </i> or <i> Klebsiella pneumoniae. </i> <br> <br> <i> <annotation cui="C0029443;C0157749">BONE AND JOINT INFECTIONS</annotation> </i> caused by <i> Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae </i> or <i> Enterobacter </i> species. <br> <br> <i> <annotation cui="C1112209">INTRA ABDOMINAL INFECTIONS</annotation> </i> caused by <i> Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium </i> species (Note most strains of <i> Clostridium difficile </i> are resistant) or <i> Peptostreptococcus </i> species. <br> <br> <i> <annotation cui="C0025289">MENINGITIS </i> caused by <i> Haemophilus influenzae</annotation>, Neisseria meningitidis </i> or <i> Streptococcus pneumoniae. </i> Ceftriaxone has also been used successfully in a limited number of cases of <annotation cui="C0025289">MENINGITIS</annotation> and shunt infection caused by <i> Staphylococcus epidermidis* and Escherichia coli* </i> <br> <br> *Efficacy for this organism in this organ system was studied in fewer than ten infections. <br> <br> <i> SURGICAL PROPHYLAXIS </i> The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of <annotation cui="C0392618">postoperative infections</annotation> in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. <br> <br> When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure. <br> <br> |00c96589-6998-4088-a312-ba831433ded6;03283208-8616-4117-9d2b-aa8046017a4f;0799b639-1d06-4ad4-8bcd-4922db100717;128bb292-d174-4769-b3e6-9f16617f31e3;1781fc07-5a2a-4b31-aad9-d0457eb704f4;24e1525f-a347-4745-b577-5dad60ef9f45;2b55e178-987d-4ab7-b12b-be9ab2588292;33529ede-844c-4dcf-9fc4-93962535981a;35c69667-b48d-4fda-823b-c4c05a7cc82b;365fc265-8e6c-432f-9fda-911f5f7fb451;392fc0f1-b910-4d97-9b6d-00e1b2bc9d78;3b36beb7-db94-4b07-8c81-bd2b601a6601;3c5e2c32-58ff-48da-aabe-93562868a390;471fde4e-1661-4ca0-9d3e-18522139687a;4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1;4d1ad77f-2c6b-4250-82e5-ab3574444e08;52802c0d-a617-4ba9-8f98-5a652025306c;53df951b-2eee-44b1-bae2-df7ed85bc0ed;5cf93bc5-9e4c-4734-bc02-c7d0ac071022;60bc6eab-fc04-476f-a894-d3cd56fe8f6f;67153914-16bc-490d-82d7-638061618467;6cc898bd-f6c7-4d44-b2f7-a5f9410c4d0b;750fdf6b-e2b1-4d28-a8b1-81b326c714a2;7dfb35c5-91a3-4193-94d7-ae2c5d787bc9;7ea1db43-40fa-417b-8911-ae98092070a0;8351aa37-552d-471d-b293-c564dcb6ec29;86ec0a92-a552-4a6d-9125-a54f95e43392;87859aea-e6d8-4d68-8ce3-135163a7fdd8;8828d4c9-6e71-4d0a-9ca1-bd0d231184ab;9467f6c9-3e59-45c6-a1be-77200f2d4554;9d1f630b-e759-4395-9d01-ddc90e4fea75;a0135a49-0c38-4235-908e-cf773e34dc62;ba1dfe30-7ea1-4662-8a70-add5670b1c7a;befd73ff-cb3b-4543-8a8e-bdb9b7fc1ff0;c3122a02-0a44-49f8-947f-109092c38a13;cb52fd1e-2ddf-4f45-b5c3-3d56b907270e;d4ff7c80-f38f-484e-8c95-2fb322500530;dac396fb-748d-45ea-9830-17c6eeb8834f;dc28e719-6fe0-4d9e-a624-adb76b04b299;de028434-46cf-44f6-8ac6-889c7c6943b3;e3485086-7a10-45fa-aa83-ee6fbbf39c59;e38c48f6-4d07-422b-9bb2-3c1025946e86;f5d7ae2f-5485-42e2-af2b-bd7f06df85d7;
10268|5da36930-d3da-4b5c-9e22-2b141bc01a9c| <annotation cui="C0085580">Essential hypertension</annotation>, alone or as an adjunct. <br> <br> |05cf3bdc-d5ac-4be5-9e74-5ffff726d9f3;18297bc9-5ea2-48ff-9ba4-e9b9492e9cdc;18365878-543c-4715-8ddd-4504697a73d6;2594e3d8-af38-4ba0-9370-0a261e2d1042;26ba8da4-9752-46d3-a1ab-c5eee2bbd5ee;27bb47f9-f177-41c6-8e0c-69331e933278;2afec728-a2f5-4c29-953d-f9c63fc15034;37ba0233-ed75-498a-a067-6220da573653;3ac3c7a4-e2c0-4cc9-8d49-ee7f02c05219;493a8b7e-5bb1-4db2-91a7-77ed87864131;53908945-540f-4d34-8f0a-b4a87676634e;59e18725-100a-4816-bc7e-bcc416a7d3ce;5da36930-d3da-4b5c-9e22-2b141bc01a9c;6ce41f90-e721-4141-8ea6-8c89e64099dd;a04eefaf-ba3c-448d-8ece-4aa9ab2e3508;a2b73026-2451-406f-b866-9dc16177cb44;a32082a4-75a7-4295-9500-32d1b15a3dfc;b44f38da-edd2-45f7-8c26-73d01ffa86b6;d4a220de-4721-4f24-97d2-df0fde48d7e9;d8c6a541-1e02-48c9-92f2-cc850a0c12da;db7500f3-f8a6-46b1-bb64-9727617a9643;ddbbdb09-3202-42d7-bbb0-08331dde2f54;e9888fe1-a2ed-41b5-b5dd-df7fff3fad37;
10295|e13c4267-603e-31c3-2515-91314059e091| Folic acid is effective in the treatment of <annotation cui="C0002888">megaloblastic anemias</annotation> due to a <annotation cui="C0016412">deficiency of folic acid</annotation> (as may be seen in tropical or nontropical sprue) and in <annotation cui="C0002871">anemias</annotation> of nutritional origin, pregnancy, infancy, or childhood. <br> <br> |067aaa4f-6e77-44d4-a648-df1c2611e730;19a60d50-7319-44d9-9ade-72922cfcb39d;221cbb40-e12a-4a14-a070-7f8743d6e0c6;2333e487-e286-4b5e-9f12-a8e7e68c6d85;2DEEE7BA-BBD9-4827-8265-9E770E9D93BC;2e2313cf-ee59-4b22-acb1-530c50c17ff2;3a1b39df-bc52-4ad7-87f6-ea77cac706f2;554470f9-ce42-43bd-a87e-1481154862bb;61d4f671-10a2-4aff-8012-e9d4fecf15cc;65356126-cb6b-4652-8455-a58dd8f274b3;748977db-fd10-46b8-a219-381ba34e55cd;7bdfb785-2462-4b8e-bdaf-508f9b464526;8a75968b-93d7-486b-8a70-fcfafdda7016;96323347-844c-45fc-b32c-25406e53646c;A37E08C3-92CB-4BFB-901F-219C6CDCFFE2;E2CAAB63-1E0D-44E8-B9A8-BDFB59CE1288;a5477715-93d0-4240-9a96-c4f47e99604c;a912f6c4-2ca6-438e-912c-4acf02a3e0bd;b561a04c-b0a6-4da1-9955-172672f10669;bbe3541f-719d-45bb-86fa-6b903e95238d;bd9b7d5a-a7d2-45bd-ae38-ab9e1e9e651c;c8fe09f0-b32b-43e3-8de7-ed38593b33b4;ca34af96-e70f-447f-8d85-dcc436f62f47;d63ab68c-1f50-4455-afd0-d7391e355e49;dbb9324c-8d42-474c-aea7-b2ba5490ec29;e13c4267-603e-31c3-2515-91314059e091;e215318c-4f8b-4711-ae76-f370d1da0f3b;f27c6eb3-9fea-41b6-9ac4-01ef11a9a93d;ff80ef4d-e04c-9f83-2b56-cccc30028f72;
10303|e3469758-5111-4c30-a7fc-12444e914515| Finasteride is indicated for the treatment of symptomatic <annotation cui="C0005001">benign prostatic hyperplasia</annotation> (<annotation cui="C0005001">BPH</annotation>) in men with an enlarged prostate to <br> <br>  Improve symptoms <br>  Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. <br> <br> |1cfbda56-d700-4049-8a51-e24af8a622c4;344a2e9e-24fa-4550-863e-ff56df0bf15c;5e2ea873-f8a4-4b19-b79f-93f957114352;7813e1fc-0081-0e69-136e-a7c7dc4ed589;87b26764-074f-40f2-8d4b-446c03bf4d68;aae33c98-7c57-49bd-9b1e-3af0b1201e08;adfb8f6b-a7bb-4ac2-b2aa-fec6d56630ad;be37d74f-2c78-41bc-8a17-cd53d1a92d2e;c59f8018-fff8-4884-a3c8-bc306e2c8f64;c9a3cb34-9a8e-4538-ab90-32e08d8acc3a;e3469758-5111-4c30-a7fc-12444e914515;
10311|19a69a72-ac5d-45d5-a94d-a5aaecbe4730| JANTOVEN is indicated for <br> <br> <ol><li> Prophylaxis and treatment of <annotation cui="C0042487">venous thrombosis</annotation> and its extension, <annotation cui="C0034065">pulmonary embolism</annotation> (<annotation cui="C0034065">PE</annotation>). </li><li> Prophylaxis and treatment of <annotation cui="C0040038">thromboembolic complications</annotation> associated with <annotation cui="C0004238">atrial fibrillation</annotation> (<annotation cui="C0004238">AF</annotation>) and/or cardiac valve replacement. </li><li> Reduction in the risk of death, recurrent <annotation cui="C0027051">myocardial infarction</annotation> (<annotation cui="C0027051">MI</annotation>), and <annotation cui="C0040038">thromboembolic events</annotation> such as <annotation cui="C0038454">stroke</annotation> or systemic embolization after <annotation cui="C0027051">myocardial infarction</annotation>. </li></ol> <b> Limitations of Use </b> <br> <br> Warfarin Sodium has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary <annotation cui="C0040038">thromboembolic complications</annotation> that may result in serious and possibly fatal sequelae. <br> <br> |19a69a72-ac5d-45d5-a94d-a5aaecbe4730;3ebcb71e-9a7e-4969-abb9-7c7d3e3aae3c;3fb2aa58-3a40-4255-a261-e2db5b9a5dde;4445c26e-ec5c-40f4-956b-93c12fc73c1d;5907ef77-9c4d-4e3f-be7b-6157ebad2173;75f9abdf-52f2-48ee-b65b-9160c38564ec;77f258d9-f380-4815-8140-0b2bfda3099c;8ad881e0-ca41-42ad-9d7d-eb85b3a30af0;ab047628-67d0-4a64-8d77-36b054969b44;ab50f13c-7ec9-44b4-9a9f-ee3ddda6c8ea;b1b766b1-0327-48cd-ab01-e85038cf365f;ba41b963-ec4a-4421-ac93-26654876a6be;bd72a7c7-ff12-4b95-8d39-4426231bd5aa;c0f238ff-2804-4150-9766-22a5111b4e74;cd6d1b85-0ba2-4a10-a5b8-25496ae13fa3;d91934a0-902e-c26c-23ca-d5accc4151b6;e9d8fb69-a4c7-48cb-a4a9-e5d18eb4fd63;fe64cc25-d490-48b8-afa4-88cd9c3f6ee0;feaa5f6f-9753-4f37-ab81-04c9c6b45e6a;
10312|f035ba75-944e-45bb-95dd-e6c8df91a504| Glimepiride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with <annotation cui="C0011860">type 2 diabetes mellitus</annotation> [see <i> Clinical Studies (14.1) </i> ] <i> . </i> <br> <br> <div> Important Limitations of Use </div> Glimepiride tablets USP should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. <br> <br> |1a20e954-9007-43d7-b056-cbc88214951a;222b630b-7e09-43b4-9894-3d87f10add91;28eefc95-d92e-4555-b6c5-2933860b0610;3f626e54-b043-4556-9568-ace556cff9e9;9b74fbac-9e04-4927-9981-1e3dace89c6d;f035ba75-944e-45bb-95dd-e6c8df91a504;
10316|4d0c38b0-8089-45b1-613f-563176c53e43| <div> <annotation cui="C1704272">Benign Prostatic Hyperplasia</annotation> (<annotation cui="C1704272">BPH</annotation>) </div> Doxazosin mesylate is indicated for the treatment of both the <annotation cui="C0600039">urinary outflow obstruction</annotation> and obstructive and irritative symptoms associated with <annotation cui="C1704272">BPH</annotation> obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). Doxazosin mesylate may be used in all <annotation cui="C1704272">BPH</annotation> patients whether hypertensive or normotensive. In patients with <annotation cui="C0020538">Hypertension</annotation> and <annotation cui="C1704272">BPH</annotation>, both conditions were effectively treated with doxazosin mesylate monotherapy. Doxazosin mesylate provides rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. Sustained improvements with doxazosin mesylate were seen in patients treated for up to 14 weeks in double blind studies and up to 2 years in open label studies. <br> <br> <div> <annotation cui="C0020538">Hypertension</annotation> </div> Doxazosin mesylate is also indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. Doxazosin mesylate may be used alone or in combination with diuretics, beta adrenergic blocking agents, calcium channel blockers, or angiotensin converting enzyme inhibitors. <br> <br> |01d055aa-3662-482f-92f6-0b76b6633ab4;05e29a60-ebf9-470a-b565-40a6f1f6e102;096fec41-0af3-4ceb-8b72-2a86b8aeb937;0ae00cc4-9e6b-42bb-9d3c-c5d2e45fde1a;17d13f2e-6b0e-4b66-8351-6c590f79536b;3130fbe7-7cf5-4f52-8a74-099f3892b461;345478A6-8389-4229-92B3-6E40DA7B06FD;3a5f4fca-f967-4d21-ae62-a096b8d184ff;3ed04255-7d9c-464c-bfa6-c355755862d8;426f6918-7705-4988-a875-823196f43859;445e0341-5f8a-4a59-9cc5-f93177f5bf9c;4abe1804-ae5f-4401-b84c-8ca6a71fbf74;4d0c38b0-8089-45b1-613f-563176c53e43;4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b;74b231df-489b-44af-8860-2b457d6103ed;AE6C88E4-C6E6-4C5F-8248-F1D01D73DAB2;a374edef-e4ef-48ba-a3f5-5f816b24d7de;b4095fd5-83cb-4789-964a-c921656b10a2;d7bb63a9-5ad7-449e-b1f2-7254370bada8;ea2a9cd6-1b03-4d96-9081-5cbc45473020;eefc47bc-c10f-49bb-8ef7-5999f798ab39;feea8d72-5781-46d5-831d-855f478c704d;
10318|833fb607-f9df-491e-bf67-33370ff7a746| Clobetasol propionate cream emollient is a super high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive <annotation cui="C0037274">dermatoses</annotation>. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g week because of the potential for the drug to suppress the hypothalamic pituitary  adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended. <br> <br> In the treatment of moderate to severe <annotation cui="C0406317">plaque type psoriasis</annotation>, clobetasol propionate cream emollient applied to 5% to 10% of body surface area can be used up to 4 consecutive weeks. The total dosage should not exceed 50 g week. When dosing for more than 2 weeks, any additional benefits of extending treatment should be weighed against the risk of HPA suppression. Treatment beyond 4 consecutive weeks is not recommended. Patients should be instructed to use clobetasol propionate cream emollient for the minimum amount of time necessary to achieve the desired results (see PRECAUTIONS and INDICATIONS AND USAGE ). Use in pediatric patients under 16 years of age has not been studied. <br> <br> |109b741f-624e-455c-97ff-2ad0034182df;20cf8e9a-7889-4005-b926-f41d1b055a57;218da851-af52-48e6-bfd5-2e716d0a85f0;2d4fa3a3-dc1c-4d3c-9959-4751e09d25be;38b59fd2-8d8c-45d8-bf30-55f2c668523a;39f719f6-4e44-4aff-bad1-7529bf75bda2;4a761afb-a48a-4a5a-8700-ad93601a260f;52858738-a71c-4330-a7b3-e9c6c2161e04;54eca64c-af43-48ba-bf86-bab9d8e46bb6;830a28fb-9b80-4fbb-99dc-56ec80e4e581;833fb607-f9df-491e-bf67-33370ff7a746;8cfa527c-69c5-4722-8246-c3b4ce591a5f;8d08ceaf-d1a9-4352-9046-111b5aa4e80d;91571297-03ad-441e-8ec6-f78c21fbe5e8;95e9ad40-5c53-490b-8313-7fb3541d431e;976d9c90-1800-4dac-9b92-48284b29d2b9;A188664A-8FA1-479F-9493-0DA4A6C592F7;a086ead1-b906-4198-af19-5423957c9e2a;aaba92a9-65fb-4150-aec0-9d9f721ca5a5;acecf5ab-dd5e-4046-ab47-b9ff415d4b2b;afd20e23-b7a6-46ca-bd8d-b7af9ff84201;b22a7bb3-108b-4485-a721-1ea89adac36e;b269d3ad-fbae-4ef9-8b3e-e0477ab4615a;b6b530b3-5218-4838-adee-08e477757b98;bb220bb0-8b82-4acf-87ac-9ac8c3c66d25;c74a755b-b9a2-48cb-9387-f62a37a7a926;c77ababd-a449-4e89-a9c6-b7e401120ba1;d2a1bcea-66db-4dd9-b586-7beef185a754;d4c73fb0-9675-4c41-a8bd-dd4cb2db1169;df79a35c-ce5c-452e-b81e-50a014fc94f4;f5ea346b-f507-4224-88a6-4c891c4b1ad5;fb29b17b-96af-4a78-bc91-83cf8c5c2b1d;fdfd83ee-dfb4-4c12-a74e-a0053e34e08c;
10319|834bc56a-657d-4733-9a60-47040cb5c7bf| <ol><li> Prevention of <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> associated with highly emetogenic cancer chemotherapy, including cisplatin 50 mg/m 2 . </li><li> Prevention of <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. </li><li> Prevention of <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> associated with radiotherapy in patients receiving either total body irradiation, single high dose fraction to the abdomen, or daily fractions to the abdomen. </li><li> Prevention of <annotation cui="C0520904">postoperative nausea</annotation> and/or <annotation cui="C0042963">vomiting</annotation>. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that <annotation cui="C0027497">nausea</annotation> and/or <annotation cui="C0042963">vomiting</annotation> will occur postoperatively. In patients where <annotation cui="C0027497">nausea</annotation> and/or <annotation cui="C0042963">vomiting</annotation> must be avoided postoperatively, ondansetron tablets, USP are recommended even where the incidence of <annotation cui="C0520904">postoperative nausea</annotation> and/or <annotation cui="C0042963">vomiting</annotation> is low. </li></ol> |0934b7ad-41c4-418d-86e3-a2ea4e7bb4c7;162f2088-9fb1-47e7-b88c-45104be7e7bb;16ed3ca8-c85c-4d06-9c4f-d5bbf344b12e;18921375-a801-4614-95f1-54cb22c32028;1a0c4dc6-643e-4ee7-92a9-edb98049a5ba;1b03afa8-ea60-4382-b62f-872e3c146792;267abdd4-02f8-c04d-d009-d838f7e0a905;2e5372a6-718e-49d4-a312-04a7f4498b4b;2edc0788-dc38-4d21-ba8e-71f159e2d3b1;302da2e0-3538-42fd-b712-45725a790fb0;330cc74e-0f50-477d-85b1-fec1438c81f6;340f1a87-0bc6-46bf-8f16-80a5348ad15f;354d8b2c-de37-4f88-a04d-5c8d431485ab;3627f459-6b9e-41e9-802a-58f39a5131ce;36c80e18-671c-4612-a8e7-07962bb102e0;38435346-d505-4bdd-bbc6-a7bcba411033;384a5cfb-05dd-2b79-73f4-a01a47a9eb3e;3c327aa6-a790-4262-a79b-51856976d560;3e7056d3-0dd0-44f5-bdc9-8648a77b4e19;42abd7f6-d3b0-4133-b9ca-258f699f7162;476e704c-95ae-4591-94f7-ee4ab827ff13;482162fc-1ea6-4012-ae59-76911a047821;4d069ba1-8e20-03b8-1f10-9b13d0858ff8;4dbbc510-5dea-42da-a321-91fe3f4fc041;52dc6871-47d3-11dc-99cc-f742b487c00e;57578387-1918-4e56-a564-f14fb22340bf;5fad6aba-321a-4ed3-8d8e-2806aaeb2ff7;69017f9f-1815-46d2-8e40-71cad10fa9d1;6a11f61b-2318-4382-2b91-4366e4bb53fa;6c450150-a7a4-46f3-b62a-848eeefada06;6e76d0ef-93ca-4be9-8384-65656fe8bd47;77c8c6c2-cf86-4795-b035-0501e6635f27;7c45c2a6-0565-44e6-b538-a15a1bf72007;7eed9b3a-207f-49ca-83cd-8172357363d3;834bc56a-657d-4733-9a60-47040cb5c7bf;90d19fd2-6de4-4e55-9469-53b8957c8326;91eddc2b-50d6-4f5b-8916-62525fbdc375;92c758a3-e749-4a15-be4b-ee30b364b2b0;93f6d82b-0594-4b48-9711-201d79a03315;95ccc5e8-2199-448a-b771-48979d7b5a83;9f015e60-1aec-4ae7-b28f-42f6c8f50455;BE758639-894F-430F-1191-30181991FBFD;a194b8f8-163c-4e48-bc8b-871391010bab;a360d43c-bed8-4f41-ab36-e2aa77dfbff2;a67eaa4d-7aa4-4a55-9198-62a51261c2ef;a87d78b2-7170-4979-9291-1505bed2f3ca;a95ca4f4-c4de-4822-9a08-209d10bf5136;a9fdc04a-b4e5-4eed-be1f-8a629dc447be;aa5cd244-dbd5-4cd6-a9f6-e045405ae519;ac3dfb81-a4c7-4147-9374-c234153b7c51;af0cc6be-f37e-48fa-a635-f669a9cefb63;b0285c99-924b-416f-aa86-af1f47f5a330;b4f49bd9-67e4-37be-f936-28876681f14b;bb4bc810-db26-471b-9ce7-6e2fb3018af0;bd365c0e-7f76-4904-8f21-bed9ec2d0360;be5930d2-0008-4e61-9715-684c29a9c613;bf47aac9-ffb5-4e06-a3de-7caf50cbec77;bf5cbf1b-af47-419e-bc32-6d6b94a785b5;c286dba1-e6b1-4cf0-936d-9af42d8eedc3;c29ca6df-621d-44b6-98fc-b48666573366;c5378585-dd35-4123-82b9-91395b56c3eb;c71a30dd-ff55-437b-ace5-d64c3c72ca27;c7d61d98-fe86-4340-9b86-47eb92acaa0e;c851ac17-0068-4320-94d4-fd955a26e1ac;ca09dd2c-02ed-4d26-af3c-aaff4120887e;cab63f24-8728-4927-aba5-53e8d2e44cdb;ce3259a1-89f8-dd38-3e9f-296063af3e5e;cf10d256-dd89-4a91-a3ed-81db505a79c2;d0360f27-1ca3-4995-b277-28091ac388fc;d117de5f-64e5-464c-b782-de0f07e66c8e;d337b07d-5d72-428d-ac31-d8afbfd3b44b;d787900f-f617-478d-a65b-eef170e929f9;d9a71b42-ddfc-49d5-7280-0fc0041dba41;d9d5dd5d-6101-46bf-ac11-b105f625c78c;db20996a-9fdb-4375-b2cf-5ef953123aa8;ddbeb79e-90d4-4c83-9b69-e7915867edbe;ddf0ba8e-fc37-4829-b55c-9a1a62288dfd;dfa2dfa8-26b2-4623-8dab-af9e9f32320f;dffd0d9d-2bfa-41cb-b995-ff25481104ab;e5ab38a2-5921-4320-a313-e0080c078046;e5e8353f-4e4c-4036-9376-2ac205d13b14;e6c549a7-774f-4274-9bc5-1149fed5c526;e8ff7386-44d0-4bec-8c7a-1b299d18b48f;eee5217a-eba8-463a-812d-bf3c66f0934f;f6107154-0530-4e1f-93b0-6cb2277ef917;f927b041-1d05-478c-ac26-066d9c782c5e;fc3d39e0-8bf2-4c29-b872-66a1cf8bb2fb;fd2b39f2-1f18-478c-ae17-485ddbcb35ac;
10320|9ffdb1e8-fdc8-44d4-b558-210954138b2f| Cilostazol Tablets USP are indicated for the reduction of symptoms of <annotation cui="C0021775">intermittent claudication</annotation>, as indicated by an increased walking distance. <br> <br> |1162b345-b45c-448e-a399-b3cce63ea37b;151d1497-7655-44ce-8e97-dd1cd91f686a;1eb9a361-cd8d-44b0-bf40-42b97a470ddd;24d75b58-bafb-4440-b8d7-4f4079c08b0b;26610bfe-4c3c-4c20-8b6d-b7c18cd6fe23;5f4fc5df-5077-4cad-a5dc-1b54a73904cc;8e49409b-6bb1-4b8a-8a5b-4cb1a291660e;9c72d2f4-c586-4456-80b3-cec69b7d9ee0;9dfc5f4b-3936-4607-8495-439a27433e81;9ffdb1e8-fdc8-44d4-b558-210954138b2f;ADA307F1-B6B1-4B64-A060-5C254B1948F2;a6292311-9cb2-49ff-b8bf-12e2dbd196cd;b4509afc-539b-4d7f-97d4-5e9c98c2f65a;c4597231-fec0-435d-a0c6-8c237e3d60a9;ceac1ae3-c343-28ca-c083-b748d21a15e6;efa614a9-e857-45a7-a8c3-faa6195fa1ec;
10322|b916f972-10be-4e14-8603-087955fa9ad7| Kionex Suspension is indicated for the treatment of <annotation cui="C0020461">hyperkalemia</annotation>. <br> <br> |b916f972-10be-4e14-8603-087955fa9ad7;
10445|939cc631-e90c-405e-9aca-809b2c4c32ef| Benzonatate is indicated for the symptomatic relief of <annotation cui="C0010200">cough</annotation>. <br> <br> |00acfc04-3ad0-487e-87dd-e6e632c05b45;03fb833b-a334-4ad2-8849-0336782d8b79;05b19502-15cb-4272-8efe-6b37b1863e63;0fb9ef32-9df6-5202-5117-c027e6a30064;15dd2f41-952b-40d2-a9bb-5e1cb8802e5e;18e689cf-f504-464f-88d6-cc89aa05a6fc;20bb73cc-09e6-46f5-ac59-700946306e39;2367894c-3bdc-487e-98b5-631daf7a2317;27388883-e698-4501-b8c9-78c76ae9b1e1;29a88bdc-0aa7-4a4b-bbd5-47998ad1d87e;2e25e25e-7bbe-411e-89fa-5182eda96df9;331c70dc-005e-4d96-a35c-4d2d810aa3b1;355fb435-e8d8-4e0f-a12d-04de4397ff04;3a998e44-8fd0-458b-9f26-96ffeec10b00;446d268a-fc0f-4027-b380-1083a3a252b5;47f4e6bb-b77a-46d6-b3c8-f6a8f5382bb6;4b2f8f55-aa98-484e-8d6e-6813d208bae0;507e46db-b82a-472d-9e08-3588b89d6e6a;51a6d28c-2c9c-4e6b-8a4c-29aac6745256;5eecff3d-476c-420c-b56e-3ad17496cdbf;6412628b-bf67-45b9-992d-82531286b370;7b0e4dde-f2c4-415c-893f-6811380a0e66;7bc216b1-89d6-4aaa-90d1-4839131162cd;8d4934b7-b401-430b-b094-b2177fbc0271;8edd07a0-5f5b-9000-bafb-dbf8ff7609d4;9192ed6e-3383-4147-a2bd-796562cd81eb;939cc631-e90c-405e-9aca-809b2c4c32ef;9a71725a-64b6-4800-a79c-aa4b2d74d44f;a8861d0d-3ca8-4b46-adc5-5dd322142b96;abb4360a-4c52-45b6-9b80-df3c1bfc4c59;b85137e4-5e8b-4134-9a8e-1e6f9da63f92;e0f1b5cf-863c-42fa-acd9-43a7e30b4054;
11458|22009d23-999c-4fa6-bfe7-21395f577236| <b> <annotation cui="C1269683">Major Depressive Disorder</annotation> </b> Bupropion hydrochloride extended release tablets (XL) are indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation>. <br> <br> The efficacy of bupropion in the treatment of a <annotation cui="C0024517">major depressive episode</annotation> was established in two 4 week controlled trials of inpatients and in one 6 week controlled trial of outpatients whose diagnoses corresponded most closely to the <annotation cui="C1269683">Major Depression</annotation> category of the APA Diagnostic and Statistical Manual (DSM) (see CLINICAL TRIALS ). <br> <br> A <annotation cui="C0024517">major depressive episode</annotation> (DSM IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2 week period and represent a change from previous functioning depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. <br> <br> The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo controlled trial with the sustained release formulation of bupropion (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use bupropion hydrochloride extended release tablets (XL) for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient. <br> <br> <b> <annotation cui="C0085159">Seasonal Affective Disorder</annotation> </b> Bupropion hydrochloride extended release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of <annotation cui="C0085159">Seasonal Affective Disorder</annotation>. <br> <br> The efficacy of bupropion hydrochloride extended release tablets (XL) for the prevention of seasonal major depressive episodes was established in 3 controlled trials of adult outpatients with a history of <annotation cui="C1269683">Major Depressive Disorder</annotation> with an autumn winter seasonal pattern as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) criteria (see CLINICAL TRIALS ). <br> <br> <annotation cui="C0085159">Seasonal Affective Disorder</annotation> is characterized by recurrent major depressive episodes, most commonly occurring during the autumn and or winter months. Episodes may last up to 6 months in duration, typically beginning in the autumn and remitting in the springtime. Although patients with <annotation cui="C0085159">Seasonal Affective Disorder</annotation> may have depressive episodes during other times of the year, the diagnosis of <annotation cui="C0085159">Seasonal Affective Disorder</annotation> requires that the number of seasonal episodes substantially outnumber the number of non seasonal episodes during the individual's lifetime. <br> <br> |02500709-7f2c-4251-bd8c-94ab6cdadd4c;165475dd-a250-48bb-b4c8-65c189194a9b;1c230d18-4aec-4105-83cc-43e763f1a64a;1de23b24-eb8c-4d16-a929-297132bf00d2;22009d23-999c-4fa6-bfe7-21395f577236;2315d6e5-144d-4163-9711-f855c759cf8e;235952e6-f748-4408-a8e7-7d980da0e5e6;29848192-7de3-4c0d-a822-1268dcf128b0;5036aa56-e21a-4971-a399-057a77377f4c;5c5210b3-95c6-41f0-945a-3c3567b19b05;5cb7fd36-ae36-409b-af79-9c432e1cf5d9;5f36e697-5a4c-419f-882e-d2d35e829635;64d4bbee-1cc4-409e-b65a-1f2e927cf0d1;6a3c0df3-7ed1-4c69-b963-374f9baccff3;6d0a12dc-3873-4a46-a927-9e5630b569c0;76e29f61-4f1e-4426-9865-b88dea3d0bb4;7d359680-2a9e-426a-a033-6906f51af1b5;7d6bdc28-f334-47f3-8336-c3bebbf57461;82f5292b-b113-4f10-9469-04386fa8e9d4;84718f90-579a-481f-8f39-713e1ed18871;8a2b58d6-ca8e-41e1-837f-928fa46e2097;8b245b30-1ee2-4d4b-8e8e-45d084bb7b6f;8e7c87cc-0479-4aed-9376-7adbe704c9d9;90d1bade-5fc7-4a3e-8d73-99c99906f2e0;91f37277-4aa2-44e0-a1ea-f47e9144c567;96b168d7-a9f9-4b76-ac9a-edda436c0e4e;9720518e-9f70-4811-84ca-69a526d8a904;97330579-8790-c2a8-af59-fe46ce39c58a;9bfe1903-3313-44b7-a27c-fc0775426f94;9c6e2044-c040-403c-bcd6-99ca1e6bba73;9dca0aba-821e-42fd-8353-d62348c098dc;a1e768fd-c28f-4b49-822d-ccc315b4099c;a435da9d-f6e8-4ddc-897d-8cd2bf777b21;a4a56e4e-849d-4928-8d32-528080feb67e;a4d91839-eefa-44dc-8162-eb4f8bd426a2;a5ddc0dc-c176-4705-a9a0-e4ecaf1f5667;ad02c7d6-3c14-4e1e-9ec7-3cc1ede84189;b358c1f1-044c-4dd5-a8e8-ef7800315104;b4219281-d79f-45ac-86dd-82c399415032;c6785b89-6058-0807-1761-66b59416a850;c7b80939-0b2d-4dbc-b921-2081cfd5ae3e;cbc8c074-f080-4489-a5ae-207b5fadeba3;ce537247-2cf3-465a-8150-45aff92a5d00;cec41945-8d64-4793-8784-4c2b8ec37b0f;d7c0dfda-2e49-4a9e-8fbb-cc40217ccc28;dee3f124-bc24-4a37-b2eb-501a66fef064;e3fb04de-2a55-456f-8ecc-ac44dc8e5b5a;e962fb9a-d9fb-49c5-a8b4-0b355b8f829b;e9cef726-267e-4e4f-ac12-d92a8664bf20;f2b2bbd5-720b-4871-9785-a60df6e2e00a;fdd1fa5e-9dbf-4951-a8e9-33d06e05bdba;fddc9630-2f9a-4104-888f-3714587d4fe7;
3022|3F994C51-D9E5-450A-E4BE-EEB12D70D2A7|PULMICORT TURBUHALER is indicated for the maintenance treatment of <annotation cui="C0004096">asthma</annotation> as prophylactic therapy in adult and pediatric patients six years of age or older. It is also indicated for patients requiring oral corticosteroid therapy for <annotation cui="C0004096">asthma</annotation>. Many of those patients may be able to reduce or eliminate their requirement for oral corticosteroids over time. <br> <br> PULMICORT TURBUHALER is NOT indicated for the relief of acute bronchospasm. <br> <br> |3F994C51-D9E5-450A-E4BE-EEB12D70D2A7;
3533|4D705C57-FA98-46E0-97F3-38E1B0ADA76B|Transderm Sc p is indicated in adults for prevention of <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> associated with <annotation cui="C0026603">motion sickness</annotation> and recovery from anesthesia and surgery. The patch should be applied only to skin in the postauricular area. <br> <br> |4D705C57-FA98-46E0-97F3-38E1B0ADA76B;
3750|f9a73185-88de-4d7b-b3c0-bbf231483241| ZYPREXA RELPREVV is available only through a restricted distribution program <i> [see Warnings and Precautions ( 5.2 )]. </i> ZYPREXA RELPREVV must not be dispensed directly to a patient. For a patient to receive treatment, the prescriber, healthcare facility, patient, and pharmacy must all be enrolled in the ZYPREXA RELPREVV Patient Care Program. To enroll, call 1 877 772 9390. <br> <br> <div> <annotation cui="C0036341">Schizophrenia</annotation> </div> ZYPREXA RELPREVV is indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation>. Efficacy was established in two clinical trials in patients with <annotation cui="C0036341">Schizophrenia</annotation> one 8 week trial in adults and one maintenance trial in adults <i> [see Clinical Studies ( 14.1 )] </i> . <br> <br> |f9a73185-88de-4d7b-b3c0-bbf231483241;
4288|f757f066-8288-4d6c-8c5e-2471007c7966| REVATIO is indicated for the treatment of <annotation cui="C0152171">pulmonary arterial hypertension</annotation> (WHO Group I) to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when REVATIO was added to background epoprostenol therapy. <br> <br> Studies establishing effectiveness included predominately patients with NYHA Functional Class II III symptoms and etiologies of <annotation cui="C0152171">primary pulmonary hypertension</annotation> (71%) or pulmonary hypertension associated with connective tissue disease (25%). <br> <br> <i> Limitation of Use </i> <br> <br> The efficacy of REVATIO has not been adequately evaluated in patients taking bosentan concurrently. <br> <br> |f158fe10-d5dc-4432-b2c9-fc665401291b;f757f066-8288-4d6c-8c5e-2471007c7966;
4292|9050af7a-19c6-4670-937a-9445605de995| AZASAN is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active <annotation cui="C0003873">Rheumatoid Arthritis</annotation> to reduce signs and symptoms. <br> <br> <div> <b> Renal Homotransplantation </b> </div> AZASAN is indicated as an adjunct for the prevention of rejection in renal homotransplantation. Experience with over 16,000 transplants shows a 5 year patient survival of 35% to 55%, but this is dependent on donor, match for HLA antigens, anti donor or anti B cell alloantigen antibody, and other variables. The effect of azathioprine on these variables has not been tested in controlled trials. <br> <br> <div> <b> <annotation cui="C0003873">Rheumatoid Arthritis</annotation> </b> </div> AZASAN is indicated for the treatment of active <annotation cui="C0003873">Rheumatoid Arthritis</annotation> (<annotation cui="C0003873">RA</annotation>) to reduce signs and symptoms. Aspirin, non steroidal anti inflammatory drugs and or low dose glucocorticoids may be continued during treatment with AZASAN. The combined use of azathioprine with disease modifying anti rheumatic drugs (DMARDs) has not been studied for either added benefit or unexpected adverse effects. The use of AZASAN with these agents cannot be recommended. <br> <br> |040d010a-b1b2-4db7-905d-8aa7f1bab0cd;0a83e716-b688-433f-ac27-ae95132810cf;0b383e60-5353-4231-af66-b639a3b2f02c;128846a7-18c6-4bc4-b3a0-9aeed0e8b986;49212741-389f-4112-94a9-d14ea2115825;6163F0B3-031B-4552-9299-B3F735762D24;7500c65e-9680-4719-b426-90a7162352c9;82b29384-1243-4b98-82df-3708f5ce642a;9050af7a-19c6-4670-937a-9445605de995;aaa6c540-4c84-48a0-939c-cd423134fa2a;aeab212e-2f56-498d-a286-400ba360a7d2;b1b0fa3e-11c3-46d0-9537-6b372c2a1b56;ceab8e8b-d022-4d0c-a552-cc5782446248;d32704ed-df7f-4111-986d-229ae6f433af;d65bc662-2ae8-4ddb-acc8-f616e72e6140;e385894f-212b-4582-a63a-a0767fd97645;
4346|ec476b11-0b3c-4139-b1eb-a3daa76bc271| <div> Neoplastic Diseases </div> Methotrexate is indicated in the treatment of <annotation cui="C0349557">gestational choriocarcinoma</annotation>, <annotation cui="C0008493">chorioadenoma destruens</annotation> and <annotation cui="C0020217">hydatidiform mole</annotation>. <br> <br> In <annotation cui="C1961102">acute lymphocytic leukemia</annotation>, methotrexate is indicated in the prophylaxis of <annotation cui="C0023418">meningeal leukemia</annotation> and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of <annotation cui="C0023418">meningeal leukemia</annotation>. <br> <br> Methotrexate is used alone or in combination with other anticancer agents in the treatment of <annotation cui="C0006142">breast cancer</annotation>, epidermoid <annotation cui="C0278996">cancers of the head and neck</annotation>, advanced <annotation cui="C0026948">mycosis fungoides</annotation> (<annotation cui="C0079773">cutaneous T cell lymphoma</annotation>), and <annotation cui="C0242379">lung cancer</annotation>, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage <annotation cui="C0024305">non Hodgkin s lymphomas</annotation>. <br> <br> Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse free survival in patients with non metastatic <annotation cui="C0029463">osteosarcoma</annotation> who have undergone surgical resection or amputation for the primary tumor. <br> <br> <div> <annotation cui="C0033860">Psoriasis</annotation> </div> Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling <annotation cui="C0033860">Psoriasis</annotation> that is not adequately responsive to other forms of therapy, <i> but only when the diagnosis has been established, as by biopsy and or after dermatologic consultation. </i> It is important to ensure that a <annotation cui="C0033860">Psoriasis</annotation> flare is not due to an undiagnosed concomitant disease affecting immune responses. <br> <br> <div> <annotation cui="C0003873">Rheumatoid Arthritis</annotation> including Polyarticular Course <annotation cui="C0553662">Juvenile Rheumatoid Arthritis</annotation> </div> Methotrexate is indicated in the management of selected adults with severe, active <annotation cui="C0003873">Rheumatoid Arthritis</annotation> (ACR criteria), or children with active polyarticular course <annotation cui="C0553662">Juvenile Rheumatoid Arthritis</annotation>, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first line therapy including full dose non steroidal anti inflammatory agents (NSAIDs). <br> <br> Aspirin, (NSAIDs), and or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored (see PRECAUTIONS , Drug Interactions ). Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued. <br> <br> |03c66d8c-186a-4923-9a32-07ab07d472ad;18705002-da4b-4562-b0d9-df3d56a16c84;271ff7a2-4904-a0ae-778e-0b5ec8e78d76;27dd39ca-207e-44db-8da1-a0689f0d6b6f;2cb70aa1-f73a-41c8-9a7f-edbcf1a06efd;4767fe9f-aa42-46cd-8101-9df7101f55e1;47bb478d-0e3e-423a-9737-1231152add1d;4a246ce7-c04e-4119-9201-23e5f90152a8;5c960719-19a3-442d-a24b-189b4760ab69;68623ad0-a395-4847-88d4-48413c1f4fcf;6c95e493-f9ec-476e-88e2-e066f197ed8e;70c09984-2b36-424f-8b27-3fd0cd4e833d;78794e3d-f293-4eeb-22ac-8f536d5947eb;8df0780e-0fbd-4ab8-80b0-7a5eaa08ec0a;9b34b1d8-d125-41a2-9f6f-3fab67b573bd;9c4a4784-b063-4c8f-b915-aeb18cb149be;A551FAC0-8738-40B3-9B03-602F794A4B66;b585f621-f6c9-4735-ab61-bd1b401f3df0;d71b1856-99d8-4a9e-9189-f87b6675f80a;d85e0fbd-89ff-4157-abe6-87ce307658be;e942f8db-510f-44d6-acb5-b822196f5e8c;ec476b11-0b3c-4139-b1eb-a3daa76bc271;f13eeab7-f376-4912-aef2-450ea027de6d;
4498|a162fd5b-b2ab-4d45-8861-71b60b92acb4| <b> OXYTROL </b> is a muscarinic antagonist indicated for the treatment of <annotation cui="C0878773">overactive bladder</annotation> with symptoms of urge urinary incontinence, urgency, and frequency. <br> <br> |a162fd5b-b2ab-4d45-8861-71b60b92acb4;
4706|99d6ba1a-1599-48a3-8dbd-a8b06af20fe1| Albuterol sulfate extended release tablets are indicated for the relief of <annotation cui="C0006266">bronchospasm</annotation> in adults and children 6 years of age and older with reversible <annotation cui="C0600260">obstructive airway disease</annotation>. <br> <br> |071e819b-43cd-48f7-b63e-c891936dcfc4;12d06309-0483-48c6-a9f2-b25dcc31db72;133fb50a-68d3-4d1b-a47a-67d07cc48da5;16efdd16-04db-4874-92de-d1de22aee074;1c1f3881-2b68-4bdb-a12f-8134fe8ba961;285a656c-f77f-4e77-b0a8-a0e9c901803f;29d24a6d-f9c1-4300-97c7-fec26bdbc22b;2e439746-9808-4102-a92f-bf6c3f1e3513;2e7c1e97-b8b2-44c0-aeac-18f9142a522b;2ec64742-5802-49f0-bbbe-95580730c0a7;34b6ab14-9ed5-4651-9be6-84685e6aa919;3e95d573-74b2-4b0e-9397-c2cdaf7f41e5;4f0d280b-747e-4232-9d4d-a5c964f0daad;53176c67-ebcd-4b07-a08a-f2df3c541af9;574824f3-51cc-4b94-9c10-e3204d8b19f8;5F06A992-93AE-461D-B605-9962249DAEBA;5daaf067-49a2-4067-afa4-39411c87524f;69ffacaa-c7e5-4016-9e77-79f7d724baad;6f422539-5708-46fd-944d-c88a12fc5ec3;774b1ef9-015e-4e8e-9c52-d305de1ef85e;7fe2669f-ca2a-fd31-e09c-fd2819a8308c;808E2B04-9E84-440A-B00E-2CBE858041DA;8a9b20e4-82e6-4151-9c9d-39aaf2a767e2;8d215fe3-1cf6-4bb3-b005-75f1a9d62235;99d6ba1a-1599-48a3-8dbd-a8b06af20fe1;9bca4410-32a6-4e1e-af7a-23f372e778c2;A000ABB9-92A1-4C84-8932-CD40C476DC00;C07DF5A8-A4ED-4A2F-AC97-BF5F4E55D80D;D476C926-4C3D-4C33-B244-3B58E988ECB3;a3219f37-5605-4e90-ab11-45fbf1e982ee;a9d01507-ae72-4322-93d5-5d857b1b2caa;ab1cbed4-50c4-4769-9947-1927333f278c;b1a801d6-9573-4997-9b4a-aec6db6459ed;b49edc01-1ea6-4f88-883a-bb4bc2bf4b3f;b72742df-1a6b-4483-aff3-3e79db5e015d;becf2107-bbc9-4b7b-87a5-3221ff6fc5cf;cad98bce-bb10-4a04-94e7-d6f55ae60cda;cb4f1002-9372-4fac-aea3-99142f93dd37;cbcc9dbb-5758-4979-b84b-891f3d04f61e;d3544356-e36a-4ce6-8235-cb0531c658ad;d8f090fb-c591-4d6a-98b7-925b0bb17c38;e0d31515-28cf-4041-9007-a5a9b52dc78d;e0ec9932-b2a3-4776-a7e8-2aeded019da4;ecc00500-58b8-491f-80df-dc6c89a08cae;f454947c-6055-474b-bf35-29a379e01aa3;f5c2fe10-c61f-4cbe-bc45-7ab14baa691c;fa5ebedb-069c-4a1e-9a25-b6fa957e6c2b;
490|09f13452-8f90-426e-9687-d30be75db9d7| <div> <annotation cui="C0041671">Attention Deficit Disorders</annotation>, <annotation cui="C0027404">Narcolepsy</annotation> </div> <b> <annotation cui="C0041671">Attention Deficit Disorders</annotation> </b> (previously known as <annotation cui="C1263846">Minimal Brain Dysfunction</annotation> in Children). Other terms being used to describe the behavioral syndrome below include <annotation cui="C1263846">Hyperkinetic Child Syndrome</annotation>, Minimal <annotation cui="C0270611">Brain Damage</annotation>, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. <br> <br> Methylin is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. <br> <br> <div> <b> Special Diagnostic Considerations </b> </div> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. <br> <br> Characteristics commonly reported include chronic history of short attention span, distractibility, emotional lability, impulsivity, and moderate to severe hyperactivity; minor neurological signs and abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics. <br> <br> Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and or primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms. <br> <br> |09f13452-8f90-426e-9687-d30be75db9d7;330e620f-4b7f-4101-91dd-feddb7a823ed;495f0c2b-cd79-4bf3-a381-f7c2a2513366;533fc1a6-b4cf-4d73-9d41-b4fe9fe5c8af;6281ca7c-2aec-4f14-b7e4-82401a701c96;739bbd64-d9e1-4771-967b-a2cd08f4eaf5;a7713510-2a7c-4c34-9fc2-a96fcdd52891;e817377f-bc72-415a-acd2-7136746b2479;f04e8194-7077-42cf-99ee-b61e42a76cf0;f931d3af-c32a-4406-8799-9b097f41594b;
4976|3fa5b81e-81fd-4017-8e87-a4a4c08119fd| ANDRODERM is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. <br> <br> <ol><li> <annotation cui="C0022735">Primary hypogonadism</annotation> <annotation cui="C2931285;C0403818">(congenital or acquired): testicular failure</annotation> due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, <annotation cui="C0022735">Klinefelter Syndrome</annotation>, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (FSH, LH) above the normal range. </li><li> <annotation cui="C0022735">Hypogonadotropic hypogonadism</annotation> (congenital or acquired): idiopathic gonadotropin or luteinizing hormone releasing hormone (LHRH) deficiency or pituitary hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. </li></ol> <b> Important limitations of use </b>   Safety and efficacy of ANDRODERM in males less than 18 years old have not been established [ <i> see Use in Specific Populations (8.4) </i> ]. <br> <br> |053a7300-0bce-11e0-9d16-0002a5d5c51b;3fa5b81e-81fd-4017-8e87-a4a4c08119fd;48f8aa83-e043-41b8-9a20-dbb098045895;6e9cbce2-6e73-400f-9333-421a42afa3ae;77215d87-ad22-4169-bd5f-a453f10b21ef;8677ba5b-8374-46cb-854c-403972e9ddf3;9f2aae1f-898d-4955-be31-678e0cf85395;ac40e05b-6e67-4ff9-a0e8-2e897e71b282;ac47efbe-025b-4688-bcd3-a10a0b012b34;c506aaa3-04f8-4eb1-8dc4-e964cdd08e7f;d466910c-9a76-44e8-8759-4717ec2c591f;
558|0DD5FD1C-AB03-4860-87D6-4A95DF6E7B7A|Diovan is indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with other antihypertensive agents. <br> <br> |0DD5FD1C-AB03-4860-87D6-4A95DF6E7B7A;
5610|c56b20d8-eeee-4d87-94a1-ae186f9b550e| COVERA HS is indicated for the management of <annotation cui="C0020538">hypertension</annotation> and <annotation cui="C0002962">angina</annotation>. <br> <br> |c56b20d8-eeee-4d87-94a1-ae186f9b550e;
6071|05506250-1641-4b64-ac0c-69f96c46a773| <div> Treatment of <annotation cui="C0035258">Restless Legs Syndrome</annotation> </div> HORIZANT (gabapentin enacarbil) Extended Release Tablets are indicated for the treatment of moderate to severe primary <annotation cui="C0035258">Restless Legs Syndrome</annotation> (<annotation cui="C0035258">RLS</annotation>) in adults. <br> <br> HORIZANT is not recommended for patients who are required to sleep during the daytime and remain awake at night. <br> <br> <div> Management of <annotation cui="C0032768">Postherpetic Neuralgia</annotation> </div> HORIZANT ( gabapentin enacarbil ) Extended Release Tablets are indicated for the management of <annotation cui="C0032768">Postherpetic Neuralgia</annotation> (<annotation cui="C0032768">PHN</annotation>) in adults. <br> <br> |05506250-1641-4b64-ac0c-69f96c46a773;
6412|7ff89589-149c-4007-8144-5f60131b8c33| <ol><li> For the treatment of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> not responsive to non narcotic analgesics. </li><li> For detoxification treatment of opioid <annotation cui="C0085281">addiction</annotation> (heroin or other morphine like drugs). </li><li> For maintenance treatment of opioid <annotation cui="C0085281">addiction</annotation> (heroin or other morphine like drugs), in conjunction with appropriate social and medical services. </li></ol> NOTE <br> <br> Outpatient maintenance and outpatient detoxification treatment may be provided only by Opioid Treatment Programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid <annotation cui="C0085281">addiction</annotation> who is hospitalized for conditions other than opioid <annotation cui="C0085281">addiction</annotation> and who requires temporary maintenance during the critical period of his her stay, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone. <br> <br> |092d78eb-6423-495c-bf0d-e6532bea7138;0b72a120-ca4e-4b90-7d89-52967a39adb3;20127592-3a20-e280-2c70-f3d4e1ce009f;3c926b78-999e-4d26-9498-7f1bcaf0b992;4a3b2bc3-d837-4ca9-aee1-452633b6a06b;544483e6-6f9d-4371-9e93-313e54e0ea05;5E70E915-B946-4A80-BCC6-3F49BC30F2F5;7ff89589-149c-4007-8144-5f60131b8c33;8C363F90-C378-48AE-ABBC-AEB25C9BF5CB;9bbe219f-3bf1-44f4-a709-cd108c4fa9ef;C54BAAEE-8EA4-45F5-A5C8-BB84CF86832F;DA0A54C6-8B53-4774-8C40-E615AC8D804D;a36705c4-867f-41f1-94c9-78b8b31836ce;cf10ec82-1f41-45c0-b438-5ade38b5625a;d5bd3e97-b3f6-4bc2-9fb7-02921be35cdb;ec41ab86-a948-44e4-b21c-c65a22cdf294;ec694185-fcb9-49d9-aaf5-e88861346c7c;f2057290-4286-4581-9711-50a0a834e228;
10|aac77fa1-04ad-497e-bbed-a21f538064c3|Felodipine extended release tablets are indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. <br> <br> Felodipine extended release tablets may be used alone or concomitantly with other antihypertensive agents. |2aad9cdf-6431-4661-5cb4-f69e735f47e4;2e4298cf-02e9-49c7-9803-887161e1989a;33de7317-dbe6-4660-9d7e-2babc9c9f657;4bfc1982-6fe6-4d6d-99f2-f2d1cd708540;4c5e4905-ddc6-4579-aea0-994d03dd52b3;60fb803e-ccf7-46f2-b506-e157ce440f87;71dde844-9dd0-406c-943e-9995a28c43c7;aac77fa1-04ad-497e-bbed-a21f538064c3;b4d6ab4c-6bc9-42d4-acf2-9fb0e871fd8c;b951455c-c235-4e23-9e21-08672d108726;f94ae052-5d59-4750-aab7-1fdb989503aa;
1000|4999bbd9-44ed-4749-9730-be2337bdf490| To reduce the development of drug resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> Doxycycline is indicated for the treatment of the following infections <br> <br> <annotation cui="C0035793">Rocky mountain spotted fever</annotation>, <annotation cui="C0041471">typhus fever</annotation> and the <annotation cui="C0041471">typhus</annotation> group, <annotation cui="C0034362">Q fever</annotation>, <annotation cui="C0035597">rickettsialpox</annotation>, and <annotation cui="C0241893">tick fevers</annotation> caused by <i> Rickettsiae </i> . <br> <annotation cui="C0035243">Respiratory tract infections</annotation> caused by <i> Mycoplasma pneumoniae </i> . <br> <annotation cui="C0024286">Lymphogranuloma venereum</annotation> caused by <i> Chlamydia trachomatis </i> . <br> <annotation cui="C0029291">Psittacosis</annotation> (<annotation cui="C0029291">ornithosis</annotation>) caused by <i> Chlamydia psittaci </i> . <br> <annotation cui="C0040592">Trachoma</annotation> caused by <i> Chlamydia trachomatis </i> , although the infectious agent is not always eliminated as judged by immunofluorescence. <br> Inclusion <annotation cui="C0009770">conjunctivitis caused by <i> Chlamydia</annotation> trachomatis </i> . <br> Uncomplicated urethral, endocervical or rectal infections in adults caused by <i> Chlamydia trachomatis </i> . <br> <annotation cui="C0311389">Nongonococcal urethritis</annotation> caused by <i> Ureaplasma urealyticum </i> . <br> <annotation cui="C0035021">Relapsing fever</annotation> due to <i> Borrelia recurrentis </i> . <br> <br> Doxycycline is also indicated for the treatment of infections caused by the following gram negative microorganisms <br> <br> <annotation cui="C0007947">Chancroid</annotation> caused by <i> Haemophilus ducreyi </i> . <br> <annotation cui="C0032064">Plague</annotation> due to <i> Yersinia pestis </i> (formerly <i> Pasteurella pestis </i> ). <br> <annotation cui="C0041351">Tularemia</annotation> due to <i> Francisella tularensis </i> (formerly <i> Pasteurella tularensis </i> ). <br> <annotation cui="C0008354">Cholera</annotation> caused by <i> Vibrio cholerae </i> (formerly <i> Vibrio comma </i> ). <br> <annotation cui="C0006818">Campylobacter fetus infections</annotation> caused by <i> Campylobacter fetus </i> (formerly <i> Vibrio fetus </i> ). <br> <annotation cui="C0006309">Brucellosis</annotation> due to <i> Brucella </i> species (in conjunction with streptomycin). <br> <annotation cui="C0004771">Bartonellosis</annotation> due to <i> Bartonella bacilliformis </i> . <br> <annotation cui="C0018190">Granuloma inguinale</annotation> caused by <i> Calymmatobacterium granulomatis </i> . <br> <br> Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. <br> <br> Doxycycline is indicated for treatment of infections caused by the following gram negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug <br> <br> <i> Escherichia coli </i> <br> <i> Enterobacter aerogenes </i> (formerly <i> Aerobacter aerogenes </i> ) <br> <i> Shigella </i> species <br> <i> Acinetobacter </i> species (formerly <i> Mima </i> species and <i> Herellea </i> species) <br> <annotation cui="C0035243">Respiratory tract infections</annotation> caused by <i> Haemophilus influenzae </i> . <br> <annotation cui="C0035243;C0042029">Respiratory tract and urinary tract infections</annotation> caused by <i> Klebsiella </i> species. <br> <br> Doxycycline is indicated for treatment of infections caused by the following gram positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug <br> <br> <annotation cui="C0041912">Upper respiratory infections</annotation> caused by <i> Streptococcus pneumoniae </i> (formerly <i> Diplococcus pneumoniae </i> ). <br> <br> <annotation cui="C0037278">Skin and skin structure infections</annotation> caused by <i> Staphylococcus aureus </i> . <br> <br> <annotation cui="C0003175">Anthrax</annotation> due to <i> Bacillus anthracis </i> , including <annotation cui="C0155866">inhalational anthrax</annotation> (post exposure) to reduce the incidence or progression of disease following exposure to aerosolized <i> Bacillus anthracis </i> . <br> <br> Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. <br> <br> When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections <br> <br> Uncomplicated <annotation cui="C0018081">gonorrhea</annotation> caused by <i> Neisseria gonorrhoeae </i> . <br> <annotation cui="C0039128">Syphilis</annotation> caused by <i> Treponema pallidum </i> . <br> <annotation cui="C0043388">Yaws</annotation> caused by <i> Treponema pertenue </i> . <br> <annotation cui="C0023860">Listeriosis</annotation> due to <i> Listeria monocytogenes </i> . <br> <annotation cui="C0017575">Vincent's infection</annotation> caused by <i> Fusobacterium fusiforme </i> . <br> <annotation cui="C0001261">Actinomycosis</annotation> caused by <i> Actinomyces israelii </i> . <br> Infections caused by <i> Clostridium </i> species. <br> <br> In <annotation cui="C0152499">acute intestinal amebiasis</annotation>, doxycycline may be a useful adjunct to amebicides. <br> <br> In severe <annotation cui="C0001144">acne</annotation>, doxycycline may be useful adjunctive therapy. <br> <br> |08c07b97-137a-437f-b6c8-f83e301ef030;091c71be-dd6c-4f7a-9af0-3222686345a5;0c01acd6-123b-43f3-b639-b039e83baa27;0f342e3a-189f-41ec-9583-1733d2437ad2;120b912d-87d4-4463-ae46-5e48ca33db49;1292FA83-E2A1-4FDA-B0DD-CCF763265FE1;14300ca2-d99d-40c6-a771-2aeceb344dce;15d40152-f9f5-4ca0-ae93-a57911baadf1;19b19a55-972c-47c1-b031-cad69c624fa1;205c4672-2006-4999-9897-33079fefa3a1;214a9cfe-a522-4022-81d4-e59f447401fe;2342cfb7-6ac2-471e-8b69-44d4e9bfe765;2a3b79e8-f14c-4b44-9d3e-3c92a82269bd;2bcde264-5f6f-47f6-ae2e-1b7010deacf7;33C9CD03-A005-476A-9A57-50BFE913674A;34878e92-c843-4cce-812e-a82cbb96df2b;369cc496-f093-4745-b4dc-c38ef0b9da5c;37045a6a-defa-4041-9bc1-18784f49e3f1;37efefc3-cc45-49d1-9dfd-c47d6e6becd5;3d9aa97a-665a-44d4-990f-3d1a54c04174;407d9920-7110-4299-b0fa-36661070f076;41fd9969-059c-47a6-a424-4382804407c0;422811d6-915c-41a5-be70-212e65d6f647;426a574a-a832-4723-beb1-4e869b6539af;495c671e-6eba-4c9b-a5b2-229520a77d68;4999bbd9-44ed-4749-9730-be2337bdf490;4ae0ff63-c577-478e-9fa0-b7c22a8e7de4;4c6791a0-e7ef-4645-a460-8f9a13f3d166;4d0ba36c-0a4a-4faf-9f1d-79e5273808d5;4ec4c8ca-ce83-4948-8626-21eb82ae5c19;500be4f9-1ce7-4a40-b6b1-d0b12f0856dd;53eb28f5-41c5-4470-8878-1c5085c27166;5878bfaf-66b2-4a78-b6b0-f6405d44ebef;5fbef611-39db-4a8e-8f46-090c95a27042;60e29e4c-7512-4aba-95a9-be987129ad63;6adc5bb0-69a5-4c9f-b569-1eee446afcd2;706e50a5-1998-46ab-a635-402fc5489865;78f1e08f-0a80-4ab0-a39a-640ecf775620;7e29a5ba-57d1-46c5-a93f-ba6b3d6b3327;8224b9c5-5c4b-4dda-bc58-47b6604c2884;829dbd3d-5c2b-47b8-96a5-423af78c93b9;86e1102c-47bc-4f27-a4d0-7261b3deba63;87fce959-ba71-46b8-911d-2004658196ce;96424d21-3fa4-4a32-8b98-fd593748f236;9a3ab62e-97c0-49fa-87ea-f33214f2ea5a;9b52e0a7-f024-4d8a-a59e-374946e60b44;9d9f5a4d-e3d2-4adb-bce0-ed2aab9a368e;9f6c6dff-befc-4e1c-8a62-7c783c23fb3a;a121fa30-2aaf-4dde-a08e-a67381333751;a569ba80-ffea-40b2-9fbe-a42810b1fccb;a65325a7-ae0a-4704-99c4-a3a2e4e1dcf2;b34eb07b-d8a7-4762-a457-9d64dd86b205;b3fa8d62-cec4-416b-b979-56a945423ae1;b5952252-875f-479c-8864-89f18c974fb1;bf667704-f439-4e8a-a4a5-dd150462a125;c4aae81f-0219-450f-aa60-953964f74172;c6d4e685-d1b3-4e81-b6f5-47db218ed117;c84c9328-b364-467c-84e1-d87af1cd1887;c96d3986-9d92-4ec4-a319-a50aeb2f4fe7;cabbc39d-0fb6-4d0e-8966-7e60f02cc3c7;cfb4ae70-0bd4-4585-bbaf-507b18437866;d583b8b9-e5c7-45d6-8fc1-d51f51a16181;d6f98d3c-5a20-4cbf-9a9c-abef10b9e465;d95bdf63-69a2-47b9-b909-97c74b6d7731;e358437f-7c6b-4e49-957d-d7f5b8f4b8f5;e563fe71-0316-4caf-9b50-59e2c5e2596e;ef019728-72a2-4152-97e9-471053776837;f9b9ca8a-5cfc-446a-8330-36cf96625a57;fac9b9c0-7ea2-4986-9552-dc46a32b7c99;fafe6400-b7c9-485c-b76e-0b85b29db801;fef7f0c9-48a1-46b4-a19c-c23d272a8ca2;
10000|ba02a95d-d82e-4a13-90b4-a219abc0249a| Desipramine hydrochloride tablets, USP are indicated for the treatment of <annotation cui="C0011570">depression</annotation>. <br> <br> |3433c754-cc2e-4e72-bd82-16ed4af3144d;711d8455-9ce1-45b4-875d-007b2e0b27ec;7500ac1b-a1ca-46ed-8f4e-5998310c676e;7ec5f73f-32b6-48c3-b16e-891d06edf6eb;a8450022-7caf-489e-a6c7-2415fd092032;ba02a95d-d82e-4a13-90b4-a219abc0249a;be70fddf-644a-44ad-bfdf-0914dd12b1af;c7cdd04c-6c34-4780-8b21-a6f9fc74cf46;f3127fff-2943-424d-8b8b-80aa320a2d07;
10003|3a3344dc-9cc8-41da-859e-295d053597c1| <div> <b> <annotation cui="C0014544">Epilepsy</annotation> </b> </div> Carbamazepine extended release tablets, USP are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of Carbamazepine as an anticonvulsant was derived from active drug controlled studies that enrolled patients with the following <annotation cui="C0036572">seizure</annotation> types <br> <br> <ol><li> <annotation cui="C0751495">Partial seizures</annotation> with complex symptomatology (psychomotor, temporal lobe). Patients with these <annotation cui="C0036572">seizures</annotation> appear to show greater improvement than those with other types. </li><li> Generalized tonic clonic <annotation cui="C0036572">seizures</annotation> (grand mal). </li><li> Mixed <annotation cui="C0036572">seizure</annotation> patterns which include the above, or other partial or <annotation cui="C0234533">generalized seizures</annotation>. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). </li></ol> <div> <b> <annotation cui="C0040997">Trigeminal Neuralgia</annotation> </b> </div> Carbamazepine extended release tablets, USP are indicated in the treatment of the <annotation cui="C0030193">pain</annotation> associated with true <annotation cui="C0040997">Trigeminal Neuralgia</annotation>. <br> <br> Beneficial results have also been reported in <annotation cui="C0154731">glossopharyngeal neuralgia</annotation>. <br> <br> This drug is not a simple analgesic and should not be used for the relief of trivial aches or <annotation cui="C0030193">pains</annotation>. <br> <br> |00fe4618-6b16-4431-9c07-495872012eaf;0526a054-3eda-49b4-b390-7d5d16e30af8;157f67bd-74f0-4d68-9058-8fa707c564be;232ef732-ee6d-4ac7-8e78-c619b611fbbe;25cca2b1-9020-4d8a-bc22-b8063e57f9e1;27bea47a-664a-44e3-8063-2d9eac0a2a50;2a8c7366-ce89-47ce-8123-96f26812fca0;32bbe864-7374-44da-8c6e-e733f0648243;3a3344dc-9cc8-41da-859e-295d053597c1;536811ab-308b-4866-9185-9e4149483512;6903e7ef-8b5c-4b64-a87d-62f1f102bc75;6fca30bd-28e5-4e32-b194-97c84966900d;743d1398-942d-4d2f-9547-79c395238447;7a1e523a-b377-43dc-b231-7591c4c888ea;7f9ed987-5e34-4536-a22f-4898c9797e61;80fe34a5-629f-40ee-9a45-3711feaabac2;89332a92-cbf8-bf1b-694f-8d03e8f057a0;8d409411-aa9f-4f3a-a52c-fbcb0c3ec053;8e06995c-26c9-4ef3-9421-16a2360db628;8e9e18aa-6c9d-4172-87b4-4bec6f485cb9;97e6e175-75e8-437b-b457-ddb1ae4e857d;988cce8b-eb9f-4bf7-85bc-a736575d98b1;99e20867-a5eb-4474-b846-619ee45f40b8;9de2e32b-2835-42a2-830d-297852e3e72a;a3360ae2-3ead-40bc-a967-2abecc9f9b7c;a3f9a1e3-133e-4a97-be1e-d92deef34ddc;b1c25d7b-adab-45a2-9369-4a49c69ff04e;bc03e499-5bac-4293-bff4-6864153a624d;bf0d012f-da14-8ce3-d74f-56172cddebc5;bf2e0dfa-d6ca-4961-9627-b666266f58f1;bfd63965-56e6-4af7-b7ef-45a5105d4d35;c13bc0b8-7900-4ef4-98ed-e1315a08d95d;c758cdd7-824a-4e13-9f98-5f1fe0fe7f9b;ccb97a82-315f-4a23-b98f-37d3a63ac381;ce5aec7a-e161-46bf-8fc0-afb41689e59a;d0a2b6f1-df0e-4b62-b340-75e96d8030a7;dda719fe-21a2-4547-b2be-f7f712008d19;e5160019-ccdb-46d5-8510-6ea7084ca854;e7c1ba46-75b8-4ce4-85e8-c4f4644ca31a;e91f9de3-3fdd-0a6b-71ce-53a2cc142816;ece26b17-d6bf-4b0c-b9b2-17a58aae95a1;ee15d911-73c7-4bc6-96f2-089a8aa64e18;f38feadf-3fa4-430c-99ed-374023f8132c;fbca2152-0022-47a5-a1ea-58950b45bcbf;fbf67fc8-8d29-4ae2-a533-75461754c5b1;fd97d064-4c55-481d-b7ef-cfb948fc75b4;
10021|dc6a2d33-aa04-4a04-9cde-901b744d24ca| <div> <annotation cui="C0242698">Left Ventricular Dysfunction</annotation> Following <annotation cui="C0027051">Myocardial Infarction</annotation> </div> Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a <annotation cui="C0027051">Myocardial Infarction</annotation> and have a left ventricular ejection fraction of 40% (with or without symptomatic <annotation cui="C0018802">heart failure</annotation>) [see Clinical Studies (14.1)]. <br> <br> <div> <annotation cui="C0020538">Hypertension</annotation> </div> Carvedilol tablets are indicated for the management of <annotation cui="C0085580">essential hypertension</annotation> [see Clinical Studies (14.2)]. It can be used alone or in combination with other antihypertensive agents, especially thiazide type diuretics [see Drug Interactions (7.2)]. <br> <br> |07d77acd-a87c-4d35-8c88-36ef374e0967;0b802a9c-332f-4ea8-bb34-75c677264654;0db9d532-d62c-46c5-b4b9-855d78d01314;1e453c21-a8a8-dc54-5591-74c972d41727;264a3dc1-596c-43ab-a20c-65c80ab22f2a;29082d8c-bbde-4620-924f-02dcf1764919;2ba6d893-ae2a-4535-b904-667d206f93af;354d1689-53f9-42d3-8308-08b6d9a04404;4400de87-e9c4-4a0e-9275-1715a12ab46d;473d1684-944c-4a65-aef4-6379f97a0178;506005f3-d79d-4de1-8bd2-71ade18b8d47;577b23c1-bd6d-41a4-a7c5-ebe7b92e37bd;6686069e-7e43-4963-8a66-961e0b36d84d;68c275e8-992a-4520-8065-ab6d615d89cc;7cc14b86-0833-4c3c-91f3-7963d7052fd5;7d485d38-5d43-4a54-bc63-82734035c66a;7ef4022c-1176-44a3-9943-04a289331de3;80e0016f-e77e-4eec-876e-baff9e640de2;81bc612d-5674-45b9-a1f5-2cb4fa625747;8da1445a-1d21-4c4f-aa55-da9957bf8cb1;9bab0a6b-8ed4-46e4-8326-2f9e3c87559b;9bb93e9a-1bac-4a2e-a5fe-16197e129367;A6EB861C-085E-442A-8E71-722587493D5D;ad96f237-1e3a-45ff-9c47-fed3544dc943;b23021d4-c00a-e0ef-eb93-1dc824ae56ca;b4647b22-9a70-4259-a8f6-fac0ce1ac5c5;b92976c0-4529-3b96-d35f-1d4757d4bf61;bbf4dd22-f1e3-4101-89fb-31f5df3bfbc4;c0787d56-11fc-4643-83ac-1b17bb2a9817;c4a21f67-7812-4634-beba-f8e85c63c5f2;c57982f2-c7da-488a-7ea9-b9609439ac68;c5b907f8-84a0-5fb2-e7ec-4c82246195f5;cee9bce2-add0-48e8-80c6-ea2183ee7698;cf777244-1f06-439a-a9e1-19da761f193d;d068b6a4-63c0-40fc-b3a3-7145bde7ed72;d5a28e57-7304-4e23-98a3-bae14d8ed25f;d7736758-ad06-4ddb-bdf0-eda27a0acae5;da8a670b-a9ce-445f-af31-7588c6c67e29;da8b8c20-0130-4aa9-924d-4a4f28c3f767;dc6a2d33-aa04-4a04-9cde-901b744d24ca;dd818d91-cddf-474f-aa68-43e416da8b8e;e1f0823b-4226-4773-be2b-235a28b5ae86;e5026c19-733f-41a4-a0c9-e48a9a742460;e5319aa4-ed6a-4bcc-bc72-b692891a6dae;e843534e-47a2-46e3-92bb-d079467be606;fbbab179-d1eb-48a6-8e2b-1c71606fe50d;fdb12700-116b-4203-8d74-9a94b9401fe6;
10023|ab3a8a2d-714a-4beb-af8a-99bc3ac3ebbe|METROGEL is indicated for the topical treatment of inflammatory lesions of <annotation cui="C0035854">rosacea</annotation>. <br> |2b2a552d-ea3c-472c-bf61-f4d878cc4874;ab3a8a2d-714a-4beb-af8a-99bc3ac3ebbe;
10029|649d285c-8fcb-48dd-aa5e-2f34128102f5|Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY  lactamase negative) strains of the designated microorganisms in the conditions listed below <br> <br> <b> <annotation cui="C0699744;C0555970;C0031350">Infections of the ear, nose, and throat</annotation>   </b> due to <i> Streptococcus </i> spp. (   and  hemolytic strains only), <i> pneumoniae </i> , <i> Staphylococcus </i> spp., or <i> influenzae. </i> <br> <br> <b> <annotation cui="C1279247">Infections of the genitourinary tract</annotation>   </b> due to <i> coli, P. mirabilis, </i> or <i> faecalis. </i> <br> <br> <b> <annotation cui="C0037278">Infections of the skin</annotation> and skin structure </b>   due to <i> Streptococcus </i> spp. (   and  hemolytic strains only), <i> Staphylococcus </i> spp., or <i> coli. </i> <br> <br> <b> <annotation cui="C0149725">Infections of the lower respiratory tract</annotation> </b>  due to <i> Streptococcus </i> spp. (   and  hemolytic strains only), <i> S </i> . <i> pneumoniae, Staphylococcus </i> spp., or <i> influenzae </i> . <br> <br> <b> <annotation cui="C0018081">Gonorrhea</annotation>, acute uncomplicated (ano genital and urethral infections) </b>   due to <i> gonorrhoeae </i> (males and females). <br> <br> <i> pylori </i> eradication to reduce the risk of <annotation cui="C0013295">duodenal ulcer</annotation> recurrence <br> <br> <b> Triple Therapy </b> Amoxicillin clarithromycin lansoprazole <br> <br> Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with <i> pylori </i> infection and <annotation cui="C0013295">duodenal ulcer disease</annotation> (active or 1 year history of a <annotation cui="C0013295">duodenal ulcer</annotation>) to eradicate <i> pylori. </i> Eradication of <i> pylori </i> has been shown to reduce the risk of <annotation cui="C0013295">duodenal ulcer</annotation> recurrence. (See <b> CLINICAL STUDIES </b> and <b> DOSAGE AND ADMINISTRATION </b> .) <br> <br> <b> Dual Therapy </b> Amoxicillin lansoprazole <br> <br> Amoxicillin, in combination with lansoprazole delayed release capsules as dual therapy, is indicated for the treatment of patients with <i> pylori </i> infection and <annotation cui="C0013295">duodenal ulcer disease</annotation> (active or 1 year history of a <annotation cui="C0013295">duodenal ulcer</annotation>) <b> who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. </b> (See the clarithromycin package insert, <b> MICROBIOLOGY </b> .) Eradication of <i> pylori </i> has been shown to reduce the risk of <annotation cui="C0013295">duodenal ulcer</annotation> recurrence. (See <b> CLINICAL STUDIES </b> and <b> DOSAGE AND ADMINISTRATION </b> .) <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of amoxicillin capsules, amoxicillin tablets, amoxicillin tablets (chewable) and amoxicillin for oral suspension and other antibacterial drugs, amoxicillin capsules, amoxicillin tablets, amoxicillin tablets (chewable) and amoxicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> Indicated surgical procedures should be performed. <br> <br> |01484f7c-24c9-4c0a-8ae5-c483cb7e6aaa;015f1664-8b4c-4cb6-8a01-aba440f2b452;09660a95-a7b3-4d1f-832c-a4fa7a5b7ddd;0dbb3a86-a601-4d40-ab44-01901660181a;13bd4214-9b7f-425b-af5f-fc1ddc678230;1d480bbc-9716-427e-a558-e6dd48a90edf;20c86622-85b7-4827-a317-57aee79dfe57;269fa5f9-974e-4cea-8f6b-a2913a6dc1cb;2b55a812-a862-4f35-a6ce-25cff716e63d;2d526d15-6014-4389-8dc9-20ea8e512cc2;31c12a11-7bce-4457-b413-feaad0da9c49;3599277f-1f6e-43f0-9e09-0ec2ec5a0df1;3ac57b9d-0b78-485b-acbd-4b1f9328204a;3afc3097-a757-49a0-aaec-85ac267aabb1;3cacd754-73f4-496e-a529-9ca39fa6692d;3e1df272-caf6-4247-8ccf-4e37bfe67e0a;432287dc-6d16-4a64-bc5f-ec1327104f7e;4ba96ba5-7e7c-4225-981f-593964c61a0c;4c0f348a-a65d-409c-8668-207c82a5e3cb;4d68df6a-6e96-47a4-abeb-6afc7cc84bbc;4fb7837e-964c-4d38-a3a5-b384b1bd6e08;520b05ef-420e-47d5-9491-63a7ba9e5423;5d22f9b8-3022-42e8-a427-fc43c589c92c;610ead3d-a415-4762-8c3c-91c87665f138;6136dcbf-9bde-4b5b-82b3-d7cb8bdb817b;649d285c-8fcb-48dd-aa5e-2f34128102f5;6dcd320a-2ba4-4dad-8173-1cef72b4c816;70e213e7-473a-464c-8e58-26bf921d5c40;768ba0a1-7b08-4b16-8083-b314168650b8;78cabf7c-f342-4285-bc5a-9f24789d44ed;79a0421c-eeaf-40fd-a3b5-fd7d941ae530;7e3a4517-1934-4e03-b96b-4ad65ab076c5;843f6053-63d9-47d2-81f1-b6aa78a7c20c;878f5bb7-1fda-4ac9-8190-c7e5571993e2;8865ccfb-6ab7-45f2-807f-11c9aa681836;88e76bdd-39f2-48c4-91ca-609511afd382;8d53dc31-a51f-4326-a6cd-5aa6aebda3ed;8da47758-aa37-4eed-bd37-8a48914c21cf;9327ca14-edb1-4542-89a4-377a790de06d;98e9274c-c02e-44d9-8cc5-17536ef03a77;99103779-6d2f-4e4b-9b7f-0b24d7c6bf4e;9963c7b5-e2f5-40d8-b976-61fb453d17f3;9a8cd40a-6fb6-46b6-b692-da8669097e02;9ea9486c-822a-a38b-7eed-8d3740ee502b;a06f4905-2c1b-42ae-9c47-5d95e532c2a2;a0f5c480-7ada-4593-83c4-4cf15eaabd7d;afbcbf79-e7cd-4615-a999-9941573882b5;b03d1cc5-6142-474b-9670-a364393d4142;b18eca1d-0133-4266-829b-9a0bd925c4f2;b23637eb-16ff-4e92-96e5-d6efd5cc4ee8;b41ecd6b-4c54-44c8-aa3f-1868faad07c6;b44a012a-d4d3-4383-8770-ce37367704ee;be65d31a-87c1-4f37-a55d-7395bfe3642a;c48c8351-ee27-47c6-a88b-c642c6baf5e1;c5774511-bee9-4ebb-a9aa-9e74de8d840e;cdad645a-c939-496e-973c-d1a22ffe6b29;d42fbeff-dcca-447c-83e2-c59690b7dc1a;d46f1091-33dc-4f8f-9c34-75dcfedb4b4c;daa89601-3e7c-4d9e-9bed-fd6abf20348e;de8990a6-f3b6-478f-acbe-eda961b6da4b;e4e9a872-2bda-4e9e-9803-eb4782489978;e82de7ec-0ca3-4afb-aa09-5ec5e7895b9d;ee3875c6-5c49-4386-8ad2-5fe3208ed9e9;ef7e6645-e771-4441-8bc4-07547cf30e22;f0b9c446-37c1-4e0a-9e39-eb7fabaf7c7b;f180e621-7bc1-4581-b34f-04c38a47d219;f1bf6b2f-d00a-4c3c-a55c-46bb0ad6d5c6;f27aa99b-2b77-48d6-8af4-3ae26c04d5b6;f884225c-7845-4df1-ba35-dc53010ed0b0;
10036|cd4d1aeb-debf-458a-83c1-fa098d4d3415| <b> <annotation cui="C0030567">Parkinson's Disease</annotation> </b> <br> Ropinirole Hydrochloride Tablets are indicated for the treatment of the signs and symptoms of <annotation cui="C0030567">idiopathic Parkinson's disease</annotation>. <br> The effectiveness of Ropinirole Hydrochloride Tablets were demonstrated in randomized, controlled trials in patients with early <annotation cui="C0030567">Parkinson's disease</annotation> who were not receiving concomitant L dopa therapy as well as in patients with advanced disease on concomitant L dopa (see CLINICAL PHARMACOLOGY Clinical Trials ). <b> <br> </b> <br> <br> <br> <b> <annotation cui="C0035258">Restless Legs Syndrome</annotation> </b> <br> Ropinirole Hydrochloride Tablets are indicated for the treatment of moderate to severe primary <annotation cui="C0035258">Restless Legs Syndrome</annotation> (<annotation cui="C0035258">RLS</annotation>). <br> <br> Key diagnostic criteria for <annotation cui="C0035258">RLS</annotation> are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with moderate to severe <annotation cui="C0035258">RLS</annotation>. <br> <br> |0fa94d3d-ec03-4eb7-93b2-8e1d7ff6c3e0;1669653f-d7bd-453b-8d56-997a637f913a;1c1b2587-3d65-4d21-b913-9a3918435b8e;1cb783ed-5496-4b4d-995b-e81157f9f8d1;414cd6c4-4926-4dfc-93c4-f04f4b7eeac3;5525c364-3574-4029-89dc-1efc6d85c03c;6f7fc849-8a38-47a1-bc39-54801a86416c;7734ef0b-584f-42dd-a8b5-adbdf4e4df93;85971b31-6f7d-421c-bf3c-5b33f3c1e781;88c5b939-a658-4972-b849-e5c00a447b53;9682167e-7f40-40c5-95c2-dccb054f826f;9a8eb66e-21fe-468d-aeec-44a8aa4c7869;a543b4fb-186a-40f4-8c88-861b7db2b3e9;bee2269a-22e8-413f-99bb-ea64169b4491;c3b91380-1a23-4b44-bd1d-4888e43fe8b9;cd4d1aeb-debf-458a-83c1-fa098d4d3415;d52d231b-f407-f6a0-466e-0f714244010d;de0bb94f-4fd8-4f27-5ba6-6f392dd5160f;e05b026c-c46f-473a-b23c-56b463f95df1;f1b2850e-097b-4a59-9c65-7cde77f30894;f5ce07b9-ad0d-4b72-9daf-8662775af093;
10041|5043d03e-3c9d-4c96-b48d-187f02a1d27c| Metformin hydrochloride tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with <annotation cui="C0011860">type 2 diabetes mellitus</annotation>. <br> <br> Metformin hydrochloride extended release tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with <annotation cui="C0011860">type 2 diabetes mellitus</annotation>. <br> <br> |0115de44-8e34-44f7-a31f-902de0b98088;01727812-61c5-4ca0-904f-587a8da87a32;05d4df4b-dfe8-4828-b423-a3d4f2c4114a;060c694c-804c-4d32-a6d6-d6575be7ac2f;08acf5ac-bd95-46db-b183-efb3203bf6a4;0d052e09-5e70-40ef-b4ff-c6833f3284f0;0e8b5d49-bc5f-48a1-b353-34056900e852;0ff1ba75-3c86-4baf-a6b1-1bb883839866;160a9256-66ab-4ffd-8aed-30d23087b6a4;24cde2c2-dac7-4cdb-8329-c2f88ebd4f98;29d05ca3-0ca0-4019-9b6c-6ecb86f903f6;2a84c550-aed8-4058-961f-351a5e4cf7a1;2b01a50f-e517-4f6c-bee5-9925ff029e55;31f8110b-fc54-4d57-a07c-8528ca5e6074;3286eb86-9650-44b3-8353-847b4c803174;33347f3b-c347-4a52-b788-4e67894edc51;33ea2845-df5d-4e6d-8168-d1f8a876c94f;37a431ab-466c-4f8b-b06d-826d35fd3710;3814cfed-029f-4231-bba3-89b2b4e01392;3a1c46e5-8165-4b39-bf5f-a871805f1d3f;3cfc5665-ec57-475b-a942-8bc9197b88f0;416a6446-81cc-43af-8d9c-788c91a2a1d3;41a8bb80-7b0b-476c-8134-5d161c3239c8;45b983e3-b24d-4000-85e4-0441be9683be;495738b9-2511-446b-833c-164c0119035b;4a0166c7-7097-4e4a-9036-6c9a60d08fc6;4a0fec1d-d351-4f98-81e9-1550f7506284;4ac6d01a-af26-44e7-ae2e-3618de0080aa;4b0d0379-513c-4a7e-9b68-a929f75f1f81;4f70f907-08d5-4c2e-a4be-32c6124faa7b;5043d03e-3c9d-4c96-b48d-187f02a1d27c;508248c9-fc88-4be0-b509-591001be04e8;5270d04e-f4f7-1305-1b60-d7eec0a042f9;542c7f49-abdc-4937-bca2-f51c553c5286;548d0e95-6116-47bc-ab35-2eda2a163875;56d13a1c-b289-4528-b23c-60f5427b4552;5742fd25-09c5-4264-99c1-249ab823d3cd;5bf90d5b-abc7-43cd-9c42-ab6f9af5e81d;5cf490d1-edb7-4b3f-9a01-a44ec7e8369c;5fb922d2-e71b-4f67-847e-92d820ebc3d6;6249318a-dd65-4323-b501-386305aad059;76a420f0-e607-43f1-ac4d-89856d7829a7;822733f4-d25b-4923-aea1-575c646cd1e5;84188812-96ad-4ad2-bd58-0f8c7cff15cb;8cbcee12-3eb1-4726-9212-5dddc39a3b0f;93c8ceff-b70b-4a53-9c87-7c76e342e2c6;95905ef9-1de6-41eb-aa34-ac750e93e292;98c4b9a5-b8da-4bf0-bd52-7fc79152e414;9c74e4f2-b323-41eb-9e43-848ab82b527b;A6632467-8691-490D-9C0A-E0A0DA6691AB;a098f1d0-577e-474e-baab-d200c896a294;a488f7cb-10b4-43e2-a468-e032c5ca0de1;aa2194dd-fbb1-49e6-9898-a5f03d411cd4;ab2084b3-eb1b-4c52-9196-76a43f280961;afc6132b-de07-4ed9-b70c-3768eb8e80da;b14ef252-fe31-4dfd-840d-2588f591cb7c;b8004451-7b26-425b-b5ea-cbb1b08e30e3;bbaad5e9-38dd-4c4a-b278-8d1fb01200cb;bd64d499-0e99-4e48-bf0a-70f67e955d8b;bfdc6d04-2859-4a0c-add9-81ab131526ca;c5a24f9d-cb96-465d-855a-1eca7267149a;c6c86ef1-5a9d-4fa8-9996-d61d3c5f5f16;c7a29365-76f1-42dc-9891-e13e54295d52;c7ddc3df-9e08-4f0a-b633-cf93e9c9bd73;c80870d1-b42f-4478-9844-7eebf99d43a3;c82a10fa-1e8e-46b6-890a-737de3f34ee1;cb7720c1-c4ff-46b8-a36b-b6fe4f8e34bc;cce3253c-0d18-4c77-8b5c-79bafd5f9ed8;d0039cce-21cf-e620-af35-b863099d41e8;d2872d9a-1552-461d-9a77-d161f494351a;d55c402e-10d6-4de2-8d41-8681d5689cdb;da930058-8908-4fa3-8035-303abc9624fa;da99b8c4-f85e-409f-93a8-0e4758d74552;deabe62c-54bc-452d-8826-0238d25330db;dfca0a45-e134-4eb1-8afe-bf8d9cfd0b46;e0677ab0-23d3-2e88-780f-d949fcf10557;e21989bb-d7ba-2dd0-d2d3-a99fc799f2a6;e455ec79-08cd-4d75-9cb2-625d3912ee88;eb2b5c45-4244-4f2c-a9a7-26ac44f0b670;eccbb36d-7937-4a36-9ec7-c8aebe8ad925;ed03e4ec-311e-4a63-b7fa-cb4258b4b5fb;ed71d7ea-f5af-4406-8b0d-68e17cb1e61e;f0a43cae-0f19-4a60-8a82-895cc4ea0001;f0eacf51-58ca-41d8-9f43-30b335fe1431;febcda43-7c1f-459d-a7bf-b91efd064017;
10043|28304576-5611-4cbf-b051-07437d76f330| Promethazine hydrochloride injection is indicated for the following conditions <br> <br> <ol><li> Amelioration of <annotation cui="C1527304">allergic reactions</annotation> to blood or plasma. </li><li> In <annotation cui="C0002792">anaphylaxis</annotation> as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. </li><li> For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. </li><li> For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. </li><li> Active treatment of <annotation cui="C0026603">motion sickness</annotation>. </li><li> Prevention and control of <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> associated with certain types of anesthesia and surgery. </li><li> As an adjunct to analgesics for the control of <annotation cui="C0030201">postoperative pain</annotation>. </li><li> Preoperative, postoperative, and obstetric (during labor) sedation. </li><li> Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. </li></ol> |01b3a05f-6002-4cf9-96ac-ff0eed8a196c;01da3604-e28b-404e-8d14-ab3b9f8d03e3;047b9a7c-586b-4635-a63e-2c7ce9ec34e7;05907a49-537f-4bf2-8a5f-5e905f19fece;0912ad93-55ea-404f-ab8e-9a2a60da5dac;097505e3-6abd-490d-89b9-334944c59b04;0af133fc-a27d-4099-908a-0bdf7c64f22b;0e8199de-86cb-4450-a118-96927c9d59bf;10d38e48-21d9-4c56-9532-5de06c1d0ad5;146e817f-2dd9-4dba-e7a0-a12d24f5db7c;23a83c87-ad92-46af-aeed-12e93ab3255d;23ca7622-22b2-4f99-b923-13d289e93f9f;24086b53-a85c-443e-ad85-c1295ddf23c7;28304576-5611-4cbf-b051-07437d76f330;28304576-5611-4cbf-b051-67437d76f330;2d846985-d9a2-48ec-be96-31384527b4da;3087a1cb-fda5-4115-86b6-1cce480a2f8e;3185D299-AB4C-4BF1-86A4-3C126144B245;33d6acff-2858-46b2-bb9d-37b520ff015a;365138a6-28d8-4881-a3e9-02c80aaf83e8;36c9c162-90af-4f7b-9f56-5d81ed850dbe;3919fb0c-a0b6-470b-9ff2-63600bcbfbc9;3bed818a-e9a5-4a9c-bf5d-92ef717f5196;3c994fc1-824d-4a35-9be9-0554329ab3b5;3cf7f19d-efbc-49eb-a4b6-cfbe45a7286e;481866da-a712-48a5-853f-8e84aacaab6d;4bf3912c-8339-401e-9711-dad6acf15f11;4e9096f8-7c23-48a9-a5c3-75ada0f15f9d;4eaa8291-9cde-4205-857b-925ea8d618ba;501b3b8f-dabb-47d9-bb09-09b4ffd0fb46;50692fb9-2fde-4808-a8de-f1464a2896d8;5af67c79-cd14-4873-8d6f-39453b439aad;5bd84972-c373-44ad-08b2-e3d59c7e5256;636bb9bc-0cc5-4d6a-85be-6471acf01ffc;64972f75-d329-4897-941b-ad7fd71c6804;65b2f396-666b-4b08-890f-19429844e74b;6685915c-1493-4382-8638-e922416d809f;68db2148-fd39-485e-86fc-f51813f32435;6ad2e46c-c76b-4ca3-bfc7-9f903515b1b4;73a5ab08-ce67-44c4-8f1c-43131578fda8;749af379-2de0-4644-ae06-e8b03d863582;7687ec92-3c5c-4b3c-90cc-212b03658f75;7a137adf-39b7-4b14-80da-c3cac9ad562a;7ce351d8-47be-4937-aad2-153208c93b53;7d766cf7-a21c-4eaf-bbdc-00f2939ef19a;8027df84-862f-4c21-96e2-fbca2c46f5e2;8028f8a5-606d-4e5c-aa55-68184d09c17e;818a4d9a-c8a2-476c-b70c-0840b6d603a1;83169f64-42b9-43c2-b143-3282e7993a05;850e3749-0af0-ce42-c683-5700a2804aa1;85f183af-6781-4ceb-9c21-c4ee9a06c355;892fc7ea-be3d-4dfe-bfa0-2df97a6f03d9;8ecd1a37-7506-4307-aca3-8cb2a7eb5c03;9aa7b3f2-4429-4a61-ad8e-876afb14cc45;AAAF4D12-4E68-45F9-AC10-2238480A0160;CB06C97D-3B98-4C29-BCB2-5B04F41DB481;a32255f0-0077-489e-bdc6-869aca8cd434;a326ed98-e9ef-430f-a6b4-17d0d560474b;a8fe4bc5-961b-4441-b8e2-ef93e4e137b6;ad808072-3d50-4f8d-b590-7bdc3d7578da;add1d778-f9f7-4844-b39b-524824cb446d;afb16e94-03bf-4ea2-b2fe-e65f274e55a9;b8a7573c-e8e0-4b33-ac8c-da9a8fe948c8;ba08126e-9354-406d-bf48-a1ad40900797;bbdbc61c-3923-4832-b0a5-c0365dd8f5f9;bd8d1f9a-242c-440b-a5eb-a50f64a1c1d9;bf597543-c480-4835-abcc-aa3ab83e8b8b;c0c0d4f0-8396-485b-a585-71df01491f6f;c222fb52-f1dd-4aa8-80be-b6bd91a04f89;c809171c-d424-4a17-a98d-f280a892b410;cb5950f9-dc5a-4a30-9f3e-08b006f27dd5;d3b5ca09-9a02-45bf-a18c-1250ba9be309;da246971-20b8-b46e-8366-9700d3604cf1;e23c09c2-47f5-47c1-825f-cbd8e3440058;e5be207b-122b-490f-a0d6-841132e45180;e849c26d-73a7-46ee-af42-e668e8d9b7bc;ed16846a-b054-4625-b4e4-4a951e95c92e;f83a009b-d6fe-4277-a522-daa8a6a27156;fa5cd572-8c5c-4097-b5e2-1fcc69aee315;ff1dddab-72a0-4125-859e-554bece2d2b3;
10048|d273fd06-d0ed-49b2-a4a9-2ad7ac38ff2f| Nortriptyline hydrochloride is indicated for the relief of symptoms of <annotation cui="C0011570">depression</annotation>. <annotation cui="C0011573">Endogenous depressions</annotation> are more likely to be alleviated than are other depressive states. <br> <br> |249af6ba-f96e-4884-ae15-921e75913a58;375f06ce-97ea-4b4c-8d90-6b2091be18fa;378B3AED-D694-46B8-8629-FF72285ED29A;3fcabf90-357a-4a06-b680-9572dc28bcfe;595838d9-95ee-4842-981a-87a6eff8423e;59ff8000-09a3-b94a-fa18-970fcb00039c;651972ea-b8b9-47fb-b84a-d96ef8217c83;7b4a3438-57b4-4d88-9843-cc9da529f6f2;8dba3dbb-beb8-4ab2-8251-314877e9c345;8eef261f-5c78-a88f-37c4-46e6b0e0f0ee;AEE2C1A1-D848-4C3B-8C6D-8A4F6CE94C28;a87668a8-5688-40a2-a36e-95cbd685ac60;afbb5dd9-e6e7-4475-8328-5751ccd61eec;afde60c2-55a2-45d8-b381-a6c8896ed896;b58d473a-b19f-4d2a-b1ae-dd398d7a29e1;bdd0e87b-a1d0-4d6a-b56c-38d84184cdc2;d273fd06-d0ed-49b2-a4a9-2ad7ac38ff2f;e17dc299-f52d-414d-ab6e-e809bd6f8acb;e1f5e650-e83f-4343-a025-fc90f645a796;f5447ae3-e88d-4c2b-aaaa-6012a8facb6a;fe8c40b4-d48c-42a1-b8eb-a27adaec4029;
1005|fde7e9b2-c2d8-47bb-abe1-ec987da951ab| Theophylline is indicated for the treatment of the symptoms and reversible airflow <annotation cui="C0028778">obstruction</annotation> associated with chronic <annotation cui="C0004096">asthma</annotation> and other <annotation cui="C0746102">chronic lung diseases</annotation>, e.g., <annotation cui="C0013990">emphysema</annotation> and <annotation cui="C0008677">chronic bronchitis</annotation>. <br> <br> |038c2b07-8028-4dc4-847c-adafe1b0e81a;06ab3df7-e64a-4c46-8a70-38561ffea5f5;09325220-e4c5-4fac-aefd-ee3e42602198;1750235a-ad52-4231-abe5-d3c441ba39e8;25b2fdbe-2f18-4153-835a-7a67bff83ef8;2676f761-4fe5-40a9-a07d-ed2542847883;3829d74e-b3ab-46df-a08b-f0327b63304e;56fc2167-ceb6-4e3e-8ff7-5e400dfbd533;699a4e05-95cb-4b28-8927-d97a4afbf463;6C08B50E-CC9F-4C49-D7AE-F0FDDCB10199;78a99bfe-6ebe-4ace-80b0-ee019921435e;7a5a367f-8461-4b15-99fc-f89aa7d5936e;92949b28-9d8f-4e6a-b81a-c49018c0e03c;9940057a-831f-4bdb-8741-d10c0ca24925;A918AE8C-6485-42D2-AEBA-3785197C3D7B;b3f30758-5bc3-4c7a-96f1-0207889ff1e6;b6a476e8-9ceb-4320-873d-946df820b502;bba266d2-1d22-49a9-b3db-e4f06802a8a9;c248b178-951c-4710-933b-d9a6a8555688;c4c80b87-fc6e-436d-84de-7a0cd9d895eb;d70152c7-9da5-4096-ac5b-c8118cf48500;e118df30-a578-4cf0-93c8-689d15415ec2;f24f8e9c-ac46-4101-9250-9005af0edf72;fc61fd7e-63ca-4714-851f-31b2a045903d;fd40d7d3-285e-fac0-11a1-6213d067a371;fde7e9b2-c2d8-47bb-abe1-ec987da951ab;
10054|35e4dff3-f430-4761-b8ff-5875c52495cd| Nifediac CC extended release tablets are indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with other antihypertensive agents. <br> <br> |19592ac2-e193-47c4-b93e-e1d124d005d6;1e80b790-a57e-46ee-a257-4f59ca6502ce;35e4dff3-f430-4761-b8ff-5875c52495cd;409af9d8-67ee-4532-903f-a7bd5ad3d2e2;61f55d0f-247d-4b12-9075-f11b9250ed5e;674d17c2-1fd4-4e14-892f-d88091b2b6d7;6c587586-b966-49a8-913b-7fafbca2127a;6fafbe75-fcae-4afd-9745-02e641cefb31;75f6811d-0906-4ed4-8619-eb3eed103d9b;983bd055-d289-4fb1-a69c-5a7f178a07d1;ad65c43d-91c7-4c7c-b16f-5025c764cad6;adaa3246-d0fc-417c-9a16-81d76f153903;b95cd483-64ca-4840-948d-eaf1e13e58b2;f3b11f4f-936b-4b75-9cb5-9ef14ee95144;fa952140-c9f6-472d-a04f-96c44fe9bca8;
10059|f02310a3-92ea-9ec4-f218-38ddb8eb0334| Levothyroxine sodium is used for the following indications <br> <br> <annotation cui="C0020676">Hypothyroidism</annotation>   As replacement or supplemental therapy in congenital or <annotation cui="C0700502">acquired hypothyroidism</annotation> of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis</annotation>. Specific indications include  <annotation cui="C0700502;C0271789;C0220998;">primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism</annotation> and <annotation cui="C0271790">subclinical hypothyroidism</annotation>. <annotation cui="C0700502">Primary hypothyroidism</annotation> may result from functional deficiency, <annotation cui="C0004258">primary atrophy</annotation>, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of <annotation cui="C0018021">goiter</annotation>. <br> <br> Pituitary TSH Suppression   In the treatment or prevention of various types of euthyroid <annotation cui="C0018021">goiters</annotation> (see <b> WARNINGS </b> and <b> PRECAUTIONS </b> ), including <annotation cui="C0040137">thyroid nodules</annotation> (see <b> WARNINGS </b> and <b> PRECAUTIONS </b> ), <annotation cui="C0040149;C0677607">subacute or chronic Iymphocytic thyroiditis</annotation> (<annotation cui="C0677607">Hashimoto's thyroiditis</annotation>), <annotation cui="C0342208">multinodular goiter</annotation> (see <b> WARNINGS </b> and <b> PRECAUTIONS </b> ), and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin dependent well differentiated <annotation cui="C0007115">thyroid cancer</annotation>. <br> <br> |0213903b-9662-465e-a668-f228cedf5e9e;05897f7a-4d31-497f-aa9e-52708b361640;0db64694-4056-4d3f-ac41-1ba382a00f89;0e134d0a-00e2-96d1-7d94-b74f91356ce6;100951d4-c98e-0aef-2c21-ba9f702ea7a9;101de879-bb0a-4157-9c0d-2c5720dd454e;11ac52ef-ffdd-47f9-b80a-32198f3cdcf0;1ad32038-f484-4469-93fe-d3da81d8b9ea;1e11ad30-1041-4520-10b0-8f9d30d30fcc;1f2e9f8f-0662-4fd4-b53c-776b6a395a30;285887c6-3b60-4335-a323-272924b29e0c;3218d7d0-08c8-4e96-a717-94a8cbad2092;3c4d6008-6a68-4733-8845-37e7634ffbb5;3e5544bb-142b-4cfb-89a0-b97cb521e1db;40840f67-7066-4bb6-85c1-73eb2618cd26;4220ded0-36b2-4e48-8280-aecfce89ebe2;46a9e4e6-af7f-4f60-a888-c6d3afce8113;48428150-629d-4745-9238-18c52cb2adf8;5723c7a7-2a1d-4ab6-bf39-b2165ae781a6;5915b2bb-ae53-4781-91ed-ff90188fe1d8;5be7ee95-a27e-409d-881f-927f42074033;5fd9d708-57dd-4ec8-9b7f-4068b4f10bcd;60b347e3-2559-40f9-884c-a410c8a0579c;66a3bd4a-770b-4f67-bfa7-6d5e23f2ecbf;6977f0ea-3343-4f99-bcc6-85acfeb69710;6a18ecda-5e53-4b9a-88c7-7956707d1dc1;70df9c08-665f-4b12-9b11-e5521ebca3ea;71139e30-10c8-4474-b7a3-b575c3fd32f9;758588c3-c63e-491b-0aa2-4f50d80cb174;87d9513d-9e70-4e42-9ead-b0d6e6266fcf;89bb1c1d-0bd0-d8d0-7099-28109c595fd9;8b1296d5-a37e-4ab1-97e9-2aff1be59e82;8e8cb147-ba81-465a-99c3-34afdebcbd4e;951c6e16-7251-42ed-ac19-d8367a6aee4f;96758019-bef6-447e-b291-1907358ed4fa;97eec39f-6274-2622-13e6-0ad902390301;99aebc74-0e34-4ab3-bb59-d9fb2b9a4444;B5C93AB1-317E-4F99-9EC5-E47B30FAF650;a0bef5df-f192-4c0b-be61-2f28b982e8fd;a2d6e9b1-07a9-0fab-8d10-e8109aae780f;a3845f91-e0fe-42aa-8043-aeaac43f8eef;a4e39e5c-59ee-4ba2-bf7f-62b5eae3afbc;a7572a87-bf42-4597-b8db-687c211e1d41;a8a29300-98d0-48aa-8c32-f5ecdda6fa17;abc47c3b-d2f9-4ff2-accc-363fa7b2602f;abe005b2-d962-4ba7-9cb6-a09d35e68ae7;af563d57-4255-4ce8-b7b0-34b74e84f558;b722a6c8-c44b-4ec7-9402-02dc7e965753;b8fb4dcd-2531-40d3-bbfb-ccdc8ce327c4;b9aea421-ae9b-439a-90a3-07a0a50e835d;bebe7897-2ee4-4aa1-b499-5b822bd03971;c2b44229-61ad-4289-b198-c4f0660f1e56;c7138be5-8902-414c-8ebc-61725f878a6f;d28a6713-70d8-76a6-8b89-cf8bfe319803;d2a08338-1dfc-4058-b139-b1070f21b27a;dc827fec-2b59-416f-b203-252c03b686d5;e0dcc021-0831-41dd-9750-251c2f71a614;e557fe6a-a88f-4132-9325-f80cf12881c3;e8762009-4fa0-2d80-65eb-a94275a53e38;e95720f2-91c9-a6d0-f7d5-8bcb94d07bbc;ed164076-0d55-4487-baae-d961f9d1f40d;ee5e2e30-8750-e7ab-8200-9577fff4e585;eee6bc98-49fe-476e-b833-63073c135f4a;f02310a3-92ea-9ec4-f218-38ddb8eb0334;f887a801-744c-43c2-81d6-6433b1089667;f8aba2df-9771-4f53-b7db-0a05d41f0012;fce4372d-8bba-4995-b809-fb4e256ee798;
1006|a56f100f-0f42-4188-81ab-04644b824040| Glyburide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with <annotation cui="C0011860">type 2 diabetes mellitus</annotation>. <br> <br> |018a7a0d-4b38-4e59-bc37-621ae8786f51;0a5938a1-9fbc-4089-bbf7-f107202265ee;0c959f5c-8829-48bc-84e5-c23aa1d2a9bf;172ff8f1-586d-4df1-a4ef-13185d1b40dd;19ef0b2d-15e7-4985-b3a7-a980105638d1;2200ef58-d210-41e6-a535-e8c735507395;23064b69-955b-4ed5-aac3-12a60e0a763a;2d8fbab4-d7a7-4f4f-bbcc-56e603f72f73;30ea750d-b4b5-4c58-bd94-0100dc55a613;33418bba-c5ea-4c0f-9d28-31dc2724c6c3;4dc7d63c-a178-4d8a-bfb8-2bfb974021a2;4f6fbb6d-f865-46e2-ad07-50d4937c3318;58200048-a278-4f9a-b705-affc358537fb;60cc988d-4175-4d7b-9021-299c46602a4c;623df1a0-1771-4644-aaa9-6ae5ceacdf2c;6af5f069-e9dd-4faa-b4ed-af6941d25033;8c58076b-f061-477f-942f-534760a5d349;8cbbe136-a9a7-4990-b245-a25135ae389c;9b711ce9-f8cb-4ef0-b0c8-9477b1b30230;9c42ec74-7c7f-4d0c-84bc-b6529814a80b;a49158db-654b-4f8a-b716-7ea1667a1be8;a51e7563-e156-4274-94ab-977044a3ad0a;a53e29b3-7436-419f-ad6c-0a805d97ab1a;a56a8f2d-86fc-4deb-a12b-0692c7fd2e5b;a56f100f-0f42-4188-81ab-04644b824040;a7fce80a-2f13-43cc-8e1c-561f7d3ec3d5;aeba91ea-3d29-4b8d-af42-0740e7216463;b61ab462-de4d-4ec4-b0b1-5e6863d9279e;e2c957dd-71f0-4685-8a11-64f05ae71325;ecc78714-9c3b-4499-9a2f-6fd1aeffbd01;
10072|bdb43b40-d34d-47f0-b522-a0ad2d2b1185| Focalin XR is indicated for the treatment of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>) in patients aged 6 years and older. <br> <br> The effectiveness of Focalin XR in the treatment of <annotation cui="C1263846">ADHD</annotation> in patients aged 6 years and older was established in two placebo controlled studies in patients meeting DSM IV criteria for <annotation cui="C1263846">ADHD</annotation> [ <i> see Clinical Studies </i> <i> </i> <i> (14) </i> ]. <br> <br> A diagnosis of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (ADHD; DSM IV) implies the presence of hyperactive impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months lack of attention to details careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months fidgeting squirming; leaving seat; inappropriate running climbing; difficulty with quiet activities; on the go ; excessive talking; blurting answers; can t wait turn; intrusive. The Combined Types requires both inattentive and hyperactive impulsive criteria to be met. <br> <br> Special Diagnostic Considerations <br> <br> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM IV characteristics. <br> <br> Need for Comprehensive Treatment Program <br> <br> Focalin XR is indicated as an integral part of a total treatment program for <annotation cui="C1263846">ADHD</annotation> that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician s assessment of the chronicity and severity of the child s symptoms. <br> <br> Long Term Use <br> <br> The effectiveness of Focalin XR for long term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Focalin XR for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient [ <i> see Dosage </i> <i> a </i> <i> nd Administration </i> <i> </i> <i> (2.3) </i> ]. <br> <br> |00f1d83e-93cc-4bbe-9c3b-c488062271ab;1a1da905-42a0-4748-9c39-67eca45deccc;bdb43b40-d34d-47f0-b522-a0ad2d2b1185;
10073|8b9f1984-cce8-4b5b-baee-77ba9eff2a56| Cyclobenzaprine HCl is indicated as an adjunct to rest and physical therapy for relief of <annotation cui="C0037763">muscle spasm</annotation> associated with acute, painful musculoskeletal conditions. <br> <br> Improvement is manifested by relief of <annotation cui="C0037763">muscle spasm</annotation> and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. <br> <br> <i> Cyclobenzaprine HCl should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because <annotation cui="C0037763">muscle spasm</annotation> associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. </i> <br> <br> Cyclobenzaprine HCl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. <br> <br> |07c34dcb-6816-430a-89a6-35afd93bb2ee;092e2b22-37b3-4bea-9945-6480121175ce;0e185b89-d7cc-477f-ab8c-7c6f44e5c9e7;1154688c-1383-442b-a3a5-ec01e038795c;1534e79c-12cf-493e-8034-c1083f900ff5;19567e4e-2afe-41e7-b8d1-956843b75687;220ebc47-d310-4668-8b51-47a4981b46ef;390151d4-5fcb-46e2-92e6-de184827f43d;3dfb1c4d-3ffe-4ffb-918e-1f7d07f5011e;3f0512a2-66ef-453d-b0c5-ac58c3cd5c95;47bed841-47a2-4112-9b80-7b978c90593e;49f500af-0ee8-4384-91d9-8822cffac976;4aedb1f7-2649-487c-800f-01ca890cafb7;4eddf137-fd00-43d0-96ed-16f057806d4e;54a6b01c-5a7c-4710-93fa-69fd2c2549e3;592871f6-0eb2-4624-9e10-bd8bf767c002;59500ba3-b16e-46f9-a867-6c54f1f8fd6a;615f1e2f-63ec-4e20-bb74-293b5baf1d43;61b5704e-b635-4e3f-b6f9-a7faf5d3b6b6;639dc006-495f-4160-9258-babf4ef3c5d3;67c46f2e-59fe-4c20-a07d-79935d496d1f;68347db5-9f3d-430e-bd8a-16071077648f;6b3eccd8-2078-47d6-ac69-e7206ca27914;6b470377-a5b9-494f-abaf-c0454b5108b9;6d549942-9f30-4b4c-b6ae-c7d63fec779f;6ecd47d4-c618-48b1-a38d-1d558d54fd09;7ccfab67-8393-4af0-9023-97a785f7cb6f;7d94cbbf-b090-465b-9cf4-870db279d8fe;884b2f1f-ba7c-4218-b7b8-d4bd3f56482e;8b9f1984-cce8-4b5b-baee-77ba9eff2a56;94dbab72-615e-45c9-bb05-70748b4b6aaa;97c78d60-3498-476f-924a-b76078c5f97a;9875e2a2-e8d6-430f-8eb6-c0103ad276db;99aca2c3-afe6-4f74-83b8-beb08bb2b502;9c6086ce-121c-450c-b439-76ffacf1c2b4;9ec8690d-5983-4e20-ab5d-700f5a7bc1cc;a4187ac9-cdef-4a65-8966-e329acbe9ee2;a88fa950-23d9-49fd-9340-b38a357760bf;aa5af84e-428e-47ee-9f4e-41dac29d1979;ac490da0-6347-4f5d-bcae-c23261b43725;b3dee0d7-20e2-4340-82da-da5560d377c5;b881411d-e1a3-4748-8e89-7d62ffb24b22;b8ca1d80-6ea9-4a3f-ab06-beedf845de8f;bb7bf4f3-6806-4f37-b61b-13407f759b36;bd89c175-7eb7-6abf-d30f-c6563ec0a525;c18058a0-9c69-49cf-8454-db3b98427808;c21a7f59-09c3-485a-b6d9-3b784b7e9042;c68204a7-d00c-4ce7-bfda-bff58b2ed67e;dd2d3cf8-293c-4c3b-bdce-81f5c6a220ef;dd546a0e-e5be-4232-8ad8-fcd7d5f9a903;e2f44c02-d3aa-4f12-bedb-2497cdc28a58;e9063c42-e71a-4cce-9cd9-9ed6a192c6bb;ee3f98d0-71bb-42d3-b863-5bf92adf6353;eeff0c85-985f-4333-80f0-66e8fc31d37f;f1e5977e-31d2-11df-b51e-3b5856d89593;f4fee702-2561-4317-b219-23d4543f2c75;fae7e4a7-ca63-4af4-a43a-c5d85cce1961;ff573a22-261d-4096-ad47-03e9bcebf331;
10082|7bb07118-4b39-4b0b-914a-a4675f732c11| Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections (<annotation cui="C0032285">pneumonia</annotation> see <b> WARNINGS </b> ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. <u> As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see <b> DOSAGE AND ADMINISTRATION </b> for specific dosing recommendations. </u> <br> <br> <div> Adults </div> <b> Acute bacterial exacerbations of <annotation cui="C0024117">chronic obstructive pulmonary disease</annotation> </b> due to <i> Haemophilus influenzae, Moraxella catarrhalis </i> or <i> Streptococcus pneumoniae. </i> <br> <br> <b> <annotation cui="C0275556">Acute bacterial sinusitis</annotation> </b> due to <i> Haemophilus influenzae, Moraxella catarrhalis </i> or <i> Streptococcus pneumoniae. </i> <br> <br> <b> <annotation cui="C0694549">Community acquired pneumonia</annotation> </b> due to <i> Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae </i> or <i> Streptococcus pneumoniae </i> in patients appropriate for oral therapy. <br> <br> <b> NOTE Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following </b> <br> <br> <ol><li> patients with cystic fibrosis, </li><li> patients with nosocomially acquired infections, </li><li> patients with known or suspected bacteremia, </li><li> patients requiring hospitalization, </li><li> elderly or debilitated patients, or </li><li> patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). </li></ol> <b> <annotation cui="C0031350">Pharyngitis</annotation> <annotation cui="C0040425">tonsillitis</annotation> </b> caused by <i> Streptococcus pyogenes </i> as an alternative to first line therapy in individuals who cannot use first line therapy. <br> <br> <ol><li> NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. </li></ol> <b> Uncomplicated <annotation cui="C0037278">skin and skin structure infections</annotation> </b> due to <i> Staphylococcus aureus, Streptococcus pyogenes, </i> or <i> Streptococcus agalactiae. </i> Abscesses usually require surgical drainage. <br> <br> <b> <annotation cui="C0311389">Urethritis</annotation> and <annotation cui="C0007860">cervicitis</annotation> </b> due to <i> Chlamydia trachomatis </i> or <i> Neisseria gonorrhoeae. </i> <br> <br> <b> <annotation cui="C0019247">Genital ulcer disease</annotation> </b> in men due to <i> Haemophilus ducreyi </i> (<annotation cui="C0007947">chancroid</annotation>). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of <annotation cui="C0007947">chancroid</annotation> in women has not been established. <br> <br> Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non gonococcal <annotation cui="C0311389">Urethritis</annotation> may mask or delay the symptoms of incubating syphilis. All patients with sexually transmitted <annotation cui="C0311389">Urethritis</annotation> or <annotation cui="C0007860">cervicitis</annotation> should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow up tests for these diseases should be initiated if infection is confirmed. <br> <br> Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> <div> Pediatric Patients </div> (See <b> PRECAUTIONS Pediatric Use </b> and <b> CLINICAL STUDIES IN PEDIATRIC PATIENTS </b> ). <br> <br> <b> <annotation cui="C0271429">Acute otitis media</annotation> </b> caused by <i> Haemophilus influenzae, Moraxella catarrhalis </i> or <i> Streptococcus pneumoniae. </i> (For specific dosage recommendation, see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <b> <annotation cui="C0694549">Community acquired pneumonia</annotation> </b> due to <i> Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae </i> or <i> Streptococcus pneumoniae </i> in patients appropriate for oral therapy. (For specific dosage recommendation, see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <b> NOTE Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following </b> <br> <br> <ol><li> patients with cystic fibrosis, </li><li> patients with nosocomially acquired infections, </li><li> patients with known or suspected bacteremia, </li><li> patients requiring hospitalization, or </li><li> patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). </li></ol> <b> <annotation cui="C0031350">Pharyngitis</annotation> <annotation cui="C0040425">tonsillitis</annotation> </b> caused by <i> Streptococcus pyogenes </i> as an alternative to first line therapy in individuals who cannot use first line therapy. (For specific dosage recommendation, see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <ol><li> NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. </li></ol> Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. <br> <br> |035002de-abec-4da4-8010-c42d186c04a2;035ce971-cf46-40c0-9b2f-ae52ab4e3468;13cbc9d9-4e59-4731-b9ef-41084859fecf;14191b8c-6048-4c6e-880f-39068a77770d;1a252370-5a2d-4558-9c5d-aa591efb089d;1daf9566-168f-4e05-b23e-fdcb09183171;1e505c90-79e4-4267-83c4-2fbb93d75cc6;24ea9765-6d74-4681-8110-5a6fc0b04db5;284f1e3c-45e4-40fc-a56a-bfacec331016;32ae8f5a-ea78-4e64-a58a-856ed8cf4f78;38bf22b9-59d5-4a05-b517-24e48a61d1cc;3b631aa1-2d46-40bc-a614-d698301ea4f9;447aaf48-3bea-4047-8032-a3c878576093;4a13b574-ff5e-417e-bef4-279fcc3d5280;51835dc6-68c7-44b0-980c-f9b38b8d7203;53e2801a-323d-448e-8278-92d672904b0f;54ba24c0-11dd-4392-8f0f-0160d6373b85;5673a9ed-58f2-464c-b2e9-6dc46077cb69;57160dd7-1f61-42de-9e87-ded819bb6bdb;58b72e4c-f419-4a70-b894-93a5804d9993;5a96f4e1-6b80-42a2-8d85-95a1ff892099;5aa85ecb-aff6-4dd7-a764-a9ba94f1e02d;5f63c0cf-b688-412a-8b0a-7c9ae9cf52ce;61c43eb6-c29f-4572-8897-954636a760a1;6307a49b-753a-4232-a51d-bf6d0537b05b;65D8ADAA-04C8-4C5E-AE57-2FBAE0979178;679af699-714d-a3a3-674b-fc9ae4474a9a;6fadde9e-dab3-4d01-b3fb-795eef7eff2f;782c1bb9-75c4-4258-97b6-fd776ca970f5;7bb07118-4b39-4b0b-914a-a4675f732c11;7bc7f987-ec1b-4b31-addc-9ff8d2a428ff;7c960f3a-829f-452f-8206-ff9a72c01468;84629614-e14c-47c9-b642-c6aa8b431929;85ff97e4-f161-4570-aa75-4b0dc4076e8f;86071c7f-9f11-4783-9492-22beb55682e6;8f0b9785-1b5c-41f0-a6f2-80088aab18b1;8fe7a7f5-289d-4546-8d08-33dd0664c5f6;918925cc-8da9-4016-998c-c06ed4676ae4;966c8f58-fde1-4af0-964b-c0bddbb05b36;9e5bb949-c9be-48cd-b0a2-6b7fd536e777;a7bf9202-9590-49c8-bde1-78517e60850f;ace05c47-3ed1-4b78-8d1c-279d1329fe3a;b69917c0-95d5-4b29-b0e3-07054a4fd79f;b749df83-49b0-433e-8a62-589a048dd716;c225d9ad-e119-4059-b76e-9a272979eb9a;c61229e8-75cb-4776-9883-c5630bc38a32;c9bb38a9-b637-4146-b66e-54b5a0862316;ccf371e5-268c-4a89-a39b-4ca25e5035fc;d0a35bcc-32c8-476e-94ff-a42c230cc7de;d2f4907f-b952-403b-229e-cc5b8327a773;d470695c-c0d7-4361-8783-45f58a932ac4;da7761ce-f58e-64e0-91b4-4eb375829b31;db52b91e-79f7-4cc1-9564-f2eee8e31c45;dd39f0d3-62f7-c081-c21e-26b521d77084;e135bf9d-b8f1-49e1-9b43-afdcd2b9c8f0;e8aae11c-7baa-443c-9db7-fca6694b4988;ee77db05-991c-4467-a299-5e79554c7f5d;efdef52a-ccc9-4612-bd91-ff5ca55a8193;f5b6daad-b5a9-462d-8e10-db22a7af1c72;f6a52c0b-45db-422e-8c22-e867a11b4439;fb5cf9d5-afe9-4d74-a60c-17b38d9b084c;fe9a82be-dbf0-b51e-055e-139c35b00898;
10084|7d745d52-ed8b-43cb-a672-aba1e0938ae8| Doxepin is recommended for the treatment of <br> <br> <ol><li> Psychoneurotic patients with <annotation cui="C0011570">Depression</annotation> and/or <annotation cui="C0003469">anxiety</annotation>. </li><li> <annotation cui="C0011570">Depression</annotation> and/or <annotation cui="C0003469">anxiety</annotation> associated with <annotation cui="C0001973">alcoholism</annotation> (not to be taken concomitantly with alcohol). </li><li> <annotation cui="C0011570">Depression</annotation> and/or <annotation cui="C0003469">anxiety</annotation> associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). </li><li> Psychotic <annotation cui="C0011581">depressive disorders</annotation> with associated <annotation cui="C0003469">anxiety</annotation> including <annotation cui="C0011574">involutional depression</annotation> and <annotation cui="C0005586">manic depressive disorders</annotation>. </li></ol> The target symptoms of <annotation cui="C0027932">psychoneurosis</annotation> that respond particularly well to doxepin include <annotation cui="C0003469">anxiety</annotation>, tension, <annotation cui="C0011570">Depression</annotation>, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. <br> <br> Clinical experience has shown that doxepin is safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin is not recommended for use in children under 12 years of age. <br> <br> |0a25f89b-4e92-43a8-9a06-ef8c2e559442;137a953b-3c48-405f-86a6-ff778cb7f5f2;1533343b-f1ed-4c3a-bb36-23a748452b05;1edc1fca-9ac7-4adf-b894-bf8ca392ce4d;1ede17e6-19e9-455c-ad16-8029a590735c;24dd378e-0ef9-4ef8-8032-f81c1d87b3b8;481e2766-32bb-48b9-b0e4-ffccbb3297bb;4e9b122b-eddf-42d3-aeae-bee38badb2d5;54ad0284-c32d-4904-ae9a-5384ee53b2d8;6b769b58-daa9-4e5b-b416-381a5e7b167b;71cff7cd-0410-4194-9cdd-af404a869edd;7d745d52-ed8b-43cb-a672-aba1e0938ae8;87865653-2874-43e5-82c5-dea2f9bbbd6e;9ad86cfb-e91d-4e25-8bbc-fae3891c76d8;AA69C63C-CED6-4676-A16B-554F1AF7D210;b5dbe26d-4272-48c3-932c-0060d205b1de;c97a2f91-fe58-4d78-afc2-1a4ceb1f9344;ee103e51-e6be-c112-65c4-e93708bebf82;fa31c1a5-91ed-4726-ab58-fbe98056fe5e;
10087|a4ab4f05-1c18-442a-8618-c2c92e589703| <div> <annotation cui="C0020538">Hypertension</annotation> </div> Amlodipine besylate tablets are indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. It may be used alone or in combination with other antihypertensive agents. <br> <br> <div> <annotation cui="C1956346">Coronary Artery Disease</annotation> (<annotation cui="C1956346">CAD</annotation>) </div> <div> <annotation cui="C0699826">Chronic Stable Angina</annotation> </div> Amlodipine besylate tablets are indicated for the symptomatic treatment of <annotation cui="C0699826">Chronic Stable Angina</annotation>. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents. <br> <br> <div> <annotation cui="C0002963">Vasospastic Angina</annotation> <annotation cui="C0002963;C000296">(Prinzmetal's or Variant Angina</annotation>) </div> Amlodipine besylate tablets are indicated for the treatment of confirmed or suspected <annotation cui="C0002963">Vasospastic Angina</annotation>. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. <br> <br> <div> Angiographically Documented <annotation cui="C1956346">CAD</annotation> </div> In patients with recently documented <annotation cui="C1956346">CAD</annotation> by angiography and without heart failure or an ejection fraction < 40%, amlodipine besylate tablets are indicated to reduce the risk of hospitalization due to <annotation cui="C0002962">Angina</annotation> and to reduce the risk of a coronary revascularization procedure. <br> <br> |0141c088-8fc2-4041-880e-a79ce0de6fdd;06df17aa-6831-498c-9c28-37502a1f3260;090f3e51-8129-4b5d-97f9-ab410e14df2d;0f5c9961-6a9e-462e-b2e9-bfab1ca0ee63;180ee374-24f2-4b9c-9d54-8815f2b1dc9b;213502a2-f667-4da6-a4b9-462eb303c401;24e90827-104e-436c-81ac-78d3758e5723;2784f6dd-9115-4def-ad94-7141dbb6f738;278a3cd3-0506-429d-b419-b72d40718d68;2bac4ec4-9542-4927-8121-a7cd1858075b;3063bf03-830e-492b-bb4f-4d01c255f210;3518853a-4c5b-4161-a178-8da7f656f009;37b4cfba-6673-402e-bb5a-82b4ab6ef49b;3911a46c-80fe-4b70-a4ba-416de597481b;3c0ff5b6-de91-4c37-bd8f-a9b1341ebc96;3ca226a5-b121-47d4-967f-bc2b40687dac;44e5ad27-e062-461a-bdf4-192d852fbc49;48072673-1f7f-4fa8-aebb-00b4dba4a0ae;551b2b79-492f-4d90-bc96-eceed77bf89c;6a542f10-2d9f-44a2-ad71-12032c99e225;6c75cd90-7dac-4876-bfbd-50d842176475;767c1e67-4cfb-4358-a963-3d58122c8e83;7aaf923d-5b82-4a85-bb10-5850087da487;873b5b9a-b198-46f7-abe0-898ad0809b47;992fd3c4-ce10-4653-9c32-451209422510;a3201369-1c77-4a05-bbd0-0dd333305ace;a3294d91-4aa9-4a94-be6a-28ccf2d74326;a4ab4f05-1c18-442a-8618-c2c92e589703;abd6a2ca-40c2-485c-bc53-db1c652505ed;b00570ff-4081-4514-b45b-eb6f753450f5;b4b30c56-7403-4f69-9a8e-3d82a37e8bc5;b52e2905-f906-4c46-bb24-2c7754c5d75b;b6f298ba-2d7e-4a3c-9edb-8b60aba716d6;bef1a169-9186-43e9-b673-64fdb658984f;c1ecc118-b372-40c6-819e-56092cafe595;c32059ed-73cd-4a2c-9690-276e7068041e;c83b8444-0558-44e5-8701-9919848072be;cacb3551-c579-41cb-bed6-4b4d8b0644fc;d233a645-805b-45be-ae20-534367bc15ff;dc4be1cf-7dbb-456c-b8dd-07b16cca8ce0;dd6f9f66-148a-4ecc-9fb9-a58e2b6fbc79;efd9eda5-f497-45a3-ae13-dee729add999;f3357a72-a68f-4ee5-be56-03f1dd8bef83;f699d501-3f23-4261-904a-4877ba200c38;f9d9d64a-3a3c-44ad-b40d-02789f29eb04;fc285a1f-9b43-4bdf-8679-44e25654b84c;fda0739d-b355-478c-acae-8f773a3ec4b3;ff042130-c43a-4281-a731-809a54a1a7f1;
1009|61b1a335-fca5-4a57-b24f-ae7d081d06ed| <div> <annotation cui="C0020538">Hypertension</annotation> </div> Losartan potassium tablets are indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. They may be used alone or in combination with other antihypertensive agents, including diuretics. <br> <br> <div> Hypertensive Patients With <annotation cui="C0149721">Left Ventricular Hypertrophy</annotation> </div> Losartan potassium tablets are indicated to reduce the risk of <annotation cui="C0038454">Stroke</annotation> in patients with <annotation cui="C0020538">Hypertension</annotation> and <annotation cui="C0149721">Left Ventricular Hypertrophy</annotation>, but there is evidence that this benefit does not apply to Black patients. (See <b> PRECAUTIONS </b> , <b> Race </b> and <b> CLINICAL PHARMACOLOGY </b> , <b> Pharmacodynamics and </b> <b> Clinical Effects </b> , <i> Reduction in the Risk of <annotation cui="C0038454">Stroke</annotation> </i> , <i> Race </i> <i> . </i> ) <br> <br> <div> <annotation cui="C0022658">Nephropathy</annotation> in Type 2 Diabetic Patients </div> Losartan potassium tablets are indicated for the treatment of <annotation cui="C0011881">diabetic nephropathy</annotation> with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio 300 mg g) in patients with <annotation cui="C0011860">type 2 diabetes</annotation> and a history of <annotation cui="C0020538">Hypertension</annotation>. In this population, losartan potassium tablets reduce the rate of progression of <annotation cui="C0022658">Nephropathy</annotation> as measured by the occurrence of doubling of serum creatinine or <annotation cui="C2316810">end stage renal disease</annotation> (need for dialysis or renal transplantation) (see <b> CLINICAL PHARMACOLOGY </b> , <b> Pharmacodynamics </b> <b> and Clinical Effects </b> ). <br> <br> |00c34d67-720a-ccc7-d545-d5448f8b108e;149f17ea-98b4-46cc-a80b-e56d18c8b266;2410e0c7-8166-403b-8c55-89ed084c2955;2e1f1640-c6ff-456f-8bec-ec3251065f46;3049c71a-a422-4c02-bafb-d876f068911a;31366b4b-dfd6-4fda-babe-2cb3d2c14a2b;3233c707-70b6-4c29-8210-913eeb2a38ed;3d6a61cd-77c4-4f52-b826-c030df979270;41a61cf1-30a3-472b-a592-b17a610daaba;42e16ddf-4eb1-447e-9c90-06844f9e1246;442471c7-65eb-454c-a5ff-ac6134cbc8bb;46c2cb4b-eb65-45f5-891f-5e574adc962d;499df918-9c97-4e13-ab56-0bec5d61d652;4b0c8bda-2ee3-4e57-8637-aef38410ef21;4c2347db-79a3-4279-87f8-9fa91e6d00e3;5ac32c20-169d-475a-fc8a-934f758d6ab0;61b1a335-fca5-4a57-b24f-ae7d081d06ed;69605072-f130-4054-95b0-ff3c34554fb9;7f3b370c-ca97-e0a5-dbd2-870d7c7782cf;80e8e178-e79a-4c46-91c9-65831e6ad141;8574acd5-ad13-424f-bdfe-152c6623b24c;9199238d-8b24-4ca8-bd24-c200853416f6;9251e824-4aad-4a27-bd5b-041b42f68ba5;9c5d9912-68d9-4222-937a-ee8d1d8b61d7;9ccd6823-e813-472c-99cd-c6ef25e74bed;a092eef4-78b8-43b9-80fc-61341c37ea43;a4644f7f-ccb3-5ef5-1a08-f6daa6e77f6d;ad03e5cc-c36d-4ff0-9b25-5d13e2909230;b21683fc-1126-8ead-2742-1fe93a83c1e4;b8e3cb50-26a0-46ba-a1cb-d4e2e20ca882;c66550cd-4bee-4507-8f2d-2cff68cca8cd;c99c5895-c3a0-4c44-9e42-59c4ef11d75c;d0c74b1a-6c1c-4e25-b7d8-1d7a4e38e7a4;d7e2ff3a-7b3d-45ee-bf6f-de79619f64f2;d8a91143-7f4c-47d6-916e-b239dc23ae6a;e3dffeff-e499-4b88-88ec-a968a35e1e18;e5886220-43b7-46e1-9034-5242ba245bd1;e7f6b25b-ec4c-4c3a-a541-617d2d9ab393;e8979bdc-eae4-4db9-ab70-68e078a9c661;f51fd4fa-ea55-487e-b886-ae105dd5a854;f88c39fa-ed74-42f4-a886-c268daf8f3a6;
10090|499fc2bc-3311-4caa-288a-327d40eb26d9| Adult Patients Ketorolac tromethamine is indicated for the short term ( 5 days) management of moderately <annotation cui="C0278140">severe, acute pain</annotation> that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM ketorolac tromethamine, and the oral dosage form is to be used only as continuation treatment, if necessary. Combined use of IV IM and the oral dosage form is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION , and ADVERSE REACTIONS ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. <br> <br> Pediatric Patients The safety and effectiveness of single doses of ketorolac tromethamine injection have been established in pediatric patients between the ages of 2 and 16 years. Ketorolac tromethamine as a single injectable dose, has been shown to be effective in the management of moderately <annotation cui="C0278140">severe acute pain</annotation> that requires analgesia at the opioid level, usually in the postoperative setting. There is limited data available to support the use of multiple doses of ketorolac tromethamine injection in pediatric patients. Safety and effectiveness have not been established in pediatric patients below the age of 2 years. Use of ketorolac tromethamine injection in pediatric patients is supported by evidence from adequate and well controlled studies of ketorolac tromethamine injection in adults with additional pharmacokinetic, efficacy and safety data on its use in pediatric patients available in the published literature (see CLINICAL PHARMACOLOGY Clinical Studies, WARNINGS , and PRECAUTIONS ). <br> <br> Ketorolac tromethamine injection has been used concomitantly with morphine and meperidine and has shown an opioid sparing effect. For <annotation cui="C1135120">breakthrough pain</annotation>, it is recommended to supplement the lower end of the ketorolac tromethamine injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Ketorolac tromethamine and narcotics should not be administered in the same syringe (see DOSAGE AND ADMINISTRATION Pharmaceutical Information for Ketorolac Tromethamine Injection). <br> <br> |0772d6cb-0007-47c1-b3c9-28a1dc71b454;0baa018b-b653-4313-818d-3b0d726df492;153d3376-4e38-4f5e-8bf7-4b77bcbb2ebe;16399285-31cf-4ae2-b28e-76abf961e6e1;1a5ce8d6-92d6-4f78-80b4-cf9a11e147ed;2837a082-3a34-6f81-5e43-45a70295686b;31da4540-1589-492c-8be6-382179e8ece2;36087b99-a193-4dee-a103-8739484f4591;3d5a25e6-a117-47fd-b23e-d67597552c0f;42e7d810-ab12-4487-5082-b2a050e75e61;463cb005-7ba6-4f8c-835d-ba8f1714a6e1;499fc2bc-3311-4caa-288a-327d40eb26d9;4f49a276-a199-4f98-afaf-10a3eca91923;63b51e87-a223-4d62-b94e-60adf4872376;688f5dec-a6db-43c6-a1f8-5df99d08d395;6d0bc721-390c-4475-9915-d3bcccc60b76;7dad59b7-0ae1-4750-9122-9ab103db4bf0;86142f73-00fc-48d6-8383-3c28bd0b5832;8accbb78-fc64-45d5-69b0-35c23a1d2a2e;9a6df709-e016-44e1-8e1d-dea46689c3c8;C0336606-7366-41CE-9CEF-AA6524B92B11;a036819d-d0d8-4d95-93c9-d362d943ec2d;a41b9710-a1ec-41be-8417-b03c5d802ae2;b4b2ee9a-f59d-4c2f-878c-04a870e2a369;b701aef5-3f70-4bc2-abe7-7047b6a6e2a5;cff1fed3-1f30-4da9-93b4-8eebd0fd88b3;dce94664-7e3d-4592-86ac-2a94231e484b;dd489c86-08c0-4457-86f3-c4f36a70276c;e61ae711-e6d2-44e4-b7d7-943a9d06f985;e8593016-2bec-4c62-a10f-e7e944c26755;f713500a-20b8-8e20-c4cc-956805170335;
10091|3201acf4-101d-4273-b4e7-2512e755b56d| Testosterone cypionate injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. <br> <br> <ol><li> <annotation cui="C0022735">Primary hypogonadism</annotation> (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. </li><li> <annotation cui="C0022735">Hypogonadotropic hypogonadism</annotation> (congenital or acquired) idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. </li></ol> |108facca-c6d2-48fa-ba48-667c9498c61b;3201acf4-101d-4273-b4e7-2512e755b56d;4195516a-c8e6-457c-b805-43c9a3ca8b77;837570cb-8a33-4129-ad41-bead378d9987;96f8439e-516e-4b50-84f0-68984c833245;a34023dc-fc54-4f66-bab0-9596502c23a3;a38f852b-e260-42c9-a37a-e07c97a01c42;cfbb53d4-b868-4a28-8436-f9112eb01c39;f60c5520-b336-44a2-95d5-f274939fa595;
10093|694abc50-a512-423f-9bf0-f8d9ac99f030| Gemfibrozil tablets are indicated as adjunctive therapy to diet for <br> <br> <ol><li> Treatment of adult patients with very high elevations of serum triglyceride levels <annotation cui="C0020480;C0020473">(Types IV and V hyperlipidemia</annotation>) who present a risk of <annotation cui="C0030305">pancreatitis</annotation> and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V <annotation cui="C0020473">hyperlipidemia</annotation>). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of <annotation cui="C0030305">pancreatitis</annotation>. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of <annotation cui="C0030305">pancreatitis</annotation> or of <annotation cui="C2585575">recurrent abdominal pain</annotation> typical of <annotation cui="C0030305">pancreatitis</annotation>. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of <annotation cui="C0030305">pancreatitis</annotation> in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. </li><li> Reducing the risk of developing <annotation cui="C0010068">coronary heart disease</annotation> only in Type IIb patients without history of or symptoms of existing <annotation cui="C0010068">coronary heart disease</annotation> who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL  and raise HDL cholesterol) and who have the following triad of lipid abnormalities: low HDL cholesterol levels in addition to elevated LDL cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for <annotation cui="C0010068">coronary heart disease</annotation>. Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE ADJUSTED ALL CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. </li></ol> In a subgroup analysis of patients in the Helsinki Heart Study with above median HDL cholesterol values at baseline (greater than 46.4 mg dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see <b> Table I </b> ). <br> <br> The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL cholesterol. Diseases contributory to <annotation cui="C0020473">hyperlipidemia</annotation> such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with <annotation cui="C0020480">familial hypertriglyceridemia</annotation>. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. <br> <br> |0ce067fa-abeb-41a3-9bbe-7956f9a96278;16a775ec-47e7-491f-8c48-319ce43dcd3b;1c8945d1-2292-4c31-8ba4-19bece8cec8d;22ea8379-50aa-4550-98f0-708d6da97e79;2911a53a-3f37-4c4b-b424-a6d98e41aab7;317d8d2c-c347-4dec-9e20-bc6dbb1cbcde;3357b98b-fb76-4993-a655-5e307d315d41;34620a46-49ba-4593-960e-a8ec41721a20;3c40a933-527d-49e8-81ce-631e9c646000;3dae4466-86f8-4133-84c1-cba8e237ae28;3e286434-895a-41c4-8f7c-9ade565227cf;43086a47-1aba-44f2-656e-18cfd15e6021;5c09fe54-697e-4cd5-9a26-7c9c7fa9a864;694abc50-a512-423f-9bf0-f8d9ac99f030;75269c5c-8b6f-4496-9a93-1eba4208e1f7;75cac02c-56e3-4dfe-b1e2-4ce166b28833;76185935-589d-41ba-a96c-3739eefd6b7a;7632214b-7d22-4edb-af0f-bf9609d371b4;78ec73e1-6420-467f-8496-042d8d9a1d0b;7e877a90-e00f-45b2-a8e9-a9f70dfa8927;9150afcf-6e63-49b9-9daa-64b8ae65fee4;9fa2de4d-a921-48c1-a0b8-48bb579862a1;A1DA5A84-7529-4F62-867F-808A6CAB40B8;ade1420f-ccd4-4fef-b105-a0fbfbe9a53b;b57eeb99-679e-4136-80f4-85421e21400b;beade464-5f49-42c8-8373-a1406ccbacd7;c1608dac-9f44-4cf8-83d5-f8ef0c7839b6;c45cdbdb-414f-4bbf-a643-3a3d9de63a6b;c48855b7-215e-453b-b3b1-a0f9dee7221f;d709812f-e958-4065-a447-c2c00ddd7677;d8ec3de8-7f83-4c29-87cb-3f3ffc2689b8;e2ec8e47-8f4e-44cc-82ff-1d4511d3fadd;ee012874-1a59-4803-bb72-a9a133218ce7;f4179a86-7f9c-4bbd-b10d-3507c8327dc9;fb2df26c-60c6-4aef-986d-242364489717;fdcee21a-097d-4354-bc91-e92cfdffac62;fe33138d-03ef-443d-9a78-783d4669eda8;
10096|9d650081-f71d-448d-9ad6-a837d4042200| Citalopram hydrobromide is indicated for the treatment of <annotation cui="C0011570">depression</annotation>. <br> <br> The efficacy of citalopram hydrobromide in the treatment of <annotation cui="C0011570">depression</annotation> was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the DSM III and DSM III R category of major depressive disorder (see CLINICAL PHARMACOLOGY ). <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms depressed mood, loss of interest in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. <br> <br> The antidepressant action of citalopram hydrobromide in hospitalized depressed patients has not been adequately studied. <br> <br> The efficacy of citalopram hydrobromide in maintaining an antidepressant response for up to 24 weeks following 6 to 8 weeks of acute treatment was demonstrated in two placebo controlled trials (see CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use citalopram hydrobromide for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient. <br> <br> |001714c1-a292-40be-bfbd-0ff67193ace6;04766f1d-7a69-49ed-8fd3-1a6305505d47;0745c9eb-9514-4410-bc1d-6ddad497dbfd;08DF7DDD-2529-4B74-A3F2-8D5FC54E2BA0;08b6d5da-5919-4760-9e16-3b478a14d6d7;0979fb90-9c22-4b74-8648-1174b905654d;11e31dab-be16-4a7e-83ac-f8c5840683eb;16bda7b5-a5a5-4478-9df3-beb396bd677f;18480829-b5a7-6327-0122-11f61d2fc053;22edd948-d2fe-4df1-b797-1b7d92fc29cf;245cedcd-e11d-4128-b74b-f2156ef804c1;2632b547-2e13-447f-ac85-c774e437d6a8;29408d84-7b00-4cee-969c-8095f8083ff5;2bd09e0d-66ec-43e7-b1ff-74ab102391cb;2c334836-2a99-491c-92c2-ffcced3e1ca4;30abc373-2373-449c-9bb1-b22238402357;34d1685a-8e6a-46bc-8977-550979bf4ddd;351ca54b-0eb6-4e93-8ab4-82fb18dcc9e1;3993eb55-f0e8-496c-a496-19dc509699e8;399c2713-4ed0-4be7-87f7-f32450d03fba;3da2a185-28af-418f-bc86-fd1ed50e2de0;4259d9b1-de34-43a4-85a8-41dd214e9177;44a11767-6833-4f60-9ff6-ea7c963892f2;455CF957-7933-7D09-3F3E-E63D6E8A1150;47eb1f95-d143-4982-8fee-27b49d5e6ae6;484db0b4-f7dc-4fd6-b279-00104e92bd1b;4af1988d-ffd5-4c5f-bcc2-6c47d9ea9479;52bf0f9e-e6c3-4dd8-921d-2e74605e07d1;549d5c59-7c9b-4b86-bdfb-c544b12dac46;5caff592-a90f-420d-a6ec-9b2dc914529e;613768da-6140-4c11-affc-85ba8fe92018;62f9e5da-6215-4d6d-8601-ea01ec2655ab;646a7fe6-ca0c-4ca9-b413-a812305ec23e;653233ce-04c3-4059-9d45-a7075ddbf920;680C1266-49B5-D75C-B825-2B34DDAEE350;6a402640-1c9d-4fca-8b5b-e1ac1dd4ca5a;6c8942f8-963a-4007-a147-b77ac629e4d4;6c96373f-6744-49d4-aec5-3720bc993fab;6daeb45c-451d-b135-bf8f-2d6dff4b6b01;6ebe41cf-c3b6-4b40-bc46-cb43df87182b;774d9d1f-523b-4061-850a-00607da15787;793c9089-8139-4d21-9e8c-64eb0d554063;7c713ff4-357a-4469-bbca-2ee6e353c973;825c0c49-5fbf-6d8b-cb8c-94ebf0eda043;84AFE6C1-378C-4444-9D57-7444D8916ABA;871a7ee6-f420-427b-b0e1-b5516d7e1593;8cf6e5be-7e69-4cfd-9174-c5333d641078;962be3cf-4ded-47bf-9b59-d689367d6eb4;9ce0e304-583e-4850-ba40-c3534cf1b068;9d650081-f71d-448d-9ad6-a837d4042200;AEC4204D-8A0C-443A-AAD1-1958DB28C60D;AFA26CDE-E512-48D1-A9AE-3E1CEE2F7F72;C0FCB440-2C9F-4841-B164-5AB7168D81D9;a6949652-b15b-435b-9097-2219f398ac05;a6ad0d10-3d6b-454c-a5a1-d95079befc48;ada3c661-d9d9-4fe8-89df-fc4d5daf31a2;b05c85d1-2474-4803-a0c0-585d5f764d4b;b29fab7c-1282-4bb9-a650-24890501caec;b78bd80f-7354-48db-bbdb-deeeb4a9c2f6;b808f809-40fa-43c6-a33f-2ec21a293051;bdd825e4-46c9-4f55-b2ac-36d7bb933d66;bfccb051-7d05-4457-9823-9b460ee12232;c09b3e6d-220c-4c45-89d3-89bf92472261;c15bb450-3f06-4452-8b07-d10647745e1d;c4603d19-fb82-4966-90d4-e63b1d4d0442;c87aebb5-c9a1-4db0-b1e5-137353b83735;cf64d0c0-7f1c-443d-93d5-1c41abb4e81d;dce6a871-db80-4b59-9b30-ff970a05fa35;e7a2cbdd-1bdb-4e59-a3dd-298a189753ae;f3a26d92-b662-4896-82eb-261948042408;
10099|911802e4-2aeb-4447-99ae-6029cdd2d7dd| Trazodone hydrochloride tablets are indicated for the treatment of <annotation cui="C0011570">depression</annotation>. The efficacy of trazodone has been demonstrated in both inpatient and outpatient settings and for depressed patients with and without prominent <annotation cui="C0003469">anxiety</annotation>. The depressive illness of patients studied corresponds to the Major Depressive Episode criteria of the American Psychiatric Association's Diagnostic and Statistical Manual, III. a <br> <br> Major Depressive Episode implies a prominent and relatively persistent (nearly every day for at least two weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least four of the following eight symptoms change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts. <br> <br> |0607a7bf-1833-41f0-99e3-b8ce87fa26f8;072c4627-897d-4659-bbb3-aa3777e161de;10124262-e443-49a5-a1cc-8cc34c74d953;12579d55-bccd-4711-b97e-bd5f5bf107f0;1bbfacc2-5afc-4c6c-9301-8b17046916ec;28080f0c-0b6c-4d95-8a53-6474bb876b0e;2d082996-ff62-4e65-a4b1-191520238c6a;2e516944-5fe5-4e8f-808c-99a901a19e51;324d2543-477d-4c0b-bfa0-d76cb4e5cd48;35141f40-10a0-482e-b2d2-0ca6742bb635;3a581900-cbe3-45ed-ab56-8a86b847bd7e;4005feb3-1349-4ca9-9a51-dc84426e4a55;4006d439-e2de-4590-82e9-fc9d56e3ec1b;42a9e649-9093-4519-b4a6-eb630f4d9368;49196e9e-aeef-4663-8be9-6b523ae7fb7a;4e0ce52d-2639-42a2-a4e4-7854421fa1b6;6b1141e6-f233-4440-87c2-cd349d76d1ec;6f43cdc2-4f8e-4a5f-976a-d3aaac65593d;71961ab1-951d-1493-f76c-2ff25cca2a85;790c69e7-7e2c-4799-8fbc-fa9475a722a2;85966659-36f8-044b-dd40-d8ef2134e42a;911802e4-2aeb-4447-99ae-6029cdd2d7dd;A699724B-7412-479E-9894-4CF6EC454D8B;a20c04a6-1f16-4c20-ab87-8f753b48d2cc;af82c9b0-1c3a-407a-aa5d-f15b9217b5c6;b48c8d16-ad28-47f2-9a85-4ef97bdd4bfc;b60a9829-f356-4e43-97d5-7666fe11588c;b693593c-aa3a-451d-b075-96ed4eacedb1;c2f25ef2-b6c6-4dc7-bce2-ef2537e9f76a;c3478688-77e0-09b0-0653-5716b2de5042;c9d7e0a3-58bb-4694-9c6e-2cf3e6713d9b;d741974c-c1aa-4c9c-bca5-054b999856cd;d8b3eb1d-b396-4210-8310-63ab05be0cf4;df555ed8-2d8c-45fd-8bf1-aa72c49090c0;
1010|d3fba206-e9ee-4fe5-b3cb-cabc4bcead58| <div> <annotation cui="C1269683">Major Depressive Disorder</annotation> </div> Escitalopram tablets USP is indicated for the acute and maintenance treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> in adults [ <i> see Clinical Studies ( 14.1 ) </i> ]. <br> <br> Information related to usage of <u> e </u> scitalopram in adolescents is approved for Forest Laboratories, Inc.'s Escitalopram Oxalate Tablets and Oral Solution. However, due to Forest Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that adolescent usage information. <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms depressed mood, loss of interest in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. <br> <br> <div> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> </div> Escitalopram is indicated for the acute treatment of <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (<annotation cui="C0270549">GAD</annotation>) in adults [ <i> see Clinical Studies ( 14.2 ) </i> ]. <br> <br> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (DSM IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following symptoms restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. <br> <br> |13bb8267-1cab-43e5-acae-55a4d957630a;23ff2d62-b5ff-4837-8b54-439a65609d90;2a33f95e-4245-4437-86a9-fcfc87e26edb;3750b79d-8dac-46c1-82d1-cfe9bcac6a86;38ca3165-cd85-40b0-bf2e-57110585332e;4a08b6cf-7ba0-54a9-14e0-a6e8d1e4854e;5d28721d-097f-400e-8690-d133c76e07be;61f27814-bc32-4de5-b12a-29fe1ee9771e;9a6c8116-396d-413b-b8e7-5eb321781bd5;abb3d9a1-c528-b446-68e0-77be2cd93821;b40ad7ec-1779-450a-8a04-b5e54b6a7494;b49f45d7-432f-4529-b382-3a65f7643e2d;b813427b-dd6a-4aec-900a-ed26f9fcee61;ba60c357-8e61-4a3d-b1dc-25602dbbfc2a;c871d3fe-5ca2-410c-976d-9ec4b72c878f;cd65aa65-94d0-4e88-8af3-20f692432644;d3fba206-e9ee-4fe5-b3cb-cabc4bcead58;e2fc3b79-3424-43e3-99c7-7ac5017b0b70;
10109|f2901045-904f-47bd-74a1-c561facd7f25| Vancomycin hydrochloride is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin resistant (beta lactam resistant) staphylococci. It is indicated for penicillin allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. <br> <br> Vancomycin hydrochloride is effective in the treatment of <annotation cui="C0520767">staphylococcal endocarditis</annotation>. It s effectiveness has been documented in other infections due to staphylococci, including <annotation cui="C0036690">septicemia</annotation>, <annotation cui="C0029443">bone infections</annotation>, <annotation cui="C0149725">lower respiratory tract infections</annotation>, skin, and <annotation cui="C0037278">skin structure infections</annotation>. When <annotation cui="C0038160">staphylococcal infections</annotation> are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. <br> <br> Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for <annotation cui="C0014118">endocarditis</annotation> caused by <i> Streptococcus viridans </i> or <i> bovis </i> . For <annotation cui="C0014118">endocarditis</annotation> caused by enterococci (e.g., <i> faecalis </i> ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. <br> <br> Vancomycin hydrochloride has been reported to be effective for the treatment of diphtheroid <annotation cui="C0014118">endocarditis</annotation>. Vancomycin hydrochloride has been used successfully in combination with either rifampin, an aminoglycoside, or both in early onset <annotation cui="C0340359">prosthetic valve endocarditis</annotation> caused by <i> epidermidis </i> or diphtheroids. <br> <br> Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin hydrochloride. <br> <br> The parenteral form of vancomycin hydrochloride may be administered orally for treatment of antibiotic associated <annotation cui="C1257843">pseudomembranous colitis</annotation> produced by <i> difficile </i> and for <annotation cui="C0038157">staphylococcal enterocolitis</annotation>. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. <b> Vancomycin hydrochloride is not effective by the oral route for other types of infection. </b> <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |0dc0459b-3d5c-45a8-85d4-ad4927b683ee;1494d2fe-3818-45e1-adb1-adb5acc26e69;1e46fd1c-cb3c-4160-80bb-ed37a5cd7483;2fd9de3f-a95f-451c-a687-d2e1306e53bf;37592c56-6679-48f4-169f-3a00c2ab114e;622b9406-1c06-4323-8ca2-873cb9112dd4;6e8f9e57-8376-4ce5-8ef0-50b3dd3e1168;73ce6c76-7636-49e3-a912-02d56353e009;91c050cf-3b2d-48bc-7297-e8dc68225e5a;99e523d8-9bde-43cb-8434-497015e5dcbd;a03e74b0-047f-4c55-8cdb-5296bf3ebfda;b51bb864-da6a-40df-8940-ec4ded792e89;cad65674-4e33-460c-b861-d96f2550ecdd;d9303631-4301-4704-b85f-7547e88c68df;debeaebb-d03b-446a-ac7d-27d3184bf48b;f2901045-904f-47bd-74a1-c561facd7f25;ff01d0cb-bb52-4ba4-9d16-e37e787b903d;
1011|09692f56-468c-4884-ae95-d2fb9d984e4c| <div> <annotation cui="C0004096">Asthma</annotation> </div> Montelukast sodium is indicated for the prophylaxis and chronic treatment of <annotation cui="C0004096">Asthma</annotation> in adults and pediatric patients 12 months of age and older. <br> <br> <div> <annotation cui="C0015263">Exercise Induced Bronchoconstriction</annotation> </div> Montelukast sodium is indicated for prevention of <annotation cui="C0015263">exercise induced bronchoconstriction</annotation> (<annotation cui="C0015263">EIB</annotation>) in patients 15 years of age and older. <br> <br> <i> Pediatric use information for patients ages 6 to 14 years of age for acute prevention of <annotation cui="C0015263">exercise induced bronchoconstriction</annotation> (<annotation cui="C0015263">EIB</annotation>) is approved for Merck Sharp & Dohme Corp s montelukast tablet products. However, due to Merck Sharp & Dohme Corp s marketing exclusivity rights, this drug product is not labeled with that pediatric information. </i> <br> <br> <div> <annotation cui="C2607914">Allergic Rhinitis</annotation> </div> Montelukast sodium is indicated for the relief of symptoms of <annotation cui="C0018621">seasonal allergic rhinitis</annotation> in patients 2 years of age and older and <annotation cui="C0035457">perennial allergic rhinitis</annotation> in patients 6 months of age and older. <br> <br> |09692f56-468c-4884-ae95-d2fb9d984e4c;3c170992-0023-4ae1-90de-e7260448ce07;3d4451a9-d73d-b9de-68ec-853bfeff6e4b;4eabe2b1-7f4d-4720-bf70-191e6df67c79;6d69e73a-76cb-4ece-9cf9-e9adb4f523b4;7636a692-558f-4649-86d9-b6699c3eeca1;7caa5173-dacc-4ab4-aa6f-3324001cddc2;9794b747-3a45-48eb-9c3e-bc5b015f6591;a5620aa9-3028-48e1-a9d2-0860a8fe7e1d;b2de3aab-8346-047c-9e34-de9fec43fb39;b5f0e397-55f7-47c0-b1d4-377ce48dd9a3;ba42b0a9-83f1-4283-a853-f99cdd0761b9;c43d1edb-c162-4317-9a89-d84e4eff5512;c5d2963f-3b67-40cb-9731-245d095bc668;d606a983-3146-4f50-a9d5-634cb4aef580;da038cf6-cfad-43a4-ab8e-d81d028d6087;ed2caffa-a75c-1c27-ae30-2d8280eaea7d;fb58bfdc-f799-4498-bd23-b1655a3d3ac3;
10111|2dc2b889-8443-4f7f-83be-86c68e179804| Diltiazem hydrochloride extended release capsules USP (once a day dosage) are indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with other antihypertensive medications. <br> <br> Diltiazem hydrochloride extended release capsules USP (once a day dosage) is indicated for the management of <annotation cui="C0699826">chronic stable angina</annotation> and <annotation cui="C0002962">angina</annotation> due to <annotation cui="C0010073">coronary artery spasm</annotation>. <br> <br> |07505514-a07a-4b5a-a4c1-317f2f679676;0c68a168-91a2-4d1f-85e7-b22b92ef1c2e;1042fa13-e6af-46b9-8008-6c941f0978b1;13b758d6-fbd8-4783-80c5-fcfa7f3abe42;1b67a7ed-32e9-432a-962e-4a424b9f4610;1e3be38e-d773-479f-9478-6e1bff5b715a;22C4CE8C-32CF-46B3-8483-2344A1F0BDC7;2dc2b889-8443-4f7f-83be-86c68e179804;510e9cc4-0529-4c28-b6e6-180e2e47d17d;56573e9d-7bd2-694c-cd6d-26039590e548;5e80e933-51fb-7f42-afa6-141743ff4563;61bf535a-3ed5-4c50-b285-6dcee0624c2d;6c6a38e7-7e9f-59b8-05b8-10802ff8d8fb;6f71ba5e-7bd6-409a-80c6-2f22d975aefc;77fd7414-85aa-4161-87ff-dbff9e97ee02;813eb1bb-1475-4958-821d-e97c5abb7462;867fd84c-902e-4ddc-a3ec-2204c1de2c5e;8d9d9de2-1e81-4f6d-af20-734ee67407ba;922508dc-0d0a-48c4-a002-1cd8867b15f9;960ccc49-cafa-4c89-8bb4-c6418e0e2426;9942f1a2-f66d-4d9e-9794-49bee8abf5ab;9c4b18ea-718e-48ea-9c8f-5868fe136ec2;AF12246F-890C-4C31-BB77-136F47DDA222;a02d87b9-bb28-45b7-8bf4-d17daca78c28;a5391476-8480-401d-8bb5-0726d8195770;a6ad506a-a3f9-45be-ae03-24313b9a9b7c;a91f6d42-e74e-461b-af00-44a118ecc502;ab7c7e95-616d-4208-b865-95ceddc45d3d;afec3ac0-1316-4b78-b476-1003f52fd39b;b4626a8d-a28d-4937-aa61-b9d958ae336c;b76047ff-d21d-44c4-acad-ea80fb520c22;bac9d5bb-1dd5-4057-a9a6-953dc7b597c7;c9f74c57-3fe9-470b-9096-31d0acb22f7e;cc04f1f5-23db-4286-b997-f720edecbe5d;cc1fe717-8308-433e-9688-39a2dd4c479a;cce1108d-5b73-429d-a091-8b990dfd576b;d64c7be0-cbf8-4166-b1e0-db5e322d28c9;d6a81f9f-3a51-4e86-aeb3-8352186b3528;dc932468-b50b-474e-b11a-66fbf2fac206;e8c8dd18-9d95-4068-9762-bec1eb1bc25c;ea03fee0-d40b-70cb-b23d-8d2001e22af5;ec7e93b8-666c-4d2f-8d08-07931e09f748;fb1c4767-dd02-4abc-9cb7-f85bb12a4867;fc3cb2c2-9617-30d0-42a2-8fbda866cbaa;
10113|706e938f-a0a0-42f6-b99b-60c31cbfb441|Palladone Capsules are indicated for the management of <u> persistent, </u> <annotation cui="C0278140;C0278139">moderate to severe pain</annotation> in patients requiring continuous, around the clock analgesia with a high potency opioid for an extended period of time generally weeks to months or longer. Palladone Capsules should only be used in patients who are already receiving opioid therapy, have demonstrated opioid tolerance, and who require a minimum total daily dose of opiate medication equivalent to 12 mg of oral hydromorphone. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine day, or at least 30 mg oral oxycodone day, or at least 8 mg oral hydromorphone day, or an equianalgesic dose of another opioid, for a week or longer. Appropriate patients for treatment with Palladone include patients who require high doses of potent opioids on an around the clock basis to improve pain control, and patients who have difficulty attaining adequate analgesia with immediate release opioid formulations. <br> <br> <b> Palladone Capsules are NOT intended to be used </b> <br> <br> <ol><li> as the first opioid product prescribed for a patient. </li><li> in patients who require opioid analgesia for a short period of time. </li><li> on an as needed basis (i.e., prn). </li></ol>An evaluation of the appropriateness and adequacy of immediate release opioids is advisable prior to initiating therapy with any modified release opioid. Prescribers should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non opioid analgesics, such as non steroidal anti inflammatory drugs and acetaminophen, to opioids, in a plan of pain management such as outlined by the World Health Organization, the Agency for Health Research and Quality, the Federation of State Medical Boards Model Policy, or the American Pain Society. <br> <br> <b> Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Patients receiving opioids should be routinely monitored for signs of misuse, abuse, and addiction. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Patients at increased risk may still be appropriately treated with modified release opioid formulations; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction. </b> <br> <br> |706e938f-a0a0-42f6-b99b-60c31cbfb441;
10114|4fb81272-194b-476e-a5a9-ea5c1d31c69f| Amantadine hydrochloride capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of <annotation cui="C0021400">Influenza</annotation> A virus. Amantadine hydrochloride capsules are also indicated in the treatment of <annotation cui="C0242422">parkinsonism</annotation> and drug induced extrapyramidal reactions. <br> <br> <div> <annotation cui="C0021400">Influenza</annotation> A Prophylaxis </div> Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of <annotation cui="C0021400">Influenza</annotation> A <annotation cui="C0042769">virus infection</annotation>. Because amantadine does not completely prevent the host immune response to <annotation cui="C0021400">Influenza</annotation> A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an <annotation cui="C0021400">Influenza</annotation> A outbreak, amantadine prophylaxis should be considered for the 2  to 4 week time period required to develop an antibody response. <br> <br> <div> <annotation cui="C0021400">Influenza</annotation> A Treatment </div> Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by <annotation cui="C0021400">Influenza</annotation> A virus strains especially when administered early in the course of illness. There are no well controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of <annotation cui="C0021400">Influenza</annotation> A virus pneumonitis or other complications in high risk patients. <br> <br> There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of <annotation cui="C0042769">viral respiratory tract illnesses</annotation> other than those caused by <annotation cui="C0021400">Influenza</annotation> A virus strains. <br> <br> The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules. <br> <br> <ol><li> Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. </li><li> <annotation cui="C0021400">Influenza</annotation> viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on <annotation cui="C0021400">Influenza</annotation> drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules. </li></ol> <div> <annotation cui="C0030567">Parkinson's Disease</annotation> Syndrome </div> Amantadine hydrochloride capsules are indicated in the treatment of <annotation cui="C0030567">idiopathic Parkinson's disease</annotation> (<annotation cui="C0030567">Paralysis Agitans</annotation>), <annotation cui="C0030568">postencephalitic parkinsonism</annotation> and <annotation cui="C0030569">symptomatic parkinsonism</annotation> which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop <annotation cui="C0242422">parkinsonism</annotation> in association with <annotation cui="C0877854">cerebral arteriosclerosis</annotation>. In the treatment of <annotation cui="C0030567">Parkinson's disease</annotation>, amantadine is less effective than levodopa, ( ) 3 (3,4 dihydroxyphenyl) L alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. <br> <br> <div> Drug Induced Extrapyramidal Reactions </div> Amantadine hydrochloride is indicated in the treatment of drug induced extrapyramidal reactions. Although anticholinergic type side effects have been noted with amantadine when used in patients with drug induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. <br> <br> |01417F60-DBF3-4041-BF3C-51E6C9216F06;062b646c-5ad9-4836-9e47-8678e1f2da7e;070d3275-4b91-441f-a4e6-5a67b7d768a5;14452da8-3b48-497d-9017-bdfb967b7f56;15e83cd1-79a7-4a96-bc18-7818228a4877;17f205dd-0feb-4c49-a0e1-2d0c362c6bd7;2b6e5b07-b3ba-4717-9ccd-029c0b08cc7f;33a3e25d-80fa-479f-a419-d9487281deff;4fb81272-194b-476e-a5a9-ea5c1d31c69f;5232b933-1df9-43b4-8ac2-61bfa4855e68;620eb102-b6b7-4107-9d9d-018f3c70bf99;63d9d4aa-5f92-45b0-98d0-d6ec38b727cb;7ef565b0-00ac-428e-b00c-e0c905659ecd;87db36f3-c831-4a84-a3c5-e9d6cc7191af;944ab74b-2657-4821-9f2a-e695b5f24d97;a2caed21-e9a3-228e-70a8-de30a1b368be;a8e74473-aaf7-47b5-9266-1d0814b06fdb;b208a0ad-a5e6-4f62-97a1-9f7a480fa325;c40ecd11-0b6e-4f13-bfba-8f011c60ca16;c446aed2-1add-4b09-9cc2-69ab95ae12d2;c74c9424-278d-4a52-8866-db66f6c3ac67;
10117|711d9458-4f79-4a75-84c5-95f8068bde70| <div> <annotation cui="C0014544">Seizure Disorders</annotation> </div> Clonazepam is useful alone or as an adjunct in the treatment of the <annotation cui="C0238111">Lennox Gastaut syndrome</annotation> (<annotation cui="C0595948">petit mal variant</annotation>), <annotation cui="C0347869;C0014550">akinetic and myoclonic seizures</annotation>. In patients with <annotation cui="C0014553">absence seizures</annotation> (<annotation cui="C0014553">petit mal</annotation>) who have failed to respond to succinimides, clonazepam may be useful. <br> <br> In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. <br> <br> <div> <annotation cui="C0030319">Panic Disorder</annotation> </div> Clonazepam is indicated for the treatment of <annotation cui="C0030319">Panic Disorder</annotation>, with or without <annotation cui="C0001818">agoraphobia</annotation>, as defined in DSM IV. <annotation cui="C0030319">Panic Disorder</annotation> is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and or a significant change in behavior related to the attacks. <br> <br> The efficacy of clonazepam was established in two 6  to 9 week trials in <annotation cui="C0030319">Panic Disorder</annotation> patients whose diagnoses corresponded to the DSM IIIR category of <annotation cui="C0030319">Panic Disorder</annotation> (see CLINICAL PHARMACOLOGY Clinical Trials ). <br> <br> <annotation cui="C0030319">Panic Disorder</annotation> (DSM IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. <br> <br> The effectiveness of clonazepam in long term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). <br> <br> |1617e8e2-54a8-4119-b865-d20d2350df3e;1aef0069-80ea-483d-ac70-c8d485462c5b;1db2ad9e-1a0f-4903-9129-7b2c1eb34266;1e1f2ba3-7b22-4f24-b707-c6d002b96f87;26b1d362-e727-49db-9e81-ee80ca97795c;2a005db6-1b26-3187-d3ad-bd3334100de2;38538a48-3f73-d43d-6d1d-fd87247ea4d1;3a9d9447-4459-439e-8792-6016bf4bccfc;3b4a0f73-24fc-435a-bd2c-f2bea57b670b;46881a4c-0c1b-4970-a37b-52f5438f0356;49d24679-eafd-4cf6-b011-b6b5c3fc15ef;4d586471-8b20-4899-94ad-31e0a519e99e;52a03dbc-0510-40ec-8a33-15bf1c404622;542f22e8-dad2-47a8-93b6-30936715d73b;56932302-d7e0-4b4b-ae10-3b64b56dab1c;6ceb3755-486a-4ee3-869d-ffaa39bc53d8;711d9458-4f79-4a75-84c5-95f8068bde70;79a3305b-be80-416f-a346-5a907f7b669e;7fe78a8d-1e6a-431e-958e-f1f1b420efa2;87d39a93-7a51-4662-8e57-f9950c995caa;9a29cc1b-df4f-489a-85ee-82eadd18b218;9af9e5de-69a6-48b3-aa53-f0a7898d51e7;ACBCE0E8-5098-4785-943B-8BDB5FF17FAB;a0a964e0-ffee-4c25-89b0-2d0887fb51f0;a58fe03c-2b5c-40dc-b592-3e376b2dc9f0;ae7bbf44-c5af-4bda-bc22-2388498ad529;af2385dd-0a2d-4e64-86c8-d6616f48fb9d;b8211ed9-1c60-3199-d218-5c3367b066ab;bc74a2bf-86ab-4bd4-9b36-75467f83b541;bd7c463b-eee6-496a-a781-91ca48629f7d;bda569c3-106c-41c1-913c-6f6e8e60bfd4;be578419-3419-4e9e-88ba-18c6ca660642;ced338a8-903f-4919-bf87-a375ae8ea219;d4a99e71-878c-461f-869c-563d246272c0;d5e73906-9a82-4c81-9325-03aa8ae2808a;e0c27a29-b895-4132-a2c2-8da4c0722d03;eb75c672-8c72-4967-b97b-4119d49a9cb1;ebc11109-e7bf-452d-b675-4b3236d54164;ec0e596c-baca-417d-8aa4-a1878100064d;ec134b69-3d24-44d3-b890-7ea641f5e502;f78213e2-c758-4a1d-810f-f9b2c2c35ecc;f90f8801-e566-4288-b661-f31450aff84a;ff316953-15c5-434d-abbf-7b675492e2cc;
10119|28d5753e-862a-4811-8b9f-6707361f8475| Orphenadrine citrate extended release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with <annotation cui="C0184567">acute painful</annotation> musculoskeletal conditions. <br> <br> |0f50125a-6d89-4b2b-b48b-daac6129182c;233915f1-7d58-4b4c-a2bb-e73179d61d07;2753a96d-406b-47d1-b0a5-3f9e0cebd789;28d5753e-862a-4811-8b9f-6707361f8475;34769dda-f555-460e-9064-98ab205393c5;7b76c8a7-dd0c-481c-8299-26dfd38ce066;8408d24e-3948-548d-bb12-b1edf0c05e12;8768cd6b-e79d-4b6d-8981-2f01ce28047b;8ca9438d-320f-4499-aee7-6b8ca7cccc65;c840e4b6-5b96-4346-8298-1078c166327a;c8d8596a-b81f-4b83-a2f3-a55922ca4a82;cd5ca6c6-0132-81bf-3307-1c321f716500;d0ea1b70-97a9-4593-905e-93c53ead73a7;
1012|1e400a04-69ff-8578-25c1-c4cc7cce657d| <br> <br> <div> <b> <annotation cui="C0032768">Postherpetic Neuralgia</annotation> </b> </div> Gabapentin is indicated for the management of <annotation cui="C0032768">Postherpetic Neuralgia</annotation> in adults. <br> <br> <div> <b> <annotation cui="C0014544">Epilepsy</annotation> </b> </div> Gabapentin is indicated as adjunctive therapy in the treatment of <annotation cui="C0751495">partial seizures</annotation> with and without secondary generalization in patients over 12 years of age with <annotation cui="C0014544">Epilepsy</annotation>. Gabapentin is also indicated as adjunctive therapy in the treatment of <annotation cui="C0751495">partial seizures</annotation> in pediatric patients age 3 to 12 years. <br> <br> |03646015-2d86-4d6d-958f-94687899b838;06f5461f-0a34-42e1-b84a-567ffafd8e99;0936a88f-b569-49c4-951b-14e8f6273b53;0a44132f-0c86-461c-94e3-bb3903619376;119ff7cc-5a38-490a-a982-7431b34d061c;125e4e70-b067-4daf-b017-8175def72d32;14d261dc-9511-4595-9361-adcf8e916d5f;161f2ca3-e746-40f2-95c7-f37ee62dfe2d;182472eb-d955-0b0b-5028-e93c67a913e7;1a619a14-0b63-4cba-80e7-474c9a1c90b9;1bc85f95-c26a-4037-a02a-2248f6518fe2;1dc96b52-7d43-4274-922f-3a070a165086;1e400a04-69ff-8578-25c1-c4cc7cce657d;236ecbbb-16a3-404b-b6de-5308c641c1a0;237b3a0c-8389-40e1-8fb0-1f6f4ed5bfb4;24716fdd-bbbd-43ff-99fc-3a601467bba0;25cf6c40-a239-4dd0-9cad-28da84d285db;2f45060b-ce5c-4869-87c0-fd7d2224e86c;2fe659eb-a8b4-491b-9195-fe979d7f0373;3865a6e3-112c-490c-82ac-35401336b16e;38d9d7d7-9f81-4517-acee-e34232215800;391e3f26-00fc-4ef0-aa5c-24264781a6a9;3a6ffb9f-4e3f-449c-a7e4-1315c7f026bd;41d1ead3-046e-4abf-ae0a-cb126a1f5848;43fb50c1-e6d0-4e59-aa57-640b939899a4;45c2c375-bab6-52d0-6125-70d49b74885f;48017784-d2b7-43cc-94bf-5c950d6be263;4e054319-5d50-49c3-9fe1-681234d81dc1;4e37278a-7d7f-4b6d-aaa6-1a808234af9e;501e8d07-bfc3-4427-b7d5-93c4d5874ab4;559849c3-0431-441c-a65a-7bf5d716cc5e;5ac5271e-316c-4802-a172-aa602d22571f;5dbdcf46-c0d9-4249-81fa-75bef5a69d84;5f02a461-8a24-4a56-9930-bbf1f0015568;632cb507-5675-2392-0460-b09c0dd14650;66e3f3fd-5e5e-4db6-a32e-40a88fef42fc;697071e0-f051-46c6-8b02-9131be9d4d28;6b3ca748-7172-4c53-b5ae-7e17dad918eb;6c554c68-7b9c-4863-beb2-a6a0aa45c61e;6fa84b06-4292-43c2-888e-3e62b4c19a3d;722de2a9-38b3-4518-b262-ba0d1346d0ba;749ade13-082b-40de-be54-541627075d74;74a05b3b-8e4f-4c72-881c-8215d40d14b9;772d9e7a-3811-455a-99e6-f2a3d0769b9b;78edc5af-9a37-45f7-893a-414eb890f07b;7b7e9d25-c6d4-43aa-9e0a-5427ed2ebdaf;7c3b232a-3e9f-4249-9e5a-295482ee288a;7cc64fca-e559-4299-bcd4-dca932695ae4;7d1c0aab-5385-4d42-805c-7be2b6cdfe4b;7dbc4275-2472-4eba-a8b1-6e4fe5cab5bf;7e351770-8975-4417-a599-feaa3cba7514;857f774c-ebd1-4332-860e-0c8647cbd70a;88b0347d-4341-4fa5-8002-8b934f862fde;8a300ebc-7f47-42e7-942b-921584eada3d;8c6b6588-d4a2-4377-a113-931666db2a9a;91bfbccd-2cd2-4ff7-9b3e-70dbdded1e2b;9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a;98bb408d-c402-4da6-8f9d-5de4833dedc4;998dcd24-c6f0-463c-9d13-e5c72b0e8fa0;99adb2c7-4725-4768-a2d9-856a87f33192;A36432F9-BDDD-4B22-BE6D-ED6AC2B3846A;a1201cd7-6ce8-443c-b556-a3361e54f3d4;a2109f51-f1e5-4ba5-b3b1-3e3ebee6cf1d;a2a4c832-286a-46ba-9b6f-fa1e6e01a813;a33dd4d8-7d6e-4d15-ae49-9c400059c794;a5e50344-e351-494b-9a60-af023b255937;a7baa9ea-6cd5-4a86-8936-8e47ed794db5;a806ba79-f8f0-4fe7-b754-59921a93d5ed;a99cffb0-4504-4e61-b8a7-69aa35c04b01;aa2e353f-860b-4d10-9a62-aad1c533b8aa;aaf4d420-13a9-412e-b0ea-64234b49a57e;b11dbff5-ceee-4a63-a093-f6efebdc2f6f;b2df0e0e-43ba-47ab-b8f9-22c8010772ba;b53c69ca-3f9d-285d-7568-aba4a6c87b05;be462235-9fa6-457d-b4bb-31277eab1387;c375ec41-b099-4bb0-a23a-76f3f7a858b7;c64c09c9-0567-4a4f-b2c6-8f667986c9af;c9a05f0c-b5f0-422c-9d67-6d0efc921a74;ce4a0985-fac9-4688-9a48-0f2943bf6434;ce99bebb-8b73-4d45-b922-9c22e18f32ce;cff7de45-148b-4e96-88fd-6052bf75b5f7;d44e1bb6-8971-26f8-466d-26bcbcc0c3fe;d7bd10f4-c7b8-4a4d-a183-18e0fdda9498;d8f08084-ef02-4819-9842-727920232972;d9a88774-1fb2-4a5d-8753-686af1f0e174;e116597c-1782-4fc1-9550-4a08777d1056;e317f249-deb4-4679-8c9f-a7c24d07120b;e5f8fd45-47c8-41c8-a011-58b27e4fdf21;e61dca43-98d6-4692-a007-4c81a56906ed;e83f9532-9671-4815-866c-72ff4795738b;e9f2d8a6-fabe-436d-8fba-4976229692f9;ec88f3f4-50f1-4e92-942e-0d377b26619e;edd51b3d-f69e-4390-89ae-bf8065f4120f;f7c1fd34-d615-43a2-8989-898fe11f90df;
10120|bf92a7d7-395b-4e2c-a3c4-66ebdbfd1052| Fluconazole for Oral Suspension is indicated for the treatment of <br> <br> <ol><li> Oropharyngeal and <annotation cui="C0239295">esophageal candidiasis</annotation>. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of <annotation cui="C0006840">Candida urinary tract infections</annotation>, <annotation cui="C0031154">peritonitis</annotation>, and <annotation cui="C0153252">systemic Candida infections</annotation> including <annotation cui="C0877445">candidemia</annotation>, <annotation cui="C0153252">disseminated candidiasis</annotation>, and <annotation cui="C0032285">pneumonia</annotation>. </li><li> <annotation cui="C0085436">Cryptococcal meningitis</annotation>. Before prescribing fluconazole for <annotation cui="C0001175">AIDS</annotation> patients with <annotation cui="C0085436">Cryptococcal meningitis</annotation>, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non HIV infected patients have not been conducted. </li></ol> Fluconazole is also indicated to decrease the incidence of <annotation cui="C0006840">candidiasis</annotation> in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. <br> <br> Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly. <br> <br> |00866401-6936-478e-8848-bb1cfe83e82e;08afda78-eb23-4c0e-ba02-690598e5af9c;15638656-0430-4157-bb13-32ede85131e1;2554e49e-97a6-4543-b844-e60f05f7ae8e;260e7bba-36c7-4d29-8781-48b25e75cf60;26672A97-ADF3-9F1D-4BDC-B2606747BBF5;26d01204-4002-4f4e-9c50-49c5a74858db;28ca966f-b02d-4471-bb2d-f147738dd091;3da5f41d-5200-45ac-b89d-00881237ec85;45f027f5-3bd9-4f2e-8626-1526bc559abf;49421564-d2d3-4f69-93b2-bd9eec7feb8f;4d7cf836-d115-456c-a636-6f05eae043cd;5314ab7a-e750-4e6b-8ef2-e37f831e088b;578a6b9f-a77a-4619-8d13-7810f30fa04b;5d8db96a-c0f5-44c5-aadd-72433ea30e46;5fa71668-364e-467a-929c-ae2c9acd66ac;6ebf24fd-41cd-4b3c-8176-a1436253ba2d;6f400537-0d6b-3800-4803-53536250f511;737e0fac-a2d2-4053-a0d7-edbfb6248f69;82a362e8-65e7-4270-b11c-2be167618964;85f181a3-ea62-48c8-9b6d-9b43b7b47808;892aa268-0790-4e2c-8faa-d8cbeb200abd;89d96ed5-53f3-486c-89b2-f0eb63959a2f;8e80f9d8-2577-4fd9-a455-e6c6dc244c3a;91431bad-6a95-4cea-b5b1-a0160d19ef5a;926100a4-98b2-40ec-8592-56f86fa0cf22;9843b969-33e1-4859-8eae-0055bb71d933;9ce3a3cc-bad7-485b-b7b9-914e8053ce04;D7FA1D79-4CD3-4A55-B74B-B31E82E616A3;a2360c52-f2b3-43c6-8485-292d828a7488;aebbf53e-43d2-4d44-8838-481723c4749e;afde17e7-b95b-4cd5-97eb-e361724014bd;b3d97a44-9ae7-43d2-9e7e-60cae66a5adf;b3efaffa-9ef9-4a4f-998e-aa7d2eb61fc9;bf588f7e-89de-4b4e-8d33-c1ff2be1b34e;bf92a7d7-395b-4e2c-a3c4-66ebdbfd1052;c0d505ad-eba0-498d-890c-ebcab8386c62;cd24a261-9c15-42b4-8040-89d2dbda174e;cf26b007-df4f-4936-b2d3-183969761f69;d3ca59bd-ae00-48ab-89aa-87c7f56e9989;dd975843-c3e4-44f4-bb0d-33b294c1f6fb;e563332a-f866-4395-85d3-5ccd217d1ebf;ea52219d-7f3d-4aea-b733-c35b446312e2;f1991013-5fdf-4a5b-940a-0ae68a2462d1;f694c617-3383-416c-91b6-b94fda371204;
10127|716bf76f-ae98-498d-8960-0b35aa90c92b| Carefully consider the potential benefits and risks of diclofenac sodium delayed release tablets and other treatment options before deciding to use diclofenac sodium delayed release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <b> WARNINGS </b> ). <br> <br> Diclofenac sodium delayed release tablets, are indicated <br> <br> <ol><li> For relief of the signs and symptoms of <annotation cui="C0029408">osteoarthritis</annotation> </li><li> For relief of the signs and symptoms of <annotation cui="C0003873">rheumatoid arthritis</annotation> </li><li> For acute or long term use in the relief of signs and symptoms of <annotation cui="C0038013">ankylosing spondylitis</annotation> </li></ol> |0055edbf-f1f6-4b50-8e41-202c5a2a7883;05a94f49-3f12-462c-9180-ae75719d3441;0c3ac260-586d-4203-855b-f7518e89484e;0c4281ab-1cd8-4e45-904c-9b9f5940c3bb;1582c050-925a-4af8-a44f-948017946ae6;1728cd89-1bb4-4b55-8e1c-9181702e4c51;19b4ff5c-adb7-a0d0-7ef2-4ae05047fd94;1b291d0a-1350-4637-bab3-f0bf43ab2a13;1d1d442c-b423-4843-a15b-197dbfeb5df1;24845e58-5bfe-4a74-beec-696a564fb68c;2cc4fc25-1948-445d-aa50-81fc7a5222a5;2d92077c-75d2-4b34-8704-71660f77a63b;3330ea92-fc9d-4541-b378-be399b0995d3;36ce096d-625f-4907-bfaa-49ac04dc7df1;40879600-ba6c-43a8-aa5d-d0d41503d593;42fcf2b5-3466-4493-8a47-c4675538ece3;4b0d7319-a587-4648-bded-5b35b8efa1cb;4c1e3237-288d-4d30-b8e9-8a935602ee17;546c9817-e41b-4b1d-a1dd-1e9304c97557;688fa1d0-6e17-4191-8618-8f62bc7765d3;6b7fb6b7-2f58-4cb6-b48f-e9b4cf292365;70c96b78-3702-4216-819f-1071770494bf;716bf76f-ae98-498d-8960-0b35aa90c92b;717341fc-e067-0005-215c-053f6d12e0d1;77b60a0c-e49a-4ad4-abb1-b662c24ab782;7a7ee8e2-5137-4abf-9d75-5db51a69b88b;807a0f13-93e5-4388-b3e9-5edc2a319640;87d5a720-f154-4c4b-b2d4-0ae58455dda0;8E6E1AEA-D1C9-F6BF-2A8C-0504437BE95C;8a33def9-169d-4370-ba72-9d7a4117530e;93879f33-d484-471d-94e2-a5ba37eb44d5;97532b47-41c4-41e5-a89b-fc788528204b;9e2244cb-f50f-4fbb-b6b8-acbba8459081;a0a86ecf-e6fe-4c85-ac60-f62fd63e2590;a1339d2d-066e-459c-93b7-1ba839b15e2e;a57b897e-0cbe-4ac3-969f-b00357a0cfa8;ae0257c5-c16e-4c95-83b6-f9ae02792884;bd27460e-46ff-4450-a4f2-a41420c1f93d;be8ba28b-2739-4db0-8bde-414f4cec4c02;bfa8cb40-3528-4d41-ae77-444e521e30c0;c1888b7a-0a14-4e24-9ba7-1458154d07d9;d349b4ca-3aec-44a8-a4d5-87be4c822190;d44134d1-2ca9-4249-872c-65a7186870c8;d751e65a-5086-4303-864b-bd9ed895a239;d77f1654-4423-464f-a846-6767a2377ce1;df63e944-bfb7-453d-bbd8-63f545826784;e424b30d-8f40-48b7-bb99-415f92d84ed0;e780534f-5b33-42f8-ae35-ccf8ee652035;e8527a76-4efc-4ead-a11d-87252693fa36;eff16712-d4c4-4e7b-bf38-c467de1095f4;f0e00d55-02b7-4642-a60e-6a5841932ca5;f32c0225-fd21-468a-90f5-6083071e80fb;fac1f8e7-f2b4-4de3-bd5c-d798d12273c1;ffbf7573-c726-42f6-bbd5-5d2533d8288f;
10129|03b03029-2a91-2170-9318-bb721ec00b02| Carefully consider the potential benefits and risks of etodolac extended release tablets and other treatment options before deciding to use etodolac extended release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <b> WARNINGS </b> ). <br> <br> Etodolac extended release tablets are indicated <br> <br> * For relief of signs and symptoms of <annotation cui="C0553662">juvenile arthritis</annotation> <br> <br> * For relief of the signs and symptoms of <annotation cui="C0003873">rheumatoid arthritis</annotation> <br> <br> * For relief of the signs and symptoms of <annotation cui="C0029408">osteoarthritis</annotation> <br> <br> |01F99FFF-4CD8-401F-9481-9CAC4E87BA2D;01e3d8df-4aa3-4508-a827-e81ce01233ea;03b03029-2a91-2170-9318-bb721ec00b02;13a5bcfc-d2b3-4ba6-a8e0-b019bf59e918;17c8639e-f1ae-4733-992c-27506591871e;1c49e27f-e028-4d79-b4c7-cb1c46ba8e4d;27236095-98b3-4588-9840-f247a7e29207;2c5b44b4-78d5-43b2-827d-d2763b6672b3;4b5513c3-b57f-46f1-9855-dad1063aa4c9;4d682f98-1e8a-4c2b-6df3-169d2ed10dc1;545fbc05-05f7-40ea-a4cb-1ac64d6b19ab;58340508-b1cb-4607-9158-f2b3700accba;58f0a8e6-a430-4e20-a097-28fecdbbbd6b;5e85f9c3-8f5f-4a60-9b1b-b8fa2e4844fd;62e9b4a2-868d-45ea-af45-f193e7ad52bc;65b5d8e3-8dcc-4297-ae85-5b5cb7c81f61;7e2f72a2-a76f-46a0-9a0b-4414633bb864;816576ac-c49d-4762-9722-e30493d6af83;82ef8726-d6c8-458a-86d5-4ec5fd514681;86719bea-90f8-4696-ad0c-10a31967c850;86c7b7b8-3a98-e5f4-c558-5b5caede6377;885A90B0-7C9F-4BC9-9F22-2C16F15EB108;8966c049-dc10-4522-9d97-abee99334c3d;9b78a9d6-5600-4e01-83d9-bd348b110cf6;9c244c88-dcc4-44fb-b0d9-13732dc705f5;a8984705-a43a-4977-808a-44df42930de1;a91c0e86-9601-c77a-9166-5005f4b95e21;b17228a1-38c3-4fa3-a83d-0654f18edabc;ba37476d-05a4-48cb-9cee-6b10e0dd5bf4;bc9b721d-bc0b-4269-b388-8f2d411af779;ccd211e9-aae4-40f5-a3ef-621c9e584e63;cf17926c-ed90-4fd0-80af-ccee084075e8;d7cf7ed9-d7b4-4dcc-8a25-a9177c54f847;db60911a-2bb1-4e8c-baf0-7cf281bf5778;e78781c4-ac46-43b6-af8c-331233a3bb6b;ec82b108-6a6f-4d1b-82cb-831d4ed36c80;ee10e027-5953-4d10-8c58-5f2412978a49;f3bf1675-8fda-40d3-8427-0a6a6133a3d3;fb5ccbff-d578-4b48-9bed-175b9a48aafe;
1013|d534867a-e4ef-46ce-b61d-857387ce450a| <div> <annotation cui="C1269683">Major Depressive Disorder</annotation> </div> Fluoxetine capsules are indicated for the acute and maintenance treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> in adult patients and in pediatric patients aged 8 to 18 years The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods, should periodically be re evaluated . <br> <i> [see ]. Clinical Studies (14.1) </i> <br> <br> <i> [see ] Dosage and Administration (2.1) </i> <div> <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> </div> Fluoxetine capsules are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> (<annotation cui="C0028768">OCD</annotation>) The effectiveness of fluoxetine capsules in long term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo controlled trials. Therefore, the physician who elects to use fluoxetine capsules for extended periods, should periodically re evaluate the long term usefulness of the drug for the individual patient <br> <i> [see ]. Clinical Studies (14.2) </i> <br> <br> <i> [see )]. Dosage and Administration (2.2 </i> <div> <annotation cui="C0006370">Bulimia Nervosa</annotation> </div> Fluoxetine capsules are indicated for the acute and maintenance treatment of <annotation cui="C0006370">binge eating</annotation> and <annotation cui="C0042963">vomiting</annotation> behaviors in adult patients with moderate to severe <annotation cui="C0006370">Bulimia Nervosa</annotation> The physician who elects to use fluoxetine capsules for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient . <br> <i> [see ]. Clinical Studies (14.3) </i> <br> <br> <i> [see )] Dosage and Administration (2.3 </i> <div> <annotation cui="C0030319">Panic Disorder</annotation> </div> Fluoxetine capsules are indicated for the acute treatment of <annotation cui="C0030319">Panic Disorder</annotation>, with or without <annotation cui="C0001818">agoraphobia</annotation>, in adult patients . The effectiveness of fluoxetine capsules in long term use, i.e., for more than 12 weeks, has not been established in placebo controlled trials. Therefore, the physician who elects to use fluoxetine capsules for extended periods, should periodically re evaluate the long term usefulness of the drug for the individual patient <br> <i> [see Clinical Studies (14.4) </i> <i> ] </i> <br> <br> <i> [see ]. Dosage and Administration (2.4) </i> <div> Fluoxetine Capsules and Olanzapine in Combination Depressive Episodes Associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> </div> . Fluoxetine capsules and olanzapine in combination are indicated for the acute treatment of depressive episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> in adult patients. Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>. <br> <i> When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax </i> <br> <br> <br> <br> |02d91219-7a5b-492f-b0f6-6de0d0236542;02e761f7-24e4-4685-8fb5-0fe9cbbff8f7;06d71a33-5578-4012-b11d-764f45bc1e6a;0a2787f9-0166-4fa7-9f02-7d355609dabf;0d97a780-be38-4f5e-ba45-d3b5be262c63;0e31b689-9a56-4222-b4ec-055ff44b5ee5;0e817af0-85f5-46a5-82a4-e08b1f701e86;1cbda269-2d69-453a-abe3-734a684d835a;1dc008e7-5b9b-ddcd-c369-9dc080bbd00b;20274ff0-f18c-4333-afab-e85ea236dea4;28d1233a-12b6-4b24-9ab6-079b005826ae;2ef69eb9-ef5b-431f-aeb2-34fc360a7bb5;35fee753-acd7-4da2-bd60-973dc6c0b21f;369dbfba-9de4-433c-8680-2ec047b8f8d9;37bc2c81-ac05-4a7f-aa8f-cc138dd9b895;3ccada47-7eb9-285d-5059-06afb4466114;4410511e-48ea-4ff4-9535-752863a0ee8f;45454555-7402-41cb-a452-e6a76e04f387;464d0fc2-b307-42dd-853d-9d878358d6af;4e81573a-ea76-47f8-897e-0e1d98550e46;59de2889-c3d3-4ebf-8826-13f30a3fa439;5e47c25f-c865-470d-8ea3-b4f9ca2ba5ba;5e814a91-4bb2-4c8d-bdb5-c64ce5babf07;5f356c1b-96bd-4ef1-960c-91cf4905e6b1;608d4639-06d7-4b0d-ad2d-02e556c17f7c;62c47df4-2c71-437e-b142-bc193f6277f0;662f3e16-bf42-4127-8e56-4eb45780e059;6bc0214b-b6f9-463d-a689-a93e59512b60;7125a96a-0e98-4984-8b57-a2e7a99b7b0d;821b8070-9f6c-4810-8eed-d42a31627d3b;837a3746-7f9a-43a5-a021-e70856df34ee;8609ed02-0b30-4c82-bab1-4d51d92ec224;88989ab9-8143-404d-8488-67a289e525b4;894ece20-b681-4b7b-a452-113844594b31;8953d343-d137-4ca5-a73f-3ceff1505b55;930a8a8c-a81a-4110-bb2e-c87e531cbd83;9ab14775-86b8-4a84-bec5-007dd29f3101;9e1353d7-83d1-4522-9352-5545db044a50;a1575590-4bdd-4f66-91fb-337e5f681747;a2d6beb9-bec4-4623-bcc9-7f1bfddb9f0b;abccfe74-aaf9-4729-a196-2d666f9562b5;ac0fe5db-e89e-4de7-9bba-15c966776f2a;aca0b44e-598d-490b-87f4-f6701d1aad9e;b050b0ee-107c-4f82-8031-92ec68baa6a2;b07f9eab-44ac-4667-bd46-52d736daa5d6;bb06af33-8ff7-0b02-0029-d628f62e1382;befdb67d-62e6-4f40-9183-30b6e0718c53;bfd18a45-06cc-4281-b181-40eb5d192a9b;c3edb2c8-acff-47f6-aa8a-21a07287cd76;c88f33ed-6dfb-4c5e-bc01-d8e36dd97299;d31c9625-30c8-4efd-a31f-13930705d573;d534867a-e4ef-46ce-b61d-857387ce450a;db1c840d-ab22-4a4c-9ced-ae82c869dd9b;e07fa54e-f4ee-496d-a7e9-533c85564be1;e5336cf0-04c9-45f2-b364-5d9132726c52;e6c2595a-1470-4cf4-93ea-0fedf917cf85;e9d6c462-84af-4371-bc05-78cb0bcb589d;ecd112ab-7420-4fe4-9288-a3f1fd83eee1;f27ef79a-d212-4752-8300-b88b61d0464d;f719162f-cb78-487c-b172-ac10d009e6f5;f7994951-93d4-42cb-88f5-b8ad8e9f5037;
10132|722a733e-60ee-4ef8-83d8-a3196160ac76| Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with <annotation cui="C0242339">dyslipidemia</annotation> at risk for <annotation cui="C0004153">atherosclerotic vascular disease</annotation>. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total C and LDL C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. <br> <br> <u> Primary Prevention Of <annotation cui="C0010054">Coronary Heart Disease</annotation> </u> In individuals without symptomatic cardiovascular disease, average to moderately elevated total C and LDL C, and below average HDL C, lovastatin tablets are indicated to reduce the risk of <br> <br>   <annotation cui="C0027051">Myocardial infarction</annotation> <br> <br>   <annotation cui="C0002965">Unstable angina</annotation> <br> <br>   Coronary revascularization procedures <br> <br> (See CLINICAL PHARMACOLOGY , Clinical Studies.) <br> <br> <u> <annotation cui="C0010054">Coronary Heart Disease</annotation> </u> Lovastatin tablets are indicated to slow the progression of <annotation cui="C0010054">coronary atherosclerosis</annotation> in patients with <annotation cui="C0010054">Coronary Heart Disease</annotation> as part of a treatment strategy to lower total C and LDL C to target levels. <br> <br> <u> <annotation cui="C0020443">Hypercholesterolemia</annotation> </u> Therapy with lipid altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for <annotation cui="C0004153">atherosclerotic vascular disease</annotation> due to <annotation cui="C0020443">Hypercholesterolemia</annotation>. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total C and LDL C levels in patients with <annotation cui="C0342879">primary hypercholesterolemia</annotation> (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. <br> <br> <u> Adolescent Patients With Heterozygous <annotation cui="C0020445">Familial Hypercholesterolemia</annotation> </u> Lovastatin tablets are indicated as an adjunct to diet to reduce total C, LDL C and apolipoprotein B levels in adolescent boys and girls who are at least one year post menarche, 10 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present <br> <br> LDL C remains >189 mg/dL or <br> <br> LDL C remains > 160 mg/dL <u> and </u> <br> <br> there is a positive family history of premature cardiovascular disease or <br> <br> two or more other CVD risk factors are present in the adolescent patient <br> <br> <b> General Recommendations </b> Prior to initiating therapy with lovastatin, secondary causes for <annotation cui="C0020443">Hypercholesterolemia</annotation> (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total C, HDL C, and TG. For patients with TG less than 400 mg dL(<4.5 mmol L), LDL C can be estimated using the following equation <br> <br> LDL C = total C   [0.2 x (TG) + HDL C] <br> <br> For TG levels >400 mg dL (>4.5 mmol L), this equation is less accurate and LDL C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL C may be low or normal despite elevated total C. In such cases, lovastatin tablets are not indicated. <br> <br> The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below <br> <br> After the LDL C goal has been achieved, if the TG is still 200 mg dL, non HDL C (total C minus HDL C) becomes a secondary target of therapy. Non HDL C goals are set 30 mg dL higher than LDL C goals for each risk category. <br> <br> At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL C is 130 mg dL (see NCEP Guidelines above). <br> <br> Since the goal of treatment is to lower LDL C, the NCEP recommends that LDL C levels be used to initiate and assess treatment response. Only if LDL C levels are not available, should the total C be used to monitor therapy. <br> <br> Although lovastatin may be useful to reduce elevated LDL C levels in patients with combined <annotation cui="C0020443">Hypercholesterolemia</annotation> and <annotation cui="C0020557">hypertriglyceridemia</annotation> where <annotation cui="C0020443">Hypercholesterolemia</annotation> is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** <br> <br> *** Classification of Hyperlipoproteinemias <br> <br> The NCEP classification of cholesterol levels in pediatric patients with a familial history of <annotation cui="C0020443">Hypercholesterolemia</annotation> or premature cardiovascular disease is summarized below <br> <br> Children treated with lovastatin in adolescence should be re evaluated in adulthood and appropriate changes made to their cholesterol lowering regimen to achieve adult goals for LDL C. <br> <br> |058b94d0-9811-4dd2-a28d-377a26e5e6f8;0a680e13-0356-4e08-a7fe-78b96ba51b9d;0e15feec-d27e-4861-8152-c5a8b8ccacd4;10a557fe-6620-4b15-862a-d3ff5dece612;15ca7e87-e640-4788-b3d5-a15a0e3aa034;165c9a95-de9b-44fc-a26a-40737a0d6bfd;18e678d8-f1cd-4970-8ae1-f701186180a4;18fae555-8c03-4cec-8c65-c7fdaea4b958;1ac3b68a-ca60-43c5-a208-f92f10008521;347c802f-4ea9-41d4-80d6-e4a183f22179;3895e5cb-14d0-4676-9e57-3c224806bf3e;41b6dbdc-a41a-426e-8ad4-c5d52ee87ae8;462dce28-bed1-4885-972b-a6e1028fcead;4fc5df6d-9253-409c-9c4f-26159aa651bd;50b7fc3e-de79-4b08-a2b7-b05110ec70fb;520428f1-2cd5-447f-8782-c8505ce65b72;5a33d7f7-6a79-62df-baaa-57950e256842;5f2cff3a-8862-4c87-90aa-0ca16def7914;61caf965-1172-4200-ad56-a3815388c044;722a733e-60ee-4ef8-83d8-a3196160ac76;73f92f9b-3715-4699-ba60-1ffecd677e23;8c2ead65-6489-4841-9bd8-97165b94aab3;8d2199d5-80bd-497f-8c74-f3e613b9800d;930C6836-88DC-483F-A95E-481522D2DD68;9ab4e06f-2d51-4247-bf43-4636b416e96a;A694C480-76F3-42C3-BB67-BED50E12C1AE;b1f9a948-f807-4256-b221-e431167f9d54;b6442f16-1548-4224-b03d-cf6f672055ad;caf7c3af-8256-4557-af40-e8143e9af9f1;d3620ebe-87e1-4a93-96cc-ff20ddbb30b2;d8d3b5b9-7ac7-445a-96c7-b5218417d9f8;db39f510-b247-46a4-a5ad-8da13697ec0c;df7ddf4f-d569-431e-81f1-9129d7043150;e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01;f5766e3f-374d-47b5-b141-2767cb7a4693;f65dbfca-bfb4-42ed-9b05-34769d81d04c;
1015|198a4140-f4c0-4478-9157-ee1d68d0bb96| Carefully consider the potential benefits and risks of ketoprofen immediate release capsules and ketoprofen extended release capsules before deciding to use ketoprofen immediate release capsules and ketoprofen extended release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). <br> <br> Ketoprofen immediate release capsules and ketoprofen extended release capsules are indicated for the management of the signs and symptoms of <annotation cui="C0003873">rheumatoid arthritis</annotation> and <annotation cui="C0029408">osteoarthritis</annotation>. <br> <br> Ketoprofen extended release capsules are not recommended for treatment of acute pain because of its extended release characteristics (see CLINICAL PHARMACOLOGY Pharmacokinetics ). <br> <br> Ketoprofen immediate release capsules are indicated for the management of <annotation cui="C0030193">pain</annotation>. Ketoprofen immediate release capsules are also indicated for treatment of <annotation cui="C0149875">primary dysmenorrhea</annotation>. <br> <br> |198a4140-f4c0-4478-9157-ee1d68d0bb96;51f3222f-bc05-4117-881d-85880b092e42;6b36cfde-9ecd-4532-88ee-14261f729d06;79f475c8-f978-c0ee-b900-f270b59c492d;9bc31f67-cfce-4ad6-9c07-3845ead3542c;b3180408-a3c0-4e02-8535-dea390a52277;b7967cca-921e-49af-b64b-78c87ca7f776;c2c99853-1268-4998-a44b-2bf0c0b70fd2;d471d6b5-2a16-41a0-9058-cbe5dfa3011f;dc21a4f9-d8f3-4804-ba3e-a26cae143f26;ecf6bc02-233d-2c3b-1ba0-e5d708338e45;f0d14edb-7e04-4155-8034-1bed7f0318b0;f9d258bc-2ae3-4cc8-a5d4-987164c1e0b4;
10184|231e2433-31fe-4612-80f0-ba00dee3b26a| <div> <annotation cui="C0036341">Schizophrenia</annotation> </div> ABILIFY is indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation>. The efficacy of ABILIFY was established in four 4 6 week trials in adults and one 6 week trial in adolescents (13 to 17 years). Maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents <i> [see CLINICAL STUDIES (14.1) ] </i> . <br> <br> <div> <annotation cui="C0853193">Bipolar I Disorder</annotation> </div> <b> Acute Treatment of <annotation cui="C0349208;C0338831">Manic and Mixed Episodes</annotation> </b> <br> <br> ABILIFY is indicated for the acute treatment of <annotation cui="C0349208;C0338831">manic and mixed episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>, both as monotherapy and as an adjunct to lithium or valproate. Efficacy as monotherapy was established in four 3 week monotherapy trials in adults and one 4 week monotherapy trial in pediatric patients (10 to 17 years). Efficacy as adjunctive therapy was established in one 6 week adjunctive trial in adults <i> [see CLINICAL STUDIES (14.2) ] </i> . <br> <br> <b> Maintenance Treatment of <annotation cui="C0853193">Bipolar I Disorder</annotation> </b> <br> <br> ABILIFY is indicated for the maintenance treatment of <annotation cui="C0853193">Bipolar I Disorder</annotation>, both as monotherapy and as an adjunct to either lithium or valproate. Maintenance efficacy was demonstrated in one monotherapy maintenance trial and in one adjunctive maintenance trial in adults <i> [see CLINICAL STUDIES (14.2) ] </i> . <br> <br> <div> Adjunctive Treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> </div> ABILIFY is indicated for use as an adjunctive therapy to antidepressants for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> (<annotation cui="C1269683">MDD</annotation>). Efficacy was established in two 6 week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode <i> [see CLINICAL STUDIES (14.3) ] </i> . <br> <br> <div> Irritability Associated with <annotation cui="C0004352">Autistic Disorder</annotation> </div> ABILIFY is indicated for the treatment of irritability associated with <annotation cui="C0004352">Autistic Disorder</annotation>. Efficacy was established in two 8 week trials in pediatric patients (aged 6 to 17 years) with irritability associated with <annotation cui="C0004352">Autistic Disorder</annotation> (including symptoms of aggression towards others, deliberate self injuriousness, temper tantrums, and quickly changing moods) <i> [see CLINICAL STUDIES (14.4) ] </i> . <br> <br> <div> <annotation cui="C0085631">Agitation</annotation> Associated with <annotation cui="C0036341">Schizophrenia</annotation> or Bipolar <annotation cui="C0338831">Mania</annotation> </div> ABILIFY Injection is indicated for the acute treatment of <annotation cui="C0085631">Agitation</annotation> associated with <annotation cui="C0036341">Schizophrenia</annotation> or <annotation cui="C0005586">bipolar disorder</annotation>, <annotation cui="C0338831">manic</annotation> or mixed. Psychomotor <annotation cui="C0085631">Agitation</annotation> is defined in DSM IV as excessive motor activity associated with a feeling of inner tension . Patients experiencing <annotation cui="C0085631">Agitation</annotation> often manifest behaviors that interfere with their diagnosis and care (eg, threatening behaviors, escalating or urgently distressing behavior, or self exhausting behavior), leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the <annotation cui="C0085631">Agitation</annotation>. Efficacy was established in three short term (24 hour) trials in adults <i> [see CLINICAL STUDIES (14.5) ] </i> . <br> <br> <div> Special Considerations in Treating Pediatric <annotation cui="C0036341">Schizophrenia</annotation>, <annotation cui="C0853193">Bipolar I Disorder</annotation>, and Irritability Associated with <annotation cui="C0004352">Autistic Disorder</annotation> </div> Psychiatric disorders in children and adolescents are often serious mental disorders with variable symptom profiles that are not always congruent with adult diagnostic criteria. It is recommended that psychotropic medication therapy for pediatric patients only be initiated after a thorough diagnostic evaluation has been conducted and careful consideration given to the risks associated with medication treatment. Medication treatment for pediatric patients with <annotation cui="C0036341">Schizophrenia</annotation>, <annotation cui="C0853193">Bipolar I Disorder</annotation>, and irritability associated with <annotation cui="C0004352">Autistic Disorder</annotation> is indicated as part of a total treatment program that often includes psychological, educational, and social interventions. <br> <br> |0424faf3-202f-438a-b65e-2a228790b8f9;16710a27-aa76-4dd7-92e8-7d3c7efe3e42;217e52b5-3a7b-4bbe-af3c-b18de7d426c3;231e2433-31fe-4612-80f0-ba00dee3b26a;440012b2-4fab-4e2e-ba7f-6ca5558d1e23;b6243233-8846-4ea8-a2fa-a563e48fdc29;c040bd1d-45b7-49f2-93ea-aed7220b30ac;d8275c2d-f42d-4f32-aa9f-03a202c8e99f;d9fc9628-40da-4eaa-ba7e-412c90abe35c;e8fe516e-25fc-45f6-9a88-542deaa1c3e8;ffb6ef30-2619-4652-864c-4d5e94526a15;
10185|effe46a4-c383-4171-8ab4-2af9de316f08| Cephalexin capsules, USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms <br> <br> <ol><li> <annotation cui="C0035243">Respiratory tract infections</annotation> caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin capsules, USP are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsules, USP in the subsequent prevention of rheumatic fever are not available at present.) </li><li> <annotation cui="C0029882">Otitis media</annotation> due to Streptococcus pneumoniae, Haemophilus influenzae , Staphyloccus aureus, Streptococcus pyogenes, and Moraxella catarrhalis </li><li> Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes </li><li> <annotation cui="C2242472">Bone infections</annotation> caused by Staphylococcus aureus and/or Proteus mirabilis </li><li> Genitourinary tract infections, including <annotation cui="C0149524">acute prostatitis</annotation>, caused by Escherichia coli, Proteus mirabilis , and Klebsiella pneumoniae </li></ol> <i> Note </i> Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, cephalexin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |037608ba-5c96-42a3-92a6-fb956bf2516d;03f6f6ae-66bc-6819-8ba9-7c9c3fbef90d;0bca5df2-55c2-491f-9283-f68f2b04c405;10d94a20-5b0d-4d39-934e-9595be20b7bb;12b6bac5-00a3-437b-a172-d4e09c273c8c;19307ff0-71de-477b-965d-ea243e5ede3a;1d3e6d33-5dc2-498e-8efa-e3c4fca15dff;1fc40f29-1d19-4ee3-97d3-f9dddf27f2ae;22ab5dba-bfce-498d-a644-9ca0e343b1cf;25b87a16-3e28-45b5-9ae8-98053f1f387a;25ef498a-7a7e-4543-a544-b9d0e99f9cd9;278c84f7-530c-45d5-bdcb-78a3cc1a3700;27f5aa5b-28ca-4154-b37e-18a931bf3398;2b388b1e-cd59-42de-ba72-858485b070b7;2b425c29-a6eb-448b-b317-7a360c5a9b55;309584ff-4353-44bf-bdaf-851ceb0ca7c3;37ec3f8b-51d1-4d74-a4ee-9240c734b1a6;3fed2817-fc0d-43cd-9f02-948fbc76672c;45d5d3f1-43e6-41e4-b2b4-51ba9085a526;4e334e50-19c4-449b-b77f-549a461c7f84;561d93f2-0282-4dec-bac9-840923657df7;5681d4d2-9b67-4cac-9b94-8368f9978231;5de0f7c1-d152-45f7-bfb7-9e5404d9f74b;5dfec608-4a61-45d6-b535-42c4cb8a170c;5efa48e3-1f8e-4a69-b41f-bf1adc754f94;68fba58a-7748-4581-8432-f5286c46d90a;6abc40af-be15-405e-845c-c31866b3d6f6;6ce11859-aa21-4b3f-bd59-3cd26deca82b;6fa9d90d-d3da-47eb-859c-ad5589d3e1a9;704ed0b7-4ad3-4bb6-beac-221d20238216;715cecc7-27e4-4cb6-9ba4-9d81b734480b;75262b2e-4b10-4a37-b32a-828f17aebd03;7ae019f7-ae75-4a5a-a7a7-38cb0992c127;803cdf4c-77ec-4b9b-bc2d-873eb236f9c7;80f6f146-a91c-4452-bc83-2e47c5671d91;8494bec5-8404-43e4-bfa1-a7270b8dfbf7;87f388c6-c942-47f5-b685-0f7ce0e431f4;88c0130e-d901-43da-bd37-14704be586d5;8e28f049-6110-4473-830f-c494191a7197;9a75fb7c-c249-4885-8a8f-78678b537452;b5da860d-9cfc-4020-bc81-11f2a01e660b;b8136dc3-3942-4c72-a18c-00a6d823887d;c5604b48-d58f-45ac-8602-72241ed4b906;c5f1a7f6-a5a4-48f1-9022-d6d402bfd349;c6d56d5e-856e-4e48-85f7-fce2beade4d1;c9202158-e3e4-4efc-9cc7-58e92d7fde8d;cb31cd1b-100d-4a24-b314-1ddcd6a95314;d5baab72-2d4b-42aa-973e-860a22b23a90;d9a049bd-2161-4a9b-8f6d-0c7d2bfdb0ed;de8d97fd-3a76-4019-a640-882066c25c19;e2447895-d026-4829-a942-50c670d55cb2;ec678657-42f1-4a51-a596-129033e2ff60;effe46a4-c383-4171-8ab4-2af9de316f08;
10193|754EE84C-AD16-4B06-BD1C-6791C758F908|Mirtazapine tablets are indicated for the treatment of <annotation cui="C1269683">major depressive disorder</annotation>. <br> <br> The efficacy of mirtazapine in the treatment of <annotation cui="C1269683">major depressive disorder</annotation> was established in six week controlled trials of outpatients whose diagnoses corresponded most closely to the Diagnostic and Statistical Manual of Mental Disorders   3rd edition (DSM III) category of <annotation cui="C1269683">major depressive disorder</annotation> (see <b> CLINICAL PHARMACOLOGY </b> ). <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms depressed mood, loss of interest in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. <br> <br> The effectiveness of mirtazapine in hospitalized depressed patients has not been adequately studied. <br> <br> The efficacy of mirtazapine in maintaining a response in patients with <annotation cui="C1269683">major depressive disorder</annotation> for up to 40 weeks following 8 to 12 weeks of initial open label treatment was demonstrated in a placebo controlled trial. Nevertheless, the physician who elects to use mirtazapine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <b> CLINICAL PHARMACOLOGY </b> ). <br> <br> |010f9162-9f7f-4b6d-a6e4-4f832f26f38e;0201a4eb-f127-4e45-92a7-b65a1af65b24;10c0ed21-833a-4267-b388-56d0c1ebada8;1501000f-664d-42ef-bff0-f85a7996b11c;18fbbcbb-73bd-4d22-8f4e-9a2777f0daf8;2373655d-ac74-43f5-a041-9f41a5b92206;310d8699-2c46-44e8-8c5f-79f01517a4a6;34c0b734-98ca-4aec-965f-e55edd3317f3;3a8a4490-9243-4201-944d-cea27d3d69f5;3c7b2832-44fb-42eb-acb9-374346505e84;3c8cb887-1bce-4902-90d2-4355506c4197;4531cb5a-64ca-4e6a-98c2-7aaad8d7f630;4801d296-7194-4c8c-895d-0dc1a3e6eb25;5542170c-79d3-4c5d-8008-50f2cdcb4f0a;59c61b34-d646-4cd5-8262-3df160064f4c;6837b69b-2f86-42cf-b48d-b4a3c7b5413f;711aa80b-8fc6-49e6-9494-3db31d9b53a4;754EE84C-AD16-4B06-BD1C-6791C758F908;82a615a0-e74a-49cb-9a57-ffbb3df604d5;8731e418-0cdb-44d2-b534-382c6467a6b9;89ae6a33-933f-47aa-a2de-2a71cd3f7d44;8b3c5f72-20eb-4e07-9ddf-f4e6b6dfa795;8feda54f-a3fa-4108-bfc4-c15b0eab4396;912e850f-a0bf-4e07-a800-43479eeffb05;a4c012f0-50b6-42fb-9f06-a14632f23f2e;aa05d606-29fd-443e-802b-1d65584d6bb1;aad22f7f-33d8-d9c0-5003-091679a7a400;aecec663-16ed-4c34-a00a-af6b99b3e1b6;afc24c74-7567-4c1c-ba93-f103f1df398e;b5e3a5a3-a17a-4f82-8cab-8c11fa8be0bc;b8df747e-dfce-4411-b892-086532ffabfb;d4a251ea-458f-4dd7-b102-53ba947958f3;d9578264-6ae5-44e3-90af-6ba61fe270a5;dd2f25f6-7688-48e1-92e7-aab152ff7413;e2a39ae4-774c-46c3-b978-0aa4110fef2c;e4d52964-e5ef-4ecc-9e22-03e1305a769a;f23631be-c7ae-46e9-b771-a70be17bc9f0;
102|fb8ef96b-ed37-4439-9294-834ef2e2a7c6| Therapy with lipid altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. <br> <br> <div> Prevention of Cardiovascular Disease </div> In adult patients without clinically evident <annotation cui="C0010068">coronary heart disease</annotation>, but with multiple risk factors for <annotation cui="C0010068">coronary heart disease</annotation> such as age, smoking, hypertension, low HDL C, or a family history of early <annotation cui="C0010068">coronary heart disease</annotation>, atorvastatin calcium tablets are indicated to <br> <br> <ol><li> Reduce the risk of <annotation cui="C0027051">myocardial infarction</annotation> </li><li> Reduce the risk of <annotation cui="C0038454">stroke</annotation> </li><li> Reduce the risk for revascularization procedures and <annotation cui="C0002962">angina</annotation> </li></ol> In patients with type 2 diabetes, and without clinically evident <annotation cui="C0010068">coronary heart disease</annotation>, but with multiple risk factors for <annotation cui="C0010068">coronary heart disease</annotation> such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to <br> <br> <ol><li> Reduce the risk of <annotation cui="C0027051">myocardial infarction</annotation> </li><li> Reduce the risk of <annotation cui="C0038454">stroke</annotation> </li></ol> In patients with clinically evident <annotation cui="C0010068">coronary heart disease</annotation>, atorvastatin calcium tablets are indicated to <br> <br> <ol><li> Reduce the risk of non fatal <annotation cui="C0027051">myocardial infarction</annotation> </li><li> Reduce the risk of fatal and non fatal <annotation cui="C0038454">stroke</annotation> </li><li> Reduce the risk for revascularization procedures </li><li> Reduce the risk of hospitalization for <annotation cui="C0018802">CHF</annotation> </li><li> Reduce the risk of <annotation cui="C0002962">angina</annotation> </li></ol> <div> <annotation cui="C0020473">Hyperlipidemia</annotation> </div> Atorvastatin calcium tablets are indicated <br> <br> <ol><li> As an adjunct to diet to reduce elevated total C, LDL C, apo B, and TG levels and to increase HDL C in patients with <annotation cui="C0342879">primary hypercholesterolemia</annotation> (heterozygous familial and nonfamilial) and mixed <annotation cui="C0242339">dyslipidemia</annotation> ( Fredrickson Types IIa and IIb); </li><li> As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); </li><li> For the treatment of patients with <annotation cui="C0020479">primary dysbetalipoproteinemia</annotation> ( Fredrickson Type III) who do not respond adequately to diet; </li><li> To reduce total C and LDL C in patients with homozygous <annotation cui="C0020445">familial hypercholesterolemia</annotation> as an adjunct to other lipid lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; </li><li> As an adjunct to diet to reduce total C, LDL C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous <annotation cui="C0020445">familial hypercholesterolemia</annotation> if after an adequate trial of diet therapy the following findings are present: </li></ol> <div> Limitations of Use </div> Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( <i> Fredrickson </i> Types I and V). <br> <br> |10a7ba02-42d6-4cae-8904-b256e2da5496;17a163ef-b349-4e32-bc8c-b02bac7f65d6;194218c4-3f18-4b6b-a0d9-acc8c862d4b7;200601d6-2c98-42dd-bece-76fc350c5356;28e28cc3-349a-427a-b19c-77503ef43db4;2a8de5aa-936a-493e-a0e3-813cbc969c6d;4053ed16-9219-4657-b86f-52ef6b66d005;634ec8e3-6d83-4cb2-90a3-fc9c973b06bf;6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d;7fcb451e-4834-4905-852b-ec1efe9115f0;808c5c03-9fd7-4d8b-b4d0-57c7527b42df;865f4e70-ead8-4480-96a4-6ca7b7d8ed69;8a201c80-a51d-4c1c-963b-488c071908c0;901550e6-22be-68c9-eb86-f85a9c9dd998;a3c08a6d-f986-4efc-9f96-3f0e652704dc;afd5c7b3-4886-4250-9a12-b61451f65eb5;c6e131fe-e7df-4876-83f7-9156fc4e8228;d385e07a-c16f-4aef-8e55-af95bd1c7526;d9adb9e4-c495-9530-e5e3-7e3b01d53e4c;da09f66e-9093-4e07-9820-e7d8ccd594f3;e480e538-4ea7-47e6-9e5d-dc0f8179e06c;e556c1d1-f677-4fc1-a2e9-406bc4b7fb9e;f60a672d-8d6d-4d67-9a47-5547357e7b5b;fb8ef96b-ed37-4439-9294-834ef2e2a7c6;
10205|762daef1-2ad2-444d-958b-f0a69c8ac259| Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis related clinical events as a function of cholesterol level, the presence or absence of <annotation cui="C0010068">coronary heart disease</annotation>, and other risk factors. <br> <br> <div> Primary Prevention of Coronary Events </div> In hypercholesterolemic patients without clinically evident <annotation cui="C0010068">coronary heart disease</annotation>, pravastatin sodium tablets are indicated to <br> <br>   Reduce the risk of <annotation cui="C0027051">myocardial infarction</annotation> <br> <br>   Reduce the risk of undergoing myocardial revascularization procedures <br> <br>   Reduce the risk of cardiovascular mortality with no increase in death from non cardiovascular causes <br> <br> <div> <annotation cui="C0020473">Hyperlipidemia</annotation> </div> Pravastatin sodium tablets are indicated as an adjunct to diet to reduce <annotation cui="C0020557">elevated Total C, LDL C, ApoB, and TG levels</annotation> and to increase HDL C in patients with <annotation cui="C0342879">primary hypercholesterolemia</annotation> and mixed <annotation cui="C0242339">dyslipidemia</annotation> (Fredrickson Type IIa and IIb). 8 <br> <br> Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with <annotation cui="C0020557">elevated serum triglyceride</annotation> levels (Fredrickson Type IV). <br> <br> Pravastatin sodium tablets are indicated for the treatment of patients with <annotation cui="C0020479">primary dysbetalipoproteinemia</annotation> (Fredrickson Type III) who do not respond adequately to diet. <br> <br> Pravastatin sodium tablets are <b> indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present </b> <br> <br> <br> <br> <ol><li> LDL C remains 190 mg/dL or </li><li> LDL C remains 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. </li></ol> Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP guidelines below). <br> <br> Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total C, HDL C, and TG. For patients with triglycerides (TG) < 400 mg dL (< 4.5 mmol L), LDL C can be estimated using the following equation <br> <br> LDL C = Total C   HDL C   1 5 TG <br> <br> For TG levels > 400 mg dL (> 4.5 mmol L), this equation is less accurate and LDL C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL C may be low or normal despite elevated Total C. In such cases, HMG CoA reductase inhibitors are not indicated. <br> <br> Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient s response to therapy. <br> <br> The National Cholesterol Education Program s Treatment Guidelines are summarized below <br> <br> After the LDL C goal has been achieved, if the TG is still 200 mg dL, non HDL C (Total C minus HDL C) becomes a secondary target of therapy. Non HDL C goals are set 30 mg dL higher than LDL C goals for each risk category. <br> <br> At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL C is 130 mg dL (see NCEP Treatment Guidelines, above). <br> <br> Since the goal of treatment is to lower LDL C, the NCEP recommends that LDL C levels be used to initiate and assess treatment response. Only if LDL C levels are not available, should the Total C be used to monitor therapy. <br> <br> As with other lipid lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL C). <br> <br> The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below <br> <br> |1123d56c-16f0-4f81-b56f-67b1f343ae1e;1ec7ef4d-8ea8-4189-b1ac-b8ac57d7ebe2;2e736bd6-01cc-4180-b97c-dd10b2250630;3ff75342-03b6-462f-b6db-80bc1a52fe6c;44a07041-456a-4b0b-9a8a-9e1715327d33;481cb8c7-578d-4db0-862e-a010b1af47d7;762daef1-2ad2-444d-958b-f0a69c8ac259;969dd35d-fbf5-4a26-b083-d68f10085445;9e58806e-08ba-4813-885a-bde5cf82b26d;AD3DA3C3-66B2-09FE-2C85-AAF4367E3732;a5ca8004-9a18-4030-a56c-8938c4823c64;c129f662-9ae7-45b6-9a02-15b569e051fc;e007e7c6-7d5d-4d5c-9a6c-c82d9e9cfaf7;e4e9610a-765b-4237-a598-0f4b27a4553e;ea2d1275-8437-4979-8199-24eb9678be94;
10218|fc1c497a-8619-4455-8f9f-6ef4f2df00ab| <div> Adult Patients </div> <u> <annotation cui="C0019345">Cold Sores</annotation> (<annotation cui="C0019345">Herpes Labialis</annotation>) </u> Valacyclovir hydrochloride tablets are indicated for treatment of <annotation cui="C0019345">Cold Sores</annotation> (<annotation cui="C0019345">herpes labialis</annotation>). The efficacy of valacyclovir hydrochloride tablets initiated after the development of clinical signs of a <annotation cui="C0019345">cold sore</annotation> (e.g., papule, vesicle, or ulcer) has not been established. <br> <br> <u> <annotation cui="C0019342">Genital Herpes</annotation> </u> <i> Initial Episode </i> Valacyclovir hydrochloride tablets are indicated for treatment of the initial episode of <annotation cui="C0019342">Genital Herpes</annotation> in immunocompetent adults. The efficacy of treatment with valacyclovir hydrochloride tablets when initiated more than 72 hours after the onset of signs and symptoms has not been established. <br> <br> <i> Recurrent Episodes </i> Valacyclovir hydrochloride tablets are indicated for treatment of recurrent episodes of <annotation cui="C0019342">Genital Herpes</annotation> in immunocompetent adults. The efficacy of treatment with valacyclovir hydrochloride tablets when initiated more than 24 hours after the onset of signs and symptoms has not been established. <br> <br> <i> Suppressive Therapy </i> Valacyclovir hydrochloride tablets are indicated for chronic suppressive therapy of recurrent episodes of <annotation cui="C0019342">Genital Herpes</annotation> in immunocompetent and in HIV infected adults. The efficacy and safety of valacyclovir hydrochloride tablets for the suppression of <annotation cui="C0019342">Genital Herpes</annotation> beyond 1 year in immunocompetent patients and beyond 6 months in HIV infected patients have not been established. <br> <br> <i> Reduction of Transmission </i> Valacyclovir hydrochloride tablets are indicated for the reduction of transmission of <annotation cui="C0019342">Genital Herpes</annotation> in immunocompetent adults. The efficacy of valacyclovir hydrochloride tablets for the reduction of transmission of <annotation cui="C0019342">Genital Herpes</annotation> beyond 8 months in discordant couples has not been established. The efficacy of valacyclovir hydrochloride tablets for the reduction of transmission of <annotation cui="C0019342">Genital Herpes</annotation> in individuals with multiple partners and non heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] Sexually Transmitted Diseases Treatment Guidelines). <br> <br> <u> <annotation cui="C0019360">Herpes Zoster</annotation> </u> Valacyclovir hydrochloride tablets are indicated for the treatment of <annotation cui="C0019360">Herpes Zoster</annotation> (<annotation cui="C0019360">shingles</annotation>) in immunocompetent adults. The efficacy of valacyclovir hydrochloride tablets when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir hydrochloride tablets for treatment of disseminated herpes zoster have not been established. <br> <br> <div> <i> <b> Pediatric Patients </b> </i> </div> <u> <annotation cui="C0019345">Cold Sores</annotation> (<annotation cui="C0019345">Herpes Labialis</annotation>) </u> Valacyclovir hydrochloride tablets are indicated for the treatment of <annotation cui="C0019345">Cold Sores</annotation> (<annotation cui="C0019345">herpes labialis</annotation>) in pediatric patients 12 years of age. The efficacy of valacyclovir hydrochloride tabletsinitiated after the development of clinical signs of a <annotation cui="C0019345">cold sore</annotation> (e.g., papule, vesicle, or ulcer) has not been established. <br> <br> Labeling describing use of valacyclovir HCL in pediatric patients with chickenpox (ages 2 to 18 years) is approved for GlaxoSmithKline s Valtrex Caplets. However, due to GlaxoSmithKline s marketing exclusivity rights, a description of that pediatric use is not approved for this valacyclovir HCL tablet product. <br> <br> <div> <b> <i> Limitations of Use </i> </b> </div> The efficacy and safety of valacyclovir hydrochloride tablets have not been established in <br> <br> <ol><li> Immunocompromised patients other than for the suppression of <annotation cui="C0019342">Genital Herpes</annotation> in HIV infected patients with a CD4+ cell count 100 cells/mm3. </li><li> Patients < 12 years of age with <annotation cui="C0019345">Cold Sores</annotation> (<annotation cui="C0019345">herpes labialis</annotation>). </li><li> Patients < 2 years of age or 18 years of age with chickenpox. </li><li> Patients < 18 years of age with <annotation cui="C0019342">Genital Herpes</annotation>. </li><li> Patients < 18 years of age with <annotation cui="C0019360">Herpes Zoster</annotation>. </li><li> Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) infection. </li></ol> Labeling describing use of valacyclovir HCL in pediatric patients with chickenpox (ages 2 to 18 years) is approved for GlaxoSmithKline s Valtrex Caplets. However, due to GlaxoSmithKline s marketing exclusivity rights, a description of that pediatric use is not approved for this valacyclovir HCL tablet product. <br> <br> |11d1e166-9577-47b0-a338-d11ab3ba44aa;1aa34beb-b06b-410c-b483-ba0bd903944a;1ad90fbf-1fae-4f3f-9aea-6a28420e9f10;21a09954-398a-4514-93c3-7bce55384fa5;26634bf1-c6d8-4d48-9a4e-845c47df07f8;2d38cbdb-4e4d-4174-461d-7a3b6475e6a5;2f0ecd75-e4b4-4493-b7a4-1666fc555c70;3172560a-e692-41f0-9ac3-bf6bfb90c4d6;3277c17e-f953-2b0a-fe0a-4f5d1aeace9d;3fc60483-3dd9-4d52-a0eb-fceba330e019;40668538-2526-f573-05c9-f589092e6e81;4acf51de-26f7-42b2-8acc-61b800627ef3;56bf715d-8280-4557-9f98-9693932199e5;61ea67c2-8c0e-486f-8c0c-6167a1d3d95a;6b2db776-4f30-4a17-a250-79654b86eca0;823e203e-acc2-4d75-ae42-f33ca2a1bcd1;a9e1d18e-ad45-4183-bd98-53c7e0b36556;af1fef85-fb8e-478d-999a-5a8adc42baa3;b0e6fa63-7b34-4453-a259-34ffd917f4d7;b28980df-064b-4fd4-8bf3-1589987671ab;b6b16acc-608a-418a-bf53-f0e44d7f123a;bcfc31a1-b604-4cd1-a9e0-681e60d4cd2e;c89fdb3a-99cb-4e47-88bb-782f5e402f15;d7aa2791-95d9-4732-afe4-89d70f01d152;d8028584-4186-41d6-b74b-2535971aa216;e228913a-8f12-4a4f-bc14-ba44d6e9ece9;f5cfb61e-d971-4a9c-b9ef-4f3368fe02f5;f8e0d8f8-cb73-4206-a484-88f5c4fbd719;fc1c497a-8619-4455-8f9f-6ef4f2df00ab;
10291|a8291f89-c8e2-435f-8226-75a53438d4d7| <div> Indication </div> Olux E Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive <annotation cui="C0037274">dermatoses</annotation> in patients 12 years of age or older. <br> <br> <div> Limitations of Use </div> <ol><li> Olux E Foam should not be applied to the face, axillae, or groin. </li><li> Olux E Foam should not be used if there is skin atrophy at the treatment site. </li><li> Treatment should be limited to 2 consecutive weeks and patients should not use greater than 50 grams or more than 21 capfuls per week. </li></ol> |a8291f89-c8e2-435f-8226-75a53438d4d7;
10749|7d12b4e9-ed44-43c0-9e46-f6c195300f03| GRALISE is indicated for the management of <annotation cui="C0032768">postherpetic neuralgia</annotation>. <br> <br> GRALISE is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration. <br> <br> |7d12b4e9-ed44-43c0-9e46-f6c195300f03;
10829|136a7070-2dca-4157-a470-56dd534f149a| This product may be used in <annotation cui="C0016807">functional intestinal disorders</annotation> to reduce symptoms such as those seen in mild dysenteries and diverticulitis. It can also be used to control gastric secretion , visceral <annotation cui="C0037763">spasm</annotation> and hypermotility in <annotation cui="C0010692">cystitis</annotation>, <annotation cui="C0152163">pylorospasm</annotation> and associated <annotation cui="C0000729">abdominal cramps</annotation>. Along with appropriate analgesics, this product is indicated in symptomatic relief of <annotation cui="C0151824;C0152169">biliary and renal colic</annotation> and as a drying agent in the relief of symptoms of <annotation cui="C0009443">acute rhinitis</annotation>. This product is effective as adjunctive therapy in the treatment of <annotation cui="C0030920">peptic ulcer</annotation> and <annotation cui="C0022104">irritable bowel syndrome</annotation>, acute <annotation cui="C0014356">enterocolitis</annotation> and other <annotation cui="C0559031">functional gastrointestinal disorders</annotation>. <br> <br> |136a7070-2dca-4157-a470-56dd534f149a;2b4cf7e7-207a-41e8-a573-2739412807a0;2d5fa637-0696-40fe-9bc1-fcb6f07a50f6;2fcc0dcc-9c97-4b7d-91b0-11f5c2fd046a;5361160c-c979-4a4f-8a46-fcf85560c967;5e39fbb6-7865-4252-9ba3-bb841a1cec0b;788d1714-5276-4833-914a-e4d89fa351f1;8504adad-f6d0-4671-b655-4b62bf29a516;cfcda432-1227-484b-9369-84f6bcf66086;
11018|b325028e-0722-4c8c-9fdb-ab6fb0dc460c|Hydromorphone Hydrochloride Injection is indicated for the relief of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> such as that due to surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. <br> <br>|b325028e-0722-4c8c-9fdb-ab6fb0dc460c;
1104|1C3A94FF-91F0-4BC1-8BC8-1B6AA87E8026|Diclofenac sodium delayed release tablets are indicated for the acute and chronic treatment of signs and symptoms of <annotation cui="C0003873">rheumatoid arthritis</annotation>, <annotation cui="C0029408">osteoarthritis</annotation>, and <annotation cui="C0038013">ankylosing spondylitis</annotation>. <br> <br> |1C3A94FF-91F0-4BC1-8BC8-1B6AA87E8026;A4FD2D68-019F-4C89-8923-4E61262F6EEE;
11157|ecc6049d-2c2a-40e0-8780-158b166af406| TEMOVATE Gel is a super high potency cor ticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive <annotation cui="C0037274">dermatoses</annotation>. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g week because of the potential for the drug to suppress the hypothalamic pituitary adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended. <br> <br> |29735bf2-e08e-4f60-a640-0e3b9ccca80f;52858738-a71c-4330-a7b3-e9c6c2161e04;736325f3-a369-4d70-b608-3d6ba37b6a6b;b8c0d9e3-498c-4721-bbc9-c1450b56ba14;ecc6049d-2c2a-40e0-8780-158b166af406;f9df643a-015d-4101-ac8f-c1e05b052df5;
11274|8930c2ef-7c1a-4d6e-b44b-ed91d0686d37| Hydromorphone hydrochloride tablets are indicated for the management of <annotation cui="C0030193">pain</annotation> in patients where an opioid analgesic is appropriate. <br> <br> |1e55260d-7c0d-45a2-9e2f-e829f25b60b7;2115e839-c64f-4a6f-9001-bf91ddd89630;2427814c-f32b-8ac5-99b8-5e886fd2d001;37565441-0d95-4743-a695-d7b3326f58a1;39003b2e-be25-402e-b755-96c7b41a7639;3afae8b9-bb24-447a-bc7f-041c8326a438;471f8bb8-c23f-49f2-8685-2b2aa514e076;4a63f06d-a99b-96d5-c55d-ff03ed82943a;4c5c1cc8-c42b-46e3-ad68-8e22f57101f2;4daba60f-af60-4c7e-916e-f2ad7e7532c5;76D9DED3-66F2-44D5-8495-C4A8129DE0B3;78353952-324c-4a8d-818c-6537fca21d4e;7c122909-cedb-469a-99de-a44bcd51238d;7db1d180-8419-462b-a454-5dd01e4b7795;86638efd-9eb9-440e-b48b-b1bd52ccbc61;8930c2ef-7c1a-4d6e-b44b-ed91d0686d37;a6c981fb-28f9-4eff-962b-226736f7d0c8;b344c8dc-0792-491e-8f51-b2e02ed7a4fe;c5779977-a604-4010-a79e-11b83e216814;cc574063-6ede-4da7-82c4-7450c92b229b;d42f2e61-f65a-42f2-bec5-2d248d788e78;d596ee4f-71e7-4072-95fa-98f5ee261ff1;d5c50998-0e29-4ade-b661-e01f75996bad;e9c9ef18-7dfc-4322-b2fc-29b934c30f8b;
11384|199a42ae-4d19-4e68-934d-dabd27084988| Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the <annotation cui="C0010200">cough</annotation> reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage. <br> <br> |199a42ae-4d19-4e68-934d-dabd27084988;758cced1-db76-41f4-9bdc-d016637a49cf;83233a7e-856c-47d3-b6af-c6c642694486;ce85fa92-783e-4f71-b7ae-bc0eb0410e13;
1143|97713356-f42b-4a67-95f6-561afa68c0c2| <div> Prevention of <annotation cui="C0027497">Nausea</annotation> and <annotation cui="C0042963">Vomiting</annotation> Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy </div> Ondansetron Injection is indicated for the prevention of <annotation cui="C0027497">Nausea</annotation> and <annotation cui="C0042963">Vomiting</annotation> associated with initial and repeat courses of emetogenic cancer chemotherapy, including high dose cisplatin <i> [see Clinical Studies (14.1) ]. <br> </i> Ondansetron Injection is approved for patients aged 6 months and older. <br> <br> <div> Prevention of <annotation cui="C0520904">Postoperative Nausea</annotation> and/or <annotation cui="C0042963">Vomiting</annotation> </div> Ondansetron Injection is indicated for the prevention of <annotation cui="C0520904">Postoperative Nausea</annotation> and or <annotation cui="C0042963">Vomiting</annotation>. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and or <annotation cui="C0042963">Vomiting</annotation> will occur postoperatively. In patients in whom nausea and or <annotation cui="C0042963">Vomiting</annotation> must be avoided postoperatively, Ondansetron Injection is recommended even when the incidence of <annotation cui="C0520904">Postoperative Nausea</annotation> and or <annotation cui="C0042963">Vomiting</annotation> is low. For patients who do not receive prophylactic Ondansetron Injection and experience nausea and or <annotation cui="C0042963">Vomiting</annotation> postoperatively, Ondansetron Injection may be given to prevent further episodes <i> [see Clinical Studies (14.3) ] </i> . <br> Ondansetron Injection is approved for patients aged 1 month and older. <br> <br> |866571f1-4b10-423d-8d08-ce9aa65ede51;97713356-f42b-4a67-95f6-561afa68c0c2;
1147|ac66be47-babc-41eb-b259-03a7020cec23|Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections (<annotation cui="C0032285">pneumonia</annotation>: see WARNINGS) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. <br> <br> <b> <annotation cui="C0026918">Mycobacterial Infections</annotation> <br> </b>  Prophylaxis of <b>Disseminated <annotation cui="C0026919">Mycobacterium avium complex (MAC) Disease</annotation></b>  <br> Azithromycin tablet, taken alone or in combination with rifabutin at its approved dose, is indicated for the prevention of disseminated <annotation cui="C0026919"><i> Mycobacterium avium </i> complex (MAC) disease</annotation> in persons with advanced HIV infection. (See DOSAGE AND ADMINISTRATION, CLINICAL STUDIES) <br> <br> <b> Treatment of Disseminated <annotation cui="C0026919"><i> Mycobacterium avium </i> complex (MAC) Disease </annotation></b> <br> Azithromycin tablet, taken in combination with ethambutol, is indicated for the treatment of disseminated MAC infections in persons with advanced HIV infection. (See DOSAGE AND ADMINISTRATION, CLINICAL STUDIES)  |ac66be47-babc-41eb-b259-03a7020cec23;de7f60ec-40ff-4f5f-8f72-5ff9711cc574;fb0ff563-b87b-439b-885d-49572d3c0c12;
11592|4abecc19-e956-4d05-a51e-73dba23dc131| Clobetasol Propionate Lotion, 0.05% is a super high potent corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive <annotation cui="C0037274">dermatoses</annotation> only in patients 18 years of age or older (see PRECAUTIONS ). Treatment should be limited to 2 consecutive weeks. The total dosage should not exceed 50 g (50 mL or 1.75 fl.oz.) per week. <br> <br> For the treatment of moderate to severe <annotation cui="C0406317">plaque psoriasis</annotation>, localized lesions (less than 10% body surface area) that have not sufficiently improved after the initial 2 week treatment with Clobetasol Propionate Lotion, 0.05% may be treated for up to 2 additional weeks. Any additional benefits of extending treatment should be weighed against the risk of HPA axis suppression before prescribing for more than 2 weeks. <br> <br> Patients should be instructed to use Clobetasol Propionate Lotion, 0.05% for the minimum amount of time necessary to achieve the desired results (see PRECAUTIONS ). <br> <br> Use in patients younger than 18 years of age is not recommended due to numerically high rates of HPA axis suppression (see PRECAUTIONS Pediatric Use ). <br> <br> |4abecc19-e956-4d05-a51e-73dba23dc131;
11823|91fa852c-b43d-4a55-983b-74aa6827125d| COUMADIN is indicated for the prophylaxis and or treatment of <annotation cui="C0042487">venous thrombosis</annotation> and its extension, and <annotation cui="C0034065">pulmonary embolism</annotation>. <br> <br> COUMADIN is indicated for the prophylaxis and or treatment of the <annotation cui="C0040038">thromboembolic complications</annotation> associated with <annotation cui="C0004238">atrial fibrillation</annotation> and or cardiac valve replacement. <br> <br> COUMADIN is indicated to reduce the risk of death, recurrent <annotation cui="C0027051">myocardial infarction</annotation>, and <annotation cui="C0040038">thromboembolic events</annotation> such as <annotation cui="C0038454">stroke</annotation> or systemic embolization after <annotation cui="C0027051">myocardial infarction</annotation>. <br> <br> |02fddbda-e9e1-41f0-b1a9-b46f4f24705c;0750d877-b6f0-46bb-8c1a-46a7c27ebefb;14629e09-a46c-496b-8fe2-1c09ddcd4f71;1509e2c4-2dd3-4e6f-88ca-06e9520d8ffc;23b776e0-7a03-4946-0110-6f70e70031e8;36a919ce-7a21-40c0-9af5-2299bf2b1f97;801e4da1-5459-47d2-b67b-009f0a3247cc;87315917-3e54-44e6-bb64-2f722501c11b;91cecd43-afd8-47a0-963e-167a194ef446;91fa852c-b43d-4a55-983b-74aa6827125d;9321c20d-04f4-2bcd-a080-43c9e45025b2;D174F2B8-FEE2-4817-AD6C-364A1880E24B;a0cfad4b-043e-451e-bfd6-1fe1ac1bd0d6;a1150d78-57cc-4216-beff-f7ea7364ab89;ac5d715d-6b6e-40d5-a5df-e3b884c3ef84;c90be37c-0ad0-4ccd-8fe7-b9a3427f0d80;c95f0b0d-77ef-e753-be04-2228139df2d3;
11961|31e81b55-ddf1-20c0-8d25-b5712435c366| Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with <annotation cui="C0011860">type 2 diabetes mellitus</annotation> (see DOSAGE AND ADMINISTRATION ). <br> <br> |0003458f-352a-46fa-9d99-230daa76ae29;07ad4366-4b21-f633-49f3-c2b35f88168d;101cdc41-2131-4425-b550-6a0a60b5f4a4;1249298e-9d2c-41e6-94ac-95f8e75d6c26;1873bce1-172f-4eb0-b5bc-cb7d444a8d8e;31e81b55-ddf1-20c0-8d25-b5712435c366;35134bd9-d3ea-49c9-9f0c-b5aa2737c945;3b20ae5e-9807-46c2-9de1-b64e76e61730;4b43f23c-3354-41e7-a1ec-81f6fe341f86;4d04a96c-8dee-49f1-be92-f410afc23a68;557594ea-5de0-42ae-a04b-d20dd27c6073;5a10ec35-1616-4014-8f1c-4344e87007dc;5b03bc3e-a672-e66b-88d7-f63c748851ab;5d9cf81e-8271-4d56-9d68-4b24dc54715a;5eda246b-ac51-46e7-b473-35937f84ed05;657f1b51-2f82-44f6-a23d-97f4b34b3c45;6e8707b3-2c87-4b08-9dc5-ab347b698042;72d88c6d-2f0a-4bf8-aa7f-1e1811794187;85cbba14-ab8e-43b1-9f7d-3a0e6a28b0fc;897e946d-075f-4048-bc32-ec5d6da9c388;94ae9bb7-a909-4a16-b430-2612af59ebc6;b5c912bf-d1b3-4c65-9049-0d91a382d236;b627bd98-13b2-4340-9d67-d23e7e6a24d1;c68bb847-5d17-4d63-99d4-e72f92a31392;ebb9f080-b11d-5d18-36f0-627107e7fbcd;
12007|4a9f22fe-7f2e-4597-beb1-e1f950d2de33| PENNSAID is a nonsteroidal anti inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of <annotation cui="C0409959">osteoarthritis of the knee(s)</annotation>. <br> <br> |4732a181-9fe0-49b4-b486-e2da9ad66e31;4a9f22fe-7f2e-4597-beb1-e1f950d2de33;bb530269-5c2e-4821-8fca-2fea108f8f26;
13132|A83D7327-ABA2-43E0-A510-9EEABF1BC560| Carefully consider the potential benefits and risks of Flector Patch and other treatment options before deciding to use Flector Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <b> WARNINGS </b> ). <br> <br> Flector Patch is indicated for the topical treatment of <annotation cui="C0184567">acute pain</annotation> due to minor <annotation cui="C0080194">strains</annotation>, <annotation cui="C0038045">sprains</annotation>, and <annotation cui="C0009938">contusions</annotation>. <br> <br> |2cc5e92b-044b-46a4-85eb-bcfe04c9d4be;5e46b7e9-e640-4db5-882f-73a5dd2482d2;A83D7327-ABA2-43E0-A510-9EEABF1BC560;e58641de-b6fd-484c-8902-b9262d7ce251;
13886|b20c6938-cf96-4175-9eb3-d6ae3a43059c| Zipsor is indicated for relief of <annotation cui="C0278138;C0278139">mild to moderate acute pain</annotation> in adults (18 years of age or older). <br> <br> |61420046-b04b-4532-a21d-65986966f681;b20c6938-cf96-4175-9eb3-d6ae3a43059c;fa385cd1-c221-11dd-ad8b-0800200c9a66;
13930|acb3a25e-5746-4df6-89fd-cf3023e755cc| Clobex Shampoo is a super high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of <annotation cui="C0406326">scalp psoriasis</annotation> in patients 18 years of age and older. Treatment should be limited to 4 consecutive weeks of the potential for the drug to suppress the hypothalamic pituitary adrenal (HPA) axis. There were insufficient numbers of non Caucasian patients to determine whether they responded differently than Caucasian patients with regards to efficacy and safety. <br> <br> |13cdccfa-f8fc-4b81-8fa7-1fa5a8da0338;9539c24e-3fc4-44a6-a40c-bb53260df2f2;a4f82a4c-bc7e-4927-936e-add854812559;acb3a25e-5746-4df6-89fd-cf3023e755cc;
13990|3e593725-3fc9-458e-907d-19d51d5a7f9c| NORPRAMIN is indicated for the treatment of <annotation cui="C0011570">depression</annotation>. <br> <br> |3e593725-3fc9-458e-907d-19d51d5a7f9c;
14125|a2a2ca0b-a685-4a60-b9c9-ffc3b6666c97| <br> <br> GELNIQUE is indicated for the treatment of <annotation cui="C0878773">overactive bladder</annotation> with symptoms of urge urinary incontinence, urgency, and frequency [ <i> see </i> <i> Clinical Studies 14 </i> ]. <br> <br> |a2a2ca0b-a685-4a60-b9c9-ffc3b6666c97;acf0324b-2fac-4403-bac8-131b3e1cf5cd;c6754623-b14c-4fc3-8719-48eee3119156;
14589|be478f3c-40f6-47cc-8ab9-f420a9372b1c| EQUETRO is indicated for the treatment of acute <annotation cui="C0349208;C0338831">manic and mixed episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>. <br> <br> A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. A mixed episode is characterized by the criteria for a manic episode in conjunction with those for a major depressive episode (depressed mood, loss of interest or pleasure in nearly all activities). <br> <br> The efficacy of EQUETRO in acute <annotation cui="C0338831">mania</annotation> was established in 2 placebo controlled, double blind, 3 week studies in patients meeting DSM IV criteria for <annotation cui="C0853193">Bipolar I Disorder</annotation> who currently displayed an acute <annotation cui="C0349208;C0338831">manic or mixed episode</annotation> (see <b> CLINICAL PHARMACOLOGY </b> ). <br> <br> The effectiveness of EQUETRO for longer term use and for prophylactic use in <annotation cui="C0338831">mania</annotation> has not been systematically evaluated in controlled clinical trials. Therefore, physicians who elect to use EQUETRO for extended periods should periodically re evaluate the long term risks and benefits of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> |be478f3c-40f6-47cc-8ab9-f420a9372b1c;
14612|1940300f-2b4a-4016-a1bb-21f821797a89| Voltaren Gel is indicated for the relief of the <annotation cui="C0030193">pain</annotation> of <annotation cui="C0029408">osteoarthritis</annotation> of joints amenable to topical treatment, such as the knees and those of the hands. <br> <br> <ol><li> Voltaren Gel has not been evaluated for use on the spine, hip, or shoulder. </li></ol> |137c4e7a-e671-413e-b687-89490ef98974;1940300f-2b4a-4016-a1bb-21f821797a89;26b2d99e-d471-4758-8aa0-a26ef464eb35;4c9f995c-d687-483a-b6bb-11c8b263681b;60045fc6-f0d9-4f67-ba91-c3b317596437;636dfa0a-0a93-4f22-9f0c-4131bd523df3;e1685937-3980-40e3-8f04-998174fef3a2;ea23fc47-3b7b-4fad-ae34-b6eb6913d957;
14779|9899c4b5-e520-41f3-9dbf-e7da12924dd8| Hyoscyamine Sulfate is effective as adjunctive therapy in the treatment of <annotation cui="C0030920">peptic ulcers</annotation>. It can also be used to control gastric secretion, visceral <annotation cui="C0037763">spasm</annotation> and hypermotility in <annotation cui="C0022104">spastic colitis</annotation>, spastic <annotation cui="C0005697">bladder</annotation>, <annotation cui="C0010692">cystitis</annotation>, <annotation cui="C0152163">pylorospasm</annotation>, and associated <annotation cui="C0000729">abdominal cramps</annotation>. May be used in <annotation cui="C0016807">functional intestinal disorders</annotation> to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and <br> acute enterocolitis. For use as adjunctive therapy in the treatment of <annotation cui="C0022104">irritable bowel syndrome</annotation> (<annotation cui="C0022104">irritable colon</annotation>, <annotation cui="C0022104">spastic colon</annotation>, <annotation cui="C0022104">mucous colitis</annotation>) and <annotation cui="C0559031">functional gastrointestinal disorders</annotation>. Also used as adjunctive therapy in the treatment of <annotation cui="C0005697">neurogenic bladder</annotation> and <annotation cui="C0695242">neurogenic bowel</annotation> disturbances (including the <annotation cui="C0221037">splenic flexure syndrome</annotation> and neurogenic colon). Hyoscyamine Sulfate is indicated <br> along with morphine or other narcotics in symptomatic relief of <annotation cui="C0151824;C0152169">biliary and renal colic</annotation>; as a "drying agent" in the relief of symptoms of <annotation cui="C0009443">acute rhinitis</annotation>; in the therapy of <annotation cui="C0242422">parkinsonism</annotation> to reduce <annotation cui="C0026837">rigidity</annotation> and <annotation cui="C0040822">tremors</annotation> and to control associated <annotation cui="C0037036">sialorrhea</annotation> and <annotation cui="C0020458">hyperhidrosis</annotation>. May be used in the therapy of <annotation cui="C0274704">poisoning by anticholinesterase agents</annotation>. <br> <br> <br> |38f12473-08e0-4970-a6ef-a825cc7de8d8;3a200492-c460-4b19-ac16-b64493904b88;422fe1f6-43d6-4580-8788-b92f8527e10a;480d688d-2103-443c-90cc-feb861bdce13;5bb0d56c-d58e-4f9f-9848-d241cac5b3db;6f31e729-e36b-4b6e-98de-88077b29bf2b;7056cb58-8520-4e5d-bfb3-549c980f6a54;843d2e6f-9110-4b0d-894f-63b1b206b5ec;9899c4b5-e520-41f3-9dbf-e7da12924dd8;a0e8f7d7-9316-4b78-acc8-17519b9b3165;bc07d46e-de9a-43ac-b344-ab29911b1fae;c5049243-5741-4d60-b65e-f3102fa7cc56;c98d2f36-51b6-4b20-a278-27311303973f;ccfdbaac-2c51-46da-82f2-76e76969dbd8;d2b55db1-be5f-4fe0-b31d-21bbe85a34f1;e09f23ca-e6f8-46c3-b713-97b86e3d5c97;e219b697-45d8-4388-8c79-4b98961fc525;e2528b56-c35a-48f1-8d48-495d1be4550f;f33a4774-9fbb-4782-a7e1-068e83b7504d;f4dd9a8f-be58-4fac-b13b-b436589480ca;f9aaec2b-7ae2-459b-8649-afe760ae5fa2;
15074|ffca32a2-fbef-40bb-b0f0-73f63e18e747| <div> Treatment of <annotation cui="C0018621;C0035457">Seasonal or Perennial Allergic Rhinitis</annotation> </div> RHINOCORT AQUA Nasal Spray is indicated for the treatment of nasal symptoms of <annotation cui="C0018621;C0035457">seasonal or Perennial Allergic Rhinitis</annotation> in adults and children six years of age and older. <br> <br> |ffca32a2-fbef-40bb-b0f0-73f63e18e747;
15382|55d5f933-42ff-4c80-a102-0ccb7f76b082| CALAN tablets are indicated for the treatment of the following <br> <br> <div> <annotation cui="C0002962">Angina</annotation> </div> <ol><li> <annotation cui="C0002965">Angina at rest</annotation> including: <annotation cui="C0002963">Vasospastic (Prinzmetal's variant) Angina</annotation> <annotation cui="C0002965">Unstable (crescendo, pre infarction) Angina</annotation> </li><li> <annotation cui="C0699826">Chronic stable angina</annotation> (classic <annotation cui="C0577698">effort associated Angina</annotation>) </li></ol> <div> <annotation cui="C0003811">Arrhythmias</annotation> </div> <ol><li> In association with digitalis for the control of ventricular rate at rest and during stress in patients with <annotation cui="C0741289">chronic atrial flutter</annotation> and/or <annotation cui="C0004238">atrial fibrillation</annotation> (see WARNINGS: Accessory bypass tract ) </li><li> Prophylaxis of repetitive <annotation cui="C0030590">paroxysmal supraventricular tachycardia</annotation> </li></ol> <div> <annotation cui="C0085580">Essential hypertension</annotation> </div> |006cf920-04ae-0b53-cb91-85481972abc2;06907eb6-9e1b-44e4-a4c3-f53e2819c559;0c604923-4a37-45ac-ad93-3610a5eadc16;10881745-3a16-44c3-9b94-60433218f1d6;55d5f933-42ff-4c80-a102-0ccb7f76b082;756adc68-e145-4163-bee5-6db7ca0579d8;8676ce2f-2dac-4407-b751-315b57f48577;90841684-4f00-450f-b366-6fc914ca8c54;a0343397-897b-46d6-943f-a87e07e1de10;c9d71191-b32a-44f9-bc5a-283a06884c82;ce2ec7ef-878c-4c30-a848-0de9fd66f437;ed1e0c14-3571-43f9-88fc-5a4d2b598263;
15439|a7f5284b-ff9d-4198-ab0f-bb9fd727662e| Levetiracetam injection is an alternative for adult patients (16 years and older) when oral administration is temporarily not feasible. <br> <br> <div> <annotation cui="C0751495">Partial Onset Seizures</annotation> </div> Levetiracetam is indicated as adjunctive therapy in the treatment of <annotation cui="C0751495">Partial Onset Seizures</annotation> in adults with <annotation cui="C0014544">epilepsy</annotation>. <br> <br> <div> <annotation cui="C0014550">Myoclonic Seizures</annotation> in Patients with <annotation cui="C0270853">Juvenile Myoclonic Epilepsy</annotation> </div> Levetiracetam is indicated as adjunctive therapy in the treatment of <annotation cui="C0014550">Myoclonic Seizures</annotation> in adults with <annotation cui="C0270853">Juvenile Myoclonic Epilepsy</annotation>. <br> <br> <div> Primary <annotation cui="C0494475">Generalized Tonic Clonic Seizures</annotation> </div> Levetiracetam is indicated as adjunctive therapy in the treatment of primary <annotation cui="C0494475">Generalized Tonic Clonic Seizures</annotation> in adults with <annotation cui="C0270850">idiopathic generalized epilepsy</annotation>. <br> <br> |a7f5284b-ff9d-4198-ab0f-bb9fd727662e;a92107d6-5006-4f6a-ace8-6e18ab14677c;
1549|1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA|Prevention of <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> associated with initial and repeat courses of emetogenic cancer chemotherapy, including high dose cisplatin. Efficacy of the 32 mg single dose beyond 24 hours in these patients has not been established. <br> <br> |1FE32FFA-3D69-420F-CC81-B10BB1AFD5BA;1cd37c76-84d0-4091-b68c-e2f67127a2e0;2a09af01-3983-466f-8ed8-c849af848b56;693ba38b-4cbe-4a6a-9c80-b9d2f554edce;8e66d883-2977-46c3-be24-41eba7a903b3;d931b294-8834-4c7f-ac05-9aeb078cd86e;
16679|36cc9115-bef3-48fa-93ff-bcda24cf26e2| DITROPAN XL (oxybutynin chloride) is a once daily controlled release tablet indicated for the treatment of <annotation cui="C0878773">overactive bladder</annotation> with symptoms of urge urinary incontinence, urgency, and frequency. <br> <br> DITROPAN XL is also indicated in the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., <annotation cui="C0080178">spina bifida</annotation>). <br> <br> |033a9242-bbf2-49d5-8403-d07e99107130;0c71bdfb-01db-49ac-a8e9-0037df0d24af;242b4766-bc2b-0073-d72d-1bf879bbee24;2b0384a5-c65a-454d-9761-716af8afe5bd;3272aaff-8d07-4be5-987f-ef3c5079a133;35918293-0c0b-4796-b237-ac596afab777;36cc9115-bef3-48fa-93ff-bcda24cf26e2;46dab1c0-bbde-922c-39d7-6be818b49d12;63b1ee49-8b05-4a0f-96bc-a27f986fe14d;82c40f61-91a1-4946-b63f-0251aa01740c;a7a00c9f-183c-49fd-9b14-e6acdca826a8;ae9f59bd-78bd-4d1c-9e8c-8d787f76fad5;c5950dba-d92b-46a0-993f-af9f9ddb52bf;c8a755b6-881f-4568-8d1b-1347755230c9;e2d6e56e-43dc-4724-a158-0a690c644d97;f1e476a9-467c-46eb-80b5-ca38ca73bfb5;fb54818b-efdd-4d08-9fd0-64f903180220;
17240|89a7bfbd-051f-4d87-a642-96b0df81b8e2| Solaraze (diclofenac sodium) Gel is indicated for the topical treatment of <annotation cui="C0022602">actinic keratoses</annotation> (<annotation cui="C0022602">AK</annotation>). Sun avoidance is indicated during therapy. <br> <br> |89a7bfbd-051f-4d87-a642-96b0df81b8e2;
2434|ce990712-49c1-4f66-9ee4-c770e8ec394c| Levothyroxine Sodium for Injection is indicated for the treatment of <annotation cui="C0238298">myxedema coma</annotation>. Important Limitations of Use The relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established. Caution should be used when switching patients from oral levothyroxine products to Levothyroxine Sodium for Injection as accurate dosing conversion has not been studied. <br> <br> |ce990712-49c1-4f66-9ee4-c770e8ec394c;
2455|d7335594-50c9-4ae2-a3e3-b9a375187b62| <div> <b> 1.1 </b> <b> Acute Treatment of <annotation cui="C0149931">Migraine</annotation> </b> </div> CAMBIA <b> </b> (Diclofenac Potassium for Oral Solution) <b> </b> is indicated for the acute treatment of <annotation cui="C0149931">Migraine</annotation> attacks with or without <annotation cui="C0236018">aura</annotation> in adults (18 years of age or older). <br> <br> <div> <b> 1.2 </b> <b> Important Limitations </b> </div> <ol><li> CAMBIA is not indicated for the prophylactic therapy of <annotation cui="C0149931">Migraine</annotation>. </li><li> The safety and effectiveness of CAMBIA have not been established for cluster headache, which is present in an older, predominantly male population. </li></ol> |d7335594-50c9-4ae2-a3e3-b9a375187b62;
2553|acb6e57b-af44-432f-a4de-a293a2e20121| CALAN SR is indicated for the management of <annotation cui="C0085580">essential hypertension</annotation>. <br> <br> |0742cf97-601b-4c13-a6c3-1a6a616ed292;15f8fd1a-4a8e-4949-8c5c-dd7c897b0791;189d8bed-8a53-4126-9409-41ef48678dc9;3820E40E-51DB-4D28-ACAC-4AD23345AA53;3bee2d26-138c-4641-a217-a38d3d657461;3c215e6c-d85a-4102-a1c2-f00fa3169a55;3f427e9a-1d6a-433a-aaf1-8e1ac54b5b95;4eb349bb-c46b-4809-81af-6f924a5e34ef;64c10f09-54eb-4512-b574-d3189b60c1e2;6ae13cb4-0316-40d1-9216-c7d5556aaed3;6cbb1f0d-8243-4455-96ac-b5553bb2820f;6eedb5d5-720f-1e8b-d04b-43e42c14ed82;749cc072-ef8d-6401-9c08-aea484a4e58a;7c822705-827f-43c7-8c27-35bc31cf6484;8834bbd7-c7ae-41e0-9d54-0178f76886ae;887b91f5-f117-47e6-8d59-87ac61d17175;968b40c6-3583-44e7-8c00-3aa37d96eab3;98a3ef97-b447-4bfc-b284-13acd00bda5b;acb6e57b-af44-432f-a4de-a293a2e20121;af1249b0-e889-4f02-bdc2-54862de0545e;af945823-aeae-48b2-97c0-e99e4bd0923f;c86084bc-33aa-eece-5a96-6c0dad2d1a32;d1a0aa24-0f81-498a-8c25-5095b2bb8f57;e96aaa64-63ac-4016-99c1-f05b8dd3fee9;ea970d03-ddc7-4174-83f8-58f05ad97220;ed6f7087-995c-4a8e-b9bd-9e0cadd09767;edabc504-cfb9-410f-b1fa-9fc6910f0816;f3b3580a-4e6b-402f-bf88-f3157d9139b1;f77f9742-9100-4b64-ac73-dff94079b888;
2647|3ee6835a-7a7d-49a9-8460-2f1dd270ead3| Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex <annotation cui="C0005697">neurogenic bladder</annotation> (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). <br> <br> |0c019ff6-ce85-4711-a9d1-39804ebfae56;12c48560-20f6-4f2a-a4f3-d2b92acdaee1;17d61203-a462-4393-b261-72bf48d51942;19fba9db-69ff-4136-ad6b-04a33b6b6789;1c6dfc08-b177-41eb-9865-368252a1b8bb;2325ddde-9a20-40c6-9a3d-5ac6dc6de91d;27156BA6-3A64-B463-5D85-D1B959D5032C;3a0edd83-7936-4a35-afee-ac92445d4d57;3ee6835a-7a7d-49a9-8460-2f1dd270ead3;5fcc6e9f-d5f0-4521-b6f3-315146b65f82;615f3d95-197c-4fec-b81f-c26449c93c3b;6fe50857-cb51-4bf1-80d4-6d99ef65c3f6;9211307b-a1cc-412f-9de2-323d42dfac21;98526d8f-9f39-d138-1cf9-fa5335bf2ba5;9e22e910-f2f3-4dbb-91c3-09483361fa47;CE850693-BC70-41E8-8AF8-426898631F42;aa24982c-1662-4745-90f8-b8466edfaec6;b037d82b-a8f0-498d-b096-3ae6507205ed;b332845c-5c31-44d7-a5c0-020c0688b42b;cb7aba8d-6913-4f57-8eb4-c6d6ff0b2a29;d2aa1b90-bea7-4a93-b2e7-22710548ff55;fd72314e-773a-4e9d-8aa7-ec51592e4c90;
2891|c3bb34c1-89b2-48c3-9ad2-16b4b2bce5f9| Theophylline in 5% Dextrose Injections USP are indicated as an adjunct to inhaled beta 2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow <annotation cui="C0028778">obstruction</annotation> associated with <annotation cui="C0004096">asthma</annotation> and other <annotation cui="C0746102">chronic lung diseases</annotation>, <i> e.g., </i> <annotation cui="C0013990">emphysema</annotation> and <annotation cui="C0008677">chronic bronchitis</annotation>. <br> <br> |3e4221f1-dade-4482-b5e5-2d75a96154d6;c3bb34c1-89b2-48c3-9ad2-16b4b2bce5f9;e18c0cee-a592-4c78-e08e-9898b7d4bf12;
3205|5c73928d-2b96-42f5-1fb9-90965c214c21| Budesonide is indicated for <br> <br> <ol><li> the treatment of mild to moderate active <annotation cui="C0010346">Crohn's disease</annotation> involving the ileum and/or the ascending colon and </li><li> the maintenance of clinical remission of mild to moderate <annotation cui="C0010346">Crohn's disease</annotation> involving the ileum and/or the ascending colon for up to 3 months. </li></ol> |4a578d93-087e-42f7-a258-a49afef41dea;5c73928d-2b96-42f5-1fb9-90965c214c21;70532afa-4006-4883-feb2-927faaee8e20;d361c2ed-99e8-4089-bbba-cbcf2b239228;
3465|220cd180-8a71-4530-b8ca-8864bee9caa0| <div> Monotherapy </div> Finasteride tablets USP, 5 mg are indicated for the treatment of symptomatic <annotation cui="C0005001">benign prostatic hyperplasia</annotation> (<annotation cui="C0005001">BPH</annotation>) in men with an enlarged prostate to <br> <br> <ol><li> Improve symptoms </li><li> Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. </li></ol> <div> Combination with Alpha Blocker </div> Finasteride tablets USP, 5 mg administered in combination with the alpha blocker doxazosin is indicated to reduce the risk of symptomatic progression of <annotation cui="C0005001">BPH</annotation> (a confirmed 4 point increase in American Urological Association (AUA) symptom score). <br> <br> <div> Limitations of Use </div> Finasteride is not approved for the prevention of prostate cancer. <br> <br> |220cd180-8a71-4530-b8ca-8864bee9caa0;32266029-c710-44dd-943f-7e31d0afa622;63ed2cec-c677-45bd-a802-64a9ec54046f;77589cc3-c440-4695-800c-82a0e5128a6c;7c01f541-1c88-400c-41a9-7cbb9dee50c0;8330011c-7e20-4a1c-954f-b98bb0ad78b7;f149569c-05d1-4dba-b35a-4ed6a633f776;fde9c9e4-5275-4aa5-8f56-56037b3db0c7;
5091|6d8304ba-1f38-428c-afc6-63a132e559ca|<u> <annotation cui="C0020538">Hypertension</annotation> </u> <br> <br> Amlodipine besylate is indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. It may be used alone or in combination with other antihypertensive agents. <br> <br> <u> <annotation cui="C0340288">Chronic Stable Angina</annotation> </u> <br> <br> Amlodipine besylate is indicated for the treatment of <annotation cui="C0340288">Chronic Stable Angina</annotation>. Amlodipine besylate may be used alone or in combination with other antianginal agents. <br> <br> <u> <annotation cui="C0002963">Vasospastic Angina</annotation> <annotation cui="C0002963">(Prinzmetal's or Variant Angina</annotation>) </u> <br> <br> Amlodipine besylate is indicated for the treatment of confirmed or suspected <annotation cui="C0002963">Vasospastic Angina</annotation>. Amlodipine besylate may be used as monotherapy or in combination with other antianginal drugs. <br> <br> |11bde4d6-fb19-4783-8664-c0d116ddd2d1;136b1141-c4d4-4151-b9ba-3c148afd5fb3;4336a551-afff-4d92-b05b-2a8e2000feef;5b1e1926-d2d4-8bb1-185c-f0da07247b51;6E9A6C82-9F25-4C71-B09A-929BD5D7B1CF;6d8304ba-1f38-428c-afc6-63a132e559ca;8157ca93-d926-4264-b606-f73b2b38842a;a10fa641-ac6b-466d-bcba-31c678a74be8;ff768f8c-a695-440f-9474-bddc35064288;
6536|88c45123-f475-4dd0-bbac-c261868924ef| Oleptro is indicated for the treatment of <annotation cui="C1269683">major depressive disorder</annotation> (<annotation cui="C1269683">MDD</annotation>) in adults. The efficacy of Oleptro has been established in a trial of outpatients with <annotation cui="C1269683">MDD</annotation> as well as in trials with the immediate release formulation of trazodone <i> [see Clinical Studies (14) ] </i> . <br> <br> |88c45123-f475-4dd0-bbac-c261868924ef;
7068|4e07adb4-7807-47d3-b9a9-2332a3047410| PROPECIA is indicated for the treatment of <annotation cui="C0162311">male pattern hair loss</annotation> (<annotation cui="C0162311">androgenetic alopecia</annotation>) in <b> MEN ONLY </b> . <br> <br> Efficacy in bitemporal recession has not been established. <br> <br> PROPECIA is not indicated for use in women. <br> <br> |4e07adb4-7807-47d3-b9a9-2332a3047410;
7092|2919e43b-69a8-434c-a2d2-1f3ecd7554c0| KEPPRA XR is indicated as adjunctive therapy in the treatment of <annotation cui="C0751495">partial onset seizures</annotation> in patients 16 years of age with <annotation cui="C0014544">epilepsy</annotation>. <br> <br> |01fd698a-b7b2-45d0-927c-619abe7a7f6f;0815e947-ecc1-496f-9419-ebdb6a6f24c9;18648f51-a37c-41e1-b451-123bc0cf5446;2919e43b-69a8-434c-a2d2-1f3ecd7554c0;3e75ef6b-142b-906b-7ab6-948a2db98206;4dc61085-f769-4a14-bb99-570264f999f4;4e0cf847-af7b-4eac-80dd-f51db270fa16;5ebddbf4-eeea-4097-9cac-62dd811d0499;63328937-ec82-445b-8bf8-f528f7803326;6ec4db1a-33d2-4ede-be1c-dae2f5c23c07;6ecf5268-7ed3-458e-b281-aec3c51656d7;7cb669d7-d1aa-43b3-a322-0a2eaa13c656;abc9fada-c5c2-4e07-fb8a-4d1518f7657e;
7157|11bf60e0-d81d-4bd3-ac1b-376151d2754d|Diclofenac Sodium Ophthalmic Solution, 0.1% is indicated for the treatment of postoperative <annotation cui="C0021368">inflammation</annotation> in patients who have undergone cataract extraction. <br> <br> |06141D73-9A59-4626-C372-390566602B77;11bf60e0-d81d-4bd3-ac1b-376151d2754d;39dfffb0-612a-48f3-8db5-1a59899b91e9;41c80e79-36fd-4b90-bae1-55d6042c3ca2;52d22a6b-3acd-4694-9df5-8cfa9cc2bb2b;65037222-146c-493d-aa1c-e6df89bf5b8d;6bec35d6-500d-4570-b2ff-ce7b4fc801df;888d7749-bdbc-4788-a215-9c0447aee79a;d9e299df-ad21-4ebb-a7a4-287a4c337e90;
7305|17b69d90-d955-4403-84e5-1465379d961c| VANCOCIN HCl Capsules may be administered orally for treatment of <annotation cui="C0014356">enterocolitis</annotation> caused by <i> Staphylococcus aureus </i> (including methicillin resistant strains) and antibiotic associated <annotation cui="C1257843">pseudomembranous colitis</annotation> caused by <i> difficile. </i> Parenteral administration of vancomycin is not effective for the above indications; therefore, VANCOCIN HCl Capsules must be given orally for these indications. <b> Orally administered VANCOCIN HCl Capsules are not effective for other types of infection. </b> <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of VANCOCIN HCl Capsules and other antibacterial drugs, VANCOCIN HCl Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |0e7ead22-9618-418f-85a1-4d5ed0949f78;17b69d90-d955-4403-84e5-1465379d961c;29785dd0-f94f-48b5-9194-b4a796c464ce;b7f386c7-8b78-4751-b6ae-e171925c2d54;c8d63431-46d0-407b-b350-bb8e57e34f65;dc61c457-0ebe-4cd1-85ac-2830a1b09784;f04711a7-652e-427d-a7f5-65d4a1c3cae4;
7349|18f94d60-1385-483d-abed-b6ef38452225|Glimepiride tablets is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with <annotation cui="C0011860">noninsulin dependent (Type 2) diabetes mellitus</annotation> (<annotation cui="C0011860">NIDDM</annotation>) whose hyperglycemia cannot be controlled by diet and exercise alone. Glimepiride may be used concomitantly with metformin when diet, exercise, and glimepiride or metformin alone do not result in adequate glycemic control. <br> <br> Glimepiride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent. Combined use of glimepiride and insulin may increase the potential for hypoglycemia. <br> <br> In initiating treatment for noninsulin dependent diabetes, diet and exercise should be emphasized as the primary form of treatment. Caloric restriction, weight loss, and exercise are essential in the obese diabetic patient. Proper dietary management and exercise alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. In addition to regular physical activity, cardiovascular risk factors should be identified and corrective measures taken where possible. <br> <br> If this treatment program fails to reduce symptoms and or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of glimepiride must be viewed by both the physician and patient as a treatment in addition to diet and exercise and not as a substitute for diet and exercise or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet and exercise alone may be transient, thus requiring only short term administration of glimepiride. <br> <br> During maintenance programs, glimepiride monotherapy should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations. Secondary failures to glimepiride monotherapy can be treated with glimepiride insulin combination therapy. <br> <br> In considering the use of glimepiride in asymptomatic patients, it should be recognized that blood glucose control in <annotation cui="C0011860">NIDDM</annotation> has not definitely been established to be effective in preventing the long term cardiovascular and neural complications of diabetes. However, the Diabetes Control and Complications Trial (DCCT) demonstrated that control of HbA 1c and glucose was associated with a decrease in retinopathy, neuropathy, and nephropathy for insulin dependent diabetic (IDDM) patients. <br> <br> |18f94d60-1385-483d-abed-b6ef38452225;DBAE4496-6D22-48B0-A100-70F686D7C0BD;
7703|dd2e786c-29a7-40f8-a5f3-7641413f5036| Levsin is effective as adjunctive therapy in the treatment of <annotation cui="C0030920">peptic ulcer</annotation>. In acute episodes, Levsin injection can be used to control gastric secretion, visceral <annotation cui="C0037763">spasm</annotation> and hypermotility in <annotation cui="C0022104">spastic colitis</annotation>, spastic <annotation cui="C0005697">bladder</annotation>, <annotation cui="C0010692">cystitis</annotation>, <annotation cui="C0152163">pylorospasm</annotation>, and associated <annotation cui="C0000729">abdominal cramps</annotation>. For use as adjunctive therapy in the treatment of <annotation cui="C0022104">irritable bowel syndrome</annotation> (<annotation cui="C0022104">irritable colon</annotation>, <annotation cui="C0022104">spastic colon</annotation>, <annotation cui="C0022104">mucous colitis</annotation>) and <annotation cui="C0559031">functional gastrointestinal disorders</annotation>. Also as adjunctive therapy in the treatment of <annotation cui="C0005697">neurogenic bladder</annotation> and <annotation cui="C0695242">neurogenic bowel</annotation> disturbances (including the <annotation cui="C0221037">splenic flexure syndrome</annotation> and neurogenic colon). Parenterally administered Levsin is also effective in reducing gastrointestinal motility to facilitate diagnostic procedures such as endoscopy or hypotonic duodenography. Levsin may be used to reduce <annotation cui="C0030193">pain</annotation> and hypersecretion in <annotation cui="C0030305">pancreatitis</annotation>, in certain cases of <annotation cui="C1621824">partial heart block</annotation> associated with vagal activity, and as an antidote for <annotation cui="C0274704">poisoning by anticholinesterase agents</annotation>. <br> <br> <ol><li> IN ANESTHESIA: </li><li> Levsin injection is indicated as a pre operative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. Levsin protects against the peripheral muscarinic effects such as <annotation cui="C0428977">bradycardia</annotation> and excessive secretions produced by halogenated hydrocarbons and cholinergic agents such as physostigmine, neostigmine, and pyridostigmine given to reverse the actions of curariform agents. </li><li> IN UROLOGY: </li><li> Levsin injection may also be used intravenously to improve radiologic visibility of the kidneys. It is also indicated along with morphine or other narcotics in symptomatic relief of <annotation cui="C0151824;C0152169">biliary and renal colic</annotation>. </li></ol> |dd2e786c-29a7-40f8-a5f3-7641413f5036;
9004|a1741a0b-3d4c-42dc-880d-a06e96cce9ef| <br> <b> MALES </b> <br> Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. <ol><li> <annotation cui="C0022735">Primary hypogonadism</annotation> (congenital or <annotation cui="C0403818">acquired)   testicular failure</annotation> due to cryptorchidism, bilateral torsion,orchitis, vanishing testes syndrome; or orchidectomy. </li><li> <annotation cui="C0022735">Hypogonadotrophic hypogonadism</annotation> (congenital or acquired)   idiopathic or gonadotropic LHRH deficiency,or pituitary   hypothalamic injury from tumors, trauma or radiation. </li></ol> If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. <br> <br> <ol><li> Androgens may be used to stimulate puberty in carefully selected males with clearly <annotation cui="C0034012">delayed puberty</annotation>. These patients usually have a familial pattern of <annotation cui="C0034012">delayed puberty</annotation> that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X ray of the hand and wrist to determine bone age should be taken every 6 months to assess the effect of treatment on epiphyseal centers (see WARNINGS ). </li></ol> |67e2cc36-a379-11dc-8314-0800200c9a66;91736ab6-139c-4a1c-a81b-f9d8118b24a8;a0af5e80-8d01-4aa9-9f33-926735fdd38a;a1741a0b-3d4c-42dc-880d-a06e96cce9ef;
979|5dc0f75a-1e14-469f-af4f-c668a32f2328| AzaSite is indicated for the treatment of <annotation cui="C0009768">bacterial conjunctivitis</annotation> caused by susceptible isolates of the following microorganisms <br> <br> CDC coryneform group G <i> Efficacy for this organism was studied in fewer than 10 infections. </i> <br> <br> <i> Haemophilus influenzae </i> <br> <i> Staphylococcus aureus </i> <br> <i> Streptococcus mitis </i> group <br> <i> Streptococcus pneumoniae </i> <br> <br> |5dc0f75a-1e14-469f-af4f-c668a32f2328;
9909|214b6a39-9d7f-4c4d-8e40-a5c4ef05c3d8| Budesonide Inhalation Suspension is indicated for the maintenance treatment of <annotation cui="C0004096">asthma</annotation> and as prophylactic therapy in children 12 months to 8 years of age. <br> <br> Budesonide Inhalation Suspension is NOT indicated for the relief of acute bronchospasm. <br> <br> |0950cd08-a48b-4376-9647-da22cf5a8a70;214b6a39-9d7f-4c4d-8e40-a5c4ef05c3d8;2414058b-5d39-42f2-915f-03a5e1101ab5;2e0fa140-85a0-42db-ba15-a068120076b4;33cd9834-76df-4f26-3fa2-aab6b9eee8f2;4f339e84-33be-44d1-bbae-e0579da12c7f;ca6ae964-3b4b-4c24-a939-0100791ce1fe;cf2c0eb4-f95a-465c-b7e4-e0b3c06924bb;d70092e2-07e2-4a23-aa6a-0e2444e12ee2;
1079|681888c9-af79-4b7d-ae80-c3f4f6f1effd| STROMECTOL is indicated for the treatment of the following infections <br> <br> <b> <annotation cui="C0348997">Strongyloidiasis of the intestinal tract</annotation>  </b> . STROMECTOL is indicated for the treatment of <annotation cui="C0348997">intestinal (i.e., nondisseminated) Strongyloidiasis</annotation> due to the nematode parasite <i> Strongyloides stercoralis </i> . <br> <br> This indication is based on clinical studies of both comparative and open label designs, in which 64 100% of infected patients were cured following a single 200 mcg kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) <br> <br> <b> <annotation cui="C0029001">Onchocerciasis</annotation> </b> . STROMECTOL is indicated for the treatment of <annotation cui="C0029001">Onchocerciasis</annotation> due to the nematode parasite <i> Onchocerca volvulus </i> . <br> <br> This indication is based on randomized, double blind, placebo controlled and comparative studies conducted in 1427 patients in <annotation cui="C0029001">Onchocerciasis</annotation> endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC C). <br> <br> NOTE STROMECTOL has no activity against adult <i> Onchocerca volvulus </i> parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with <annotation cui="C0029001">Onchocerciasis</annotation>, since this procedure will eliminate the microfilariae producing adult parasites. <br> <br>|681888c9-af79-4b7d-ae80-c3f4f6f1effd;
11008|5914ef00-19b1-4e22-9ad3-2b62b455af9d| Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac tromethamine. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. <br> <br> <div> <annotation cui="C0184567">Acute Pain</annotation> in Adult Patients </div> Ketorolac tromethamine tablets are indicated for the short term ( 5 days) management of moderately <annotation cui="C0278140">severe Acute Pain</annotation> that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine, and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary. <br> <br> The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see <b> WARNINGS </b> , <b> PRECAUTIONS </b> , <b> DOSAGE AND ADMINISTRATION </b> , and <b> ADVERSE </b> <b> REACTIONS </b> ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine tablet therapy is not to exceed 5 days. <br> <br> |5914ef00-19b1-4e22-9ad3-2b62b455af9d;
11423|16478b3d-501b-481d-a2a0-8393df6273c3| Diltiazem hydrochloride injection is indicated for the following <br> <br> <b> <annotation cui="C0004238">Atrial Fibrillation</annotation> or <annotation cui="C0004239">Atrial Flutter</annotation>. </b> Temporary control of <annotation cui="C1281999">rapid ventricular rate in Atrial Fibrillation</annotation> or <annotation cui="C0004239">Atrial Flutter</annotation>. It should not be used in patients with <annotation cui="C0004238">Atrial Fibrillation</annotation> or <annotation cui="C0004239">Atrial Flutter</annotation> associated with an accessory bypass tract such as in Wolff Parkinson White (WPW) syndrome or short PR syndrome. <br> <br> <b> <annotation cui="C0030590">Paroxysmal Supraventricular Tachycardia</annotation>. </b> Rapid conversion of <annotation cui="C0030590">paroxysmal supraventricular tachycardias</annotation> (<annotation cui="C0030590">PSVT</annotation>) to sinus rhythm. This includes <annotation cui="C0039232">AV nodal reentrant tachycardias</annotation> and <annotation cui="C0242514">reciprocating tachycardias</annotation> associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. <br> <br> The use of diltiazem hydrochloride injection should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. <br> <br> <b> For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. </b> <br> <br> In domestic controlled trials in patients with <annotation cui="C0004238">atrial fibrillation</annotation> or <annotation cui="C0004239">atrial flutter</annotation>, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts <annotation cui="C0004238">atrial fibrillation</annotation> or <annotation cui="C0004239">atrial flutter</annotation> to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short lived, but may last from 1 to 3 hours. <br> <br> A 24 hour continuous infusion of diltiazem injection in the treatment of <annotation cui="C0004238">atrial fibrillation</annotation> or <annotation cui="C0004239">atrial flutter</annotation> maintained at least a 20% heart rate reduction during the infusion in 83% of patients. <br> <br> Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. <br> <br> In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. <br> <br> In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting <annotation cui="C0030590">PSVT</annotation> to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. <br> <br> Symptoms associated with the <annotation cui="C0003811">arrhythmia</annotation> were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. <br> <br> |16478b3d-501b-481d-a2a0-8393df6273c3;232cfe02-88f7-45e1-adbf-571ba7ebf650;39010b9b-d240-4891-9d35-f804e7fe2857;445a4720-bb65-4146-90c7-a49fb14a2c74;453b73bd-c52d-4d72-a0b3-47588e723e0b;5e36488b-8f2d-4dc9-b803-af1829e6fdd0;875d1ed5-74b7-4494-ccad-96d2eec23c5a;bba03666-ff4f-4bf6-fa92-78e1ec2d9073;c095d1a1-e31c-4c9e-bafd-e1407c210aaa;
11646|cbc8c074-f080-4489-a5ae-207b5fadeba3| WELLBUTRIN SR is indicated for the treatment of <annotation cui="C1269683">major depressive disorder</annotation>. <br> <br> The efficacy of bupropion in the treatment of a <annotation cui="C0024517">major depressive episode</annotation> was established in two 4 week controlled trials of depressed inpatients and in one 6 week controlled trial of depressed outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) (see CLINICAL PHARMACOLOGY). <br> <br> A <annotation cui="C0024517">major depressive episode</annotation> (DSM IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2 week period and represent a change from previous functioning depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. <br> <br> The efficacy of WELLBUTRIN SR in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo controlled trial (see CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use WELLBUTRIN SR for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient. <br> <br> |02500709-7f2c-4251-bd8c-94ab6cdadd4c;165475dd-a250-48bb-b4c8-65c189194a9b;1c230d18-4aec-4105-83cc-43e763f1a64a;1de23b24-eb8c-4d16-a929-297132bf00d2;22009d23-999c-4fa6-bfe7-21395f577236;2315d6e5-144d-4163-9711-f855c759cf8e;235952e6-f748-4408-a8e7-7d980da0e5e6;29848192-7de3-4c0d-a822-1268dcf128b0;5036aa56-e21a-4971-a399-057a77377f4c;5c5210b3-95c6-41f0-945a-3c3567b19b05;5cb7fd36-ae36-409b-af79-9c432e1cf5d9;5f36e697-5a4c-419f-882e-d2d35e829635;64d4bbee-1cc4-409e-b65a-1f2e927cf0d1;6a3c0df3-7ed1-4c69-b963-374f9baccff3;6d0a12dc-3873-4a46-a927-9e5630b569c0;76e29f61-4f1e-4426-9865-b88dea3d0bb4;7d359680-2a9e-426a-a033-6906f51af1b5;7d6bdc28-f334-47f3-8336-c3bebbf57461;82f5292b-b113-4f10-9469-04386fa8e9d4;84718f90-579a-481f-8f39-713e1ed18871;8a2b58d6-ca8e-41e1-837f-928fa46e2097;8b245b30-1ee2-4d4b-8e8e-45d084bb7b6f;8e7c87cc-0479-4aed-9376-7adbe704c9d9;90d1bade-5fc7-4a3e-8d73-99c99906f2e0;91f37277-4aa2-44e0-a1ea-f47e9144c567;96b168d7-a9f9-4b76-ac9a-edda436c0e4e;9720518e-9f70-4811-84ca-69a526d8a904;97330579-8790-c2a8-af59-fe46ce39c58a;9bfe1903-3313-44b7-a27c-fc0775426f94;9c6e2044-c040-403c-bcd6-99ca1e6bba73;9dca0aba-821e-42fd-8353-d62348c098dc;a1e768fd-c28f-4b49-822d-ccc315b4099c;a435da9d-f6e8-4ddc-897d-8cd2bf777b21;a4a56e4e-849d-4928-8d32-528080feb67e;a4d91839-eefa-44dc-8162-eb4f8bd426a2;a5ddc0dc-c176-4705-a9a0-e4ecaf1f5667;ad02c7d6-3c14-4e1e-9ec7-3cc1ede84189;b358c1f1-044c-4dd5-a8e8-ef7800315104;b4219281-d79f-45ac-86dd-82c399415032;c6785b89-6058-0807-1761-66b59416a850;c7b80939-0b2d-4dbc-b921-2081cfd5ae3e;cbc8c074-f080-4489-a5ae-207b5fadeba3;ce537247-2cf3-465a-8150-45aff92a5d00;cec41945-8d64-4793-8784-4c2b8ec37b0f;d7c0dfda-2e49-4a9e-8fbb-cc40217ccc28;dee3f124-bc24-4a37-b2eb-501a66fef064;e3fb04de-2a55-456f-8ecc-ac44dc8e5b5a;e962fb9a-d9fb-49c5-a8b4-0b355b8f829b;e9cef726-267e-4e4f-ac12-d92a8664bf20;f2b2bbd5-720b-4871-9785-a60df6e2e00a;fdd1fa5e-9dbf-4951-a8e9-33d06e05bdba;fddc9630-2f9a-4104-888f-3714587d4fe7;
11848|17210abc-58f6-442e-8ff2-7971333c82f6| Severe <annotation cui="C0085580">essential hypertension</annotation> when the drug cannot be given orally or when there is an urgent need to lower blood pressure. <br> <br> |04b4c1c2-093c-4f48-a6b4-3e290fae51b4;17210abc-58f6-442e-8ff2-7971333c82f6;218c002d-283b-4008-bc38-365cfd53830d;40231804-35ea-4f3f-9a0c-33929f9d8ed1;43ce0ecb-6d62-44bf-8539-823ae03eb9f4;4924a3a0-58c6-4f28-8e72-8a4fc6de055c;c3797028-c625-4f70-ae69-8a5f6f23f1b8;e31239e0-8c5a-4d10-9404-af32278484a3;f34904dc-c945-4de4-8594-34e4f4ac1983;
12067|1df1a585-bf69-44a1-ae78-0994f807c736| Diltiazem hydrochloride tablets are indicated for the management of <annotation cui="C0699826">chronic stable angina</annotation> and <annotation cui="C0002962">angina</annotation> due to <annotation cui="C0010073">coronary artery spasm</annotation>. <br> <br> |026ee806-ba22-45d5-b0ef-ab382bb3d219;08883bd8-34f2-42af-b567-cd76b057f553;1bb603e2-bdb1-441e-9b64-40046dff7a5e;1df1a585-bf69-44a1-ae78-0994f807c736;22b680aa-d888-47e0-b88f-ec6484f96157;2ff06b26-430d-4710-99ee-1f060079cc58;400f14ec-3af3-434a-bc40-65cf0c902678;461fe23f-4453-4e3f-9621-0e3fda057d14;5443ea50-d4f6-4a75-8c8d-f6dd6978d45e;69ca7cae-fdf3-413a-900b-95cf6e9e7b63;d4ee32b2-1608-4db3-a0db-399c0314edb8;da1c1a8e-c9dd-4c20-b061-638f2d0cecda;dfc6784a-896b-49a8-b72e-83239fa4b388;dfd30506-59e5-4578-879e-fbd6fdd90515;f3e7ecef-f360-4987-a4f5-933214130ab2;
12749|87b8cd3c-2849-4b50-b63e-9ea379165c07| Albuterol tablets are indicated for the relief of <annotation cui="C0006266">bronchospasm</annotation> in adults and children 6 years of age and older with reversible <annotation cui="C0600260">obstructive airway disease</annotation>. <br> <br> |1bb952b7-8826-40a1-ac7b-38ec1bd9b94e;2ce4fa42-c406-40fe-a4ff-e5b2b2a17780;5a56892b-7485-4570-9a1d-53ef23f07cbe;87b8cd3c-2849-4b50-b63e-9ea379165c07;953ab65b-b157-41b3-8f90-98fa9d7f20c5;A4663CBB-0265-482A-8BA0-DD6F703E0965;A78ED96A-BE70-497D-BD65-CB0D797969A3;A8454E30-AAE5-43AC-9184-953406E0F3B8;f248b57a-2c06-4ed8-817e-e6ff42f5ce88;
13092|1bec1223-5239-4eb6-a9e8-62444106d2c0| Silenor is indicated for the treatment of <annotation cui="C0917801">insomnia</annotation> characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration [ <i> see Clinical Studies (14) </i> ] <i> . </i> <br> <br> |1bec1223-5239-4eb6-a9e8-62444106d2c0;
1340|1e9666ef-4271-4834-8496-ccb3125d83db| <div> Olanzapine for Injection <annotation cui="C0085631">Agitation</annotation> Associated with <annotation cui="C0036341">Schizophrenia</annotation> and Bipolar I <annotation cui="C0338831">Mania</annotation> </div> Olanzapine for Injection is indicated for the treatment of acute <annotation cui="C0085631">Agitation</annotation> associated with <annotation cui="C0036341">Schizophrenia</annotation> and bipolar I <annotation cui="C0338831">Mania</annotation>. <br> <br> Efficacy was demonstrated in 3 short term (24 hours of IM treatment) placebo controlled trials in agitated adult inpatients with <annotation cui="C0036341">Schizophrenia</annotation> or <annotation cui="C0853193">bipolar I disorder</annotation> <annotation cui="C0349208;C0338831">(manic or mixed episodes</annotation>) <i> [see </i> <b> CLINICAL STUDIES ( 14.3 ) </b> <i> ]. </i> <br> <br> Psychomotor agitation is defined in DSM IV as excessive motor activity associated with a feeling of inner tension. Patients experiencing <annotation cui="C0085631">Agitation</annotation> often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the <annotation cui="C0085631">Agitation</annotation>. <br> <br> |1e9666ef-4271-4834-8496-ccb3125d83db;
13857|cc9e8fbc-ba36-444c-a61b-38dc4fd856b2| SPRIX is indicated in adult patients for the short term (up to 5 days) management of <annotation cui="C0278139;C0278140">moderate to moderately severe pain</annotation> that requires analgesia at the opioid level. <br> <br> |265a485e-0641-463d-b163-9fcb32cf0d7f;cc9e8fbc-ba36-444c-a61b-38dc4fd856b2;
15473|3cea5803-a446-4d2c-9747-f3fb034332c8| <b> ACUVAIL </b> ophthalmic solution is indicated for the treatment of <annotation cui="C0030193">pain</annotation> and <annotation cui="C0021368">inflammation</annotation> following cataract surgery. <br> <br> |3cea5803-a446-4d2c-9747-f3fb034332c8;
17090|bff3f426-44fc-4dbf-96df-df44011103e8| Doxycycline hyclate is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with <annotation cui="C0266929">adult periodontitis</annotation>. <br> <br> |41b98a75-77e8-46a9-aab4-65908f49f984;bff3f426-44fc-4dbf-96df-df44011103e8;
17331|EE91667E-B636-43CE-5796-3A9E738557A3|DILAUDID HP is indicated for the relief of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> in opioid tolerant patients who require larger than usual doses of opioids to provide adequate pain relief. Because DILAUDID HP contains 10 mg of hydromorphone hydrochloride per mL, a smaller injection volume can be used than with other parenteral opioid formulations. Discomfort associated with the intramuscular or subcutaneous injection of an unusually large volume of solution can therefore be avoided. <br> <br> |3832ede8-d3fc-455d-ecab-3b77be5869f5;4d33b072-0755-4b8c-9558-2551306756a3;EE91667E-B636-43CE-5796-3A9E738557A3;f0b78db9-a38c-41bb-8233-5e93f7f18c5c;f68235ab-a367-4604-986c-04e55f1181da;fc55530f-f7d5-4835-96aa-609314b0c6fc;
18297|2c718fc7-2921-4d02-b273-784e513f8299| ATRIDOX is indicated for use in the treatment of chronic <annotation cui="C0266929">adult periodontitis</annotation> for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing. <br> <br> |2c718fc7-2921-4d02-b273-784e513f8299;
1992|2D367E16-FC74-4A63-AC6D-85E038164DE5|Glyburide tablets are indicated as an adjunct to diet to lower the blood glucose in patients with <annotation cui="C0011860">non insulin dependent diabetes mellitus</annotation> (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. <br> <br> Glyburide may be used concomitantly with metformin when diet and glyburide or diet and metformin alone do not result in adequate glycemic control (see metformin insert). <br> <br> In initiating treatment for <annotation cui="C0011860">non insulin dependent diabetes</annotation>, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. If this treatment program fails to reduce symptoms and or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of glyburide must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitution or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient, thus requiring only short term administration of glyburide. <br> <br> During maintenance programs, glyburide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgment should be based on regular clinical and laboratory evaluations. <br> <br> In considering the use of glyburide in asymptomatic patients, it should be recognized that controlling blood glucose in <annotation cui="C0011860">non insulin dependent diabetes</annotation> has not been definitely established to be effective in preventing the long term cardiovascular or neural complications of diabetes. <br> <br> |03542333-a884-42dc-960f-75198f18eafd;1c5c56eb-44ef-4dc0-a689-86088d7a5cbf;2D367E16-FC74-4A63-AC6D-85E038164DE5;CA26071D-1FF4-4000-8104-17F211CC6B71;
2231|cd937378-0fba-4cf2-a638-833112e99788| Virt PN DHA is indicated for the supplemental requirements of patients with <annotation cui="C0162429">nutritional deficiencies</annotation> or are in need of nutritional supplementation. <br> <br> |cd937378-0fba-4cf2-a638-833112e99788;
236|cfbb4ddc-00e9-403e-8529-41eb96b81618| CARDURA XL (doxazosin mesylate extended release tablets) is indicated for the treatment of the signs and symptoms of <annotation cui="C0005001">benign prostatic hyperplasia</annotation> (<annotation cui="C0005001">BPH</annotation>). <br> <br> CARDURA XL is not indicated for the treatment of hypertension. <br> <br> |cfbb4ddc-00e9-403e-8529-41eb96b81618;
2540|64311378-2da2-4835-a222-5df5204c59c2| PRUDOXIN Cream is indicated for the short term (up to 8 days) management of moderate <annotation cui="C0033774">pruritus</annotation> in adult patients with <annotation cui="C0011615">atopic dermatitis</annotation> or <annotation cui="C0149922">lichen simplex chronicus</annotation>. (See DOSAGE AND ADMINISTRATION. ) <br> <br> |64311378-2da2-4835-a222-5df5204c59c2;d83f9f24-584f-4a30-88c6-1a6f8f9f878a;e3a51eb8-cb8b-498f-bf3e-e464cc4acdca;
2588|1d5bce9c-a788-4c52-a69e-c53174b8d061| Therapy with lipid altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. <br> <br> <div> Prevention of <annotation cui="C0007222">Cardiovascular Disease</annotation> </div> In hypercholesterolemic patients without clinically evident <annotation cui="C0010068">coronary heart disease</annotation> (<annotation cui="C0010068">CHD</annotation>), pravastatin sodium tablets, USP are indicated to <br> <br> <ol><li> reduce the risk of <annotation cui="C0027051">myocardial infarction</annotation> (<annotation cui="C0027051">MI</annotation>). </li><li> reduce the risk of undergoing myocardial revascularization procedures. </li><li> reduce the risk of cardiovascular mortality with no increase in death from non cardiovascular causes. </li></ol> <div> <annotation cui="C0020473">Hyperlipidemia</annotation> </div> Pravastatin sodium tablets, USP are indicated <br> <br> <ol><li> high density lipoprotein cholesterol (HDL C) in patients with <annotation cui="C0342879">primary hypercholesterolemia</annotation> and mixed <annotation cui="C0242339">dyslipidemia</annotation> ( Fredrickson Types IIa and IIb). 1 </li><li> a s an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). </li><li> for the treatment of patients with <annotation cui="C0020479">primary dysbetalipoproteinemia</annotation> ( Fredrickson Type III) who do not respond adequately to diet. </li><li> as an adjunct to diet and lifestyle modification for treatment of <annotation cui="C0342882">heterozygous familial hypercholesterolemia</annotation> (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a. LDL C remains 190 mg/dL or <br> b. LDL C remains 160 mg/dL and: there is a positive family history of premature <annotation cui="C0007222">Cardiovascular Disease</annotation> (<annotation cui="C0007222">CVD</annotation>) or <br> two or more other <annotation cui="C0007222">CVD</annotation> risk factors are present in the patient. </li></ol> <div> Limitations of Use </div> Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( <i> Fredrickson </i> TypeI and V). <br> <br> |00bf4e02-633e-453b-8c3c-fb8b1d829887;187997be-2dbf-40af-885f-16df6ba9ae46;1b00f510-c86d-46f6-b427-311a8fd14955;1d5bce9c-a788-4c52-a69e-c53174b8d061;24b45003-6e3e-4aeb-a091-2da8a9f8d4f8;6ca01de3-a0f9-4cfb-b36a-723c7c42e2a4;70dd0d8a-4b4c-43ec-a179-88c0d5dbc536;84f3e019-fd4c-4208-8246-df771d6e025d;88295e57-9167-48a0-b52f-6ec9cef61109;897ad8b7-921d-eb02-a61c-3419e662a2da;9736d9b1-9dca-36a3-5324-3bbeda537aca;99cc0546-bb2d-751e-edfd-1c15a1182e0c;99e0e848-f8f3-4b42-b880-8fbc42633948;a453647b-16de-4795-a550-4f52eac10a26;b4a580e1-5eef-4400-b4de-0a478d668df3;c216d285-0492-43db-98d4-ce5715df2ee0;ca779f66-4b9d-41da-ad0e-e4f58db9fbac;dcf45e4f-b46e-6fbb-b67a-2ff619ab1780;e0c167a4-d8fe-4797-ac83-4364c4c5f9bb;
3113|3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b| <div> Treatment of <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> Associated With a History of <annotation cui="C0267055">Erosive Esophagitis</annotation> </div> PROTONIX I.V. for Injection is indicated for short term treatment (7 to 10 days) of patients with <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> (<annotation cui="C0017168">GERD</annotation>) and a history of <annotation cui="C0267055">Erosive Esophagitis</annotation>. <br> <br> <div> Pathological Hypersecretion Associated with <annotation cui="C0043515">Zollinger Ellison Syndrome</annotation> </div> PROTONIX I.V. for Injection is indicated for the treatment of pathological hypersecretory conditions associated with <annotation cui="C0043515">Zollinger Ellison Syndrome</annotation> or other neoplastic conditions. <br> <br> |3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b;48f4d638-d2a1-47fa-9a81-3acda1b1b1e3;51e4144a-489e-436c-609a-39305f8f56ba;
3255|d956367b-fd7d-46fc-9533-38a6e02b0b59| <div> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> </div> NIRAVAM is indicated for the treatment of <annotation cui="C0270549">Generalized Anxiety Disorder</annotation>. <br> <br> The efficacy of alprazolam in the treatment of <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> was demonstrated in 5 short term, placebo controlled trials. [ <i> see Clinical Studies ( 14.1 ) </i> ]. <br> <br> <div> <annotation cui="C0030319">Panic Disorder</annotation> </div> NIRAVAM is also indicated for the treatment of <annotation cui="C0030319">Panic Disorder</annotation>, with or without <annotation cui="C0001818">agoraphobia</annotation>. <br> <br> The efficacy of alprazolam in the treatment of <annotation cui="C0030319">Panic Disorder</annotation> was established in 2 short term, placebo controlled trials. [ <i> see Clinical Studies ( 14.2 ) </i> ]. <br> <br> Demonstrations of the effectiveness of NIRAVAM by systematic clinical study are limited to 4 months in duration for <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> and 4 to 10 weeks duration for <annotation cui="C0030319">Panic Disorder</annotation>; however, patients with <annotation cui="C0030319">Panic Disorder</annotation> have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient. <br> <br> |d956367b-fd7d-46fc-9533-38a6e02b0b59;ff1630b4-2044-433c-96bc-0bb4ae8d42a0;
3574|09120812-5cd3-46b3-ad2f-4712df57f8d0| <div> <annotation cui="C1269683">Major Depressive Disorder</annotation> </div> Fluoxetine is indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation>. <br> <br> <div> Adult </div> The efficacy of fluoxetine was established in 5  and 6 week trials with depressed adult and geriatric outpatients ( 18 years of age) whose diagnoses corresponded most closely to the DSM III (currently DSM IV) category of <annotation cui="C1269683">Major Depressive Disorder</annotation> (see <b> CLINICAL TRIALS </b> ). <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms depressed mood, loss of interest in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. <br> <br> The effects of fluoxetine in hospitalized depressed patients have not been adequately studied. <br> <br> The efficacy of fluoxetine 20 mg once daily in maintaining a response in <annotation cui="C1269683">Major Depressive Disorder</annotation> for up to 38 weeks following 12 weeks of open label acute treatment (50 weeks total) was demonstrated in a placebo controlled trial. <br> <br> <div> Pediatric (children and adolescents) </div> The efficacy of fluoxetine in children and adolescents was established in two 8  to 9 week placebo controlled clinical trials in depressed outpatients whose diagnoses corresponded most closely to the DSM III R or DSM IV category of <annotation cui="C1269683">Major Depressive Disorder</annotation> (see <b> CLINICAL TRIALS </b> ). <br> <br> The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should be reevaluated periodically. <br> <br> <div> <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> </div> <div> Adult </div> Fluoxetine is indicated for the treatment of obsessions and compulsions in patients with <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> (<annotation cui="C0028768">OCD</annotation>), as defined in the DSM III R; i.e., the obsessions or compulsions cause marked distress, are time consuming, or significantly interfere with social or occupational functioning. <br> <br> The efficacy of fluoxetine was established in 13 week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM III R category of <annotation cui="C0028768">OCD</annotation> (see <b> CLINICAL TRIALS </b> ). <br> <br> <annotation cui="C0028768">OCD</annotation> is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego dystonic and or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. <br> <br> The effectiveness of fluoxetine in long term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo controlled trials. Therefore, the physician who elects to use fluoxetine for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <div> Pediatric (children and adolescents) </div> The efficacy of fluoxetine in children and adolescents was established in a 13 week, dose titration, clinical trial in patients with <annotation cui="C0028768">OCD</annotation>, as defined in DSM IV (see <b> CLINICAL TRIALS </b> ). <br> <br>  <div> <annotation cui="C0006370">Bulimia Nervosa</annotation> </div> Fluoxetine is indicated for the treatment of <annotation cui="C0006370">binge eating</annotation> and <annotation cui="C0042963">vomiting</annotation> behaviors in patients with moderate to severe <annotation cui="C0006370">Bulimia Nervosa</annotation>. <br> <br> The efficacy of fluoxetine was established in 8 to 16 week trials for adult outpatients with moderate to severe <annotation cui="C0006370">Bulimia Nervosa</annotation>, i.e., at least three bulimic episodes per week for 6 months (see <b> CLINICAL TRIALS </b> ). <br> <br> The efficacy of fluoxetine 60 mg day in maintaining a response, in patients with bulimia who responded during an 8 week acute treatment phase while taking fluoxetine 60 mg day and were then observed for relapse during a period of up to 52 weeks, was demonstrated in a placebo controlled trial (see <b> CLINICAL TRIALS </b> ). Nevertheless, the physician who elects to use fluoxetine for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <div> <annotation cui="C0030319">Panic Disorder</annotation> </div> Fluoxetine is indicated for the treatment of <annotation cui="C0030319">Panic Disorder</annotation>, with or without <annotation cui="C0001818">agoraphobia</annotation>, as defined in DSM IV. <annotation cui="C0030319">Panic Disorder</annotation> is characterized by the occurrence of unexpected panic attacks, and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and or a significant change in behavior related to the attacks. <br> <br> The efficacy of fluoxetine was established in two 12 week clinical trials in patients whose diagnoses corresponded to the DSM IV category of <annotation cui="C0030319">Panic Disorder</annotation> (see <b> CLINICAL TRIALS </b> ). <br> <br> <annotation cui="C0030319">Panic Disorder</annotation> (DSM IV) is characterized by recurrent, unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four or more of the following symptoms develop abruptly and reach a peak within 10 minutes 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) fear of losing control; 10) fear of dying; 11) paresthesias (numbness or tingling sensations); 12) chills or hot flashes. <br> <br> The effectiveness of fluoxetine in long term use, i.e., for more than 12 weeks, has not been established in placebo controlled trials. Therefore, the physician who elects to use fluoxetine for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> |09120812-5cd3-46b3-ad2f-4712df57f8d0;10a49211-025b-4d63-b60c-fadfd9b731c0;11544DEA-2F5E-1536-584A-5D1F37A99770;142F9B27-65A7-4ADD-BDCC-2468695FEDFF;180A07FD-1F6A-4617-B8E0-F938C65BA273;3195db14-0cae-4b49-9fba-49b869fe92a8;34efe868-f01a-49c7-ab02-9f659b1689f8;4e4d8017-9c1d-41eb-affb-8046e3548be9;50c8f400-8704-45bf-a7c7-696b5d54fefc;F63868AF-7C5B-430A-81E7-2483286936F1;cb8c497a-4c4e-4af7-84d0-04c8c4636630;d82283c9-57b9-483e-8de4-a92cac6d263f;e1171b54-c1a3-4220-bc8a-92f49f270183;
3606|22e635cb-98c0-e4f9-6a71-62d7487a0a6c| EXALGO is indicated for the management of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> in <u> opioid tolerant </u> patients requiring continuous, around the clock opioid analgesia for an extended period of time. <br> <br> Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl hour, 30 mg oral oxycodone day, 8 mg oral hydromorphone day, 25 mg oral oxymorphone day or an equianalgesic dose of another opioid, for a week or longer. <br> <br> <u> Limitations of Use </u> <br> <br> EXALGO is not for use <br> <br> <ol><li> As an as needed (prn) analgesic </li><li> For pain that is mild or not expected to persist for an extended period of time </li><li> For acute pain </li><li> For postoperative pain. </li></ol> |22e635cb-98c0-e4f9-6a71-62d7487a0a6c;f26ababe-f6f0-443e-8d91-4d2a174675bc;
374|58860ee1-5a9d-4422-b9bc-78e8b7958b53| <div> <annotation cui="C0006266">Bronchospasm</annotation> </div> VENTOLIN HFA is indicated for the treatment or prevention of <annotation cui="C0006266">Bronchospasm</annotation> in patients 4 years of age and older with reversible <annotation cui="C0600260">obstructive airway disease</annotation>. <br> <br> <div> <annotation cui="C0015263">Exercise Induced Bronchospasm</annotation> </div> VENTOLIN HFA is indicated for the prevention of <annotation cui="C0015263">Exercise Induced Bronchospasm</annotation> in patients 4 years of age and older. <br> <br> |22367ff1-5edf-429a-955a-728e42695f60;254422f6-37e0-4dc1-ad3b-b2e20009a7b5;4983a17f-0ea9-4369-9626-6a2ca311210d;58860ee1-5a9d-4422-b9bc-78e8b7958b53;77f24a8c-0a9a-4708-a401-3f56b5d4f2c1;7bdda27b-e123-4f33-87e2-63f33b2b061e;829f381a-7888-4579-a2c5-4359764813c3;8e701d71-1dcb-4b84-bada-84e4f04f5e62;911f605d-5451-49e2-a484-00f619f2012b;938ab43d-bf4c-477f-b918-aabe738d562b;d92c5d6b-ff10-4087-36a2-1cfc464cb967;
4576|29bd0efa-fb16-4e69-bb96-8f6bcf80b9f7| Fluconazole for Oral Suspension is indicated for the treatment of <br> <br> <ol><li> <annotation cui="C0553694">Oropharyngeal</annotation> and <annotation cui="C0239295">esophageal candidiasis</annotation>. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida <annotation cui="C0042029">urinary tract infections</annotation>, <annotation cui="C0031154">peritonitis</annotation>, and <annotation cui="C0153252">systemic Candida infections</annotation> including <annotation cui="C0877445">candidemia</annotation>, <annotation cui="C0153252">disseminated candidiasis</annotation>, and <annotation cui="C0032285">pneumonia</annotation>. </li><li> <annotation cui="C0085436">Cryptococcal meningitis</annotation>. Before prescribing fluconazole for AIDS patients with <annotation cui="C0085436">Cryptococcal meningitis</annotation>, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non HIV infected patients have not been conducted. </li></ol> <b> Prophylaxis </b> <br> <br> Fluconazole for Oral Suspension is also indicated to decrease the incidence of <annotation cui="C0006840">candidiasis</annotation> in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and or radiation therapy. <br> <br> Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly. <br> <br>  <div> CLINICAL STUDIES </div> <div> <annotation cui="C0085436">Cryptococcal Meningitis</annotation> </div> In a multicenter study comparing fluconazole (200 mg day) to amphotericin B (0.3 mg kg day) for treatment of <annotation cui="C0085436">Cryptococcal Meningitis</annotation> in patients with AIDS, a multivariate analysis revealed three pretreatment factors that predicted death during the course of therapy abnormal mental status, cerebrospinal fluid cryptococcal antigen titer greater than 11024, and cerebrospinal fluid white blood cell count of less than 20 cells mm 3 . Mortality among high risk patients was 33% and 40% for amphotericin B and fluconazole patients, respectively (p = 0.58), with overall deaths 14% (9 of 63 subjects) and 18% (24 of 131 subjects) for the 2 arms of the study (p = 0.48). Optimal doses and regimens for patients with acute <annotation cui="C0085436">Cryptococcal Meningitis</annotation> and at high risk for treatment failure remain to be determined. (Saag, <i> et al </i> . N Engl J Med 1992; 32683 9.) <br> <br> <div> Pediatric Studies </div> <div> <annotation cui="C0553694">Oropharyngeal</annotation> <annotation cui="C0006840">Candidiasis</annotation> </div> An open label, comparative study of the efficacy and safety of fluconazole (2 to 3 mg kg day) and oral nystatin (400,000 I.U. 4 times daily) in immunocompromised children with <annotation cui="C0553694">Oropharyngeal</annotation> <annotation cui="C0006840">Candidiasis</annotation> was conducted. Clinical and mycological response rates were higher in the children treated with fluconazole. <br> <br> Clinical cure at the end of treatment was reported for 86% of fluconazole treated patients compared to 46% of nystatin treated patients. Mycologically, 76% of fluconazole treated patients had the infecting organism eradicated compared to 11% for nystatin treated patients. <br> <br> * Subjects without follow up cultures for any reason were considered nonevaluable for mycological response. <br> <br> The proportion of patients with clinical relapse 2 weeks after the end of treatment was 14% for subjects receiving fluconazole and 16% for subjects receiving nystatin. At 4 weeks after the end of treatment, the percentages of patients with clinical relapse were 22% for fluconazole and 23% for nystatin. <br> <br> |29bd0efa-fb16-4e69-bb96-8f6bcf80b9f7;
4867|c88f81ac-1643-4c08-ae2c-63cbe956db7e| DILAUDID INJECTION is indicated for the management of <annotation cui="C0030193">pain</annotation> in patients where an opioid analgesic is appropriate. <br> <br> DILAUDID HP INJECTION is indicated for the management of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> in opioid tolerant patients who require higher doses of opioids. <br> <br> |c88f81ac-1643-4c08-ae2c-63cbe956db7e;
5060|5ba45168-ad5d-4ea9-bd85-fc2fa2b13dad| <b> ACULAR </b> ophthalmic solution is indicated for the temporary relief of <annotation cui="C0022281">ocular itching</annotation> due to <annotation cui="C0339164">seasonal allergic conjunctivitis</annotation>. <b> ACULAR </b> ophthalmic solution is also indicated for the treatment of postoperative <annotation cui="C0021368">inflammation</annotation> in patients who have undergone cataract extraction. <br> <br> |22eb1082-edd6-4332-894e-44e76cc38413;3196b192-439c-4a71-a002-358efdd5b6e6;5ba45168-ad5d-4ea9-bd85-fc2fa2b13dad;79e29a86-1b44-4d95-8d84-5a2e8f23ddcf;b5f5bdb5-2a0e-437e-a6da-aa262cdc9b89;c94644d3-7b64-4f3d-a0c7-12c77466a0fc;d9a186ba-74a9-b6d4-1109-1e045ba1763e;e2f53384-6c90-4a9f-aacf-281233581742;
5257|e4f90075-0c18-4bb6-a580-70aa2a01642e| <div> <annotation cui="C1269683">Major Depressive Disorder</annotation> </div> Fluoxetine USP is indicated for the acute and maintenance treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> in adult patients and in pediatric patients aged 8 to18 years [ <i> see Clinical Studies (14.1) </i> ] <i> . </i> <br> <br> The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods, should periodically be re evaluated [ <i> see Dosage and Administration (2.1) </i> ]. <br> <br> |887fc670-db67-4cfe-967b-46b38375dae5;e4f90075-0c18-4bb6-a580-70aa2a01642e;
7526|e542de29-b400-4b2e-9d5e-0f7c53091f8c| SARAFEM is indicated for the treatment of <annotation cui="C0520676">premenstrual dysphoric disorder</annotation> (<annotation cui="C0520676">PMDD</annotation>). <br> <br> The efficacy of fluoxetine in the treatment of <annotation cui="C0520676">PMDD</annotation> was established in 3 placebo controlled trials ( <i> see </i> CLINICAL TRIALS ). <br> <br> The essential features of <annotation cui="C0520676">PMDD</annotation>, according to the DSM IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with <annotation cui="C0520676">PMDD</annotation> include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. <br> <br> The effectiveness of SARAFEM in long term use, that is, for more than 6 months, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use SARAFEM for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient. <br> <br> |116d2452-1f06-438a-8740-b6415aec5f1e;c06f80cf-be99-0b77-ebd7-7a5f1561d4b4;e542de29-b400-4b2e-9d5e-0f7c53091f8c;
8370|49f82130-6f8a-412c-b625-e75906e74675| Doxycycline Hyclate is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with <annotation cui="C0266929">adult periodontitis</annotation>. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |0c7f3ff6-5132-4dc1-be60-5247b5384bc4;22a3c998-7d46-49a5-b202-3ca7989a6078;3105a84b-655e-4940-9d11-4209cdb05d6b;49f82130-6f8a-412c-b625-e75906e74675;6339395b-0125-4b18-8743-894e8a97f11b;
9076|dfced9d3-10af-493e-ad30-8034f39616fe| Sodium polystyrene sulfonate is indicated for the treatment of <annotation cui="C0020461">hyperkalemia</annotation>. <br> <br> |905c3ee5-d1a7-4deb-a345-4a42296704fa;dfced9d3-10af-493e-ad30-8034f39616fe;
9246|aa15c93a-ff4c-447a-8a21-96da506d8997| <div> Indication </div> ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of <annotation cui="C0035854">rosacea</annotation> in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of <annotation cui="C0035854">rosacea</annotation>. <br> <br> <div> Limitations of Use </div> This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. ORACEA should not be used for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. <br> To reduce the development of drug resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated. <br> <br> Efficacy of ORACEA beyond 16 weeks and safety beyond 9 months have not been established. <br> <br> ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of <annotation cui="C0035854">rosacea</annotation>. <br> <br> |4e954825-3f60-4dbb-a1be-b146fe1acae4;aa15c93a-ff4c-447a-8a21-96da506d8997;
9588|4fad0873-f79c-4f07-9fac-5060be6b38fe| <b> ACULAR LS </b> ophthalmic solution is indicated for the reduction of <annotation cui="C0151827">ocular pain</annotation> and burning stinging following corneal refractive surgery. <br> <br> |416e6f6e-796d-6f75-7357-617348657265;4fad0873-f79c-4f07-9fac-5060be6b38fe;6bf40382-faef-dfd0-838b-6e45e853a7c5;947e29c2-a270-48e0-ba96-c7ed676db871;9cc9791b-490b-4f0a-8820-849245240747;f9b4404c-67bc-4c8a-aa75-1d668a6eed16;
10228|776ccac6-471d-4c41-8c52-a8e90bd832c5| <b> <annotation cui="C0002963">Vasospastic Angina</annotation> </b> <br> <br> Nifedipine is indicated for the management of <annotation cui="C0002963">Vasospastic Angina</annotation> confirmed by any of the following criteria 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) <annotation cui="C0002962">Angina</annotation> or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of <annotation cui="C0002963">Vasospastic Angina</annotation>, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when <annotation cui="C0002962">Angina</annotation> is refractory to nitrates and or adequate doses of beta blockers. <br> <br> <b> <annotation cui="C0699826">Chronic Stable Angina</annotation> (Classical <annotation cui="C0577698">Effort Associated Angina</annotation>) </b> <br> <br> Nifedipine is indicated for the management of <annotation cui="C0699826">Chronic Stable Angina</annotation> (<annotation cui="C0577698">effort associated Angina</annotation>) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and or organic nitrates or who cannot tolerate those agents. In <annotation cui="C0699826">Chronic Stable Angina</annotation> (<annotation cui="C0577698">effort associated Angina</annotation>) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing <annotation cui="C0002962">Angina</annotation> frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and betablocking agents may be beneficial in patients with <annotation cui="C0699826">Chronic Stable Angina</annotation>, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See WARNINGS ). <br> <br> |0cc236dc-95fa-49cc-aeb8-6590de157585;0d592c37-b38c-4fb6-a1d3-96531384ae8d;1937ff14-34a2-40b4-3261-7e3f484409fe;1ee3c427-81f4-4bdd-a17b-138553c57369;2d934d80-6d28-415d-8963-bf8d1e4b038c;5733e038-7cb5-434b-aa8e-abb25e6252c9;776ccac6-471d-4c41-8c52-a8e90bd832c5;AC0F6540-07E5-446E-BE46-A82E6F27B1E3;a3daa0fc-7ec3-42c2-91b2-8418331dd0fc;ac0cd4d1-34c1-46b4-ad61-f10d7c0e06c9;e04aa152-b08d-47f7-b976-f8bee4c386db;776ccac6-471d-4c41-8c52-a8e90bd832c5;
10390|3736d691-e8b9-4fdd-aeca-9e96cf907c51| <div> <annotation cui="C0030567">Parkinson's Disease</annotation> </div> Mirapex (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of <annotation cui="C0030567">idiopathic Parkinson's disease</annotation>. <br> <br> The effectiveness of MIRAPEX tablets was demonstrated in randomized, controlled trials in patients with early <annotation cui="C0030567">Parkinson's Disease</annotation> who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see <b> CLINICAL STUDIES </b> ). <br> <br> <div> <annotation cui="C0035258">Restless Legs Syndrome</annotation> </div> MIRAPEX tablets are indicated for the treatment of moderate to severe primary <annotation cui="C0035258">Restless Legs Syndrome</annotation> (<annotation cui="C0035258">RLS</annotation>). <br> <br> Key diagnostic criteria for <annotation cui="C0035258">RLS</annotation> are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with symptoms of <annotation cui="C0035258">RLS</annotation>. <br> <br> |3736d691-e8b9-4fdd-aeca-9e96cf907c51;96a79b8f-a749-4668-96c5-60c487942621;b5504316-3907-444c-b604-ec9a18cdcd6d;
10462|fa6e4661-1bee-4a64-b982-9d44dbdb8498| Sucralfate Suspension is indicated in the short term (up to 8 weeks) treatment of active <annotation cui="C0013295">duodenal ulcer</annotation>. <br> <br> |0bd18d2a-07b3-4155-b08a-bdd0cfd0bd2e;0fb67b1c-b4c0-46f2-8a81-df1510e006aa;23e8fee2-0bdd-466e-8233-17a3e5867956;944fa24b-29dd-479e-8aad-a5fcbde68dfa;ccc083ac-8563-4c32-8bcd-c1b12270b1ad;fa6e4661-1bee-4a64-b982-9d44dbdb8498;
1048|5356920e-4b73-421b-8125-ee417cd67ad3| THYROID tablets are indicated <br> <br> <ol><li> As replacement or supplemental therapy in patients with <annotation cui="C0020676">hypothyroidism</annotation> of any etiology, except transient <annotation cui="C0020676">hypothyroidism</annotation> during the recovery phase of subacute thyroiditis. This category includes <annotation cui="C0342200">cretinism</annotation>, <annotation cui="C0027145">myxedema</annotation>, and ordinary <annotation cui="C0020676">hypothyroidism</annotation> in patients of any age (children, adults, the elderly), or state (including pregnancy); <annotation cui="C0700502">primary hypothyroidism</annotation> resulting from functional deficiency, <annotation cui="C0004258">primary atrophy</annotation>, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of <annotation cui="C0018021">goiter</annotation>; and <annotation cui="C0271789">secondary (pituitary), or tertiary (hypothalamic) hypothyroidism</annotation> (See WARNINGS ). </li><li> As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid <annotation cui="C0018021">goiters</annotation>, including <annotation cui="C0040137">thyroid nodules</annotation>, <annotation cui="C0040149;C0677607">subacute or chronic Iymphocytic thyroiditis</annotation> (Hashimoto's), <annotation cui="C0342208">multinodular goiter</annotation>, and in the management of <annotation cui="C0007115">thyroid cancer</annotation>. </li></ol> |3b2ef0c1-8caf-f44d-3ab6-2eb2e208ab30;5356920e-4b73-421b-8125-ee417cd67ad3;55aa1982-ed08-4268-90dd-d094a436cedb;7617f4a4-8812-44c4-8386-bc991f4d3a77;82cc78b5-20f2-4a4d-a633-012ed0542c09;
10506|ff24761a-002a-b445-fd5b-446913d6231e| <div> <annotation cui="C0020538">Hypertension</annotation> </div> Atenolol is indicated in the management of <annotation cui="C0020538">Hypertension</annotation>. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide type diuretic. <br> <br> <div> <annotation cui="C0002962">Angina Pectoris</annotation> Due to Coronary Atherosclerosis </div> Atenolol is indicated for the long term management of patients with <annotation cui="C0002962">Angina Pectoris</annotation>. <br> <br>   <div> <annotation cui="C0155626">Acute Myocardial Infarction</annotation> </div>  Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected <annotation cui="C0155626">acute myocardial infarction</annotation> to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient?s clinical condition allows (see <b> DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , </b> and <b> WARNINGS ). </b> In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit. <br> <br>    |05533121-f28c-4006-bc7d-567988f27e01;0bcd32df-eaf7-468d-abe7-d2615e83f67a;15c0c2df-f195-45f9-a1e4-1ed2a43c2216;1eb4f6dd-0f94-0130-5aca-ed0a0defb503;200e9378-f0be-4d8c-a243-9283cd4f1977;2339e482-333c-4dcf-881e-8b65181810ef;2492d5f6-00b0-42c9-a793-2be83ea81ad1;25a72ec9-de0f-44e5-90b8-da1aab0d3588;27522eb0-9e11-45cb-9137-fc50dc78ba80;27c29f1d-a908-41fb-86bd-a0370b3117ef;2ff35cc7-97a1-4388-803b-2efaf776e4d2;308c0bb7-e8cc-4920-8f23-cf8e7c004341;3a8c88aa-ca0d-4c23-8ffb-e6d913ef619c;59f296ff-48d4-4f26-b2a1-98cc82fc3c0c;707e110b-0635-0c8e-9eae-63a6fade79e6;71adae77-b8f2-428f-9f56-3c334dffd048;73ed701f-df55-4b30-acda-a00e3227fe55;75e4f9de-ab9c-4b15-bdc0-05e4cda1737c;77331CAD-4576-4AF6-88F4-6F0F70CB0D68;78470162-0f92-4f46-a9c8-902f94ddcc7f;79000ef8-702c-47ec-aafc-9bc1dfd83e77;7b6f6f55-aef9-4521-b0b5-1f4e17ee7ad3;865ea555-ba24-4f2c-8791-cf681b76ad3f;86bac633-4f6f-4ecf-b3b4-317591666129;87b3326b-7751-4aa5-b9c1-7e72a9daae1f;8c137b74-6a28-4760-b8d5-f453efa95a9e;8dd93a47-d14c-49be-9c22-97c0cdbec75a;95762713-18df-424c-8c50-13aded4bbd8c;97ec87b2-322a-438b-ba95-69040c580eb6;99721d00-0a3e-4966-8bce-7cfa8a9146b2;9ca0ff77-6658-42ef-95ab-5896d7f947ed;a2d29601-21aa-4e78-a725-6c1ea982e3ac;a7048c81-6769-436b-8397-fbaa7489fcdf;aa39a909-3ce1-4350-8dfb-6b2a32c41729;aae36822-9c1b-4600-81d6-da022d56c03e;afa4e524-0d4d-4223-91f7-d22ed7c507ff;b2751336-b0db-47dc-ab42-56dabb15a488;b68595c6-d772-4b25-a42c-5c911bf67d36;b8585313-58f6-42af-bab7-e524ccdacd08;b8cfe18e-7328-4832-aff8-0b4b9e715172;b900115a-faac-4244-94bc-c1ef2f88aa38;b90fcfe1-15f5-4dec-8294-6db4aee5a4d7;c10f83e7-3aca-4087-8208-8c0a93413b01;cad3d03b-4e1b-434f-90f1-cca2789e96ab;d9680c5a-df82-407c-9729-a9c9c59bda78;db801706-1362-44c7-92ab-f584f96c7e1c;f36d4ed3-dcbb-4465-9fa6-1da811f555e6;f9bd1793-4e13-47e0-98cd-30ee06390a64;fcfc9676-4edc-460e-6199-8161b824908f;ff24761a-002a-b445-fd5b-446913d6231e;
10604|2687d670-8af6-42a2-9081-fee112e80fc0| Sucralfate is indicated in <br> <br> <ol><li> Short term treatment (up to 8 weeks) of active <annotation cui="C0013295">duodenal ulcer</annotation>. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x ray or endoscopic examination. </li><li> Maintenance therapy for <annotation cui="C0013295">duodenal ulcer</annotation> patients at reduced dosage after healing of acute ulcers. </li></ol> |04e60cc5-bdce-4b76-9ec4-3c531fec081d;180ed49f-7461-4e92-8699-6ab46096f5b5;1e03f716-32c8-4173-99d8-ae8826d9d043;2687d670-8af6-42a2-9081-fee112e80fc0;2bde09da-d053-447e-84e5-a3cc29abd91b;3466a12d-f390-4315-b4ed-57e71e1d8c1f;47b60d73-2abe-4fe5-a8bb-826b5a86ca27;62819787-beb7-408a-9e23-a61b4720e99c;8ba7933f-169e-42d4-8dfe-736f38070f29;c0320d58-a947-451e-96fb-7c9d5ef92bf4;c48dda77-c4a6-4241-91dd-2cef599b0833;c7a43df7-eb37-4273-9250-87953b1fd270;c87c6b50-6977-4fa7-ae98-40c0753f7aee;d67dcaad-56c1-4e77-a0c8-655970808414;e37d6f6c-e7b7-4285-9991-3152c0d6e192;ec2db707-3cad-473d-8a04-05f23574b612;f6d7a9a8-dec5-4439-9c21-08b14d0a41b1;f8ea3dc2-6142-444c-9aba-14158a7a43bb;
11278|bff7e0aa-0c01-4f6e-89ed-da27cc36706e| Carefully consider the potential benefits and risks of CELEBREX and other treatment options before deciding to use CELEBREX. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [ <i> see Warnings and Precautions (5) </i> ] <br> <br> <div> <annotation cui="C0029408">Osteoarthritis</annotation> (<annotation cui="C0029408">OA</annotation>) </div> CELEBREX is indicated for relief of the signs and symptoms of <annotation cui="C0029408">OA</annotation> [ <i> see Clinical Studies (14.1) </i> ] <br> <br> <div> <annotation cui="C0003873">Rheumatoid Arthritis</annotation> (<annotation cui="C0003873">RA</annotation>) </div> CELEBREX is indicated for relief of the signs and symptoms of <annotation cui="C0003873">RA</annotation> [ <i> see Clinical Studies (14.2) </i> ] <br> <br> <div> <annotation cui="C0553662">Juvenile Rheumatoid Arthritis</annotation> (<annotation cui="C0553662">JRA</annotation>) </div> CELEBREX is indicated for relief of the signs and symptoms of <annotation cui="C0553662">JRA</annotation> in patients 2 years and older [ <i> see Clinical Studies (14.3) </i> ] <br> <br> <div> <annotation cui="C0038013">Ankylosing Spondylitis</annotation> (<annotation cui="C0038013">AS</annotation>) </div> CELEBREX is indicated for the relief of signs and symptoms of <annotation cui="C0038013">AS</annotation> [ <i> see Clinical Studies (14.4) </i> ] <br> <br> <div> <annotation cui="C0184567">Acute Pain</annotation> (<annotation cui="C0184567">AP</annotation>) </div> CELEBREX is indicated for the management of <annotation cui="C0184567">AP</annotation> in adults [ <i> see Clinical Studies (14.5) </i> ] <br> <br> <div> <annotation cui="C0149875">Primary Dysmenorrhea</annotation> (<annotation cui="C0149875">PD</annotation>) </div> CELEBREX is indicated for the treatment of <annotation cui="C0149875">PD</annotation> [ <i> see Clinical Studies (14.5) </i> ] <br> <br> |05cf80f2-12a0-46b0-bcb7-1c982ed7bd3e;0e3ae600-374f-4ddb-9454-dae0d8076987;14e50e10-bbe0-4a2c-983a-19bfa79bdef7;22d6020b-a76e-5068-e98c-299310df2898;27e5f619-b249-470b-b506-845d280fd9ba;29712b18-c82e-4397-800f-e2920f406f29;2aea0f50-b823-42ba-ab13-b40168bd55a2;73eb9256-dcda-4eb1-8a6e-700522146f2e;90f074fa-f205-4039-822e-d09049812237;925b0408-2ba4-4d4c-a1cd-ddfa7115234d;a6854053-029c-419f-8c79-8b59a2600fa1;b6bd0101-ebf0-43e8-99bf-21cb032b05d6;b8ad0b63-76cf-4fa8-9326-d4b750f02374;bff7e0aa-0c01-4f6e-89ed-da27cc36706e;e3591a83-fbb4-4679-89f0-ce3a2331ed54;fe09528e-a072-4bc8-84eb-e79ed06cd553;
1164|f63155b9-ea71-4a30-be32-37173f87bcbf| CONCERTA is indicated for the treatment of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see <i> Clinical Studies (14) ] </i> . <br> <br> A diagnosis of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (ADHD; DSM IV) implies the presence of hyperactive impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months lack of attention to details careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months fidgeting squirming; leaving seat; inappropriate running climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive impulsive criteria to be met. <br> <br> <div> Special Diagnostic Considerations </div> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM IV characteristics. <br> <br> <div> Need for Comprehensive Treatment Program </div> CONCERTA is indicated as an integral part of a total treatment program for <annotation cui="C1263846">ADHD</annotation> that may include other measures (psychological, educational, social). Drug treatment may not be indicated for all patients with <annotation cui="C1263846">ADHD</annotation>. Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms. <br> <br> |034fb7cd-e183-475e-8beb-64fd88facc8f;038ae416-4bd5-411b-bd28-d4f0af5c2ab7;12a36e92-cb00-48d5-8981-89d8cce8c4c6;1a88218c-5b18-4220-8f56-526de1a276cd;2bfb390f-ba99-4d21-8a9e-50fa8ec217c0;2c312c31-3198-4775-91ab-294e0b4b9e7f;ecd88778-0540-4f6f-9bbd-61d42f1a9515;effd952d-ac94-47bb-b107-589a4934dcca;f63155b9-ea71-4a30-be32-37173f87bcbf;
11924|99991CC3-7271-44FC-91C3-3CAB0BBE7645|Because of its life threatening side effects and the substantial management difficulties associated with its use (see <b> WARNINGS </b> below), amiodarone HCl is indicated only for the treatment of the following documented, life threatening recurrent <annotation cui="C0085612">ventricular arrhythmias</annotation> when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. <br> <br> Recurrent <annotation cui="C0042510">ventricular fibrillation</annotation>. <br> <br> Recurrent hemodynamically unstable <annotation cui="C0042514">ventricular tachycardia</annotation>. <br> <br> As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone favorably affects survival. <br> <br> Amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life threatening <annotation cui="C0085612">ventricular arrhythmias</annotation>, and who have access to appropriate monitoring facilities, including in hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. Because of the life threatening nature of the arrhythmias treated, potential interactions with prior therapy, and potential exacerbation of the arrhythmia, initiation of therapy with amiodarone should be carried out in the hospital. <br> <br> |080d74e0-a5c0-49b6-83e4-4ee9e81c345f;09a6638c-aefb-4112-b9e6-eae89ea7c247;0e70dd96-53ca-4bc3-ba70-0bd63dd94d5b;108cd13a-b2d1-45a2-a654-650aa88155f4;1aa2d919-37fc-4867-ae2d-f6be26528284;2ebbeed4-0112-4279-a5b7-607ab0b0f8d6;2eceb4d5-0c47-49c3-8263-46f689388efe;3e8db251-e3c5-4fba-be9a-6044a92f0beb;48f8c54d-0d7e-4469-86ca-93221d6c8f7d;51be39a2-9134-402c-95ad-defe47406ff8;57df7b65-7829-4364-894f-ae4c2772c733;7551b0a2-bfbd-4a9e-9348-654724c13a29;7ccd3733-c3af-4a11-8500-0f99194c1472;99991CC3-7271-44FC-91C3-3CAB0BBE7645;a0f63765-a291-486c-b198-68a7f2414b83;aeaa8449-e47e-4173-8f85-37c022fd170f;b41cbcb5-9c5d-4e45-a4f2-952df5f22c00;bac761ca-9467-49d9-b6fc-b57cd27ee5f7;e1a80191-fcb5-4aab-a972-accabe6ae9c7;
12121|b2608b36-03d1-46b6-9633-88d21306a317| <div> <b> 1.1 </b> <b> <annotation cui="C0020538">hypertension</annotation> </b> </div> Diovan (valsartan) is indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with other antihypertensive agents. <br> <br> <div> <b> <annotation cui="C0018802">heart failure</annotation> </b> </div> Diovan is indicated for the treatment of <annotation cui="C0018802">heart failure</annotation> (NYHA class II IV). In a controlled clinical trial, Diovan significantly reduced hospitalizations for <annotation cui="C0018802">heart failure</annotation>. There is no evidence that Diovan provides added benefits when it is used with an adequate dose of an ACE inhibitor. <i> [ </i> <i> See </i> <i> Clinical Studies </i> <i> (14.2)] </i> <i> </i> <br> <br> <div> <b> Post <annotation cui="C0027051">myocardial infarction</annotation> </b> </div> In clinically stable patients with <annotation cui="C0023212">left ventricular failure</annotation> or <annotation cui="C0242698">left ventricular dysfunction</annotation> following <annotation cui="C0027051">myocardial infarction</annotation>, Diovan is indicated to reduce cardiovascular mortality. <i> [ </i> <i> See </i> <i> Clinical Studies </i> <i> (14.3 </i> <i> ) </i> <i> ] </i> <br> <br> |12084cb5-13db-42ea-b91c-1d361960fba7;7494496c-02fc-4509-ae9e-cbd000fa45a1;8e4382de-df78-4821-b11e-c423442a7ff8;b2608b36-03d1-46b6-9633-88d21306a317;c6488119-6547-4abd-bc15-a809b6107d4f;d73a7aa3-5b5f-4532-9936-752366a2430d;
12644|e2902ed1-cfeb-4815-adc3-129c577917a1| MIRAPEX ER tablets are indicated for the treatment of the signs and symptoms of <annotation cui="C0030567">idiopathic Parkinson's disease</annotation>. <br> <br> |e2902ed1-cfeb-4815-adc3-129c577917a1;
12730|76a76f8e-d7c6-4621-b0a4-d5db0c24f089| <div> Prevention of <annotation cui="C0007222">Cardiovascular Disease</annotation> </div> In adult patients without clinically evident <annotation cui="C0010068">coronary heart disease</annotation>, but with multiple risk factors for <annotation cui="C0010068">coronary heart disease</annotation> such as age, smoking, hypertension, low HDL C, or a family history of early <annotation cui="C0010068">coronary heart disease</annotation>, LIPITOR is indicated to <br> <br> <ol><li> Reduce the risk of <annotation cui="C0027051">myocardial infarction</annotation> </li><li> Reduce the risk of <annotation cui="C0038454">stroke</annotation> </li><li> Reduce the risk for revascularization procedures and <annotation cui="C0002962">angina</annotation> </li></ol> In patients with type 2 diabetes, and without clinically evident <annotation cui="C0010068">coronary heart disease</annotation>, but with multiple risk factors for <annotation cui="C0010068">coronary heart disease</annotation> such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to <br> <br> <ol><li> Reduce the risk of <annotation cui="C0027051">myocardial infarction</annotation> </li><li> Reduce the risk of <annotation cui="C0038454">stroke</annotation> </li></ol> In patients with clinically evident <annotation cui="C0010068">coronary heart disease</annotation>, LIPITOR is indicated to <br> <br> <ol><li> Reduce the risk of non fatal <annotation cui="C0027051">myocardial infarction</annotation> </li><li> Reduce the risk of fatal and non fatal <annotation cui="C0038454">stroke</annotation> </li><li> Reduce the risk for revascularization procedures </li><li> Reduce the risk of hospitalization for <annotation cui="C0018802">CHF</annotation> </li><li> Reduce the risk of <annotation cui="C0002962">angina</annotation> </li></ol> <div> <annotation cui="C0020443">Hypercholesterolemia</annotation> </div> LIPITOR is indicated <br> <br> <ol><li> as an adjunct to diet to reduce elevated total C, LDL C, apo B, and TG levels and to increase HDL C in patients with <annotation cui="C0342879">primary hypercholesterolemia</annotation> (heterozygous familial and nonfamilial) and mixed <annotation cui="C0242339">dyslipidemia</annotation> (Fredrickson Types IIa and IIb); </li><li> as an adjunct to diet for the treatment of patients with elevated serum TG levels(Fredrickson Type IV); </li><li> for the treatment of patients with <annotation cui="C0020479">primary dysbetalipoproteinemia</annotation> (Fredrickson Type III) who do not respond adequately to diet; </li><li> to reduce total C and LDL C in patients with <annotation cui="C0342881">homozygous familial hypercholesterolemia</annotation> as an adjunct to other lipid lowering treatments (eg, LDL apheresis) or if such treatments are unavailable; </li><li> as an adjunct to diet to reduce total C, LDL C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with <annotation cui="C0342882">heterozygous familial hypercholesterolemia</annotation> if after an adequate trial of diet therapy the following findings are present: a.LDL C remains 190 mg/dL or b.LDL C remains 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient </li></ol> Therapy with lipid altering agents should be a component of multiple risk factor intervention in individuals at increased risk for atherosclerotic vascular disease due to <annotation cui="C0020443">Hypercholesterolemia</annotation>. Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate (see National Cholesterol Education Program (NCEP) Guidelines, summarized in Table 7). <br> <br> After the LDL C goal has been achieved, if the TG is still 200 mg dL, non HDL C (total C minus HDL C) becomes a secondary target of therapy. Non HDL C goals are set 30 mg dL higher than LDL C goals for each risk category. <br> <br> Prior to initiating therapy with LIPITOR, secondary causes for <annotation cui="C0020443">Hypercholesterolemia</annotation> (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, and alcoholism) should be excluded, and a lipid profile performed to measure total C, LDL C, HDL C, and TG. For patients with TG <400 mg dL (<4.5 mmol L), LDL C can be estimated using the following equation LDL C = total C   (0.20 [TG] + HDL C). For TG levels >400 mg dL (>4.5 mmol L), this equation is less accurate and LDL C concentrations should be determined by ultracentrifugation. <br> <br> LIPITOR has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). <br> <br> The NCEP classification of cholesterol levels in pediatric patients with a familial history of <annotation cui="C0020443">Hypercholesterolemia</annotation> or premature cardiovascular disease is summarized below <br> <br> |76a76f8e-d7c6-4621-b0a4-d5db0c24f089;
12934|a6c0e721-2021-4983-a305-49bdf8f135a9| <b> <annotation cui="C0040425">Tonsillitis</annotation> and or <annotation cui="C0031350">Pharyngitis</annotation> </b> <br> <br> MOXATAG is a penicillin class antibacterial indicated for the treatment of <annotation cui="C0040425">Tonsillitis</annotation> and or <annotation cui="C0031350">Pharyngitis</annotation> secondary to <i> Streptococcus pyogenes (S. pyogenes) </i> in adults and pediatric patients 12 yrs and older. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of MOXATAG and other antibacterial drugs, MOXATAG should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |35e9aa4c-fd8d-4444-9d1a-62723ba29491;4f1bf9ad-216e-4489-9513-fb7e98173bfe;a6c0e721-2021-4983-a305-49bdf8f135a9;
132|0a2215ba-fdc1-4439-b4c5-679933c4a6fb| Thyroid hormone drugs are indicated <br> <br> <ol><li> As replacement or supplemental therapy in patients with <annotation cui="C0020676">hypothyroidism</annotation> of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes <annotation cui="C0342200">cretinism</annotation>, <annotation cui="C0027145">myxedema</annotation> and ordinary <annotation cui="C0020676">hypothyroidism</annotation> in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); <annotation cui="C0700502">primary hypothyroidism</annotation> resulting from functional deficiency, <annotation cui="C0004258">primary atrophy</annotation>, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of <annotation cui="C0018021">goiter</annotation>; and <annotation cui="C0271789">secondary (pituitary), or tertiary (hypothalamic) hypothyroidism</annotation> (see WARNINGS ). </li><li> As pituitary thyroid stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid <annotation cui="C0018021">goiters</annotation>, including <annotation cui="C0040137">thyroid nodules</annotation>, subacute or <annotation cui="C0677607">chronic lymphocytic thyroiditis</annotation> (Hashimoto s) and <annotation cui="C0342208">multinodular goiter</annotation>. </li><li> As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. </li></ol> Liothyronine sodium tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. <br> <br> |0a2215ba-fdc1-4439-b4c5-679933c4a6fb;36a95013-bc64-415b-b429-d5318912df89;51452b31-ff68-4e0c-b982-c15502ebf1d3;55bc9030-d71f-4464-9754-155ee02b1c7c;cfa4a974-3d3a-4772-a2da-1b2383672e0a;d4e23cbd-2e01-46c2-a690-0b87158d7003;e660bf02-07a6-47f2-aace-de51bf6bf844;fb6dbbf8-45fd-4956-9b12-9125474c825d;
13623|2eda833b-1357-4ed4-a093-194524fcb061| <div> <annotation cui="C0026764">Multiple Myeloma</annotation> </div> THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed <annotation cui="C0026764">Multiple Myeloma</annotation> (<annotation cui="C0026764">MM</annotation>). <br> <br> <div> <annotation cui="C0343467">Erythema Nodosum Leprosum</annotation> </div> THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe <annotation cui="C0343467">Erythema Nodosum Leprosum</annotation> (<annotation cui="C0343467">ENL</annotation>). <br> <br> THALOMID is not indicated as monotherapy for such <annotation cui="C0343467">ENL</annotation> treatment in the presence of moderate to severe neuritis. <br> <br> THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of <annotation cui="C0343467">ENL</annotation> recurrence. <br> <br> |2eda833b-1357-4ed4-a093-194524fcb061;
1373|3e0ccb95-3e8e-477c-b4d2-6060ee05f930| Tramadol hydrochloride extended release tablets are indicated for the management of <annotation cui="C0278139;C0278140">moderate to moderately severe chronic pain</annotation> in adults who require around the clock treatment of their <annotation cui="C0030193">pain</annotation> for an extended period of time. <br> <br> |004de5a4-80f8-4040-a6ea-be5e99352a36;039f9e7c-97f5-4062-8656-6f355c82008e;1682439d-b619-465f-a41e-53ce59891616;2347726f-7755-7026-426c-6f7741776179;246a45d0-0953-4f4f-8175-dab3bafac2db;2fd193e2-7aa7-4119-b540-7e28e82fbd13;322513fd-6be0-4cd9-a0ea-7e4b5b578336;3e0ccb95-3e8e-477c-b4d2-6060ee05f930;40644857-0b2d-4fe5-9f6a-d0e864e94a94;4d7cbe57-2993-4e6c-a9e7-643b0ba3a4ee;6077eae6-aea0-427f-be15-9f1b3f33db0c;69378dd6-6412-4aa5-a6cb-f3461f55452f;92ff3520-e022-4d5f-a6c8-1320c9f2ddfa;a7f97e5b-66d4-4faf-b2f6-b99e44e57d84;b85f71ac-7c97-4c92-a230-95a1d8efc132;bfdc4a52-a3a8-4f1e-8ab3-5c37d7a7d0a2;dc0eabd0-2acc-4018-886c-27ba98f87cc8;dc420d50-6192-482d-b3da-3be55870a79a;e16f98cf-6957-4fbe-88ef-ae9a7560538e;f2bd24a1-01cd-461b-a330-0456a0e5ee58;ffa394f7-2e07-4455-9ed9-4271e05cd762;
145|b172773b-3905-4a1c-ad95-bab4b6126563| <div> <annotation cui="C0024305">Non Hodgkin's Lymphoma</annotation> (<annotation cui="C0024305">NHL</annotation>) </div> Rituxan (rituximab) is indicated for the treatment of patients with <br> <br> <ol><li> Relapsed or refractory, low grade or follicular, CD20 positive, B cell <annotation cui="C0024305">NHL</annotation> as a single agent </li><li> Previously untreated follicular, CD20 positive, B cell <annotation cui="C0024305">NHL</annotation> in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single agent maintenance therapy. </li><li> Non progressing (including stable disease), low grade, CD20 positive, B cell <annotation cui="C0024305">NHL</annotation> as a single agent after first line CVP chemotherapy </li><li> Previously untreated diffuse large B cell, CD20 positive <annotation cui="C0024305">NHL</annotation> in combination with CHOP or other anthracycline based chemotherapy regimens </li></ol> <div> <annotation cui="C0023434">Chronic Lymphocytic Leukemia</annotation> (<annotation cui="C0023434">CLL</annotation>) </div> Rituxan (rituximab) is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20 positive <annotation cui="C0023434">CLL</annotation>. <br> <br> <div> <annotation cui="C0003873">Rheumatoid Arthritis</annotation> (<annotation cui="C0003873">RA</annotation>) </div> Rituxan (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately  to severely  active <annotation cui="C0003873">Rheumatoid Arthritis</annotation> who have had an inadequate response to one or more TNF antagonist therapies. <br> <br> <div> <annotation cui="C0521173">Granulomatosis</annotation> with <annotation cui="C0264939">Polyangiitis</annotation> (GPA) (<annotation cui="C0043092">Wegener's Granulomatosis</annotation>) and <annotation cui="C0343192">Microscopic Polyangiitis</annotation> (<annotation cui="C0343192">MPA</annotation>) </div> Rituxan (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with <annotation cui="C0521173">Granulomatosis</annotation> with <annotation cui="C0264939">Polyangiitis</annotation> (GPA) (<annotation cui="C0043092">Wegener's Granulomatosis</annotation>) and <annotation cui="C0343192">Microscopic Polyangiitis</annotation> (<annotation cui="C0343192">MPA</annotation>). <br> <br> <div> Limitations of Use </div> Rituxan is not recommended for use in patients with severe, active infections. <br> <br> |b172773b-3905-4a1c-ad95-bab4b6126563;
14735|05248b68-16a9-488d-a39f-5137d2410471| MOXEZA solution is indicated for the treatment of <annotation cui="C0009768">bacterial conjunctivitis</annotation> caused by susceptible strains of the following organisms <br> <br> <i> Aerococcus viridans* </i> <br> <br> <i> Corynebacterium macginleyi* </i> <br> <br> <i> Enterococcus </i> <i> faecalis* </i> <br> <br> <i> Micrococcus luteus* </i> <br> <br> <i> Staphylococcus arlettae* </i> <br> <br> <i> Staphylococcus aureus </i> <br> <br> <i> Staphylococcus capitis </i> <br> <br> <i> Staphylococcus epidermidis </i> <br> <br> <i> Staphylococcus haemolyticus </i> <br> <br> <i> Staphylococcus hominis </i> <br> <br> <i> Staphylococcus saprophyticus* </i> <br> <br> <i> Staphylococcus warneri* </i> <br> <br> <i> Streptococcus mitis* </i> <br> <br> <i> Streptococcus pneumoniae </i> <br> <br> <i> Streptococcus parasanguinis* </i> <br> <br> <i> Escherichia coli* </i> <br> <br> <i> Haemophilus influenzae </i> <br> <br> <i> Klebsiella pneumoniae* </i> <br> <br> <i> Propionibacterium acnes </i> <br> <br> <i> Chlamydia trachomatis </i> * <br> <br> *Efficacy for this organism was studied in fewer than 10 infections. <br> <br> |05248b68-16a9-488d-a39f-5137d2410471;
14759|4a233572-2471-4e99-a45e-2de978abcf16| Metronidazole gel is indicated for topical application in the treatment of inflammatory papules and pustules of <annotation cui="C0035854">rosacea</annotation>. <br> <br> |33a06972-62b7-4131-81da-77ae692b4869;43d5e570-f359-564d-9bb4-51784ad97b6f;43ed872b-63ac-4a22-9c9e-cc0e05bcc41e;4a233572-2471-4e99-a45e-2de978abcf16;537f1a8a-db9a-15f3-4833-56befc31bb10;5f6014f9-4a54-47c6-a290-01472e6c0fe7;818dbe07-0267-4682-b171-5ab022ef9801;85a9ba62-eeb8-419e-a21f-e3db1eda7fc4;86da8d86-5ab2-f668-fdfd-b0e93e6a2245;99eaa138-0cfa-45e1-abbf-a88271707979;ab766931-e685-4a81-9939-06da80d9099e;c4e07c26-245d-3e51-6a47-fccde22334d2;c5e18ef7-8bf7-c100-cd24-c727f03f435c;c7156e83-f344-4e9f-a42d-6dc8ce90a0b9;c860c7ef-c1e1-488b-8236-c87d8421820b;de4cb39f-cc6e-98fb-05e5-103f3aca2dad;
1478|29c0e001-4855-4903-aa1d-64e4dd155b8a| <div> <b> 1.1 </b> <b> <annotation cui="C0020538">hypertension</annotation> </b> </div> Diovan (valsartan) is indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with Diovan. <br> <br> Control of <annotation cui="C0020538">High Blood Pressure</annotation> should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National <annotation cui="C0020538">High Blood Pressure</annotation> Education Program s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of <annotation cui="C0020538">High Blood Pressure</annotation> (JNC). <br> <br> Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in <annotation cui="C0027051">myocardial infarction</annotation> and cardiovascular mortality also have been seen regularly. <br> <br> Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <annotation cui="C0020538">hypertension</annotation> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <annotation cui="C0020538">hypertension</annotation> (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. <br> <br> Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, <annotation cui="C0018802">heart failure</annotation>, or diabetic kidney disease). These considerations may guide selection of therapy. <br> <br> Diovan may be used alone or in combination with other antihypertensive agents. <br> <br> <div> <b> <annotation cui="C0018802">heart failure</annotation> </b> </div> Diovan is indicated for the treatment of <annotation cui="C0018802">heart failure</annotation> (NYHA class II IV). In a controlled clinical trial, Diovan significantly reduced hospitalizations for <annotation cui="C0018802">heart failure</annotation>. There is no evidence that Diovan provides added benefits when it is used with an adequate dose of an ACE inhibitor. <i> [ </i> <i> See </i> <i> Clinical Studies </i> <i> (14.2)] </i> <i> </i> <br> <br> <div> <b> Post <annotation cui="C0027051">myocardial infarction</annotation> </b> </div> In clinically stable patients with <annotation cui="C0023212">left ventricular failure</annotation> or <annotation cui="C0242698">left ventricular dysfunction</annotation> following <annotation cui="C0027051">myocardial infarction</annotation>, Diovan is indicated to reduce cardiovascular mortality. <i> [ </i> <i> See </i> <i> Clinical Studies </i> <i> (14.3 </i> <i> ) </i> <i> ] </i> <br> <br> |27bee6c9-118a-4609-8949-2eb161b0c5c4;29c0e001-4855-4903-aa1d-64e4dd155b8a;5ddba454-f3e6-43c2-a7a6-58365d297213;7026f0a7-3f08-4116-aa0b-eb61dc3804ab;e80642ad-bb06-4546-ae33-5bc70cf05cee;
14816|C6DBB330-4926-49D3-936D-488975985484|Metronidazole Cream, 1%, is indicated for the topical treatment of inflammatory lesions and <annotation cui="C0041834">erythema</annotation> of <annotation cui="C0035854">rosacea</annotation>. <br> <br> |1787c491-d92c-4239-9d9f-6a91b629835d;C6DBB330-4926-49D3-936D-488975985484;
15882|d9d15879-3883-4963-9c93-73d5251484fa| ARICEPT is indicated for the treatment of <annotation cui="C0002395">dementia of the Alzheimer's type</annotation>. Efficacy has been demonstrated in patients with mild, moderate, and severe <annotation cui="C0002395">Alzheimer's disease</annotation>. <br> <br> |00a9d965-4c27-419b-a23a-b109864e47fa;042a59ea-131a-4806-b0f4-2f791d4414e2;091faac1-ed92-4be0-8f4e-c5a2918c117c;0baef0fd-e6c0-4ee8-bb7e-1d2e89d6e0ec;18628d9b-dd09-4063-8e02-ca47ce643b87;1c845e89-e899-4094-bae6-c14602dbf288;2e82418b-3175-4843-ab6b-86e6be3619ed;3257494f-8f44-4978-b92d-bde87b2444b6;46b3a402-b20d-4860-8f09-83ae900f55a6;4c9889fd-2cb3-02da-f034-46120acc38c3;4fbb6318-f83f-47ce-ab6c-09e92460bb6d;553f0dab-2d75-4e40-bec1-1cc515b3d81c;61305453-a377-4324-b518-af046259d750;65d15ea7-ab7e-45f2-b88d-9f51016c5a7a;6bbb7b73-910b-4664-8856-4c6adbbb48cb;6fc913fb-dd80-482d-a4a8-fb595cfba1a1;76225f98-55a3-46d8-a6d0-0113df784ebc;76bf638e-dbde-418e-8977-1caf009990bc;79ad107b-bb20-4ed3-89f0-d7c862f3957c;83218148-c1ec-4d94-92cb-cbb479f48c27;92955094-5466-4f1c-b00d-71b27353f088;98e451e1-e4d7-4439-a675-c5457ba20975;aaf76c17-da55-4117-8796-220cc4bb5e70;abfaa250-8ab6-4f4b-b4a1-f9eecf9c2fcd;adb67d38-99f4-44ea-b2c2-b472be7bafc7;b7c926f0-8771-41d7-95be-3d4110dc0603;c0dbc5c0-af7f-4364-8c30-6687a8f7d96c;d476668d-576f-41c9-a1de-4568efaa55d9;d9d15879-3883-4963-9c93-73d5251484fa;dd062ac4-e7f5-4f93-8504-41a0107ec1bf;df1d05be-d885-428e-9a05-417736b2f6ab;e08dc0ab-3c86-43d4-ab18-ce4212657484;e8ac5d36-8116-456f-8274-3defac54bb24;ec5cc9e9-aa3a-4c54-b0a1-de1449701f78;fbec890c-214a-4ef1-adf7-22f274328ec6;
15933|fffb4e00-c921-4958-aeab-18deae4a2e38| MARINOL Capsules is indicated for the treatment of <br> <br> <ol><li> <annotation cui="C0003123">anorexia</annotation> associated with weight loss in patients with AIDS; and </li><li> <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. </li></ol> |08adbfd9-789a-4888-a9e2-2a6dac867885;1f1af798-17d5-47d0-b129-21d4aa1eb125;5050ed63-c6bc-4761-9a81-ef8e5f3f378e;5bbac0b1-ddc2-400b-8e0d-1e1d484720ca;68b4168b-5782-4e68-a25a-5b4e4408dbce;a6269fc3-ca40-444f-8035-d6a391d037e0;fffb4e00-c921-4958-aeab-18deae4a2e38;
16246|9a57a63e-f856-aafa-037a-c08f2fea6496| <br> <br> <div> <b> <annotation cui="C0036341">schizophrenia</annotation> </b> </div> Oral olanzapine is indicated for the treatment of <annotation cui="C0036341">schizophrenia</annotation>. Efficacy was established in three clinical trials in adult patients with <annotation cui="C0036341">schizophrenia</annotation> two 6 week trials and one maintenance trial. <b> [ </b> see <b> Clinical Studies ( 14.1 )]. </b> <br> <br> When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see <b> Warnings and Precautions ( 5.5 , 5.6 </b> <i> ) </i> ]. <br> <br> <i> Information describing the use of olanzapine tablets in pediatric patients with <annotation cui="C0036341">schizophrenia</annotation> is approved for Eli Lilly and Company s olanzapine drug product labeling. However, due to Eli Lilly and Company s marketing exclusivity rights, this drug product is not labeled with that pediatric information. </i> <br> <br> <br> <br> <br> <br> <div> <b> <annotation cui="C0853193">bipolar I disorder</annotation> <annotation cui="C0349208;C0338831">(Manic or Mixed Episodes</annotation>) </b> </div> <div> Monotherapy </div> Oral olanzapine is indicated for acute treatment of <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0853193">bipolar I disorder</annotation> and maintenance treatment of <annotation cui="C0853193">bipolar I disorder</annotation>. Efficacy was established in three clinical trials in adult patients with <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> of <annotation cui="C0853193">bipolar I disorder</annotation> two 3  to 4 week trials and one monotherapy maintenance trial. [see <b> Clinical Studies ( 14.2 ) </b> ]. <br> <br> When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see <b> Warnings and Precautions ( 5.5, 5.6 ) </b> ]. <br> <br> <i> Information describing the use of olanzapine tablets in pediatric patients with <annotation cui="C0853193">bipolar I disorder</annotation> is approved for Eli Lilly and Company s olanzapine drug product labeling. However, due to Eli Lilly and Company s marketing exclusivity rights, this drug product is not labeled with that pediatric information. </i> <br> <br> <br> <br> <div> Adjunctive Therapy to Lithium or Valproate </div> Oral olanzapine is indicated for the treatment of <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> as an adjunct to lithium or valproate. Efficacy was established in two 6 week clinical trials in adults. The effectiveness of adjunctive therapy for longer term use has not been systematically evaluated in controlled trials [see <b> Clinical Studies (14.2) </b> ]. <br> <br> <div> <b> Special Considerations in Treating Pediatric <annotation cui="C0036341">schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> </b> </div> <i> Information on treating pediatric patients with <annotation cui="C0036341">schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> is approved for Eli Lilly and Company s olanzapine drug product labeling. However, due to Eli Lilly and Company s marketing exclusivity rights, this drug product is not labeled with that pediatric information. </i> <br> <br> <div> Olanzapine and Fluoxetine in Combination Depressive Episodes Associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> </div> Oral olanzapine and fluoxetine in combination is indicated for the treatment of depressive episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>, based on clinical studies in adult patients. When using olanzapine and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. <br> <br> Olanzapine monotheraphy is not indicated for the treatment of depressive episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>. <br> <br> |0e986037-41c9-431e-b007-0e7764523fdd;296e29ff-206d-409a-8c0f-10b2ec081be5;2cb1bebe-0ced-46d8-bf21-c28a9acc4a15;30a963ab-b2ee-4949-8c3c-00d0f308dd61;3347d1c8-04c9-5ce1-8cda-b38e0412b709;3989d366-c9a5-476f-9649-213bace07768;4464f13c-b9b9-4464-a05e-5b2cdc091fb2;5f3a9abd-aaca-48b9-8cc9-79bb21179ff5;636665be-9d7e-443a-8134-e8cc47e6ba24;66ef201f-85eb-44f0-9ef0-1b618c6e0bff;676ace4e-7706-742d-cab0-430dd1f83408;709d79a1-2742-4629-af43-161be166833a;71c6577c-ffea-4934-bc10-2d35942f8a16;75616c31-8fed-4014-a9f2-4a028eccd586;7881c39e-0624-4c14-a6c3-7a9dc81c198c;7c6ff491-c30c-4ada-85a0-cbee98f2fe32;7f243027-7047-47c4-8b66-288c60ec2008;7fd4c66a-1535-4651-b01a-42ba69e0a965;842b438f-86c7-44f2-a614-06915757a4dd;96165590-b287-0ed9-3723-752af59aedad;9a57a63e-f856-aafa-037a-c08f2fea6496;a1dfb4e7-4143-4422-b7a7-292e4fd75044;a3c9ea17-3793-494a-8b32-44e48f9f4503;abd4a67a-6334-427b-9ad4-4fafefa49e51;aff02cff-d079-bc82-6182-a24c4c6e09a6;c0d705bf-b719-4c7b-b83d-c17d41cbbfad;d5051fbc-846b-4946-82df-341fb1216341;d6a92eba-0841-474b-96f3-778f060ab133;d974d2a4-fc65-42ff-8138-cfcfd7381534;d976599a-0ee0-4fa4-afe6-bdfbca570afe;dd0b2525-4e2f-44fc-9302-0ae4ebb1e135;e24a692e-0dd5-4637-bb3b-bca2538870da;f6ec3e3e-24c3-4360-b712-ca6017af1347;
16555|2deb758c-659e-4e5a-a087-0e9c422f2fe1| <div> <annotation cui="C0030567">Parkinson's Disease</annotation> </div> REQUIP XL (ropinirole extended release tablets) is indicated for the treatment of the signs and symptoms of <annotation cui="C0030567">idiopathic Parkinson's Disease</annotation>. <br> <br> |1e565a1d-8886-437b-8e61-031455732a5c;2deb758c-659e-4e5a-a087-0e9c422f2fe1;2ed1aae8-ca68-41f7-8922-3662329117c4;6c24b96c-7d8d-494a-b7cd-49fe6138a66d;a402c1d1-8841-faa9-e9b9-d490fc6353bd;c1859eee-b5b9-401e-34ac-254a30218555;cedabd80-c526-409a-b1fb-f46de085a3db;ec0612a1-ccb1-bb51-8881-04faf491e093;
16791|879be756-991a-42c5-a381-9c8c2ad1fbdb| Terbutaline sulfate is indicated for the prevention and reversal of <annotation cui="C0006266">bronchospasm</annotation> in patients 12 years of age and older with <annotation cui="C0004096">asthma</annotation> and reversible <annotation cui="C0006266">bronchospasm</annotation> associated with <annotation cui="C0006277">bronchitis</annotation> and <annotation cui="C0013990">emphysema</annotation>. <br> <br> |2cc059f3-de3a-4ccd-93a3-2850828b1acb;352e3476-2bc4-4995-9fd9-4a8864417f1a;382dcebb-6e41-4335-818d-b5822e3fb884;4ae8fb3d-9df3-4948-bb07-6e4169521f15;586cbc83-85d1-cd0f-d4a2-39b20dbcc82f;613df3cb-4d55-4d12-ab08-a932481aaa0b;879be756-991a-42c5-a381-9c8c2ad1fbdb;8a15f833-8817-48e0-9372-b876865e3b92;a89dcda2-2633-4c63-a6fe-d6d7bf0cdf32;cec31032-f366-4524-9e01-63146e473b2b;e691d5be-50b3-4076-be83-d18efd9489cb;ed2af9a9-8bc4-4c6a-b8df-e8fc88c93d6c;fbf54709-5857-4dbc-9233-ebd7abff88c8;
17305|4cd4baf4-18d2-434f-b80b-4f4b19996cf9| Triostat (liothyronine sodium injection) (T 3 ) is indicated in the treatment of <annotation cui="C0238298">myxedema coma</annotation> precoma. <br> <br> <i> Triostat </i> can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. <br> <br> |4cd4baf4-18d2-434f-b80b-4f4b19996cf9;a8b39730-de19-497d-bde8-6594aa528403;
1749|2B1B7B5F-2F20-418C-B1AC-794C2EF1CE5E|ARICEPT is indicated for the treatment of <annotation cui="C0002395">dementia of the Alzheimer's type</annotation>. Efficacy has been demonstrated in patients with mild to moderate <annotation cui="C0002395">Alzheimer's Disease</annotation>, as well as in patients with severe <annotation cui="C0002395">Alzheimer's Disease</annotation>. <br> <br> |2B1B7B5F-2F20-418C-B1AC-794C2EF1CE5E;
1835|54662ff4-10d8-425f-a2ae-978715093da1| Tramadol hydrochloride is indicated for the management of <annotation cui="C0278139;C0278140">moderate to moderately severe pain</annotation> in adults. <br> <br> |1c120d54-5eff-d265-56e7-a5cf4aee48f1;1f012f4e-bd71-48be-a1b9-ab1c8037520a;34ef3f2e-883d-431e-a6cd-b351a0d2c9bb;380436f7-7a26-462b-a098-315b48d9ba68;3d1cd856-3bc2-4f0f-8ae0-269a8dc812fb;3da3815b-fa99-4b20-8564-96d32d84df28;45f59e6f-1794-40a4-8f8b-3a9415924468;485af94f-5ecd-4f25-9774-61ce4cff0921;54662ff4-10d8-425f-a2ae-978715093da1;58b802cb-2443-4f5b-9718-7d54c6d50cb4;5fd73b94-8e76-4274-8259-7c353bc1a32d;6d3b4049-2bfd-4874-b984-8fb231bff27c;6f3a2ab8-f437-456f-ae35-67a965396052;7bef8b51-1a86-4dd9-9294-d208a9424115;9CDAF357-6EA9-4B6A-860F-C28EDC653FFD;AC7A6838-AA9F-4855-B410-351649A272C3;AE7C54B1-B440-4CCA-97E8-E5B825413D32;C33601EC-EF89-4BD4-8485-F81871AFAD94;afc36069-62f2-458c-aefd-dda8d8764a80;bc3ecbf6-0abe-44bf-97a4-630fb5b92320;ca026c60-a160-4e42-bff4-be774526891b;cabccc8a-6f9f-414c-93f0-6dec331ed74b;d15a592c-d02b-5bf9-11bb-005141ce5472;d5576a76-b16c-4db2-a762-c03194b1e44c;d832d94d-454c-4f83-addc-ed349a269231;ee7179b7-6a08-4eeb-a787-5d697b02c4a2;f05e00b3-25d1-4d96-a5d0-f6260b2507ac;
1935|3aa936a1-1ce2-4725-8e18-2d3636b187d9| Metformin HCL Tablets as monotherapy, is indicated as an adjunct to diet and exercise to improve glycemic control in patients with <annotation cui="C0011860">type 2 diabetes</annotation>. Metformin HCL is indicated in patients 10 years of age and older. <br> <br> Metformin HCL may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults (17 years of age and older). <br> <br> |3aa936a1-1ce2-4725-8e18-2d3636b187d9;468AF59B-81E9-4876-9903-EACAECD28B3B;553777EE-8ECA-4A89-89B7-317A3E9084F6;72a8a091-97bf-4df3-a196-e83e4add8fc6;9d896352-3611-4161-b7b7-826eaf8288c0;A3878E6A-ABB9-4994-8D5A-EA4DC2E85226;A57FD3FC-4C8F-4EB4-8BE0-9C7E243624BC;A757F9F8-A925-4E47-9B83-131CCCF8E470;BF1B5EE0-ED51-45E8-9ACD-D5468B51679F;e17d7cc3-e193-4f41-a457-4b6b32a9201d;
2391|a0da0dba-a56d-486b-a45b-e8a7cdfbeac6| HALCION is indicated for the short term treatment of <annotation cui="C0917801">insomnia</annotation> (generally 7 10 days). Use for more than 2 3 weeks requires complete reevaluation of the patient (see WARNINGS ). <br> <br> Prescriptions for HALCION should be written for short term use (7 10 days) and it should not be prescribed in quantities exceeding a 1 month supply. <br> <br> |0cdd2d17-92fa-4534-a1d3-d47733fbb6d8;12c0c495-a032-382e-9b04-37018090cad0;3aa63f5c-2490-4bce-bc5e-35331d5d51ad;5add318e-11b9-42f8-b052-0d8cebb32fcf;6D743386-A8E4-4A3F-AC82-C046896F35AE;73db8a0e-02a9-4613-8feb-e847c965d34f;9bf087eb-daeb-41f7-80b5-5fc70927011d;a0da0dba-a56d-486b-a45b-e8a7cdfbeac6;aef73b7b-c72b-4775-abd6-8f0144cfb14d;b130a3b2-e34a-411f-b3d8-121ae81c98e0;db1311ad-9732-4fdb-80dc-95b09077e3d0;db564864-17fc-4ba5-a438-a467ef57a0ca;
2492|3a680766-06c8-4643-94c1-0f1bba5cdd8c| AVELOX Tablets and I.V. are indicated for the treatment of adults ( 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) <br> <br> <b> <annotation cui="C0275556">Acute Bacterial Sinusitis</annotation> </b> caused by <i> Streptococcus pneumoniae, Haemophilus influenzae </i> , or <i> Moraxella catarrhalis </i> . <br> <br> <b> Acute Bacterial Exacerbation of <annotation cui="C0008677">Chronic Bronchitis</annotation> </b> caused by <i> Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, </i> <i> Klebsiella pneumoniae, </i> methicillin susceptible <i> Staphylococcus aureus, </i> or <i> Moraxella catarrhalis. </i> <br> <br> <b> <annotation cui="C0694549">Community Acquired Pneumonia</annotation> </b> caused by <i> Streptococcus pneumoniae </i> (including multi drug resistant strains*), <i> Haemophilus influenzae, Moraxella catarrhalis, </i> methicillin susceptible <i> Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, </i> or <i> Chlamydia pneumoniae </i> . <br> <br> * MDRSP, Multi drug resistant <i> Streptococcus pneumoniae </i> includes isolates previously known as PRSP (Penicillin resistant <i> pneumoniae </i> ), and are strains resistant to two or more of the following antibiotics penicillin (MIC 2 g mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim sulfamethoxazole. <br> <br> <b> Uncomplicated <annotation cui="C0037278">Skin and Skin Structure Infections</annotation> </b> caused by methicillin susceptible <i> Staphylococcus aureus </i> or <i> Streptococcus pyogenes </i> . <br> <br> <b> Complicated <annotation cui="C1112209">Intra Abdominal Infections</annotation> </b> including <annotation cui="C0275524">polymicrobial infections</annotation> such as <annotation cui="C0000833">abscess</annotation> caused by <i> Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, </i> or <i> Peptostreptococcus species </i> . <br> <br> <b> Complicated <annotation cui="C0037278">Skin and Skin Structure Infections</annotation> </b> caused by methicillin susceptible <i> Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, </i> or <i> Enterobacter cloacae </i> (See Clinical Studies ). <br> <br> Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |222e661d-e956-441a-a02b-b70e0f05c328;3a680766-06c8-4643-94c1-0f1bba5cdd8c;56b4f979-bf20-4908-9d7c-5536221d77f8;69deea75-b24f-4d4c-8150-2404a23ef618;be8e0025-5726-4965-9510-e7e657687d23;fe9226f8-64f4-4eff-8339-ed3fce0896f2;
3193|4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4| <div> <annotation cui="C0020538">Hypertension</annotation> </div> TOPROL XL is indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. It may be used alone or in combination with other antihypertensive agents <i> [see Dosage and Administration (2) ] </i> . <br> <br> <div> <annotation cui="C0002962">Angina Pectoris</annotation> </div> TOPROL XL is indicated in the long term treatment of <annotation cui="C0002962">Angina Pectoris</annotation>, to reduce <annotation cui="C0002962">angina</annotation> attacks and to improve exercise tolerance. <br> <br> <div> <annotation cui="C0018802">Heart Failure</annotation> </div> TOPROL XL is indicated for the treatment of stable, symptomatic (NYHA Class II or III) <annotation cui="C0018802">Heart Failure</annotation> of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, TOPROL XL decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for <annotation cui="C0018802">Heart Failure</annotation>. <br> <br> |2548b18c-5dfe-419d-a602-319d135cb096;2568f163-206f-410b-a353-cd0cfbf1e6d4;2d948600-35d8-4490-983b-918bdce488c8;31d8610a-ab22-49e5-a762-6b08244ee93a;361cc106-6167-43e1-93af-46b3faa5cedf;3bb7dd79-89e2-4d5b-ab4b-8fa2a4025506;44f64f0e-1b68-4478-1fb7-c1bc9402deec;4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4;61289821-90a6-4c78-968d-af4099ffaf14;634bacdf-4191-4073-847d-413d0b0ee217;6d4d276e-59a6-4b91-beb0-c19a02c9e1ef;7d2303a0-f088-495a-a6d0-c59acfe5137b;7e87a7ee-b16e-464a-a77c-0f7a40e04cf7;9feb7a87-75be-46bd-9fe0-288d67b312b1;a0c8c0ac-863c-4385-94d2-f6691bee66d9;a8374722-d2b5-4eb3-bbcd-6ddc52e763ba;ac561677-2058-479f-a545-623451ef89a6;acad5e19-27c5-44fb-80f7-c05aa6859ecf;af828aa9-95f6-49c4-8b83-b5309dbddbf0;ba79d7ec-a781-c617-beee-909ea2f0672b;c20170ea-0e24-4e82-b9cb-aebdbfcc022a;c50e8e36-42df-406b-8e63-eb8bf3f07e89;e1a16fed-bcf7-4a7e-8203-7abc8a041a66;e52001cb-1daa-4651-a8b1-f48a4e9cdfd1;e525f000-a7cd-4665-910e-cc058360f1c6;fef6ca76-25e5-400e-b269-1d689abe34de;ff391fc7-a0ab-4f8c-927e-2588053c7021;
3215|d7434c6c-5a26-46e0-bade-0c54d71112fc| <div> <annotation cui="C0004096">Asthma</annotation> </div> SINGULAIR Registered trademark of Merck Sharp & Dohme Corp., a subsidiary of <b> Merck & Co., Inc. </b> <br> Copyright 1998 2010 Merck Sharp & Dohme Corp., a subsidiary of <b> Merck & Co., Inc. </b> <br> All rights reserved <br> <br> is indicated for the prophylaxis and chronic treatment of <annotation cui="C0004096">Asthma</annotation> in adults and pediatric patients 12 months of age and older. <br> <br> <div> <annotation cui="C0015263">Exercise Induced Bronchoconstriction</annotation> </div> SINGULAIR is indicated for prevention of <annotation cui="C0015263">exercise induced bronchoconstriction</annotation> (<annotation cui="C0015263">EIB</annotation>) in patients 15 years of age and older. <br> <br> <div> <annotation cui="C2607914">Allergic Rhinitis</annotation> </div> SINGULAIR is indicated for the relief of symptoms of <annotation cui="C0018621">seasonal allergic rhinitis</annotation> in patients 2 years of age and older and <annotation cui="C0035457">perennial allergic rhinitis</annotation> in patients 6 months of age and older. <br> <br> |10cd5ca5-6f8b-417c-af11-a2054a2dde34;1525056d-c2c2-4956-9ed5-2d925bff459b;34eee405-05c1-449a-a06f-ca676056c665;78eea56d-15a6-4ceb-b755-d1a3e9707f32;8c166755-7711-4df9-d689-8836a1a70885;99c5d8c4-92d6-41b3-9caa-777fce558261;a99f55de-39d1-483a-ba88-dbda5613c6a7;d7434c6c-5a26-46e0-bade-0c54d71112fc;e8d9021d-73aa-4c96-8b8a-e90069e78555;
3438|7a4840d6-98e3-4523-81a0-ef0b3a47d0c2| DOLOPHINE is indicated for the <br> <br> <ol><li> Management of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> when a continuous, around the clock opioid analgesic is needed for an extended period of time. </li><li> Detoxification treatment of opioid <annotation cui="C0085281">Addiction</annotation> (heroin or other morphine like drugs). </li><li> Maintenance treatment of opioid <annotation cui="C0085281">Addiction</annotation> (heroin or other morphine like drugs), in conjunction with appropriate social and medical services. </li></ol> <b> <u> Limitations of Use </u> </b> <br> <br> DOLOPHINE is not for use <br> <br> <ol><li> As an as needed (prn) analgesic For pain that is mild or not expected to persist for an extended period of time For acute pain For postoperative pain </li></ol> <b> Conditions For Distribution And Use Of Methadone Products For The Treatment Of Opioid <annotation cui="C0085281">Addiction</annotation> </b> <br> <br> Code of Federal Regulations, Title 42, Sec 8 <br> <br> Methadone products when used for the treatment of opioid <annotation cui="C0085281">Addiction</annotation> in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Administration and approved by the designated state authority. Certified treatment programs shall dispense and use methadone in oral form only and according to the treatment requirements stipulated in the Federal Opioid Treatment Standards (42 CFR 8.12). See below for important regulatory exceptions to the general requirement for certification to provide opioid agonist treatment. <br> <br> Failure to abide by the requirements in these regulations may result in criminal prosecution, seizure of the drug supply, revocation of the program approval, and injunction precluding operation of the program. <br> <br> Regulatory Exceptions To The General Requirement For Certification To Provide Opioid Agonist Treatment During inpatient care, when the patient was admitted for any condition other than concurrent opioid <annotation cui="C0085281">Addiction</annotation> (pursuant to 21CFR 1306.07(c)), to facilitate the treatment of the primary admitting diagnosis). <br> <br> During an emergency period of no longer than 3 days while definitive care for the <annotation cui="C0085281">Addiction</annotation> is being sought in an appropriately licensed facility (pursuant to 21CFR 1306.07(b)). <br> <br> |6059a68d-5434-4a0e-9f53-b793c3dc8630;7a4840d6-98e3-4523-81a0-ef0b3a47d0c2;802ab399-479b-4271-a2a7-07aadde91cff;d0e6a966-179a-45e0-8444-4c1b8523f8d2;d3b7a707-78af-4fd5-9b66-b63050bbd6f6;eddf7077-02fb-4771-9823-31984f4ff2bb;
4152|fcf35c8b-b5a5-4806-827f-148cd3c8d3e5| VANDAZOLE is indicated in the treatment of <annotation cui="C0085166">bacterial vaginosis</annotation> (formerly referred to as <i> Haemophilus </i> <annotation cui="C0042267">vaginitis</annotation>, <annotation cui="C1622505"><i> Gardnerella </i> vaginitis</annotation>, <annotation cui="C0085166">nonspecific vaginitis</annotation>, <i> Corynebacterium </i> <annotation cui="C0042267">vaginitis</annotation>, or anaerobic vaginosis) in non pregnant women. <br> <br> |27d71471-8f89-4a1e-8c55-020a58961454;fcf35c8b-b5a5-4806-827f-148cd3c8d3e5;
458|5368755a-dd37-4e34-843f-ece6bac8ef6a| Metronidazole topical lotion is indicated for topical application in the treatment of inflammatory papules and pustules of <annotation cui="C0035854">rosacea</annotation>. <br> <br> <div> CLINICAL STUDIES </div> A controlled clinical study was conducted in 144 patients with moderate to severe <annotation cui="C0035854">rosacea</annotation>, in which metronidazole topical lotion was compared with its vehicle. Applications were made twice daily for 12 weeks during which patients were instructed to avoid spicy foods, thermally hot foods and drinks, alcoholic beverages, and caffeine. Patients were also provided samples of a soapless cleansing lotion and, if requested, a moisturizer. Metronidazole topical lotion was significantly more effective than its vehicle in mean percent reduction of inflammatory lesions associated with <annotation cui="C0035854">rosacea</annotation> and in the investigator's global assessment of improvement. The results of the mean percent reduction in inflammatory lesion counts from baseline after 12 weeks of treatment and the investigators' global assessment of improvement at week 12 are presented in the following table <br> <br> |5368755a-dd37-4e34-843f-ece6bac8ef6a;970a767a-7a65-4cdf-84fe-4dbe0a77b80a;
5493|3dc5f411-3312-4add-8198-161eed98132b| <b> Treatment of Anaerobic Infections </b> <br> <br> Metronidazole Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. <br> <br> Metronidazole is effective in <i> <annotation cui="C0004669">Bacteroides fragilis </i> infections</annotation> resistant to clindamycin, chloramphenicol and penicillin. <br> <br> <b> <annotation cui="C1112209">Intra abdominal Infections</annotation>, </b> including <annotation cui="C0031154">peritonitis</annotation>, <annotation cui="C0243001">intra abdominal abscess</annotation> and <annotation cui="C0023885">liver abscess</annotation>, caused by <i> Bacteroides </i> species including the <i> fragilis </i> group <i> fragilis, B. distasonis, B. ovatus, </i> <i> thetaiotaomicron, B. vulgatus). </i> <i> Clostridium </i> species, <i> Eubacterium </i> species, <i> Peptococcus </i> species, and <i> Peptostreptococcus </i> species. <br> <br> <b> <annotation cui="C0037278">Skin and Skin Structure Infections</annotation> </b> caused by <i> Bacteroides </i> species including <i> fragilis </i> group, <i> Clostridium </i> species, <i> Peptococcus </i> species, <i> Peptostreptococcus </i> species and <i> Fusobacterium </i> species. <br> <br> <b> Gynecologic Infections, </b> including <annotation cui="C0014179">endometritis</annotation>, <annotation cui="C0269050">endomyometritis</annotation>, <annotation cui="C0041343">tubo ovarian abscess</annotation>, and post surgical <annotation cui="C0404521">vaginal cuff infection</annotation>, caused by <i> Bacteroides </i> species including the <i> fragilis </i> group, <i> Clostridium </i> species, <i> Peptococcus </i> species and <i> Peptostreptococcus </i> species. <br> <br> <b> <annotation cui="C0684256">Bacterial Septicemia</annotation> </b> caused by <i> Bacteroides </i> species including the <i> fragilis </i> group and <i> Clostridium </i> species. <br> <br> <b> Bone and Joint Infections, </b> as adjunctive therapy, caused by <i> Bacteroides </i> species including the <i> fragilis </i> group. <br> <br> <b> <annotation cui="C0007684">Central Nervous System (CNS) Infections</annotation>, </b> including <annotation cui="C0025289">meningitis</annotation> and <annotation cui="C0006105">brain abscess</annotation>, caused by <i> Bacteroides </i> species including the <i> fragilis </i> group. <br> <br> <b> <annotation cui="C0149725">Lower Respiratory Tract Infections</annotation>, </b> including <annotation cui="C0032285">pneumonia</annotation>, <annotation cui="C0014009">empyema</annotation>, and <annotation cui="C0024110">lung abscess</annotation>, caused by <i> Bacteroides </i> species including the <i> fragilis </i> group. <br> <br> <b> <annotation cui="C0014118">Endocarditis</annotation> </b> caused by <i> Bacteroides </i> species including the <i> fragilis </i> group. <br> <br> <b> Prophylaxis </b> The prophylactic administration of Metronidazole Injection, USP preoperatively, intraoperatively, and postoperatively may reduce the incidence of <annotation cui="C0392618">postoperative infection</annotation> in patients undergoing selective colorectal surgery which is classified as contaminated or potentially contaminated. <br> <br> Prophylactic use of Metronidazole Injection, USP should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION ). <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |21f92715-5550-4181-a170-e715c3c9e5b3;25ef25b3-477b-40a4-afc3-04d2333ce709;291a45f6-ed27-4dcc-8364-358d08623797;3193a61d-acc4-445a-8bb9-328568d43937;31999703-3b31-4820-9319-1e5675c1ad82;3908517e-eb15-42a9-b651-fb2ec625e11b;394e0a80-4fb6-425c-b614-52c118db769e;3dc5f411-3312-4add-8198-161eed98132b;504ee940-05e5-457d-95d2-311d5e0f5fff;50f37ffb-81e3-43a1-9ff7-a1d23b5cfcd5;6b35138f-491b-46cf-97d3-55f43e651d63;6d969bc3-8182-4b4b-862e-3fb6a5cfc04f;8df92539-5acf-46b1-b7e2-e9fac21b30ae;9db2ddc3-8193-4efc-bd39-f532ccec47c5;A66ABF44-9AE9-4342-B69A-EBAA1F9B7D78;A9987047-9C99-45A5-829B-AE8B189CBFD4;a2883ca1-5a9a-4259-9d80-46ab67274384;a775da83-6554-4229-afb8-92cdcfb4503e;b3027944-1c31-46fe-a9fa-1fea55f8171b;b39cc0e4-57ad-4d70-a105-44ebccf201f8;b5349a88-9275-489e-8c71-2bd22eb9e520;b989cb92-dbe5-4325-bcd3-43fe8a5f13b7;c49de241-088a-4ac1-ae9e-bab7a8b22417;c9fc6a64-cd68-46bd-a470-843b5d44eb2b;d2112f37-5080-4a19-bcc3-6386b49abe1d;d552db0a-959c-4ad9-ab65-d7cc541baf7e;d7b3d7f0-ea9c-45fd-9aa9-699ed93ac11a;e1e7e127-e99e-80e9-1606-71261658b0c1;ecf64245-20b1-4bff-9fcc-b8a16905e27b;efb2f572-1e11-43e3-a653-eaeafc17ec79;eff2f83e-d2b0-4ff5-afbd-76b45763af93;f0a90f3c-a6c2-4e84-af9d-6f0470bce59b;f3505fef-f135-4b1f-b743-846342625a79;fb79c214-e6ff-499a-9e23-a759bef9b7cb;fd191c06-9d3b-4e46-9f79-90f6af614947;fe23dfcf-cb33-4363-9b0a-c3a4d1d7d6de;
5639|5d103551-978f-472a-9c62-51e6e4dea068| <div> Healing of Erosive or Ulcerative <annotation cui="C0017168">GERD</annotation> </div> ACIPHEX is indicated for short term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative <annotation cui="C0017168">gastroesophageal reflux disease</annotation> (<annotation cui="C0017168">GERD</annotation>). For those patients who have not healed after 8 weeks of treatment, an additional 8 week course of ACIPHEX may be considered. <br> <br> <div> Maintenance of Healing of Erosive or Ulcerative <annotation cui="C0017168">GERD</annotation> </div> ACIPHEX is indicated for maintaining healing and reduction in relapse rates of <annotation cui="C0018834">heartburn</annotation> symptoms in patients with erosive or ulcerative <annotation cui="C0017168">gastroesophageal reflux disease</annotation> (<annotation cui="C0017168">GERD</annotation> Maintenance). Controlled studies do not extend beyond 12 months. <br> <br> <div> Treatment of Symptomatic <annotation cui="C0017168">GERD</annotation> </div> ACIPHEX is indicated for the treatment of daytime and nighttime <annotation cui="C0018834">heartburn</annotation> and other symptoms associated with <annotation cui="C0017168">GERD</annotation> in adults and adolescents 12 years of age and above. <br> <br> <div> Healing of <annotation cui="C0013295">Duodenal Ulcers</annotation> </div> ACIPHEX is indicated for short term (up to four weeks) treatment in the healing and symptomatic relief of <annotation cui="C0013295">Duodenal Ulcers</annotation>. Most patients heal within four weeks. <br> <br> <div> <i> Helicobacter pylori </i> Eradication to Reduce the Risk of <annotation cui="C0013295">Duodenal Ulcer</annotation> Recurrence </div> ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with <i> <annotation cui="C0079487">pylori </i> infection</annotation> and <annotation cui="C0013295">duodenal ulcer disease</annotation> (active or history within the past 5 years) to eradicate <i> pylori </i> . Eradication of <i> pylori </i> has been shown to reduce the risk of <annotation cui="C0013295">Duodenal Ulcer</annotation> recurrence. {See <i> CLINICAL STUDIES </i> ( 14.5 ) and <i> DOSAGE AND ADMINISTRATION </i> ( 2.5 )}. <br> <br> In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted. {See <i> CLINICAL PHARMACOLOGY, Microbiology </i> ( 12.2 ) and the clarithromycin package insert, <i> CLINICAL PHARMACOLOGY, Microbiology </i> .} <br> <br> <div> Treatment of Pathological Hypersecretory Conditions, Including <annotation cui="C0043515">Zollinger Ellison Syndrome</annotation> </div> ACIPHEX is indicated for the long term treatment of pathological hypersecretory conditions, including <annotation cui="C0043515">Zollinger Ellison syndrome</annotation>. <br> <br> |0eed7378-67a4-4b08-aeea-32471ce2028e;52459f70-e1f5-41bb-a9f4-e68ef5f5dcf5;5d103551-978f-472a-9c62-51e6e4dea068;6e6f6c6d-4826-4817-90ff-5c3f4fbe8909;dbfa7ae4-35af-4ed3-bca4-7900cd92047c;
6511|aec8ad3a-f717-4e74-b7b9-19debdaad79a| Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with <annotation cui="C0184567">acute, painful</annotation> musculo skeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense skeletal muscles in man. <br> <br> |56bc8e4a-6771-476d-95e8-e4ef2d869cb2;aec8ad3a-f717-4e74-b7b9-19debdaad79a;
6613|e6af84de-cbfc-4a3b-bd73-6bcf77337168| For detoxification treatment of opioid <annotation cui="C0085281">addiction</annotation> (heroin or other morphine like drugs). <br> <br> For maintenance treatment of opioid <annotation cui="C0085281">addiction</annotation> (heroin or other morphine like drugs), in conjunction with appropriate social and medical services. <br> <br> |552751F7-42FF-40C7-8495-A6AA306D5C23;808a9d0b-720b-4034-a862-5122ff514608;e6af84de-cbfc-4a3b-bd73-6bcf77337168;e72841bf-364b-49b1-8e69-7e26ddcd2657;
8496|68cca7e1-120c-4ac6-8851-15a17e11bd9f| VIGAMOX solution is indicated for the treatment of <annotation cui="C0009768">bacterial conjunctivitis</annotation> caused by susceptible strains of the following organisms <br> <br> <u> <b> Aerobic Gram positive microorganisms </b> </u> <br> <br> <i> Corynebacterium </i> species* <br> <br> <i> Micrococcus luteus* </i> <br> <br> <i> Staphylococcus aureus </i> <br> <br> <i> Staphylococcus epidermidis </i> <br> <br> <i> Staphylococcus haemolyticus </i> <br> <br> <i> Staphylococcus hominis </i> <br> <br> <i> Staphylococcus warneri* </i> <br> <br> <i> Streptococcus pneumoniae </i> <br> <br> <i> Streptococcus </i> viridans <i> group </i> <br> <br> <u> <b> Aerobic Gram negative microorganisms </b> </u> <br> <br> <i> Acinetobacter lwoffii* </i> <br> <br> <i> Haemophilus influenzae </i> <br> <br> <i> Haemophilus parainfluenzae </i> * <br> <br> <u> <b> Other microorganisms </b> </u> <br> <br> <i> Chlamydia trachomatis </i> <br> <br> *Efficacy for this organism was studied in fewer than 10 infections. <br> <br> |68cca7e1-120c-4ac6-8851-15a17e11bd9f;
8621|94688946-19f1-4f46-903a-2e9c9b89b0f5| METROGEL VAGINAL is indicated in the treatment of <annotation cui="C0085166">bacterial vaginosis</annotation> (formerly referred to as <i> Haemophilus </i> <annotation cui="C0042267">vaginitis</annotation>, <annotation cui="C1622505"><i>Gardnerella </i> vaginitis</annotation>, <annotation cui="C0085166">nonspecific vaginitis</annotation>, <i> Corynebacterium </i> <annotation cui="C0042267">vaginitis</annotation>, or anaerobic vaginosis). <br> <br> <b> NOTE </b> For purposes of this indication, a clinical diagnosis of <annotation cui="C0085166">bacterial vaginosis</annotation> is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of <annotation cui="C0085166">bacterial vaginosis</annotation> include (a) markedly reduced or absent <i> Lactobacillus </i> morphology, (b) predominance of <i> <annotation cui="C0085166">Gardnerella</annotation> </i> morphotype, and (c) absent or few white blood cells. <br> <br> Other pathogens commonly associated with vulvovaginitis, e.g., <i> Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans </i> , and <i> Herpes simplex </i> virus should be ruled out. <br> <br> |150384e6-1f49-4e79-9c44-b704778ecb65;1e48a661-d836-4f79-a07b-fdbffb35dcfc;8f974c5f-6b14-214e-f551-d096c332648d;918f50d4-5468-400e-b51f-72ac883af46e;94688946-19f1-4f46-903a-2e9c9b89b0f5;bd3b62b6-4a80-495b-a1d3-d54eb15baf79;d36b7894-2152-452d-9bba-38067c52c79e;
9247|4383c6ec-53ad-4c79-b0af-316b3284b2fb| GLUMETZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with <annotation cui="C0011860">type 2 diabetes mellitus</annotation>. <br> <br> <i> Important Limitations of Use </i> <br> <br> GLUMETZA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. <br> <br> |4383c6ec-53ad-4c79-b0af-316b3284b2fb;fb832474-88d9-4e29-95cd-fbc446944cc4;
9295|0b0ba593-fe54-456c-a3d7-651c50036e3e|<div> <annotation cui="C0085166">Bacterial Vaginosis</annotation> (BV) </div> Flagyl ER 750 mg tablets are indicated in the treatment of women with BV. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of Flagyl ER and other antibacterial drugs, Flagyl ER should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |0b0ba593-fe54-456c-a3d7-651c50036e3e;
9537|5012f997-9fb2-4c3d-99fd-4f7efd7c39af|Dyrenium (triamterene) is indicated in the treatment of <annotation cui="C0013604">Edema</annotation> associated with <annotation cui="C0018802">congestive heart failure</annotation>, <annotation cui="C0023890">cirrhosis</annotation> of the liver and the <annotation cui="C0027726">nephrotic syndrome</annotation>; steroid induced <annotation cui="C0013604">Edema</annotation>, <annotation cui="C0238094">idiopathic edema</annotation> and <annotation cui="C0013604">Edema</annotation> due to <annotation cui="C0271728">secondary hyperaldosteronism</annotation>. <br> <br> Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of <annotation cui="C0271728">secondary hyperaldosteronism</annotation>. <br> <br> <i> Usage in Pregnancy </i> . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. <br> <br> <annotation cui="C0013604">Edema</annotation> during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when <annotation cui="C0013604">Edema</annotation> is due to pathologic causes, just as they are in the absence of pregnancy. Dependent <annotation cui="C0013604">Edema</annotation> in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with <annotation cui="C0013604">Edema</annotation>, including generalized edema, in the majority of pregnant women. If this <annotation cui="C0013604">Edema</annotation> produces discomfort, increased recumbency will often provide relief. In rare instances, this <annotation cui="C0013604">Edema</annotation> may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. <br> <br> |5012f997-9fb2-4c3d-99fd-4f7efd7c39af;
10024|644ddc43-b2fa-44bd-aeb7-2547defb85e0| <div> Treatment of <annotation cui="C0021400">Influenza</annotation> </div> TAMIFLU is indicated for the treatment of uncomplicated acute illness due to <annotation cui="C0021400">Influenza</annotation> infection in patients 1 year and older who have been symptomatic for no more than 2 days. <br> <br> <div> Prophylaxis of <annotation cui="C0021400">Influenza</annotation> </div> TAMIFLU is indicated for the prophylaxis of <annotation cui="C0021400">Influenza</annotation> in patients 1 year and older. <br> <br> <div> Limitations of Use </div> The following points should be considered before initiating treatment or prophylaxis with TAMIFLU <br> <br> <ol><li> Efficacy of TAMIFLU in patients who begin treatment after 48 hours of symptoms has not been established. </li><li> TAMIFLU is not a substitute for early <annotation cui="C0021400">Influenza</annotation> vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. </li><li> There is no evidence for efficacy of TAMIFLU in any illness caused by agents other than <annotation cui="C0021400">Influenza</annotation> viruses types A and B. </li><li> <annotation cui="C0021400">Influenza</annotation> viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on <annotation cui="C0021400">Influenza</annotation> drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU. </li></ol> |03a2a7f0-406c-4784-84c1-5fd5f5be4773;1948cafd-b5b3-4212-9d5d-8c293b1baad5;644ddc43-b2fa-44bd-aeb7-2547defb85e0;ca868d3d-177d-42c4-b05b-7beae7343b53;ee3c9555-60f2-4f82-a760-11983c86e97b;
10368|19a92a99-f73a-42f5-b048-28ba0b4df9e6| Buspirone hydrochloride tablets are indicated for the management of <annotation cui="C0003469">anxiety disorders</annotation> or the short term relief of the symptoms of <annotation cui="C0003469">Anxiety</annotation>. <annotation cui="C0003469">Anxiety</annotation> or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (<annotation cui="C0270549">GAD</annotation>). Many of the patients enrolled in these studies also had coexisting <annotation cui="C0086132">depressive symptoms</annotation> and buspirone relieved <annotation cui="C0003469">Anxiety</annotation> in the presence of these coexisting <annotation cui="C0086132">depressive symptoms</annotation>. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (300.02) is described in the American Psychiatric Association s Diagnostic and Statistical Manual, III 1 as follows Generalized, persistent <annotation cui="C0003469">Anxiety</annotation> (of at least 1 month continual duration), manifested by symptoms from three of the four following categories <br> <br> <ol><li> Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. </li><li> Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse, and respiration rate. </li><li> Apprehensive expectation: <annotation cui="C0003469">Anxiety</annotation>, worry, fear, rumination, and anticipation of misfortune to self or others. </li><li> Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling on edge, irritability, impatience. </li></ol> The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild <annotation cui="C0086132">depressive symptoms</annotation> are common in <annotation cui="C0270549">GAD</annotation>. <br> <br> The effectiveness of buspirone in long term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for <annotation cui="C0270549">GAD</annotation>. However, in a study of long term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient. <br> <br> |0053914d-6a91-405c-879d-96015aed4ad7;0568f0c0-2f05-374d-11bf-c74796629535;0eefdd8d-7745-47ae-a204-f35687f3db11;123ce8fe-2eb7-4bd0-8e9b-d468135c4497;19a92a99-f73a-42f5-b048-28ba0b4df9e6;1bbebece-7102-4a4e-8efd-69a8e333d084;239dcefe-45a9-48f5-a6f1-1ac6546e0da2;2acc7da1-d5b8-4404-a3c6-d51ed82cc4fd;337ba17d-bfc5-40d8-9c57-978fe38d842f;4b044819-2959-4914-b564-d944201246fd;556e1e60-a6f3-4244-8ea8-881846ba7a9b;67f176cd-cddf-4c04-970f-ba5e7e00f787;6fac36b4-b223-479e-913f-f8c9cdb9e119;72bff09c-826e-4394-a7e7-41d56ce9605b;7c9eafb9-9ce1-4b28-900c-8fcb4b23424e;7e79a157-c89d-4215-af29-5ff4d823cb47;8351a3c5-e06e-4d27-a504-f36e0b22d41f;8ed30856-84d2-dd2b-04d4-b101f6030bc0;91bb5fc9-5121-43c2-b2af-149240d4189a;a3fe0ccd-565f-4d0a-a7ba-2fad7a819358;aca8b358-d172-43d6-95bb-8064b8ed680c;ae450460-d5e2-4bc9-8a22-eee0018b3c69;b150e196-4af1-4f56-abce-0324d322c082;b3240f73-c506-4591-a441-3bfab2fb1281;b534c251-f15c-4831-96b8-d496fd916c23;b971e151-4a68-4c01-8f9b-8c56f6bad18a;bbf2015c-0093-4e53-b25e-33f5d2987a7a;c78cf4ff-51b2-851e-89cc-98ea543e3865;e57280e0-8ab1-49a6-852c-bc45596028fa;f35ec9aa-2be6-40c9-9112-b9e3b80f8fa8;
10467|8c126bb8-732a-4949-8754-2f50b5543638| Duraclon is indicated in combination with opiates for the treatment of <annotation cui="C0278140">severe pain</annotation> in <annotation cui="C0006826">cancer</annotation> patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with <annotation cui="C0027796">neuropathic pain</annotation> than somatic or visceral pain (see <b> Clinical Trials </b> ). <br> <br> The safety of this drug product has only been established in a highly selected group of <annotation cui="C0006826">cancer</annotation> patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see <b> WARNINGS </b> ). <br> <br> |2a5b46ec-4c16-48a5-9e58-8d28a3f21274;34a3d45b-0300-4a93-ba4c-ec3cef584023;6e562c90-2e37-47ac-9c3f-12460f96dc33;8c126bb8-732a-4949-8754-2f50b5543638;bd44ea11-0650-4f9e-8663-b9be5f7bcd8d;c60f781a-ad68-419a-8f87-137664f2bb43;f6798f73-b5a6-434b-a627-aa102b123dd5;
10533|d1013494-bf62-4e68-9f0c-e6571137f20f| <b> Predialysis Patients </b> <br> <br> Rocaltrol is indicated in the management of <annotation cui="C0020503">secondary hyperparathyroidism</annotation> and resultant <annotation cui="C0005944">metabolic bone disease</annotation> in patients with moderate to severe <annotation cui="C0022661">chronic renal failure</annotation> (Ccr 15 to 55 mL min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of 100 pg mL is strongly suggestive of <annotation cui="C0020503">secondary hyperparathyroidism</annotation>. <br> <br> <b> Dialysis Patients </b> <br> <br> Rocaltrol is indicated in the management of <annotation cui="C0020598">hypocalcemia</annotation> and the resultant <annotation cui="C0005944">metabolic bone disease</annotation> in patients undergoing chronic renal dialysis. In these patients, Rocaltrol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of <annotation cui="C0029405">osteitis fibrosa cystica</annotation> and defective mineralization. <br> <br> <b> <annotation cui="C0020626">Hypoparathyroidism</annotation> Patients </b> <br> <br> Rocaltrol is also indicated in the management of <annotation cui="C0020598">hypocalcemia</annotation> and its clinical manifestations in patients with postsurgical <annotation cui="C0020626">Hypoparathyroidism</annotation>, <annotation cui="C0342342">idiopathic hypoparathyroidism</annotation>, and <annotation cui="C0033806">pseudohypoparathyroidism</annotation>. <br> <br> |3289b482-8733-484d-b1db-d7f4cdcd1ac2;517f23e8-4ad5-46e7-8dc4-473d5dcb09c8;66a69351-5b09-4368-a9fa-acf81b5ad882;84262b69-df29-41d0-9e97-6e1188096aeb;DC293A1C-995D-40FA-AC99-68DF12EB6D9E;ae2d0165-1b19-4406-9f28-f4b1579c3dbf;cdcaffc6-e14e-4607-b77b-fc78a8382f60;d1013494-bf62-4e68-9f0c-e6571137f20f;d3d69786-ac48-4a71-bbd8-83172e86d577;e26e13c4-7e45-4e66-8c0d-7fc68e24cdd5;
10545|96b0cdfb-4893-459a-b787-a788f5e8ed0c| LYRICA is indicated for <br> <br> <div> Management of <annotation cui="C0027796">neuropathic pain</annotation> associated with <annotation cui="C0740447">diabetic peripheral neuropathy</annotation> </div> <div> Management of <annotation cui="C0032768">postherpetic neuralgia</annotation> </div> <div> Adjunctive therapy for adult patients with <annotation cui="C0751495">partial onset seizures</annotation> </div> <div> Management of <annotation cui="C0016053">fibromyalgia</annotation> </div> |0c5d6728-be43-4e1b-9f14-a7ce920e12a3;23c1160f-be23-4afe-8427-34fd651a62fa;3e1fb774-7460-44d2-bf96-a17c59999676;3f09e0ac-80dc-271b-1700-a8d499535a10;423acd42-650c-43fa-98f1-7d0fccceff6b;60185c88-ecfd-46f9-adb9-b97c6b00a553;617f7fbb-4211-43c0-831b-9179aee68a9b;663a5fbb-e8cd-4092-afc7-63d9e3f85f76;66be8d30-b813-423f-a89b-6945aaf9f796;67ddab5a-5443-4ce3-89ac-bf54b795c5a8;6a72c1ac-0b15-4933-b1d5-18d2fb064765;6f51d7bf-aba2-4f10-911a-3cbc4d501a00;749cb705-4e45-4305-87e6-51934acdfa13;850a0897-a8c5-4aff-b6db-0ac2cbbab701;8953e4d7-699b-4f4a-921c-1ff7c85e71a9;8fb45a78-b2d8-45dd-b844-0de21d1fdde9;96b0cdfb-4893-459a-b787-a788f5e8ed0c;a262d7c6-2aa9-433c-b801-d8b2dcd68a0f;aac6c6a4-17a3-4643-bc89-db7259aca03a;c1a37bf6-6b1c-41be-9396-c7284a49a624;c1ca3940-3135-4c55-9abf-b185a59cc7b0;d4660235-ecaf-450a-8ac6-f3bd8ebf226d;df07288d-2604-49c6-a6d2-4a18083f2cfd;f5d5af18-c21c-4152-9226-a5c111c9785f;
11106|f9be442d-0782-4b93-828f-9ebbf67dbced| CLEOCIN Vaginal Cream 2%, is indicated in the treatment of <annotation cui="C0085166">bacterial vaginosis</annotation> (formerly referred to as <i> Haemophilus </i> <annotation cui="C0042267">vaginitis</annotation>, <i> <annotation cui="C0085166">Gardnerella</annotation> </i> <annotation cui="C0042267">vaginitis</annotation>, <annotation cui="C0085166">nonspecific vaginitis</annotation>, <i> Corynebacterium </i> <annotation cui="C0042267">vaginitis</annotation>, or anaerobic vaginosis). CLEOCIN Vaginal Cream 2%, can be used to treat non pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES .) <br> <br> <b> NOTE </b> For purposes of this indication, a clinical diagnosis of <annotation cui="C0085166">bacterial vaginosis</annotation> is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of <annotation cui="C0085166">bacterial vaginosis</annotation> include (a) markedly reduced or absent <i> Lactobacillus </i> morphology, (b) predominance of <i> <annotation cui="C0085166">Gardnerella</annotation> </i> morphotype, and (c) absent or few white blood cells. <br> <br> Other pathogens commonly associated with vulvovaginitis, eg, <i> Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans </i> , and <i> Herpes simplex </i> virus should be ruled out. <br> <br> |1e0abbaa-81eb-47a2-ad25-9512c4386a45;3db26227-208d-4fdd-8426-1d9be5cda9b4;706dd0b6-367c-4950-88fe-7a6c0661c2b9;997a23c8-f0d7-49d5-af33-e11f2ddab3c7;b52bdaf7-3b54-4165-9ab0-9dfa08170e47;d952e542-d040-42ec-b40e-198195bfe8d0;dfa15be0-7f3b-4cc5-90b4-9471851af410;f9be442d-0782-4b93-828f-9ebbf67dbced;
12395|a1567da9-af74-4afd-9ac5-8b53ec5d7cbf| Indication <br> <br> VECTICAL Ointment is indicated for the topical treatment of mild to moderate <annotation cui="C0406317">plaque psoriasis</annotation> in adults 18 years and older. <br> <br> Limitations of Use <br> <br> VECTICAL Ointment should not be applied to the eyes, lips, or facial skin. <br> <br> |7fa4ab07-3d8e-4300-91f3-b1e17cba8691;a1567da9-af74-4afd-9ac5-8b53ec5d7cbf;
12599|80393410-dd51-4cac-b27c-50ece00cca37| Bethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) <annotation cui="C0080274">urinary retention</annotation> and for <annotation cui="C0005697">neurogenic atony of the urinary bladder</annotation> with retention. <br> <br> |138ed3d0-57db-4df1-8124-06033ecc76f0;5513ddc8-90c8-4548-8188-5a807465cdc4;6a0a2d15-e67c-41d9-85fd-bafe9b3fb7e2;770ccafd-2b4f-46e1-807c-55f9925657e9;80393410-dd51-4cac-b27c-50ece00cca37;80ee6156-18b8-45aa-9402-b40647173da8;8693204e-3bb5-4ada-93a4-eda563615db9;CB6A43E9-5663-47E1-8F77-ED4CB806436D;a5138965-a698-413c-9981-d25313caa02e;e9445fc1-8a27-4a93-8fe7-90ae5f2aaab7;
12741|24595bb3-07ea-4d5f-9bb3-2c2332a1fc62| Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. <br> <br> Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (eg, erythromycin). <br> <br> <b> Anaerobes </b> Serious <annotation cui="C0035243">respiratory tract infections</annotation> such as <annotation cui="C0014009">empyema</annotation>, anaerobic <annotation cui="C0032285">pneumonitis</annotation> and <annotation cui="C0024110">lung abscess</annotation>; serious <annotation cui="C0037278;C0149778">skin and soft tissue infections</annotation>; <annotation cui="C0036690">septicemia</annotation>; <annotation cui="C1112209">intra abdominal infections</annotation> such as <annotation cui="C0031154">peritonitis</annotation> and <annotation cui="C0243001">intra abdominal abscess</annotation> (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); <annotation cui="C0030790">infections of the female pelvis</annotation> and genital tract such as <annotation cui="C0014179">endometritis</annotation>, nongonococcal <annotation cui="C0041343">tubo ovarian abscess</annotation>, <annotation cui="C0030455">pelvic cellulitis</annotation> and postsurgical <annotation cui="C0404521">vaginal cuff infection</annotation>. <br> <br> <b> Streptococci </b> Serious <annotation cui="C0035243">respiratory tract infections</annotation>; serious <annotation cui="C0037278;C0149778">skin and soft tissue infections</annotation>. <br> <br> <b> Staphylococci </b> Serious <annotation cui="C0035243">respiratory tract infections</annotation>; serious <annotation cui="C0037278;C0149778">skin and soft tissue infections</annotation>. <br> <br> <b> Pneumococci </b> Serious <annotation cui="C0035243">respiratory tract infections</annotation>. <br> <br> Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. <br> <br> <div> In Vitro Susceptibility Testing </div> A standardized disk testing procedure Bauer AW, Kirby WMM, Sherris JC, et al Antibiotic susceptibility testing by a standardized single disc method. <i> Am J Clin Pathol </i> <b> 45 </b> 493 496, 1966. Standardized disc susceptibility test. <i> Federal Register </i> <b> 37 </b> 20527 29, 1972. is recommended for determining susceptibility of aerobic bacteria to clindamycin. A description is contained in the CLEOCIN Susceptibility Disk insert. Using this method, the laboratory can designate isolates as resistant, intermediate, or susceptible. Tube or agar dilution methods may be used for both anaerobic and aerobic bacteria. When the directions in the CLEOCIN Susceptibility Powder insert are followed, an MIC of 1.6 mcg mL may be considered susceptible; MICs of 1.6 to 4.8 mcg mL may be considered intermediate and MICs greater than 4.8 mcg mL may be considered resistant. <br> <br> CLEOCIN Susceptibility Disks 2 mcg. See package insert for use. <br> <br> CLEOCIN Susceptibility Powder 20 mg. See package insert for use. <br> <br> For anaerobic bacteria the minimal inhibitory concentration (MIC) of clindamycin can be determined by agar dilution and broth dilution (including microdilution) techniques. If MICs are not determined routinely, the disk broth method is recommended for routine use. THE KIRBY BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of Clindamycin HCl and other antibacterial drugs, Clindamycin HCl should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |24595bb3-07ea-4d5f-9bb3-2c2332a1fc62;
12975|1f56e340-dcba-4774-b9d9-8e02dd7c3f69| <div> Adults (Clarithromycin Extended Release Tablets) </div> Clarithromycin extended release tablets are indicated for the treatment of adults with mild to moderate infection caused by susceptible strains of the designated microorganisms in the conditions listed below <br> <br> <annotation cui="C0155804">Acute maxillary sinusitis</annotation> due to <i> Haemophilus influenzae </i> , <i> Moraxella catarrhalis </i> , or <i> Streptococcus pneumoniae </i> . <br> <br> Acute bacterial exacerbation of <annotation cui="C0008677">chronic bronchitis</annotation> due to <i> Haemophilus influenzae </i> , <i> Haemophilus parainfluenzae </i> , <i> Moraxella catarrhalis </i> or <i> Streptococcus pneumoniae </i> . <br> <br> <annotation cui="C0694549">Community Acquired Pneumonia</annotation> due to <i> Haemophilus influenzae </i> , <i> Moraxella catarrhalis </i> , <i> Streptococcus pneumoniae </i> , <i> Chlamydia pneumoniae </i> (TWAR) or <i> Mycoplasma pneumoniae </i> . <br> <br> <b> THE EFFICACY AND SAFETY OF CLARITHROMYCIN EXTENDED RELEASE TABLETS IN TREATING OTHER INFECTIONS FOR WHICH OTHER FORMULATIONS OF CLARITHROMYCIN ARE APPROVED HAVE NOT BEEN ESTABLISHED. </b> <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of clarithromycin and other antibacterial drugs, clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |1f56e340-dcba-4774-b9d9-8e02dd7c3f69;790d3557-0b33-4b92-974a-14dc3e95d62b;a58fc044-95b2-4443-93b0-2ca7a6f6c159;d9db2fd3-a668-4d37-9082-18f6ceb8c3cb;f21494ed-c5e8-4ddf-b140-ecd68c5c312b;
13128|6b2cc55a-250e-4316-9225-3bb93b90025e| NEXICLON XR is indicated in the treatment of <annotation cui="C0020538">hypertension</annotation>. NEXICLON XR may be employed alone or concomitantly with other antihypertensive agents. <br> <br> |6b2cc55a-250e-4316-9225-3bb93b90025e;9fbc1f6d-37cc-437e-9d1a-c2fa5785b39a;
13143|406151ad-6c0a-4d66-86fc-e076df9671a3| Calcitriol Injection is indicated in the management of <annotation cui="C0020598">hypocalcemia</annotation> in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in <annotation cui="C0035086">renal osteodystrophy</annotation>. <br> <br> |045f46c7-c637-443b-8427-c461b3d7ca55;406151ad-6c0a-4d66-86fc-e076df9671a3;459595e0-3bb1-426e-bebb-19146262c375;4d6046c2-4a28-47b1-9bb4-51fadeded2d2;63d26a82-4b79-44ce-52a4-395e4368acd4;add1e536-b6ed-4ba1-abd6-084b6845e3a4;
13804|b0d460ed-73d0-44e6-9ba3-b2f5345df08e| <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: <br> <br> UPPER RESPIRATORY TRACT <b> <br> <br> <annotation cui="C0031350">Pharyngitis</annotation> <annotation cui="C0040425">tonsillitis</annotation> </b> caused by <i> Streptococcus pyogenes </i> . <br> <br> NOTE: The usual drug of choice in the treatment and prevention of <annotation cui="C0038395">streptococcal infections</annotation>, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of <i> Streptococcus pyogenes </i> from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. <b> <br> <br> <annotation cui="C0029882">Otitis Media</annotation> </b> caused by <i> Streptococcus pneumoniae </i> , <i> Haemophilus influenzae </i> (including  lactamase producing strains), and <i> Moraxella (Branhamella) catarrhalis </i> (including  lactamase producing strains). (See <b> CLINICAL STUDIES </b> .) <br> <br> NOTE: In the treatment of <annotation cui="C0029882">Otitis Media</annotation> due to  lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific  lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing  lactamase inhibitors. <br> <br> <b> <annotation cui="C0149512">Acute Sinusitis</annotation> </b> caused by <i> Streptococcus pneumoniae </i> , <i> Haemophilus influenzae </i> (including  lactamase producing strains), and <i> Moraxella (Branhamella) catarrhalis </i> (including  lactamase producing strains). <br> <br> LOWER RESPIRATORY TRACT <b> <br> <br> <annotation cui="C0442886">Secondary Bacterial Infection</annotation> of <annotation cui="C0149514">Acute Bronchitis</annotation> and Acute Bacterial Exacerbation of <annotation cui="C0008677">Chronic Bronchitis</annotation> </b> caused by <i> Streptococcus pneumoniae </i> , <i> Haemophilus influenzae </i> (including  lactamase producing strains), and <i> Moraxella (Branhamella) catarrhalis </i> (including  lactamase producing strains). <br> <br> SKIN AND SKIN STRUCTURE <br> <b> <br> Uncomplicated <annotation cui="C0037278">Skin and Skin Structure Infections</annotation> </b> caused by <i> Staphylococcus aureus </i> (including penicillinase producing strains) and <i> Streptococcus pyogenes </i> . Abscesses usually require surgical drainage. |0613b659-2b72-451d-b4a5-30a442364dff;0f96e4fe-8daf-492b-8fd8-90ff25243077;14527f4a-ce99-449d-a5a5-9edd7fb28dee;17a1975e-ce3b-4057-ae5b-8d191319caa7;3391de8b-7bc9-4624-a5c4-836135b39d99;3ec55c0a-1456-412e-972f-352b3135c8f2;6737ed97-9559-44c7-889b-6bc0e20eb36b;6da33de9-7100-419f-a19f-565701b445ad;75d57e35-ffeb-4d88-8dba-5458e284fd82;92da8862-a021-45e3-acdd-6cf6e0c8dc94;97675251-70b8-43bc-93ea-f9ef6bb8cb68;a547cc0a-6af0-49c7-a5ea-c41684cc36ae;b0d460ed-73d0-44e6-9ba3-b2f5345df08e;b9111a81-07c4-4458-b994-a4ad504986d8;c6b4fe73-ce77-4adf-b787-2bdb2dd74f84;c6d3c1ff-d873-4903-befa-c0ba47034c6e;d5574dfc-203f-4540-bce2-c5f83aefc6bd;
14259|4074b555-7635-41a9-809d-fae3b3610059| Anafranil is indicated for the treatment of obsessions and compulsions in patients with <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> (<annotation cui="C0028768">OCD</annotation>). The obsessions or compulsions must cause marked distress, be time consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM III R (circa 1989) diagnosis of <annotation cui="C0028768">OCD</annotation>. <br> <br> Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. <br> <br> The effectiveness of Anafranil for the treatment of <annotation cui="C0028768">OCD</annotation> was demonstrated in multicenter, placebo controlled, parallel group studies, including two 10 week studies in adults and one 8 week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate to severe <annotation cui="C0028768">OCD</annotation> (DSM III), with mean baseline ratings on the Yale Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH OC). Patients taking CMI experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. CMI treated patients experienced a 3.5 unit decrement on the NIMH OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg day for most adults and 3 mg kg day (up to 200 mg) for all children and adolescents. <br> <br> The effectiveness of Anafranil for long term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo controlled trials. The physician who elects to use Anafranil for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient ( <i> see </i> <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> |057dded1-9441-40bf-97e6-1049e5c8b8ac;32f05aed-18b6-4269-b10c-5d10f5bf7ca2;33c772f8-08f0-4f99-8fbd-4de48ad82d89;3823106e-6be3-4154-a607-caa3a69dc75c;3c67bab7-783a-4943-944e-938395b1c3cb;4074b555-7635-41a9-809d-fae3b3610059;4c32971e-feb3-4388-9cd6-d1f99f258b0d;5af7ec26-5666-41a9-a0a9-1c3b09f6638e;75347df1-105c-45a2-9c4d-36f3340feac6;7ffd89f1-43ae-4092-8575-d404311da716;db752dbd-be41-4cdd-8a13-ed1ff9ef7461;
1432|1f35ed70-4947-4d4d-b4c8-71ce520fc445| <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> <br> <br> <br> <br> <b> NOTE CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIO EQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM PER MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). </b> <br> <br> <br> <br> <br> <br> <b> Cefuroxime Axetil Tablets </b> <br> <br> Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below <br> <br> <br> <br> <br> <br> <b> 1. </b> <br> <br> <b> <annotation cui="C0031350">Pharyngitis</annotation> <annotation cui="C0040425">Tonsillitis</annotation> </b> <br> <br> caused by <br> <br> <i> Streptococcus pyogenes. </i> <br> <br> <br> <br> <br> <br> <b> NOTE </b> <br> <br> The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin resistant strains of <br> <br> <i> Streptococcus pyogenes. </i> <br> <br> <br> <br> <br> <br> <b> 2. </b> <br> <br> <b> <annotation cui="C0271429">Acute Bacterial Otitis Media</annotation> </b> <br> <br> caused by <br> <br> <i> Streptococcus pneumoniae </i> <br> <br> , <br> <br> <i> Haemophilus influenzae </i> <br> <br> (including beta lactamase producing strains), <br> <br> <i> Moraxella catarrhalis </i> <br> <br> (including beta lactamase producing strains), or <br> <br> <i> Streptococcus pyogenes. </i> <br> <br> <br> <br> <br> <br> <b> 3. </b> <br> <br> <b> <annotation cui="C0155804">Acute Bacterial Maxillary Sinusitis</annotation> </b> <br> <br> caused by <br> <br> <i> Streptococcus pneumoniae </i> <br> <br> or <br> <br> <i> Haemophilus influenzae </i> <br> <br> (non beta lactamase producing strains only). (See <br> <br> <b> CLINICAL STUDIES </b> <br> <br> section.) <br> <br> <br> <br> <br> <br> <b> NOTE </b> <br> <br> In view of the insufficient numbers of isolates of beta lactamase producing strains of <br> <br> <i> Haemophilus influenzae </i> <br> <br> and <br> <br> <i> Moraxella catarrhalis </i> <br> <br> that were obtained from clinical trials with cefuroxime axetil tablets for patients with <annotation cui="C0155804">acute bacterial Maxillary Sinusitis</annotation>, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta lactamase producing <br> <br> <i> Haemophilus influenzae </i> <br> <br> or <br> <br> <i> Moraxella catarrhalis </i> <br> <br> . <br> <br> <br> <br> <br> <br> <b> 4. </b> <br> <br> <b> Acute Bacterial Exacerbations of <annotation cui="C0008677">Chronic Bronchitis</annotation> and <annotation cui="C0442886">Secondary Bacterial Infections</annotation> of <annotation cui="C0149514">Acute Bronchitis</annotation> </b> <br> <br> caused by <br> <br> <i> Streptococcus pneumoniae </i> <br> <br> , <br> <br> <i> Haemophilus influenzae </i> <br> <br> (beta lactamase negative strains), or <br> <br> <i> Haemophilus parainfluenzae </i> <br> <br> (beta lactamase negative strains). (See <br> <br> <b> DOSAGE AND ADMINISTRATION </b> <br> <br> section and <br> <br> <b> CLINICAL STUDIES </b> <br> <br> section.) <br> <br> <br> <br> <br> <br> <b> 5. </b> <br> <br> <b> Uncomplicated <annotation cui="C0037278">Skin and Skin Structure Infections</annotation> </b> <br> <br> caused by <br> <br> <i> Staphylococcus aureus </i> <br> <br> (including beta lactamase producing strains) or <br> <br> <i> Streptococcus pyogenes. </i> <br> <br> <br> <br> <br> <br> <b> 6. </b> <br> <br> <b> Uncomplicated <annotation cui="C0042029">Urinary Tract Infections</annotation> </b> <br> <br> caused by <br> <br> <i> Escherichia coli </i> <br> <br> or <br> <br> <i> Klebsiella pneumoniae </i> <br> <br> . <br> <br> <br> <br> <br> <br> <b> 7. </b> <br> <br> <b> Uncomplicated <annotation cui="C0018081">Gonorrhea</annotation>, </b> <br> <br> urethral and endocervical, caused by penicillinase producing and non penicillinase producing strains of <br> <br> <i> Neisseria gonorrhoeae </i> <br> <br> and uncomplicated <annotation cui="C0018081">Gonorrhea</annotation>, rectal, in females, caused by non penicillinase producing strains of <br> <br> <i> Neisseria gonorrhoeae </i> <br> <br> . <br> <br> <br> <br> <br> <br> <b> Early <annotation cui="C0024198">Lyme Disease</annotation> (<annotation cui="C0017677">erythema migrans</annotation>) </b> <br> <br> caused by <br> <br> <i> Borrelia burgdorferi. </i> <br> <br> |07170ee3-1a24-424f-a2a2-00bc92e98f85;0a145288-733a-4966-b7ae-dc96eb103d8c;16a686e6-63f4-478f-a673-02dde9474eda;1c747919-7968-40aa-80b2-e2f7d499a801;1f35ed70-4947-4d4d-b4c8-71ce520fc445;1fd2babd-4737-45ad-9464-a7479a3816d9;2f439b86-59d6-4350-aeb4-c904b3781db4;3bbb25db-ec98-4469-6e9c-8685ab20b0cc;42105671-ad7c-462c-b42f-1cdad94753d2;56ecdeb7-89ba-420f-bbaf-65e4dab305d3;5b6288fa-49da-4f44-b779-86e8404921db;61d3f51b-a8ed-4be5-849c-4bf653538d3e;65daa2aa-cc4a-4eba-b7dc-7a151806865a;68e22782-f3a6-4e2c-8612-3f1608547919;703cc338-c0b6-4a02-b8db-c27aeff181df;708b7a4d-ba1f-47b5-be4d-a01c2a7017ff;7e7517b6-8f9f-4600-881a-9ed8bc1f454a;8cc2bf2e-d51f-4abd-bc08-660c5e5f00de;8da31eca-51cf-4a01-9159-740f772b0f15;98ea197c-b3ff-47bc-8d0f-fce91b539959;9D7666AB-D48A-4507-A120-D7E1229543FD;9ccf0781-4fb3-496e-bd58-54381ea33510;a1c53a0c-78b0-4c6e-b2bc-0ee90cbe9e73;a7b50175-e978-4edd-9d61-593df4806657;ae5682dc-61f0-48ff-9d0d-7ce1aa1c39de;cc834761-8700-4970-ba49-b8ddecb51a1b;ee8787d8-3b83-4a8c-9447-09571aa40964;f4797359-d4a0-4967-86d3-d348518b3fe4;f799137f-9676-42d4-9130-a9685cc9302c;
14464|df3c1900-a076-4a3a-a2a8-5939d818451f| UROXATRAL is indicated for the treatment of signs and symptoms of <annotation cui="C0005001">benign prostatic hyperplasia</annotation>. <br> <br> <div> Important Limitations of Use </div> UROXATRAL is not indicated for the treatment of hypertension. <br> <br> UROXATRAL is not indicated for use in the pediatric population. <br> <br> |df3c1900-a076-4a3a-a2a8-5939d818451f;
14670|813507ec-1fc1-420f-ac5c-5c794b1059cd| <div> Monotherapy </div> AVODART (dutasteride) Soft Gelatin Capsules are indicated for the treatment of symptomatic <annotation cui="C0005001">benign prostatic hyperplasia</annotation> (<annotation cui="C0005001">BPH</annotation>) in men with an enlarged prostate to <br> <br> <ol><li> improve symptoms, </li><li> reduce the risk of <annotation cui="C0341742">acute urinary retention</annotation> (<annotation cui="C0341742">AUR</annotation>), and </li><li> reduce the risk of the need for <annotation cui="C0005001">BPH</annotation> related surgery. </li></ol> <div> Combination With Alpha Adrenergic Antagonist </div> AVODART in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic <annotation cui="C0005001">BPH</annotation> in men with an enlarged prostate. <br> <br> <div> Limitations of Use </div> AVODART is not approved for the prevention of prostate cancer. <br> <br> |647540fc-bef5-4aa3-be4c-6b30655f366c;813507ec-1fc1-420f-ac5c-5c794b1059cd;dc330e70-a1d3-400b-3aaf-46067e3fd090;ebda6db1-f6ea-4962-a99d-85ad5c96a5aa;
14938|c43da258-73bb-4ca5-bfe8-1c8a0500f91d| <div> <b> Treatment </b> <b>  Resistant <annotation cui="C0036341">Schizophrenia</annotation> </b> </div> CLOZARIL (clozapine) is indicated for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatment for <annotation cui="C0036341">Schizophrenia</annotation>. Because of the significant risk of agranulocytosis and seizure associated with its use, CLOZARIL should be used only in patients who have failed to respond adequately to treatment with appropriate courses of standard drug treatments for <annotation cui="C0036341">Schizophrenia</annotation>, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. (See WARNINGS.) <br> <br> The effectiveness of CLOZARIL in a treatment resistant schizophrenic population was demonstrated in a 6 week study comparing CLOZARIL and chlorpromazine. Patients meeting DSM III criteria for <annotation cui="C0036341">Schizophrenia</annotation> and having a mean BPRS total score of 61 were demonstrated to be treatment resistant by history and by open, prospective treatment with haloperidol before entering into the double blind phase of the study. The superiority of CLOZARIL to chlorpromazine was documented in statistical analyses employing both categorical and continuous measures of treatment effect. <br> <br> Because of the significant risk of agranulocytosis and seizure, events which both present a continuing risk over time, the extended treatment of patients failing to show an acceptable level of clinical response should ordinarily be avoided. In addition, the need for continuing treatment in patients exhibiting beneficial clinical responses should be periodically reevaluated. <br> <br> <b> Reduction in the Risk of Recurrent Suicidal Behavior in <annotation cui="C0036341">Schizophrenia</annotation> or <annotation cui="C0036337">Schizoaffective Disorders</annotation> </b> <br> <br> CLOZARIL is indicated for reducing the risk of recurrent suicidal behavior in patients with <annotation cui="C0036341">Schizophrenia</annotation> or <annotation cui="C0036337">schizoaffective disorder</annotation> who are judged to be at chronic risk for reexperiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that puts him herself at risk for death. <br> <br> The effectiveness of CLOZARIL in reducing the risk of recurrent suicidal behavior was demonstrated over a 2 year treatment period in the InterSePT Trial (see Clinical Trial Data under CLINICAL PHARMACOLOGY). Therefore, CLOZARIL treatment to reduce the risk of suicidal behavior should be continued for at least 2 years (see DOSAGE AND ADMINISTRATION). <br> <br> The prescriber should be aware that a majority of patients in both treatment groups in InterSePT received other treatments as well to reduce suicide risk, such as antidepressants and other medications, hospitalization, and or psychotherapy. The contributions of these additional measures are unknown. <br> <br> |53bdb79c-c4cf-4818-b1f0-225e67a14536;5f0c6f5f-b906-4c8f-8580-3939a476a1c1;77660c47-a2ad-4f1d-80d6-bdc315f04cbf;8672ee49-ee2e-4239-98ce-7e23e1ab7b10;883b5d43-0339-7dc1-f775-93791fb9b978;b7b7541a-1fe4-4b11-b6b7-68fb5510faa4;c43da258-73bb-4ca5-bfe8-1c8a0500f91d;d5c8a456-6f3c-4963-b321-4ed746f690e4;
15144|f317cd06-2851-4a52-86d3-6efde3a4c243| Codeine sulfate is an opioid analgesic indicated for the relief of <annotation cui="C0278138;C0278140">mild to moderately severe pain</annotation> where the use of an opioid analgesic is appropriate. <br> <br> |5819bdf7-300e-45b8-8f3a-447b53656293;82ce83dd-6b7c-4efa-9ad4-d31ddc1b4517;f317cd06-2851-4a52-86d3-6efde3a4c243;fa3ed180-298a-4f9d-9d05-15182d7218bf;
15626|d08d5bb4-3039-405c-843e-63a41a14a324| Clonidine Transdermal System is indicated in the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be employed alone or concomitantly with other antihypertensive agents. <br> <br> |045ce36b-b8fc-4875-b2b8-9be9d5493bba;08c223a7-248a-444f-87ba-0844045e2b17;091a191f-4380-4960-834c-0618da738403;0b11db18-80e7-4af9-9ec8-bcaf904ddd5f;0bde4636-7f34-467e-b9b9-8d281145177d;0ff45a92-c92f-4867-8d1a-c37c7aad9b48;189a4d3e-45dc-4ac3-b4b7-34348531c459;1e22a445-fde5-40f8-846c-f20c77980a57;1e5dd189-21a4-40ac-a8f9-10b758dcfc8c;21bfa28f-20df-43fd-bb80-b720d3b40696;23f20b4e-e90a-4634-ab69-168151b4e90b;29283327-3a8a-486d-a9fc-ba5cdc91a09b;2b12df1f-5915-4431-a70b-bc440cf11aa4;2c04fc9b-5f83-4a3a-87e3-2b07affd0ad0;2e54ffb4-9549-499a-8522-b046c1f7ddd1;3b373f21-1fdb-4701-9193-1120337f3f98;4d2d4378-b729-4aa6-8dcd-c8019f289652;535e0576-81f2-e608-7b41-286536c83072;55467afd-098e-4a9a-af02-add3f0a9af19;5f63b704-d515-408c-b8f4-fd35cb97ab9e;625852df-7b39-45c8-ba0a-cbcac798aa47;6d63d646-63a0-4a35-aced-ea06bd10c410;7adfc439-e6d0-4593-87dd-0eef36d33c6d;7ba2fc36-7ee1-46f9-bcfb-fb76a6addbe5;809d8d33-9459-4e74-8cd2-5f5a9670cb95;81dd2c3f-724d-44c3-ab0e-f0e111958741;82c7da04-771f-4a9d-b8c9-159307a83328;835bb6d3-6437-499d-85e5-e012f17d356c;841e761e-5238-4f29-a533-e82d1637201b;854c5011-1abf-4ce8-bc8f-65cd02483c72;95f2ca27-e70e-4055-a293-4fd190f59051;996d9246-e5d2-48a2-be8d-9ef5c8f64b1c;9a467091-c5e8-4375-b9ec-72183477daa5;a756191e-085a-4a1a-bb88-b7c174cdcefd;a842ab83-3531-44dd-a8a8-64dd89e87026;afbc8ef1-ebf2-47fb-84dd-5d2c4dd1cfbf;b307387e-dfc9-48a7-bda3-dd1a67ed30a6;b470a149-d9eb-4e92-9be0-78da3660d6ea;bcc6273b-3091-4420-8f2f-667fd5fcfb33;bceab3bd-04d4-46b1-8ded-0e79b0a30740;bdeec94c-ebe4-44ce-8cf8-3333438a0504;c1143cd8-4325-4dcf-a12f-8badfdba682f;c8cc9a81-b2e2-4872-a6fc-6f2ea8fe5748;cf3a4559-30f0-4b2f-8db8-08d3660ee02c;d08d5bb4-3039-405c-843e-63a41a14a324;d1e9d3b4-5912-4956-831f-b5d0d5426b5a;d7f569dc-6bed-42dc-9bec-940a9e6b090d;d8474008-b1e2-550c-0aa7-600512c240ac;d89ab416-2b0e-4cb0-a869-04e0a5f6ba0a;dc980bd7-3d02-4a02-8a48-f62a92da45fe;defc0e8b-6ffd-43f9-a88d-5c4afb2b8060;e11ee6d5-95c5-46c4-bed1-1d17ba6e4e9a;f4ac82b0-d0fb-4720-a277-5b2b8013cb3f;f83b414f-1127-4c9c-9233-505dddbbf99c;fe0f5dcb-65dd-4d31-80d6-8b97eb040063;
15635|d2b23109-e033-4535-912e-92d07f498edc| TRANXENE is indicated for the management of <annotation cui="C0003469">anxiety disorders</annotation> or for the short term relief of the symptoms of <annotation cui="C0003469">Anxiety</annotation>. <annotation cui="C0003469">Anxiety</annotation> or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <br> TRANXENE tablets are indicated as adjunctive therapy in the management of <annotation cui="C0751495">partial seizures</annotation>. <br> <br> The effectiveness of TRANXENE tablets in long term management of <annotation cui="C0003469">Anxiety</annotation>, that is, more than 4 months, has not been assessed by systematic clinical studies. Long term studies in <annotation cui="C0014544">epileptic</annotation> patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient. <br> <br> TRANXENE tablets are indicated for the symptomatic relief of acute <annotation cui="C0236663">alcohol withdrawal</annotation>. <br> <br> |499a6989-8912-44b7-b1eb-ee8f85ae378f;54722d55-d620-488f-87eb-e1e3b129c2f9;6d686bb2-3901-4f78-aac7-bf2b83824765;6e9edbfc-1950-4893-9d38-e82b119ddb9a;7abac94c-ba0e-415b-9196-72caf153cc7c;92a354fb-efb3-4ebf-acfa-1c258d8664a6;a6cc08b8-146e-430f-af39-8b866698b997;d2b23109-e033-4535-912e-92d07f498edc;d57138fd-067d-43f8-80d5-9190cf90ef3d;f22310ac-5481-4270-ab46-88ad4f654b45;
16477|a11548a0-9c0f-4729-907c-75d8f99a6c85| ZEBETA is indicated in the management of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with other antihypertensive agents. <br> <br> |2564646d-183c-4759-8726-155a4c22aa2b;4f20df45-3f9c-4a91-b394-e93a08111ec3;621d9058-804a-4f46-a047-ea6e432eee49;70f7b118-8a74-40d9-8a7c-c39744a6ebd7;7f888a0c-189e-4c76-86d8-7bc6f21e3b16;a11548a0-9c0f-4729-907c-75d8f99a6c85;a1dc3675-ca21-4fdc-bc4d-e82381e31851;b9bbf9ed-4781-42a9-bc3e-deda9f05e810;d82243b9-3e56-4a2b-8750-cb95ec106885;dba0b86a-5581-45a8-a956-716c2a718eb0;
16611|a0a046c1-056d-45a9-bfd9-13b47c24f257| <div> <annotation cui="C0010346">Crohn's Disease</annotation> </div> REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active <annotation cui="C0010346">Crohn's Disease</annotation> who have had an inadequate response to conventional therapy. <br> <br> REMICADE is indicated for reducing the number of draining <annotation cui="C0341318;C0034895">enterocutaneous and rectovaginal fistulas</annotation> and maintaining fistula closure in adult patients with fistulizing <annotation cui="C0010346">Crohn's Disease</annotation>. <br> <br> <div> Pediatric <annotation cui="C0010346">Crohn's Disease</annotation> </div> REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active <annotation cui="C0010346">Crohn's Disease</annotation> who have had an inadequate response to conventional therapy. <br> <br> <div> <annotation cui="C0009324">Ulcerative Colitis</annotation> </div> REMICADE is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active <annotation cui="C0009324">Ulcerative Colitis</annotation> who have had an inadequate response to conventional therapy. <br> <br> <div> Pediatric <annotation cui="C0009324">Ulcerative Colitis</annotation> </div> REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active <annotation cui="C0009324">Ulcerative Colitis</annotation> who have had an inadequate response to conventional therapy. <br> <br> <div> <annotation cui="C0003873">Rheumatoid Arthritis</annotation> </div> REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active <annotation cui="C0003873">Rheumatoid Arthritis</annotation>. <br> <br> <div> <annotation cui="C0038013">Ankylosing Spondylitis</annotation> </div> REMICADE is indicated for reducing signs and symptoms in patients with active <annotation cui="C0038013">Ankylosing Spondylitis</annotation>. <br> <br> <div> <annotation cui="C0003872">Psoriatic Arthritis</annotation> </div> REMICADE is indicated for reducing signs and symptoms of active <annotation cui="C0003864">arthritis</annotation>, inhibiting the progression of structural damage, and improving physical function in patients with <annotation cui="C0003872">Psoriatic Arthritis</annotation>. <br> <br> <div> <annotation cui="C0406317">Plaque Psoriasis</annotation> </div> REMICADE is indicated for the treatment of adult patients with chronic severe (i.e., extensive and or disabling) <annotation cui="C0406317">Plaque Psoriasis</annotation> who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. REMICADE should only be administered to patients who will be closely monitored and have regular follow up visits with a physician <i> [see </i> <i> Boxed Warnings , Warnings and Precautions (5) ] </i> . <br> <br> |a0a046c1-056d-45a9-bfd9-13b47c24f257;
16676|fcb96831-1c51-4003-adc2-3a3c34e45feb| EVOCLIN Foam is indicated for topical application in the treatment of <annotation cui="C0001144">acne vulgaris</annotation> in patients 12 years and older. <br> <br> |2e6f96d0-d928-4775-a7db-3e998fce675b;fcb96831-1c51-4003-adc2-3a3c34e45feb;
17348|e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc| Thalitone (chlorthalidone USP) is indicated in the management of <annotation cui="C0020538">hypertension</annotation> either alone or in combination with other antihypertensive drugs. <br> <br> Chlorthalidone is indicated as adjunctive therapy in <annotation cui="C0013604">Edema</annotation> associated with <annotation cui="C0018802">congestive heart failure</annotation>, <annotation cui="C0023890">hepatic cirrhosis</annotation>, and corticosteroid and estrogen therapy. <br> <br> Chlorthalidone has also been found useful in <annotation cui="C0013604">Edema</annotation> due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. <br> <br> <b> Usage in Pregnancy </b> The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. <br> <br> <annotation cui="C0013604">Edema</annotation> during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when <annotation cui="C0013604">Edema</annotation> is due to pathologic causes just as it is in the absence of pregnancy (however, see <b> WARNINGS </b> below). Dependent <annotation cui="C0013604">Edema</annotation> in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease) but that is associated with <annotation cui="C0013604">Edema</annotation>, including generalized edema, in the majority of pregnant women. If this <annotation cui="C0013604">Edema</annotation> produces discomfort, increased recumbency will often provide relief. In rare instances, this <annotation cui="C0013604">Edema</annotation> may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. <br> <br> |15dd224a-87ad-48dc-80b1-e8382a452c4c;193c85ba-43c2-4be2-82cf-7b394a83390e;527180e9-7172-4811-87bb-bb47439b5542;950bb805-3ca7-4f54-b4fb-c9e23cb33ae2;bb7112ae-3a37-4525-8c7f-c0f4100ffc0a;c10e3a16-d94f-442f-9303-4ded0adaecc1;e2eb7dad-3ea3-439c-dcbb-d1d61aa49dfc;
2074|1b86bd94-7734-4080-8fab-11d226f71a37| Lotensin is indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with thiazide diuretics. <br> <br> In using Lotensin, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that Lotensin does not have a similar risk (see WARNINGS). <br> <br> Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. <br> <br> |09e383a8-e912-4cf7-8fb3-05545af80dd0;1b86bd94-7734-4080-8fab-11d226f71a37;2c438366-8cad-7be6-1006-15d5a25c7a9b;420a70f6-7b8b-42d0-8511-5320c841ef85;56027610-8270-52f9-5e0d-782630d98e45;56ffd662-60a6-4b43-a7ea-f778714dfbbd;5b647f4a-a6fe-49db-bd8f-9ca75dce7653;60f0fb82-d870-4f07-82af-e4aeb79ed023;74898baf-c41a-4b24-9522-ece64ab7a516;756a3a26-7230-410b-bfb1-7f074688ff05;8fdc8bda-635a-401f-a9b5-8a2a514b429e;99b9019c-f650-5465-5edf-80f656d06611;9f2fce5a-fee9-4df3-8aef-b1d2cc9a14c4;a2431e04-d610-4d3f-ac93-3d96e28b984f;a852de3b-0efb-46cf-9472-2cab96f67972;cb3c47b7-4f27-40a0-ac8b-c4df0b100909;d73713c3-3c48-4cce-8437-1723ca54d077;decda177-7c1a-4d28-84fc-c6d7aa251561;f2da9586-8baa-4852-8669-80dade6363cf;f85164b6-a03e-4944-bae5-cd1389929f83;
282|7d7d44b4-d405-4c48-9e79-cc128dd7aaeb|Carisoprodol Tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with <annotation cui="C0184567">acute, painful</annotation> musculoskeletal conditions. <br> <br> |1fa79b11-6491-4543-8548-8aaa624f7ff8;7d7d44b4-d405-4c48-9e79-cc128dd7aaeb;
2969|3f6b2c5a-e581-414f-bc9e-eaf66a5685cd| Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. <br> <br> Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the <b> WARNING </b> box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). <br> <br> <b> Anaerobes </b> Serious <annotation cui="C0035243">respiratory tract infections</annotation> such as <annotation cui="C0014009">empyema</annotation>, anaerobic <annotation cui="C0032285">pneumonitis</annotation> and <annotation cui="C0024110">lung abscess</annotation>; serious <annotation cui="C0037278;C0149778">skin and soft tissue infections</annotation>; <annotation cui="C0036690">septicemia</annotation>; <annotation cui="C1112209">intra abdominal infections</annotation> such as <annotation cui="C0031154">peritonitis</annotation> and <annotation cui="C0243001">intra abdominal abscess</annotation> (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); <annotation cui="C0030790">infections of the female pelvis</annotation> and genital tract such as <annotation cui="C0014179">endometritis</annotation>, nongonococcal <annotation cui="C0041343">tubo ovarian abscess</annotation>, <annotation cui="C0030455">pelvic cellulitis</annotation> and postsurgical <annotation cui="C0404521">vaginal cuff infection</annotation>. <br> <br> <b> Streptococci </b> Serious <annotation cui="C0035243">respiratory tract infections</annotation>; serious <annotation cui="C0037278;C0149778">skin and soft tissue infections</annotation>. <br> <br> <b> Staphylococci </b> Serious <annotation cui="C0035243">respiratory tract infections</annotation>; serious <annotation cui="C0037278;C0149778">skin and soft tissue infections</annotation>. <br> <br> <b> Pneumococci </b> Serious <annotation cui="C0035243">respiratory tract infections</annotation>. <br> <br> Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. <br> <br> |00088ecd-e45d-4080-b124-e66376ad7694;05a75685-0af5-407c-ac57-e380c882b49d;14319e53-5148-4857-2093-7a83b0efc3be;166d6d61-e9ce-4c8a-91ec-72d7a9d0af8d;192643cb-325b-4951-925f-ee2bc3e21983;1dbd8448-c1e5-46df-8060-50ef82380445;1ef87b6c-9d32-44ac-8c55-8bf01424cc45;2367340c-d297-4a3f-8253-6d27a0ed39cb;300e15d2-7782-45d9-bb9d-b1acc520cc64;363d5e7d-2734-4a26-8b7c-a75a707dbaae;375c42d4-e222-45a5-a0f3-34c871abca42;3f6b2c5a-e581-414f-bc9e-eaf66a5685cd;458e043d-6584-4503-b398-2032d3cce2f1;49a643c3-14ef-4bfd-bb66-be05e1696c7e;4b33e408-01cb-4cd0-b9aa-aa5409228d91;4ced0e9d-fd23-419f-9053-3d4c0340d5dd;54e4cd15-3d98-4e04-b07c-9dcefb37578e;63a0466c-af7d-4696-a950-19b73b55a65a;73502d97-7131-4767-95fc-e5eaaa940ba7;7a6967b3-5563-4bed-9eee-d400f800e799;7d72c291-d96f-468d-b3bb-8c255c4906b1;84329aad-63fc-54b1-dc05-c08461f00221;91d2ee16-af0b-429f-b859-ed5cc95599df;9250d33e-3429-4ad5-398b-b9b7943d9ff9;9891d1bd-b662-4242-a01e-8151463bbf2d;98f47953-c344-421c-a171-3a822be34728;9ac0f81d-27f2-4db5-ad07-346f40133084;ab528098-e7c1-4f92-acb2-b664320a95a1;ab7233b1-b68e-458b-9e1d-4fc3fa15e8b6;b0442dc3-7f06-4f67-ab14-f338ae5173e7;b225ab20-bc7c-43af-ae93-0f07d5948e1c;b8133f76-8880-4b91-a451-b3f831ad6853;b91d122d-a68d-4158-8f63-68c886d05bdf;bd1c1648-4733-4233-8337-469fe11bd0cb;bd79aebb-b221-4844-8e4a-f848b7c52f16;bdb9e366-7234-422d-a3ab-0765824bb7a7;bf606d63-712e-4345-9231-ea35db44743b;c8616135-1ba4-4256-ada7-1d6ae20a4416;cd483920-c315-4397-84b8-57d393e753fd;df4d7c10-d50b-4aee-88c1-cd4e4dc890a8;df9a2a41-b132-4f43-8940-b2d773b1369a;e17229b3-7246-4886-abe6-58e39c4e47ef;e4505f39-ebb0-4a0b-b91e-17fc42466c21;eabd3c7f-028d-4299-4b9b-60c75af7ee01;f9e6ed50-ad03-4a9e-8760-8733e04a058c;fc294a54-61f1-4d3c-8b42-8376935b21f7;fc2f2fe8-040a-4280-80fa-7f47ce63bb09;
3059|8704702e-0889-4a47-9a92-588a8d72d503| <br> <br> <br> <br> <br> <br> <br> <br> Alfuzosin hydrochloride is indicated for the treatment of signs and symptoms of <annotation cui="C0005001">benign prostatic hyperplasia</annotation>. <br> <br> <div> <b> Important Limitations of Use </b> </div> Alfuzosin hydrochloride is not indicated for the treatment of hypertension. <br> <br> Alfuzosin hydrochloride is not indicated for use in the pediatric population. <br> <br> |0feb7a22-7416-4502-bf6e-6341782d11ab;23ba1d84-686f-41f6-ac83-8d839ae25350;26fcc267-c8d7-e059-1bcf-830dded43690;2d4f6e4f-e385-b872-38c6-b7d1a9e8f9b9;30f97b8e-4486-4b5f-896a-d7dfa1e2e33a;6220496a-b651-4e7b-9a41-0ea949de3df0;8704702e-0889-4a47-9a92-588a8d72d503;be485a4c-aba3-43fa-9904-403595bc3f96;d2af616e-673a-4fdd-ace8-db2d0f154604;f861c40a-504b-42c0-a17d-af35c0f187f9;
3823|4d954024-a191-46e3-ba71-2a7d5b0c65d5| Lotensin is indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with thiazide diuretics. <br> <br> |11b3ea2b-02dd-40dc-b073-f8f25bf1a2d2;4d954024-a191-46e3-ba71-2a7d5b0c65d5;a216253b-27cb-42ef-b5a8-67fb05aafb88;c51a3704-c5b3-471f-afcb-0602da0f3dce;cc51387c-c645-4d27-954e-5efba5d0db98;
3937|a1e9d249-33d1-4b14-b92e-8f4dccded1da| Levalbuterol HCl Inhalation Solution is indicated for the treatment or prevention of <annotation cui="C0006266">bronchospasm</annotation> in adults, adolescents, and children 6 years of age and older with reversible <annotation cui="C0600260">obstructive airway disease</annotation>. <br> <br> |1700a5b8-4029-424a-bfed-15f6737dd210;206bbdec-04f0-40e3-a259-32fc6bce20d8;218ab3f0-4d1e-4c33-a7e8-27807f029d83;320fea02-8aa3-44c8-b52a-a118418d1f78;35eb525b-72a5-4ef9-a36a-531e9e6b3560;4c4cf6b3-36d4-4b41-84e9-682012d7e4e2;91b2b443-bdc7-4045-bb94-906199125f49;a1e9d249-33d1-4b14-b92e-8f4dccded1da;d91161c1-cae8-4d69-a37c-fb7b64b7736a;
4270|7fa41601-7fb5-4155-8e50-2ae903f0d2d6| MULTAQ is indicated to reduce the risk of hospitalization for <annotation cui="C0004238">atrial fibrillation</annotation> in patients in sinus rhythm with a history of paroxysmal or <annotation cui="C2585653">persistent atrial fibrillation</annotation> (<annotation cui="C0004238">AF</annotation>) <i> [see Clinical Studies (14) ]. </i> <br> <br> |236d4549-f44b-4677-b857-acedd10b9920;7fa41601-7fb5-4155-8e50-2ae903f0d2d6;
6001|49ef8384-946d-43cb-b9be-f174e789d7dc| Diuretics such as chlorthalidone are indicated in the management of <annotation cui="C0020538">hypertension</annotation> either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of <annotation cui="C0020538">hypertension</annotation>. <br> <br> Chlorthalidone is indicated as adjunctive therapy in <annotation cui="C0013604">edema</annotation> associated with <annotation cui="C0018802">congestive heart failure</annotation>, <annotation cui="C0023890">hepatic cirrhosis</annotation>, and corticosteroid and estrogen therapy. <br> <br> Chlorthalidone has also been found useful in <annotation cui="C0013604">edema</annotation> due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. <br> <br> |49ef8384-946d-43cb-b9be-f174e789d7dc;
6490|bcf04f49-8d0b-4563-9d0f-93939cdf6a6c| To reduce the development of drug resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. <br> <br> Adults and Adolescents: <annotation cui="C0694549">Community Acquired Pneumonia</annotation>: Caused by <i> Haemophilus influenzae </i> (including  lactamase producing strains), <i> Haemophilus parainfluenzae </i> (including  lactamase producing strains), <i> Streptococcus pneumoniae </i> (penicillin susceptible strains only), and <i> Moraxella catarrhalis </i> (including  lactamase producing strains) (see <b> CLINICAL STUDIES ). </b> <br> <br> Acute Exacerbations of <annotation cui="C0008677">Chronic Bronchitis</annotation>: Caused by <i> Haemophilus influenzae </i> (including  lactamase producing strains), <i> Haemophilus parainfluenzae </i> (including  lactamase producing strains), <i> Streptococcus pneumoniae </i> (penicillin susceptible strains only), and <i> Moraxella catarrhalis </i> (including  lactamase producing strains). <br> <br> <annotation cui="C0155804">Acute Maxillary Sinusitis</annotation>: Caused by <i> Haemophilus influenzae </i> (including  lactamase producing strains), <i> Streptococcus pneumoniae </i> (penicillin susceptible strains only), and <i> Moraxella catarrhalis </i> (including  lactamase producing strains). <br> <br> <b> NOTE </b> For information on use in pediatric patients, see <b> Pediatric Use </b> and <b> DOSAGE AND ADMINISTRATION . </b> <br> <br> <annotation cui="C0031350">Pharyngitis</annotation>/<annotation cui="C0040425">Tonsillitis</annotation>: Caused by <i> Streptococcus pyogenes </i> (see <b> CLINICAL STUDIES ). </b> <br> <br> <b> NOTE </b> Cefdinir is effective in the eradication of <i> pyogenes </i> from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following <i> pyogenes </i> <annotation cui="C0031350">Pharyngitis</annotation> <annotation cui="C0040425">tonsillitis</annotation>. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. <br> <br> Uncomplicated <annotation cui="C0037278">Skin and Skin Structure Infections</annotation>: Caused by <i> Staphylococcus aureus </i> (including  lactamase producing strains) and <i> Streptococcus pyogenes </i> . <br> <br> |06d55c37-5b80-45b6-bfea-6b00fd960ed4;06fbdb63-d32f-4212-9962-f1de15597dda;38f6adf7-e26c-4764-8ec9-360813874dd4;5fb3c464-ab1a-4e2f-ba7a-9aa59b94ca00;7490df67-56c0-4a1c-8533-2107f3e8aea5;7cab718d-2a6f-4792-b94c-be87ebed5cf3;929126e0-302f-47a5-b1a9-3474ff9befc7;BB96F3CF-FD80-40C9-A6AA-C7464AB3226F;a1f49fe1-b511-4f6b-a912-8ae8662d95a5;a3262279-1f9e-401b-9b02-6da3ef374b46;a4587ea9-c06b-4603-beea-1ef926a4d0be;a78a68a4-5425-43c4-81cc-7733b72445b8;a84712bf-221d-4366-9cf0-b8c19428c276;a9c339ac-14a5-465e-a4fe-1d361d017ccf;bcf04f49-8d0b-4563-9d0f-93939cdf6a6c;c3ca8720-8e27-47ed-9829-a42ae9eb885d;cb7366ce-1778-451f-aba5-65cf73c9b87a;d9243be5-bd27-4f37-ba8b-9f6f55f8b3e4;de3441e3-7fd2-4d29-a8b7-0f9b66e35c9c;df26edb0-9bd6-449c-a187-0be0c9e2600c;e1aba7cf-52f5-461d-a8f5-9bb580da99d0;f910ec1a-3896-45b9-b8b2-df50a50064a1;
6875|c9bdfcda-82a0-4084-b9b2-1e367c0418d6| KAPVAY (clonidine hydrochloride) extended release is indicated for the treatment of <annotation cui="C1263846">attention deficit hyperactivity disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>) as monotherapy and as adjunctive therapy to stimulant medications. <br> <br> The efficacy of KAPVAY in the treatment of <annotation cui="C1263846">ADHD</annotation> is based on two controlled trials (one monotherapy and one adjunctive to stimulant medication) in children and adolescents ages 6 17 who met DSM IV criteria for <annotation cui="C1263846">ADHD</annotation> hyperactive or combined hyperactive inattentive subtypes [see Clinical Studies (14) ]. In the adjunctive study, KAPVAY was administered to patients who had been on a stable regimen of either methylphenidate or amphetamine (or their derivatives) and who had not achieved an optimal response. The effectiveness of KAPVAY for longer term use (more than 5 weeks) has not been systematically evaluated in controlled trials. <br> <br> A diagnosis of <annotation cui="C1263846">ADHD</annotation> implies the presence of hyperactive impulsive and or inattentive symptoms that cause impairment and were present before the age of 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months lack of attention to details careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months fidgeting squirming; leaving seat; inappropriate running climbing; difficulty with quiet activities; "on the go"; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive impulsive criteria to be met. <br> <br> <div> </div> Special Diagnostic Considerations <br> <br> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM IV characteristics. <br> <br> <div> </div> Need for Comprehensive Treatment program <br> <br> KAPVAY is indicated as an integral part of a total treatment program for <annotation cui="C1263846">ADHD</annotation> that may include other measures (psychological, educational, and social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. KAPVAY is not intended for use in patients who exhibit symptoms secondary to environmental factors and or other primary psychiatric disorders, including psychosis. Appropriate educational vocational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe KAPVAY will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms and on the level of functional impairment. <br> <br> NOTE This extended release formulation of clonidine hydrochloride is also approved for the treatment of <annotation cui="C0020538">hypertension</annotation> in adults under the trade name JENLOGA. <br> <br> |c9bdfcda-82a0-4084-b9b2-1e367c0418d6;
8673|c0f1fcfd-8863-4032-bf80-185df60a4ba0| For the treatment of <annotation cui="C0036341">schizophrenia</annotation>; to control <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation>; for relief of <annotation cui="C0085631">restlessness</annotation> and apprehension before surgery; for <annotation cui="C0162565">acute intermittent porphyria</annotation>; as an adjunct in the treatment of <annotation cui="C0039614">tetanus</annotation>; to control the manifestations of the <annotation cui="C0338831">manic</annotation> type of <annotation cui="C0005586">manic depressive illness</annotation>; for relief of intractable <annotation cui="C0019521">hiccups</annotation>; for the treatment of severe <annotation cui="C0260653">behavioral problems</annotation> in children (1 to 12 years of age) marked by combativeness and or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short term treatment of <annotation cui="C0424295">hyperactive</annotation> children who show excessive motor activity with accompanying <annotation cui="C0149654">conduct disorders</annotation> consisting of some or all of the following symptoms impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. <br> <br> |112393f8-b374-4ee0-8fcc-f229fadbe637;298de270-99a5-47cc-9116-a91fd6099385;33c01749-ef88-4e9c-8b45-0f026af1d5fd;533f3ed8-4569-48e2-95ee-efe428896b8d;8e86b2c6-b449-4abc-97fb-e78702bb1b83;9ba1cfd8-14c9-4de6-88cb-8a78a1d40a53;b028fb3d-2939-4197-b31c-ac327f9593ec;b9d57be1-17cb-42ac-8334-ef3494be7f17;c0f1fcfd-8863-4032-bf80-185df60a4ba0;c267e103-028c-4a57-9f6e-89a652599342;c63d6612-3fd2-44dd-a5c7-a093766b91f2;f15e9f35-1e3e-4217-b8e2-1d6096dbee1b;
8841|dac31f82-b35e-49b9-aff9-f0101292f1be| <div> Treatment of <annotation cui="C0085166">Bacterial Vaginosis</annotation> </div> Clindesse is indicated for the treatment of <annotation cui="C0085166">Bacterial Vaginosis</annotation> (formerly referred to as <i> Haemophilus </i> <annotation cui="C0042267">vaginitis</annotation>, <i> <annotation cui="C0085166">Gardnerella</annotation> </i> <annotation cui="C0042267">vaginitis</annotation>, <annotation cui="C0085166">nonspecific vaginitis</annotation>, <i> Corynebacterium </i> <annotation cui="C0042267">vaginitis</annotation>, or anaerobic vaginosis) in non pregnant women. <br> <br> |dac31f82-b35e-49b9-aff9-f0101292f1be;
9473|99265e39-af23-43eb-a552-305f0a218fdf| <br> <br> <br> 1 INDICATIONS AND USAGE <br> Carisoprodol Tablets are indicated for the relief of discomfort associated with <annotation cui="C0184567">acute, painful</annotation> musculoskeletal conditions in adults. <br> Carisoprodol Tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more <br> prolonged use has not been established and because <annotation cui="C0184567">acute, painful</annotation> musculoskeletal conditions are generally of short duration. [see Dosage and Administration (2)]. <br> <br> |037618dc-8aed-4a96-93a5-69971f2a3742;12ad4a89-b695-d2fa-6123-e5cbe11a7d4a;5000bfb2-d2da-45cb-acd7-86a4e8ea3b0d;6297cf20-830a-11dc-94c8-0002a5d5c51b;6543c6ba-852e-40fb-b7ec-1331b9c83656;6b9532e9-69e0-4e87-9e68-c6ec113ff8b3;76a36c15-38d3-442e-84a0-b0649a213d13;79637c7b-fe7b-436c-892b-6c36abfdcacc;79ee419f-59ce-495b-8ec9-d1c6bb070d91;7ae8ca71-6b24-4cf0-aa66-33d92ae9899b;7c9184c0-7a2e-11df-8c8d-0002a5d5c51b;7d453424-c1b7-4424-86b4-052d4b894e44;85e1b5e3-80e9-44c5-923f-d08a69823d30;88820a09-8541-438f-b39c-452b2fa25ec6;88cd0b26-6575-4132-9749-0f038d8663c7;8cdc62f6-1477-138d-b09a-7398bffc621c;94778fd1-1cbc-4fbf-b167-25beb1d80769;989b3762-6917-4e3f-9010-323665645626;99265e39-af23-43eb-a552-305f0a218fdf;9932a519-0ea2-4b52-9d93-cd0f5f63d592;9e517e32-d5ac-438d-b613-306e6aa6c45b;a8d61975-6d26-417e-8d1a-c9949e8970bf;a9a0c7de-bec2-4fc0-82de-6396d5006183;acbffee5-0536-4597-b349-7ad9fc20e879;ad627894-4d1e-4dae-8421-9aa1ce9a0208;b0894fd5-ba59-419b-8a34-28c2e16359ed;b38e1880-9152-4ca4-93e3-b9f6d14db958;be6e93e8-7a92-4f76-a5b4-21673d1487dd;c226ae27-7323-4740-8ce1-361acb90f1cb;c4a6a7e6-e49b-4202-b9d3-62c76a13b106;c6f62299-5cab-4251-8bc3-8239dbd6b48e;cda9bd9c-380e-4088-8233-c9e1b1b30784;d1db05b0-edcd-414c-b824-493226157b44;e313c0f4-246f-4a83-804c-163b5dda30e7;f26dfb00-c55e-4cac-bc15-4f608e78a372;f34bb31d-706b-454f-98e9-0b23d45c091f;
993|903939b3-a01d-4593-85ca-cfe8d4d48d3e| Clarithromycin for oral suspension is indicated for the treatment of mild t moderate infections caused by susceptible strains of the designated microor ganisms in the conditions as listed below <br> <br> Adults <annotation cui="C0031350">Pharyngitis</annotation> <annotation cui="C0040425">Tonsillitis</annotation> due to <i> Streptococcus pyogenes </i> (The usual drug of choice in the treatment and prevention of <annotation cui="C0038395">streptococcal infections</annotation> and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of <i> pyogenes </i> from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) <br> <br> <annotation cui="C0155804">Acute maxillary sinusitis</annotation> due to <i> Haemophilus influenzae, Moraxella catarrhalis, </i> or <i> Streptococcus pneumoniae </i> <br> <br> Acute bacterial exacerbation of <annotation cui="C0008677">chronic bronchitis</annotation> due to <i> Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, </i> or <i> Streptococcus pneumoniae </i> <br> <br> <annotation cui="C0694549">Community Acquired Pneumonia</annotation> due to <i> Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, </i> or <i> Chlamydia pneumoniae </i> (TWAR). <br> <br> Uncomplicated <annotation cui="C0037278">skin and skin structure infections</annotation> due to <i> Staphylococcus aureus, </i> or <i> Streptococcus pyogenes </i> (Abscesses usually require surgical drainage.) <br> <br> Disseminated <annotation cui="C0026918">mycobacterial infections</annotation> due to <i> Mycobacterium avium, </i> or <i> Mycobacterium intracellulare </i> <br> <br> In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non clarithromycin containing therapy is recommended. (For information on development of resistance see <u> Microbiology </u> section.) The eradication of <i> pylori </i> has been demonstrated to reduce the risk of <annotation cui="C0013295">duodenal ulcer</annotation> recurrence. <br> <br> Children <annotation cui="C0031350">Pharyngitis</annotation> <annotation cui="C0040425">Tonsillitis</annotation> due to <i> Streptococcus pyogenes </i> <br> <br> <annotation cui="C0694549">Community Acquired Pneumonia</annotation> due to <i> Mycoplasma pneumoniae, Streptococcus pneumoniae, </i> or <i> Chlamydia pneumoniae </i> (TWAR) <br> <br> <annotation cui="C0155804">Acute maxillary sinusitis</annotation> due to <i> Haemophilus influenzae, Moraxella catarrhalis, </i> or <i> Streptococcus pneumoniae </i> <br> <br> <annotation cui="C0271429">Acute otitis media</annotation> due to <i> Haemophilus influenzae, Moraxella catarrhalis, </i> or <i> Streptococcus pneumoniae </i> <br> <br> <b> NOTE </b> For information on otitis media, see <b> <u> CLINICAL STUDIES Otitis Media . </u> </b> <br> <br> Uncomplicated <annotation cui="C0037278">skin and skin structure infections</annotation> due to <i> Staphylococcus aureus, </i> or <i> Streptococcus pyogenes </i> (Abscesses usually require surgical drainage.) <br> <br> Disseminated <annotation cui="C0026918">mycobacterial infections</annotation> due to <i> Mycobacterium avium, </i> or <i> Mycobacterium intracellulare </i> <br> <br> Prophylaxis Clarithromycin for oral suspension is indicated for the prevention of disseminated <i> Mycobacterium avium </i> complex (MAC) disease in patients with advanced HIV infection. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of clarithromycin and other antibacterial drugs, clarithromycin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |066f4be0-054c-4b34-aa0d-941ddc529610;144e4973-d24a-4003-b5b1-d59fd835d884;22457862-0f88-4be8-b507-1c8f264269f2;2e899f4a-a2e9-445c-a0ed-6ad811e997e6;38642D80-AAA6-4196-A033-3977FF35B48A;3fed77ce-ad29-48e2-a28b-6d1501d0b090;4b9d7052-a54f-3ee1-ab0e-633b087f4802;52c09a36-879b-4b0e-b3a5-f4a4bba9bde5;624a18c4-f07a-4f8a-9a14-bbfd9c6c7c68;73bd377e-cd9a-4d34-aa6e-7a1e44b47b89;81506e45-3d35-4462-ad4c-1584a186023b;882bbf32-8a87-4479-a2a8-92637abfdd75;8aa4f3fc-720b-448b-ae8b-9bb3a9ff6d42;903939b3-a01d-4593-85ca-cfe8d4d48d3e;90d35dd6-a918-c4ab-bc7e-43652ce9b3b4;92ae2611-637c-4a9e-8e95-2d8fa8191f03;94c182ed-f2d6-4f7f-bdd9-69b136c54623;9aaffb41-408c-4372-8fd5-1d649450c0e9;aa44552c-3cfe-4111-8aa5-4251aeed9be9;adedec4c-e9b0-44ef-9ed9-741adcdc84d7;b98b02bb-2609-49a0-b29f-e5911aa0cbc1;c14051fd-deeb-4340-b9a9-9482ef6c198c;f3a50f13-b028-4135-8f20-bfb62a9bc0a9;fa1a9323-3b54-4b6b-850d-ae5b7d5ccbc6;fa89af8a-4c53-4389-a2e1-22d4ca8b4bb9;
10165|be38b325-3a6f-4569-9ae0-a03feff8535d| LEVITRA is indicated for the treatment of <annotation cui="C0242350">erectile dysfunction</annotation>. <br> <br> |08b737e8-9d9c-4d04-b91b-1f0c5fe065c7;0e5139d8-bf61-4f21-a36b-81b96b9b07d1;34c30372-08b0-4060-8aba-779b5bc1e5dd;4e66ad5c-572c-4819-8b6e-6930c33cc210;517fbb02-8793-4647-83c7-25a91be49622;80971965-5c77-4950-b65d-7996b802d2cd;8f935afa-f845-46cd-b61a-db7a48e559c0;a01def95-c0ef-43b9-bd9e-5565b2385ad3;b3bbc16e-8305-469a-9dc3-8e698339a98b;be38b325-3a6f-4569-9ae0-a03feff8535d;f18a82f7-ce44-4f9c-ae69-d3ad1d375564;
10388|895cb85a-5ec8-4070-babf-d1325c028677| <div> <annotation cui="C0020538">Hypertension</annotation> </div> BYSTOLIC is indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation> <i> [see Clinical Studies ( 14.1 )] </i> . BYSTOLIC may be used alone or in combination with other antihypertensive agents <i> [see Drug Interactions ( 7 )] </i> . <br> <br> |895cb85a-5ec8-4070-babf-d1325c028677;
10554|1086a7b4-b89b-4bee-8120-5f752626c046| <div> <annotation cui="C0948089">Acute Coronary Syndrome</annotation> (<annotation cui="C0948089">ACS</annotation>) </div> <ol><li> For patients with non ST segment elevation <annotation cui="C0948089">ACS</annotation> [<annotation cui="C0002965">unstable angina</annotation> (<annotation cui="C0002965">UA</annotation>)/non ST elevation <annotation cui="C0027051">myocardial infarction</annotation> (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, <annotation cui="C0027051">myocardial infarction</annotation> (<annotation cui="C0027051">MI</annotation>), or <annotation cui="C0038454">Stroke</annotation> as well as the rate of a combined endpoint of cardiovascular death, <annotation cui="C0027051">MI</annotation>, <annotation cui="C0038454">Stroke</annotation>, or refractory <annotation cui="C0022116">ischemia</annotation>. </li><li> For patients with ST elevation <annotation cui="C0027051">myocardial infarction</annotation> (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re infarction, or <annotation cui="C0038454">Stroke</annotation>. The benefit for patients who undergo primary percutaneous coronary intervention is unknown. </li></ol> The optimal duration of Plavix therapy in <annotation cui="C0948089">ACS</annotation> is unknown. <br> <br> <div> Recent <annotation cui="C0027051">MI</annotation>, Recent <annotation cui="C0038454">Stroke</annotation>, or Established <annotation cui="C1704436">Peripheral Arterial Disease</annotation> </div> For patients with a history of recent <annotation cui="C0027051">myocardial infarction</annotation> (<annotation cui="C0027051">MI</annotation>), recent <annotation cui="C0038454">Stroke</annotation>, or established <annotation cui="C1704436">Peripheral Arterial Disease</annotation>, Plavix has been shown to reduce the rate of a combined endpoint of new <annotation cui="C0948008">ischemic stroke</annotation> (fatal or not), new <annotation cui="C0027051">MI</annotation> (fatal or not), and other vascular death. <br> <br> |0005e2a8-3ab9-4173-a46f-9c53881379e2;0078fb3d-3595-4ae1-a059-1d5e81c879cf;01b14603-8f29-4fa3-8d7e-9d523f802e0b;03bec9ad-cd22-44d3-9b82-2796157de1d1;079ed521-3ff0-47fa-86d5-a336732056cc;10360cf0-1671-3cbe-cd7c-2c8e8753bd1b;1086a7b4-b89b-4bee-8120-5f752626c046;3d021d9b-c0b8-41a3-a99b-37f50d2a20ae;3e08ca1d-35ef-4b65-9799-5c62c6444d26;488e765a-7f2d-4323-8a5c-114a46862e8f;4da4da53-91ae-4d4f-145f-255c5db443a5;4dbcad6e-90d5-4f38-9b69-72bbcac38fcc;7109fd74-54c8-4abd-90cd-71892edfd243;710bede3-2742-4413-8772-63b2a955fab5;a9a3c560-2408-4dd0-9f83-ee3e3a549c7b;ae07b785-b522-41c6-b27c-24c4d5cd814d;b5aa951f-72de-bea1-98a2-a4085c64a361;bc747f6d-f52c-4dcb-bda5-2d0a9f954147;c3248d43-3dd6-4ca9-afca-528c7abe0fce;c62e99a1-0612-4c76-9c72-80c6b78e3567;cb1ce9ec-4f07-4cc9-85bb-663ee1f2ccc7;d37db064-3a5a-4a0c-a60b-b4b417fe742a;de099108-7445-4632-b85f-93a1bc05adf0;f1d77dba-9dae-4f30-b3e3-b4898993f865;f3cb9331-a57d-428c-a13c-7ba5f2eeab14;
10638|da10031f-9da8-49a2-a019-5ce80c4b7ede| For the treatment of functional bowel <annotation cui="C0022104">irritable bowel syndrome</annotation>. <br> <br> |150078be-0792-4053-b6d3-641cae923b09;399ff144-aeaa-4d9b-a1fb-1a4a5635c0a7;407f57c5-0aca-48c1-a886-2f2185805a42;54582bac-9386-4070-bfce-8c392172d24d;57ab6992-7b98-4503-b4bb-98d76ccf603e;59b1b2cc-73ce-49cf-a87a-05a2d6428be5;5a553bda-1e3d-4b80-913f-73dd54655033;7454bfef-ee61-4226-839e-47bba65f9125;823052b8-1ee4-4628-aa97-b862406b0d75;8b7af7c1-72ce-4d29-947f-aa6dd24f078b;8c29140b-e181-4807-870f-28e315c6d4c4;D59FA254-7959-47C9-BB77-AB7946A1A127;a3fa1a75-cf2b-452e-9e4c-25ef37b711be;a5937c7b-cdfc-46e6-a0fa-541b24f91d47;aa8350bd-f832-4983-baed-2a6978819b49;ac145b81-5f26-4914-b47f-6c4958e94146;ad7e6eaa-42b8-45fd-aca4-e4b64a9ef20f;b65264c5-2d4a-4290-a084-ddd533e9e954;b8c72fd8-6030-4c0a-80a6-d36cf698a576;baf1bea8-c573-4ef8-8630-7b51a8e53cac;bb099db9-f635-4a64-8892-6236971dec45;bd2cba10-70ec-4d1f-b46c-53d1de2ee130;c2aac506-3f10-4116-9b65-6341aaaf9893;c56598d5-9cd1-4cce-b172-ac338775aec7;d2c074e8-9ee2-4bbf-a0a4-6aeba4ad9d50;d70e3238-cb91-44eb-8598-f8713b89be97;da0e1f63-cb90-4c2a-908f-7d81e672be10;da10031f-9da8-49a2-a019-5ce80c4b7ede;ddf980b2-0a5b-4848-b67b-8f54d1dc5ab7;e576f409-d319-4878-9863-25988be7fde1;f325dd3d-8ebe-4aa3-8c45-43438c75defe;f4b07de4-cc96-4615-b1cc-8338920bdeee;fcca6fd5-6a67-4bb9-b9f2-634c87b8cc31;
10657|c397a9da-862f-4f3f-8109-7d21691de53a| Diazepam is indicated for the management of <annotation cui="C0003469">anxiety disorders</annotation> or for the short term relief of the symptoms of <annotation cui="C0003469">Anxiety</annotation>. <annotation cui="C0003469">Anxiety</annotation> or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <br> In acute <annotation cui="C0236663">alcohol withdrawal</annotation>, diazepam may be useful in the symptomatic relief of acute <annotation cui="C0085631">agitation</annotation>, <annotation cui="C0040822">tremor</annotation>, impending or acute <annotation cui="C0001957">delirium tremens</annotation> and <annotation cui="C0233777">hallucinosis</annotation>. <br> <br> Diazepam is a useful adjunct for the relief of skeletal <annotation cui="C0037763">muscle spasm</annotation> due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), <annotation cui="C0026838">spasticity</annotation> caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff man syndrome. <br> <br> Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. <br> <br> The effectiveness of diazepam in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. <br> <br> |09c6e0a1-85ad-4450-cb99-7a6b7b0d3aff;187e6805-d568-4fa6-8515-46e6677d9a4e;1995880f-e2f3-4eda-b7ff-b28141d38185;1aaf9375-ae3d-4fed-9cd1-24102e00be1a;1e6c2f52-73ff-429b-8f1b-9b5b61ce1ac5;23d3765c-8f10-4bfc-9489-e1ed064ad813;2befa9af-080e-4bad-8654-5de50029ad12;2c2339ed-d8d7-4fe3-f197-41adb8931fc1;2d96a6cb-326f-4c04-b5d7-24d7f7c20699;38399c4a-f304-41ef-aa7d-05c468a7802e;41044928-dd1f-40bf-1fa6-709dff559124;484acfc4-6f1a-4abe-9eaa-b1b8ea7f90e6;48aa32cb-047a-414a-822e-82a5f26d8817;5051e98b-3817-61aa-dba8-bd8be2f0c086;528b98f2-0055-4c40-a3a1-10f70971366a;66ea2936-8b6c-4b72-b077-ecf88e83fee7;78d5a77d-5ca7-4f16-b4d0-fce86456593c;792c3767-f660-4d13-89ed-c69e925f2232;7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f;9a0ce899-0504-4095-85b1-d7957fe3f72c;b1e06f3a-8e4a-4d88-9893-83eacaeb31ea;b326c66d-5762-4d16-933c-619fa2088ccd;b5488932-2f9f-4110-af27-82e422d63ed4;ba953b22-f0cd-4be5-9e0e-178bded88727;c2768add-5e01-4ff4-afa3-230380d59a1f;c397a9da-862f-4f3f-8109-7d21691de53a;d1b5762f-307c-4c99-977d-d91d7dd22141;e5f4151c-ee35-4ff7-8374-ab202642373c;
1081|7733052d-177b-49da-949e-4d950bd2afeb| Diazepam rectal gel is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory, patients with <annotation cui="C0014544">epilepsy</annotation>, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased <annotation cui="C0036572">seizure</annotation> activity. <br> <br> Evidence to support the use of diazepam rectal gel was adduced in two controlled trials (see CLINICAL PHARMACOLOGY, CLINICAL STUDIES subsection) that enrolled patients with <annotation cui="C0751495;C0234533">partial onset or generalized convulsive seizures</annotation> who were identified jointly by their caregivers and physicians as suffering intermittent and periodic episodes of markedly increased <annotation cui="C0036572">seizure</annotation> activity, sometimes heralded by nonconvulsive symptoms, that for the individual patient were characteristic and were deemed by the prescriber to be of a kind for which a benzodiazepine would ordinarily be administered acutely. Although these clusters or bouts of <annotation cui="C0036572">seizures</annotation> differed among patients, for any individual patient the clusters of <annotation cui="C0036572">seizure</annotation> activity were not only stereotypic but were judged by those conducting and participating in these studies to be distinguishable from other <annotation cui="C0036572">seizures</annotation> suffered by that patient. The conclusion that a patient experienced such unique episodes of <annotation cui="C0036572">seizure</annotation> activity was based on historical information. <br> <br> |7733052d-177b-49da-949e-4d950bd2afeb;A84A73A7-8E3A-4985-8BE0-04B3028F5E49;
1115|5ecaa34e-1bed-49a5-b97c-a8f8c0d885a7| <div> <annotation cui="C0018099">Gout</annotation> Flares </div> COLCRYS (colchicine, USP) tablets are indicated for prophylaxis and the treatment of acute <annotation cui="C0018099">Gout</annotation> flares. <br> <br> <ol><li> Prophylaxis of <annotation cui="C0018099">Gout</annotation> Flares: COLCRYS is indicated for prophylaxis of <annotation cui="C0018099">Gout</annotation> flares. </li><li> Treatment of <annotation cui="C0018099">Gout</annotation> Flares: COLCRYS tablets are indicated for treatment of acute <annotation cui="C0018099">Gout</annotation> flares when taken at the first sign of a flare. </li></ol> <div> <annotation cui="C0031069">Familial Mediterranean fever</annotation> (<annotation cui="C0031069">FMF</annotation>) </div> COLCRYS (colchicine, USP) tablets are indicated in adults and children 4 years or older for treatment of <annotation cui="C0031069">Familial Mediterranean fever</annotation> (<annotation cui="C0031069">FMF</annotation>). <br> <br> |56c130d1-7581-4152-99a2-0014ee9366c0;5ecaa34e-1bed-49a5-b97c-a8f8c0d885a7;
11335|18b7c145-3e8f-4e7e-c6b5-080d4139a008| DEXEDRINE is indicated in <br> <br> <div> <annotation cui="C0027404">Narcolepsy</annotation> </div> <div> <annotation cui="C1263846">Attention Deficit Disorder with Hyperactivity</annotation> </div> As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM IV) implies the presence of hyperactive impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months lack of attention to details careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months fidgeting squirming; leaving seat; inappropriate running climbing; difficulty with quiet activities; on the go ; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive impulsive criteria to be met. <br> <br> <div> <i> <b> Special Diagnostic Considerations </b> </i> </div> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presences of the required number of DSM IV characteristics. <br> <br> <div> <i> <b> Need for Comprehensive Treatment Program </b> </i> </div> DEXEDRINE is indicated as an integral part of a total treatment program for <annotation cui="C1263846">ADHD</annotation> that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician s assessment of the chronicity and severity of the patient s symptoms. <br> <br> |18b7c145-3e8f-4e7e-c6b5-080d4139a008;3cd6be27-de51-4a5f-93b1-b08680cff5b7;69c40af8-3710-46bf-bd3d-137fe5eea23e;a0860402-057c-40ce-902c-6ec5d6545132;a37b6ef9-78b4-4b18-8797-ecb583502500;
12261|1495284D-750F-437E-8525-6834CCCB78EB|<i> Allergic states </i> Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in <annotation cui="C0004096">asthma</annotation>, <annotation cui="C0011615">atopic dermatitis</annotation>, <annotation cui="C0011616">contact dermatitis</annotation>, drug <annotation cui="C0020517">hypersensitivity reactions</annotation>, <annotation cui="C0848309;C0018621">perennial or seasonal allergic rhinitis</annotation>, and <annotation cui="C0036830">serum sickness</annotation>. <br> <br> <i> <annotation cui="C0037274">Dermatologic diseases</annotation> </i> Bullous <annotation cui="C0011608">dermatitis herpetiformis</annotation>, <annotation cui="C0011606">exfoliative erythroderma</annotation>, <annotation cui="C0026948">mycosis fungoides</annotation>, <annotation cui="C0030807">pemphigus</annotation>, and severe <annotation cui="C0014742">erythema multiforme</annotation> (<annotation cui="C0038325">Stevens Johnson syndrome</annotation>). <br> <br> <i> <annotation cui="C0014130">Endocrine disorders</annotation> </i> <annotation cui="C0001403;C0271738">Primary or secondary adrenocortical insufficiency</annotation> (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), <annotation cui="C0001627">congenital adrenal hyperplasia</annotation>, <annotation cui="C0020437">hypercalcemia</annotation> associated with cancer, and nonsuppurative <annotation cui="C0040147">thyroiditis</annotation>. <br> <br> <i> <annotation cui="C0017178">Gastrointestinal diseases</annotation> </i> To tide the patient over a critical period of the disease in <annotation cui="C0010346">regional enteritis</annotation> and <annotation cui="C0009324">ulcerative colitis</annotation>. <br> <br> <i> <annotation cui="C0018939">Hematologic disorders</annotation> </i> <annotation cui="C0002879">Acquired (autoimmune) hemolytic anemia</annotation>, <annotation cui="C1260899">congenital (erythroid) hypoplastic anemia</annotation> (<annotation cui="C1260899">Diamond Blackfan anemia</annotation>), <annotation cui="C0043117">idiopathic thrombocytopenic purpura</annotation> in adults, <annotation cui="C0034902">pure red cell aplasia</annotation>, and selected cases of <annotation cui="C0154301">secondary thrombocytopenia</annotation>. <br> <br> <i> Miscellaneous </i> Diagnostic testing of <annotation cui="C0001622">adrenocortical hyperfunction</annotation>, <annotation cui="C0040896">trichinosis</annotation> with neurologic or myocardial involvement, <annotation cui="C0041318">tuberculous meningitis</annotation> with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. <br> <br> <i> Neoplastic diseases </i> For the palliative management of <annotation cui="C0023418">leukemias</annotation> and <annotation cui="C0024299">lymphomas</annotation>. <br> <br> <i> Nervous system </i> Acute exacerbations of <annotation cui="C0026769">multiple sclerosis</annotation>, <annotation cui="C0006114">cerebral edema</annotation> associated with primary or metastatic brain tumor, craniotomy, or head injury. <br> <br> <i> Ophthalmic diseases </i> <annotation cui="C0029077">Sympathetic ophthalmia</annotation>, <annotation cui="C1956391">temporal arteritis</annotation>, <annotation cui="C0042164">uveitis</annotation>, and ocular inflammatory conditions unresponsive to topical corticosteroids. <br> <br> <i> <annotation cui="C0022658">Renal diseases</annotation> </i> To induce a diuresis or remission of <annotation cui="C0033687">proteinuria</annotation> in <annotation cui="C1704321">idiopathic nephrotic syndrome</annotation> or that due to <annotation cui="C0409974">lupus erythematosus</annotation>. <br> <br> <i> <annotation cui="C0035204">Respiratory diseases</annotation> </i> <annotation cui="C0005138">Berylliosis</annotation>, fulminating or disseminated <annotation cui="C0041327">pulmonary tuberculosis</annotation> when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. <br> <br> <i> <annotation cui="C0035435">Rheumatic</annotation> disorders </i> As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in <annotation cui="C0149896">acute gouty arthritis</annotation>, <annotation cui="C0035440">acute rheumatic carditis</annotation>, <annotation cui="C0038013">ankylosing spondylitis</annotation>, <annotation cui="C0003872">psoriatic arthritis</annotation>, <annotation cui="C0003873">rheumatoid arthritis</annotation>, including <annotation cui="C0553662">juvenile rheumatoid arthritis</annotation> (selected cases may require low dose maintenance therapy). For the treatment of <annotation cui="C0011633">dermatomyositis</annotation>, <annotation cui="C0085655">polymyositis</annotation>, and <annotation cui="C0024141">systemic lupus erythematosus</annotation>. <br> <br> |00f36d47-e971-4f05-be7b-8e354339ca62;0277cc0a-2fd4-4605-a310-b613be84ee26;0372f916-0a26-4115-8075-2d575bfbc15e;0ee281c8-7624-46b1-a8fe-e2a295e6c46a;1399ff8e-378e-4624-96e4-867402bdbe05;1495284D-750F-437E-8525-6834CCCB78EB;1ae5e09b-90e5-4c8f-bf41-87d71ccfd267;20d1ffa7-0a0a-4a16-a2ec-347c21693e80;2ceb3a01-f5bb-4538-b5c1-cea400901d02;2e792ffd-1a5a-415b-8cd9-7f84ac4c5e51;320747b3-5cf1-4e0c-b670-c6a9e72a8845;428cc7bb-e0f9-466c-b38f-11ac22cda752;4a728c5e-0de6-4f05-b293-5d7799b7edf1;537B424A-3E07-4C81-978C-1AD99014032A;5564ee46-7bd7-4b2a-ad51-d01f7fda0461;5cd6b7e5-e52b-4ac3-96d8-8d3f5245cf43;7021a1c8-d2b4-455d-b6fd-4d2658b7b55b;736861fa-1df8-4afd-ba4a-dd7d7bffd865;7658e4b2-5b0d-487a-a603-8fd264cb02ea;7a7ee007-cd02-4f3f-8f0f-82c4964da6e6;7cf5c17c-a80b-4547-83b2-0d53e2b933f7;7d16a8fc-81d6-495b-9fdb-a540d6b883b9;827ce261-307b-4398-8993-333c08e601fe;89e1d458-7caa-430f-9c54-360889899a73;8ed678e2-8a6a-418d-af99-af46d54ae5c4;ae770b46-173e-42f8-b83e-efeb11b0fb11;b15200fb-1826-472b-a907-e677a272513b;b605c62b-5d6b-462e-93aa-2a956d2239fe;bf8acfdb-8dc8-4a69-90b0-33c680c421d6;c68c10f0-6970-4157-904c-b56ef80c5842;c6eb10d2-2251-482b-8a57-fea31c05bc7e;cca2c160-9188-48e8-9505-49a52388dcb7;ce01733f-33b7-483e-9bc4-cf43937e6998;da9af3d2-c0fb-4e92-bb57-5e868d8c6696;e021aa60-bfeb-4125-a946-0ea013aeeed2;e59d3b87-af2e-4262-b89d-e95aa79f11b7;e5c28db5-efce-49a7-9e5f-12338d1f216b;ec27c135-8ffd-4487-a4fa-7c0514e843e6;ec65c1ea-31af-4858-8c17-885b3f24a49c;ff045cba-f55a-4368-8045-d783694adb85;
12420|81d1bed6-8fb5-4191-9396-234366667fad| Carefully consider the potential benefits and risks of nabumetone and other treatment options before deciding to use nabumetone. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <b> WARNINGS </b> ). <br> <br> Nabumetone tablets are indicated for relief of signs and symptoms of <annotation cui="C0029408">osteoarthritis</annotation> and <annotation cui="C0003873">rheumatoid arthritis</annotation>. <br> <br> |09796ddd-64db-417d-9bfb-94b6300187a3;0a4d39b0-396f-4ae0-9332-68557c6d4f74;10420984-5dc8-4f81-bba2-0c820b3ed19a;113dbe00-742e-aac8-8570-dd4d31349159;11e2e5bf-c5bf-46db-920a-93711827aa5e;19d480c3-dbca-4082-80c5-64185bc5b545;232fc22e-ac54-44db-8cf0-c7965b3554c1;2f7eb033-3912-4c1c-aa11-ac34c36ffe8a;3dda6795-861d-47cd-bf36-f5dd364fa7ec;49374999-336c-4699-9789-5d83acb08551;5276f530-14bc-492d-974b-913fd06bf52e;53656d70-6572-4669-6465-6c6973555341;62eba9b3-c088-4638-8683-07387b336399;6952ef79-a3c9-4a74-b539-bd1a343d6852;72400d93-7ec6-494a-8dc0-6de8f6c0c531;81d1bed6-8fb5-4191-9396-234366667fad;84eca2bc-f7d2-422b-bb41-04a55488e86c;87028b13-0aab-4e90-b92e-6b0c54e59bbb;8fa594c9-75f3-474b-bba3-b8110bafb82c;9df9212a-cf34-42b4-bd84-796b9e981eb0;b0cafa5c-8643-414d-a14b-e8b369ae8033;b3ad48a5-bea2-463d-8934-76daca3de5de;b52901fa-5f7e-418b-aae5-842da7610434;b5d8f94b-6c76-4a68-9e7c-e301938ed381;bdd14d4f-7165-459a-874d-62545946c9b3;d36383cc-e25f-a08b-e120-1f0b6fbafc8b;e21f89cf-ec07-4b07-9c9b-796b0111df39;e66a5a08-7121-4987-bda1-7f3dbc5ed680;faf361cd-46d2-4656-85db-d6a38453a9ad;fcbc1d42-a883-435a-a8a8-e12c308a87d8;
12504|0971fa2e-d660-48b0-9fbb-96a2db167b92| Diethylpropion hydrochloride is indicated in the management of <annotation cui="C1281429">exogenous obesity</annotation> as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg m 2 or higher and who have not responded to appropriate weight reducing regimen (diet and or exercise) alone. Below is a chart of BMI based on various heights and weights. BMI is calculated by taking the patient s weight, in kilograms (kg), divided by the patient s height, in meters (m), squared. Metric conversions are as follows pounds divided by 2.2 = kg; inches x 0.0254 = meters. <br> <br> The usefulness of agents of this class <b> (see CLINICAL PHARMACOLOGY) </b> should be measured against possible risk factors inherent in their use such as those described below. Diethylpropion hydrochloride is indicated for use as monotherapy only. <br> <br> |04bd05c4-0d36-4580-94ec-2119d8d58644;0971fa2e-d660-48b0-9fbb-96a2db167b92;330965ca-154f-42d2-bb7c-9494bf036c92;355a06ff-557d-4252-884d-8f3ee165b658;3a283f1b-486f-4100-8f97-aa0350cc9b8d;4fdbc049-6497-4ea0-8788-d2b2963328f7;701ba14c-e668-4308-8430-765a7aad47fa;a750a1ef-8f3e-4870-97eb-3697aaca1818;af3d7879-7160-5b02-01e4-bd02f53c8018;b26c2f51-7436-4622-a174-3f3978a1fda2;ba26f274-f385-49be-aef1-7041d146b9f7;d6ef01d5-791a-ac09-39c0-de1f6e035c65;dab53f4f-68d4-4477-a2b6-ad44a956332b;
1272|07cd75b9-ffc1-43aa-ab30-4e5ded98102d| ZOVIRAX (acyclovir) Ointment 5% is indicated in the management of initial <annotation cui="C0019342">genital herpes</annotation> and in limited non life threatening mucocutaneous <annotation cui="C0019348">Herpes simplex</annotation> virus infections in immunocompromised patients. <br> <br> |07cd75b9-ffc1-43aa-ab30-4e5ded98102d;456071c1-74b9-42c2-a893-00f0bfbd0430;50278e0e-da1e-45ee-9fcb-672b2a219911;
12788|a85d5629-748d-4920-b0d6-3012a0ace1a3| PROVIGIL is indicated to improve wakefulness in adult patients with <annotation cui="C0917799">excessive sleepiness</annotation> associated with <annotation cui="C0027404">Narcolepsy</annotation>, <annotation cui="C0520679">obstructive sleep apnea</annotation>, and shift work disorder. <br> <br> In <annotation cui="C0520679">OSA</annotation>, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. <br> <br> In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their <annotation cui="C0917799">excessive sleepiness</annotation>. <br> <br> The effectiveness of modafinil in long term use (greater than 9 weeks in <annotation cui="C0027404">Narcolepsy</annotation> clinical trials and 12 weeks in <annotation cui="C0520679">OSA</annotation> and SWD clinical trials) has not been systematically evaluated in placebo controlled trials. The physician who elects to prescribe PROVIGIL for an extended time in patients with <annotation cui="C0027404">Narcolepsy</annotation>, <annotation cui="C0520679">OSA</annotation>, or SWD should periodically reevaluate long term usefulness for the individual patient. <br> <br> |0c634b7a-cce6-4c3d-9c49-63593755f49c;108a276f-b07b-d94f-4488-c3e3b6683d4f;5053c113-69df-4ade-a186-02bc054c23d1;8b79d52e-e6e5-4aaf-8835-242c72d6ee38;91d2f78d-8501-45d8-b6ff-33b393f75079;9f3b0bd2-72a3-411f-aeec-b533373f1a97;a85d5629-748d-4920-b0d6-3012a0ace1a3;def2a743-ec37-452e-8e6b-b15f72ad2215;e16c26ad-7bc2-d155-3a5d-da83ad6492c8;eba3a655-074b-46b3-88cf-3e6b2c0c8b15;f3b3097f-80b8-4410-af21-dcdea144e3c3;fd75a8a7-a8ab-4141-9af9-989a220b9c19;
13923|e433dc68-6b2a-4c48-beae-4ec946f1ff1e| VESIcare is a muscarinic antagonist indicated for the treatment of <annotation cui="C0878773">overactive bladder</annotation> with symptoms of <annotation cui="C0150045">urge urinary incontinence</annotation>, urgency, and urinary frequency. <br> <br> |9acee910-cdb2-4052-b8b3-c26aff1c8716;e433dc68-6b2a-4c48-beae-4ec946f1ff1e;
14024|673f5ad2-c09b-4a89-9407-efdadd007917| <div> <annotation cui="C0020538">Hypertension</annotation> </div> BYSTOLIC is indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>, to lower blood pressure <i> [see Clinical Studies ( 14.1 )] </i> . BYSTOLIC may be used alone or in combination with other antihypertensive agents <i> [see Drug Interactions ( 7 )] </i> . <br> <br> Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BYSTOLIC. <br> <br> Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). <br> <br> Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. <br> <br> Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <annotation cui="C0020538">Hypertension</annotation> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <annotation cui="C0020538">Hypertension</annotation> (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. <br> <br> Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. <br> <br> |673f5ad2-c09b-4a89-9407-efdadd007917;8b8ad213-1dc8-454e-a524-075685c0e1a8;
1428|54686520-506f-7765-7220-436f736d6963| <annotation cui="C0035457;C0018621">Perennial and seasonal allergic rhinitis</annotation> <br> <annotation cui="C0035460">Vasomotor rhinitis</annotation> <br> <annotation cui="C0009766">Allergic conjunctivitis</annotation> due to inhalant allergens and foods <br> Mild, uncomplicated allergic skin manifestations of <annotation cui="C0042109">urticaria</annotation> and <annotation cui="C0002994">angioedema</annotation> <br> Amelioration of <annotation cui="C1527304">allergic reactions</annotation> to blood or plasma <br> <annotation cui="C0221207">Cold urticaria</annotation> <br> <annotation cui="C0343065">Dermatographism</annotation> <br> <br> As therapy for <annotation cui="C0002792">anaphylactic reactions</annotation> <i> adjunctive </i> to epinephrine and other standard measures after the acute manifestations have been controlled. <br> <br> |21c25efc-9230-4c62-97d1-a465b12d6638;54686520-506f-7765-7220-436f736d6963;76f11fdd-6089-47a1-b1a1-ee1bf490dc97;8aa0e888-3e56-41f1-9305-03dc4fb18571;8d2bd313-3ab3-4fed-81d6-d2d81edcb206;963ded24-0367-44ca-a68d-66c385e76e69;A3C95613-3C12-440C-9C9A-D0A999E05631;b9e618d2-1178-d8e3-5479-8442b41ed8ff;e2bf4d46-6585-41d9-868c-98603b165d5b;ef230444-80fd-4724-9e84-08b32c06a033;
14566|18f1a4fc-dfca-4dde-8a11-f7e6d9e5656d| Benicar is indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. <br> <br> Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). <br> <br> Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. <br> <br> Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <annotation cui="C0020538">hypertension</annotation> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <annotation cui="C0020538">hypertension</annotation> (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. <br> <br> Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. <br> <br> It may be used alone or in combination with other antihypertensive agents. <br> <br> |18f1a4fc-dfca-4dde-8a11-f7e6d9e5656d;33770d80-754f-11de-8dba-0002a5d5c51b;ae3e0a4e-3a0c-4589-adb0-8fc3a5510f5b;
14968|496b346b-ca79-4483-a950-bed9464e6a9d| <div> <annotation cui="C0020538">Hypertension</annotation> </div> Ramipril capsules are indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. It may be used alone or in combination with thiazide diuretics. <br> <br> |055bb582-67cd-425a-8823-d543c14305ce;2e6303e8-1c22-451f-8733-a55e237ff961;496b346b-ca79-4483-a950-bed9464e6a9d;6337161a-4ce8-4c58-a812-f19819acea87;7e9e84f7-ff47-463d-bf47-7a9745960aae;a1064f8a-90f5-4c66-9f3c-cd5f17260eb9;a4b65854-1438-42c1-badd-4fa2245277ab;a8cdec12-81d1-4ef4-82c0-d05d93c37a07;abec7409-1d19-631b-1884-8f40337ef865;d6d57158-e8f9-4c91-8317-0374e0c87d33;
15569|2861a407-7898-489d-a43c-1e316341863e| To reduce the development of drug resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules USP and other antibacterial drugs, dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> Dicloxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug. (see <b> CLINICAL PHARMACOLOGY Susceptibility Plate Testing </b> ) <b> . </b> <br> <br> Dicloxacillin may be used to initiate therapy in suspected cases of resistant <annotation cui="C0038160">staphylococcal infections</annotation> prior to the availability of laboratory test results. The penicillinase resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase resistant penicillin. <br> <br> |2861a407-7898-489d-a43c-1e316341863e;33434f66-1d36-4506-9b3d-9755c978d9b2;3393668f-ea58-442e-b293-c7107b69d1af;5913023a-e3e4-4961-8adb-a299d9e66a37;5e878949-ae82-41e9-9fc6-3c54fe28c032;65c3e99b-ec77-416c-ad70-596d6f0a9c31;8478f242-c715-4984-ac1d-dc79dc28665e;9e2bbe03-44cb-45d1-acdb-b61d9016055e;c17cd62d-ff5d-47ba-8673-3346c7f2365f;e12a13dd-b93d-452c-8671-aec751ddaa4d;
15627|833c7a0b-5f64-4363-94d5-9a179049113a| <div> <b> 1.1 </b> <b> </b> <b> <annotation cui="C0020538">hypertension</annotation> </b> </div> Tekturna is indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with Tekturna. <br> <br> Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). <br> <br> Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. <br> <br> Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <annotation cui="C0020538">hypertension</annotation> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <annotation cui="C0020538">hypertension</annotation> (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. <br> <br> Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. <br> <br> |4c222831-90af-4336-8bf6-5628ddf24326;833c7a0b-5f64-4363-94d5-9a179049113a;
15842|d44bd66b-90e6-4447-803c-7c3bc02bf877| <div> <annotation cui="C0014544">Epilepsy</annotation> </div> <div> Adjunctive Use </div> Lamotrigine tablets are indicated as adjunctive therapy for <annotation cui="C0751495">partial seizures</annotation> and the <annotation cui="C0234533">generalized seizures</annotation> of <annotation cui="C0238111">Lennox Gastaut syndrome</annotation> in adults and pediatric patients ( 2 years of age). <br> <br> <div> Monotherapy Use </div> Lamotrigine tablets are indicated for conversion to monotherapy in adults with <annotation cui="C0751495">partial seizures</annotation> who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. <br> <br> Safety and effectiveness of lamotrigine have not been established (1) as initial monotherapy, (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate, or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <div> <annotation cui="C0005586">Bipolar Disorder</annotation> </div> Lamotrigine tablets are indicated for the maintenance treatment of <annotation cui="C0853193">Bipolar I Disorder</annotation> to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. The effectiveness of lamotrigine in the acute treatment of mood episodes has not been established. <br> <br> The effectiveness of lamotrigine as maintenance treatment was established in 2 placebo controlled trials of 18 months duration in patients with <annotation cui="C0853193">Bipolar I Disorder</annotation> as defined by DSM IV (see <b> CLINICAL STUDIES </b> , <b> <annotation cui="C0005586">Bipolar Disorder</annotation> </b> ). The physician who elects to use lamotrigine for periods extending beyond 18 months should periodically re evaluate the long term usefulness of the drug for the individual patient. <br> <br> |03f1d6d9-0300-46d8-8c6e-eeda78bf45d4;0a268a3a-4179-4f87-8125-53172992b0a8;0b0f0209-edbd-46f3-9bed-762cbea0d737;0f2f7421-56d4-45d0-9d2d-dc1edaede039;11800356-759d-4a8d-8811-e7942a3db6f5;14799df4-c425-4946-9168-9028c1f2e571;173bb299-f774-e888-0ecf-7520ac220d78;17a20462-d9d2-43ac-bcad-603e8cc76e3b;19c64c47-0410-4c7d-bad8-dbcd8fb94d1a;20e156df-a2b6-4710-b526-0419cd17dd33;22a9788c-5a9b-411e-844e-4a0b12d1d095;24f3f23f-c54b-4f75-a966-108b6c5ef3b7;25bbfc59-b566-1f01-8b30-b03fa3906069;2bff8e82-83e6-0430-abde-0a27ad460852;3448839b-4933-4ef9-a80a-9e504d2c5696;35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234;3960b810-f239-4ee0-a82f-fc79d6856199;4b72ea7a-a0b0-4980-84ad-84f64e2e6368;4f7c068e-f499-436b-a533-15e5bf6cfbd2;50fcf452-2d21-493e-a1dd-0c6ea9ac6184;51819994-9155-474f-bee9-392e356db838;5ac43f18-ae9f-40b8-b1e3-4d6e5b867150;5ce98225-2eb3-4386-bda1-48cb4c132562;5fb7c70d-410f-46a6-9906-edd5106c34d0;63726971-3809-0dc3-8502-d89095dc8401;6c925a5d-e154-475c-8478-ab7a271d68b9;71a48f30-97f8-44d9-aaff-71447c553688;7332e0ea-fbd0-43fb-8d1e-f7068504c61d;780fc63a-6aaf-4b27-a053-c593f3838dd4;7d032419-4429-4e10-a11f-b8d2f6360835;8b52a051-d892-464c-9318-4ace5a5b514f;8e2fc056-755f-447a-98d6-351879729e13;91198340-cf13-4c76-93fd-0c3ef7c300b3;a278a8ab-4c68-439a-8672-da32175dc1f5;a8a5b330-0158-00b7-195e-6234292653cf;a9a4309e-fe43-4a26-a30f-c6577d650336;aea4c8d6-12c7-4729-a199-94e378d42303;b5e88a0b-5504-4a69-8c72-02311c70e9c9;b829f9b2-f0ac-408a-a6f4-18b72150227d;b945d1c8-1b00-4dde-bbdc-30880e970905;c638ab70-05dd-4f8b-9a11-b33a75f8c504;d3fe5f79-89c6-4947-b0d9-9c2afef1b8f7;d44bd66b-90e6-4447-803c-7c3bc02bf877;d7e3572d-56fe-4727-2bb4-013ccca22678;d8de0c54-16a3-4c06-b1e7-58f966093d2b;db61fe47-1987-421f-ab4e-6545ff014090;dbe07049-223d-4e54-b1ab-5b57bb9ad8ae;e08920c2-04a3-4fb5-acc5-0af3140f82e9;e1a0da17-d67c-e44f-bd42-33c4009e4cdd;e849033b-a3bc-408e-88de-7cd1d2660949;e879e3e4-0cbc-4e69-9466-63d445d4f0cc;f31e1854-6068-4e45-b1e5-6def862fc466;
16308|dce12085-d6c4-48a5-959b-e771c413c9c5| <div> Treatment of <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> (<annotation cui="C0017168">GERD</annotation>) with <annotation cui="C0267055">Erosive Esophagitis</annotation> </div> NEXIUM I.V. for Injection is indicated for the short term treatment of <annotation cui="C0017168">GERD</annotation> with <annotation cui="C0267055">Erosive Esophagitis</annotation> in adults and pediatric patients 1 month to 17 years, inclusively as an alternative to oral therapy when oral NEXIUM is not possible or appropriate. <br> <br> |c325bbfc-46f3-471e-7bbc-ed0d6965d13b;dce12085-d6c4-48a5-959b-e771c413c9c5;
16417|ae50721d-ee15-4ee7-9fe7-afd98c56461b| SPORANOX (itraconazole) Oral Solution is indicated for the treatment of <annotation cui="C0553694">oropharyngeal</annotation> and <annotation cui="C0239295">esophageal candidiasis</annotation>. <br> <br> (See CLINICAL PHARMACOLOGY Special Populations , WARNINGS , and ADVERSE REACTIONS Post marketing Experience for more information.) <br> <br> |ae50721d-ee15-4ee7-9fe7-afd98c56461b;
16677|e8a485af-a78b-49a0-9bf4-75e1cd5bb740| Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of <annotation cui="C0751495">partial seizures</annotation> in adults and as monotherapy in the treatment of <annotation cui="C0751495">partial seizures</annotation> in children aged 4years and above with <annotation cui="C0014544">epilepsy</annotation>, and as adjunctive therapy in children aged 2 years and above with <annotation cui="C0014544">epilepsy</annotation>. <br> <br> |17325a80-fb9c-4a83-b4b4-98e0b999d852;1c713b59-a628-42e6-b166-ae71c3913284;1ccdb12e-3c52-4fb4-a2db-aeb8ca5757f7;42abbb51-a476-4837-bdf9-01eb288ceec2;449ee75b-882b-e208-d761-0ffa14d61a12;4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b;4f43644d-9b04-6911-9be5-81b6e25557cc;524c025b-809b-440f-a756-e3518d7c92db;682a1210-b26e-426e-8ffe-d25d91bdd608;6ebd3c83-7d28-4a73-9070-bbb3f9b547b1;7ecd5eef-46f4-407f-9b63-ba65adb3eced;84bbd612-4232-42de-8090-5e01d4bb6c0c;92919b7e-b499-4afb-8f78-1b1fff099bae;9dcbdfb5-0ee4-45b2-8351-001ed2e1a1f5;c84ef3b3-dd15-47b7-a663-0c5d643428ea;ca6bfbbb-fcca-4c15-a160-ee5791ed2f6e;d9741f36-0abd-49b7-9f43-e9700663122b;e61cfb01-55fc-42d5-8d9a-25d73f905e04;e8a485af-a78b-49a0-9bf4-75e1cd5bb740;
17086|ea79f802-e9ac-480b-91e6-1e3900b11803| <div> Treatment of <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> (<annotation cui="C0017168">GERD</annotation>) </div> <i> Healing of <annotation cui="C0267055">Erosive Esophagitis</annotation> </i> <br> <br> NEXIUM is indicated for the short term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed <annotation cui="C0267055">Erosive Esophagitis</annotation>. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of NEXIUM may be considered. <br> <br> <i> Maintenance of Healing of <annotation cui="C0267055">Erosive Esophagitis</annotation> </i> <br> <br> NEXIUM is indicated to maintain symptom resolution and healing of <annotation cui="C0267055">Erosive Esophagitis</annotation>. Controlled studies do not extend beyond 6 months. <br> <br> <i> Symptomatic <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> </i> <br> <br> NEXIUM is indicated for short term treatment (4 to 8 weeks) of <annotation cui="C0018834">heartburn</annotation> and other symptoms associated with <annotation cui="C0017168">GERD</annotation> in adults and children 1 year or older. <br> <br> <div> Risk Reduction of NSAID Associated <annotation cui="C0038358">Gastric Ulcer</annotation> </div> NEXIUM is indicated for the reduction in the occurrence of <annotation cui="C0038358">gastric ulcers</annotation> associated with continuous NSAID therapy in patients at risk for developing <annotation cui="C0038358">gastric ulcers</annotation>. Patients are considered to be at risk due to their age ( 60) and or documented history of <annotation cui="C0038358">gastric ulcers</annotation>. Controlled studies do not extend beyond 6 months. <br> <br> <div> <i> pylori </i> Eradication to Reduce the Risk of <annotation cui="C0013295">Duodenal Ulcer</annotation> Recurrence </div> Triple Therapy (NEXIUM plus amoxicillin and clarithromycin) NEXIUM, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with <i> pylori </i> infection and <annotation cui="C0013295">duodenal ulcer disease</annotation> (active or history of within the past 5 years) to eradicate <i> pylori </i> Eradication of <i> pylori </i> has been shown to reduce the risk of <annotation cui="C0013295">Duodenal Ulcer</annotation> recurrence [ <i> see Clinical Studies (14) and Dosage and Administration (2) </i> ]. <br> <br> In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [ <i> see Clinical Pharmacology (12.4) and the clarithromycin package insert, Clinical Pharmacology, Microbiology </i> ]. <br> <br> <div> Pathological Hypersecretory Conditions Including <annotation cui="C0043515">Zollinger Ellison Syndrome</annotation> </div> NEXIUM is indicated for the long term treatment of pathological hypersecretory conditions, including <annotation cui="C0043515">Zollinger Ellison Syndrome</annotation>. <br> <br> |3cdffcf9-b5fa-4622-9e83-ce29ececcc93;6f650345-0bca-4fe9-96eb-4d7ac80928ec;7aae16cb-addc-468a-be00-6c5be248da29;9af7a792-d38a-4b2a-b5d6-855d2183b029;9b653e01-81f3-49b1-89a2-a56988ad94a3;a373596c-9fb3-426e-bf92-54cdd6dfc3ec;ea79f802-e9ac-480b-91e6-1e3900b11803;f4853677-1622-4037-688b-fdf533a11d96;
18062|5783976b-0862-44e5-9b19-0f41d236d5c3| Enter section text here <br> <br> <div> <annotation cui="C0007131">Non Small Cell Lung Cancer</annotation> (<annotation cui="C0007131">NSCLC</annotation>) </div> <br> <br> TARCEVA monotherapy is indicated for the treatment of patients with locally advanced or metastatic <annotation cui="C0007131">Non Small Cell Lung Cancer</annotation> after failure of at least one prior chemotherapy regimen [see Clinical Studies ( 14.1 )]. <br> <br> Results from two, multicenter, placebo controlled, randomized, Phase 3 trials conducted in first line patients with locally advanced or metastatic <annotation cui="C0007131">NSCLC</annotation> showed no clinical benefit with the concurrent administration of TARCEVA with platinum based chemotherapy [carboplatin and paclitaxel or gemcitabine and cisplatin] and its use is not recommended in that setting [see Clinical Studies ( 14.3 )]. <br> <br> <div> <annotation cui="C0346647">Pancreatic Cancer</annotation> </div> <br> <br> TARCEVA in combination with gemcitabine is indicated for the first line treatment of patients with locally advanced, unresectable or <annotation cui="C0346976">metastatic pancreatic cancer</annotation> [see Clinical Studies ( 14.3 )]. <br> <br> |5783976b-0862-44e5-9b19-0f41d236d5c3;57bccb29-1c47-4c64-ab6a-77960a91cc20;
1825|2be0c5c9-e52d-4840-bbb4-a0fd6116661a| <div> <annotation cui="C0019348">Herpes Simplex Infections</annotation> in lmmunocompromised Patients </div> Acyclovir Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous <annotation cui="C0019348">herpes simplex</annotation> (HSV 1 and HSV 2) in immunocompromised patients. <br> <br> <div> Initial Episodes of <annotation cui="C0019342">Herpes Genitalis</annotation> </div> Acyclovir Injection is indicated for the treatment of severe initial clinical episodes of <annotation cui="C0019342">Herpes Genitalis</annotation> in immunocompetent patients. <br> <br> <div> <annotation cui="C0276226">Herpes Simplex Encephalitis</annotation> </div> Acyclovir Injection is indicated for the treatment of <annotation cui="C0276226">Herpes Simplex Encephalitis</annotation>. <br> <br> <div> Neonatal <annotation cui="C0019348">Herpes Simplex Virus Infection</annotation> </div> Acyclovir Injection is indicated for the treatment of neonatal <annotation cui="C0019372">herpes infections</annotation>. <br> <br> <div> <annotation cui="C0008049">Varicella</annotation> Zoster Infections in lmmunocompromised Patients </div> Acyclovir Injection is indicated for the treatment of <annotation cui="C0008049">varicella</annotation> zoster (<annotation cui="C0019360">shingles</annotation>) infections in immunocompromised patients. <br> <br> |2be0c5c9-e52d-4840-bbb4-a0fd6116661a;926efc9b-9126-4855-b76b-a58bd68b42d4;cb64dfab-52ee-4312-bc9c-c3d04efe9109;
18353|00bdb48f-8b8f-4cc5-bb63-77213f2279cb| <div> Reduction in Risk of <annotation cui="C0027051">Myocardial Infarction</annotation>, <annotation cui="C0038454">Stroke</annotation>, and Death from Cardiovascular Causes </div> Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, <annotation cui="C0038454">Stroke</annotation>, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of <annotation cui="C0027051">Myocardial Infarction</annotation>, <annotation cui="C0038454">Stroke</annotation>, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid lowering therapy). <br> <br> <div> <b> <i> <annotation cui="C0020538">hypertension</annotation> </i> </b> </div> Ramipril capsules are indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with thiazide diuretics. <br> <br> In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS. ) <br> <br> In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non black patients. (See WARNINGS, Angioedema. ) <br> <br> |00bdb48f-8b8f-4cc5-bb63-77213f2279cb;2f528bdb-66c3-45d4-9d37-63c093bfd5b5;8b59207a-ea5c-4697-a8b6-94c3015a00de;
2096|4f610abd-d22e-464a-b463-e86a09d7bdcb| ZOVIRAX Cream is indicated for the treatment of <annotation cui="C1274321">recurrent herpes labialis</annotation> (<annotation cui="C0019345">cold sores</annotation>) in adults and adolescents (12 years of age and older). <br> <br> |04af8c80-d0ff-49b0-bc82-8c644eacf067;0da14760-1131-4936-9a42-c40fc4db5cd0;125dbe4e-94ba-45bd-a714-f9c4b8e8b5c2;4f610abd-d22e-464a-b463-e86a09d7bdcb;
2627|3bf80420-7482-44c0-a117-30793ba89544| <br> <br> <annotation cui="C0020473">Hyperlipidemia</annotation> and Mixed <annotation cui="C0242339">Dyslipidemia</annotation> <br> <br> CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total C, LDL C, ApoB, nonHDL C, and triglycerides and to increase HDL C in adult patients with primary <annotation cui="C0020473">Hyperlipidemia</annotation> or mixed <annotation cui="C0242339">Dyslipidemia</annotation>. Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non pharmacological interventions alone has been inadequate. <br> <br> <br> <br> <br> <br> <annotation cui="C0020557">Hypertriglyceridemia</annotation> <br> <br> CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with <annotation cui="C0020557">Hypertriglyceridemia</annotation>. <br> <br> <br> <br> <br> <br> <annotation cui="C0020479">Primary Dysbetalipoproteinemia</annotation> (<annotation cui="C0020479">Type III Hyperlipoproteinemia</annotation>) <br> <br> CRESTOR is indicated as an adjunct to diet for the treatment of patients with <annotation cui="C0020479">Primary Dysbetalipoproteinemia</annotation> (<annotation cui="C0020479">Type III Hyperlipoproteinemia</annotation>). <br> <br> <br> <br> <br> <br> Homozygous <annotation cui="C0020445">Familial Hypercholesterolemia</annotation> <br> <br> CRESTOR is indicated as adjunctive therapy to other lipid lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL C, Total C, and ApoB in adult patients with homozygous <annotation cui="C0020445">Familial Hypercholesterolemia</annotation>. <br> <br> <br> <br> <br> <br> Slowing of the Progression of <annotation cui="C0004153">Atherosclerosis</annotation> <br> <br> CRESTOR is indicated as adjunctive therapy to diet to slow the progression of <annotation cui="C0004153">Atherosclerosis</annotation> in adult patients as part of a treatment strategy to lower Total C and LDL C to target levels. <br> <br> <br> <br> <br> <br> Limitations of Use <br> <br> The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. <br> <br> CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. <br> <br> |3bf80420-7482-44c0-a117-30793ba89544;
3129|fd4889db-5565-4a68-ac2e-3eee62ff8353| <div> <annotation cui="C0020538">Hypertension</annotation> </div> ZESTRIL is indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. <br> <br> <div> <annotation cui="C0018801">Heart Failure</annotation> </div> ZESTRIL is indicated as adjunctive therapy in the management of <annotation cui="C0018801">Heart Failure</annotation> in patients who are not responding adequately to diuretics and digitalis. <br> <br> <div> <annotation cui="C0155626">Acute Myocardial Infarction</annotation> </div> ZESTRIL is indicated for the treatment of hemodynamically stable patients within 24 hours of <annotation cui="C0155626">Acute Myocardial Infarction</annotation>, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. <br> <br> In using ZESTRIL, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that ZESTRIL does not have a similar risk (See WARNINGS ). <br> <br> In considering the use of ZESTRIL, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non Blacks. In addition, ACE inhibitors have been associated with a higher rate of angioedema in Black than in non Black patients (See WARNINGS , Anaphylactoid and Possibly Related Reactions ). <br> <br> |033c20a9-c298-4185-a48f-0bf8a2ac918a;0e6364a4-6d66-4151-8197-d45e2a762895;16e335a2-9f78-4bf3-9594-fcb85b04a824;1979fd2a-7e2b-4d9a-9286-1066a0da944c;215516de-ed61-4b68-bf61-db15fa4f76cf;21e8592c-ea81-4604-b694-8e095b046593;234ea375-5df6-4e0e-b3bc-2a08fa5a0b11;27CCB2F4-ABF8-4825-9B05-0BB367B4AC07;29ef155f-59f1-4c3f-8323-3d278f5bcbcb;2d73866f-d2d8-43b2-9797-74f452f23945;30e1c176-c8e1-4b8e-ab8a-1e71afa7226f;316e93cd-fee5-4861-bb03-9ddbcb6bb5ab;3256f7d1-67b1-498b-9647-7d5c6696ca6b;3d6164d7-3083-41c5-a6a6-7e144fe29f7d;3f1be379-943c-4d0c-8478-0adbbdaf5249;43e2c8d1-3704-4323-bcaf-f582572b81f7;46c75a9e-b527-495a-a1b1-dc07cd515939;46f17ba7-a78c-4a9e-7597-27654f097bd3;4ebf9ad0-f03c-401f-a66c-7a6d93bcd290;52b87520-de0b-40fd-bf59-c5bcaccb27c2;56a07381-7c51-4607-8131-f925a20d9074;59fd2167-4da4-9143-83bd-3b6aa5051511;5e3a6976-e6d6-4a3d-87bb-2c716de23506;631825ef-67f4-473a-a2b8-90cb3edfc4df;6490cffe-28e5-434a-9ff0-81cd37cc9f31;6b834a22-009f-47f9-a407-22140b611877;7076fa36-403c-4a2f-8d45-10c0b36b65fc;73d57e3a-d527-4676-acfa-7b4e40070424;7646eb57-7d3a-406d-a1f7-aabf84344be3;78a0fce9-377c-4bca-8e23-aba167087d03;7a9a9434-ac16-480f-972e-684d568bb5b9;8c3dbe03-c6c0-0ac7-b0a6-8d67320f909f;8d418173-0ec3-4684-8708-0cc65edb664b;90d909cf-2976-42d8-aba0-7eb33a88ba43;91da743d-69f2-4d52-afbe-2a9deb001867;958fea43-5dc8-48ef-9d2f-f59d989e3a7d;98f292b0-03d4-4321-9031-94fd9c0b8808;9b73c97f-b898-471f-be8a-96324a3e3b86;9c52ca06-463b-479f-ad14-48f3d57fea14;A4CB25AF-EB0D-4EAE-8452-CD60DDF486FC;a1c30704-69a4-47fa-b948-9fbc38f2ef85;a2b1db6a-3a3e-4d10-b627-3e83c9f52f59;a4158757-6fc8-4e41-a41b-b9af6c925be8;a840cf7e-e9e6-4622-92b1-1e81b4c3bd24;a8ad5c56-0368-fbb5-290d-c32d19b8ab06;ac86ff67-9564-4179-adff-e0d14f45acb4;ad6e2a1c-7c17-4a47-85b1-5dfcbc378e01;b844e3c2-9ff3-40bc-87a8-ff42069ea415;c621c33b-cb67-4ea6-b2bd-96c20a244ea4;c7d18687-9a6b-4d56-8d16-3830ad17cb8d;c7e7d939-8f5c-4443-b6cf-c306e06ddf67;c92bb7dc-b99f-48d0-bc9a-b7f69b1c3d7d;ccdcd2b7-160d-465d-acd4-9002bf86989e;d29730f9-8b34-4c69-82bc-baf2eeb819a7;d46dfc37-6600-3d22-ef29-ca4d1980d8b9;db57a1c8-83d3-4348-85e5-8fe3b950cce5;e2e82277-2dc6-435b-8c79-d2c9375afe1a;e6898cf8-34c8-44d5-8a86-fbe3be847b16;e927801e-5de4-44f9-b543-789c093de655;e9385674-c074-4854-9b5c-655846cd8e09;ed531598-d340-47a8-9406-1d71bec6167c;ee74bf5e-95cc-4b4a-9ebe-2980a7f3230c;f3b5094e-5dcb-48d0-8c1a-c8d2e83a8ad9;f4428c70-aef9-4e37-bc54-32ab7d39c45f;f6f3c339-2c9d-4d07-14a1-6d6c7daf26c6;f867b5c8-0d5c-4dfa-8024-de919b1b6c6e;fd4889db-5565-4a68-ac2e-3eee62ff8353;ff2a36b2-5267-34fe-0c83-c0a31f73f73d;
3142|4a9c6e0e-72dd-4ed4-a8bb-8a6aee506681|BENICAR is indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It may be used alone or in combination with other antihypertensive agents. <br> <br> |370faf80-e054-4b14-b4b3-a7b32d61a4ac;4a9c6e0e-72dd-4ed4-a8bb-8a6aee506681;8c07a4af-dd56-40e4-bd27-dcc0112f6f99;b91de288-ed7b-4b8d-b4d8-b84055bd501a;d4b8a490-d96f-414e-b020-9460625c40ef;
3365|f5174611-2734-4610-b12f-eb5a7f39d7b6| <b> <annotation cui="C0019360">Herpes Zoster</annotation> Infections </b> acyclovir is indicated for the acute treatment of <annotation cui="C0019360">Herpes Zoster</annotation> (<annotation cui="C0019360">shingles</annotation>). <br> <b> <annotation cui="C0019342">Genital Herpes</annotation> </b> acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of <annotation cui="C0019342">Genital Herpes</annotation>. <br> <b> <annotation cui="C0008049">Chickenpox</annotation> </b> acyclovir is indicated for the treatment of <annotation cui="C0008049">Chickenpox</annotation> (<annotation cui="C0008049">varicella</annotation>). <br> <br> |053c1056-b85d-4954-8690-ebdfb09c7f9b;0a1eb087-50a2-441a-a3fe-3d93e31fe39f;12EA5042-8EA6-4EE9-A734-684A73EDB373;1a7332f2-c91d-447a-aecc-411ecb53dc44;1dd310b2-9697-464d-8fee-20d909c367ac;2765bc8d-787f-4a04-b120-b6fbb086dba9;2f9d7db0-6dee-47b6-be50-9192204daf4d;303c1dba-7c14-4fc9-9e87-a9b705168491;3b80d222-4d88-4ddd-afbf-8f316e9463d5;407bcc5d-d2a7-4258-bc96-7d162de00636;41bea43a-f58c-2c6f-4d31-406ceb456077;4cfd7e94-6691-46ca-8c66-afb370ff372e;62bdcf22-51f3-4c81-9bd4-a2dc48bec580;6403db5e-67d9-7f53-d2e2-0a0d601ca4e1;6e203fa9-ee97-1e08-8d6a-fb57cfa13e19;7008d09b-c551-4851-b131-cf1e785c944e;70894da8-4669-4847-b1d6-590a4bfad9b7;7fdeb609-24c4-5024-52c3-6a32bc7f3fcc;8b2f3919-d473-4c45-9c04-129a8c4fc69a;8e380021-c3d3-460b-b877-f3c0a3b53090;A88D64EF-E6C9-4DE0-B1FC-39C76EC4BD0C;AB044C63-96B6-4B02-86CB-E1B93C59EB63;a2db7131-bf31-47bf-bf61-594f919af1f2;a68e610a-841c-4b69-9233-673d060561e8;adb392a7-589e-40ae-b644-12b6364d0aad;b1d5cf4f-f41d-4fa2-baf6-e40fab677440;bdee576a-24bf-41a0-b948-e4c8a33cc8d0;bf1e7864-07c5-4c2c-a075-fad00612ee2a;c48d04a4-e8ca-4948-a2ff-b45ea44b49b0;cc9c128a-1c84-4078-9182-c01cbd7a0040;d13b8cdd-59fd-472b-8125-a19f42ef5402;d7e62753-9165-34f1-59d7-f639b8dc1b39;dcc29902-1fe6-4713-947e-335503959464;de024b17-89ed-4480-92a6-4e287c813fdc;e428cc2a-0319-4e32-8f09-c1cc104c72f6;e947e72f-b5e1-4a5a-a7f6-58c2c8a387cb;f0d8278e-f521-451b-9093-16571eccd284;f3cbd634-77c8-3306-bdbd-a4598b20603e;f5174611-2734-4610-b12f-eb5a7f39d7b6;f7c4592e-205a-493a-857a-62f32d75176c;f94a46a2-2e86-4d98-ec89-9483a41d290a;ffa99978-6b66-49ab-9bd2-8ef6f6846cd7;
4354|c76c3c6f-c3e0-4e35-ab01-5468585e0d9d| Dipyridamole is a coronary vasodilator and is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of <annotation cui="C1956346">coronary artery disease</annotation> in patients who cannot exercise adequately <br> <br> |c76c3c6f-c3e0-4e35-ab01-5468585e0d9d;
4798|2aa98b7c-ce62-41c0-90a7-091bb9599c7a| <div> <annotation cui="C0020538">Hypertension</annotation> </div> Ramipril capsules are indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. They may be used alone or in combination with thiazide diuretics. <br> <br> <div> <annotation cui="C0018802">Heart Failure</annotation> Post <annotation cui="C0027051">Myocardial Infarction</annotation> </div> Ramipril capsules are indicated in stable patients who have demonstrated clinical signs of <annotation cui="C0018802">congestive heart failure</annotation> within the first few days after sustaining acute myocardial infarction. Administration of ramipril capsules to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure related hospitalization and progression to severe resistant <annotation cui="C0018802">Heart Failure</annotation> [ <i> see Clinical Studies ( 14.3 ) </i> ]. <br> <br> |2aa98b7c-ce62-41c0-90a7-091bb9599c7a;
640|ecd69437-dd1a-453b-991d-5c5f277a3abd| Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as <annotation cui="C0009766">allergic conjunctivitis</annotation>, <annotation cui="C0035854">acne rosacea</annotation>, <annotation cui="C0259799">superficial punctate keratitis</annotation>, <annotation cui="C0153027">herpes zoster keratitis</annotation>, <annotation cui="C0022081">iritis</annotation>, <annotation cui="C0010543">cyclitis</annotation>, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in <annotation cui="C0013604">edema</annotation> and <annotation cui="C0021368">inflammation</annotation>; <annotation cui="C0339289">corneal injury</annotation> from chemical, radiation, or thermal burns, or penetration of foreign bodies. <br> <br> |0de5bcce-0cc2-4b49-bd0d-714f1c7ec3bf;580b36d2-1400-4096-aff1-cbc1f6d0ad4c;6bdcefbe-51e3-4ca4-afda-5aeca7b6fa73;a0aa9dc9-265c-4dd6-9b03-276a47217839;a2c2385e-74a8-4a18-92ec-be8a1380e13a;b61aec30-66c0-4abe-a8ad-2d98d88f21b8;c7700945-e498-4f01-9719-83cee899860d;d51402de-6021-4dc0-86ed-328d159af4f8;de0c3d8a-8115-4283-b420-018282195684;ea3ddaa3-bd52-4160-9991-f17eda28f3d5;ecd69437-dd1a-453b-991d-5c5f277a3abd;
6611|8D589FED-78C4-41F8-3F89-468A367A6C79|Dipyridamole injection is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of <annotation cui="C1956346">coronary artery disease</annotation> in patients who cannot exercise adequately. <br> <br> In a study of about 1100 patients who underwent coronary arteriography and dipyridamole injection assisted thallium imaging, the results of both tests were interpreted blindly and the sensitivity and specificity of the dipyridamole thallium study in predicting the angiographic outcome were calculated. The sensitivity of the dipyridamole test (true positive dipyridamole divided by the total number of patients with positive angiography) was about 85%. The specificity (true negative divided by the number of patients with negative angiograms) was about 50%. <br> <br> In a subset of patients who had exercise thallium imaging as well as dipyridamole thallium imaging, sensitivity and specificity of the two tests was almost identical. <br> <br> |02e40b4e-80bb-4456-9d16-6f8a2f7ec5f0;6093dcd9-82d2-414f-8507-eda22c14f626;8D589FED-78C4-41F8-3F89-468A367A6C79;af761b27-1df6-4d2f-a621-8b9950538e1c;
7108|421cf8e0-ef59-4a19-9d1c-e1ec6596f32b| Dextroamphetamine sulfate is indicated <br> <br> <b> In <annotation cui="C0027404">Narcolepsy</annotation>. </b> <br> <br> <b> In <annotation cui="C1263846">Attention Deficit Disorder with Hyperactivity</annotation> </b> , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. <br> <br> |421cf8e0-ef59-4a19-9d1c-e1ec6596f32b;5bc88dc0-b6b2-4c3f-8ecb-03e41b085e1d;6b8c97ac-c83c-4a1f-a33c-121239253abf;967951a7-cb68-45b5-b94d-1aad5b0cd025;BD31F331-DBAE-4908-955C-AB817E97DD3C;Bed3c03f4-2829-423f-a595-dc09c9cc0e40;b2ad8d2b-ed94-43cd-95ea-85e91d997f26;e05cf690-d45a-4696-a1bf-40c9350cc084;ec2d13f3-d14f-47e4-abe9-7763f95a8e94;
7610|9d008401-4746-4dc5-94ab-4462f959fb73| <div> <annotation cui="C0020538">Hypertension</annotation> </div> Ramipril capsules USP are indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. It may be used alone or in combination with thiazide diuretics. <br> <br> <div> Reduction in the Risk of <annotation cui="C0027051">Myocardial Infarction</annotation>, <annotation cui="C0038454">Stroke</annotation>, and Death from Cardiovascular Causes </div> Ramipril capsules USP are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, <annotation cui="C0038454">Stroke</annotation>, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of <annotation cui="C0027051">Myocardial Infarction</annotation>, <annotation cui="C0038454">Stroke</annotation>, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet, or lipid lowering therapy) [see <i> Clinical Studies ( 14.2 ) </i> ]. <br> <br> |06fff633-04cb-4217-a9c5-e6337fc90f82;0fc34cd8-86e6-4034-73bd-4263a68ba046;36b586cc-94f5-5264-6eb3-569c7356b24b;9d008401-4746-4dc5-94ab-4462f959fb73;ef252592-017a-4e57-92bc-d03994241e85;
8091|c9b57101-2455-463d-b8d7-b2316cecd67a| <div> <annotation cui="C1269683">Major Depressive Disorder</annotation> </div> <b> </b> Paroxetine is indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation>. <br> <br> The efficacy of paroxetine <i> </i> in the treatment of a <annotation cui="C0024517">major depressive episode</annotation> was established in 6 week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM III category of <annotation cui="C1269683">Major Depressive Disorder</annotation> (see CLINICAL PHARMACOLOGY Clinical Trials). A <annotation cui="C0024517">major depressive episode</annotation> implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms Change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. <br> <br> The effects of paroxetine in hospitalized depressed patients have not been adequately studied. <br> <br> The efficacy of paroxetine in maintaining a response in <annotation cui="C1269683">Major Depressive Disorder</annotation> for up to 1 year was demonstrated in a placebo controlled trial (see CLINICAL PHARMACOLOGY Clinical Trials). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient. <br> <br> <br> <br> <div> <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> </div> <b> </b> Paroxetine is indicated for the treatment of obsessions and compulsions in patients with <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> (<annotation cui="C0028768">OCD</annotation>) as defined in the DSM IV. The obsessions or compulsions cause marked distress, are time consuming, or significantly interfere with social or occupational functioning. <br> <br> The efficacy of paroxetine was established in two 12 week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM IIIR category of <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> (see CLINICAL PHARMACOLOGY Clinical Trials). <br> <br> <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego dystonic and or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. <br> <br> Long term maintenance of efficacy was demonstrated in a 6 month relapse prevention trial. In this trial, patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY Clinical Trials). Nevertheless, the physician who elects to use paroxetine <i> </i> for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). <br> <br> <br> <br> <div> <annotation cui="C0030319">Panic Disorder</annotation> </div> <b> </b> Paroxetine is indicated for the treatment of <annotation cui="C0030319">Panic Disorder</annotation>, with or without agoraphobia, as defined in DSM IV. <annotation cui="C0030319">Panic Disorder</annotation> is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and or a significant change in behavior related to the attacks. <br> <br> The efficacy of paroxetine was established in three 10  to 12 week trials in <annotation cui="C0030319">Panic Disorder</annotation> patients whose diagnoses corresponded to the DSM IIIR category of <annotation cui="C0030319">Panic Disorder</annotation> (see CLINICAL PHARMACOLOGY Clinical Trials). <br> <br> <annotation cui="C0030319">Panic Disorder</annotation> (DSM IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. <br> <br> Long term maintenance of efficacy was demonstrated in a 3 month relapse prevention trial. In this trial, patients with <annotation cui="C0030319">Panic Disorder</annotation> assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY Clinical Trials). Nevertheless, the physician who prescribes paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient. <br> <br> <br> <br>  <div> <annotation cui="C0031572">Social Anxiety Disorder</annotation> </div> <b> </b> Paroxetine is indicated for the treatment of <annotation cui="C0031572">Social Anxiety Disorder</annotation>, also known as <annotation cui="C0031572">social phobia</annotation>, as defined in DSM IV (300.23). <annotation cui="C0031572">Social Anxiety Disorder</annotation> is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. <br> <br> The efficacy of paroxetine was established in three 12 week trials in adult patients with <annotation cui="C0031572">Social Anxiety Disorder</annotation> (DSM IV). Paroxetine has not been studied in children or adolescents with <annotation cui="C0031572">social phobia</annotation> (see CLINICAL PHARMACOLOGY Clinical Trials). <br> <br> The effectiveness of paroxetine in long term treatment of <annotation cui="C0031572">Social Anxiety Disorder</annotation>, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well controlled trials. Therefore, the physician who elects to prescribe paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). <br> <br> <br> <br> <div> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> </div> <b> </b> Paroxetine is indicated for the treatment of <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (<annotation cui="C0270549">GAD</annotation>), as defined in DSM IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <br> The efficacy of paroxetine in the treatment of <annotation cui="C0270549">GAD</annotation> was established in two 8 week placebo controlled trials in adults with <annotation cui="C0270549">GAD</annotation>. Paroxetine has not been studied in children or adolescents with <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (see CLINICAL PHARMACOLOGY Clinical Trials). <br> <br> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (DSM IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms Restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. <br> <br> The efficacy of paroxetine in maintaining a response in patients with <annotation cui="C0270549">Generalized Anxiety Disorder</annotation>, who responded during an 8 week acute treatment phase while taking paroxetine and were then observed for relapse during a period of up to 24 weeks, was demonstrated in a placebo controlled trial (see CLINICAL PHARMACOLOGY Clinical Trials). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). <br> <br> <br> <br> |027c7db2-2a36-477f-90bf-608ff3a0e14e;040d8193-0ca7-33cd-e300-44bb5b5ee0e4;07f245c5-fcb0-3008-d69e-10290cadbfa6;08320ea3-8f93-6f04-5d1c-f69af3eb5a81;087ff0d3-1761-47ea-a8c1-7c4cb679af97;0a580de2-95d2-49b6-a1e2-6daf70f1f8c8;0d4fb45b-e45b-4519-96a3-a8a106450f87;0fb2e3cc-b9b5-48a6-b487-1e558dfd56db;16348d76-055f-4a7a-9de9-00144c9ee339;21b3b8a2-bfed-4945-954d-6a42ea61888f;326e8ab0-6886-4749-9544-885b37070051;32fd11aa-2996-496d-ac3b-76a6afe22e3c;40226242-da82-4dd7-bca2-eebb14501264;40dcf270-64bb-bca0-db08-6b233a3430f8;42646d8c-2c00-4575-b215-bad0789a1ce0;450eb95f-7650-4050-9d7b-4c68d7a16fa3;49d3b871-f9fd-4d58-8405-8682c0c6e238;4a765347-d687-4af1-a33f-fbff972c6252;555c3588-1fc0-490b-8ccf-bee553b0496a;590CD4BB-C1BD-4CF1-893A-1E418621EED4;605c1d23-c97c-4ea4-92d0-fed351de9d2e;619e10bb-6e5d-4ec3-a85a-6270965f5389;65ee7ef8-cc68-41d1-cc8b-c01a056409a9;6c47a65b-2665-4391-ad69-25c4f5a8b010;6c4d4603-190a-496f-a40f-bc09853b9820;6d5fcdb2-4d84-4b20-87e3-58a43e567500;7b9e9d36-9b7d-4d47-8d8a-d37da85e7b24;821309e9-249a-4eac-a20c-e1d9978a82d7;84b1b1f0-d375-4fda-99af-9487f8ef50c7;8725c835-443a-474a-98b9-7d23991a161f;89dd7e24-85fc-4152-89ea-47ec2b48a1ed;922d17f7-58c7-7b82-5f80-b808a9db5da2;9eaec71a-3641-4afd-8d92-91c89d9a6edd;a6bb4f0a-1555-4550-a7a4-99609674b1e7;a73cf8ee-f99b-4972-8939-0d394a527134;a93796a3-56fc-4af6-99ba-f76707c32e5d;b0edc273-fd24-46b4-9e30-ee01277ef98f;b5a8f864-a53d-48d9-aca6-6b64017fb168;beb15c4c-9ad8-4fa4-d28c-cef6ed9871b5;c0acc97d-3d8d-4a7f-8acd-99050b0af2f1;c34e9941-34e8-484f-8f67-829f7cde8642;c702df3b-584f-4a8e-8554-aa611e18ac4f;c9b57101-2455-463d-b8d7-b2316cecd67a;d8a896c2-b0c2-4b44-a4e3-cb6a8ea472ee;e1ea4019-bb66-403c-a3d5-6ae056a59116;e63fe922-b35a-406c-8737-f3f5e6d5a30d;ea2e434b-c25a-4761-a81c-a4a1a0e0d579;f235ee45-9517-45de-8df7-9a06fdb43380;ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7;
8400|ca68879c-0214-4d7c-93b0-bdaf8ef23f8e| PERSANTINE tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of <annotation cui="C0032787">postoperative thromboembolic complications</annotation> of cardiac valve replacement. <br> <br> |004bada0-dbf7-4a94-8792-6833d7eeda2b;0146650f-d6e6-4a9c-8925-415b3c92b0e7;1b82871b-f60b-4485-9a45-026aeb18b484;1d27873f-b29b-4873-954b-bf50544981e7;312aadb1-435c-4aa7-8e46-6506cedacaa0;5ba4d60d-0715-40db-b3f0-1e9d69a29f28;5dab2bdc-8e4c-450a-8a57-7581584e8bd8;93ba8d29-1ac7-fe80-b571-f8c6617c1d49;a18b2af5-7c4a-4b7f-92c7-8a76e34da373;ae7585ec-1280-40fe-b888-613b8a0e6ef6;bb13afb5-d582-40bd-a266-71f2b99e6797;ca68879c-0214-4d7c-93b0-bdaf8ef23f8e;cc41deca-c10f-437d-b639-e5875712f168;dcf785b2-e923-43bf-93bb-00a9501479f4;
8691|1ff30eb1-95a6-437e-a618-297891c0c03d| <div> <annotation cui="C0020473">Hyperlipidemia</annotation> and Mixed <annotation cui="C0242339">Dyslipidemia</annotation> </div> CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total C, LDL C, ApoB, nonHDL C, and triglycerides and to increase HDL C in adult patients with primary <annotation cui="C0020473">Hyperlipidemia</annotation> or mixed <annotation cui="C0242339">Dyslipidemia</annotation>. Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non pharmacological interventions alone has been inadequate. <br> <br> <div> <annotation cui="C0020557">Hypertriglyceridemia</annotation> </div> CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with <annotation cui="C0020557">Hypertriglyceridemia</annotation>. <br> <br> <div> <annotation cui="C0020479">Primary Dysbetalipoproteinemia</annotation> (<annotation cui="C0020479">Type III Hyperlipoproteinemia</annotation>) </div> CRESTOR is indicated as an adjunct to diet for the treatment of patients with <annotation cui="C0020479">Primary Dysbetalipoproteinemia</annotation> (<annotation cui="C0020479">Type III Hyperlipoproteinemia</annotation>). <br> <br> <div> Homozygous <annotation cui="C0020445">Familial Hypercholesterolemia</annotation> </div> CRESTOR is indicated as adjunctive therapy to other lipid lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL C, Total C, and ApoB in adult patients with homozygous <annotation cui="C0020445">Familial Hypercholesterolemia</annotation>. <br> <br> <div> Slowing of the Progression of <annotation cui="C0004153">Atherosclerosis</annotation> </div> CRESTOR is indicated as adjunctive therapy to diet to slow the progression of <annotation cui="C0004153">Atherosclerosis</annotation> in adult patients as part of a treatment strategy to lower Total C and LDL C to target levels. <br> <br> <div> Limitations of Use </div> The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. <br> <br> CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. <br> <br> |1a69848d-95d7-41e8-a3a0-aa5367d4f03b;1ff30eb1-95a6-437e-a618-297891c0c03d;4f2f91bb-f119-4e29-8499-f36f436707b3;5dfefed9-5b84-41f7-a8a4-e118f9518d3e;778b1225-3c5d-4683-9888-8b3306a6e49d;a16450f1-77ea-4017-b4ed-a3c5401f9dbf;ab9f816e-df48-4d90-b8ca-98477659531a;bb0f3b5e-4bc6-41c9-66b9-6257e2513512;c5f46f1b-3594-4ff4-b208-a7b9f830e87e;fa54df87-41d5-96a7-07b6-e700b640bc66;
8742|79b15110-e484-4b84-8947-15653746773c|Diethylpropion hydrochloride tablets are indicated in the management of <annotation cui="C1281429">exogenous obesity</annotation> as a short term adjunct (a few weeks) in a regiment of weight reduction based on caloric restriction. The usefulness of agents of this class should be measured against possible risk factors inherent in their use such as those described (see CLINICAL PHARMACOLOGY ). <br> <br> |79b15110-e484-4b84-8947-15653746773c;
8838|93ddb778-854f-4486-adca-4c5f9071a741| <div> <b> 1.1 </b> <b> Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML </b> <b> ) </b> </div> Newly diagnosed adult and pediatric patients with <annotation cui="C0279543">Philadelphia chromosome positive chronic myeloid leukemia</annotation> in chronic phase. <br> <br> <div> <b> Ph+ CML in <annotation cui="C0005699">blast crisis</annotation> (<annotation cui="C0005699">BC</annotation>), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon alpha (IFN) Therapy </b> </div> Patients with <annotation cui="C0279543">Philadelphia chromosome positive chronic myeloid leukemia</annotation> in <annotation cui="C0005699">blast crisis</annotation>, accelerated phase, or in chronic phase after failure of interferon alpha therapy. <br> <br> <div> <b> <annotation cui="C1960397">Ph+ Acute lymphoblastic leukemia</annotation> (ALL) </b> </div> Adult patients with relapsed or refractory <annotation cui="C1960397">Philadelphia chromosome positive acute lymphoblastic leukemia</annotation>. <br> <br> <div> <b> M </b> <b> yelodysplastic Myeloproliferative Diseases ( </b> <b> MDS MPD </b> <b> ) </b> </div> Adult patients with <annotation cui="C1301355">myelodysplastic myeloproliferative diseases</annotation> associated with PDGFR (platelet derived growth factor receptor) gene re arrangements. <br> <br> <div> <b> 1.5 </b> <b> <annotation cui="C1112486">aggressive systemic mastocytosis</annotation> (<annotation cui="C1112486">ASM</annotation>) </b> </div> Adult patients with <annotation cui="C1112486">aggressive systemic mastocytosis</annotation> without the D816V c Kit mutation or with c Kit mutational status unknown. <br> <br> <div> <b> <annotation cui="C0346421">hypereosinophilic syndrome</annotation> (<annotation cui="C0346421">HES</annotation>) and or <annotation cui="C0346421">chronic eosinophilic leukemia</annotation> (<annotation cui="C0346421">CEL</annotation>) </b> </div> Adult patients with <annotation cui="C0346421">hypereosinophilic syndrome</annotation> and or <annotation cui="C0346421">chronic eosinophilic leukemia</annotation> who have the FIP1L1 PDGFR fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and or <annotation cui="C0346421">CEL</annotation> who are FIP1L1 PDGFR fusion kinase negative or unknown. <br> <br> <div> <b> <annotation cui="C0392784">Dermatofibrosarcoma Protuberans</annotation> (<annotation cui="C0392784">DFSP</annotation>) </b> </div> Adult patients with unresectable, recurrent and or <annotation cui="C0392784">metastatic dermatofibrosarcoma protuberans</annotation>. <br> <br> <div> <b> Kit+ </b> <b> <annotation cui="C0238198">gastrointestinal stromal tumors</annotation> (<annotation cui="C0238198">GIST</annotation>) </b> </div> Patients with Kit (CD117) positive unresectable and or metastatic malignant <annotation cui="C0238198">gastrointestinal stromal tumors</annotation>. <br> <br> <div> <b> Adjuvant Treatment of <annotation cui="C0238198">GIST</annotation> </b> </div> Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive <annotation cui="C0238198">GIST</annotation>. <br> <br> |211ef2da-2868-4a77-8055-1cb2cd78e24b;93ddb778-854f-4486-adca-4c5f9071a741;
9385|5fa97bf5-28a2-48f1-8955-f56012d296be| <div> <annotation cui="C0026764">Multiple Myeloma</annotation> </div> REVLIMIDin combination with dexamethasone is indicated for the treatment of patients with <annotation cui="C0026764">Multiple Myeloma</annotation> (<annotation cui="C0026764">MM</annotation>) who have received at least one prior therapy. <br> <br> <div> <annotation cui="C0026986">Myelodysplastic Syndromes</annotation> </div> REVLIMIDis indicated for the treatment of patients with transfusion dependent <annotation cui="C0002871">anemia</annotation> due to low  or intermediate 1 risk <annotation cui="C0026986">Myelodysplastic Syndromes</annotation> (<annotation cui="C0026986">MDS</annotation>) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. <br> <br> |5fa97bf5-28a2-48f1-8955-f56012d296be;
9410|19ebf09d-cf0d-4744-a874-a3a9f0b624b4| PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows <br> <br> <ol><li> Recent <annotation cui="C0027051">MI</annotation>, Recent <annotation cui="C0038454">Stroke</annotation> or Established <annotation cui="C1704436">Peripheral Arterial Disease</annotation> For patients with a history of recent <annotation cui="C0027051">myocardial infarction</annotation> (<annotation cui="C0027051">MI</annotation>), recent <annotation cui="C0038454">Stroke</annotation>, or established <annotation cui="C1704436">Peripheral Arterial Disease</annotation>, PLAVIX has been shown to reduce the rate of a combined endpoint of new <annotation cui="C0948008">ischemic stroke</annotation> (fatal or not), new <annotation cui="C0027051">MI</annotation> (fatal or not), and other vascular death. </li><li> <annotation cui="C0948089">Acute Coronary Syndrome</annotation>  For patients with non ST segment elevation <annotation cui="C0948089">Acute Coronary Syndrome</annotation> (<annotation cui="C0002965">unstable angina</annotation>/non Q wave <annotation cui="C0027051">MI</annotation>) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, <annotation cui="C0027051">MI</annotation>, or <annotation cui="C0038454">Stroke</annotation> as well as the rate of a combined endpoint of cardiovascular death, <annotation cui="C0027051">MI</annotation>, <annotation cui="C0038454">Stroke</annotation>, or refractory <annotation cui="C0022116">ischemia</annotation>.  For patients with ST segment elevation <annotation cui="C0155626">acute myocardial infarction</annotation>, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re infarction or <annotation cui="C0038454">Stroke</annotation>. This benefit is not known to pertain to patients who receive primary angioplasty. </li></ol> |0d3e4f7c-0ce1-4631-a801-e3812f7dd456;19ebf09d-cf0d-4744-a874-a3a9f0b624b4;EDAE8DF1-CAF9-FF72-1304-5AE8B355F8E7;
9459|3e2c9a35-6a39-41d7-ad84-3c0bb8894b09| <div> Adjunctive Therapy </div> LAMICTAL XR is indicated as adjunctive therapy for primary <annotation cui="C0494475">generalized tonic clonic (PGTC) seizures</annotation> and <annotation cui="C0751495">partial onset seizures</annotation> with or without secondary generalization in patients 13 years of age. <br> <br> <div> Monotherapy </div> LAMICTAL XR is indicated for conversion to monotherapy in patients 13 years of age with <annotation cui="C0751495">partial seizures</annotation> who are receiving treatment with a single antiepileptic drug (AED). <br> <br> Safety and effectiveness of LAMICTAL XR have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from two or more concomitant AEDs. <br> <br> <div> Limitation of Use </div> Safety and effectiveness of LAMICTAL XR for use in patients less than 13 years of age have not been established. <br> <br> |3e2c9a35-6a39-41d7-ad84-3c0bb8894b09;
10415|913b6cfe-1fb0-44a8-817a-26374bbce995| Intermezzo (zolpidem tartrate) sublingual tablet is indicated for use as needed for the treatment of <annotation cui="C0917801">insomnia</annotation> when a middle of the night awakening is followed by difficulty returning to sleep. <br> <br> <u> Limitations of Use </u> Intermezzo is not indicated for the treatment of middle of the night <annotation cui="C0917801">insomnia</annotation> when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking. <br> <br> |913b6cfe-1fb0-44a8-817a-26374bbce995;962a2fd0-8337-11dd-ad8b-0800200c9a66;
10615|fbf22eeb-27f5-46aa-be39-5aef43101369| Guanfacine tablets are indicated in the management of <annotation cui="C0020538">hypertension</annotation>. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide type diuretics. <br> <br> |6fdcebac-0a5a-4858-b0e6-87f77ba53bf1;886e050c-dd22-4f35-ac3b-243f091125c3;9FC0BDC2-5BA2-48DD-AA87-7B0050A2D6CE;a81b956b-f004-4426-ba20-375ccf21eb71;d5c505ea-4886-49c8-a965-3ccc43868cc6;e889f164-a92c-412d-960a-59391e4151fe;fbf22eeb-27f5-46aa-be39-5aef43101369;
10939|5d181743-a0fc-4d17-953d-b17a936f9ecc| <div> </div> <i> <annotation cui="C0020538">Hypertension</annotation> </i> <br> <br> VASOTEC is indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. <br> <br> VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive. <br> <br> <div> </div> <i> <annotation cui="C0018802">Heart Failure</annotation> </i> <br> <br> VASOTEC is indicated for the treatment of symptomatic <annotation cui="C0018802">congestive heart failure</annotation>, usually in combination with diuretics and digitalis. In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization (see <b> CLINICAL PHARMACOLOGY, <annotation cui="C0018802">Heart Failure</annotation>, Mortality Trials </b> for details and limitations of survival trials). <br> <br> <div> </div> <i> Asymptomatic <annotation cui="C0242698">Left Ventricular Dysfunction</annotation> </i> <br> <br> In clinically stable asymptomatic patients with <annotation cui="C0242698">Left Ventricular Dysfunction</annotation> (ejection fraction 35 percent), VASOTEC decreases the rate of development of overt <annotation cui="C0018802">Heart Failure</annotation> and decreases the incidence of hospitalization for <annotation cui="C0018802">Heart Failure</annotation> (see <b> CLINICAL PHARMACOLOGY, <annotation cui="C0018802">Heart Failure</annotation>, Mortality Trials </b> for details and limitations of survival trials). <br> <br> In using VASOTEC consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that VASOTEC does not have a similar risk (see <b> WARNINGS </b> ). <br> <br> In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non blacks (see <b> WARNINGS, Head and Neck Angioedema </b> ). <br> <br> |05c12da2-8814-4afd-bec0-30cf4cdd2b33;08f90170-f53c-4272-92ae-951cf115e271;165703a0-16d0-b7ff-5b66-88f1f7fa0600;23bd6b87-db93-4614-a394-4aa8566ebfb0;27c971a9-5c54-4085-be89-c85e84317294;2B9B72F5-EF3D-8401-BB91-9B75F80A1809;2a6f5fe2-add6-4c6d-b07c-ce707bf49203;308d6011-cffd-49d3-85d1-251dfe77cf5d;34f1c417-40c5-41b6-978c-b57689fe7f3f;39631f1f-5d19-43c1-b504-bf56d991ed97;53ac99fe-8ff3-4a6f-b90e-d602e1019acb;5bfdf9b3-7e3a-4153-a0b8-2f5cc514a16b;5cc4f6f0-8925-81e1-b210-b5a4509a25a9;5d181743-a0fc-4d17-953d-b17a936f9ecc;66234596-162c-4a33-b87e-635839655654;66f5c697-4daa-4b5f-8ee2-40fc70960459;6c8d1720-4129-4d96-b037-b0b82b2d1f2e;78d80ec5-5283-47b5-85bd-315372ef60d9;8abc2534-c20f-4344-8d29-c52b0bfd76b8;AC0289A6-9533-4F8C-B46C-506DCE1B90B5;F103B9F9-E081-419D-A2D8-B86ACDA834DD;bad08ec8-7f9e-47b6-83b9-437e0191080f;d41d6d19-086c-4e17-814c-6fd6f3e81e24;d42cd274-ee43-4be7-b006-24dce0fb6cf6;d59a23ba-9e28-42a3-8bfe-a3742fdfdebe;dd7f12a7-7fe5-470b-b151-6ccf19945638;e31289f1-4b59-418a-a893-c748ce073f6c;e7a26859-167b-48c8-bd36-03ac8191465c;f1ec6ac1-6b94-40bb-a329-9056f201090c;
11094|cd742c16-c003-4c4c-8fa0-a3b4d0158383| <div> <annotation cui="C0036341">Schizophrenia</annotation> </div> <i> Adults </i> Risperidone Oral Solution is indicated for the acute and maintenance treatment of <annotation cui="C0036341">Schizophrenia</annotation> [see 14.1 CLINICAL STUDIES ]. <br> <br> <i> Adolescents Due to Janssen Pharmaceuticals Corporation s marketing exclusivity rights, </i> <i> this drug product is not labeled for use in pediatric patients with <annotation cui="C0036341">Schizophrenia</annotation>. Pediatric use </i> <i> information for the treatment of pediatric patients with <annotation cui="C0036341">Schizophrenia</annotation>, 13 to 17 years of age, is </i> <i> approved for Janssen Pharmaceuticals Corporation s risperidone drug products. </i> <br> <br> <div> Bipolar <annotation cui="C0338831">Mania</annotation> </div> <i> Monotherapy   Adults and Pediatrics </i> Risperidone Oral Solution is indicated for the short term treatment of acute <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> in adults [see 14.2 CLINICAL STUDIES ]. <br> <br> <i> Due to Janssen Pharmaceuticals Corporation s marketing exclusivity rights, this drug product </i> <i> is not labeled for use in pediatric patients with bipolar <annotation cui="C0338831">Mania</annotation>. Pediatric use information for </i> <i> the treatment of pediatric patients with bipolar <annotation cui="C0338831">Mania</annotation>, 10 to 17 years of age, is approved for Janssen Pharmaceuticals Corporation s risperidone drug products. </i> <br> <br> <i> Combination Therapy   Adults </i> The combination of Risperidone Oral Solution with lithium or valproate is indicated for the short term treatment of acute <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> in adults [see 14.3 CLINICAL STUDIES ]. <br> <br> <div> Irritability Associated with <annotation cui="C0004352">Autistic Disorder</annotation> </div> <i> Pediatrics Due to Janssen Pharmaceuticals Corporation s marketing exclusivity rights, this </i> <i> drug product is not labeled for use in pediatric patients with irritability associated with autistic </i> <i> Information regarding the treatment of pediatric patients with irritability associated </i> <i> with <annotation cui="C0004352">Autistic Disorder</annotation>, 5 to 16 years of age, is approved for Janssen Pharmaceuticals </i> <i> Corporation s risperidone drug products. </i> <br> <br> |cd742c16-c003-4c4c-8fa0-a3b4d0158383;
1111|7e117c7e-02fc-4343-92a1-230061dfc5e0| <div> <annotation cui="C0036341">Schizophrenia</annotation> </div> RISPERDAL (risperidone) is indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation>. Efficacy was established in 4 short term trials in adults, 2 short term trials in adolescents (ages 13 to 17 years), and one long term maintenance trial in adults <i> [see </i> <i> Clinical Studies (14.1) ] </i> . <br> <br> <div> Bipolar <annotation cui="C0338831">Mania</annotation> </div> <u> Monotherapy </u> <br> <br> RISPERDAL is indicated for the treatment of acute <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>. Efficacy was established in 2 short term trials in adults and one short term trial in children and adolescents (ages 10 to 17 years) <i> [see </i> <i> Clinical Studies (14.2) ] </i> . <br> <br> <u> Adjunctive Therapy </u> <br> <br> RISPERDAL adjunctive therapy with lithium or valproate is indicated for the treatment of acute <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>. Efficacy was established in one short term trial in adults <i> [see </i> <i> Clinical Studies (14.3) ] </i> . <br> <br> <div> Irritability Associated with <annotation cui="C0004352">Autistic Disorder</annotation> </div> RISPERDAL is indicated for the treatment of irritability associated with <annotation cui="C0004352">Autistic Disorder</annotation>, including symptoms of aggression towards others, deliberate self injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short term trials in children and adolescents (ages 5 to 17 years) <i> [see </i> <i> Clinical Studies (14.4) ] </i> . <br> <br> |01859e07-1262-4cc6-b7ed-5a273cbf0c36;1522f0b9-2bbc-4785-bada-fa6ae7986bb4;1c3250f3-d291-4280-97d5-da3bb171e2b6;1c572c5b-24f6-46c6-bdd2-6774ebefbb42;1f21097c-7d48-47e5-ab09-8dc7f7e06e9d;1fd9de6d-783b-47f3-b2b7-cb633b939494;23993d21-80bf-41c4-b57d-88a620173b6b;267b6670-15c7-4425-8463-593210ed7932;2c62c65f-527e-44ed-8491-30db3eb8b902;2e5c6b7f-1d57-4114-9067-79dca009c4cc;2e8fb017-8754-421a-a76a-c41b8f48070b;44df7cdc-fa24-4e52-800b-63589cf49706;4770e42e-9ce7-42e0-a880-0908df244606;47cb9a03-7946-4142-b97b-be035dc51f7d;51b65970-02e6-4558-a4b3-38e56e0c073c;53a18eb5-4be6-40ac-aabe-d9290b483b22;5958bb43-6967-4f15-9bd1-7f06340527ff;5eadda0e-faf8-4b3c-851e-da5a5a127242;5f0bdf9d-fa78-45e8-913a-81beff57cf34;601dffbd-5987-4786-92af-853f7e60062e;69432e5f-cd08-4709-989c-841510ed001c;69d0449f-95ba-dbf6-efde-6b80edee7bad;6afd70a6-fe7b-4096-894e-86c89c3b463f;701e1cd8-2868-4d29-85a9-a2212c88165f;7073b706-1946-4ff2-8788-fb9452a59cae;713b5ac7-53d6-4139-8599-3028f789de4b;739dcf8a-ed73-5eb0-899b-7e51cb73c335;7d27c65e-b60b-4f83-a01a-02dc67f61a8b;7dd7b01a-298a-4e24-a91f-927834bda5fb;7e117c7e-02fc-4343-92a1-230061dfc5e0;82effea8-5782-4aa5-969e-b635423ae3c6;884f8f5d-a710-4896-91de-20b3f0b4134c;CB157743-E18D-F030-3EA3-813FBCD73851;a6008865-7f09-c535-f031-a6a9f40b5ff4;a6347895-5f16-43b4-92a0-b9904ac81937;a75272a5-4af8-4cc8-b718-c4926262c457;b1174730-7a95-4bf6-a425-a5bc1836a17a;b45ceaaa-1236-493a-98c1-43df2f4a08f5;b7e18194-8d57-473d-904c-bb2e576c132b;b939e746-6b5f-ae82-c5f4-79cfdf6253ea;c00809e1-e632-f246-97d9-73e1f9804587;c0c3eeb6-8a75-0b20-2008-396e63cddcdb;c4582bdf-5eda-438c-98b4-0517500501e8;caa123c0-462e-463f-a831-671783febfa9;cc52e339-0d3e-43c5-b0d5-be2bbbad931f;d0708534-89cb-4c2c-a076-c19e7f57ffcf;d0ef6df3-67e5-47b1-bcf7-f67aa030caca;daf11e04-d69c-4aaa-80e6-a4bac692736c;dce4437a-bf43-483c-8db2-5eb58fa8a559;dd1c68bd-abba-45b3-9c3c-586d77c18853;e5407ed7-794c-401c-9a5d-b221722aa22f;e5ec2af6-7777-4dc2-9cea-eefc2629d5ad;e72a2768-815f-47bf-b2f9-16a93dd10684;e812ad55-29ed-49b4-b81b-a789194de228;e92a97ef-0fe3-40b1-a938-373293a75255;ea914046-6cc2-4c7b-b12b-76c31bb18def;eb701085-3646-4129-ab01-561e4ef1ca8b;f0c765e9-edc1-4944-a4e6-91b82a29a8d7;f11dae15-b057-4258-9229-3819d0c980fe;f2e8b588-fae5-476a-b7c5-f27e72db56e3;f91f551e-926f-440d-83d2-357e9d7484fe;f9e04064-6b9e-4209-8149-8761f29d1cec;
11190|a0353c10-48c9-4d2a-8047-56ea68ace956| For the treatment of superficial <annotation cui="C0015403">ocular infections</annotation> involving the conjunctiva and or cornea caused by organisms susceptible to erythromycin. <br> <br> For prophylaxis of <annotation cui="C0029076">ophthalmia neonatorum</annotation> due to <i> gonorrhoeae </i> or <i> trachomatis </i> . <br> <br> The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase producing <i> N.gonorrhoeae </i> is not established. <br> <br> For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. <br> <br> |061ddd20-94a6-4e3c-ba84-1ebd8529eea6;1df120f1-778b-4682-9536-2919b782b074;37fcdb6e-2a9b-464f-9a0e-d3ca323fcb7a;95b15fd3-84e3-4d27-8744-b56af5e265a0;9b1c6c13-4562-4c8e-a8bb-42493dc5cadb;a0353c10-48c9-4d2a-8047-56ea68ace956;b440cf4c-9d56-4044-9895-1e27df124d06;c7a804bc-dac8-47dc-b7a8-8f2d384652f2;d8b0abac-c32c-4bd0-8247-5c6d6a9fd17f;dc3ee55d-114e-44f2-adb2-fb0c24eba732;e453b459-9aa7-4873-9b62-340a81aa050b;f6a27461-5995-460f-8ae0-4461175be1f0;fd185704-9d91-4999-8c87-bd3cb5085e15;
11318|a5e5413d-bc22-4ae1-959b-0eb0430dbd38| Misoprostol is indicated for reducing the risk of NSAID (nonsteroidal anti inflammatory drugs, including aspirin) induced <annotation cui="C0038358">gastric ulcers</annotation> in patients at high risk of complications from <annotation cui="C0038358">gastric ulcer</annotation>, eg, the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of <annotation cui="C0038358">gastric ulcers</annotation> in controlled studies of 3 months' duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use. <br> <br> |04c42f2b-d049-4892-b003-bdf346cb4ab4;10644068-fa47-4e3b-9e93-f57ebac3dd17;14f73ae3-7d8d-4d10-b668-8bd5adf8032c;150b4d91-7a2a-4c01-877d-bbafd3a7a74e;4ab12da7-5731-4e06-bf1c-bc3f2e711f12;5f6565b7-3d3e-4f5b-bf92-8d9f8002a36a;74ae4775-8190-4bab-93d0-0f209023f973;83554310-3991-4a9d-92f1-d71ccfd0fb3a;a46d05a2-5014-40ff-8f1b-9eca1b0aff3a;a5e5413d-bc22-4ae1-959b-0eb0430dbd38;c4fe14fb-0a43-4c31-9cd6-29eb0d156705;f15b41bd-ed36-4908-aba5-f0a019b7a26e;
11642|fa181279-dce7-4a3f-aba8-b9c2806fdd34| Ambien CR (zolpidem tartrate extended release tablets) is indicated for the treatment of <annotation cui="C0917801">insomnia</annotation> characterized by difficulties with sleep onset and or sleep maintenance (as measured by wake time after sleep onset). <br> <br> The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient reported assessment in adult patients only) in duration <i> [see Clinical Studies (14) ] </i> . <br> <br> |0abb0285-f09c-2110-e570-542dae5fab1a;11a7fa3f-5dd3-4ba6-8a5b-0be321c58dfa;1a32885f-7e42-4558-9142-42d441bcf23d;404c858c-89ac-4c9d-8a96-8702a28e6e76;40f9a7b1-b57b-4e70-b709-e81705e784a7;56060e77-c025-a079-9539-02b649fbf740;5a3ad211-f0a5-4238-8a03-1154fac34c86;68d4314d-1973-481e-806a-da9f5b4baeb0;704066bb-14d8-49d0-9d6e-67d1d4fcb70b;968b5154-3c38-4f20-bbeb-495bcb91cc2b;b1b0085f-d9fe-430a-9bd5-607f607bf7e1;b2c3e941-efa9-4688-b45a-ceb758df717d;b3e19295-1574-4832-936b-bbf41dfce009;fa181279-dce7-4a3f-aba8-b9c2806fdd34;
11716|001f22f8-a83d-495f-9196-d0264ef4d76e| FLOVENT DISKUS is indicated for the maintenance treatment of <annotation cui="C0004096">asthma</annotation> as prophylactic therapy in patients 4 years and older. It is also indicated for patients requiring oral corticosteroid therapy for <annotation cui="C0004096">asthma</annotation>. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time. <br> <br> FLOVENT DISKUS is NOT indicated for the relief of acute bronchospasm. <br> <br> |001f22f8-a83d-495f-9196-d0264ef4d76e;ac4fc4e3-f9a6-4176-96a9-a2c78fad96e0;b49ed7c1-123e-4b1d-fea6-0c6839fd9d6a;bcbd136e-7f0d-4da3-9c7b-b2ab75366605;
11806|7dd162fc-f208-4746-b2da-92747fa2f3d5| <div> Monotherapy <annotation cui="C0014544">Epilepsy</annotation> </div> Topiramate tablets are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary <annotation cui="C0494475">generalized tonic clonic seizures</annotation>. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials <i> [see Clinical Studies ( 14.1 )]. </i> <br> <br> <div> Adjunctive Therapy <annotation cui="C0014544">Epilepsy</annotation> </div> Topiramate tablets are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with <annotation cui="C0751495">partial onset seizures</annotation> or primary <annotation cui="C0494475">generalized tonic clonic seizures</annotation>, and in patients 2 years of age and older with <annotation cui="C0036572">seizures</annotation> associated with Lennox Gastaut syndrome <i> [see Clinical Studies ( 14.2 )]. </i> <br> <br> |011eedbd-efb1-4d4e-99f0-b6bca81fb5ad;17471bd6-4f48-40e0-952e-6a69bd0eeec9;1af94c80-2b17-409a-98f6-ce00f942351d;1f5f940c-d5b9-4d09-958d-246931e167af;202b1a2a-11dc-4c3d-aa53-27512a98a042;21628112-0c47-11df-95b3-498d55d89593;2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef;32b48ea0-a215-43b8-83b4-a5435a686d68;35312f49-decf-428d-bf5f-4215b762ed3c;39bd7142-9b39-993d-85f8-e538d4893ee5;40c158ae-07b0-fae9-eecc-5acf8273c526;47fd4c44-56fa-4864-af5d-7b65c7b746d7;4a2ef860-4349-f2a0-0815-6d47ba08e311;4d78fba4-51af-472c-8b64-5505cb4b91dc;50bc013e-b5df-40e0-95e5-2527a62dcda0;546130a3-e5f2-422d-88f0-66de19540ecb;56145d1a-1c0c-4c39-951e-45b9f324abcb;57016639-89fe-43ad-89c4-5e7a756dddec;5c44de38-a291-471d-8335-abc65e04387d;61f36cba-e314-4ec9-8c84-5259153049b5;67dcdd6e-48bc-418e-a887-805929d83ce0;6b5b0d58-bfa0-41c8-955f-e74f89506d1e;6d46258b-31d0-4e43-9acd-4c821f09ec0f;6f9d59e3-d10d-48f3-af01-83ba3e1e3a2b;756e6ebc-36fa-b6ac-a228-9d86d0ab8256;7874bf12-b05d-45ba-ac65-124ff9e20179;7dd162fc-f208-4746-b2da-92747fa2f3d5;7f3d81cc-caec-47a0-b703-fdff6fbc3f6f;7f9eb38f-0dfa-4798-b3c1-32381d33affa;8887de7e-eba5-4f00-97ca-5077cfaa361b;88c9d1ca-f3a8-4078-8de7-21fd9040dd20;8fefc750-b4a6-42a5-ae69-368b25c76365;946cd61f-d733-4edf-96b7-f5566c35ae4a;a48b6716-cf81-e694-c0c7-92c87e9d37ce;a4ff77b8-04bc-4edb-a085-8d6d8687f8d1;a703595c-1215-453e-b63e-9f0cdcdd1eaa;ac805bbd-26d5-456d-9ce8-cb91ed8703b6;af3eb64f-edfb-470f-924b-ef592b5b88dc;c6fa0c7b-eea6-48f0-9ae9-c19eb088b271;cea5f748-3127-4d36-83af-9ab3cf58503c;e4886adf-199d-4b19-a4ef-75f8f94cb54e;e608d164-5f77-40f5-a72b-26dd20ad7a8a;e883e5ac-4ee4-466e-bb6c-bff0a5ea8479;e8ac23e3-be4d-438b-9759-b2368c6b9900;e999cb0a-8e45-4fdc-9b52-f3661f5dfc33;efd1106b-d369-4651-b703-b0985ce93b79;fcbea233-0aa2-462e-9254-7c970936e44c;
12018|364238c7-11b0-442e-acd9-4a6f21b9d783| Therapy with lipid altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with <annotation cui="C0010068">coronary heart disease</annotation> (<annotation cui="C0010068">CHD</annotation>) or at high risk of CHD, simvastatin can be started simultaneously with diet. <br> <br> Reductions in Risk of CHD Mortality and Cardiovascular Events <br> <br> In patients at high risk of coronary events because of existing <annotation cui="C0010068">coronary heart disease</annotation>, diabetes, peripheral vessel disease, history of <annotation cui="C0038454">stroke</annotation> or other cerebrovascular disease, simvastatin tablets, USP are indicated to <br> <br> <ol><li> Reduce the risk of total mortality by reducing CHD deaths. </li><li> Reduce the risk of non fatal <annotation cui="C0027051">myocardial infarction</annotation> and <annotation cui="C0038454">stroke</annotation>. </li><li> Reduce the need for coronary and non coronary revascularization procedures. </li></ol> <annotation cui="C0020473">Hyperlipidemia</annotation> <br> <br> Simvastatin tablets, USP are indicated to <br> <br> <ol><li> Reduce <annotation cui="C0020443">elevated total cholesterol</annotation> (total C), low density lipoprotein cholesterol (LDL C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high density lipoprotein cholesterol (HDL C) in patients with primary <annotation cui="C0020473">Hyperlipidemia</annotation> (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed <annotation cui="C0242339">dyslipidemia</annotation> (Fredrickson type IIb). </li><li> Reduce elevated TG in patients with <annotation cui="C0020557">hypertriglyceridemia</annotation> (Fredrickson type lV <annotation cui="C0020473">Hyperlipidemia</annotation>). </li><li> Reduce elevated TG and VLDL C in patients with <annotation cui="C0020479">primary dysbetalipoproteinemia</annotation> (Fredrickson type III <annotation cui="C0020473">Hyperlipidemia</annotation>). </li><li> Reduce total C and LDL C in patients with <annotation cui="C0342881">homozygous Familial Hypercholesterolemia</annotation> as an adjunct to other lipid lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. </li></ol> Adolescent Patients with <annotation cui="C0342882">Heterozygous Familial Hypercholesterolemia</annotation> (HeFH) <br> <br> Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total C, LDL C, and Apo B levels in adolescent boys and girls who are at least one year post menarche, 10 17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present <br> <br> <ol><li> LDL cholesterol remains greater than or equal to 190 mg/dL; or </li><li> LDL cholesterol remains greater than or equal to 160 mg/dL and </li></ol> <ol><li> There is a positive family history of premature cardiovascular disease (CVD) or </li><li> Two or more other CVD risk factors are present in the adolescent patient. </li></ol> The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL C less than 130 mg dL. The optimal age at which to initiate lipid lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. <br> <br> <br> <br> <br> <br> <br> <br> Limitations of Use <br> <br> Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., <annotation cui="C0020473">Hyperlipidemia</annotation> Fredrickson types I and V). <br> <br> |012be6a1-42eb-478c-94c2-3326c40fbe72;0376351b-f1a0-43e5-a0b4-533072c49f39;0a238e82-20d5-45ec-8c13-4725d1065230;0be2e371-1f05-48d7-8f2e-f2024f3305f3;0fcdd59a-906b-43df-9c65-97d8a736b4f1;13c80d46-429e-4007-8f89-eed2ed96eccf;1c0525fc-2d95-4682-a459-7ea4fbe95c72;1c5178c9-270f-4a5b-a52b-68a56972f035;273e5d83-4890-482c-9b69-972c17e786bb;30fbaf9e-01cf-492a-b44f-dc81c17d7647;324a3791-d53e-4716-89cc-9516917407cf;330e35ed-fd6b-4123-864a-a5aa339c24d6;364238c7-11b0-442e-acd9-4a6f21b9d783;3e48217f-8175-4e9b-9fd0-909be4bbba95;4724dbb4-3613-4e6a-948f-a43d34f97f06;48bc36db-f3c2-460a-8d11-13e5c576efeb;4a81b757-0a64-4ed4-86f4-57aeb349105f;4bec3923-6221-4b8b-9a72-872a63680de1;4d19753e-8525-4c67-9657-70ba571f7e74;6336b9ee-a2f3-44cc-ae6a-43a5f68745f6;675d87cb-195c-4d28-8c10-db677e16c656;6e030b0f-8ee6-4b23-9345-7193d4280e88;6fcd7ba3-02cd-41e9-85d5-494961155d3e;7442f35f-74e8-4c35-9666-190a3baad549;79d902bd-c144-4c55-8abc-a07140a62c5e;7e3fc83f-e322-44a1-b0c3-30e6292b92d9;7fce939e-c38e-497f-ba3f-e7b6ba44bfd9;84e3af60-8814-49f6-918e-a4e1c702aa05;871251c0-36a1-4a32-9eab-ff6c1e925ca9;880b3ae3-99e5-4d4c-935c-ee232f1f2a45;881eb80b-712e-4aa2-bd23-290a3e5db6cd;8b3fe1aa-7268-4fb9-aa5a-a865fcbb4155;a0714ce3-bd46-4536-9b1e-83489c368f40;a893d609-a538-4922-98c0-f6089da66149;a92428d1-b8a5-4b3d-965d-50fd333bd743;b1ceb35b-25e0-4b7d-bea0-18099464d168;b1f2911f-f8e1-41c0-9979-cb8d683d2f2f;b3022011-4c11-7516-1f6e-ef606f5954a4;b6d5fb21-a1a8-53e5-80d9-dde0eede5ef5;cb34c06d-bb42-4b3f-aee8-9c559417ed0a;cc8258c3-6265-4b26-a1bf-df6476cc962a;cdb54447-86a5-4924-a7de-ec170f86651d;ce3ac5e8-bdef-d195-e0a0-e1a982008efe;d16d449a-a345-4b7c-8ab5-e18fb37dcb6a;d9a1a7c5-d806-4dbd-a201-5e73790d078b;dcd8802a-bf53-40da-8489-686f4a0610b3;e6d22e3b-9343-408f-9a86-59097f6e8983;e9e50cdb-4cef-4d03-9fb6-973d0c2bf293;ee80603a-7d4c-4172-aef4-286185b69acd;fdbfe194-b845-42c5-bb87-a48118bc72e7;ff4a8eab-17d5-caf4-efba-7e7688202bf5;
12074|1f0fa7d6-9309-4cf6-b842-3924ec8aebe7| <div> <annotation cui="C1269683">Major Depressive Disorder</annotation> </div> <br> Venlafaxine hydrochloride <b> </b> extended release tablets are indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> (<annotation cui="C1269683">MDD</annotation>). <br> <br> Efficacy of venlafaxine in <annotation cui="C1269683">MDD</annotation> was shown in both short term trials and a longer term trial in <annotation cui="C1269683">MDD</annotation> [ <i> see </i> <i> Clinical Studies ( 14.1 ) </i> ]. <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. |1f0fa7d6-9309-4cf6-b842-3924ec8aebe7;989705dd-929b-4b62-9ef4-e768f0e366cb;
12572|fba9cde2-8fbb-562f-f6e6-b18f8c452248| <b> </b> Fluticasone propionate nasal spray is indicated for the management of the nasal symptoms of seasonal and <annotation cui="C0035457;C2607914">perennial allergic and nonallergic rhinitis</annotation> in adults and pediatric patients 4 years of age and older. <br> <br> Safety and effectiveness of fluticasone propionate nasal spray in children below 4 years of age have not been adequately established. <br> <br> |046bdb61-2ec9-4996-93d9-0680b45693f3;0d9a521b-8314-437c-8c9f-f6188f1134fe;155d0f79-86c2-4096-97f3-5d82762ddc2e;3830675d-b45e-fc97-1f73-674b1fc38c80;3e710670-b72c-4a84-8c52-3ebae8783a32;7c692ed5-959e-4c48-aeec-0799d8979693;9d2750e4-206b-4981-9dfb-da98a0a6e403;b7ea1841-2fb1-48c8-86f9-639893fd1a84;db857d81-4b1e-42b8-972a-5bb8735d60f8;f9edc9b3-12e7-4917-a27c-8dbf6ac654ce;fba9cde2-8fbb-562f-f6e6-b18f8c452248;
12834|ebddb745-81f9-4b25-8739-b2886032ed26| <div> <annotation cui="C0242350">Erectile Dysfunction</annotation> </div> CIALIS is indicated for the treatment of <annotation cui="C0242350">Erectile Dysfunction</annotation>. <br> <br> |6a8621eb-7415-42a6-9432-630751d34c6b;e7ea978d-00a1-4c60-97bc-bb1d37d776e9;ebddb745-81f9-4b25-8739-b2886032ed26;
12915|908bc748-21e3-4f07-bab3-8e3b3da99be0| <div> <annotation cui="C1269683">Major Depressive Disorder</annotation> </div> Venlafaxine Extended Release Tablets (venlafaxine hydrochloride) are indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> (<annotation cui="C1269683">MDD</annotation>). <br> <br> Efficacy of venlafaxine in <annotation cui="C1269683">MDD</annotation> was shown in both short term trials and a longer term trial in <annotation cui="C1269683">MDD</annotation> [ <i> see Clinical Studies (14.1) </i> ]. <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two week period depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. <br> <br> <div> <annotation cui="C0031572">Social Anxiety Disorder</annotation> </div> Venlafaxine Extended Release Tablets are indicated for the treatment of <annotation cui="C0031572">Social Anxiety Disorder</annotation> (<annotation cui="C0031572">SAD</annotation>), also known as <annotation cui="C0031572">Social Phobia</annotation>, as defined in DSM IV. <br> <br> <annotation cui="C0031572">Social Anxiety Disorder</annotation> (DSM IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. <br> <br> Efficacy of venlafaxine extended release in the treatment of <annotation cui="C0031572">SAD</annotation> was established in short term <annotation cui="C0031572">SAD</annotation> trials [ <i> see Clinical Studies (14.2) </i> ]. <br> <br> |35f4790c-1235-49fe-bb9b-842f9e8c09f7;4fabbef0-1838-4f70-aaf9-9550bd5f6204;7027be98-61d6-a986-c9df-60ceef5f7ff0;908bc748-21e3-4f07-bab3-8e3b3da99be0;9136130e-b8fd-4a7c-8eea-e6277622a934;cc3ce063-d28a-4d0b-8735-09193016c49f;
13123|07c99997-31c7-4c03-ae35-49788213b43e| Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines , below). <br> <br> In patients with CHD or at high risk of CHD, simvastatin can be started simultaneously with diet. <br> <br> <div> Reductions in Risk of CHD Mortality and Cardiovascular Events </div> In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of <annotation cui="C0038454">stroke</annotation> or other cerebrovascular disease, simvastatin is indicated to <br> <br> <ol><li> Reduce the risk of total mortality by reducing CHD deaths. </li><li> Reduce the risk of non fatal <annotation cui="C0027051">myocardial infarction</annotation> and <annotation cui="C0038454">stroke</annotation>. </li><li> Reduce the need for coronary and non coronary revascularization procedures. </li></ol> <div> Patients with <annotation cui="C0020443">Hypercholesterolemia</annotation> Requiring Modifications of Lipid Profiles </div> Simvastatin tablets are indicated to <br> <br> <ol><li> Reduce elevated total C, LDL C, Apo B, and TG, and to increase HDL C in patients with <annotation cui="C0342879">primary hypercholesterolemia</annotation> (heterozygous familial and nonfamilial) and mixed <annotation cui="C0242339">dyslipidemia</annotation> (Fredrickson types IIa and IIb). </li><li> Treat patients with <annotation cui="C0020557">hypertriglyceridemia</annotation> (Fredrickson type lV <annotation cui="C0020473">hyperlipidemia</annotation>). </li><li> Treat patients with <annotation cui="C0020479">primary dysbetalipoproteinemia</annotation> (Fredrickson type lll <annotation cui="C0020473">hyperlipidemia</annotation>). </li><li> Reduce total C and LDL C in patients with homozygous <annotation cui="C0020445">familial hypercholesterolemia</annotation> as an adjunct to other lipid lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. </li></ol> <div> Adolescent Patients with Heterozygous <annotation cui="C0020445">Familial Hypercholesterolemia</annotation> (HeFH) </div> Simvastatin tablets are indicated as an adjunct to diet to reduce total C, LDL C, and Apo B levels in adolescent boys and girls who are at least one year post menarche, 10 to 17 years of age, with heterozygous <annotation cui="C0020445">Familial Hypercholesterolemia</annotation>, if after an adequate trial of diet therapy the following findings are present <br> <br> <ol><li> LDL cholesterol remains 190 mg/dL; or </li><li> LDL cholesterol remains 160 mg/dL and </li></ol> <ol><li> There is a positive family history of premature cardiovascular disease (CVD) or </li><li> Two or more other CVD risk factors are present in the adolescent patient. </li></ol> The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL C < 130 mg dL. The optimal age at which to initiate lipid lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. <br> <br> <div> General Recommendations </div> Prior to initiating therapy with simvastatin tablets, secondary causes for hypercholesterolemia (e.g., hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total C, HDL C, and TG. For patients with TG less than 400 mg dL (< 4.5 mmol L), LDL C can be estimated using the following equation <br> <br> LDL C = total C [(0.20 x TG) + HDL C] <br> <br> For TG levels > 400 mg dL (> 4.5 mmol L), this equation is less accurate and LDL C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL C may be low or normal despite elevated total C. In such cases, simvastatin tablets are not indicated. <br> <br> Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient's response to therapy. <br> <br> The NCEP Treatment Guidelines are summarized in Table 6 <br> <br> After the LDL C goal has been achieved, if the TG is still 200 mg dL, non HDL C (total C minus HDL C) becomes a secondary target of therapy. Non HDL C goals are set 30 mg dL higher than LDL C goals for each risk category. <br> <br> At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge. <br> <br> The NCEP classification of cholesterol levels in pediatric patients with a familial history of either hypercholesterolemia or premature cardiovascular disease is summarized in Table 7. <br> <br> Since the goal of treatment is to lower LDL C, the NCEP recommends that LDL C levels be used to initiate and assess treatment response. Only if LDL C levels are not available, should the total C be used to monitor therapy. <br> <br> Simvastatin is indicated to reduce elevated LDL C and TG levels in patients with Type IIb <annotation cui="C0020473">hyperlipidemia</annotation> (where hypercholesterolemia is the major abnormality). However, it has not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., <annotation cui="C0020473">hyperlipidemia</annotation> Fredrickson types I and V) 3 . <br> <br> Figure 2 |07c99997-31c7-4c03-ae35-49788213b43e;34B56F73-BEA4-4265-8B2A-C57520CF8E70;
14232|f16a9f33-45ca-4e16-0ebe-157b71abb8df| <div> <b> 1.1 </b> Treatment of <annotation cui="C2607914">Allergic Rhinitis</annotation> </div> VERAMYST (fluticasone furoate) Nasal Spray is indicated for the treatment of the symptoms of <annotation cui="C0035457;C0018621">seasonal and perennial allergic rhinitis</annotation> in patients aged 2 years and older. <br> <br> |4e444ce8-3dca-4a95-8ebf-752da67e80ff;8eaee9bf-91c7-484b-b8b1-b8242198181f;f16a9f33-45ca-4e16-0ebe-157b71abb8df;
1495|c41abc6d-1918-4b35-80cc-2b3c019822d6| <div> <annotation cui="C0014544">Epilepsy</annotation> </div> Divalproex sodium capsules (sprinkle) are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with <annotation cui="C0270834">complex partial seizures</annotation> that occur either in isolation or in association with other types of <annotation cui="C0036572">seizures</annotation>. Divalproex sodium capsules (sprinkle) are also indicated for use as sole and adjunctive therapy in the treatment of <annotation cui="C0014553;C0014553">simple and complex absence</annotation> <annotation cui="C0036572">seizures</annotation>, and adjunctively in patients with multiple <annotation cui="C0036572">seizure</annotation> types that include <annotation cui="C0014553">absence seizures</annotation>. <br> <br> Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. [see <b> Warnings and Precautions (5.2) </b> , <b> Patient Counseling Information (17.3)] </b> . <br> <br> |2e4778d8-8798-4da1-bb33-1aa1414b5809;b0f33792-dd96-40cc-a28e-acdcdca2f4b8;c41abc6d-1918-4b35-80cc-2b3c019822d6;ed710c62-8ba6-4f19-b240-3ee73cd03d67;f911748c-fb3a-fe1a-ab2a-4b40455e05ef;
15258|720512c7-9ea4-40c8-b119-b39a3f9a448b| Akne mycin is indicated for topical control of <annotation cui="C0001144">acne vulgaris</annotation>. <br> <br> |018c94b5-8379-4b08-a18c-fad9c0219c0b;2ad5cf71-bf84-478d-9c9c-5577bcb58ebc;2d14281c-0815-4d91-a161-10c34eee5bd8;3b9a1f4a-2590-4216-a3fd-8bda2b9751db;40edf1bd-42bb-4662-aff6-01fcc133c05d;51709310-195d-4070-87fa-434e2e5e07bd;720512c7-9ea4-40c8-b119-b39a3f9a448b;7a4eeb39-beb4-4554-a5ab-e752887433e1;81312193-82D8-49F8-B381-8FB866B2EC76;992be13e-2409-4799-96ef-731ac3bf3973;9a63da11-01be-4c63-a260-e6bdbb4a7a69;aa993373-f75f-440f-bdae-59892557ba2c;dd64459e-c88f-4ca8-b63b-fb96377a3921;
15583|c0333e62-bb00-4722-27b6-dca6ab4d1eb1| MERIDIA is indicated for the management of <annotation cui="C0028754">obesity</annotation>, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet. MERIDIA is recommended for <annotation cui="C0028754">obese</annotation> patients with an initial body mass index 30 kg m 2 , or 27 kg m 2 in the presence of other risk factors (e.g., diabetes, dyslipidemia, controlled hypertension). <br> <br> Below is a chart of Body Mass Index (BMI) based on various heights and weights. <br> <br> BMI is calculated by taking the patient's weight, in kg, and dividing by the patient's height, in meters, squared. Metric conversions are as follows pounds 2.2 = kg; inches 0.0254 = meters. <br> <br> <br> <br> Meridia body mass index chart. |c0333e62-bb00-4722-27b6-dca6ab4d1eb1;
15884|f8f80fca-32b7-4fba-b0ab-e87530bc36b6| <div> <annotation cui="C1263846">Attention Deficit/Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>) </div> STRATTERA is indicated for the treatment of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>). <br> <br> The efficacy of STRATTERA Capsules was established in seven clinical trials in outpatients with <annotation cui="C1263846">ADHD</annotation> four 6 to 9 week trials in pediatric patients (ages 6 to 18), two 10 week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) <i> [see Clinical Studies (14)] . </i> <br> <br> <div> Diagnostic Considerations </div> A diagnosis of <annotation cui="C1263846">ADHD</annotation> (DSM IV) implies the presence of hyperactive impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. The symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. <br> <br> The specific etiology of <annotation cui="C1263846">ADHD</annotation> is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM IV characteristics. <br> <br> For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months lack of attention to details careless mistakes, lack of sustained attention, poor listener, failure to follow through on tasks, poor organization, avoids tasks requiring sustained mental effort, loses things, easily distracted, forgetful. For the Hyperactive Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months fidgeting squirming, leaving seat, inappropriate running climbing, difficulty with quiet activities, on the go, excessive talking, blurting answers, can t wait turn, intrusive. For a Combined Type diagnosis, both inattentive and hyperactive impulsive criteria must be met. <br> <br> <div> Need for Comprehensive Treatment Program </div> STRATTERA is indicated as an integral part of a total treatment program for <annotation cui="C1263846">ADHD</annotation> that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug treatment is not intended for use in the patient who exhibits symptoms secondary to environmental factors and or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential in children and adolescents with this diagnosis and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe drug treatment medication will depend upon the physician s assessment of the chronicity and severity of the patient s symptoms. <br> <br> |23c702e2-3abc-4d7d-b88f-a089e2179f42;309de576-c318-404a-bc15-660c2b1876fb;47137273-b9c1-4cb4-99ca-2dab9690b560;6a6964c3-e022-43e3-a88e-45806c5faba8;6f6bea0c-297b-43ff-8960-ecc11243e06e;76b8f7da-7e69-4953-be59-e38397e0fd36;a671ec20-1d70-45e1-9893-025f832444c5;bdab7205-d0ff-41c3-8430-2d399dfaa759;f8f80fca-32b7-4fba-b0ab-e87530bc36b6;
1644|bcd8f8ab-81a2-4891-83db-24a0b0e25895| <div> <annotation cui="C0242350">Erectile Dysfunction</annotation> </div> CIALIS is indicated for the treatment of <annotation cui="C0242350">Erectile Dysfunction</annotation> (<annotation cui="C0242350">ED</annotation>). <br> <br> <div> <annotation cui="C0005001">Benign Prostatic Hyperplasia</annotation> </div> CIALIS is indicated for the treatment of the signs and symptoms of <annotation cui="C0005001">Benign Prostatic Hyperplasia</annotation> (<annotation cui="C0005001">BPH</annotation>). <br> <br> <div> <annotation cui="C0242350">Erectile Dysfunction</annotation> and <annotation cui="C0005001">Benign Prostatic Hyperplasia</annotation> </div> CIALIS is indicated for the treatment of <annotation cui="C0242350">ED</annotation> and the signs and symptoms of <annotation cui="C0005001">BPH</annotation> (<annotation cui="C0242350">ED</annotation> <annotation cui="C0005001">BPH</annotation>). <br> <br> |0e747223-2740-4e45-9bef-ae5f7798064a;bcd8f8ab-81a2-4891-83db-24a0b0e25895;
16651|f94b2ba4-024f-4068-8759-da6c8d31c546| ZONEGRAN is indicated as adjunctive therapy in the treatment of <annotation cui="C0751495">partial seizures</annotation> in adults with <annotation cui="C0014544">epilepsy</annotation>. <br> <br> |0ab183cf-51aa-402a-9351-53a4f112d1f9;0c160018-e3fb-4f04-9475-c4cf2cceb1b7;1e99efc7-cf3f-4368-7afb-41d8dfaeffcf;24284954-0c29-458f-a9f8-97a7ad418ca7;3164d438-90bf-420a-9a56-5498b987f91c;31BB7426-63AB-4CCB-9B83-EED9FA912992;3676af6a-198b-4453-b43a-039fb26817dd;4696e856-69c4-4e7e-b76d-d70d85c4b561;5626e08c-de45-48ff-b85f-21abdfae6574;6690c2cf-1634-93c0-7b2e-0ad4ca70cd6d;6d2f9c84-a597-4055-8815-8fbcdf4c4876;78ad1221-f07d-4afc-9ce7-5a0418101ff9;902a17d4-ce4f-476a-81d8-bb518041c814;b2433b54-da24-45c7-9d48-35f098e15814;b366d21b-885e-4374-bb49-4a5aca054297;b40ec321-1181-4e8d-8914-d30772b30cad;d049bfcf-0634-4649-a782-12976ee4c49e;f484218e-4265-7a3f-fda0-07e9c6f24dd5;f89aba5c-bd19-4476-925c-bd7bd34723bb;f94b2ba4-024f-4068-8759-da6c8d31c546;fe15e56e-8b86-4a65-825c-31d37dd81612;fe9efeaf-09e3-4836-9ade-995cd3e59e45;
16793|f8035130-1a60-4ba3-a9be-b1a739c946db| <b> <br> 1.1 <annotation cui="C0029408">Osteoarthritis</annotation> (<annotation cui="C0029408">OA</annotation>) </b> Meloxicam tablets are indicated for relief of the signs and symptoms of <annotation cui="C0029408">Osteoarthritis</annotation> [ <i> see Clinical Studies (14.1) ]. </i> <br> <br> <b> <br> 1.2 <annotation cui="C0003873">Rheumatoid Arthritis</annotation> (<annotation cui="C0003873">RA</annotation>) </b> Meloxicam tablet are indicated for relief of the signs and symptoms of <annotation cui="C0003873">Rheumatoid Arthritis</annotation> [ <i> see Clinical Studies (14.1) ]. </i> <br> <br> |0060d1b1-4cfc-4b69-86a8-9bd44a071e94;03c871ed-6686-4bfe-9b15-6ca50b91af47;06623222-188c-4ab1-976a-4cdb2037a709;06a401f0-4380-4081-86ed-a309a25abf6b;0a5ccef7-edba-4498-bec2-6b25d551e04b;0d266c0d-167c-4a28-a6ef-924d5d117e50;18a4fe07-f5f7-41d1-b7d1-85563b54d2cf;20871c7f-1e36-49ef-8e2b-70112430ca1e;2adb9f9b-c49c-4137-9e2e-8be9065639e6;3d3b548c-005e-40b0-98d0-443cf08fdcde;3d8946f4-722b-477d-9f7f-6da06c78301e;4acea0aa-973f-40e5-88b4-0e2d85ea624c;4f7f4c26-d85d-4721-8371-49c52461a3f0;5eb2e439-2ef2-496c-9aec-042029ae1305;5fe76337-eae5-4e5c-96ef-6cfa97983c6e;6aecd9bf-6cfa-4bc7-be82-d2bc27b80fe9;6c015f72-5ce3-4f56-8237-776fc2165b0c;8aafb54e-99d8-4166-8504-49162a8ec0fb;9d648594-d657-4d9a-855e-0ea91eb49c98;a381942f-0cba-4e97-4741-ad04a6af2164;a3ec45d2-bd66-48d4-8ac8-0292f1e2385a;aafd2b0f-435a-4805-9b17-c02f99df59d5;c51f3abe-02bc-4544-a22f-0f2035fb2271;c983c578-d6c4-46e3-aca6-56de081f07ab;d5e12448-1ca1-46a4-8de4-e8b94567e5a8;e65e3c28-a40b-4daa-8fd5-29f112575b68;f2197492-9932-45c7-8fe0-5284ccfb8458;f8035130-1a60-4ba3-a9be-b1a739c946db;
17291|9953df12-a2b4-4d22-b204-746fc29f7a5f| CUTIVATE (fluticasone propionate) Lotion is indicated for the relief of the inflammatory and pruritic manifestations of <annotation cui="C0011615">atopic dermatitis</annotation> in patients 1 year of age or older. The safety and efficacy of drug use for longer than 4 weeks in this population have not been established. The safety and efficacy of CUTIVATE Lotion in pediatric patients below 1 year of age have not been established. <br> <br> |0e20d1cc-5c7a-4e0d-810b-b94c4d6dd1c0;10f6099a-c53c-4b0c-b81e-136c0e9f13d9;3b5de5ca-a947-4815-8968-e09fc985e83c;3c7b3482-e2fd-4857-9394-a47fd7f4c47b;657aee47-558f-4634-a566-fc81dab2fabc;78e056e2-d39e-4d20-9ab2-332bd6973619;9953df12-a2b4-4d22-b204-746fc29f7a5f;cc79e200-ce69-4ffd-be5b-8c1a6bb88c5c;
17407|2965ef46-18db-4615-9dce-bfb0f0b3366a| <div> <annotation cui="C0018621">Seasonal Allergic Rhinitis</annotation> </div> Levocetirizine dihydrochloride is indicated for the relief of symptoms associated with <annotation cui="C0018621">Seasonal Allergic Rhinitis</annotation> in adults and children 6 years of age and older. <br> <br> <i> Pediatric use information in pediatric patients (age 2 to 5 years) with <annotation cui="C0018621">Seasonal Allergic Rhinitis</annotation> is approved for UCB Inc. s levocetirizine dihydrochloride drug product. However, due to UCB Inc. s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. </i> <br> <br> <div> <annotation cui="C0035457">Perennial Allergic Rhinitis</annotation> </div> Levocetirizine dihydrochloride is indicated for the relief of symptoms associated with <annotation cui="C0035457">Perennial Allergic Rhinitis</annotation> in adults and children 6 years of age and older. <br> <br> <i> Pediatric use information in pediatric patients (age 6 months to 5 years) with <annotation cui="C0035457">Perennial Allergic Rhinitis</annotation> is approved for UCB Inc. s levocetirizine dihydrochloride drug product. However, due to UCB Inc. s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. </i> <br> <br> <div> <annotation cui="C0578870">Chronic Idiopathic Urticaria</annotation> </div> Levocetirizine dihydrochloride is indicated for the treatment of the uncomplicated skin manifestations of <annotation cui="C0578870">Chronic Idiopathic Urticaria</annotation> in adults and children 6 years of age and older. <br> <br> <i> Pediatric use information in pediatric patients (age 6 months to 5 years) with <annotation cui="C0578870">Chronic Idiopathic Urticaria</annotation> is approved for UCB Inc. s levocetirizine dihydrochloride drug product. However, due to UCB Inc. s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. </i> <br> <br> |2965ef46-18db-4615-9dce-bfb0f0b3366a;2bc07580-0833-fbe4-ead0-f9c52cf08af5;2f42fc80-ae39-4301-b140-36e59d71666e;4f43d057-cba8-4366-86ba-4be361e4c71f;60ae7e0e-281c-40a3-a0d3-259b843ddaaa;8d416349-161d-4232-b6b4-e75214ea4841;c40c1bb4-25ce-90cb-b8dd-6a4c54cddd4a;
2049|ff61b237-be8e-461b-8114-78c52a8ad0ae| <div> <annotation cui="C0152171">Pulmonary Arterial Hypertension</annotation> </div> ADCIRCA is indicated for the treatment of <annotation cui="C0152171">Pulmonary Arterial Hypertension</annotation> (<annotation cui="C0152171">PAH</annotation>) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II   III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). <br> <br> |ff61b237-be8e-461b-8114-78c52a8ad0ae;
225|2c3f8268-ef43-d58c-7da6-dd44f8feb3be| Venlafaxine tablets are indicated for the treatment of <annotation cui="C1269683">major depressive disorder</annotation>. <br> <br> The efficacy of venlafaxine tablets in the treatment of <annotation cui="C1269683">major depressive disorder</annotation> was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM III or DSM III R category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). <br> <br> A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least four of the following eight symptoms change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. <br> <br> The efficacy of venlafaxine hydrochloride extended release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo controlled trial. The efficacy of venlafaxine tablets in maintaining an antidepressant response in patients with <annotation cui="C0221480">recurrent depression</annotation> who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets venlafaxine hydrochloride extended release capsules for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient. <br> <br> |04b9b820-228c-d7f8-519d-d65feb897199;04c95282-2e10-4ab5-baf2-62d44dd8f22f;0804aaf5-de2d-4e38-915d-4b3c0da379d4;09feeadb-d4e6-47dd-8d1e-b03052a9cc5d;106d0d7b-925b-74e7-83cb-562144ce1f92;185d90ab-1ba4-dd59-0565-e35f0fd39a2d;1be1be3a-304b-4e31-8732-335247029191;28f12fa3-b5ef-41c7-a750-32c80d8881cf;2a84b9b5-cb10-46b7-b5a3-2cd9b4ffb0f3;2bb09fc1-1c0a-4586-9af9-5aed8d4322db;2c3f8268-ef43-d58c-7da6-dd44f8feb3be;2c7742aa-7722-4c12-9e4b-b4c3ca5a7fb0;2e8f0889-57ca-498a-8e91-b8a24bbe47fd;3942d30d-827b-46c7-8454-3020d5d7865d;435cf21c-b051-49f2-8428-fa7920f2c6c3;49bef388-71ff-43b1-87a8-9fd506a0e63e;4c401522-0108-49cb-8a41-fb5ad4dd0fb1;51334651-7a7f-4653-bf9d-d5be04fd902d;5351fe67-17d9-42ec-9e8b-6585fdb9e29e;53b73f2a-d839-41b5-bc9c-aeb3e9dba304;53c3e7ac-1852-4d70-d2b6-4fca819acf26;55889b3d-74c9-4638-9a14-6a4ca3a99f7f;6148707f-625f-47be-b4bf-b5966078675d;62c02cdb-ea65-41ff-a531-4d9ea498f705;6be70efb-322e-4e65-9851-a7d167065dd8;72efad5f-0909-46a5-aa13-ac24fe015fe6;7f3aa63e-402a-41a2-b570-977795010ea8;83cb4d74-d75e-4aad-9bae-a09a5a789806;84034bf7-0ba3-060d-73f5-275de6aff417;85d3ce8b-8966-45d9-bdaf-f6f0475096e1;8FBA17DA-573A-425B-B1D7-7DDEEEF3C957;8a2302ca-5c25-4d2d-9ffe-320080934aab;8d06eb3d-16bd-495a-b58f-90877f3d5188;9a30e1b5-272b-4109-ad6c-a3c9a895822f;9b5885cc-ef96-4081-8975-9febc6772dc0;9de97bb7-36e8-4126-bede-d48375da15df;a4e1d3bc-4e97-4ff0-9e30-22a699c96072;a5e32167-9ee0-4fbb-8577-c67fbc794d78;a821ed7b-53cf-438d-b8ab-6d7ac1c08912;b23637e5-d37f-41b5-ba76-fc053e903bc2;b379b413-5d66-4adb-8521-3978f10bbd1d;b4048138-3b43-4952-9c4d-f9278792f2b5;c32ccd4d-77b4-4451-8c03-ffc6484bc1f3;d84376b8-6071-4738-96d6-182bd323e835;d87fba09-06b6-41a8-867c-a8428fce240e;db64c361-7960-4e86-8c71-5d96a381ae23;e0990ade-320e-4259-8c0e-6d5ef23bc673;e5a31f69-c237-49b7-83a2-d04eebbc30ce;eb28f976-ce74-47e1-7757-c0832c28be75;
2843|88313e5f-9426-4aac-8909-d56bde6f584f| <div> <annotation cui="C0018621">Seasonal Allergic Rhinitis</annotation> </div> XYZAL is indicated for the relief of symptoms associated with <annotation cui="C0018621">Seasonal Allergic Rhinitis</annotation> in adults and children 2 years of age and older. <br> <br> <div> <annotation cui="C0035457">Perennial Allergic Rhinitis</annotation> </div> XYZAL is indicated for the relief of symptoms associated with <annotation cui="C0035457">Perennial Allergic Rhinitis</annotation> in adults and children 6 months of age and older. <br> <br> <div> <annotation cui="C0578870">Chronic Idiopathic Urticaria</annotation> </div> XYZAL is indicated for the treatment of the uncomplicated skin manifestations of <annotation cui="C0578870">Chronic Idiopathic Urticaria</annotation> in adults and children 6 months of age and older. <br> <br> |371ca86d-7ffd-4f20-b6c6-af0a9ff7362f;7a6d9491-a4c9-497c-9c17-4037c46f9e6a;88313e5f-9426-4aac-8909-d56bde6f584f;ccfd9a79-f3fd-4786-b7ba-e4906089d8f7;
2900|bb34ee82-d2c2-43b8-ba21-2825c0954691| <div> <annotation cui="C0036341">Schizophrenia</annotation> </div> RISPERDAL CONSTA (risperidone) is indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation> <i> [see Clinical Studies (14.1) ] </i> . <br> <br> <div> <annotation cui="C0005586">Bipolar Disorder</annotation> </div> RISPERDAL CONSTA is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of <annotation cui="C0853193">Bipolar I Disorder</annotation> <i> [see Clinical Studies (14.2 , 14.3) ] </i> . <br> <br> |bb34ee82-d2c2-43b8-ba21-2825c0954691;
3128|4A0AFC61-F83D-4871-86EB-929C9428A1E3|<b> <annotation cui="C1269683">Major Depressive Disorder</annotation> </b>   Sertraline hydrochloride is indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation>. <br> <br> The efficacy of sertraline in the treatment of a <annotation cui="C0024517">major depressive episode</annotation> was established in six to eight week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM III category of <annotation cui="C1269683">Major Depressive Disorder</annotation> (see <b> Clinical </b> <b> Trials </b> under <b> CLINICAL PHARMACOLOGY </b> ). <br> <br> A <annotation cui="C0024517">major depressive episode</annotation> implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. <br> <br> The antidepressant action of sertraline in hospitalized depressed patients has not been adequately studied. <br> <br> The efficacy of sertraline in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open label acute treatment (52 weeks total) was demonstrated in a placebo controlled trial. The usefulness of the drug in patients receiving sertraline for extended periods should be reevaluated periodically (see <b> Clinical Trials </b> under <b> CLINICAL PHARMACOLOGY </b> ). <br> <br> |01800452-c353-4235-a66a-214048752e74;01a172e0-d590-4701-8d88-cf012760e4aa;0aee46a9-7c7e-4363-a05d-bf2595930f03;1292A04E-7220-4B2D-AE6F-334E1277000C;13bbfcfe-24c8-4ca5-b119-918d1ab7aa37;1611926a-6875-4c48-8cb5-54fca7871ced;162ba178-a30a-49f2-b7a3-4147f4e4dab8;1743d408-6eac-41ae-8f80-0053f9d24e85;1a58062b-e635-431a-908d-2651c6a4a21c;1fb34fc8-c673-49a6-b008-8385d37da297;22cb97e4-02b9-4e7b-8540-14659739dad4;232a00a4-761e-422f-b62a-1a16de631eb6;23ab111d-085a-14d3-ca4d-c16c1cbf6467;23fbf44e-57c3-426d-86f0-353c24f9203a;250d998f-7100-495c-81ff-10fcfd5ba61d;27CAD186-5F47-49A6-AD75-DF3A38C1C614;2d52e980-c419-4719-b928-29ad1f71647e;2dac437f-b5ef-42dd-aa0b-1f4b9b45ef43;31fd504e-5955-49f9-a77e-2720a126fbc7;3796bad0-85ff-409f-be43-28884bbc115e;39a85db1-9e59-4ab0-9e18-36757f019faa;3e2cb0ae-2284-44d0-9eff-f7d4ab6501a5;42120ff8-b353-4632-9ea9-54de9a698724;4A0AFC61-F83D-4871-86EB-929C9428A1E3;5213ff08-ba1f-4f22-99e0-9604dd13a63f;5365e9a7-ad09-4a85-95a1-a86f40c890a5;56401539-e8a5-4d22-8002-86c28d7d6370;56a6fee2-87f9-406d-b8eb-53cad24ece35;63643535-0aa4-4cb3-870b-93933e48b9c1;63e5ec33-11ad-40fc-b5c6-059cba25f9f6;65b94cce-bf02-42b3-ab57-1e4fcc8725ff;7e71a8f9-1535-44d4-bf2f-e87c1d152cf6;7f144b68-ae90-483c-b030-f6824662a734;7f6b8165-356b-4e9e-8150-16fbbb0d367a;8e1f23a2-6c16-4236-ac66-6a4b184e7b6c;9222a610-a6d9-4b06-8ea0-c23a9ba8e281;983f8b2c-89ff-4519-b0f6-db3d17b3a3e7;991668e5-0930-cd98-d04c-8301e6de6c7c;9ba5b9bd-9a6f-4e64-a9d9-1b2b03658ea4;9bc362d4-489c-4e7f-915a-3076ff8d132a;9eef4bcb-24c3-4ffc-a37f-ddd673e661ce;A8B2AD71-CFDC-4A29-8194-DEEFEA138B16;A9A68BF7-9C81-4517-870A-E93BD0E4F45C;C7AB46CD-B3A0-3F9E-97E6-E6125E1A52A2;Lb6cc6969-daa0-4211-872a-05453cb33c70;a739d5e1-046e-4ae1-be0f-ffcf4f825bda;a793ccd0-f47c-43f7-a085-62eb74ec6c35;aa1026ed-fcaa-4442-a3f8-b5e0b600b51f;ac788635-7929-48e0-af88-979fe2271501;ad1f3be2-b145-440a-b9a1-ccc668384ea5;b03b5595-b1ae-415d-8398-00405302b17b;b1de3ed9-1cb8-e419-3f25-5b0aeed5779a;c0724513-693c-42cf-9b25-d5394cc32d7c;c25f968b-7037-4f60-9a02-2189769b0cbf;c3b0b1f8-abfd-4054-8645-fd076305f4f8;c3e4f44a-5073-4b51-b0a3-958429a8554c;c478ca8c-5ec7-439a-94a0-90b95eb476b7;c78a2e94-b4e2-499e-8354-a8a46e72652d;d17d767b-08c4-4a25-ad73-03a36d56902a;d2f94500-633e-486e-9c03-2b02266b08e7;daeb5443-07d4-4b45-aae4-edea159df23b;dfc0d446-cdc0-402b-a094-eae9f1115508;e2a70629-cd46-270a-48b1-8122600b603d;e5fe446b-1118-4208-bf57-3a91d6fc78ae;e6d920ee-80bc-4247-8b50-77f463130d38;ecc38d95-880f-43ea-aa8b-41472803c780;fc9b20f5-44f1-048f-14d1-7e7d08949490;fe9e8b7d-61ea-409d-84aa-3ebd79a046b5;
3287|9869b6dd-03ed-4c6f-9c32-2c324e773b7d| <div> <annotation cui="C0014544">Epilepsy</annotation> </div> Depakote Sprinkle Capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with <annotation cui="C0270834">complex partial seizures</annotation> that occur either in isolation or in association with other types of <annotation cui="C0036572">seizures</annotation>. Depakote Sprinkle Capsules are also indicated for use as sole and adjunctive therapy in the treatment of <annotation cui="C0014553">simple and complex absence</annotation> <annotation cui="C0036572">seizures</annotation>, and adjunctively in patients with multiple <annotation cui="C0036572">seizure</annotation> types that include <annotation cui="C0014553">absence seizures</annotation>. <br> <br> Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. <i> [see Warnings and Precautions (5.2) , Patient Counseling Information (17.3) ] </i> . <br> <br> |00332c65-edad-a153-9c78-628931daa732;08a65cf4-7749-4ceb-6895-8f4805e2b01f;0a67fd2f-7fe8-4573-9be3-69ebe65a3ffe;0dc024ce-efc8-4690-7cb5-639c728fccac;0f132d75-af5c-4ac1-8e46-afd6ef10a0d5;15f8a5be-e269-2e07-60d9-1dd7bf5f5281;18f7f458-9276-4e9d-94b2-99ca8dd4cebf;1de73260-3bea-43e6-8151-baad8e7092d7;1ec1a441-218a-4c80-a0cb-69bcc327f472;26b65fec-9a5d-4b9b-9b87-c3d328c58cd0;33798a7c-c5a9-49a5-be5d-1312910ef468;349cd946-3fd9-4ea3-9140-daf5d7304a65;3700405c-5743-4c82-a3fb-48dae904eed6;4619aff4-0f80-444f-858d-42e4137aa809;47ef5501-1408-41fa-b0e5-f078f18129f5;4a2b0442-c8f0-4c57-9206-323fbef1a877;4f569120-9e22-4d0e-a368-d364549f79a0;53308478-d3e7-4770-86fd-be9bcc9bc17f;54f6e14f-7c38-4c4f-85fc-cf5b25589ba9;5bb2f9bc-a5f2-4d54-8ee4-458af72c70f8;5be815ed-18ca-4e6d-8a4b-3ea694fc3caf;64797788-fdcb-4d12-a1a4-743ad71bd17b;648859e7-659d-4a69-b3f2-ff84747ec200;68b4b5d4-b008-4ea4-b2eb-94d0fa809dc1;6cdc2ab7-87d4-23e3-ca02-aed1d9b8dc5d;72d36e53-0af8-4008-af73-418934d86567;7981f586-89c2-4ed3-874f-952c28c31cb1;95a4ddd8-b76a-4128-b2ed-8a36cd5738f9;9869b6dd-03ed-4c6f-9c32-2c324e773b7d;9b3db659-f64c-4c48-946a-6b4f1d800eba;9fb17714-bdb1-4bfa-bc04-d9c011604cde;9fef0f9c-e6ed-4b29-a473-525f2aba70bd;a221e493-2e44-4398-90dd-80b348f3f0c2;a24e8e53-07b3-49be-87e4-124f7d3aeac1;a93b0914-c1ac-4e48-b6b9-1b4e211eb072;ab6f3285-69d5-4889-ae56-84afc6f042bd;ae57c8ec-8ea5-4829-a170-a69ddd92c22d;b26359c7-73fb-4397-8d18-5775b763e168;b32d180f-f8d6-4535-a3b6-45045663a96f;b367d81d-4eca-4e28-b490-34be4c003561;bd7c11f5-340c-84e1-10d2-3f7100e74048;bfbc2cfb-8e96-4cf2-81c7-d63a1b7365c4;c628d376-4b65-4f05-b6fa-eabb1d96a7df;c8d9cd69-ceca-3057-9d1c-12c44b19f767;cd83f986-ec38-4e0e-aa03-3db5ad1629c6;cdce6a8f-02fc-448c-9a81-3d904e49ef97;cf18a4c9-ba0b-4ac3-88b8-cc5889b0898f;d3f7c414-db83-4a7a-a7aa-745c5606cdba;d5625383-dbf0-4716-bcc6-ac1c8b69923b;da69287c-2f37-4299-b444-914c1ab0054c;dbba2df7-6cb5-438f-bcde-6316f3fe10c8;dbd47222-14f1-4588-a009-9b81b55ca60d;ded64147-7a43-4055-accc-2c011828079d;e2015ac5-0441-43fd-b864-a1b1fe944450;e26005ef-77f0-4393-a2dc-b5fe460cead8;ea85f517-4773-4688-88b6-5612612330f6;eb40a594-d58d-4214-b766-9e7a815b2de8;ec5ec477-2d6e-42dc-8620-66f1e51010c0;ed277cce-453d-4174-b027-17ebf907ce97;f01e56a9-847e-4a68-93d2-f8741d0ec71c;f23831e9-ef8e-4b4e-b5b3-dd01b76084f2;f738ddad-fef0-43cb-b791-b046fdcec311;
3481|04d2a675-a9c6-4dce-b17d-dfc86865f8e1| Fluticasone propionate ointment is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive <annotation cui="C0037274">dermatoses</annotation>. <br> <br> |04d2a675-a9c6-4dce-b17d-dfc86865f8e1;16985600-3f81-4d51-8bf7-0cbbd89856a1;255e71b4-9e24-4ad2-93f6-0a0ade71d823;e7ef2aaf-749c-66c9-2bdf-7214ab00060e;ff96762d-a841-4558-befd-d14761bbe6fc;
3702|64217ed0-7b53-4b8b-8e53-2b645640ab22| Carefully consider the potential benefits and risks of meloxicam and other treatment options before deciding to use meloxicam. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <b> WARNINGS </b> ). <br> Meloxicam is indicated for relief of the signs and symptoms of <annotation cui="C0029408">osteoarthritis</annotation>. <br> <br> |040fecdb-68cf-4967-90ce-c2130b520615;39bfb379-ef90-4a87-8b22-42ab0906785d;4EC9BF84-D0B0-4092-8E3D-C67CCFB2780B;5afa7fd7-3362-4cab-9630-2d9db708165c;64217ed0-7b53-4b8b-8e53-2b645640ab22;6513e46b-3229-685b-c83b-2209454fae71;6baa5e7f-c884-45dd-8dd7-4c3b4742eb0f;6ed06682-7507-4c11-a782-42e694c21b53;8FAD5C7C-15F1-4979-99A6-BAD75D45C393;A10CE6D9-0AC9-4EAF-8C2E-56DDC490D1F0;F6C6D183-0A63-0D25-5CD7-43A2D0D63BEB;c8683c04-0e54-4e97-992b-55c2d605793c;cb44be1a-a5c4-406f-9a2c-1835a2c3f0e0;fe8480c4-b176-45ae-b4d6-fa59912fe286;
3833|adea2968-68fa-435e-9c8c-dfa0f9903b00| To reduce the development of drug resistant bacteria and maintain the effectiveness of ERY TAB and other antibacterial drugs, ERY TAB should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> ERY TAB tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below <br> <br> Upper <annotation cui="C0035243">Respiratory tract infections</annotation> of mild to moderate degree caused by <i> Streptococcus pyogenes </i> ; <i> Streptococcus pneumoniae </i> ; <i> Haemophilus influenzae </i> (when used concomitantly with adequate doses of sulfonamides, since many strains of <i> influenzae </i> are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) <br> <br> Lower <annotation cui="C0035243">Respiratory tract infections</annotation> of mild to moderate severity caused by <i> Streptococcus pyogenes </i> or <i> Streptococcus pneumoniae </i> . <br> <br> <annotation cui="C0023860">Listeriosis</annotation> caused by <i> Listeria monocytogenes </i> . <br> <br> <annotation cui="C0035243">Respiratory tract infections</annotation> due to <i> Mycoplasma pneumoniae </i> . <br> <br> <annotation cui="C0037278">Skin and skin structure infections</annotation> of mild to moderate severity caused by <i> Streptococcus pyogenes </i> or <i> Staphylococcus aureus </i> (resistant staphylococci may emerge during treatment). <br> <br> <annotation cui="C0043167">Pertussis</annotation> (<annotation cui="C0043167">whooping cough</annotation>) caused by <i> Bordetella <annotation cui="C0043167">Pertussis</annotation> </i> . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of <annotation cui="C0043167">Pertussis</annotation> in exposed susceptible individuals. <br> <br> <annotation cui="C0012546">Diphtheria</annotation> Infections due to <i> Corynebacterium diphtheriae </i> , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. <br> <br> <annotation cui="C0014752">Erythrasma</annotation> In the treatment of infections due to <i> Corynebacterium minutissimum </i> . <br> <br> <annotation cui="C0013370">Intestinal amebiasis</annotation> caused by <i> Entamoeba histolytica </i> (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. <br> <br> <annotation cui="C0149959">Acute pelvic inflammatory disease</annotation> caused by <i> Neisseria gonorrhoeae </i> Erythrocin Lactobionate I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of <annotation cui="C0149959">Acute pelvic inflammatory disease</annotation> caused by <i> gonorrhoeae </i> in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of <annotation cui="C0018081">gonorrhea</annotation> and a follow up serologic test for syphilis after 3 months. <br> <br> Erythromycins are indicated for treatment of the following infections caused by <i> Chlamydia trachomatis </i> <annotation cui="C0009763">conjunctivitis</annotation> of the newborn, <annotation cui="C0032285">pneumonia</annotation> of infancy, and <annotation cui="C0008149">urogenital infections</annotation>  during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to <i> Chlamydia trachomatis </i> . <br> <br> When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of <annotation cui="C0311389">nongonococcal urethritis</annotation> caused by <i> Ureaplasma urealyticum </i> . <br> <br> <annotation cui="C0007939">Primary syphilis</annotation> caused by <i> Treponema pallidum </i> . Erythromycin (oral forms only) is an alternative choice of treatment for <annotation cui="C0007939">Primary syphilis</annotation> in patients allergic to the penicillins. In treatment of <annotation cui="C0007939">Primary syphilis</annotation>, spinal fluid should be examined before treatment and as part of the follow up after therapy. <br> <br> Legionnaires' Disease caused by <i> Legionella pneumophila </i> . Although no controlled clinical efficacy studies have been conducted, <i> in vitro </i> and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. <br> <br> <div> Prophylaxis </div> <div> Prevention of Initial Attacks of <annotation cui="C0035436">Rheumatic Fever</annotation> </div> Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of <annotation cui="C0035436">Rheumatic Fever</annotation> (treatment of <i> Streptococcus pyogenes </i> infections of the upper respiratory tract e.g., <annotation cui="C0040425">tonsillitis</annotation>, or <annotation cui="C0031350">pharyngitis</annotation>). 3 Erythromycin is indicated for the treatment of penicillin allergic patients. The therapeutic dose should be administered for ten days. <br> <br> <div> Prevention of Recurrent Attacks of <annotation cui="C0035436">Rheumatic Fever</annotation> </div> Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of <annotation cui="C0035436">Rheumatic Fever</annotation>. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long term prophylaxis of <annotation cui="C0036689">streptococcal pharyngitis</annotation> (for the prevention of recurrent attacks of <annotation cui="C0035436">Rheumatic Fever</annotation>). 3 <br> <br> |04775721-ab87-4b66-808c-d67a21032385;04aa620e-90a3-4f22-91ee-b2de9f41e54c;14a886f7-b5e3-48ec-b77f-14b0a577d802;17f33d19-9a87-4530-a477-42848f3d3e0c;216a7517-bf53-48d1-9613-78c9536c4ebf;23a0564e-dca9-41bc-b2c7-0461169f65f9;28a270f4-f713-4d88-b83a-f5b5e9b26746;3bb441fb-3c40-45d6-bb10-c761cc8e83b0;3e53be82-0c32-4f3f-46aa-e6dc15e09e30;3e823928-c853-4617-acad-21b27174aa7b;41D549E0-23AE-4D86-B92C-2ACBDEEACA66;51841d8c-5625-448d-8184-940023aebd02;553240ad-2b80-4ab4-b229-8eaf5e755a84;63ab97a3-5f44-4881-f38b-960b4f474790;65907167-2ee1-4c8c-a950-87ac35e9f5a3;6c789378-0ec7-4874-aa42-e3418e859f86;6d8c343b-30d9-4cdb-8f55-2a20983a71c1;9231d2fa-2e91-4eef-afa3-7515bc34df0b;98C0C097-C253-4CC2-939E-6C172752D394;98d84849-4796-4483-9fe7-bf617fcd555f;C3F7CD94-D842-4F6B-A582-A38C751A790A;a0c0811e-9b05-4434-21a3-a25ebb27681f;a96c405f-bd70-4bb4-719e-ac6a79dcc213;adea2968-68fa-435e-9c8c-dfa0f9903b00;b455bbdb-a3f1-470f-aa5f-ed83ac2e228d;c9b4d3f9-72f3-403b-9399-9426d3555350;ca1326d6-c5c6-4572-96b6-e56cd944799c;d19e99aa-90ac-4777-a3c9-69620724bbb1;dc8ceafe-9597-4de6-968d-43c87a261162;ddd9ad9a-fc60-409a-a2b3-be51482ef751;e142a363-a8b8-40b9-ae9d-28777367e718;e3e27c8f-64d5-4e6e-bb2d-5dd3a2e3daa1;e7dd481b-5c2a-412e-86df-dfe1376ce38c;e83ebf1a-2719-4f52-a47d-3d5af9e8d6f4;e864096e-8581-48a4-9459-956e2b366181;fda44eb6-7901-4b80-ba0b-216f6cacf3fd;
4013|d49fc909-1e02-4e51-b957-45540d678dde| <br> <br> Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with <annotation cui="C0270834">complex partial seizures</annotation> that occur either in isolation or in association with other types of <annotation cui="C0036572">seizures</annotation>. Valproic acid is indicated for use as sole and adjunctive therapy in the treatment of <annotation cui="C0014553">simple and complex absence</annotation> <annotation cui="C0036572">seizures</annotation>, and adjunctively in patients with multiple <annotation cui="C0036572">seizure</annotation> types which include <annotation cui="C0014553">absence seizures</annotation>. <br> <br> Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. <br> <br> See <i> Warnings and Precautions (5.1) </i> for statement regarding fatal hepatic dysfunction. <br> <br> |05e16c10-ff0a-4238-8181-f3e84379ed6a;0b24089f-4c7f-4fee-9a86-89f783b76514;4067a52d-c3fa-4531-8e4f-9675e494065f;5850bfd4-df74-44fb-aef5-ea3fa7c075ee;6541ab19-3cfc-4786-9cfe-0455f428edb5;6a7f6c20-d878-409f-aadb-8c5c63df61d0;6b4331f5-4475-417a-6a9d-09c2f8334235;7386b72a-de47-48e3-b070-8bd9437c2230;740a1ae9-19f0-4a0f-a431-e4b9ffb9381a;7af84664-7e3b-43f3-a43e-beba36ffb739;7d5cb52e-37dd-4dfa-a6f4-09f9548846c6;84bbc23d-9bd3-4d48-9b64-d6eef64214b4;9d3b0fc6-c69f-4110-a606-c0b5d690b5e5;9fbfe4dc-c4df-4911-a440-099c860cb923;a3dcab36-b9df-421a-8c24-bf6ef4f9d7a8;bcf57b31-4811-4104-82b3-46fb91a53ee0;caf12ea3-06c8-44c1-9e89-3ecaff89a22b;cef3e335-5891-412f-89c4-79fcd2f145b7;d378200e-b31a-4b25-bde1-871f944830e5;d49fc909-1e02-4e51-b957-45540d678dde;da030cbb-40f6-4805-9883-0d8945afbcc3;dc5c6650-7ee8-4357-b037-08cd265b985a;ec559356-75a3-423b-9e8c-3ff88290a98a;
5212|54101870-d8a8-4b35-a31d-93480af9d181| INDICATIONS AND USAGE <br> <br> Zolpidem tartrate tablets are indicated for the short term treatment of <annotation cui="C0917801">insomnia</annotation> characterized by difficulties with sleep initiation. Zolpidem tartrate tablets have been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14) ]. <br> <br> The clinical trials performed in support of efficacy were 4 5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. <br> <br> |02b5e3bb-c976-40a3-9077-64ffe637429f;04fefd25-53d9-47b5-8a6b-1d9eb0bf68fb;0553e26c-f2aa-43aa-adf9-6eb951a501d3;1584bad1-7bf4-4805-bdd9-7eb0fac92721;1cfe5171-26bf-4a93-8bd8-2b252c1a16ad;1f1490cd-b11b-40cb-96be-865730c989e1;208db529-ae52-462d-8fd2-775b11ce6350;20dc1daf-4732-404d-9904-e046991ce59e;2a5c9a51-29de-4f83-b02e-98774d8a69e4;2a9f6195-0f8a-4ca8-c0d9-880a290cf28f;2facd90f-7356-44f4-a257-c545de2a53a6;313ccc9f-7b3e-4e42-b5d8-0e27c3c72d8e;31d13e08-b54f-469e-88d3-c96b2c5bc05d;36202145-15cc-47b9-9706-b7102da8586f;413b6f65-101e-e2cf-0802-711d080b851b;43934d82-cb79-467e-9092-23756406828b;4c149192-bfdf-4da2-abac-be4fa3e17c56;508fda39-e503-4ff5-876d-726cddc4dfa6;51c9a29c-a285-40d0-bf3a-7e8c944ee39c;54101870-d8a8-4b35-a31d-93480af9d181;5c438434-208d-4e59-a450-e0dc2bfbb16f;5e14c50e-27da-470b-a519-b26fd74cc501;636532aa-821e-4696-8888-1442953d4014;69be3294-ba4b-4393-816b-dedfa18d9947;78d35821-60e9-45b1-96d8-c126cb4a5cee;7b577a38-4a41-4926-9b40-2d41193130f5;7efb19d9-32bb-4737-ac7f-2ec21eca255c;80996f05-e322-40c5-b3b4-c12c747a88a6;89cfb1d5-437c-4c13-8f9b-b6851ffba87b;8a0a454e-b18e-4d89-bf16-943c4c968fe2;8e207ba8-f509-445a-ad03-4b6c1b1ee6cc;9245ff4b-a11f-4afd-8fa0-842fcfee4306;937e58eb-f69f-4598-bff9-85f2ae515aa0;9dea009e-d435-4268-ab25-cf48a6c69abb;A0E521C3-7807-464E-922D-CE8F23216828;A24DF8D2-E3EA-4224-AE4D-FFEB3E4BBDF1;AE0B595A-36D2-44F3-84F6-7FE9F995F4A1;D4EA84F2-A13F-4335-A184-1E87702BC396;a32884d0-85b5-11de-8a39-0800200c9a66;a4de4fbc-56d2-40ac-814e-0546bca5ca7c;a9ac3d4e-f502-41e3-95c0-0d334584566d;ab34bf06-cd41-41ae-b20b-73c5859b2fab;b87ea23e-2d54-4d10-8f10-72d4c62f3245;bc09674c-221f-40d8-9fd4-6da672496b3a;bda524fd-6c95-45a4-87e4-49f3f9d18f0d;bf1dd603-d91e-03d1-e262-d5a5b3022e07;c1e38416-5ece-4b88-8793-b49032c13672;c36cadf4-65a4-4466-b409-c82020b42452;c784cf9d-de8f-44b6-b52f-a0e7c0d35e48;c8060b86-9c24-4347-8da3-5b7b3d62aa43;d31076b4-44ac-4f8b-8df6-5200cdbea12b;d34336b1-7041-4078-beda-94bc9d9f771e;db274f7c-c2f1-48ac-8edb-295c6af3121b;de965605-268a-4479-86f7-84de949cf36f;e28b0df4-b052-4588-8a45-d17797116c3f;e617f7f2-585c-4eb5-8d35-1fc6d02ef57d;ea2067bd-1622-4d98-8012-2c09405aa88d;ef094cc5-d9cd-4d6c-ac22-f8ee6ae28528;ef8d9313-4a5b-44ff-ac1d-c914c9eb3dd9;f0c8d2e8-216d-4605-9040-27d01bbba9ac;f1977b44-59b9-4e5e-802f-d201ef5c8783;f5b905ec-5b95-bf90-60ba-3355df50acf0;f852e2c0-74fe-4389-ba96-d0c03f624c86;ff6c0109-e6f3-4920-83f3-6e39fd28a118;
7075|676e73fb-51d2-449a-8749-1a7bcc257b11| <div> (<annotation cui="C0029408">OA</annotation>) </div> MOBIC is indicated for relief of the signs and symptoms of <annotation cui="C0029408">osteoarthritis</annotation> [ <i> see Clinical Studies (14.1) </i> ]. <br> <br> <div> <annotation cui="C0003864">Arthritis</annotation> (<annotation cui="C0003873">RA</annotation>) </div> MOBIC is indicated for relief of the signs and symptoms of <annotation cui="C0003873">Rheumatoid Arthritis</annotation> [ <i> see Clinical Studies (14.1) </i> ]. <br> <br> <div> <annotation cui="C0003873">Rheumatoid Arthritis</annotation> (<annotation cui="C0553662">JRA</annotation> ) Pauciarticular and Polyarticular Course </div> MOBIC is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course <annotation cui="C0553662">Juvenile Rheumatoid Arthritis</annotation> in patients 2 years of age and older [ <i> see Clinical Studies (14.2) </i> ]. <br> <br> |676e73fb-51d2-449a-8749-1a7bcc257b11;6f6f6cc7-0833-410c-8889-206addebbfa3;72d1ad20-a10d-4c1e-8a4a-a125426d400f;
7536|c5e8e2fd-7087-4b78-9181-cc259c0be2f1| To reduce the development of drug resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> <div> Travelers <annotation cui="C0011991">Diarrhea</annotation> </div> XIFAXAN 200 mg is indicated for the treatment of patients ( 12 years of age) with travelers <annotation cui="C0011991">Diarrhea</annotation> caused by noninvasive strains of <i> Escherichia coli [ </i> <i> see Warnings </i> <i> and Precautions ( 5 ) </i> , <i> Clinical Pharmacology ( 12.4 ) </i> and <i> Clinical </i> <i> Studies </i> <i> ( 14.1 )] </i> . <br> <br> <i> <u> Limitations of Use </u> </i> <br> <br> XIFAXAN should not be used in patients with <annotation cui="C0011991">Diarrhea</annotation> complicated by fever or blood in the stool or <annotation cui="C0011991">Diarrhea</annotation> due to pathogens other than <i> Escherichia coli </i> . <br> <br> <div> <annotation cui="C0019151">Hepatic Encephalopathy</annotation> </div> XIFAXAN 550 mg is indicated for reduction in risk of overt <annotation cui="C0019151">Hepatic Encephalopathy</annotation> (<annotation cui="C0019151">HE</annotation>) recurrence in patients 18 years of age. <br> <br> In the trials of XIFAXAN for <annotation cui="C0019151">HE</annotation>, 91% of the patients were using lactulose concomitantly. Differences in the treatment effect of those patients not using lactulose concomitantly could not be assessed. <br> <br> XIFAXAN has not been studied in patients with MELD (Model for End Stage Liver Disease) scores > 25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction <i> [see Warnings and Precautions ( 5.4 ), Use in Specific Populations ( 8.7 ), Clinical Pharmacology ( 12.3 )] </i> . <br> <br> |523f0320-cc73-445a-a48d-7a181c182307;c5e8e2fd-7087-4b78-9181-cc259c0be2f1;
7917|43CBC779-48D1-48FB-F09E-2D1722B4046D|HYTRIN (terazosin hydrochloride) is indicated for the treatment of symptomatic <annotation cui="C1704272">benign prostatic hyperplasia</annotation> (<annotation cui="C1704272">BPH</annotation>). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of <annotation cui="C1704272">BPH</annotation> when treated with HYTRIN. The long term effects of HYTRIN on the incidence of surgery, acute urinary obstruction or other complications of <annotation cui="C1704272">BPH</annotation> are yet to be determined. <br> <br> HYTRIN is also indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>. It can be used alone or in combination with other antihypertensive agents such as diuretics or beta adrenergic blocking agents. <br> <br> |1bdcf20c-6806-495c-9505-1b64d66e5405;24a4243f-0855-44c1-bb78-ba6f14b273f9;24ce46de-cf8f-401f-8bb6-490b296513c5;2795c42c-8aad-41bd-f386-f075505d4e8b;2cfe38fe-f16c-4dbd-a237-15e0d12ef3ef;30503dfd-03bd-46d8-8170-d9ed096fd71d;43CBC779-48D1-48FB-F09E-2D1722B4046D;43e92495-2cf2-46dd-a80c-f0c3c88c7b73;66abc5e3-4a7c-447a-8daa-91b872b88094;68877160-c88e-4b4e-a61d-abd4dff96742;6c26db9b-f16c-4797-b6b1-bc51bf2649b5;9d8fd052-b478-447e-a884-74fcd21275bb;EE7A527D-290E-437D-BB9D-1617AFE1C1AF;a00604ff-041d-4ad4-a3bb-d0911bf0727e;a9fdefac-0145-4d34-ab25-074bc534afaf;bcd2cf96-c69f-4600-8d24-245de0f88a64;cc7b252f-551d-443b-8845-307da7394068;d156295e-43aa-4456-9c2c-b6a367c385de;d971811c-d327-4e63-808c-8d553ee471e7;fbfca9d7-bd04-4148-91c7-02b37e839d28;
7950|55f21004-9ce6-4648-94d9-73ab2c7873e8| <div> Acute Treatment of <annotation cui="C0149931">Migraine</annotation> Attacks and <annotation cui="C0009088">Cluster Headache</annotation> </div> ALSUMA (sumatriptan injection) 6 mg 0.5 mL is indicated for the acute treatment of <annotation cui="C0149931">Migraine</annotation> attacks, with or without aura, and the acute treatment of <annotation cui="C0009088">Cluster Headache</annotation> episodes. <br> <br> |55f21004-9ce6-4648-94d9-73ab2c7873e8;6a4c0c2f-497d-4c5c-84c4-9ab42780cbde;
8595|6fa00cb8-4229-4770-9d2a-d4a8542b3180| <div> <annotation cui="C0026769">Multiple Sclerosis</annotation> (<annotation cui="C0026769">MS</annotation>) </div> TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of <annotation cui="C0026769">Multiple Sclerosis</annotation> to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. The efficacy of TYSABRI beyond two years is unknown. <br> <br> Because TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate <annotation cui="C0026769">Multiple Sclerosis</annotation> therapy [see <i> Boxed Warning , Warnings and Precautions ( 5.1 ) </i> ]. <br> <br> Safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied. <br> <br> <div> <annotation cui="C0010346">Crohn's Disease</annotation> (<annotation cui="C0010346">CD</annotation>) </div> TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active <annotation cui="C0010346">Crohn's Disease</annotation> with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional <annotation cui="C0010346">CD</annotation> therapies and inhibitors of TNF  . TYSABRI should not be used in combination with immunosuppressants (e.g., 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF  [see <i> Boxed Warning , Warnings and Precautions ( 5.1 ) </i> ]. <br> <br> |6fa00cb8-4229-4770-9d2a-d4a8542b3180;
9041|b972af81-3a37-40be-9fe1-3ddf59852528| INTUNIV is indicated for the treatment of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>) as monotherapy and as adjunctive therapy to stimulant medications. The efficacy of INTUNIV was studied for the treatment of <annotation cui="C1263846">ADHD</annotation> in two controlled monotherapy clinical trials (8 and 9 weeks in duration) and one controlled adjunctive trial with psychostimulants (9 weeks in duration) in children and adolescents ages 6 17 who met DSM IV criteria for <annotation cui="C1263846">ADHD</annotation> [ see Clinical Studies (14) ]. The effectiveness of INTUNIV for longer term use (more than 9 weeks) has not been systematically evaluated in controlled trials. <br> <br> A diagnosis of <annotation cui="C1263846">ADHD</annotation> implies the presence of hyperactive impulsive and or inattentive symptoms that cause impairment and were present before the age of 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months lack of attention to details careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months fidgeting squirming; leaving seat; inappropriate running climbing; difficulty with quiet activities; "on the go"; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive impulsive criteria to be met. <br> <br> Special Diagnostic Considerations <br> <br> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM IV characteristics. <br> <br> Need for Comprehensive Treatment Program <br> <br> INTUNIV is indicated as an integral part of a total treatment program for <annotation cui="C1263846">ADHD</annotation> that may include other measures (psychological, educational, and social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. INTUNIV is not intended for use in patients who exhibit symptoms secondary to environmental factors and or other primary psychiatric disorders, including psychosis. Appropriate educational vocational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe INTUNIV will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms and on the level of functional impairment. <br> <br> |b972af81-3a37-40be-9fe1-3ddf59852528;
10252|46056e8c-dc64-42e2-8c7f-0b82fbf63d4d| Glipizide tablets are indicated as an adjunct to diet for the control of <annotation cui="C0020456">hyperglycemia</annotation> and its associated symptomatology in patients with non insulin dependent diabetes mellitus (<annotation cui="C0011860">NIDDM</annotation>; type II), formerly known as maturity onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. <br> <br> In initiating treatment for non insulin dependent <annotation cui="C0011849">diabetes</annotation>, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of <annotation cui="C0020456">hyperglycemia</annotation>. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified, and corrective measures taken where possible. <br> <br> If this treatment program fails to reduce symptoms and or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of glipizide must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone also may be transient, thus requiring only short term administration of glipizide. <br> <br> During maintenance programs, glipizide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgements should be based on regular clinical and laboratory evaluations. <br> <br> In considering the use of glipizide in asymptomatic patients, it should be recognized that controlling blood glucose in non insulin dependent <annotation cui="C0011849">diabetes</annotation> has not been definitely established to be effective in preventing the long term cardiovascular or neural complications of <annotation cui="C0011849">diabetes</annotation>. <br> <br> |06505b04-656c-47ef-83ba-ab977bdcaaf4;0a280a88-5973-4d0f-9b25-9be0c96e49c7;3030da52-4e59-44d0-9d62-4b27e38e7e91;36199637-6267-43d6-9304-d77e8948c4fd;37A18BD1-034F-4366-8323-EC4E1C52AC1E;46056e8c-dc64-42e2-8c7f-0b82fbf63d4d;5af9cea1-f70c-48af-b640-fb1048ca6beb;653e1ec7-2ffc-4876-b200-36cedf187385;83cac6c1-372e-4063-95f9-87740e05b19c;a9abe8f4-0b0b-42f7-b3d7-c678a9fcf39f;ab0646e3-3db2-4dff-8991-c796a5c899dc;ad55dfd7-ffb5-478a-aa84-1009fa921e22;c829b7bf-1a12-44b2-b5ce-fd44a1f0d333;e1f70f24-1a4d-4861-9917-859bca58b865;e253ec37-78bb-4168-b630-2b7e33607f9d;e9f904fa-5709-48df-a4cd-4604b656b1a1;f19783e8-76bd-4403-b348-b30b449bb615;
10352|00c42c5c-d19e-4130-aa08-a8bbd47d3e5b| For the prevention and treatment of <annotation cui="C0019151">portal systemic encephalopathy</annotation>, including the stages of hepatic pre coma and coma. <br> <br> Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal systemic encephalopathy, Lactulose has been given for over 2 years in controlled studies. <br> <br> |00c42c5c-d19e-4130-aa08-a8bbd47d3e5b;2a2eee86-273e-4718-8f78-34f15e193040;67e975ca-cc79-237d-6c29-4653c222e0c8;A9B8BC93-AF0F-44E6-A5F2-FF001542A81F;ff6b4568-1383-46b6-a1c6-385fc31fb210;
10361|871fc448-dfa7-492b-813c-c37e93e53cdb| Haloperidol is indicated for use in the management of manifestations of <annotation cui="C0033975">psychotic disorders</annotation>. <br> <br> Haloperidol is indicated for the control of <annotation cui="C0040188">tics</annotation> and vocal utterances of <annotation cui="C0040517">Tourette s Disorder</annotation> in children and adults. Haloperidol is effective for the treatment of severe <annotation cui="C0260653">behavior problems</annotation> in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. <br> <br> |0027b8a3-73bf-4005-a7e3-b035f451a861;0ac0cc44-3924-447d-9051-f84c44312380;2d848e8c-de42-4a09-96f1-a2d250af059d;509d0eb2-b930-4836-9669-dbebf0ac4076;54502f78-7244-454a-9171-4e73127f1456;5913794a-3aad-48ef-89ca-eebc8ae92628;59903eb9-77a2-42b3-ae09-af94ac209d32;82305b49-9fdf-425b-98d7-39c2ac156918;871fc448-dfa7-492b-813c-c37e93e53cdb;913fdc2f-36eb-47e1-aaee-7bfb542d3ed3;ad7d2f17-a4e8-4ebc-9baf-5983ac626782;b37de1e8-066b-49ea-a03a-8103733c6ee3;b488c106-f1ee-4b7b-8516-01162fb929f7;bd2a2749-4f93-400a-a06d-db7b8115ebad;c559b0b0-4087-d12a-e718-c18ccb6811e6;d3ea05de-a49e-4924-8ce8-38978302f266;df0f93db-aa16-4f30-8c49-904d269b36b1;f200975a-530f-47b6-84bf-de425b563ee0;
10482|504567d2-e4f1-428d-b524-f29db76e6dfb| GLUCOTROL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with <annotation cui="C0011860">type 2 diabetes mellitus</annotation>. <br> <br> |17d1f383-170e-4e5e-a97e-d346ee026166;27a36034-e265-445e-8ec1-9277c6ed3b35;289bda32-6198-4072-a9f3-283438bda707;3e21bcc7-6f0d-4d63-befd-aa3ac8c63e37;42308dd9-57c2-4416-a394-681f6733f566;504567d2-e4f1-428d-b524-f29db76e6dfb;5565ccec-8000-48ab-a6af-37eca2d8c993;56e0119b-a098-4912-ad7c-40d55cb56499;58a9975c-c442-4839-9809-93343e9a9e87;6a957e2e-f1ea-416b-81de-f273234e6db9;6aee7760-c378-4bc0-a5ca-15216aa02ca9;6ce1d9b9-3a71-4c10-9c09-6259088baafb;73290450-b243-4127-a07b-6835c5eb44ec;760d589c-24f1-c89a-bc01-ea57101b2f20;7f63a663-4eee-405c-9182-d36fbd234690;8438b406-9259-46d1-b26a-90fdcb5cbc50;8847574b-2380-4958-853d-ae6f8c769ad5;91f17eba-33aa-45c2-9a44-48116a9a6487;92fd71b2-cea9-4c4c-b17c-35341110b525;9f41c976-a6d5-4e10-bf62-6e2898be8d8b;a430577c-f233-40a7-bfd8-3d2bc6f98aa2;a82e0444-5ea7-45e6-9cde-97af77eb9a8e;a9f7dcc6-a64c-4ef7-a5d8-00831ecb00e5;b4f55916-91a2-4171-a361-919e7cb329b0;b738e30e-52f2-44ba-93be-090a68c5d64b;c9c3fa3e-af0c-42b9-a7c0-181642d2b1ea;ca37f71a-6261-4ada-9d4b-368329aa439a;d0b36326-e17d-4fff-aa12-a86f5284669f;d7962180-0c2b-ad3a-2404-05ef6400aac7;db62da3d-4865-4bf3-a22c-26849a85af68;dcf426b8-bcdc-8214-a1b6-6388bd3399a0;ec1de664-3135-4498-a0c9-1a9c0d3d0775;eed99b60-d043-4249-9b2a-f05e46fb588d;f4b2b88c-946c-4670-8538-84f858b7af33;f5b8c777-ec04-44b6-a5c4-251622079aca;
10489|19455240-16b6-4e25-a5c9-a6c965e5ec19| For the treatment of <annotation cui="C0009806">constipation</annotation>. In patients with a history of <annotation cui="C0401149">chronic constipation</annotation>, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. <br> <br> |0f19e4ed-c90a-4330-a7fa-bf911aa98f09;183c0621-d058-4600-9345-2b01d66cb65a;19455240-16b6-4e25-a5c9-a6c965e5ec19;287b0b8b-962b-4f05-b770-5dc9d170d1d0;461ec39f-eeb4-4460-9b5c-62367d47162b;5f1082c8-f21f-44e1-a166-793d355d54d7;6c8f865e-f2f4-4c98-8bad-68f1575e2ed5;7016bd71-c667-46fc-8c56-5023682e8bbe;a61e6ba8-b342-4815-9623-eb0c319ecc74;ba296354-b01c-4b3f-a980-b8a0ac370932;bd4d1c58-4b9b-47c1-a3c7-64f7a827d408;d21e0f18-ea2d-4be0-8f2e-78637126504e;fa13a399-a397-4a2c-b4ae-b152c35439e7;
10933|357e0e6b-cfbd-454c-82d7-cfc460dc0d68| CANASA 1000 mg Suppositories are indicated for the treatment of active <annotation cui="C2937222">ulcerative proctitis</annotation>. <br> <br> |357e0e6b-cfbd-454c-82d7-cfc460dc0d68;89d91601-152b-4398-bebe-af1c023e9935;
10934|21679c9c-27d7-47c9-828e-b4cc405816cc| Transdermal nitroglycerin is indicated for the prevention of <annotation cui="C0002962">angina pectoris</annotation> due to coronary artery disease. The onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. <br> <br> |15b3ea32-3422-4aa8-b4c2-41ee6d1aa566;21679c9c-27d7-47c9-828e-b4cc405816cc;227916ea-e308-4a0a-bdce-f6303f27ed33;2ce8c8f1-f0b7-45df-a531-42dbd9f2e56c;2dcdd1c3-6728-45fb-97aa-de21f1f5ccad;30934ddc-0823-4097-8699-d10988011d7c;3c11c1c2-8e62-4f63-8293-2f8b8d845f7e;4c7b800d-c535-4cd8-b16b-d24af0ef9a5e;4d7c7bf5-0f70-4a76-870c-f609d98e5ba9;5822a8fa-5c61-4685-a159-653a022df669;5de5366c-0719-4a4c-9483-cd99b218ee78;6117ec32-636c-2304-e6dc-f622b058ae1d;a1648bd9-8a89-4292-b703-aa83d9bd6c6d;b17f29ca-517e-4d89-84f1-024d98fc5d77;bd2f4e87-e595-4099-acb9-e36803170f72;e2c20994-a2db-4e67-a535-25bf87ef02f1;e464e9bb-48e8-4b9f-9fff-e220cfbac0c5;e98a2692-1cb9-4994-98d8-1d8d9ef1a256;efb1e4fc-73b8-43c5-ac68-d5b870cc8e10;fcd4cf8a-e3e6-7da9-6355-c60b7400291a;
11759|75bf3473-2d70-4d41-93cd-afa1015e45bb| For the relief of symptoms of <annotation cui="C0011570">depression</annotation>. <annotation cui="C0011573">Endogenous depression</annotation> is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. <br> <br> |53faac6a-fdb9-4d60-814d-b4aab9c9da58;6e780825-2a66-41fd-a04c-78fa7c4df05e;75bf3473-2d70-4d41-93cd-afa1015e45bb;75c986bd-e51f-4f8c-9590-0df4718d0b9e;93B19AE0-C0A1-4400-9A56-6827939B7E7A;d1dde497-1889-4424-af18-da7ca6459cf3;
11779|3adddbd4-0b17-4312-83a2-a8420caf045e| <b> In Anesthesia </b> <br> ROBINUL Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, ROBINUL Injection may be used intraoperatively to counteract surgically or druginduced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., <annotation cui="C0428977">bradycardia</annotation> and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the <annotation cui="C0700323">neuromuscular blockade</annotation> due to non depolarizing muscle relaxants. <br> <br> <br> <b> In <annotation cui="C0030920">Peptic Ulcer</annotation> </b> <br> For use in adults as adjunctive therapy for the treatment of <annotation cui="C0030920">Peptic Ulcer</annotation> when rapid anticholinergic effect is desired or when oral medication is not tolerated. <br> <br> |125a2d5d-0ee6-4bd8-991d-5fbfbe3e7dcb;2ade57bf-4013-4358-9e3b-8b6df7fd4045;38f88829-a226-4810-866c-1b62c47e8aee;3adddbd4-0b17-4312-83a2-a8420caf045e;61767a0d-c94c-44d8-b35c-316a5731a275;62267afe-1a73-4623-984e-646db590ec5b;d82ca14f-2116-4ec1-b497-1c9d6db4d5e7;eac7ff63-9fa3-4774-8a83-36353dd4cd7a;fe52214b-fe89-4215-a43b-5f9a85950fa9;
1185|3098a080-be86-4265-9818-7fc4beab77b7| LIALDA is indicated for the induction of remission in patients with active, mild to moderate <annotation cui="C0009324">ulcerative colitis</annotation> and for the maintenance of remission of <annotation cui="C0009324">ulcerative colitis</annotation>. <br> <br> |3098a080-be86-4265-9818-7fc4beab77b7;
12144|1b6b473a-850f-416c-ad9a-e54c06b98d57| IMDUR Tablets are indicated for the prevention of <annotation cui="C0002962">angina pectoris</annotation> due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. <br> <br> |07c1c818-44ad-44b0-aeec-2bc51193cd52;0a1e317a-7b05-4d30-9bbc-1d4ccd56ba3c;0c7f9a96-12b8-4149-9f32-78639e98dfd0;147ac314-1b2a-4c17-8c51-57cfe361b7fb;1b6b473a-850f-416c-ad9a-e54c06b98d57;3ae1adfa-6c55-4fd8-9d75-049509387ce0;3b65e78b-4ff9-4f25-90f9-c6108d3f1f32;6c86db8e-0ef6-4143-add1-8818c20be135;7345c065-3627-4fb2-8470-7e80d450b38e;8c104eaa-d2ec-4403-84a7-8d93b585698e;A48FB550-390F-4579-8514-D85DB7421721;AE8F74F0-E600-4452-8557-958B603E2709;EC09AB1C-52FA-4F41-BF65-A632DCE8F097;b35a72bb-c06b-4671-8dc2-ce0ccdf45ce9;b8e0d977-6eb7-4b14-9176-64e5738d14da;bf9e7e35-7707-42a0-88d6-6292fa52bbfa;c53983a9-8736-4f7f-9ef2-274c0d9a85bc;cc6293ae-1f81-4670-84b2-c00422c690ca;e238b564-a178-4bc6-80a9-0e423841748e;edae9116-fcbd-4f26-8087-6fb63f78c655;ef08d90f-ba26-4b68-8e3a-d0320e4b0f8e;f160ab83-126f-4e99-845a-7b27622c377f;f6c60617-2a61-448e-a79e-9003bca17e9d;
12154|758646d8-937d-4a5b-8c68-fd0802f77c28| <div> <annotation cui="C0036341">Schizophrenia</annotation> </div> Quetiapine fumarate tablets are indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation>. The efficacy of quetiapine fumarate tablets in <annotation cui="C0036341">Schizophrenia</annotation> was established in three 6 week trials in adults. The effectiveness of quetiapine fumarate tablets for the maintenance treatment of <annotation cui="C0036341">Schizophrenia</annotation> has not been systematically evaluated in controlled clinical trials <i> [see Clinical Studies (14.1) ] </i> . <br> <br> <i> Pediatric use information in patients (13 to 17 years of age) with <annotation cui="C0036341">Schizophrenia</annotation> is approved for AstraZeneca Pharmaceuticals LP s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP s marketing exclusivity rights; this drug product is not labeled for such use in those adolescent patients. </i> <br> <br> <div> <annotation cui="C0005586">Bipolar Disorder</annotation> </div> Quetiapine fumarate tablets are indicated for the acute treatment of manic episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12 week monotherapy trials in adults, in one 3 week adjunctive trial in adults <i> [see Clinical Studies (14.2) ] </i> . <br> <br> Quetiapine fumarate tablets are indicated as monotherapy for the acute treatment of depressive episodes associated with <annotation cui="C0005586">Bipolar Disorder</annotation>. Efficacy was established in two 8 week monotherapy trials in adult patients with bipolar I and <annotation cui="C0236788">bipolar II disorder</annotation> <i> [see Clinical Studies (14.2) ] </i> . <br> <br> Quetiapine fumarate tablets are indicated for the maintenance treatment of <annotation cui="C0853193">Bipolar I Disorder</annotation>, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of <annotation cui="C0005586">Bipolar Disorder</annotation> has not been systematically evaluated in controlled clinical trials <i> [see Clincial Studies (14.2) ] </i> . <br> <br> <i> Pediatric use information in patients (10 to 17 years of age) with bipolar <annotation cui="C0338831">mania</annotation> is approved for AstraZeneca Pharmaceuticals LP s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. </i> <br> <br> <div> Special Considerations in Treating Pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> </div> <i> Pediatric use information in patients (13 to 17 years of age) with <annotation cui="C0036341">Schizophrenia</annotation>, and patients (10 to 17 years of age) with bipolar <annotation cui="C0338831">mania</annotation> is approved for AstraZeneca Pharmaceuticals LP s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP s marketing exclusivity rights; this drug product is not labeled for such use in those patients. </i> <br> <br> |758646d8-937d-4a5b-8c68-fd0802f77c28;
1234|4e05d1da-0eb8-4fe0-8259-f1ebb170e0dc| <br> Galantamine tablets are indicated for the treatment of mild to moderate <annotation cui="C0011265">dementia</annotation> of the <annotation cui="C0002395">Alzheimer's type</annotation>. |02b0bed7-96d4-429a-aab0-72c37e0efdaa;0593fa48-8a47-4a0e-a9c6-2ef244470b4e;3bea9961-4d8a-4cf3-8b63-49af2b1fbb5b;4e05d1da-0eb8-4fe0-8259-f1ebb170e0dc;5b72e73f-338d-4c46-81f4-9c0fa4516455;5fd6bd00-6cd6-4e9e-b9e3-757acf1a5766;613509ee-e984-4e22-8056-e01226085f77;63bad97b-3df6-4e8f-b183-95f1e9801c8f;8f07d397-e814-41c8-a7f3-fd666b208cfb;BBDAF2F2-14E6-45C4-B807-5B22955444B0;a074f2c6-fc31-4b04-80da-b905abe839b5;a4632019-f2fa-4a32-9e1f-279f4ba35330;c4572a72-e49a-4c29-b121-a530a6b5fd4f;d1697161-ebe8-42b0-83e7-c9de4412546c;e237f9d6-aba8-4492-b093-1134ed1a75cc;e62efb5a-d2cc-4e11-9e61-10e65ef3d897;ec9b5a9c-8caf-4f9b-8c1b-209b2de556dc;fa3cb01f-85bf-5cc8-7cf3-650d8729078c;
12671|f539c374-b61e-4d9b-a0eb-f1a68545ee8c| Haloperidol Decanoate Injection is indicated for the treatment of <annotation cui="C0036341">schizophrenic</annotation> patients who require prolonged parenteral antipsychotic therapy. <br> <br> |5632ada4-05bd-4638-a27a-81d37a66a084;5DE0E919-ACB3-642D-E9E1-8BF08E6DBA79;9f0f42a8-5f7c-4be7-93ef-3ec225502cc6;af0159a8-dff5-449a-aa2b-a0c430081e21;ca9896e0-fb2e-46a4-8700-20d144c14764;f539c374-b61e-4d9b-a0eb-f1a68545ee8c;
12742|1f266d77-4f9e-44c9-a000-2f8fea3ac80b| For use as adjunctive therapy in the treatment of <annotation cui="C0030920">peptic ulcer</annotation>. <br> <br> |06bb6f89-4694-4aaa-8bff-f7f3c81d3add;1f266d77-4f9e-44c9-a000-2f8fea3ac80b;493171ca-718d-4c54-b15f-ca33488b80e7;4ec4e4e4-ce23-463b-9296-bff35b005632;725529e8-9c4b-4108-690a-e4f391439736;9690ebaf-be1b-4968-a578-28bd5372f022;a8fbd1e6-8722-42c0-9bb3-7876d1ca2cfd;a9fe52b4-9290-4e26-a142-1506572bc217;b5650ad5-471d-4639-b8da-bdb3d990c627;
12982|9257f9cd-abaf-4bb2-d9ac-4bc8f65ae558| BACTROBAN CREAM is indicated for the treatment of secondarily infected traumatic <annotation cui="C0037284">skin lesions</annotation> (up to 10 cm in length or 100 cm 2 in area) due to susceptible strains of <i> S. </i> <i> aureus </i> and <i> pyogenes </i> . <br> <br> |76bdab9d-9153-4db6-9b9a-ff376374a8ea;87734c71-a574-465d-b941-f993f9ae8b2b;9257f9cd-abaf-4bb2-d9ac-4bc8f65ae558;cad9604c-7a0d-4716-98e6-235c746a19e5;
13725|af05dde8-1c06-4cd5-bcd0-8e318874536a| RECTIV (nitroglycerin) Ointment 0.4% is indicated for the treatment of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> associated with <annotation cui="C0349071">chronic anal fissure</annotation>. <br> <br> |af05dde8-1c06-4cd5-bcd0-8e318874536a;
13824|b1b95503-1c7a-44e8-b5e0-d50b61db99d5| CHANTIX is indicated for use as an aid to smoking cessation treatment. <br> <br> |0c4ef9ad-ac23-4f48-8eb8-f5931333deaf;27c6abf0-6551-4333-980d-309b9c1eeba3;3e689dae-5058-4556-be14-df50e2803208;826c77fa-d8b2-48df-8028-720b15912d92;b1b95503-1c7a-44e8-b5e0-d50b61db99d5;f0ff4f27-5185-4881-a749-c6b7a0ca5696;f990eca6-fe6f-4423-a118-4b7b970995a1;
14190|b764c8b8-7e23-4016-830f-68312d84f3d3|In patients without structural heart disease, TAMBOCOR is indicated for the prevention of <br> <br> paroxysmal <annotation cui="C0039240">supraventricular tachycardias</annotation> (PSVT), including <annotation cui="C0039232">atrioventricular nodal reentrant tachycardia</annotation>, <annotation cui="C0340477">atrioventricular reentrant tachycardia</annotation> and other <annotation cui="C0039240">supraventricular tachycardias</annotation> of unspecified mechanism associated with disabling symptoms <br> <br> paroxysmal <annotation cui="C0004239">atrial fibrillation flutter</annotation> (PAF) associated with disabling symptoms <br> <br> TAMBOCOR is also indicated for the prevention of <br> <br> documented <annotation cui="C0085612">ventricular arrhythmias</annotation>, such as sustained ventricular tachycardia ( <u> sustained </u> VT), that in the judgment of the physician are life threatening. <br> <br> Use of TAMBOCOR for the treatment of <annotation cui="C0750197">sustained VT</annotation>, like other antiarrhythmics, should be initiated in the hospital. The use of TAMBOCOR is not recommended in patients with less severe <annotation cui="C0085612">ventricular arrhythmias</annotation> even if the patients are symptomatic. <br> <br> Because of the proarrhythmic effects of TAMBOCOR, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. <br> <br> TAMBOCOR should not be used in patients with recent myocardial infarction. (See Boxed Warnings. ) <br> <br> Use of TAMBOCOR in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed Warnings. ) <br> <br> As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of TAMBOCOR favorably affects survival or the incidence of sudden death. <br> <br> |23f74d33-9e7c-493d-b4aa-ed99ebc361a9;4f6b78d4-8ac8-464b-bb78-ee70cbc97898;89105dbf-1085-4c81-ab19-49c7b5966e7d;b764c8b8-7e23-4016-830f-68312d84f3d3;d3bcb22c-42af-433d-bda4-9add2f3092de;d462d58e-fc3c-4c92-a210-e135eb1f4b77;da585354-87e0-4f8c-90e9-3cbc3496a27a;fa68b35e-9f50-408b-9e70-e84cecf3fd6e;fa83c465-62f5-4ba7-b252-8248cbbefb22;
14237|afbefaff-97c4-4f84-b989-1595f882a885| MICROZIDE is indicated in the management of <annotation cui="C0020538">hypertension</annotation> either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, MICROZIDE may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ACE inhibitors. <br> <br> <i> Usage in Pregnancy </i> The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. <br> <br> <annotation cui="C0013604">Edema</annotation> during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when <annotation cui="C0013604">edema</annotation> is due to pathologic causes, just as they are in the absence of pregnancy. Dependent <annotation cui="C0013604">edema</annotation> in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with <annotation cui="C0013604">edema</annotation>, including generalized <annotation cui="C0013604">edema</annotation> in the majority of pregnant women. If this <annotation cui="C0013604">edema</annotation> produces discomfort, increased recumbency will often provide relief. In rare instances this <annotation cui="C0013604">edema</annotation> may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate. <br> <br> |01f1f478-5493-439f-9b99-f4f82023781c;03663116-4187-4286-a7cb-66af52bae6df;091691f1-260b-4ae3-9484-a945a905fffd;09993cda-7cd2-4ba9-8ba2-84b4e9ce3c0e;09bce4c4-96af-4b8b-8d92-86e330fef348;0a6a5b78-c747-a000-f1b0-4b1a107240d1;0af05cf5-5c4c-4e6f-af08-fd4147615d87;0bbc6889-0fd5-4763-97f4-061f5a50c7b1;0ea81a95-cb4f-42af-be32-1cd6c9ab87ae;117a86c1-50f1-4bd5-b5be-6494507cc245;126f04f3-d602-4a46-b1d2-fe45c7a639d5;1576a4be-c3ec-426e-9219-c6a0c99f294f;180451dd-0323-4810-843c-255c2ff9fbcb;1c69ab2e-10cb-407e-a59c-67e542d98a3d;1f066b90-a35d-4e4a-836e-e0f9b44fba02;256bfee6-3e21-4fdb-a1d0-0ef417b8be86;2c4954a3-35dd-4ea1-ad32-0044d6db1665;2ca0f72d-b789-4a25-8ab1-be448aeea35c;2cc3e49f-ab2f-4013-be64-83ed95c85f69;329f0bd2-e285-4d97-b3c1-f710699a0f41;33f3b980-b339-4dbf-99bd-05588c2a298c;3b369a4b-8316-4d27-abc8-e8eecee079e2;4190286c-6836-44ba-8536-ee6468c69641;48666a1e-acad-4e8c-93cb-697138b03b3e;486bad46-d856-4f02-8738-fbe4d5d3bff7;50304146-001d-3810-f223-c500a827d514;5c558d8e-5c1e-4a25-8ae8-8ff133c75683;5e168199-0f9a-48ab-8893-dddd6b217ec0;5f486a39-aaac-4afc-8960-c7b3b5226215;6a191733-410e-4e02-910f-c400829a846a;6cd81119-3835-4277-a142-1f2738e4cbfa;6d7e3b52-e26e-4e62-aa2e-31c87a6cd5bd;6f007825-e1c1-49ed-8637-014899945d25;7048941e-b9b0-4d40-96bd-66f7a5b0bd5e;75ae8b62-59c9-48cd-ae01-846e7735d964;7796dfac-bba3-40d8-a9c0-0f218a152469;7889795d-3fbb-7a37-ded0-3f9032734f96;7b38ac8a-4540-4eb2-aedd-9aa966d22190;7bc5effe-c9ed-4f20-896b-83c5bfb2c621;7f1ed1a0-f422-4c47-9ce8-b5ed41736cfe;7fa30ed1-48e2-4f05-8f6b-9f076077ed19;8655d678-8b8c-4f4e-857a-90925bfef481;8a3e269e-d803-4737-b6cd-6226b4d8f2fc;8d2431cf-8587-d2c9-ff05-08fb649fd4e7;90092d49-84da-4633-bf09-7715d3d6af70;9416208e-e3fe-4213-a4c1-2ea6ebdc5795;94b1b057-1784-461e-aa6c-5a482dd589d3;97ccae3d-0b40-467e-9dcd-d35f5034220a;9da64837-eafa-4410-90ce-1bddfd226cd9;A9ED59B9-B01C-4B39-80F6-A73053EC1AB6;a24c641e-85f0-4aac-8703-2e596d673448;a3eb7294-f913-434b-896c-da028bfebc73;afbefaff-97c4-4f84-b989-1595f882a885;afdf1170-25a0-496d-b293-36ee0db2cd1e;b2da16be-dd6a-4b62-b28b-a633e0235d29;b5851587-d60b-4aa2-92d7-52a81dff96ab;b8a7f534-eb19-4aa1-8730-d3ecf3cefb01;bd41a994-755a-40eb-983e-4a9633562178;c5829b61-c495-4981-a1d2-a666cabc96cb;cb7712f3-9a0b-442d-859d-8be5e6e2529a;d002d2c8-dbd3-447c-8d50-8df86bfbcae2;d90456e4-1942-4429-b116-0acd5fe15afb;d90916e8-88c0-4f5e-bbd9-20c5fb075de0;dfea49ab-18db-4c1b-8932-cc5b86cdd232;e2270db4-2930-4ec5-ac96-2b4542aed367;e31bd548-29ae-419a-831a-80ebb26e042f;e66b1c3c-9121-4e2a-a8c8-65b2e8c54f52;e6edac46-8e5d-4180-a35e-510ecd534367;e91e3942-2392-4824-bfc5-a839ea89d351;f14f4d97-ce6b-4e1e-8d94-0a778c4efc6c;f20e4b9d-2f50-412f-9710-223af851078b;f6f7ea4a-87aa-4866-9dc3-1928e702efc9;f70078b6-abe8-41de-b749-ae52ab0a3036;fbd5b7f2-5571-4361-af2b-4149b5f72f03;fc82f946-1772-4b87-ae32-0acdb4fe9b00;fd639e95-6ba0-486f-bec4-ab7ef081a1ea;fe6200cc-3182-473c-a90a-a8caa2fb2818;ffa41109-b01f-461b-b580-3a593648b6f3;
1441|7951139c-b271-45a4-b523-34b23800917b| APRISO capsules are indicated for the maintenance of remission of <annotation cui="C0009324">ulcerative colitis</annotation> in patients 18 years of age and older. <br> <br> |7951139c-b271-45a4-b523-34b23800917b;d5d05b1f-9f45-4f66-9f75-3c67934105de;
15184|8f44a933-1629-4e65-16a6-9ad421329aa6| BACTROBAN NASAL is indicated for the eradication of nasal colonization with methicillin resistant <i> aureus </i> in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of <annotation cui="C0343401">methicillin resistant <i> aureus </i> infection</annotation> during institutional outbreaks of infections with this pathogen. <br> <br> <b> NOTE </b> <br> <br> <ol><li> There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high risk patients from their own nasal colonization with S. aureus . </li><li> There are insufficient data at this time to recommend use of BACTROBAN NASAL for general prophylaxis of any infection in any patient population. </li><li> Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in 1 domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle treated arms of the adequate and well controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post therapy with 85% to 100% recolonization within 4 weeks. </li></ol> All adequate and well controlled trials of this product were vehicle controlled; therefore, no data from direct, head to head comparisons with other products are available at this time. <br> <br> |8f44a933-1629-4e65-16a6-9ad421329aa6;
1521|34a30bb0-143b-4624-a8ee-f88c2aefa470| Mesalamine rectal suspension is indicated for the treatment of active mild to moderate distal <annotation cui="C0009324">ulcerative colitis</annotation>, <annotation cui="C0033252">proctosigmoiditis</annotation> or <annotation cui="C0033246">proctitis</annotation>. <br> <br> |34a30bb0-143b-4624-a8ee-f88c2aefa470;743ada1c-0f04-43ea-be7d-1560164e6f6e;a4ddf68d-1502-4242-89aa-c96436bdcbf6;a666d21d-da21-498d-aea2-055326cafd70;d50f2c37-5675-49f3-bdd4-3b16d333ed40;dfeede98-5520-4fd1-be02-4971453f9e24;eb5bcaab-0f86-4817-9373-0a5e5e1982d2;
15291|805af56e-c180-47af-b9ab-ae25f61736c2| PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active <annotation cui="C0009324">ulcerative colitis</annotation>. <br> <br> |24998e63-f01e-4a07-be5b-203aadd46941;2c076918-09c0-49bd-bb11-db1e011d597c;6e71e169-bc37-4a1f-bb7d-05bb55345742;70047724-e16b-4ef7-be24-06e651d004d2;70adfac7-f8b7-405c-86aa-b1f30343d38b;805af56e-c180-47af-b9ab-ae25f61736c2;83864c82-9114-4523-bab8-2b47beb88d4e;9444ca88-e119-4027-a8bf-9f8eef7453a2;95de7015-932f-48d4-8734-5906aaee697e;ac724f97-5941-47c1-bcc9-eb5e64be815a;d31a6e7d-31b1-474e-bc7b-821b08115109;d91179bf-48ce-423c-822d-cd06b60caabe;e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606;
15358|eadfe464-720b-4dcd-a0d8-45dba706bd33| <div> <annotation cui="C0013604">Edema</annotation> </div> LASIX is indicated in adults and pediatric patients for the treatment of <annotation cui="C0013604">Edema</annotation> associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. LASIX is particularly useful when an agent with greater diuretic potential is desired. <br> <br> <div> <annotation cui="C0020538">Hypertension</annotation> </div> Oral LASIX may be used in adults for the treatment of <annotation cui="C0020538">Hypertension</annotation> alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with LASIX alone. <br> <br> |09ea0b52-dd3d-4490-999a-b0b3679d5b24;0e2376cc-2ce3-48f8-9392-5c1974543bdf;13d83c0c-6328-4d64-99c1-5a68b132fed9;153c02c7-1fa2-4088-9c00-a2e968dd747a;19926550-0376-42b1-bf67-56871e5bd7a3;1d44526e-563e-4cd2-9625-983d8c31a434;22c39257-8b25-40ae-9896-6edaa68a4997;230cb29d-697e-4257-aa33-683c8f26243f;23720055-fe58-41c8-8d5f-b060b70dfa13;2b0cbe8e-f1c0-4883-94ff-ad603af20655;30cd95a8-ee0d-413d-b26a-6f042e8e1892;3a2c0f3a-7cdb-49b2-9215-e8efcc66e05f;3a2efcd1-9490-4113-974d-21da8ebd7e03;3a731de9-de4e-b384-ede3-aea16c156e8b;40eb0186-e55e-4f93-9233-996297910dbd;43131c04-f9d1-4682-b2a3-c408058f5d81;4a6e0d9d-5473-4e05-b33f-90f48ad706ac;4aaf4dcc-ca69-45df-91f8-584043be3186;54410c7f-83a9-4797-9f81-7ca568130298;59b21dbe-30a0-405b-b39e-c19cea7ad9d6;5c50b5a3-9b39-4cad-8be5-c2a8dd3f7df5;5de52c23-89e5-4a93-8814-7571dd47633c;682d3324-7989-4784-9b1d-9f9257f00fec;77bee32b-743c-424a-ad50-926e19e1cf95;802fda1f-cfa7-422c-8d5b-e9b83a3f02d0;918887d8-5c36-49e9-832d-d03a1d15f2a8;9e493331-dddd-496e-abf8-61747fb67aba;A15D7845-5827-481D-BA3F-E4883489A5EF;EA623E21-E9FD-4EF1-843B-82CBC05AF5BF;a10def90-97c4-43dc-9312-496b8ad89dab;a6fce940-8009-4f80-99dc-a67be052d45a;a87ca064-4121-4428-9cde-bff1c288b12c;aae04ef8-9438-43f4-9418-66b55d7bd7dc;b04aba36-6b66-4e53-8b59-3a0c39bfa21b;b64c46ee-621e-4dd9-8458-beaa654a7c19;d30e72ae-dff7-065d-3aff-d70758bc8590;d562faea-2800-4ed6-9213-88f072e21134;e75f371f-a4fe-44ed-a510-c6f9825f236e;ea5805d3-400b-4978-b27d-bd2b5b1cb636;eadfe464-720b-4dcd-a0d8-45dba706bd33;f2dcb470-240b-4919-8b12-aa1f6faacd49;f3144b19-e282-4cde-82ad-c6ff69ba07cd;f8f67169-b24e-4d65-b1d2-91471b52756e;fc626d03-a44c-4a9b-b87c-d57450d45e35;
15376|CC6E8707-2E6B-4CB8-BF93-117A0AE2559D|Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. <br> <br> <i> <annotation cui="C0013604">Edema</annotation> </i> <br> <br> Furosemide is indicated in adults and pediatric patients for the treatment of <annotation cui="C0013604">Edema</annotation> associated with <annotation cui="C0018802">congestive heart failure</annotation>, <annotation cui="C0023890">cirrhosis</annotation> of the liver, and <annotation cui="C0022658">renal disease</annotation>, including the <annotation cui="C0027726">nephrotic syndrome</annotation>. Furosemide is particularly useful when an agent with greater diuretic potential is desired. <br> <br> Furosemide is indicated as adjunctive therapy in <annotation cui="C0155919">acute pulmonary edema</annotation>. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in <annotation cui="C0155919">acute pulmonary edema</annotation>. <br> <br> If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical. <br> <br> |18823BA7-C4C1-4944-9AF5-41D7015F9B53;19152554-70b0-42fb-a3d5-65ceb00e60e3;27fbf6d5-2853-4f26-bf50-9eac8bb82785;2d6a6ff9-3f12-4a6e-bba3-3f85fd54ffac;39fd32f2-6bb7-4a65-d298-e48d26bc80c7;3ec788b9-b851-4022-a3ef-8ec72bc3d258;6040a2ec-3385-44dd-9f8e-f87ad6474be7;869c9eeb-baae-4189-aa5e-0b4e1ee172d2;8e0bac29-5a8b-4d4e-93b3-2e21eb3b0650;CC6E8707-2E6B-4CB8-BF93-117A0AE2559D;a9bc9926-229c-4563-803c-df8f9e13717b;d71487aa-c181-4549-a16a-61551490dec0;e1badec1-77bd-481a-a93c-3150eaeee814;
15561|9f4e2f54-274a-4ecd-9f42-c16437018fdb| <div> Monotherapy and Combination Therapy </div> JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with <annotation cui="C0011860">type 2 diabetes mellitus</annotation>. <i> [See Clinical Studies (14) .] </i> <br> <br> <div> Important Limitations of Use </div> JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. <br> <br> JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA. <i> [See Warnings and Precautions (5.1) .] </i> <br> <br> |9f4e2f54-274a-4ecd-9f42-c16437018fdb;aaadccea-4842-493b-a0bd-0ee7645fc250;f85a48d0-0407-4c50-b0fa-7673a160bf01;
15579|5e211b18-8cdc-42ab-8756-4ce2dd94925c| Carefully consider the potential benefits and risks of indomethacin extended release capsules and other treatment options before deciding to use indomethacin extended release capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <b> WARNINGS </b> ). <br> <br> Indomethacin extended release capsules have been found effective in active stages of the following <br> <br> Moderate to severe <annotation cui="C0003873">rheumatoid arthritis</annotation> including acute flares of chronic disease. <br> <br> Moderate to severe <annotation cui="C0038013">ankylosing spondylitis</annotation>. <br> <br> Moderate to severe <annotation cui="C0029408">osteoarthritis</annotation>. <br> <br> Acute painful shoulder (<annotation cui="C0006444">bursitis</annotation> and/or <annotation cui="C0039503">tendinitis</annotation>). <br> <br> Indomethacin extended release capsules is not recommended for the treatment of acute gouty arthritis. <br> <br> Indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of <annotation cui="C0003873">rheumatoid arthritis</annotation>. In such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects. <br> <br> The use of indomethacin in conjunction with aspirin or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce <i> any </i> greater therapeutic effect than the use of indomethacin alone. Furthermore, in one of these clinical studies, the incidence of gastrointestinal side effects was significantly increased with combined therapy. (See <b> PRECAUTIONS, Drug Interactions </b> ). <br> <br> |29a6b41c-accb-4b12-92d1-cda19c2148a5;3125cb9f-d00c-47e7-9927-fbe38cadb48b;3ea8f628-53f5-41f7-aad3-10ab7d11fd3a;570faaad-3e3e-4b89-9f9a-37c90c20a5d9;5a65b650-ea9b-4d0d-b62f-5971df1e62b4;5e211b18-8cdc-42ab-8756-4ce2dd94925c;c7eb8830-21c0-6e63-3e3a-c13de600faee;d9344dbc-57a8-4fca-bb26-f36a12bf17d4;dbad7e61-2347-43b1-a422-9183e41c10ea;dc80228c-acae-44dc-9762-19bd1669bf45;
15633|2f7d5e7f-79aa-4f3a-b9a6-758d9f3ce74d| <b> <annotation cui="C0011570">Depression</annotation> </b> For the relief of symptoms of <annotation cui="C0011570">Depression</annotation>. <annotation cui="C0011573">Endogenous depression</annotation> is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. <br> <br> <b> Childhood <annotation cui="C0270327">Enuresis</annotation> </b> May be useful as temporary adjunctive therapy in reducing <annotation cui="C0270327">Enuresis</annotation> in children aged 6 years and older, after possible organic causes have been excludedby appropriate tests. In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. The effectiveness of treatment may decrease with continued drug administration. <br> <br> |01e33e76-02a7-48ca-b3d0-3ba5587566bd;1827a5aa-733a-49d9-89d9-48ea0367b230;2f7d5e7f-79aa-4f3a-b9a6-758d9f3ce74d;35a07f5f-44ca-4e9d-8f18-717a1a6bd59b;55311747-710c-43c4-821d-76323ff2520e;5c96ba0b-a846-4d13-831b-aa2b74e81021;627e6f8b-6056-42de-a279-98cc045bec96;7d52c40c-bbcb-4698-9879-d40136301d31;8c31101d-35cb-36b0-098a-de3c501060b9;a6fe8e00-a1ee-4dbb-bac7-46ac2af9aee9;eeef21dd-2f8c-469c-ad72-36b68dc8e582;
16022|7ea5a071-6f92-4a8a-8e3f-72b74fb2810a|Nitroglycerin Injection is indicated for treatment of peri operative <annotation cui="C0020538">hypertension</annotation>; for control of <annotation cui="C0018802">congestive heart failure</annotation> in the setting of <annotation cui="C0155626">acute myocardial infarction</annotation>; for treatment of <annotation cui="C0002962">angina pectoris</annotation> in patients who have not responded to sublingual nitroglycerin and b blockers; and for induction of intraoperative <annotation cui="C0020649">hypotension</annotation>. |457a026c-ebce-4701-9deb-2d7652759a99;7ea5a071-6f92-4a8a-8e3f-72b74fb2810a;8c52cdf6-87be-4719-b105-f08be096d462;E4A44835-5307-4519-06B6-3E2DCFA61C62;ab0ae3a1-8c43-40c6-2682-5089ee1c0229;
16287|42602989-2a6d-4df6-ac41-780c1aa724ae| Isoniazid is recommended for all forms of tuberculos in which organisms are susceptible. However, <annotation cui="C0151332">active tuberculosis</annotation> must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single drug treatment of active tuberculos with isoniazid, or any other medication, is inadequate therapy. <br> <br> Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis) <br> <br> Persons with <annotation cui="C0019693">human immunodeficiency virus</annotation> (<annotation cui="C0019693">HIV</annotation>) infection ( 5 mm) and persons with risk <br> <br> factors for <annotation cui="C0019693">HIV infection</annotation> whose <annotation cui="C0019693">HIV infection</annotation> status is unknown but who are suspected of <br> <br> having <annotation cui="C0019693">HIV infection</annotation>. <br> <br> Preventive therapy may be considered for <annotation cui="C0019693">HIV</annotation> infected persons who are tuberculin  negative <br> <br> but belong to groups in which the prevalence of <annotation cui="C0041296">tuberculosis infection</annotation> is high. Candidates for <br> <br> preventive therapy who have <annotation cui="C0019693">HIV infection</annotation> should have a minimum of 12 months of therapy. <br> <br> Close contacts of persons with newly diagnosed infectious tuberculosis ( 5 mm). In addition, <br> <br> tuberculin negative (less than 5mm) children and adolescents who have been close contacts of in  <br> <br> fectious persons within the past 3 months are candidates for preventive therapy until a repeat <br> <br> tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin <br> <br> test is positive (> 5 mm), therapy should be continued. <br> <br> Recent converters, as indicated by a tuberculin skin test ( 10 mm increase within a 2 year <br> <br> period for those less than 35 years old; 15 mm increase for those 35 years of age). All infants and <br> <br> children younger than 4 years of age with a > 10 mm skin test are included in this category. <br> <br> Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old <br> <br> healed tuberculosis ( 5 mm). Candidates for preventive therapy who have fibrotic pulmonary <br> <br> lesions consistent with healed tuberculosis or who have pulmonary <annotation cui="C0037116">silicosis</annotation> should have 12 <br> <br> months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. <br> <br> Intravenous drug users known to be <annotation cui="C0019693">HIV</annotation> seronegative (> 10 mm). <br> <br> Persons with the following medical conditions that have been reported to increase the risk of <br> <br> tuberculosis ( 10 mm) <annotation cui="C0037116">silicosis</annotation>; diabetes mellitus; prolonged therapy with adrenocorti  <br> <br> costeroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, <br> <br> such as leukemia or Hodgkin s disease; end stage renal disease; clinical situations associated <br> <br> with substantial rapid weight loss or chronic under nutrition (including intestinal bypass <br> <br> surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic <br> <br> ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper <br> <br> gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive <br> <br> therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have <br> <br> pulmonary <annotation cui="C0037116">silicosis</annotation> should have 12 months of isoniazid or 4 months of isoniazid and <br> <br> rifampin, concomitantly. <br> <br> Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high incidence groups <br> <br> <ol><li> Foreign born persons from high prevalence countries who never received BCG vaccine. </li><li> Medically under served low income populations, including high risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. </li><li> Residents of facilities for long term care (e.g., correctional institutions, nursing homes, and mental institutions). </li></ol> Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have > 10 mm induration from a PPD Mantoux tuberculin skin test. <br> <br> Finally, persons under the age of 35 who a) have none of the above risk factors (1 6); b) belong to none of the high incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. <br> <br> The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1 6) and on an individual basis insituations where there is likelihood of serious consequences to contacts who may become infected. <br> <br> |1247f0c8-25be-49b0-96e1-22b1cf50dc00;1553312b-ed76-421c-a055-2579bdcf366c;42602989-2a6d-4df6-ac41-780c1aa724ae;43cc6759-3dc6-4a54-a2a1-5afa8ebd76c3;45df9851-27b4-4cce-aed1-c15314876fc1;5aa596d6-2a56-4cd3-8318-3ca54711be13;5ab01773-d1e4-4b87-884a-9e5b3f13bdcb;60a6b514-fa7f-4bc7-85b0-e5a14fa56b59;7367f8da-1212-4f9e-b854-198dd92bf411;77795c31-1cdf-4a20-b4a1-cd15f5b310f1;78E738D9-9C13-4FBD-BFFA-77B003CDADAC;9499f1cf-2f46-4047-8b71-90aee7dee854;c42a2926-8542-49aa-b61b-19a19a31bcb4;da8f086b-00c6-45a9-9694-16654c11fb12;db8a3ae7-fb5b-47a9-a9f7-f57cd90501c2;e43d77c2-f7e8-4d84-9425-37adb38410f0;ec0df56a-7746-45f2-88dc-a975cf48abc9;
16742|e4c2273a-b35a-4e75-9758-970b04d01a87| CUVPOSA is indicated to reduce chronic severe <annotation cui="C0013132">drooling</annotation> in patients aged 3 to 16 years with neurologic conditions associated with problem <annotation cui="C0013132">drooling</annotation> (e.g. <annotation cui="C0007789">cerebral palsy</annotation>). <br> <br> |e4c2273a-b35a-4e75-9758-970b04d01a87;
17521|e9e91ea6-a701-42f0-8770-fb99044c14f0| Asacol HD is indicated for the treatment of moderately active <annotation cui="C0009324">ulcerative colitis</annotation>. Safety and effectiveness of Asacol HD beyond 6 weeks has not been established. <br> <br> |03a3bff5-e652-4771-9bf7-3b6850423cc5;e9e91ea6-a701-42f0-8770-fb99044c14f0;
17580|06de3c9d-63bf-47c1-f78c-4fbdd482928a| Carefully consider the potential benefits and risks of INDOCIN and other treatment options before deciding to use INDOCIN. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). <br> <br> Indomethacin has been found effective in active stages of the following <br> <br> <ol><li> Moderate to severe <annotation cui="C0003873">rheumatoid arthritis</annotation> including acute flares of chronic disease. </li><li> Moderate to severe <annotation cui="C0038013">ankylosing spondylitis</annotation>. </li><li> Moderate to severe <annotation cui="C0029408">osteoarthritis</annotation>. </li><li> Acute painful shoulder (<annotation cui="C0006444">bursitis</annotation> and/or <annotation cui="C0039503">tendinitis</annotation>). </li><li> <annotation cui="C0149896">Acute gouty arthritis</annotation>. </li></ol> |06de3c9d-63bf-47c1-f78c-4fbdd482928a;1ce9c3c5-0cf7-4760-988d-2559adcfb200;1db9d6d7-c53f-5675-5f81-056800ed3875;1f60d27b-fa95-40dd-969f-51f977142032;23f99ba8-b565-443c-b600-5c86a090d4ea;3721e946-6f15-43bc-a4ca-aeb3788dac30;3d5df05a-f4af-48d8-b880-97dfb92e900c;4077592a-8790-4d45-8cb6-2c95a0a929de;4755e174-f5d7-451a-9649-46222a6dfced;4babe1c2-15f2-40af-b326-b256507a921c;50df5188-358e-4e59-b7d0-1dcec98c2ab0;549dba03-10c5-4da8-b893-336a6f4ded20;5647b6ca-5620-4ec4-b364-ce3b8f1e634b;564a6f8a-1f80-41e5-90f2-c2f07172130c;57c11bb8-d133-43e2-a74f-838c31296eb5;58ae8e0c-5555-4702-a61f-dde7d396a6db;603bc652-31c6-4d50-bb80-e6da5289a3c7;6422d983-a063-41ae-aa96-7ae2284cb123;6569dfd1-0164-4241-b508-ccd540d1e858;97742638-f888-0020-f9a0-088b42a625a0;9f082d89-d218-49e0-8fcb-0000b5eb04a5;b463cd5f-299a-45f8-a1b3-c9e7fe271955;b4cf01d1-0d71-4f0f-97a5-07a59744149f;b5e53529-e370-4916-a23c-8c9d945f971c;b9e8ab78-ae95-4036-b756-84b0d6ef2fac;d3c9e8ef-422a-4657-a4f9-2a668905515f;d3f12dab-1802-4d6a-9f90-6359e6b24565;f7ed39e2-5431-4e47-935c-c7441d058f94;
17772|f305b18b-8506-4414-87a1-10aa3b76a691|For the short term reduction of <annotation cui="C0595921">intraocular pressure</annotation>. May be used prior to and after intraocular surgery. May be used to interrupt an acute attack of <annotation cui="C0017601">glaucoma</annotation>. <br> <br> |f305b18b-8506-4414-87a1-10aa3b76a691;
1854|8782397b-92e9-4b14-b194-a11fc2294abc| Major indications for griseofulvin are <br> <br> <annotation cui="C0040250">Tinea capitis</annotation> (<annotation cui="C0040247">ringworm</annotation> of the scalp) <br> <br> <annotation cui="C0040252">Tinea corporis</annotation> (<annotation cui="C0040247">ringworm</annotation> of the body) <br> <br> <annotation cui="C0040259">Tinea pedis</annotation> (<annotation cui="C0040259">athlete's foot</annotation>) <br> <br> <annotation cui="C0040261">Tinea unguium</annotation> (<annotation cui="C0040261">onychomycosis</annotation>; <annotation cui="C0040247">ringworm</annotation> of the nails) <br> <br> <annotation cui="C1384589">Tinea cruris</annotation> (<annotation cui="C0040247">ringworm</annotation> of the thigh) <br> <br> <annotation cui="C2349994">Tinea barbae</annotation> (<annotation cui="C2349994">barber's itch</annotation>) <br> <br> Griseofulvin inhibits the growth of those genera of fungi that commonly cause <annotation cui="C0040247">ringworm</annotation> infections of the hair, skin, and nails, such as <br> <br> <i> Trichophyton rubrum </i> <br> <br> <i> Trichophyton tonsurans </i> <br> <br> <i> Trichophyton mentagrophytes </i> <br> <br> <i> Trichophyton interdigitalis </i> <br> <br> <i> Trichophyton verrucosum </i> <br> <br> <i> Trichophyton sulphureum </i> <br> <br> <i> Trichophyton schoenleini </i> <br> <br> <i> Microsporum audouini </i> <br> <br> <i> Microsporum canis </i> <br> <br> <i> Microsporum gypseum </i> <br> <br> <i> Epidermophyton floccosum </i> <br> <br> <i> Trichophyton megnini </i> <br> <br> <i> Trichophyton gallinae </i> <br> <br> <i> Trichophyton crateriform </i> <br> <br> <i> Note </i> Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical antifungal agents alone. <br> <br> It is <i> not </i> effective in <br> <br> Bacterial infections <br> <br> Candidiasis (Moniliasis) <br> <br> Histoplasmosis <br> <br> Actinomycosis <br> <br> Sporotrichosis <br> <br> Chromoblastomycosis <br> <br> Coccidioidomycosis <br> <br> North American Blastomycosis <br> <br> Cryptococcosis (Torulosis) <br> <br> Tinea versicolor <br> <br> Nocardiosis <br> <br> |4bb379b4-fdbd-49db-9f79-18583a7cac57;82f52d21-eacd-4edf-8ad5-a8ef090ffa2a;8782397b-92e9-4b14-b194-a11fc2294abc;af318d5d-cc39-4a63-a590-b87c50f2694f;b394ee74-53e5-493a-8ed9-95d3e8a10e88;
2008|2d77412a-e084-4406-ac33-d882aece9354| <br> <br> <div> <annotation cui="C0036341">Schizophrenia</annotation> </div> Quetiapine fumarate tablet is indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation>. The efficacy of quetiapine fumarate tablets in <annotation cui="C0036341">Schizophrenia</annotation> was established in three 6  week trials in adults. The effectiveness of quetiapine fumarate tablets for the maintenance treatment of <annotation cui="C0036341">Schizophrenia</annotation> has not been systematically evaluated in controlled clinical trials [see Clinical Studies ( <i> 14.1 </i> )]. <br> <br> <i> Pediatric use information in patients (13 to 17 years of age) with <annotation cui="C0036341">Schizophrenia</annotation> is approved for AstraZeneca Pharmaceuticals LP s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP s marketing exclusivity rights; this drug product is not labeled for such use in those adolescent patients. </i> <br> <br> <div> <annotation cui="C0005586">Bipolar Disorder</annotation> </div> Quetiapine fumarate tablet is indicated for the acute treatment of manic episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12 week monotherapy trials in adults, in one 3 week adjunctive trial in adults. [ <i> see Clinical Studies </i> ( <i> 14.2 </i> )]. <br> <br> Quetiapine fumarate tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with <annotation cui="C0005586">Bipolar Disorder</annotation>. Efficacy was established in two 8 week monotherapy trials in adult patients with bipolar I and <annotation cui="C0236788">bipolar II disorder</annotation> [ <i> see Clinical Studies </i> ( <i> 14.2 </i> )]. <br> <br> <i> Pediatric use information in patients (10 to 17 years of age) with bipolar <annotation cui="C0338831">mania</annotation> is approved for AstraZeneca Pharmaceuticals LP s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. </i> <br> <br> <div> Special Considerations in Treating Pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> </div> <i> Pediatric use information in patients (13 to 17 years of age) with <annotation cui="C0036341">Schizophrenia</annotation>, and patients (10 to 17 years of age) with bipolar <annotation cui="C0338831">mania</annotation> is approved for AstraZeneca Pharmaceuticals LP s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP s marketing exclusivity rights; this drug product is not labeled for such use in those patients. </i> <br> <br> |03325ca1-4f51-41a1-92f3-ff7f96e01cc8;0584dda8-bc3c-48fe-1a90-79608f78e8a0;0f131f23-80dd-4a42-893a-b7d86cd0e037;18e83b0c-1ab5-479e-b269-ec56136aa7b9;1d2a0b16-f272-4974-a8a0-9b8456851298;235f367b-544a-4523-a7bf-a9e2b3aa6fa0;26d92d06-44c5-51ac-27f2-cb1376f6bb68;271e9fb7-3c70-43fc-8279-5adf189f3c22;276e53bf-d3c0-4457-a76e-ee39c1cd2a3d;2d77412a-e084-4406-ac33-d882aece9354;39f4fcea-a586-4c79-a47e-d38c10601fd7;3dc79540-2f24-4920-99cd-ef6482f68eb2;3ea59594-8a2b-4b64-9aa8-1d53d9027bb0;47dc96cb-e586-44dd-a002-1b1d1bf48d3d;5e21f8fc-b32c-4100-a664-15737bdeb32c;6eeef664-ace1-47b3-9193-06ae7eb8e459;7d9d8a97-66ec-40fc-a160-d282c8205e7a;854148e7-53c2-c4c3-a5b1-2397a0b06be4;85522c25-1d1c-477c-8aa7-895ec3dfc3dc;8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6;94dfc588-1fd9-4435-93ec-c6dd4700aef5;a480fe5d-68e0-471c-85cf-a9824bd7a0ae;a951cd63-d329-47c9-965a-582fa73a07c6;cf377de3-1bfa-41ef-8ce8-4a78589dc398;e6e25ef9-2671-489e-8eca-58bedb4f59ab;fc01bdbd-9958-4a87-b59f-962a1f697740;ffe52b98-9872-48c1-90fd-8fcd37c3432f;
2378|03BE089C-07E5-4F94-BFCC-C6101B311785|<div> <annotation cui="C0002963">Vasospastic Angina</annotation> </div> Nifedipine extended release tablets are indicated for the management of <annotation cui="C0002963">Vasospastic Angina</annotation> confirmed by any of the following criteria 1) classical pattern of <annotation cui="C0002962">Angina</annotation> at rest accompanied by ST segment elevation, 2) <annotation cui="C0002962">Angina</annotation> or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of <annotation cui="C0002963">Vasospastic Angina</annotation>, provided that the above criteria are satisfied. Nifedipine extended release may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when <annotation cui="C0002962">Angina</annotation> is refractory to nitrates and or adequate doses of beta blockers. <br> <br> <div> <annotation cui="C0699826">Chronic Stable Angina</annotation> (Classical Effort Associated <annotation cui="C0002962">Angina</annotation>) </div> Nifedipine extended release tablets are indicated for the management of <annotation cui="C0699826">Chronic Stable Angina</annotation> (effort associated <annotation cui="C0002962">Angina</annotation>) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and or organic nitrates or who cannot tolerate those agents. <br> <br> In <annotation cui="C0699826">Chronic Stable Angina</annotation> (effort associated <annotation cui="C0002962">Angina</annotation>) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing <annotation cui="C0002962">Angina</annotation> frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long term safety in these patients is incomplete. <br> <br> Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta blocking agents may be beneficial in patients with <annotation cui="C0699826">Chronic Stable Angina</annotation>, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See WARNINGS .) <br> <br> <div> <annotation cui="C0020538">Hypertension</annotation> </div> Nifedipine extended release tablets are indicated for the treatment of <annotation cui="C0020538">Hypertension</annotation>. They may be used alone or in combination with other antihypertensive agents. <br> <br> |03BE089C-07E5-4F94-BFCC-C6101B311785;1f27bd46-5dde-4b2e-88c0-b450f4b94b84;24fa8535-ac4b-46d8-a752-2a7a1c578645;331db003-cc8e-4509-9415-20e48c5cc5b2;3dc7ea33-2b6f-4835-92e2-87a5ca77502b;43062486-bbac-47e4-bae1-16924338c8d8;445fbfa9-ef9a-42d3-a7d5-5a48f8b0af21;453ac443-4fd4-4b5c-b7b4-06d34dc38e0d;45eaef3e-10f2-4588-ab6d-9a9c8dbcbd80;4b05e996-c8c3-4d78-9e51-38e1056c0d24;4bb9f3b7-2cc0-487d-9afa-027ddf7d7c16;5a9b3e3a-fb7a-4cda-892f-c7232c73323c;60b85eab-17ad-4482-87d6-ca9720ca06e0;62069120-e894-42fd-8927-f1d74e449ca6;8818fc86-56a3-44d3-8347-8ef48e71ad84;8ebcb33c-f43b-4b36-9f94-9774b2a59e06;a22e8171-7f26-49b2-b719-8641ba036fc2;b10b3eaf-c28d-4d09-93e0-64c3d4090c78;b11026f8-dea0-49ac-8725-0ef7dc27923f;d1a78ff2-7672-3e69-00ef-63d203c80484;ebcf7ace-2b17-41da-93de-7f9bc1b9d10f;f4eeb69a-be32-4802-979f-6521d00861b4;
2449|2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7| <div> <annotation cui="C0036341">Schizophrenia</annotation> </div> SEROQUEL XR is indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation>. The efficacy of SEROQUEL XR in <annotation cui="C0036341">Schizophrenia</annotation> was established in one 6  week and one maintenance trial in adults with <annotation cui="C0036341">Schizophrenia</annotation> as well by extrapolation from three 6 week trials in adults with <annotation cui="C0036341">Schizophrenia</annotation> treated with SEROQUEL [ <i> see Clinical Studies </i> (14.1)]. <br> <br> <div> <annotation cui="C0005586">Bipolar Disorder</annotation> </div> SEROQUEL XR is indicated for the acute treatment of <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0853193">bipolar I disorder</annotation>, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> of <annotation cui="C0853193">bipolar I disorder</annotation> was established in one 3 week trial in adults with <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0853193">bipolar I disorder</annotation> as well by extrapolation from two 12 week monotherapy and one 3 week adjunctive trial in adults with <annotation cui="C0338831">manic</annotation> episodes associated with <annotation cui="C0853193">bipolar I disorder</annotation> treated with SEROQUEL [ <i> see Clinical Studies </i> (14.2)]. <br> <br> SEROQUEL XR is indicated for the acute treatment of depressive episodes associated with <annotation cui="C0005586">Bipolar Disorder</annotation>. The efficacy of SEROQUEL XR was established in one 8 week trial in adults with <annotation cui="C0005586;C0012634">bipolar I or II disorder</annotation> as well as extrapolation from two 8 week trials in adults with <annotation cui="C0005586;C0012634">bipolar I or II disorder</annotation> treated with SEROQUEL [ <i> see Clinical Studies </i> (14.2)]. <br> <br> SEROQUEL XR is indicated for the maintenance treatment of <annotation cui="C0853193">bipolar I disorder</annotation>, as an adjunct to lithium or divalproex. Efficacy was extrapolated from two maintenance trials in adults with <annotation cui="C0853193">bipolar I disorder</annotation> treated with SEROQUEL. The effectiveness of monotherapy for the maintenance treatment of <annotation cui="C0005586">Bipolar Disorder</annotation> has not been systematically evaluated in controlled clinical trials [ <i> see Clinical Studies </i> (14.2)]. <br> <br> <div> Adjunctive Treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> (<annotation cui="C1269683">MDD</annotation>) </div> SEROQUEL XR is indicated for use as adjunctive therapy to antidepressants for the treatment of <annotation cui="C1269683">MDD</annotation>. The efficacy of SEROQUEL XR as adjunctive therapy to antidepressants in <annotation cui="C1269683">MDD</annotation> was established in two 6 week trials in adults with <annotation cui="C1269683">MDD</annotation> who had an inadequate response to antidepressant treatment [ <i> see Clinical Studies </i> (14.3)]. <br> <br> |2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7;473a3ac4-67f4-4782-baa9-7f9bdd8761f4;
4682|6dd5868f-0bc2-48c8-238b-e857f5bd812f| BACTROBAN OINTMENT is indicated for the topical treatment of <annotation cui="C0021099">impetigo</annotation> due to <i> aureus </i> and <i> pyogenes </i> . <br> <br> |2289900b-889b-4536-9ed0-3bddb20c9387;2d97832e-c6c7-4a06-b83a-f8369c04f51e;323bcad0-1e11-4946-a151-1a33557f0bfb;3240802f-358d-48bb-9761-64f19e76e931;6a0b39c0-c207-4efc-ac2c-07506ad796df;6dd5868f-0bc2-48c8-238b-e857f5bd812f;900bb675-2f03-47e3-854e-257ec4831332;90cfa2dc-3904-4bd3-b951-dcdb141883bf;a543797a-2c1c-4ea3-bd6c-227a784f92d9;a76947bd-0430-4d79-b4c1-9d1746bc7f84;ae3defca-06d5-49ac-8a27-be5c4e9304d1;c36cd006-08ba-4b3e-b012-4f31c10bd001;c624575e-558c-4cfd-b1e0-c262ed11cff9;dc6c7600-454b-449f-af1c-ff1a8e1b8109;e2ddaea4-d914-4bc7-8913-351e7bf2e2f7;e9b61f01-3c67-42a4-a62b-10f1d1343190;f8ede7ba-fb90-4b3b-8f40-0914ae2e5a8c;ff7428fb-9ce9-4743-b58c-01a05424a57a;
4729|6b6a34e2-4de2-4dd0-adca-40f32f8d854c| Tizanidine is a short acting drug for the management of <annotation cui="C0026838">spasticity</annotation>. Because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of <annotation cui="C0026838">spasticity</annotation> is most important (see DOSAGE AND ADMINISTRATION) <br> <br> |01c0d3d3-2373-a1b7-822a-80a66291a248;0df212f5-f77b-4d94-8fd0-0b40d0e9a1c8;1fa26940-3778-4758-811e-3e1531d919df;204984ed-771c-4249-bba5-50d51c60e901;234b4e5e-8305-4d2d-840e-e69f0219c6fb;338c33be-9578-40e8-bdff-64b4e1b74a2c;3dd09a0d-a782-1d6d-a552-b71e5bcbf2fe;413ee468-c7e8-4283-8e2b-b573dcc1f607;42097235-FA5F-4052-A558-763116AFD58D;43d51c1d-5f5b-4b9e-95d0-d12ceff8d84e;4659df31-8b89-4eff-9d86-7b7e38de416b;4779b047-0dd6-460d-9ec8-5be17ac5d2fa;4c4de495-8f9c-4b74-8773-fdf6ad7290fc;4f0d83de-0810-4255-8114-443f8fb915de;5a42267f-a400-4bfd-ad7c-fad335884ba8;68d22330-830a-41ea-8c51-c31441c5a451;6b6a34e2-4de2-4dd0-adca-40f32f8d854c;6d8e0262-5ccf-4447-90dd-f5eec069664c;79a0e9fc-589e-46ef-b9da-7aa3665bf1e2;82084f4e-00d0-c298-c13a-88a6c0860b02;8c442290-31c1-40ea-aacc-935e85c221d0;939d9fec-727e-488e-adc4-cc941292b23e;9c70817f-e721-4f04-b095-0747702df614;9d222859-6697-47bf-98ec-91984002e0d9;A48B7542-EF46-4FF9-9496-468D3B4046EE;a42f3479-f2c2-8214-d547-c5cae9bfed1e;b254a0f4-efb1-4874-ae45-1dc5fe316964;b2e8ab61-db55-4bf2-a7c9-1b74e95e5901;b4227d39-6f9e-5ded-4169-087ce91a75b5;b581d63f-61cb-41b6-a7ca-24bd0b32a8ae;b68a9f81-7138-48cf-b987-b8d284e8105a;c14fa366-721d-47d1-928a-ae2fb250752d;cb8b01b3-bcec-4762-9d67-0db018ef6b22;ce7e8b54-9ca1-4ebb-9df3-a291eb53674f;d0d913a9-cfe8-4a7e-b20d-ea51828a01a1;e0132fe9-b145-4324-9f41-a86fe6ac2b85;fc1d0404-e9a8-4682-af4c-b9164d6e36ef;fce6f784-cfc5-49ef-af1f-fa6dc389ed3e;
6896|9bd7a91b-f313-4af3-8714-1102ce8f0aca| Allopurinol Sodium for Injection is indicated for the management of patients with <annotation cui="C0023418">leukemia</annotation>, <annotation cui="C0024299">lymphoma</annotation>, and solid <annotation cui="C0027651">tumor</annotation> malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. <br> <br> |10cc918f-aa44-415b-932d-2404695ac449;9bd7a91b-f313-4af3-8714-1102ce8f0aca;
7382|20B4968E-F869-6365-CAD2-E595832EBE4B| Haloperidol Injection is indicated for use in the treatment of <annotation cui="C0036341">schizophrenia</annotation>. <br> <br> Haloperidol Injection is indicated for the control of <annotation cui="C0040188">tics</annotation> and vocal utterances of <annotation cui="C0040517">Tourette s Disorder</annotation>. <br> <br> |20B4968E-F869-6365-CAD2-E595832EBE4B;4863db55-cf54-4ec3-96c7-e534a3aa8eeb;c72c2366-7b40-4cd9-845d-4b3983e6141a;e52d40f2-b658-4bc6-8a0c-74a340b762d8;
7912|43a04d8f-9dc1-4760-98fc-8f976ddc8a4b| Nitroglycerin is indicated for the acute relief of an attack or prophylaxis of <annotation cui="C0002962">angina pectoris</annotation> due to coronary artery disease. <br> <br> |041f127e-5166-4484-bc1a-0a373d1187ae;11cb2671-d3d5-425f-8509-f973b6cac876;1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6;33574801-581a-4028-befd-8e0cc8b6a892;43a04d8f-9dc1-4760-98fc-8f976ddc8a4b;78fd9e96-6bfc-4c36-b1da-3a63473aade9;79ba021e-183c-4b4d-822e-4ff5ef54ca61;85b8863e-b8e0-46f4-94a4-7c8e2c66da3f;942008d0-dd1a-48cd-8736-80872a04e0e0;9bec8131-d420-41ea-809c-6607bf5351ea;F9EB07A2-5EBC-40EA-9890-1A0B03E859FF;a1bbfe52-3519-47ca-908b-cf6008d61b1b;b32d82ee-7727-4501-a858-a8304135b11b;dcb552c1-310a-48af-81ad-a74530531dee;de06a4da-ea70-441e-bba2-e40eb51a8c3a;
9525|cb684ad9-0b72-406f-8a07-a419254ccd36| <div> <annotation cui="C0948089">Acute Coronary Syndrome</annotation> </div> Effient is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent <annotation cui="C0040053">thrombosis</annotation>) in patients with <annotation cui="C0948089">Acute Coronary Syndrome</annotation> (<annotation cui="C0948089">ACS</annotation>) who are to be managed with percutaneous coronary intervention (PCI) as follows <br> <br> <ol><li> Patients with <annotation cui="C0002965">unstable angina</annotation> (<annotation cui="C0002965">UA</annotation>) or non ST elevation <annotation cui="C0027051">myocardial infarction</annotation> (NSTEMI). </li><li> Patients with ST elevation <annotation cui="C0027051">myocardial infarction</annotation> (STEMI) when managed with primary or delayed PCI. </li></ol> Effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal <annotation cui="C0027051">myocardial infarction</annotation> (<annotation cui="C0027051">MI</annotation>), or nonfatal <annotation cui="C0038454">stroke</annotation> compared to clopidogrel. The difference between treatments was driven predominantly by <annotation cui="C0027051">MI</annotation>, with no difference on <annotation cui="C0038454">strokes</annotation> and little difference on CV death <i> [see Clinical Studies ( 14 )] </i> . <br> <br> It is generally recommended that antiplatelet therapy be administered promptly in the management of ACS because many cardiovascular events occur within hours of initial presentation. In the clinical trial that established the efficacy of Effient, Effient and the control drug were not administered to UA NSTEMI patients until coronary anatomy was established. For the small fraction of patients that required urgent CABG after treatment with Effient, the risk of significant bleeding was substantial <i> [see Warnings and Precautions ( 5.2 )] </i> . Because the large majority of patients are managed without CABG, however, treatment can be considered before determining coronary anatomy if need for CABG is considered unlikely. The advantages of earlier treatment with Effient must then be balanced against the increased rate of bleeding in patients who do need to undergo urgent CABG. <br> <br> |5fe9c118-c44b-48d7-a142-9668ae3df0c6;cb684ad9-0b72-406f-8a07-a419254ccd36;
9651|0581fd65-63f9-4705-adbd-602fe7b55874| INDOCIN I.V. is indicated to close a hemodynamically significant <annotation cui="C0013274">patent ductus arteriosus</annotation> in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear cut clinical evidence of a hemodynamically significant <annotation cui="C0013274">patent ductus arteriosus</annotation> should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x ray. <br> <br> |03c71de3-8d3c-407e-a840-3845a7622dd8;0581fd65-63f9-4705-adbd-602fe7b55874;ec482425-358c-4500-8f5d-79c1379c1fa8;
9820|ff0c9d83-6d86-4d22-939b-a838bffbcfd0| Hydroxychloroquine sulfate is indicated for the suppressive treatment and treatment of acute attacks of <annotation cui="C0024537">malaria due to Plasmodium</annotation> vivax, P. malariae, P. ovale, and susceptible strains of <i> falciparum </i> . It is also indicated for the treatment of <annotation cui="C0024138;C0024138">discoid and systemic lupus erythematosus</annotation>, and <annotation cui="C0003873">rheumatoid arthritis</annotation>. <br> <br> |16ea7eee-51c9-4305-9808-358e3ace31bd;1aa44bff-9a62-48b4-a520-98d7d524e3a9;22d4d993-b86d-478e-ac6d-7bcd217e9906;3279d780-0940-f462-9709-83c77f8ae241;6971241c-8323-456e-91a4-a404a9e100de;805a1acd-2e0d-48f1-af6b-0e5d8e06c228;a2d7be5a-98ee-4292-8715-46573dbe1c5b;adf36d25-d86e-4d2d-b90c-e29f1394667d;d5a1c868-b92f-4386-b8f9-8719dd785954;ff0c9d83-6d86-4d22-939b-a838bffbcfd0;
10168|d52d4043-9795-41d0-91f1-d558fe18d680| PRISTIQ, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of <annotation cui="C1269683">major depressive disorder</annotation> (<annotation cui="C1269683">MDD</annotation>) [ <i> see Clinical Studies ( </i> <i> 14 </i> <i> ) and Dosage and Administration ( </i> <i> 2.1 </i> <i> ) </i> ]. The efficacy of PRISTIQ has been established in four 8 week, placebo controlled studies of outpatients who met DSM IV criteria for <annotation cui="C1269683">major depressive disorder</annotation>. <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms depressed mood, loss of interest in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. <br> <br> |0f43610c-f290-46ea-d186-4f998ed99fce;2388423e-6f29-4da6-a34d-032a1e503488;4d5d349b-94a2-45a6-a33b-777ee8cfb8b0;a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35;d52d4043-9795-41d0-91f1-d558fe18d680;
10576|e87b8480-987d-4f82-87bf-cf831d6984a1| Nystatin Tablets are intended for the treatment of non esophageal mucus membrane <annotation cui="C0343886">gastrointestinal candidiasis</annotation>. <br> <br> |b2053672-3a1b-452d-9146-f4d795d82785;b70731df-fead-4f40-941e-7889a9c5d800;e87b8480-987d-4f82-87bf-cf831d6984a1;f03b294d-10cd-4bba-92c8-42ae9b110cd0;
11215|8bf65c7f-4c8d-4df5-85e0-3ea1cc79a75c| For the relief of symptoms of <annotation cui="C0011570">depression</annotation>. <annotation cui="C0011573">Endogenous depression</annotation> is more likely to be alleviated than are other depressive states. <br> <br> |063d2b43-87e6-443d-82e4-d93aaee269a8;19678220-a53d-4275-a7fd-6d7b0fd686de;20c3b9ab-3cca-4984-8fb7-a656b9288c81;255b0b8b-92b4-4d60-a312-9688014ad475;26075684-acec-4423-aefc-0ccbcc1ff297;2651139b-b5ac-009e-f3dd-51f85e3df15e;2c6bb11b-b6a3-1193-092e-d81f51047003;2f195801-64f0-4c9e-89b9-84e13bd19d7c;2f54e764-22b8-4d5a-a7ce-2e8f3a151ee0;33390747-9075-c308-4db4-ca1ef8b7e6c6;37e91a33-f4d6-4617-b107-9fefc4852862;460a2e4d-f1a2-4e08-b2da-f10bc63391db;4e0e7585-b82a-43d4-b14f-81a6b7bf084d;5d2d02fb-a121-465a-8994-89e2a9071400;60e95c23-9070-4420-8ecb-a7a1ca8fe143;61d2da8d-b435-4ada-a013-401786f7cace;6419e8b2-02cc-45ce-9ae1-94dee861f2b9;64bc0f38-9f6e-4ccd-8a35-0a16ef8c8078;705a2bae-031d-4218-82fe-4346542c0baa;83328475-128e-411e-98e1-25b56364b7eb;846927d3-9bf3-43f3-b6d7-101456f47bd9;8bf65c7f-4c8d-4df5-85e0-3ea1cc79a75c;8ec062a2-8939-45e5-994b-5c70cf820afa;8f121a02-8783-4bc9-bb8f-8fba2eef19b1;9b02f577-2a7e-1a2e-e67c-3a037eaa5200;a91647dd-1ea4-469c-b7e4-1511f5bd67b1;abfb3e0e-7243-433b-9c8c-4f39e625c9ad;acd53964-52dc-4534-b20f-14a7561b8a6c;ace47577-12a5-40c8-8c2e-786aa8654cde;b205a590-3b51-40b1-af46-60ec0b20f6fe;b2f166f4-5a54-42bd-8e60-42ae2866b00a;b424cc8f-4800-4845-9488-af1b8cb94177;b6815ba3-df6e-4208-a14b-74c3aea54a4c;c958b45e-7ca1-400a-b723-56e8c3aa98d8;d441d278-2c54-4a22-83a3-4627d49aaae4;d7cb1711-b12d-41a3-8f3a-c3152b6f46dc;e454fe56-0896-4d40-862c-95ef0fc0bc82;ea35caf8-c8c8-481a-97a2-25f68cbc240b;eab6fbd5-50ca-4c52-bbe7-29d72d647daa;f5c826ad-0d16-41e1-a499-d395f0aec2cd;fa164115-4420-41c0-b5ce-4fe848f4cfdc;fa98af45-fe92-4dbf-b813-19dfe21da1da;
11227|5861a269-1752-4378-85d3-f1a8b378b66c| <ol><li> Ursodiol is indicated for patients with radiolucent, noncalcified <annotation cui="C0008350">gallbladder stones</annotation> < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol beyond 24 months is not established. </li><li> Ursodiol is indicated for the prevention of <annotation cui="C0008350">gallstone</annotation> formation in obese patients experiencing rapid weight loss. </li></ol> |05243d8f-9057-46a9-ae50-6e16ba6cd7dc;1fc89d7b-2457-3ce1-6d10-c6dc7ce9f856;2e799e93-b5a0-40f7-95c5-b40d8a948a0d;35e3194c-ba8b-4b0d-96a6-e2c77e98fda4;5861a269-1752-4378-85d3-f1a8b378b66c;63458d86-fdec-4453-a882-63cad907e49c;8a3bc9f1-e7e3-4268-8941-a44d9f2f812b;91847322-f217-f337-81ca-ef02aca4446b;955df8fb-3341-4a1e-bbdd-152d5c06f1d6;a061bb07-a85d-4b08-877f-ce02156f0de7;aeb6c8c8-4dec-4574-8f26-b6b701b04b25;c9aa0223-3ea4-4cb7-b53b-f35e5a04cec7;cc429def-5c5d-45a6-a575-3e41d927e301;d24c32d6-792d-4d24-b915-746d2499a575;d58f4da2-bc59-4bf3-b851-1fdb73b8cccd;dded5871-205a-489c-b2e2-11f7b00b7a53;e47b49ca-bde9-448a-bf61-f943c2aa5b8e;f0497a34-29d0-7e46-bd62-e41e2cc7f713;
11512|6e952e14-69e5-4c24-8d70-986da0de20b4| Nystatin Vaginal Inserts, USP are effective for the local treatment of <annotation cui="C0700345">vulvovaginal candidiasis</annotation> (<annotation cui="C0006840">moniliasis</annotation>). The diagnosis should be confirmed, prior to therapy, by KOH smears and or cultures. Other pathogens commonly associated with vulvovaginitis (Trichomonas and <i> Haemophilus vaginalis </i> ) do not respond to nystatin and should be ruled out by appropriate laboratory methods. <br> <br> |6e952e14-69e5-4c24-8d70-986da0de20b4;
11664|3d263380-4f44-4fd8-aa2a-e69702ab258f| <div> Prophylaxis of <annotation cui="C0149871">Deep Vein Thrombosis</annotation> </div> Lovenox is indicated for the prophylaxis of <annotation cui="C0149871">Deep Vein Thrombosis</annotation> (<annotation cui="C0149871">DVT</annotation>), which may lead to <annotation cui="C0034065">pulmonary embolism</annotation> (<annotation cui="C0034065">PE</annotation>) <br> <br> <ol><li> in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.1) ]. </li><li> in patients undergoing hip replacement surgery, during and following hospitalization. </li><li> in patients undergoing knee replacement surgery. </li><li> in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness. </li></ol> <div> Treatment of Acute <annotation cui="C0149871">Deep Vein Thrombosis</annotation> </div> Lovenox is indicated for <br> <br> <ol><li> the inpatient treatment of acute <annotation cui="C0149871">Deep Vein Thrombosis</annotation> with or without <annotation cui="C0034065">pulmonary embolism</annotation>, when administered in conjunction with warfarin sodium. </li><li> the outpatient treatment of acute <annotation cui="C0149871">Deep Vein Thrombosis</annotation> without <annotation cui="C0034065">pulmonary embolism</annotation> when administered in conjunction with warfarin sodium. </li></ol> <div> Prophylaxis of Ischemic Complications of <annotation cui="C0002965">Unstable Angina</annotation> and Non Q Wave <annotation cui="C0027051">Myocardial Infarction</annotation> </div> Lovenox is indicated for the prophylaxis of ischemic complications of <annotation cui="C0002965">Unstable Angina</annotation> and non Q wave <annotation cui="C0027051">Myocardial Infarction</annotation>, when concurrently administered with aspirin. <br> <br> <div> Treatment of Acute ST Segment Elevation <annotation cui="C0027051">Myocardial Infarction</annotation> </div> Lovenox, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent <annotation cui="C0027051">Myocardial Infarction</annotation> or death in patients with acute ST segment elevation <annotation cui="C0027051">Myocardial Infarction</annotation> (STEMI) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (PCI). <br> <br> |20635579-c92d-4f6c-a332-1096d51002f2;3d263380-4f44-4fd8-aa2a-e69702ab258f;3e6bf2b3-9339-4104-bda3-ad86a1949703;5017a927-2a24-4f27-89f9-27c805bf7d59;53fd1302-9e1b-4e04-b06d-1a706547c388;741c994d-5a25-47e6-865a-33d0d4ccce11;afec67a9-ae16-4f48-bc0b-5331835e8aa2;b2a1cfef-4334-458f-b21c-7966f0e1f3bb;bbebb81f-5137-4097-b91f-7ee87bd12bcf;bd794164-0cad-4ca3-9f62-ae9118f6e4a2;d44a0b9c-848f-4d69-bf56-1befd40de766;de0b16a5-e886-482b-a0be-ab6161648134;
12037|6bdf87ae-daf1-4912-9d45-e06fa9eaaf1a| <b> Furadantin </b> is specifically indicated for the treatment of <annotation cui="C0042029">urinary tract infections</annotation> when due to susceptible strains of <i> Escherichia coli </i> , enterococci, <i> Staphylococcus aureus </i> , and certain susceptible strains of <i> Klebsiella </i> and <i> Enterobacter </i> species. <br> <br> Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. <br> <br> Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for <annotation cui="C0042029">urinary tract infections</annotation>. Consequently, many patients who are treated with Furadantin are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with <b> Furadantin </b> , other therapeutic agents with broader tissue distribution should be selected. In considering the use of <b> Furadantin </b> , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. <br> <br> |013433a1-c27c-4712-a03b-0949b2969fbb;047e8b1b-8888-40b7-b593-434e92eb333c;05f4b126-0fb9-5ee9-c89c-f229e60f84e3;09d16de0-e11e-4ca1-8073-cc0bb0677aa9;137038a6-12ed-47fd-a97c-01073c5141d1;1971e893-5fdb-41e3-a1e9-5e52deed03d1;1a86deef-0887-43b1-bb96-dbc222b15931;30dde765-909d-4f4d-a683-83c236cfbb07;380ec348-d23f-46d3-9c71-602d0549dc8c;3aada4c2-0c2a-4afb-8df1-bdac68972111;407a8f85-11c4-4404-8678-1c5e68860c8f;44fb3519-9b0d-4037-a6ea-cd237961b7a4;48a128ce-9279-4d39-b1eb-c4d2dd56f701;4dd6eeb7-1f49-41df-9525-934fec872e58;602aeac6-9e4e-4e05-8a67-b9df4d804382;62c1bb9c-79a2-41e3-9dfa-352f92253881;66dcb616-42bb-4fed-ad78-2ea080c60dd6;6acc17e8-20e2-403c-b1c5-6512201fe6a8;6bdf87ae-daf1-4912-9d45-e06fa9eaaf1a;743fca6d-9482-4e9d-b072-ea9d18da2a23;7ba9a729-a73a-4a13-a336-0284cc8a67e1;8f270a9f-12a1-44d4-bc7e-873613555801;92c6c41b-21b8-44e6-89eb-8e8c9170f4db;944c0e5f-88ff-4a46-95ef-2ea7d55063ce;b8434c69-527a-4e4b-b23f-25ba424d9660;c611e89d-dae2-4e45-a68c-a70a62e30201;d0820e60-05a4-5072-05f3-fe01883cd985;d08bda24-bc54-4e1f-81e0-5d14b50af107;d0b9ff2e-21eb-479b-86d5-42c5eed63b18;dc6bc96c-9a40-469a-9b7c-9cb570b5fd85;e5b36fbf-4db1-43b3-bf04-39022f74d0b9;e87d7f56-3666-4ba7-89b3-d8e19b78e02c;ec23de8c-7f9c-41c6-a251-35181b447b78;ec86b651-d77d-4a42-b493-24244456b3f6;fb4c9c55-63c4-4d8a-b89e-36e921b39e81;
12083|35433c7b-556c-49a0-bfb5-0d498359925b| Therapy with lipid altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for <annotation cui="C0004153">atherosclerotic vascular disease</annotation> due to <annotation cui="C0020473">hyperlipidemia</annotation>. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. <br> <br> <br> <ol><li> NIASPAN is indicated to reduce elevated TC, LDL C, Apo B and TG levels, and to increase HDL C in patients with primary <annotation cui="C0020473">hyperlipidemia</annotation> and mixed <annotation cui="C0242339">dyslipidemia</annotation>. </li><li> NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary <annotation cui="C0020473">hyperlipidemia</annotation> and mixed <annotation cui="C0242339">dyslipidemia</annotation> when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. </li><li> In patients with a history of <annotation cui="C0027051">myocardial infarction</annotation> and <annotation cui="C0020473">hyperlipidemia</annotation>, niacin is indicated to reduce the risk of recurrent nonfatal <annotation cui="C0027051">myocardial infarction</annotation>. </li><li> In patients with a history of <annotation cui="C1956346">coronary artery disease</annotation> (CAD) and <annotation cui="C0020473">hyperlipidemia</annotation>, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. </li><li> NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL C levels in adult patients with primary <annotation cui="C0020473">hyperlipidemia</annotation>. </li><li> Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe <annotation cui="C0020557">hypertriglyceridemia</annotation> who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. </li></ol> <b> Limitations of Use </b> <br> <br> No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. <br> <br> |0dfe662a-f2ac-4f10-9a08-54cbd0c6dec6;0f049ee9-ab85-401c-b1d7-06c98d559055;35433c7b-556c-49a0-bfb5-0d498359925b;414b3d30-cc7f-4f91-b21e-5090b7f5b529;c64d7717-8e8e-4e17-8f00-2b18f496b321;ccc64ee7-f581-493b-b8c2-6147a0db197e;eac1abb4-58bf-4cd0-aa66-a93e116f516c;f9b97613-c62e-40b0-a2aa-a7fde6bd5bc7;
1219|a648d0aa-efcb-4123-bf86-6a2c6fd16394| Lorazepam is indicated for the management of <annotation cui="C0003469">anxiety disorders</annotation> or for the short term relief of the symptoms of <annotation cui="C0003469">Anxiety</annotation> associated with depressive symptoms. <annotation cui="C0003469">Anxiety</annotation> or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <br> The effectiveness of lorazepam in long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. <br> <br> |0007892c-8c17-400d-b820-020aa32f433b;0209bb1e-b8fa-4fa9-a533-4dda028bd369;0448c4eb-4c59-47c3-aa2f-cccd461b483b;07cae057-a593-4e4d-a478-2d7fc9f06857;0c0b59cc-0950-4fed-8271-78d11ad21493;0c1caa9c-9ef1-459c-86c3-adb939130a9f;172f0c9b-424e-409a-bc51-46988b8ab912;19e79382-afc1-4a4d-8540-459e61e79baa;1ac2b596-3e90-42b5-bade-e04f5653f4f8;24f766c1-f92b-4e48-b2f1-9d88b1b1be0c;2c8bba31-eb1e-432c-b82d-e239ce8b34dd;36c1472b-565e-480c-ba3a-5eefe2b641ea;36d246dd-a503-755a-66cf-62652c0a4f61;3af556f7-3d8c-4079-b6bc-5051966e5f3b;415e4ee0-5f29-4963-a9b7-2f6fd98ff422;41a80241-e78d-4586-96d3-edbfee58b871;463faf3c-3a5b-42a5-92bb-b1299ca29682;4e4ca7cd-dd38-45b5-a5fa-9cbafa0f42b4;4fae1607-69d7-47ce-9b78-7474af50036d;4fcc8ba5-f954-4943-a4fc-dcfdef70c7ef;5a936b58-5039-458c-b0b4-a5a0269386a2;5ff82103-cc57-4af9-9362-82a7c686271d;62f6eb3b-813d-4890-aca9-799b7fa890df;67e14f73-3558-4ac0-a478-c0a9e1fad5dd;6807a7be-0654-4cfc-b2e1-588ffa7b1a69;711b60a3-028d-41d4-aa17-8f976e6df23e;73bfaeab-94db-48c2-a194-8b173025de78;8248a4f1-08a8-42ab-a74e-5c5a1f9223b1;84e74f60-4e4f-412f-a3ff-f3252838f371;85efece9-04fe-4b58-8340-6fd7208cfe85;89e39a69-b5d7-4de4-8114-f63149a19931;8f41b20c-0eff-4d95-9f04-bd1a80001410;90d64ec4-e3af-4e78-bf7e-9d37699c98d2;A0FBF748-B127-420B-8AD9-5E3E36F82568;a53ee482-0e0c-4e68-9a07-26a3c0ddec35;a648d0aa-efcb-4123-bf86-6a2c6fd16394;ad2a0633-50fe-4180-b743-c1e49fc110c6;b2cb1d05-d4e1-487d-aaa9-bff9a1798c5a;b370e14e-5131-4691-a252-67df6cb6ee96;b4a4a2f4-b0b0-43a6-8764-a875c2a8da27;ba6ce50e-c5a9-47ca-9803-a1ed82172b0e;bbeced15-f1e3-48de-ad54-ba46d857b5b9;c3258c0b-06c9-4589-8882-e20e8ed9c05a;d200ba28-2c61-4bd1-9f00-817e6f3c4be5;e9f1608a-1d75-4cd0-b156-795f79c1b4de;ee9e95a6-a9d7-43c1-ac3c-c9dc4b390760;f16b9773-aaef-4ae6-a216-66d0df2df167;fd9baca0-5f62-4427-bccb-f5a698891af4;
12399|29a5391d-6db4-4226-82ed-4481b3e445c8| Nystatin Oral Suspension is indicated for the treatment of <annotation cui="C0006840">candidiasis</annotation> in the oral cavity. <br> <br> |01c469b3-ec10-452c-8c02-3e7d22e40297;29a5391d-6db4-4226-82ed-4481b3e445c8;29ccf947-91c1-405a-aba6-5889e3c75d70;3651ad5b-436c-4ae9-9ab1-80b6ac8ae0a8;41034d7b-33a1-4d6d-b425-9cfefff8d518;4c25ae58-c424-44c1-85e0-63b99ecd2ecb;4c71071e-6c9f-4059-ba3f-b9c3aa643452;6976788c-b2fa-4bcc-ada0-4ae589ff5634;855277ef-d6ad-4582-a289-c8c739bf675b;8e451863-6c53-4069-bc0f-71224356bfcb;AF99AA0C-D891-4327-B406-4733F8DAC7BA;ac2bbe44-79e5-430d-b1c3-b2a565964c3e;c808de10-d308-4687-8af3-9e428b7fad8c;ceb0fc2d-9039-4961-84b6-ceb2a2649c50;d468395c-0f4c-4503-9a39-ae847524e683;d824bb63-5c1f-4399-8c0b-38a9f8c60761;f7a98d15-ce46-4358-ac6e-d10afa4d34c2;
12581|542f3fae-8bc8-4f00-9228-e4b66c9ad6a9| Korlym (mifepristone) is a cortisol receptor blocker indicated to control <annotation cui="C0020456">hyperglycemia</annotation> secondary to <annotation cui="C0001622">hypercortisolism</annotation> in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. <br> <br> LIMITATIONS OF USE <br> <br> <ol><li> Korlym should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome. </li></ol> |542f3fae-8bc8-4f00-9228-e4b66c9ad6a9;
13235|A833C24B-6DCA-44D7-A0D6-20012FA1EA77|Midazolam HCl Syrup is indicated for use in pediatric patients for sedation, anxiolysis and <annotation cui="C0002622">amnesia</annotation> prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. <br> <br> Midazolam HCl syrup is intended for use in monitored settings only and not for chronic or home use (see WARNINGS ). <b> MIDAZOLAM HCL SYRUP MUST BE USED AS SPECIFIED IN THE LABEL. </b> <br> <br> Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours (see CLINICAL PHARMACOLOGY ). <br> <br> |0be63f63-6a93-4782-8f9c-d13ca5ae44bd;20b0cdfa-e2ed-4df3-9ea8-00cc05319bfa;9864801b-6c92-45aa-9c0c-b4b49666c31d;A833C24B-6DCA-44D7-A0D6-20012FA1EA77;c03bba19-85d3-4aa7-ac11-e31a690aa27c;
13247|4ce6f7e2-a385-4485-b2d3-69e488c338d6| Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with <annotation cui="C0184567">acute, painful</annotation> musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man. <br> <br> |0149c87b-c18b-4f64-8baa-a16e54cebd9d;090a3d3d-92c3-4c30-a648-436461f81702;0db1e8dd-b4fa-491b-a529-0fb939710759;0defd325-d763-481e-afe8-86075e3c7e79;1431efe1-8b32-4bf5-936f-c4aacd57e5dd;1dd13a9c-713f-4496-abbd-91a4146571cd;28fd3d07-5718-4b93-bc4b-543388104e3c;2bdfecbb-d305-4bed-94bf-5c392b07e210;396ddbcd-82cb-4ac1-b80d-a00b290ccd0f;415499a7-3417-410c-aa49-c8172d9faf6e;41a6a652-046e-4780-9c6b-000363def056;43af0c41-9990-4902-9384-75de5ea08283;4ce6f7e2-a385-4485-b2d3-69e488c338d6;52d4d141-af4c-4fc5-88f6-b8563604fd18;54b8f75f-0b85-4685-aae6-dfc8d1fbaf76;54d8889f-6383-4b3c-b2fd-7f165562606e;5666ece8-9a10-4dcc-a7dc-3cd29df10e28;56efaf29-cf65-4293-b503-0b61287751fc;75a6b9d8-3f98-484a-aa59-7b73099e7ddc;75f2f49e-eacf-4eda-bc71-07784420bcf4;7a8032c4-9ffb-4a02-9163-a495679f4ddf;82fa1561-bd05-4e40-91cc-290505a36750;8a6ab350-2e0a-4809-b943-8bd1e7b0f779;8f91e243-7395-4ec9-adf5-37520983daf2;92123CFA-5BD5-4554-8D5D-B877D5CB9C02;9811b723-5fe4-4459-a209-7e3645774338;a8b4a448-ba6a-41ac-8603-cdfad1dd77ce;acb83cfb-59c2-424a-9413-173ac5c29134;add9e47f-11ac-e10d-bfc2-b9c52aa08fa5;b3136363-6fcb-486d-b752-d53a1f8e2d69;b5e74aec-473b-4218-88e3-8ff43e972f66;b5e8e730-30f3-4f51-aad2-89f707bd5c67;b86839dd-e0fc-4319-9abc-bcf69cf7a6e2;c048f9e5-0ff6-4eaa-8f59-c99a05a4c804;c0975b4b-73b4-4292-b50f-ff3b925c8577;cafbfe87-3a37-4191-9447-a54519579e5c;e66f6b45-282c-026d-890a-164818d1434b;ea0fa537-1928-4f92-99dc-78c939675beb;f039c8bf-8586-4467-b5c3-fe1c6e5846ac;f5f32393-581e-4f29-bff0-99cfd8a36ee9;f796783d-4ad3-4c8b-89ab-354d4dde9555;
13712|74696d65-6973-6275-7461-77696e646f77| Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support. Opioid dependent patients, including those being treated for <annotation cui="C0001973">Alcohol Dependence</annotation>, must be opioid free at the time of initial VIVITROL administration. <br> <br> <div> <annotation cui="C0001973">Alcohol Dependence</annotation> </div> VIVITROL is indicated for the treatment of <annotation cui="C0001973">Alcohol Dependence</annotation> in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration. <br> <br> <div> <annotation cui="C0524662">Opioid Dependence</annotation> </div> VIVITROL is indicated for the prevention of relapse to <annotation cui="C0524662">Opioid Dependence</annotation>, following opioid detoxification. <br> <br> |74696d65-6973-6275-7461-77696e646f77;cd11c435-b0f0-4bb9-ae78-60f101f3703f;
1401|eaad7bfe-4d18-446d-b6b8-802e267c13f8| PEDI DRI is indicated in the treatment of <annotation cui="C0037278;C0011630">cutaneous or mucocutaneous mycotic infections</annotation> caused by <i> Candida albicans </i> and other susceptible <i> Candida </i> species. <br> <br> <b> This preparation is not indicated for systemic, oral, intravaginal or ophthalmic use. </b> <br> <br> |01b44f91-9b68-464a-9693-b5d3e793bf3c;377b0312-abfe-45eb-9e6e-ae348ec83325;4d845b3f-ca26-4c47-b424-b6d783cc10e5;656fc23b-65af-465e-9bcb-67fbbfa9b84e;A6F88015-4CAC-4CB2-9012-92CC5390B5DF;d62d9d90-3ef2-4697-b6d5-bdb892394998;e1b4622c-0f9f-4c00-b42c-2aa85a5e3d4f;e5d3d8e4-3a92-4ac0-8918-d3209a30c12b;e630aa3d-11a6-4300-942a-cbdf2d016f77;eaad7bfe-4d18-446d-b6b8-802e267c13f8;fc141ac5-c14e-4abf-8f2f-98b50a0c63a4;
14079|390087a6-f3c3-4f0b-a930-79acf412f153| depo subQ provera 104 is indicated for the prevention of pregnancy in women of child bearing potential. <br> <br> depo subQ provera 104 also is indicated for management of <annotation cui="C0014175">Endometriosis</annotation> associated <annotation cui="C0030193">pain</annotation>. <br> <br> In considering use for either indication, the loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and or lactation, in the risk benefit assessment for women who use depo subQ provera 104 long term (see WARNINGS, section 1 ). <br> <br> <div> Contraception Studies </div> In three clinical studies, no pregnancies were detected among 2,042 women using depo subQ provera 104 for up to 1 year. The Pearl Index pregnancy rate in women who were less than 36 years old at baseline, based on cycles in which they used no other contraceptive methods, was 0 pregnancies per 100 women years of use (upper 95% confidence interval = 0.25). <br> <br> Pregnancy rates for various contraceptive methods are typically reported for only the first year of use and are shown in Table 2. <br> <br> <div> <annotation cui="C0014175">Endometriosis</annotation> Studies </div> The efficacy of depo subQ provera 104 in the reduction of <annotation cui="C0014175">Endometriosis</annotation> associated <annotation cui="C0030193">pain</annotation> in women with the signs and symptoms of <annotation cui="C0014175">Endometriosis</annotation> was demonstrated in two active comparator controlled studies. Each study assessed reduction in <annotation cui="C0014175">Endometriosis</annotation> associated <annotation cui="C0030193">pain</annotation> over 6 months of treatment and recurrence of symptoms for 12 months post treatment. Subjects treated with depo subQ provera 104 for 6 months received a 104 mg dose every 3 months (2 injections), while women treated with leuprolide microspheres for 6 months received a dose of 11.25 mg every 3 months (2 injections) or 3.75 mg every month (6 injections). Study 268 was conducted in the U.S. and Canada and enrolled 274 subjects (136 on depo subQ provera 104 and 138 on leuprolide). Study 270 was conducted in South America, Europe and Asia, and enrolled 299 subjects (153 on depo subQ provera 104 and 146 on leuprolide). <br> <br> Reduction in <annotation cui="C0030193">pain</annotation> was evaluated using a modified Biberoglu and Behrman scale that consisted of three patient reported symptoms (dysmenorrhea, dyspareunia, and pelvic pain not related to menses) and two signs assessed during pelvic examination (pelvic tenderness and induration). For each category, a favorable response was defined as improvement of at least 1 unit (severity was assessed on a scale of 0 to 3) relative to baseline score (Figure 2). <br> <br> Favorable Response = reduction in severity of symptom or sign of 1 point on a scale of 0 to 3, as compared to baseline <br> <br> Additionally, scores from each of the five categories were combined, with the total (composite score) considered a global measurement of overall disease improvement. For subjects with baseline scores for each of the 5 categories, a mean decrease of 4 points relative to baseline was considered a clinically meaningful improvement. Across both studies, for both treatment groups, the mean changes in the composite score met the protocol defined criterion for improvement. <br> <br> In the clinical trials, treatment with depo subQ provera 104 was limited to six months. Data on the persistence of benefit with longer treatment are not available. <br> <br> Subjects recorded daily the occurrence and severity of hot flushes. Of the depo subQ provera 104 users, 28.6% reported experiencing moderate or severe hot flushes at baseline, 36.2% at month 3, and 26.7% at month 6. Of the leuprolide users, 32.8% reported experiencing moderate or severe hot flushes at baseline, 74.2% at month 3, and 68.5% at month 6. <br> <br> Figure |390087a6-f3c3-4f0b-a930-79acf412f153;
1498|c9eaca3d-cca7-4627-bb3e-75b1c2aec9d4| <u> <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> </u> <br> <br> Vyvanse is indicated for the treatment of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>). <br> <br> The efficacy of Vyvanse in the treatment of <annotation cui="C1263846">ADHD</annotation> was established on the basis of three short term controlled trials in children ages 6 to 12 years, one short term controlled trial in adolescents ages 13 to 17 years, and two short term controlled trials in adults who met DSM IV TR criteria for <annotation cui="C1263846">ADHD</annotation>, and one maintenance trial in adults <i> [ </i> <i> see CLINICAL STUDIES (14) </i> <i> ] </i> . <br> <br> A diagnosis of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>; DSM IV ) implies the presence of hyperactive impulsive and or inattentive symptoms that cause impairment and were present before the age of 7 years. The symptoms must cause clinically significant impairment, e.g. in social, academic, or occupational functioning, and be present in two or more settings, e.g. school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months lack of attention to details careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive Impulsive Type, at least 6 of the following symptoms (or adult equivalent symptoms) must have persisted for at least 6 months fidgeting squirming; leaving seat; inappropriate running climbing; difficulty with quiet activities; "on the go"; excessive talking; blurting answers; can"t wait turn; intrusive. The Combined Type requires both inattentive and hyperactive impulsive criteria to be met. <br> <br> <u> Special Diagnostic Considerations </u> <br> <br> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM IV characteristics. <br> <br> <u> Need for Comprehensive Treatment Program </u> <br> <br> Vyvanse is indicated as an integral part of a total treatment program for <annotation cui="C1263846">ADHD</annotation> that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and or other primary psychiatric disorders, including psychosis. Appropriate educational vocational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician"s assessment of the chronicity and severity of the patient"s symptoms and on the level of functional impairment. <br> <br> |704e4378-ca83-445c-8b45-3cfa51c1ecad;a310fc51-2743-4755-8398-fed5402283f6;c9eaca3d-cca7-4627-bb3e-75b1c2aec9d4;
15360|e7bfb636-4b0a-440c-a4d3-d26393a14ac5| NUVIGIL is indicated to improve wakefulness in patients with <annotation cui="C0917799">excessive sleepiness</annotation> associated with <annotation cui="C0520679">obstructive sleep apnea</annotation>, narcolepsy and shift work disorder. <br> <br> In <annotation cui="C0520679">OSA</annotation>, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. <br> <br> In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their <annotation cui="C0917799">excessive sleepiness</annotation>. <br> <br> The effectiveness of NUVIGIL in long term use (greater than 12 weeks) has not been systematically evaluated in placebo controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re evaluate long term usefulness for the individual patient. <br> <br> |10f918f7-4782-470e-a50e-35c7c66bfd79;d878aed0-ddbf-8fa1-abf7-d3e480260845;e7bfb636-4b0a-440c-a4d3-d26393a14ac5;
15588|d0a94321-eb60-4aa6-a429-f0156f9f8e01| Norethindrone acetate is indicated for the treatment of <annotation cui="C0232940">secondary amenorrhea</annotation>, <annotation cui="C0014175">endometriosis</annotation>, and abnormal <annotation cui="C0042134">uterine bleeding</annotation> due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. <b> Norethindrone acetate is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. </b> <br> <br> |64cb920c-36e8-4d62-9d08-3ddf3989d313;69f5bc4b-758d-471b-ad8d-17c94f8e0963;d0a94321-eb60-4aa6-a429-f0156f9f8e01;f73f9807-4af6-4faa-ba9a-656a47a4c5e0;
15704|f0892106-399d-4e53-ae8d-8797c50ce7bf| <div> Symptomatic <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> </div> METOZOLV ODT is indicated as short term (4 to 12 weeks) therapy for adults with symptomatic, documented <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> (GERD) who fail to respond to conventional therapy. <br> <br> <div> <annotation cui="C0267176">Diabetic Gastroparesis</annotation> (Diabetic <annotation cui="C0152020">Gastric Stasis</annotation>) </div> METOZOLV ODT is indicated for the relief of symptoms associated with acute and recurrent <annotation cui="C0267176">Diabetic Gastroparesis</annotation> (<annotation cui="C0152020">Gastric Stasis</annotation>) in adults. <br> <br> <div> Important Limitations </div> METOZOLV ODT is indicated for adults only. Therapy should not exceed 12 weeks in duration. The safety and effectiveness in pediatric patients have not been established. <br> <br> |f0892106-399d-4e53-ae8d-8797c50ce7bf;
16478|dffb4544-0e47-40cd-9baa-d622075838cc| MYKROX Tablets are indicated for the treatment of <annotation cui="C0020538">hypertension</annotation>, alone or in combination with other antihypertensive drugs of a different class. <br> <br> <b> MYKROX TABLETS HAVE </b> NOT <b> BEEN EVALUATED FOR THE TREATMENT OF CONGESTIVE HEART FAILURE OR FLUID RETENTION DUE TO RENAL OR HEPATIC DISEASE AND THE CORRECT DOSAGE FOR THESE CONDITIONS AND OTHER EDEMA STATES HAS NOT BEEN ESTABLISHED. </b> <br> <br> <b> SINCE A SAFE AND EFFECTIVE </b> DIURETIC <b> DOSE HAS NOT BEEN ESTABLISHED, MYKROX TABLETS SHOULD </b> NOT <b> BE USED WHEN DIURESIS IS DESIRED. </b> <br> <br> <div> Usage in Pregnancy </div> The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia (see PRECAUTIONS ). <br> <br> Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. MYKROX is not indicated for the treatment of edema in pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. <br> <br> |0b619826-2567-49d7-8972-b6da5e4467df;34868f95-78d0-4089-8cbd-bec1cb730eda;449ebee4-6feb-428b-8cae-9bb0a49d1d3d;6639d111-eb21-4997-b964-f5c61bc088f2;c893c914-6195-45fa-a2bc-4e8b78004737;dffb4544-0e47-40cd-9baa-d622075838cc;e5fe856e-7fd6-47fb-87f7-7c1c621f50a0;f45f5353-38a3-42c6-bffc-96bea8dcf818;
16920|bfb90441-ebc4-4650-bbaa-28d649572919| Methimazole is indicated in the medical treatment of <annotation cui="C0020550">hyperthyroidism</annotation>. Long term therapy may lead to remission of the <br> <br> Methimazole may be used to ameliorate <annotation cui="C0020550">hyperthyroidism</annotation> in preparation for subtotal thyroidectomy or <br> <br> radioactive iodine therapy. Methimazole is also used when thyroidectomy is contraindicated or not advisable. <br> <br> |036ad971-9946-4950-8530-2a1a90bdcb1d;74238d87-5f82-4a5e-a920-a9fc68115e91;8c3a9aaa-cdde-404b-9af6-5a88ef649aac;9e6b80b8-6780-da50-f18f-30e6fe7b01b9;A3A62C66-BBA9-4A96-B409-90687CA4A76A;DC92F45F-8D27-4dcb-B72D-6B8B04C6F0CE;bfb90441-ebc4-4650-bbaa-28d649572919;f7675cf7-77df-461a-aee4-a6206970431b;
17647|f32d6e27-5b7b-4b17-af2e-0250447ee560| <b> Symptomatic <annotation cui="C0017168">Gastroesophageal Reflux</annotation> </b> Metoclopramide tablets are indicated as short term (4 to 12 weeks) therapy for adults with symptomatic, documented <annotation cui="C0017168">Gastroesophageal Reflux</annotation> who fail to respond to conventional therapy. <br> <br> The principal effect of metoclopramide is on symptoms of postprandial and daytime <annotation cui="C0018834">heartburn</annotation> with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of <annotation cui="C0151970;C0341117">esophageal ulcers and erosions</annotation> has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. <br> <br> <b> <annotation cui="C0267176">Diabetic Gastroparesis</annotation> (Diabetic <annotation cui="C0152020">Gastric Stasis</annotation>) </b> Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic <annotation cui="C0152020">Gastric Stasis</annotation>. The usual manifestations of delayed gastric emptying (e.g., <annotation cui="C0027497">nausea</annotation>, <annotation cui="C0042963">vomiting</annotation>, <annotation cui="C0018834">heartburn</annotation>, persistent fullness after meals, and <annotation cui="C0003123">anorexia</annotation>) appear to respond to metoclopramide within different time intervals. Significant relief of <annotation cui="C0027497">nausea</annotation> occurs early and continues to improve over a three week period. Relief of <annotation cui="C0042963">vomiting</annotation> and <annotation cui="C0003123">anorexia</annotation> may precede the relief of abdominal fullness by one week or more. <br> <br> |1c82c808-fc1d-4564-8120-ce2532092514;201e71d6-6a69-4ca8-9eb6-9821f45f8d18;2c7f7c84-da53-4fba-ac29-1c3652dd5b3a;2fc288bd-b176-42d5-945f-7f4ff370a57e;436391ed-1bf9-407b-1854-9796537bdf50;4ab8ddab-8226-4b5a-8774-308ed49d6bc4;55f1ee88-a455-44ba-b51a-2fcefe8eda65;59abd52d-8172-44a3-baa2-fe1fe20f78c0;6cef9808-d867-4908-964b-c57ce500dccc;6e3e5317-14b0-4786-90e7-6ed86eb4d8f5;73f4a334-66d7-4e06-82f1-562bd7cb601a;80fb18a3-824a-4360-947e-63f0a167245b;869349b7-a037-47b5-9da6-e061cefc3ced;8cdd6af4-7124-4ea5-b822-92b8edd3a442;9558e870-aa8b-4646-a701-1e9416c02f11;9daf95f8-f326-4fb0-8a14-022999c9fdeb;a637c1ac-78d1-4d44-9c79-b6da9a8f2fb9;a6e402d9-623d-444d-94f0-21f4977d3d40;a791c769-f859-4b01-a8bf-4f8ccb2ab8c1;acdb3ee0-006e-4799-8732-5488ef72f90e;ad81576a-6a25-438e-b39e-d04d7c4b9595;b73e7993-b5fb-4147-8bbe-eba686a5d051;baacecf3-b371-42c6-bf58-bd4141ddb665;cafb55ed-f2fb-4462-8b5c-c0e34cd83cbc;de55c133-eb08-4a35-91a2-5dc093027397;e15905e0-e0f6-4c8b-ac19-59724d6c4bf0;f08671b6-dc76-450a-8c8c-9d54f9611c00;f32d6e27-5b7b-4b17-af2e-0250447ee560;fae9b5cc-f32f-4e60-91f0-efbb53c1c880;fd13743d-ec41-4782-8068-4a18d4a6eb4e;
18308|FFA52DFA-8ADF-4F70-39A7-461757F226E9| <b> <annotation cui="C0267176">Diabetic Gastroparesis</annotation> (Diabetic <annotation cui="C0152020">Gastric Stasis</annotation>). </b> Metoclopramide Injection, USP is indicated for the relief of symptoms associated with acute and recurrent diabetic <annotation cui="C0152020">Gastric Stasis</annotation>. <br> <br> <b> The Prevention of <annotation cui="C0027497">Nausea</annotation> and <annotation cui="C0042963">Vomiting</annotation> Associated with Emetogenic Cancer Chemotherapy. </b> Metoclopramide Injection, USP is indicated for the prophylaxis of <annotation cui="C0042963">Vomiting</annotation> associated with emetogenic cancer chemotherapy. <br> <br> <b> The Prevention of <annotation cui="C0520904">Postoperative Nausea</annotation> and <annotation cui="C0042963">Vomiting</annotation>. </b> Metoclopramide Injection, USP is indicated for the prophylaxis of <annotation cui="C0520904">Postoperative Nausea</annotation> and <annotation cui="C0042963">Vomiting</annotation> in those circumstances where nasogastric suction is undesirable. <br> <br> <b> Small Bowel Intubation. </b> Metoclopramide Injection, USP may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. <br> <br> <b> Radiological Examination. </b> Metoclopramide Injection, USP may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and or small intestine. <br> <br> |1ecab710-8b7d-4903-80a8-de66562be55a;373ba08b-33ad-49fc-28a7-928e89a65314;5498f6aa-f4c1-49a3-b969-0711077dde81;6f4af312-ad59-412b-ba67-c5e3e91f90a3;7e14591f-0062-4159-b9d3-095b4ad68f00;917494a9-cff1-4ee6-9523-e112120373c5;FFA52DFA-8ADF-4F70-39A7-461757F226E9;a075cffe-6aeb-43f7-9533-de978a962b77;bfbc4b74-509b-4df8-be2b-d665c6a070af;cccf04bd-7463-40b8-a41f-cb1093c358d7;e2857ea0-df36-4d91-a705-a574fa323b2e;
18323|ffd8c563-275f-4942-839e-12457080ca1b| Flomax (tamsulosin hydrochloride) capsules are indicated for the treatment of the signs and symptoms of <annotation cui="C0005001">benign prostatic hyperplasia</annotation> (<annotation cui="C0005001">BPH</annotation>). FLOMAX capsules are not indicated for the treatment of hypertension. <br> <br> |0bef87bd-42fc-428f-b683-e0538b78f8d0;13a5032d-0be1-4001-916e-459f0b1a051d;1ceb560b-1a62-408d-8e30-23113e8c9dd3;276c7e26-f86a-46b9-b626-ceef76b729a4;300be29a-c56d-4daa-ba89-f207c281ea20;33633fee-489e-4d54-b827-3438b3d75a50;339c3b57-a339-4578-bfd7-46b25d911ff6;50cc1acc-1544-4f71-8beb-19b0e57b4b6b;6db9cdec-0833-4391-8764-079ce6f7e4d1;6fb8a408-8e63-41f0-adc3-ddac62b64503;713739bb-6d2d-4172-80b7-2e0a71161b3e;7350ad6e-7745-4743-9aa4-2a14ff01fef4;81ea3104-f712-47c3-a127-849b06bb6152;9ff7472f-89af-40cc-8cda-db6d61e7eb1b;aecd6c1b-d3e3-4568-b8cb-89954f0aee5d;af558603-15f3-43e4-9ee5-9d38d59ef1c1;b07f23d8-97ec-4a50-984a-b7dea69f9705;ba30cac2-62d9-4964-97ea-10ad751985e4;bcd86877-5868-49dd-840b-7860b405fac7;c00d5f7b-dad7-4479-aae2-fea7c0db40ed;c3ae55dd-6a0e-4f3a-82b6-2448e0545550;c6f64190-4911-4cfc-a9b1-bf86d4e58ed0;c8beeebe-a666-4521-ba3b-a42f2e8a8851;c9084267-e096-4dfb-b364-1a218c9d6985;d742707b-4c17-4b08-a9d0-491ba2bf6415;dda1de08-d3c3-49c7-bd3c-5842f65d5662;dddbccd5-306b-47cd-a14e-3ba3ca013988;e9372720-bd02-e4a6-0afd-42fe0c661c00;f2bb56f9-0e60-4462-b17b-46b49638a841;fb120098-b007-4a33-80b8-b7279c7668ee;ffd8c563-275f-4942-839e-12457080ca1b;
2204|53ddfe26-5a7e-4f39-8904-829a03538f63| For the relief of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> <br> <br> For preoperative medication <br> <br> For support of anesthesia <br> <br> For obstetrical analgesia <br> <br> |0084d5bc-17d5-4c58-a791-7ab3bb4590b7;53ddfe26-5a7e-4f39-8904-829a03538f63;987a91b8-dd9e-47ce-bd43-f8189a54838e;b31d1308-28c3-43f4-e0a6-2f3ed76b8975;e0e998da-f056-4fce-be8e-ed60cf3b461b;
3227|6c2b41c3-732c-477f-8790-0eecea43b2da| DEMEROL is indicated for the relief of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation>. <br> <br> |15bc51a8-1e24-4d33-9a2f-05a41c29acf0;3187a670-e0de-47b0-9c68-fdf7d2d162d6;6c2b41c3-732c-477f-8790-0eecea43b2da;7c065a08-bd12-4d43-ad9a-13228d99d106;7df4e964-2a34-4f38-4d8b-62bb637323c7;8f9e0a64-cae4-4a56-8a3e-3dec2e705759;9C4F12E5-5E69-44D4-81A5-BD72C375EEF5;AF5B3E8B-D6DC-4664-89A7-F347D1853ACE;c3ad5e7c-56e5-415c-87fe-a22a307e9b60;c550b809-fbea-4070-824d-2aeda4150fb5;cca1bdfb-3e40-4401-a2e2-78403c7237ba;e89f69d8-e3f0-4e83-b512-fa8f67c6feb5;fae5cc34-5917-4445-9516-25f97ffca8db;
3329|4C3BF7CF-A62F-4B92-C5B8-CBFC79CC97E9|<b> <annotation cui="C0038220">Status Epilepticus</annotation> </b> <br> <br> Lorazepam Injection is indicated for the treatment of <annotation cui="C0038220">Status Epilepticus</annotation>. <br> <br> <b> Preanesthetic </b> <br> <br> Lorazepam Injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of <annotation cui="C0003469">anxiety</annotation>, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (see <b> PRECAUTIONS   Information for Patients </b> ). <br> <br> |095ab8ff-83c5-4906-ae67-b04f4a58b58d;20140b19-846b-425f-b191-670e17809945;37e2cdf0-e4ba-4307-993e-198c7089cabc;4084fa74-9fd2-45ef-9d56-27bfa31d4e46;415672b5-bab8-437c-9ee4-9c729208eda3;4C3BF7CF-A62F-4B92-C5B8-CBFC79CC97E9;5fc0e987-61c9-40c4-b0d5-fcea07c8733e;608a0345-fc9c-4170-4f8d-96dbdd7e566a;AE274B1F-27C3-483B-99F1-9A9249DC2459;a9f7d22e-43fc-46c8-b2a9-a00b0d25d4ac;b5b17cde-a94c-4105-871c-54e7d2bd47e8;ba5527fb-76fc-4ee5-b62e-a141c58c957d;e9b54e42-04cf-4c62-90e1-36f7b31a4e81;
3404|0d929bf5-2eaa-4679-8334-1ac159b2b55c| REVIA is indicated in the treatment of <annotation cui="C0001973">alcohol dependence</annotation> and for the blockade of the effects of exogenously administered opioids. <br> <br> REVIA has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the <annotation cui="C0085281">addictions</annotation>. <br> <br> |06ff2d5a-e62b-4fa4-bbdb-01938535bc65;0d929bf5-2eaa-4679-8334-1ac159b2b55c;0f30f885-d0cd-4fa6-a8e0-142f08a56792;1977a47c-1029-465a-8176-3c9d70c7bbc8;3c7da2bc-e2c1-48f6-8c3f-287119b427e2;49aa3d6d-2270-4615-aafa-b440859ab870;4a63f1e0-b2a3-4355-af61-852ea3521707;81e25c6a-81b6-4cfb-91bf-be20c3ae546b;
4088|7ff22143-2093-4233-ac99-0116ee2fb7c5| ROXICODONE tablets are an immediate release oral formulation of oxycodone hydrochloride indicated for the management of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> where the use of an opioid analgesic is appropriate. <br> <br> |02029af4-f821-4a13-b195-f3fe0f67cb07;0f55e641-862e-4445-b8e2-7fa5e2e155f3;1174649e-e6eb-47ec-a8d4-379e186f8a64;11eddb9e-1cd6-4205-a3ce-c595c88e9d55;25c2a91c-dfc2-4596-8a24-63acf04a2568;3efb2cf8-9b0e-4d76-afb1-c4ecd514d534;46ff6f79-385d-4c47-ae0e-78930642da13;50b2d744-a072-41ea-80d0-b5b5204d5e3f;566ef74d-5c0b-49bf-9619-e757d16431ef;5721945b-269b-428d-9e99-b9da8dfb534f;603741db-1545-4c6f-ab7c-be9f5f42e49d;6c87f781-b347-4651-b244-33a6813d34ae;6fa888fc-a9d5-47f3-b28f-660d169875ae;7e593aec-4ef2-445c-b4e9-13dfc99296f2;7e5bf4a5-82b9-b68f-b5a2-4e1b60eaa7e6;7ff22143-2093-4233-ac99-0116ee2fb7c5;824f98e1-620b-41e5-8453-864bb67b4358;83a2a183-7354-4ba8-bd8d-9b6fd1d1a351;8c3e312d-c7e7-49f2-9e6c-776f3a387d86;928227bf-89c5-4c64-9823-0e84cc669388;97081243-cc59-4025-a5a7-4a71a260ac4c;994dfdaa-6cf7-4177-8cea-b20b56f1512a;A18447AF-D4F1-43B3-AB5E-BD425CF538A6;a113fda0-0637-4645-b05e-8a401bb0a063;a5162476-1217-41c0-bc7e-0a0f123f069f;a7a7ba28-78c5-453e-a101-61c6afa40216;aa7ac2bf-d9ed-445d-b394-4d3fe39780ca;acfe4393-bbda-4355-914b-d0c175189468;b9847cc7-67a2-408d-93cf-f9cf420346dd;bd5e0f6c-4060-46b9-8777-906fc1b2cab8;c29c8173-5c8c-44c0-a506-4c98c77826ec;c3ba0928-0eff-488e-8a29-fffdb1afdb60;c4d1d24d-c264-4423-9f7f-77260cde59a2;ccb7db8a-a4ea-4ce6-88ba-6d94d28383c2;d48c22ff-bbb4-4a93-a35b-6eebff7b8e53;d57345c9-19cf-4d12-a7b1-e0c5f78d5198;d7dceba3-96dc-4593-bc8f-318052bdb520;d908e334-b74b-4b4d-b159-c592c2ecc7f9;dd9f9d6d-9a59-4f74-8fe7-685e0c3c5fd4;df9313c5-e454-4829-bbb7-2f26d9f85e1e;f3190521-f5d9-4296-b8bb-cddbe2dde654;
4223|5c133dfe-3cb5-426b-ac30-daf814e12c47| <div> Immunocompetent Adult Patients </div> <u> <annotation cui="C0019345">Herpes labialis</annotation> (<annotation cui="C0019345">cold sores</annotation>) </u> Famciclovir tablets are indicated for the treatment of <annotation cui="C1274321">recurrent herpes labialis</annotation>. <br> <br> <u> <annotation cui="C0019342">Genital herpes</annotation> </u> <br> <br> <i> Recurrent episodes </i> Famciclovir tablets are indicated for the treatment of recurrent episodes of <annotation cui="C0019342">Genital herpes</annotation>. The efficacy of famciclovir tablets when initiated more than 6 hours after onset of symptoms or lesions has not been established. <br> <br> <i> Suppressive therapy </i> Famciclovir tablets are indicated for chronic suppressive therapy of recurrent episodes of <annotation cui="C0019342">Genital herpes</annotation>. The efficacy and safety of famciclovir tablets for the suppression of recurrent genital herpes beyond 1 year have not been established. <br> <br> <div> HIV Infected Adult Patients </div> <u> Recurrent orolabial or <annotation cui="C0019342">Genital herpes</annotation> </u> Famciclovir tablets are indicated for the treatment of recurrent episodes of orolabial or <annotation cui="C0019342">Genital herpes</annotation> in HIV infected adults. The efficacy of famciclovir tablets when initiated more than 48 hours after onset of symptoms or lesions has not been established. <br> <br> <div> Limitation of Use </div> The efficacy and safety of famciclovir tablets have not been established for <br> <br> <ol><li> Patients <18 years of age </li><li> Patients with first episode of <annotation cui="C0019342">Genital herpes</annotation> </li><li> Patients with ophthalmic zoster </li><li> Immunocompromised patients other than for the treatment of recurrent orolabial or <annotation cui="C0019342">Genital herpes</annotation> in HIV infected patients </li></ol> |2c44b8d2-3b70-4e8b-af03-2e917178f761;3c6194c0-ba69-4b16-b882-caf736a02348;3cd2e7f1-cbdb-47f6-b37f-830aaaef2482;3f02042f-8f51-4ccf-b608-5dcd75d100fb;405372a1-83bc-4843-b1b2-bd8ff2f83f87;50194d47-2761-4bfd-a35b-9c6a186694a5;5c133dfe-3cb5-426b-ac30-daf814e12c47;9bced3c4-f450-4e21-9baa-ab2efd0ed4bd;9f2714cd-0a45-235c-7490-747a9af67471;a5c46194-3692-cd26-0d85-6371974ccc44;c5617ff1-33a1-4d50-9b1c-e3fc4767f373;e563b079-a892-4505-a4ab-e6c9c8c02a51;fbc08644-e437-456d-9936-bbce99b2bd27;fcf0b0fa-bb2c-4f2c-aa9f-1f2da65d8343;
4722|992ad6dc-663e-44cb-b313-21aeb72ecc9d| Methimazole is indicated <br> <br> <ol><li> In patients with Graves disease with <annotation cui="C0020550">hyperthyroidism</annotation> or <annotation cui="C0154143">toxic multinodular goiter</annotation> for whom surgery or radioactive iodine therapy is not an appropriate treatment option. </li><li> To ameliorate symptoms of <annotation cui="C0020550">hyperthyroidism</annotation> in preparation for thyroidectomy or radioactive iodine therapy </li></ol> |4280e008-bbaf-4cc7-b588-3b4303016067;4d42cebc-5d3e-4b88-883f-5875b83a5515;992ad6dc-663e-44cb-b313-21aeb72ecc9d;a57ff449-e3b7-48b6-9acf-c719a9770e8a;ca8c1028-216d-485a-90df-b54818451bc3;
6796|ce739d68-d89c-437c-90fb-3c0c45140f22| Therapy with lipid altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for <annotation cui="C0004153">atherosclerotic vascular disease</annotation> due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. <br> <br> Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very <annotation cui="C0020557">high serum triglyceride</annotation> levels (Types IV and V hyperlipidemia) who present a risk of <annotation cui="C0030305">pancreatitis</annotation> and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (<annotation cui="C0020481">Type V hyperlipidemia</annotation>) . Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to develop <annotation cui="C0030305">pancreatitis</annotation>. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of <annotation cui="C0030305">pancreatitis</annotation> or of recurrent abdominal pain typical of <annotation cui="C0030305">pancreatitis</annotation>. Some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of <annotation cui="C0030305">pancreatitis</annotation> in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . <br> <br> |ce739d68-d89c-437c-90fb-3c0c45140f22;
7106|ca79dddc-3911-472b-bda7-a23351be09af| <div> <annotation cui="C0267509">Chronic Idiopathic Constipation</annotation> </div> Amitiza is indicated for the treatment of <annotation cui="C0267509">Chronic Idiopathic Constipation</annotation> in adults. <br> <br> <div> <annotation cui="C0022104">Irritable Bowel Syndrome</annotation> with <annotation cui="C0009806">Constipation</annotation> </div> Amitiza is indicated for the treatment of <annotation cui="C0022104">Irritable Bowel Syndrome</annotation> with <annotation cui="C0009806">Constipation</annotation> (IBS C) in women 18 years old. <br> <br> |222817c2-d4a6-43d0-8cbb-215f19acb198;417aa15d-ac74-4fa8-a312-6e51e82ba70c;ca79dddc-3911-472b-bda7-a23351be09af;d474ac6a-444d-4aa6-9986-24be6fcf811d;
8264|d2c3d585-3b01-448b-a630-3ea9aa34bccb| Medroxyprogesterone acetate tablets are indicated for <annotation cui="C0232940">secondary amenorrhea</annotation> and for abnormal <annotation cui="C0042134">uterine bleeding</annotation> due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone acetate tablets are also indicated to reduce the incidence of <annotation cui="C0014173">endometrial hyperplasia</annotation> in nonhysterectomized postmenopausal women receiving 0.625 mg conjugated estrogen. <br> <br> |2627eb11-06bf-4a45-9172-094468e3ca07;37275fd0-eb24-40a4-a93f-b818bb98414e;437edd12-2c08-4df4-8cf7-64c47e4779ac;499051ac-ffaf-4db4-be45-a409bd54991f;60cf7eda-3ee3-4f26-96be-ec97e4058735;826f674c-8ef2-400a-bf0b-877320a8cb5d;a586be28-96af-4fed-a13f-9b94fd4c7405;d2c3d585-3b01-448b-a630-3ea9aa34bccb;e5f5c46c-b8b7-4502-9d2b-8f12284d1a63;
848|89783608-d4fa-4f57-949a-e4a30366ee51| URSO 250 and URSO Forte (ursodiol) tablets are indicated for the treatment of patients with <annotation cui="C0008312">primary biliary cirrhosis</annotation>. <br> <br> |46a9db4f-b181-4050-bb8b-5adb1a8496ca;89783608-d4fa-4f57-949a-e4a30366ee51;90593214-5e4d-4b91-b308-a82311a3e4f9;aea8eb45-0452-44ad-b562-b5d9a1586c38;e8fc4fc2-fe5c-4cba-b6e0-5ceaf2157a61;fb79b62a-b450-4d7a-be28-5ee4d174fd58;
9555|81a06b90-50d3-40c1-98ca-0e344c76b2c4| 1.1 <annotation cui="C1269683">Major Depressive Disorder</annotation> Cymbalta is indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> (<annotation cui="C1269683">MDD</annotation>). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults <i> [see Clinical Studies ( 14.1 )] </i> . <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms depressed mood, loss of interest in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. <br> <br> 1.2 <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> Cymbalta is indicated for the treatment of <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (<annotation cui="C0270549">GAD</annotation>). The efficacy of Cymbalta was established in three short term trials and one maintenance trial in adults <i> [see Clinical Studies ( 14.2 )] </i> . <br> <br> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> is defined by the DSM IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and or sleep disturbance. <br> <br> 1.3 Diabetic Peripheral <annotation cui="C0027796">Neuropathic Pain</annotation> Cymbalta is indicated for the management of <annotation cui="C0027796">Neuropathic Pain</annotation> (DPNP) associated with <annotation cui="C0740447">diabetic peripheral neuropathy</annotation> <i> [see Clinical Studies ( 14.3 )] </i> . <br> <br> 1.4 <annotation cui="C0016053">Fibromyalgia</annotation> Cymbalta is indicated for the management of <annotation cui="C0016053">Fibromyalgia</annotation> (<annotation cui="C0016053">FM</annotation>) <i> [see Clinical Studies ( 14.4 )] </i> . <br> <br> |059d730b-4294-47e1-8399-4cb8c468cee8;12d274cc-77b7-469b-91c6-14105456c135;27b5ffa0-371c-42b0-b430-fc3772a66d69;2b905292-9d96-ae37-cc21-3e3f19920143;2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba;5f2147ee-2dfa-4d92-b414-b7a830c5ecdb;604b9f2f-fee6-48ef-a6c2-289bf98692b1;67927928-c20f-4e12-a327-d26561d7810a;67a3691e-5ab8-43f0-9c59-69ccf2383834;6b3d9ba5-55d3-4240-ba79-97b9f608645b;6fd7131e-7ac4-42f5-8678-316cf909d942;7db112de-473a-4407-bc1c-35d0ab748700;81a06b90-50d3-40c1-98ca-0e344c76b2c4;baaa3a1a-bada-082f-5e77-d9013c6fc109;e2d9c819-ca37-4094-b5f7-6a2f2df1bf84;e4fa801e-c3ea-40ff-9cee-e88f22f74931;
10424|922b2c82-052a-416c-984f-0dd66f2c61c4| Spironolactone is indicated in the management of <br> <br> <b> <annotation cui="C1384514">Primary hyperaldosteronism</annotation> </b> for <br> <br> <ol><li> Establishing the diagnosis of <annotation cui="C1384514">Primary hyperaldosteronism</annotation> by therapeutic trial. </li><li> Short term preoperative treatment of patients with <annotation cui="C1384514">Primary hyperaldosteronism</annotation>. </li><li> Long term maintenance therapy for patients with discrete aldosterone producing adrenal <annotation cui="C0001430">adenomas</annotation> who are judged to be poor operative risks or who decline surgery. </li><li> Long term maintenance therapy for patients with <annotation cui="C0333976;C0342495">bilateral micro or macronodular adrenal hyperplasia</annotation> (<annotation cui="C1384514">idiopathic hyperaldosteronism</annotation>). </li></ol> <b> Edematous conditions </b> for patients with <br> <br> <ol><li> <annotation cui="C0018802">Congestive heart failure</annotation>: For the management of <annotation cui="C0013604">Edema</annotation> and <annotation cui="C0020488">sodium retention</annotation> when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with <annotation cui="C0018802">Congestive heart failure</annotation> taking digitalis when other therapies are considered inappropriate. </li><li> <annotation cui="C0023890">Cirrhosis</annotation> of the liver accompanied by <annotation cui="C0013604">Edema</annotation> and/or <annotation cui="C0003962">ascites</annotation>: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. </li><li> The <annotation cui="C0027726">nephrotic syndrome</annotation>: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. </li></ol> <b> <annotation cui="C0085580">Essential hypertension</annotation> </b> <br> <br> <ol><li> Usually in combination with other drugs, spironolactone is indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. </li></ol> <b> <annotation cui="C0020621">Hypokalemia</annotation> </b> <br> <br> <ol><li> For the treatment of patients with <annotation cui="C0020621">Hypokalemia</annotation> when other measures are considered inappropriate or inadequate. Spironolactone is also indicated for the prophylaxis of <annotation cui="C0020621">Hypokalemia</annotation> in patients taking digitalis when other measures are considered inadequate or inappropriate. </li></ol> <b> Usage in Pregnancy. </b> The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. <br> <br> <annotation cui="C0013604">Edema</annotation> during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. <br> <br> Spironolactone is indicated in pregnancy when <annotation cui="C0013604">Edema</annotation> is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS Pregnancy ). Dependent <annotation cui="C0013604">Edema</annotation> in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with <annotation cui="C0013604">Edema</annotation>, including generalized edema, in the majority of pregnant women. If this <annotation cui="C0013604">Edema</annotation> produces discomfort, increased recumbency will often provide relief. In rare instances, this <annotation cui="C0013604">Edema</annotation> may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. <br> <br> |01deb112-edf1-4ed6-bc04-672d02ce66ab;0fed2822-3a03-4b64-9857-c682fcd462bc;19e50a28-8087-44c3-811b-b30d3bca5ba4;2d98eab1-6713-4b8c-a17c-f136e9972bce;2efb4720-625f-6616-b6f0-8b13a17c9d7e;322f2b36-ca93-4a57-9413-ef4efbbb3c65;3416d8b8-7692-a6a3-7a8b-28a623b346e0;4542d698-0299-4b6f-91a7-c8127384ca0c;48115c9e-c82f-438d-b178-dce1b73687db;4a8b16c6-08e8-4b93-9a4b-30fc43f332c6;617aef1f-3f2c-4d33-8baf-40995b8f6a24;6ac04cc4-b044-45a3-ac41-a4dfc4969697;7a0bba98-8f39-4020-b2a5-c487278a057a;7c850c17-9a7d-423a-86bd-ac108d1c7932;7d16b436-c76c-4ac8-b36a-149a14faecab;7e1a8152-941a-4aa4-bcb0-83c04905678f;81ce9360-f956-4d65-b086-4827f106d27e;90668e5a-0c0d-4941-94cf-8b2fba410ed7;922b2c82-052a-416c-984f-0dd66f2c61c4;a98fca05-7896-411b-8a80-1588be1fac00;ad43304a-3b3a-4708-92c7-56aa393ee906;beaf74db-4159-3b59-ef99-575c3ac99aa1;c22b0765-1777-4001-836a-2684daf2a35b;c23b6b9b-aec3-48a8-a518-76e4097f6479;e574545f-bb08-4654-98b3-bdb6666004a8;e5bf608e-c6dd-44e8-96aa-ba4660f64de0;e9ce6841-9bf6-42c2-a56d-c8d08bac2d9e;f802ebee-1c21-4254-9e14-5a83ffdb82ba;fb66327e-8261-46ae-b39a-4fa79d520844;
10518|b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0| Propylthiouracil is indicated <br> <br> <ol><li> in patients with <annotation cui="C0018213">Graves disease</annotation> with <annotation cui="C0020550">hyperthyroidism</annotation> or <annotation cui="C0154143">toxic multinodular goiter</annotation> who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option </li><li> to ameliorate symptoms of <annotation cui="C0020550">hyperthyroidism</annotation> in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole </li></ol> |103c6393-d5c9-4efd-817c-2d6e5fec1704;120de758-f102-470a-892d-a61b18ff8f71;88765882-d76e-2464-8a8f-e51afb2b4633;a57c49ae-d659-49fa-84e3-cf6d1f9e6f97;b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0;d270ea0a-bbcf-4a87-8299-8cbe03c13958;ff603c99-6620-4945-acdc-c9150b6f77d4;
10569|c83616c9-c222-4e3e-91bd-c7839406bb2a| 1.1 Healing of <annotation cui="C0267055">Erosive Esophagitis</annotation> KAPIDEX is indicated for healing of all grades of <annotation cui="C0267055">Erosive Esophagitis</annotation> (EE) for up to 8 weeks. <br> <br> 1.2 Maintenance of Healed <annotation cui="C0267055">Erosive Esophagitis</annotation> KAPIDEX is indicated to maintain healing of EE for up to 6 months. <br> <br> 1.3 Symptomatic Non Erosive <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> KAPIDEX is indicated for the treatment of <annotation cui="C0018834">heartburn</annotation> associated with non erosive <annotation cui="C0017168">Gastroesophageal Reflux Disease</annotation> (<annotation cui="C0017168">GERD</annotation>) for 4 weeks. <br> <br> |67464901-d29e-4706-b337-e3e27707fdbe;9819f033-3bbe-442e-8e92-45fec77b237d;c83616c9-c222-4e3e-91bd-c7839406bb2a;d62d754e-2310-4912-b022-603ae925710d;fd3c2497-ab34-4e19-a7c8-e599025435c8;
1059|0224b5a6-25a3-44c9-b94f-90e2e064c164| PROMETRIUM Capsules are indicated for use in the prevention of <annotation cui="C0014173">endometrial hyperplasia</annotation> in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in <annotation cui="C0232940">secondary amenorrhea</annotation>. <br> <br> |0224b5a6-25a3-44c9-b94f-90e2e064c164;849e9f62-7414-3c22-9cb1-934f953400fc;cf73c385-5173-4b54-af23-069581c5d560;dc64d6d6-b773-4f6b-b563-d389bf89bbc5;
11045|067ea8ec-99a3-4a0b-9116-4ffd6160b24b| IQUIX solution is indicated for the treatment of <annotation cui="C0010043">corneal ulcer</annotation> caused by susceptible strains of the following bacteria <br> <br> |067ea8ec-99a3-4a0b-9116-4ffd6160b24b;09b3a912-97f9-45ae-a162-9f45c860dc22;
11145|a09a3b76-36f1-4d20-930e-7e3da97e7ebd| This drug is indicated in <annotation cui="C0002453">amenorrhea</annotation> and abnormal <annotation cui="C0042134">uterine bleeding</annotation> due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. <br> <br> |83cfc12e-75d1-4284-bcc3-beadcbd27171;a09a3b76-36f1-4d20-930e-7e3da97e7ebd;a479b395-1e1a-4d2a-8feb-68a15c47225f;b79abe4a-0242-41da-b91b-df723b85f0cc;dbe573fc-32b5-4e99-b18e-e22aa0fb7165;
11155|d45fc842-2563-4421-86af-a55b3191e19b| <div> Monotherapy and Combination Therapy </div> ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with <annotation cui="C0011860">type 2 diabetes mellitus</annotation> in multiple clinical settings. [See <i> Clinical Studies (14) </i> .] <br> <br> <div> Important Limitations of Use </div> ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. <br> <br> ONGLYZA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using ONGLYZA. [See <i> Warnings and Precautions (5.1) </i> .] <br> <br> |ba48ac4b-9503-4006-f6e2-3b8a83059c03;d45fc842-2563-4421-86af-a55b3191e19b;
11207|b73ab327-ecb9-4d0c-8b89-17890153608e| Extended phenytoin sodium capsules are indicated for the control of generalized tonic clonic (<annotation cui="C0494475">grand mal</annotation>) and complex partial (psychomotor, temporal lobe) <annotation cui="C0036572">seizures</annotation> and prevention and treatment of <annotation cui="C0036572">seizures</annotation> occurring during or following neurosurgery. <br> <br> Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ). <br> <br> |836cd001-99e8-4591-860a-07094ea0de74;b73ab327-ecb9-4d0c-8b89-17890153608e;ca119a89-2394-4d34-8078-cd1fa4e8e2f1;
11258|d46fcd26-a828-4b9f-af88-1f62a7cb9598| For the relief of <annotation cui="C0278139;C0278140">moderate to moderately severe pain</annotation>. <br> <br> |6eaff86d-3b90-499e-b46f-316a35f5d811;d25b9c43-7127-4206-aa63-3b5dedfa7849;d46fcd26-a828-4b9f-af88-1f62a7cb9598;
11880|eef30745-075c-4430-8271-2c3f353f40a2| In the treatment of both <annotation cui="C0041296">Tuberculosis</annotation> and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. <br> <br> <div> <annotation cui="C0041296">Tuberculosis</annotation> </div> Rifampin is indicated in the treatment of all forms of <annotation cui="C0041296">Tuberculosis</annotation>. A three drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of <annotation cui="C0041296">Tuberculosis</annotation>, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of <annotation cui="C0041296">Tuberculosis</annotation> unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. <br> <br> Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. <br> <br> <div> Meningococcal Carriers </div> Rifampin is indicated for the treatment of asymptomatic carriers of <i> Neisseria meningitidis </i> to eliminate meningococci from the nasopharynx. <b> Rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. </b> (See <b> WARNINGS </b> .) <br> <br> Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. <br> <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> |036ab68e-5085-4edc-bd83-784b43d64eab;0609253c-505b-c6d0-241e-90ffdba25ca2;0a99a222-580b-4d80-8aaf-1c74d9a6caab;0c7adf7f-d2c3-4b3a-b81b-dcaae7cc3036;1881d0ef-38d3-4ecc-bd51-d20679b7dc2f;26a2dbca-5090-4f6c-99ed-e11a70bb5af0;363d2275-fca2-4c6d-940c-137e89d9d78c;3cc0bcd2-37d7-4a7b-808b-980d864281af;4cb11585-a53f-4ef6-a52d-8cff3a4fd8eb;540eaf0a-da8d-41ce-b9c5-0c4e0733a179;55816042-946d-4bec-9461-bd998628ff45;78c4d20c-9d9b-4f26-bc11-ff193c6c53ca;85532a0e-24fa-4a4f-9a0e-721502fa7d7e;9498a2f4-6b05-4811-80d7-9acaa9cf59a5;a086ceb6-7796-437f-865d-e25b39bd1a23;b4d41487-b8f3-4f36-9144-f0e67a2ea53a;b58b9f95-6886-40a9-a443-ad95eebebcf0;d7131853-8850-45bd-9227-c4b1916dd28d;eef30745-075c-4430-8271-2c3f353f40a2;
11883|37e65a87-c68c-40da-bc13-1f5455858fa1| Sulfasalazine tablets are indicated <br> <br> <ol><li> a)in the treatment of mild to moderate <annotation cui="C0009324">ulcerative colitis</annotation>, and as adjunctive therapy in severe <annotation cui="C0009324">ulcerative colitis</annotation>; and </li><li> b)for the prolongation of the remission period between acute attacks of <annotation cui="C0009324">ulcerative colitis</annotation> </li></ol> |37e65a87-c68c-40da-bc13-1f5455858fa1;3f915e6f-aa04-4ba6-8553-d443fb177d6d;48fbc535-a33a-45ee-85ff-9d1ec9b31d9c;6e90e3e6-b4ee-42b3-9fdc-33ef333eb79a;ad13d598-7b1b-48d3-a25b-08635b419f99;ddbe69f3-bd55-45f3-a64f-f60226c744c4;ee7129fd-525b-4ed3-b8a6-e4587697f655;
11917|a313c111-e539-47bc-9d57-c3767f74bcca| In patients without structural heart disease, propafenone is indicated to prolong the time to recurrence of <br> <br> <ol><li> paroxysmal <annotation cui="C0004239">atrial fibrillation/flutter</annotation> (PAF) associated with disabling symptoms. <br> </li><li> <annotation cui="C0030590">paroxysmal supraventricular tachycardia</annotation> (PSVT) associated with disabling symptoms. <br> </li></ol> As with other agents, some patients with <annotation cui="C0004239">atrial flutter</annotation> treated with propafenone have developed 11 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. <br> <br> The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. <br> <br> Propafenone hydrochloride tablets are also indicated for the treatment of documented <annotation cui="C0085612">ventricular arrhythmias</annotation>, such as <u> sustained </u> <annotation cui="C0042514">ventricular tachycardia</annotation>, that, in the judgement of the physician, are life threatening. Because of the proarrhythmic effects of propafenone, its use with lesser <annotation cui="C0085612">ventricular arrhythmias</annotation> is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. <br> <br> Initiation of propafenone treatment, as with other antiarrhythmics used to treat life threatening <annotation cui="C0085612">ventricular arrhythmias</annotation>, should be carried out in the hospital. <br> <br> Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular or atrial arrhythmias. <br> <br> |352d26ca-9f68-42bd-ad8c-ed647aca7009;36e02614-9346-483e-8beb-711519b80a9d;3b453b16-b050-4dda-8e2f-40924e7f7d1c;578d747f-c023-4d5a-9e9a-d4a970d8f69f;8dd938c8-d37c-4a82-b36d-dd0a2d31c8fa;9017ff99-cf37-43f4-95cc-3477f1940c54;9ad1b5f4-fbb7-46b5-a719-796d85cd4c54;a313c111-e539-47bc-9d57-c3767f74bcca;a7c8f090-c48c-44f7-9973-2cf4b491e35c;d4a552ce-f215-4ec7-b5dd-aee266ba9b08;
11996|8bb1bc4a-a019-49c8-af81-be899822428f| RYTHMOL SR is indicated to prolong the time to recurrence of symptomatic <annotation cui="C0004238">atrial fibrillation</annotation> (<annotation cui="C0004238">AF</annotation>) in patients with episodic (most likely paroxysmal or persistent) <annotation cui="C0004238">AF</annotation> who do not have structural heart disease. <br> <br> <b> Usage Considerations </b> <br> <br> <ol><li> The use of RYTHMOL SR in patients with permanent <annotation cui="C0004238">AF</annotation> or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use RYTHMOL SR to control ventricular rate during <annotation cui="C0004238">AF</annotation>. </li><li> Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. </li><li> The effect of propafenone on mortality has not been determined [see Boxed Warning] . </li></ol> |01ede254-7d2a-4a6f-a253-01d77770022e;0e9d1433-a55e-4907-bb38-abac47c7d3c7;8bb1bc4a-a019-49c8-af81-be899822428f;
12127|061cf52b-4432-422d-a97b-c3e1f8c4bab6| Oxycodone hydrochloride capsule is an opioid analgesic, indicated for the management of moderate to <annotation cui="C0278140;C0184567">severe acute and chronic pain</annotation> where use of an opioid analgesic is appropriate. <br> <br> |061cf52b-4432-422d-a97b-c3e1f8c4bab6;
12230|120ce39a-c2bc-4c07-94b5-c7d9fc0da7ec| PredniSONE Tablets are indicated in the following conditions <br> <br> <ol><li> <annotation cui="C0014130">Endocrine Disorders</annotation> <annotation cui="C0001403;C0271738">Primary or secondary adrenocortical insufficiency</annotation> (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) <annotation cui="C0001627">Congenital adrenal hyperplasia</annotation> Nonsuppurative <annotation cui="C0040147">thyroiditis</annotation> <annotation cui="C0020437">Hypercalcemia</annotation> associated with cancer <br> </li><li> <annotation cui="C0035435">Rheumatic</annotation> Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: <annotation cui="C0003872">Psoriatic arthritis</annotation> <annotation cui="C0003873">Rheumatoid arthritis</annotation>, including <annotation cui="C0553662">juvenile rheumatoid arthritis</annotation> (selected cases may require low dose maintenance therapy) <annotation cui="C0038013">Ankylosing spondylitis</annotation> Acute and <annotation cui="C1290159">subacute bursitis</annotation> Acute nonspecific <annotation cui="C0039520">tenosynovitis</annotation> Acute <annotation cui="C0003868">gouty arthritis</annotation> Post traumatic <annotation cui="C0029408">osteoarthritis</annotation> <annotation cui="C0039103">Synovitis</annotation> of <annotation cui="C0029408">osteoarthritis</annotation> <annotation cui="C0014488">Epicondylitis</annotation> <br> </li><li> <annotation cui="C0009326">Collagen Diseases</annotation> During an exacerbation or as maintenance therapy in selected cases of: <annotation cui="C0024141">Systemic lupus erythematosus</annotation> Systemic <annotation cui="C0011633">dermatomyositis</annotation> (<annotation cui="C0085655">polymyositis</annotation>) <annotation cui="C0035440">Acute rheumatic carditis</annotation> <br> </li><li> <annotation cui="C0037274">Dermatologic Diseases</annotation> <annotation cui="C0030807">Pemphigus</annotation> Bullous <annotation cui="C0011608">dermatitis herpetiformis</annotation> Severe <annotation cui="C0014742">erythema multiforme</annotation> (Stevens Johnson syndrome) <annotation cui="C0011606">Exfoliative dermatitis</annotation> <annotation cui="C0026948">Mycosis fungoides</annotation> Severe <annotation cui="C0033860">psoriasis</annotation> Severe <annotation cui="C0036508">seborrheic dermatitis</annotation> <br> </li><li> Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or <annotation cui="C0035457">perennial allergic rhinitis</annotation> <annotation cui="C0004096">Bronchial asthma</annotation> <annotation cui="C0011616">Contact dermatitis</annotation> <annotation cui="C0011615">Atopic dermatitis</annotation> <annotation cui="C0036830">Serum sickness</annotation> Drug <annotation cui="C0020517">hypersensitivity reactions</annotation> <br> </li><li> Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal <annotation cui="C0024799">marginal ulcers</annotation> <annotation cui="C0019364">Herpes zoster ophthalmicus</annotation> Anterior segment inflammation Diffuse <annotation cui="C0042167">posterior uveitis</annotation> and <annotation cui="C0008526">choroiditis</annotation> <annotation cui="C0029077">Sympathetic ophthalmia</annotation> <annotation cui="C0009766">Allergic conjunctivitis</annotation> <annotation cui="C0022568">Keratitis</annotation> <annotation cui="C0008513">Chorioretinitis</annotation> <annotation cui="C0029134">Optic neuritis</annotation> <annotation cui="C0022081">Iritis</annotation> and <annotation cui="C0022073">iridocyclitis</annotation> <br> </li><li> <annotation cui="C0035204">Respiratory Diseases</annotation> Symptomatic <annotation cui="C0036202">sarcoidosis</annotation> <annotation cui="C0242459">Loeffler's syndrome</annotation> not manageable by other means <annotation cui="C0005138">Berylliosis</annotation> <annotation cui="C0032290">Aspiration pneumonitis</annotation> Fulminating or disseminated <annotation cui="C0041327">pulmonary tuberculosis</annotation> when used concurrently with appropriate antituberculous chemotherapy <br> </li><li> <annotation cui="C0018939">Hematologic Disorders</annotation> <annotation cui="C0043117">Idiopathic thrombocytopenic purpura</annotation> in adults <annotation cui="C0154301">Secondary thrombocytopenia</annotation> in adults Acquired (<annotation cui="C0443146">autoimmune</annotation>) <annotation cui="C0002878">hemolytic anemia</annotation> <annotation cui="C0877221">Erythroblastopenia</annotation> (RBC <annotation cui="C0002871">anemia</annotation>) Congenital (erythroid) <annotation cui="C0178416">hypoplastic anemia</annotation> <br> </li><li> Neoplastic Diseases For palliative management of: <annotation cui="C0023418">Leukemias</annotation> and <annotation cui="C0024299">lymphomas</annotation> in adults <annotation cui="C0085669">Acute leukemia</annotation> of childhood <br> </li><li> <annotation cui="C0013604">Edematous</annotation> States To induce a diuresis or remission of <annotation cui="C0033687">proteinuria</annotation> in the <annotation cui="C0027726">nephrotic syndrome</annotation>, without uremia, of the idiopathic type or that due to lupus erythematosus <br> </li><li> <annotation cui="C0017178">Gastrointestinal Diseases</annotation> To tide the patient over a critical period of the disease in: <annotation cui="C0009324">Ulcerative colitis</annotation> <annotation cui="C0010346">Regional enteritis</annotation> <br> </li><li> Miscellaneous <annotation cui="C0041318">Tuberculous meningitis</annotation> with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy <annotation cui="C0040896">Trichinosis</annotation> with neurologic or myocardial involvement <br> </li></ol> |0a9ce62e-2a61-4dc3-a921-0da9ffbe1c76;0dfb483e-e93b-49b0-8253-cb4a569bacb3;10fe5a3b-84dc-4600-87c2-b80c97ce18cf;120ce39a-c2bc-4c07-94b5-c7d9fc0da7ec;1acbda65-ead7-4947-841c-8788c3ee4c00;1f2cc2d9-73d5-4539-8a0c-dba24ae4b10d;281ab967-7565-4bef-9c0c-a646589c671e;290a91e5-22ae-4d62-ab34-39a3117002e2;2fac670c-88f2-4f19-9538-678b6bfe23f5;30e64a3c-2045-405b-a22c-a1a6ba80c51e;3115aef0-fd50-4ec8-a064-3effb695f3f2;3848bfdc-21e6-4eef-a731-eec14ad39793;43b54d0d-9c26-4e72-947b-0009a0a18409;4c918ddf-2d16-49eb-b2a8-d0e00fd6b178;5092299c-3782-4ee5-b3e7-4e80bf378e3b;599fc1cd-0334-4be1-8c3d-a7f184f4b904;5b2f4fa9-817c-43c9-ac9a-750ab1d1f66f;635e93eb-9c12-7ead-b81e-bc06603c526d;63e2d3c7-8120-401b-a826-c98754797026;64ea4cd0-ba01-4c3a-8ef2-41d7b3073f8f;66dc04d3-54ea-41f8-9495-81565b03dc9a;6984a178-7903-4881-98be-76e337565c6d;78fb9762-c2b2-4e32-ac4c-e95cba11198e;947f2aa0-4d8e-4e8d-b8fe-601d50be3bc4;97c28049-1f40-4b0c-9caa-eb0770d0300d;99385bc6-e9b5-4081-831d-657bf3dfbaaf;9a76c658-6658-47a7-8f8d-b3994aef8585;9b682e76-7b10-43a9-9527-81a633b7d0c0;9fcd7814-1363-4218-92c6-b0f732795897;9fde9268-d5e8-4402-a429-df55f075861d;A784F545-F209-46D4-9350-AE64FAD9E07C;a1769552-f230-40e0-8f05-5b3b356437b6;a651e06c-6295-4ed2-8d67-334645f05b30;aa0b1582-6ef3-4697-9ea6-5391e6e57853;add8f32a-4a63-4180-8d92-d34a75e498de;b4332b67-833d-4838-9594-b2b76f98d1ab;b44702ca-0f0f-4180-9462-3e5c932c999e;b8bb74be-9a37-44ec-a7cd-58f2cf99ac75;c308ffd5-208e-4661-8451-2c6ea6594d08;c8bc83d5-b9e2-4d31-a3df-8e899aac1ba5;c960d736-2657-4b79-967f-d2c9bb4076cd;d29348a5-e903-4145-9dbd-ce604e666992;d3abe47f-8ad5-4752-b772-97b56cca19f2;db320bf8-10b5-4f2d-bce5-04e87dfd2db4;e0be1cf5-b4e4-4c07-8cfb-11f414856c80;e419b13a-68de-4d24-ba8e-3257e88905a3;e63df4be-b3d3-4873-92e3-d7fbc84d1dc4;e9d6774e-45f6-419f-b388-8dfb4dd34944;eab763ec-04bf-4e57-8351-a1d0de0c3811;f285bc65-ed88-488d-8fce-a3a608ed0514;f4a4cf97-6b6d-4406-a141-7d6a087667aa;f55cecd1-013d-4db5-9d62-e2cd53f253e4;f696623f-ecf2-407a-a676-caad2f4c0123;fb95ae26-70e8-417b-98aa-657e3dd668d7;
12363|d09dd18f-8db4-4fee-b51c-6aba56850103| Perphenazine is indicated for use in the treatment of <annotation cui="C0036341">schizophrenia</annotation> and for the control of severe <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> in adults. <br> <br> Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. <br> <br> |2d821387-4b4f-4fe3-825e-750f49755baf;6beb0c1a-9801-40d9-97d5-3488e603cc1a;6c76e98d-b8c3-441f-bac5-a9de6dc8f14f;a17c90f9-3d5d-4503-ba2c-754b45decbf8;abcfeec6-7f3a-4139-a6e6-fa42dafd8264;ad8193fb-4e3c-42e9-a4a8-49133650b86b;ca1b6a78-739b-4e2a-9332-145c887fb2ff;d09dd18f-8db4-4fee-b51c-6aba56850103;dd02a11f-6ea6-42e7-b168-bf2b9f4d54ae;f2c7e54b-ed7c-4d8f-a86d-5099a8b52f28;
12469|dedef9e5-23de-49ff-895a-30906b5c7da3| Carefully consider the potential benefits and risks of FELDENE and other treatment options before deciding to use FELDENE. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <b> WARNINGS </b> ). <br> <br> FELDENE is indicated <br> <br> <ol><li> For relief of the signs and symptoms of <annotation cui="C0029408">osteoarthritis</annotation>. </li><li> For relief of the signs and symptoms of <annotation cui="C0003873">rheumatoid arthritis</annotation>. </li></ol> |1ab9b3c7-f7b7-4cf0-8070-d0ef77232e9e;24ae3aa7-2236-4009-bce5-4c96d6f2a5ba;4314317f-436e-4c70-b418-220a4c984727;481c459d-42f1-4c64-9949-d5107c182730;4a6445cf-8ac8-41fb-9de9-f3cf81343022;53b33c73-a220-4add-ba61-b00e9e9f852b;6047dd25-8419-42ce-bd58-9e568ae7b50f;7581cd6c-799a-425a-aa73-787e7b5a63f8;8B84D814-9BB3-4677-AA3E-A04DE9302286;9d3e528b-a748-4bc5-b604-e7e9c5ab9183;AA447BAC-DFBD-44AE-B1D1-3E1BE6D7EF9E;b8b9208e-018e-4531-af47-bcaaad33f4a6;c63ddb82-846a-fbab-45e8-987c40eb6954;dedef9e5-23de-49ff-895a-30906b5c7da3;f1123fe1-b79c-430b-8548-08cd6e518482;f1f62485-4f0a-4f7e-b450-62f9ce20f13f;fffb1b0f-8cc0-42c1-960e-2e53b73a6d6e;
12491|22734527-78ad-4075-bcd5-3e6d535c61e9|For the relief of <annotation cui="C0278138;C0278139">mild to moderate pain</annotation>. <br> <br> |11476433-d06d-4b33-924f-e8066bca7455;22734527-78ad-4075-bcd5-3e6d535c61e9;49c4f24c-648b-2db2-5c00-2835d14b1275;773c3627-1635-4415-a89a-aaf74329f9c2;e83c5fef-74e9-46ed-8277-063df09a1e3d;
12623|b693e68d-f812-4993-54b6-852e3517c344| <div> <annotation cui="C0342879">Primary Hypercholesterolemia</annotation> or Mixed <annotation cui="C0242339">Dyslipidemia</annotation> </div> TRICOR is indicated as adjunctive therapy to diet to reduce elevated low density lipoprotein cholesterol (LDL C), total cholesterol (Total C), Triglycerides and apolipoprotein B (Apo B), and to increase high density lipoprotein cholesterol (HDL C) in adult patients with <annotation cui="C0342879">Primary Hypercholesterolemia</annotation> or mixed <annotation cui="C0242339">Dyslipidemia</annotation>. <br> <br> <div> Severe <annotation cui="C0020557">Hypertriglyceridemia</annotation> </div> TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with severe <annotation cui="C0020557">Hypertriglyceridemia</annotation>. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. <br> <br> Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. <br> <br> <div> Important Limitations of Use </div> Fenofibrate at a dose equivalent to 145 mg of TRICOR was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus <i> [see Warnings and Precautions (5.1)] </i> . <br> <br> |13d99b6b-99a5-49e7-8288-f07a087e344c;1f841079-8c66-4f93-a244-4c405d01e364;319a178d-7ffb-4466-85f6-de615d02f223;35e89d4e-45cf-4374-bf93-fca8d40d783b;45364845-c3b4-40a1-a677-82202ffaa5ad;5d4be1cd-0d85-ea9b-f408-a62582069d0c;6FE11357-7165-4C8B-BE0A-42C277A12BF9;86c49aff-0a4a-46b5-ac6e-26789bf17c9b;94a4a99b-24df-4e81-b409-5325d36647d2;9a883573-aa2a-4376-bb0f-3b88246d2169;9d4fa3ac-5a6d-460c-bc89-1c83fd436e90;b38489c0-ee7b-11df-b958-0002a5d5c51b;b693e68d-f812-4993-54b6-852e3517c344;ddb63851-e9b9-4ab0-8e6d-6f83d79741e5;
13734|0b46314b-604d-48ed-9d31-83a18ef4134c| OxyContin Tablets are a controlled release oral formulation of oxycodone hydrochloride indicated for the management of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> when a continuous, around the clock analgesic is needed for an extended period of time. <br> <br> OxyContin is <b> NOT </b> intended for use as a prn analgesic. <br> <br> Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non opioid analgesics, such as non steroidal anti inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. <br> <br> OxyContin is not indicated for pain in the immediate postoperative period (the first 12 24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the <annotation cui="C0030201">postoperative pain</annotation> is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) <br> <br> |000dde4b-1d94-442f-94c0-26e283e04d88;0b46314b-604d-48ed-9d31-83a18ef4134c;215fc8cf-92a0-98d6-c084-3575882f0a66;240118ae-2cf5-4e48-a182-7c37026d59b5;30D32796-AB7E-4765-B121-09277E1C1396;43aab72d-0160-3cc0-0069-8d2a98703364;46345ce2-4038-4928-916d-f3764bddf456;5d1e0e59-f3af-496d-a878-547b5467cd99;66b1190e-a11d-4005-bb95-fa32a0e2de1e;6a30d67a-49ae-4d5c-8b60-5bc8453e9341;6dbf24ce-1200-49ea-95ad-9a06f6db3c1b;88603d5f-4ad0-46ab-999f-740312dc35dc;8c9cb953-0995-4f47-83ee-c8c9dfd1b533;9a3ca129-d6f0-47e4-9f79-f7f9b3fd8692;a1b2e514-b75d-4f01-a9fd-83151f0ce813;aa4d77fb-8d49-4212-8535-9ab8ea7e30d5;bb59f14c-7c7c-4c05-8c5b-41ed92596909;d1f543fe-ebfb-4ace-a223-d928d6b648c1;d7aad54a-541f-41c6-85c9-712c88d3ba30;e18d23e3-b4b2-483f-9523-fdc2b10c6978;f06d3690-3fd4-407d-8f8d-ab0c354e61bd;
13756|7290eb06-641a-43df-9a23-74288ca1e25d| Oxycodone hydrochloride oral solution 100 mg 5 mL ( <b> 20 mg mL </b> ) is an opioid analgesic indicated for the management of moderate to <annotation cui="C0278140;C0184567">severe acute and chronic pain</annotation> in opioid tolerant patients. <br> <br> Oxycodone hydrochloride oral solution 100 mg 5 mL (20 mg mL) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. Patients considered to be opioid tolerant are those who are taking at least 30 mg of oral oxycodone per day, or at least 60 mg oral morphine per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. <br> <br> |6869fec9-1837-4221-afd8-5cc6fadd025d;7290eb06-641a-43df-9a23-74288ca1e25d;7c686a46-1f5f-46e3-945b-2ade3931718f;
14044|6987500a-2feb-48a9-9d29-89693333a801| Levofloxacin ophthalmic solution is indicated for the treatment of <annotation cui="C0009768">bacterial conjunctivitis</annotation> caused by susceptible strains of the following organisms <br> <br> <b> AEROBIC GRAM POSITIVE MICROORGANISMS </b> <br> <br> Corynebacterium species* <br> <i> Staphylococcus aureus </i> <br> <i> Staphylococcus epidermidis </i> <br> <i> Streptococcus pneumoniae </i> <br> <i> Streptococcus </i> (Groups C F) <br> <i> Streptococcus </i> (Group G) <br> Viridans group streptococci <br> <br> <b> AEROBIC GRAM NEGATIVE MICROORGANISMS </b> <br> <br> <i> Acinetobacter iwoffii </i> * <br> <i> Haemophilus influenzae </i> <br> <i> Serratia marcescens </i> * <br> <br> *Efficacy for this organism was studied in fewer than 10 infections. <br> <br> |6987500a-2feb-48a9-9d29-89693333a801;f79d2ae4-ccfb-49ca-bf0e-e505f3477d30;
14148|3057fc9c-ff77-43eb-b687-776660423742| <div> Co administration Therapy with Statins for the Treatment of Mixed <annotation cui="C0242339">Dyslipidemia</annotation> </div> Trilipix is indicated as an adjunct to diet in combination with a statin to reduce TG and increase HDL C in patients with mixed <annotation cui="C0242339">Dyslipidemia</annotation> and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL C goal. <br> <br> CHD risk equivalents comprise <br> <br> <ol><li> Other clinical forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and symptomatic carotid artery disease); </li><li> Diabetes; </li><li> Multiple risk factors that confer a 10 year risk for CHD > 20% </li></ol> <div> Treatment of Severe <annotation cui="C0020557">Hypertriglyceridemia</annotation> </div> Trilipix is indicated as adjunctive therapy to diet to reduce TG in patients with severe <annotation cui="C0020557">Hypertriglyceridemia</annotation>. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacological intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg dL) may increase the risk of developing pancreatitis. The effect of Trilipix therapy on reducing this risk has not been adequately studied. <br> <br> <div> Treatment of Primary <annotation cui="C0020473">Hyperlipidemia</annotation> or Mixed <annotation cui="C0242339">Dyslipidemia</annotation> </div> Trilipix is indicated as adjunctive therapy to diet to reduce elevated LDL C, Total C, TG, and Apo B, and to increase HDL C in patients with primary <annotation cui="C0020473">Hyperlipidemia</annotation> or mixed <annotation cui="C0242339">Dyslipidemia</annotation>. <br> <br> <div> Important Limitations of Use </div> <b> No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. </b> Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. <br> <br> <div> General Considerations for Treatment </div> Laboratory studies should be performed to establish that lipid levels are abnormal before instituting Trilipix therapy. <br> <br> Every reasonable attempt should be made to control serum lipids with non drug methods including appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that may be contributing to the lipid abnormalities. Medications known to exacerbate <annotation cui="C0020557">Hypertriglyceridemia</annotation> (beta blockers, thiazides, estrogens) should be discontinued or changed if possible, and excessive alcohol intake should be addressed before triglyceride lowering drug therapy is considered. If the decision is made to use lipid altering drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. <br> <br> Drug therapy is not indicated for patients who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. <br> <br> |3057fc9c-ff77-43eb-b687-776660423742;bbf3e782-d163-49c8-0e81-4eeabef48190;
14731|31d00e75-4fe0-4aec-9cba-c86cb78762c5| Phenytoin Sodium Injection is indicated for the control of <annotation cui="C0038220">status epilepticus</annotation> of the <annotation cui="C0014549">grand mal</annotation> type and prevention and treatment of <annotation cui="C0036572">seizures</annotation> occurring during neurosurgery. <br> <br> |01ab131c-7b06-4982-8cf0-4e60879e0c8c;035a8d4e-2063-4240-83cb-d7eebcabe301;313cb886-326c-4f27-9b7f-85d94b7e04b8;31d00e75-4fe0-4aec-9cba-c86cb78762c5;41eecbfb-b03a-4a98-ea83-8d4e347f80f6;4fecb867-7213-49ce-9d8f-433f157635d1;7317e374-847a-4b8a-851d-467a0bb9c77e;7806b2aa-074d-43fd-bc8a-7266389b0d26;ab923d09-747d-4527-9bdf-2c807a5775d2;
14810|4fee8d4c-bb21-4773-b622-87f9a4ff333a| <div> Adjuvant Treatment </div> ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early <annotation cui="C0006142">breast cancer</annotation>. <br> <br> <div> First Line Treatment </div> ARIMIDEX is indicated for the first line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic <annotation cui="C0006142">breast cancer</annotation>. <br> <br> <div> Second Line Treatment </div> ARIMIDEX is indicated for the treatment of advanced <annotation cui="C0006142">breast cancer</annotation> in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX. <br> <br> |0193ddae-c600-4e80-a578-4fe271231991;033abda0-1ddc-4da6-99e3-2721db7ea3af;03586c40-eb32-45c5-beb7-6762a6b78790;11628cdc-4e3c-4063-ee9f-c51e2386a820;1448e72e-dc7f-4618-9b37-a82c59823839;188c6fd5-6695-4d8b-af43-61d9c26abfe9;260cfda7-efe0-84b2-7f74-ea83c610c4ef;4f6df9c0-b3a1-4ba0-83b9-ba06c69c2e08;4fee8d4c-bb21-4773-b622-87f9a4ff333a;5ad69fab-7469-419e-9c52-662e07e52c86;5d7d3cfa-af46-48fd-afee-cddf39d2efde;611e1f43-1442-4cbb-b7eb-b65de15c6c70;6128eda4-ad33-4c23-8d93-5192421fd8d0;8d8cdd21-2403-4284-bdfc-d56d6e8ab117;8e4f7179-81d7-4715-9cc1-babef97fcca0;965c4cb1-f6b8-47ac-bf13-c36639aa908f;b33520de-f891-43f8-bd04-1b66795d3dd2;ca16f8de-d9a5-4c6c-957b-ae28497b67ac;ca9d4aff-ffdf-4a46-ad20-e47e5886a19e;cc0c084b-a122-736e-c136-c8cffc92f5f4;d4550afa-977e-426e-814b-705435d2af81;d4f43676-0746-4765-9689-3f1e3075fa6a;e46ed5b8-83c9-4adb-890f-0fc612371eea;f881ec1a-d330-41d8-b633-143875c06ea4;fc0a61a2-78b2-46f7-9933-63fed2c1cebc;fc6adb1b-00a2-40d7-ba92-799393fc689d;
15204|b9ef541a-93c8-4428-ba45-398aa0b327d1| AZULFIDINE EN tabs Tablets are indicated <br> <br> <ol><li> a) in the treatment of mild to moderate <annotation cui="C0009324">ulcerative colitis</annotation>, and as adjunctive therapy in severe <annotation cui="C0009324">ulcerative colitis</annotation>; </li><li> b) for the prolongation of the remission period between acute attacks of <annotation cui="C0009324">ulcerative colitis</annotation>; </li><li> c) in the treatment of patients with <annotation cui="C0003873">rheumatoid arthritis</annotation> who have responded inadequately to salicylates or other nonsteroidal anti inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti inflammatory drugs); and </li><li> d) in the treatment of pediatric patients with polyarticular course 1 <annotation cui="C0553662">juvenile rheumatoid arthritis</annotation> who have responded inadequately to salicylates or other nonsteroidal anti inflammatory drugs. </li></ol> AZULFIDINE EN tabs is particularly indicated in patients with <annotation cui="C0009324">ulcerative colitis</annotation> who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. <br> <br> In patients with <annotation cui="C0003873">rheumatoid arthritis</annotation> or <annotation cui="C0553662">juvenile rheumatoid arthritis</annotation>, rest and physiotherapy as indicated should be continued. Unlike anti inflammatory drugs, AZULFIDINE EN tabs does not produce an immediate response. Concurrent treatment with analgesics and or nonsteroidal anti inflammatory drugs is recommended at least until the effect of AZULFIDINE EN tabs is apparent. <br> <br> |257cee60-b68f-4c2b-b57d-8e4d73d17e09;599be7ea-4036-4e43-a411-1c42369b1b8c;b9ef541a-93c8-4428-ba45-398aa0b327d1;
15717|7def92fe-d521-41c0-b419-48e028f59f15| <div> Assisted Reproductive Technology </div> Crinone 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology ("ART") treatment for infertile women with progesterone deficiency. <br> <br> <div> <annotation cui="C0232940">Secondary Amenorrhea</annotation> </div> Crinone 4% is indicated for the treatment of <annotation cui="C0232940">Secondary Amenorrhea</annotation>. Crinone 8% is indicated for use in women who have failed to respond to treatment with Crinone 4%. <br> <br> |2c8ffbd2-6b7a-42c7-b29e-e4de69dad9e6;7def92fe-d521-41c0-b419-48e028f59f15;9f8dc923-65d7-42ff-b718-97e7a7e87822;
15779|daabf2ee-7f0e-4b45-a2be-8ab6d8c9d3e7| To control severe <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation>. For the treatment of <annotation cui="C0036341">schizophrenia</annotation>. <br> Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. <br> <br> |016b4aa0-ec8f-4bbc-aa07-58e3da801c3b;5e771ba7-983f-49b4-a1f2-0f335b637433;75a3992d-0d2a-498a-9b82-61ee424f3010;a0e65883-9d67-4569-af69-b6ab7ee4a536;daabf2ee-7f0e-4b45-a2be-8ab6d8c9d3e7;
1674|f5b2f9d8-2226-476e-9caf-9d41e6891c46| ADIPEX P is indicated as a short term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of <annotation cui="C1281429">exogenous obesity</annotation> for patients with an initial body mass index 30 kg m 2 , or 27 kg m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). <br> <br> Below is a chart of body mass index (BMI) based on various heights and weights. <br> <br> BMI is calculated by taking the patient s weight, in kilograms (kg), divided by the patient s height, in meters (m), squared. Metric conversions are as follows pounds 2.2 = kg; inches x 0.0254 = meters. <br> <br> The limited usefulness of agents of this class, including ADIPEX P , [ <i> see Clinical Pharmacology ( 12.1 , 12.2 ) </i> ] should be measured against possible risk factors inherent in their use such as those described below. <br> <br> Figure 1 |027d77a3-6d62-498b-8901-86f1f73362d5;03c30e22-e593-4fa9-beab-fbcf976682b0;07f4673f-680d-4dd7-90af-9751253080bf;0ee5b71b-3d8e-46d0-937d-2dbe43490e33;0ef840e9-909f-9203-e0b0-7e7740f59637;0f0e5a0c-9ae1-45ad-8e9f-47170a037c68;139b0347-9954-4913-b1c1-d9506fc91393;1993b181-f4f1-4451-92a0-7ed8f32598ba;1c6651a6-b588-4873-9f13-41b7af1c3d58;29bd88e3-215d-4c34-b22a-df159a2dd98d;3c8f78be-1852-4db9-bfb0-78dee816cbe8;42a2586d-b025-4a42-83a3-747a880ed858;446bdbdd-3a96-4422-ad31-8038f3519bca;462eefa0-6224-42c2-af3f-c598de0d8010;4af88a94-22c3-4da1-b8d9-a73ef68a51b6;554adcd6-8a4f-402a-8105-4e70f92e97ea;56f0bb46-57d5-4556-a00c-4f6820e4e6ce;5fa25497-0ef0-4a21-9688-5b52d17f8202;68fcc228-5f06-4ece-94f3-59b5b33c3325;7a971256-645a-4477-86c7-5033e0e520f6;7ca86c66-409b-4852-8631-c3ada6e60738;7f871c5e-02e5-40f3-a60d-c9d2e9f5ce66;7fb51344-baa4-4905-8ee7-a2db973786fc;80d92084-99dd-4a13-bd63-772a6363a256;851b0ef4-c656-48f4-915f-6289cac3fde4;8aa97532-fd13-44b0-9b77-6165a35b6809;ABF83FA7-E6E4-421E-940E-F6FEC0F1BDF5;a3600c42-470a-4a36-9e9a-d74504de8c40;a894c87a-f04d-4080-a52b-b3fd8b8b6e01;ac77760b-e784-a907-d0d8-114a809e42a8;adf965bd-86cc-4313-9253-c151585f3f94;b7fd9015-83f3-431a-90e2-4fe68006754e;b961e6cc-4956-405f-9e53-b55604be23f6;bd4ae9af-0c72-42ab-8809-d6556a6eea15;c5b66bc3-13d9-4902-9719-a2d41b743c9f;d60075f0-19b9-410d-b93b-d897de08f5a5;d6efcdad-418d-4f1f-90e7-a769e4815a1e;d8ddc6a0-29d0-4730-b718-1bdb2937a91c;df379f22-6bc5-45b9-920b-3dab77fe8a7e;efa6398d-fd9c-48f4-a91f-5a91b4ae5b5e;f5b2f9d8-2226-476e-9caf-9d41e6891c46;fff196d7-9ecf-4e4f-9d7a-2ae9925fba90;
16952|e4412a6a-ed4d-410d-8abb-86e1d7b72a3c| Propafenone Extended Release Capsules are indicated to prolong the time to recurrence of symptomatic <annotation cui="C0004238">atrial fibrillation</annotation> in patients without structural heart disease. <br> <br> The use of propafenone ER capsules in patients with permanent atrial fibrillation or in patients exclusively with atrial flutter or PSVT has not been evaluated. Propafenone ER capsules should not be used to control ventricular rate during <annotation cui="C0004238">atrial fibrillation</annotation>. <br> <br> The effect of propafenone ER capsules on mortality has not been determined (see black box <b> WARNINGS </b> ). <br> <br> |e4412a6a-ed4d-410d-8abb-86e1d7b72a3c;
17413|36c4da56-502e-4da1-acf7-8e81ee453dcc| MINIPRESS is indicated in the treatment of <annotation cui="C0020538">hypertension</annotation>. It can be used alone or in combination with other antihypertensive drugs such as diuretics or beta adrenergic blocking agents. <br> <br> |021370d8-a61c-4510-b717-40dadcf9a4dc;1ce90aaf-d075-4617-9a47-e8d922096d23;36c4da56-502e-4da1-acf7-8e81ee453dcc;5d7dff44-84b1-4044-bc5a-c76ea11dd5a3;7293cef3-ef9e-40dc-9995-875ef047f693;7dd1b0aa-0d5c-4255-a514-a516f78c0f64;cd52f022-ca29-4f87-8684-da63e05b3c1f;e6a029b2-802f-4cc5-8795-20e177e8d779;
1855|d2e353a9-ac30-4378-af05-189b54b63e53| For control of severe <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation>. <br> <br> For the treatment of <annotation cui="C0036341">schizophrenia</annotation>. <br> <br> Prochlorperazine is effective for the short term treatment of generalized non psychotic <annotation cui="C0003469">anxiety</annotation>. However, prochlorperazine is not the first drug to be used in therapy for most patients with non psychotic <annotation cui="C0003469">anxiety</annotation>, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). <br> <br> When used in the treatment of non psychotic <annotation cui="C0003469">anxiety</annotation>, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see <b> WARNINGS </b> ). <br> <br> The effectiveness of prochlorperazine as treatment for non psychotic <annotation cui="C0003469">anxiety</annotation> was established in 4 week clinical studies of outpatients with <annotation cui="C0270549">generalized anxiety disorder</annotation>. This evidence does not predict that prochlorperazine will be useful in patients with other non psychotic conditions in which <annotation cui="C0003469">anxiety</annotation>, or signs that mimic <annotation cui="C0003469">anxiety</annotation>, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). <br> <br> Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. <br> <br> |15453da2-c60b-42ca-a997-8ec7bc7dcade;1e660e78-2267-4e3a-bdb9-80041f88cb5f;26b5247a-9590-dd1d-7101-e406011d20e3;27c6d7d9-78f1-485f-adbb-506fd1aa8e5c;2fd7803f-fb1f-4f00-86ad-c2436b569e6d;5cfd84b0-46a3-4379-9454-62f183370a76;6b0e958b-fde0-74ea-b196-1e62f90b5bbe;718c6fee-77d5-4ba1-8a1d-f2ac059298b3;95b54f0a-5e38-4bfa-8c5e-f9c826774da0;a49905cc-dd53-43a2-8113-d8ada3f8cae9;b05bc20e-cd19-ab40-1ad0-84a115d6d69e;b733d4e1-bd73-43f3-8192-df89cbdae781;c13a266d-a692-4a8e-ba06-2984b287eeaf;d242cfe9-6aab-4c02-ab84-f4fb2f73be93;d2e353a9-ac30-4378-af05-189b54b63e53;e4f4d30e-4bb8-411c-a0d3-0be160f6745e;
2255|093fd736-5971-47af-b4ef-08c1696cebe8| Phenytoin is indicated for the control of tonic clonic (<annotation cui="C0014549">grand mal</annotation>) and psychomotor (temporal lobe) <annotation cui="C0036572">seizures</annotation>. <br> <br> Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY sections). <br> <br> |051742b5-b0f0-44a5-8d31-3288527b0638;093fd736-5971-47af-b4ef-08c1696cebe8;0c9321ae-cc4d-45f0-87d3-e2a5b4f60fde;0f94c791-8b07-4b41-927e-c9f28bec5f60;0fa9bf20-d747-4480-bc89-d1f663404cf1;1c133e0d-0639-4b6d-a21c-d48d76df2065;1fd75c5a-f56b-42a2-aa4a-9cd0344d0a6f;25acb26b-04ef-4589-8955-71d777dc813d;2b686efb-8c2f-4690-8839-78cb843e8c2c;422408c1-ca13-4743-9773-9641eca28f18;5625eadf-ff6b-4aae-ae14-32d8f9240c93;601f7353-225d-4a5d-9810-3869c2c21874;60e40004-4db1-2ccd-18bc-aebaab3267be;6794195c-47fa-47e9-9bac-cbbbdfbeef68;7b69a124-2f00-47ac-90fb-56069ab3cf9a;7e467c02-49a0-4b62-b537-430fdfa4f10e;81661cf9-430b-4f66-88fd-2cbd5b114e3b;854af572-0433-45ce-a373-593429a37698;85cc5cd9-695f-4a71-9275-e0099c505185;8848de76-8d74-4620-bcc7-a86a596e5dd9;904939e7-5f4c-4906-99ae-f45db41f46b3;9ce9adc8-6fa2-4444-8386-14cd576ac63d;9e6fc23b-9982-45f1-beb1-8c3e0765d382;A5359176-9E01-4D51-A48C-1685F4C16BCA;a00f9c78-ebe9-4afd-b4c4-dceaa7eb27e9;b7758662-dcd2-4a02-933f-8a3de70cf551;bb2b0848-1438-8d8a-22b9-551a129cc632;c020c1e8-5d37-4e7e-a7c2-b7ded1b8a60b;c40f66cc-6f4a-4b29-84ba-d265e4848735;cc521263-7ddc-4a79-a3ca-466848e32c23;da966d98-94a6-463e-aff7-771406c4c836;e54861d7-a4e4-4e47-8229-6e9c2ace21f8;ecab970d-83e9-4aad-92de-dbb73d7a151f;efd93f07-818b-41ae-abd6-49ec5175311a;
2282|dce87c26-26d2-4546-8a9a-e2267630abc8| OxyContin is the management of <annotation cui="C0278139;C0278140">moderate to severe pain</annotation> when a continuous, around the clock opioid analgesic is needed for an extended period of time. <br> <br> <i> <u> Limitations of Use </u> </i> <br> <br> OxyContin is not for use <br> <br> <ol><li> As an as needed (prn) analgesic </li><li> For pain that is mild or not expected to persist for an extended period of time </li><li> For acute pain </li><li> In the immediate postoperative period (the first 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. </li><li> For postoperative pain unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. </li></ol> OxyContin 60 mg and 80 mg tablets, a single dose greater than 40 mg, or a total daily dose greater than 80 mg are only for patients in whom tolerance to an opioid of comparable potency is established. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine day, 25 mcg transdermal fentanyl hour, 30 mg oral oxycodone day, 8 mg oral hydromorphone day, 25 mg oral oxymorphone day, or an equianalgesic dose of another opioid for one week or longer. <br> <br> |bfdfe235-d717-4855-a3c8-a13d26dadede;dce87c26-26d2-4546-8a9a-e2267630abc8;
251|b23b67eb-78b7-48eb-84ff-c95d3ce8683c| Prochlorperazine 25mg suppositories are indicated in the control of severe <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> in adults. <br> <br> |9595346e-76e5-e155-341b-ffaaafb885ab;99d9e8a9-e299-4ee4-9f04-a82a83845594;b23b67eb-78b7-48eb-84ff-c95d3ce8683c;ea381bc5-0957-4c91-826a-0ff680cebacc;
257|03607c0d-b772-435f-c985-ecce8ea8cafd| <b> CASODEX 50 mg daily is indicated </b> for use in combination therapy with a luteinizing hormone releasing hormone (LHRH) analog for the treatment of Stage D 2 <annotation cui="C1384494">metastatic carcinoma</annotation> of the prostate. <br> <br> <b> CASODEX 150 mg daily is not approved </b> for use alone or with other treatments <i> [see Clinical Studies (14.2) ]. </i> <br> <br> |020d34eb-9560-4218-9d87-dfdeff705c3a;03607c0d-b772-435f-c985-ecce8ea8cafd;0c3b8420-01ec-4a4a-97a2-222884522963;427a872b-1b0b-41cf-aca2-49ce0163c7e6;4db9bad7-6256-4473-ac48-9e56c4a24d51;59df7b06-81d0-423c-9e80-9014d424b64c;5bd7e54e-8497-4bc4-8964-151943db0626;7c295b64-ec39-42ec-9f02-da5b42e775e1;7cd5fd99-ea7f-432d-aa05-8c0ab4fffb75;82d4877e-6ebf-4f75-a108-28dc840b07fc;89c24844-4d2a-4ec6-bc28-adce7b82d0c0;8e26fbf0-511c-44d9-b484-372d7b50b55e;93e7e9ae-901a-42bc-81c8-5f384675299f;abaf380b-7434-426a-934b-73f6f094c82e;c267f783-1d39-4f27-83ed-8288577bf66d;c563bba0-7f6b-46fe-898d-3965c97525eb;d0348cf0-f79a-4579-86c9-a5d25d688659;f32eadf6-d515-4307-a722-c49f0f1aef61;
410|ff602c63-870a-4a32-b14e-27dbfb34151f| <ol><li> Sedative </li><li> Anticonvulsant For the treatment of <annotation cui="C0234533;C0751495">generalized and partial seizures</annotation>. </li></ol> |069b92ce-0061-4724-8c25-08d8596770a2;073b9e2d-b183-4e20-b8ce-fd3ab07588da;0e2ce036-5b74-4aa6-8a6b-57452315b769;7f022b36-494f-49da-b09d-82413a507392;b7392fd2-4380-4b25-9205-324f9897716b;e8e1b3d7-0272-4278-b2a3-1d10dbeb0a5a;e8f17385-5731-4cce-87bb-768b817dfa8d;f2cfc093-fdf9-4263-a9f2-ee33d8742204;ff602c63-870a-4a32-b14e-27dbfb34151f;
4238|a1f01e8e-97e9-11de-b91d-553856d89593| To reduce the development of drug resistant bacteria and maintain the effectiveness of LEVAQUIN and other antibacterial drugs, LEVAQUIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. <br> <br> LEVAQUIN Tablets Injection and Oral Solution are indicated for the treatment of adults ( 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. LEVAQUIN Injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). <br> <br> <b> Culture and susceptibility testing </b> <br> <br> Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin <i> [see </i> Microbiology (12.4) <i> ] </i> . Therapy with LEVAQUIN may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. <br> <br> As with other drugs in this class, some isolates of <i> Pseudomonas aeruginosa </i> may develop resistance fairly rapidly during treatment with LEVAQUIN . Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. <br> <br>  <div> <annotation cui="C0949083">Nosocomial Pneumonia</annotation> </div> LEVAQUIN is indicated for the treatment of <annotation cui="C0949083">Nosocomial Pneumonia</annotation> due to methicillin susceptible <i> Staphylococcus aureus </i> , <i> Pseudomonas aeruginosa </i> , <i> Serratia marcescens </i> , <i> Escherichia coli </i> , <i> Klebsiella pneumoniae </i> , <i> Haemophilus influenzae </i> , or <i> Streptococcus pneumoniae </i> . Adjunctive therapy should be used as clinically indicated. Where <i> Pseudomonas aeruginosa </i> is a documented or presumptive pathogen, combination therapy with an anti pseudomonal  lactam is recommended <i> [see </i> <i> Clinical Studies (14.1) </i> <i> ] </i> . <br> <br> <div> <annotation cui="C0694549">Community Acquired Pneumonia</annotation> 7 14 day Treatment Regimen </div> LEVAQUIN is indicated for the treatment of <annotation cui="C0694549">community acquired pneumonia</annotation> due to methicillin susceptible <i> Staphylococcus aureus </i> , <i> Streptococcus pneumoniae </i> (including multi drug resistant <i> Streptococcus pneumoniae </i> [MDRSP]), <i> Haemophilus influenzae </i> , <i> Haemophilus parainfluenzae </i> , <i> Klebsiella pneumoniae </i> , <i> Moraxella catarrhalis </i> , <i> Chlamydophila pneumoniae </i> , <i> Legionella pneumophila </i> , or <i> Mycoplasma pneumoniae </i> <i> [see </i> <i> Dosage and Administration (2.1) </i> and <i> Clinical Studies (14.2)] </i> . <br> <br> MDRSP isolates are isolates resistant to two or more of the following antibacterials penicillin (MIC 2 mcg mL), 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim sulfamethoxazole. <br> <br> <div> <annotation cui="C0694549">Community Acquired Pneumonia</annotation> 5 day Treatment Regimen </div> LEVAQUIN is indicated for the treatment of <annotation cui="C0694549">community acquired pneumonia</annotation> due to <i> Streptococcus pneumoniae </i> (excluding multi drug resistant isolates [MDRSP]), <i> Haemophilus influenzae </i> , <i> Haemophilus parainfluenzae </i> , <i> Mycoplasma pneumoniae </i> , or <i> Chlamydophila pneumoniae </i> <i> [ </i> see <i> Dosage and Administration (2.1) </i> and <i> Clinical Studies (14.3) </i> <i> ] </i> . <br> <br> <div> <annotation cui="C0275556">Acute Bacterial Sinusitis</annotation> 5 day and 10 14 day Treatment Regimens </div> LEVAQUIN is indicated for the treatment of <annotation cui="C0275556">Acute Bacterial Sinusitis</annotation> due to <i> Streptococcus pneumoniae </i> , <i> Haemophilus influenzae </i> , or <i> Moraxella catarrhalis [see Clinical Studies (14.4) ] </i> . <br> <br> <div> Acute Bacterial Exacerbation of <annotation cui="C0008677">Chronic Bronchitis</annotation> </div> LEVAQUIN is indicated for the treatment of acute bacterial exacerbation of <annotation cui="C0008677">Chronic Bronchitis</annotation> due to methicillin susceptible <i> Staphylococcus aureus </i> , <i> Streptococcus pneumoniae </i> , <i> Haemophilus influenzae </i> , <i> Haemophilus parainfluenzae </i> , or <i> Moraxella catarrhalis </i> . <br> <br> <div> Complicated <annotation cui="C0037278;C0021311">Skin and Skin Structure Infections</annotation> </div> LEVAQUIN is indicated for the treatment of complicated <annotation cui="C0037278;C0021311">Skin and Skin Structure Infections</annotation> due to methicillin susceptible <i> Staphylococcus aureus </i> , <i> Enterococcus faecalis </i> , <i> Streptococcus pyogenes </i> , or <i> Proteus mirabilis </i> <i> [see Clinical Studies (14.5) ] </i> . <br> <br> <div> Uncomplicated <annotation cui="C0037278;C0021311">Skin and Skin Structure Infections</annotation> </div> LEVAQUIN is indicated for the treatment of uncomplicated <annotation cui="C0037278;C0021311">Skin and Skin Structure Infections</annotation> (mild to moderate) including <annotation cui="C0000833">abscesses</annotation>, <annotation cui="C0007642">cellulitis</annotation>, <annotation cui="C0242301">furuncles</annotation>, <annotation cui="C0021099">impetigo</annotation>, <annotation cui="C0034212">pyoderma</annotation>, <annotation cui="C0043241">wound infections</annotation>, due to methicillin susceptible <i> Staphylococcus aureus </i> , or <i> Streptococcus pyogenes </i> . <br> <br> <div> <annotation cui="C1720797">Chronic Bacterial Prostatitis</annotation> </div> LEVAQUIN is indicated for the treatment of <annotation cui="C1720797">Chronic Bacterial Prostatitis</annotation> due to <i> Escherichia coli </i> , <i> Enterococcus faecalis </i> , or methicillin susceptible <i> Staphylococcus epidermidis </i> <i> [see Clinical Studies (14.6) ] </i> . <br> <br> <div> Complicated <annotation cui="C0042029">Urinary Tract Infections</annotation> 5 day Treatment Regimen </div> LEVAQUIN is indicated for the treatment of complicated <annotation cui="C0042029">Urinary Tract Infections</annotation> due to <i> Escherichia coli </i> , <i> Klebsiella pneumoniae </i> , or <i> Proteus mirabilis </i> <i> [see Clinical Studies (14.7) ] </i> . <br> <br> <div> Complicated <annotation cui="C0042029">Urinary Tract Infections</annotation> 10 day Treatment Regimen </div> LEVAQUIN is indicated for the treatment of complicated <annotation cui="C0042029">Urinary Tract Infections</annotation> (mild to moderate) due to <i> Enterococcus faecalis </i> , <i> Enterobacter cloacae </i> , <i> Escherichia coli </i> , <i> Klebsiella pneumoniae </i> , <i> Proteus mirabilis </i> , or <i> Pseudomonas aeruginosa </i> <i> [see Clinical Studies (14.8) ] </i> . <br> <br> <div> <annotation cui="C0520575">Acute Pyelonephritis</annotation> 5 or 10 day Treatment Regimen </div> LEVAQUIN is indicated for the treatment of <annotation cui="C0520575">Acute Pyelonephritis</annotation> caused by <i> Escherichia coli </i> , including cases with concurrent <annotation cui="C0004610">bacteremia</annotation> <i> [see Clinical Studies (14.7 </i> , <i> ] </i> . <br> <br> <div> Uncomplicated <annotation cui="C0042029">Urinary Tract Infections</annotation> </div> LEVAQUIN is indicated for the treatment of uncomplicated <annotation cui="C0042029">Urinary Tract Infections</annotation> (mild to moderate) due to <i> Escherichia coli </i> , <i> Klebsiella pneumoniae </i> , or <i> Staphylococcus saprophyticus </i> . <br> <br> <div> <annotation cui="C0155866">Inhalational Anthrax</annotation> (Post Exposure) </div> LEVAQUIN is indicated for <annotation cui="C0155866">Inhalational Anthrax</annotation> (post exposure) to reduce the incidence or progression of disease following exposure to aerosolized <i> Bacillus anthracis </i> . The effectiveness of LEVAQUIN is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. LEVAQUIN has not been tested in humans for the post exposure prevention of inhalation anthrax. The safety of LEVAQUIN in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged LEVAQUIN therapy should only be used when the benefit outweighs the risk <i> [see Dosage and Administration (2.1 </i> , <i> 2.2) </i> <i> and Clinical Studies (14.9) ] </i> . <br> <br> <div> <annotation cui="C0032064">Plague</annotation> </div> LEVAQUIN is indicated for treatment of <annotation cui="C0032064">Plague</annotation>, including pneumonic and <annotation cui="C0152936">septicemic plague</annotation>, due to <i> Yersinia pestis </i> ( <i> pestis </i> ) and prophylaxis for <annotation cui="C0032064">Plague</annotation> in adults and pediatric patients, 6 months of age and older. Efficacy studies of LEVAQUIN could not be conducted in humans with <annotation cui="C0032064">Plague</annotation> for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [ <i> see Dosage and Administration (2.1 , 2.2) </i> and <i> Clinical Studies (14.10) </i> ]. <br> <br> |0818c344-2fc5-4cee-ac06-c9cd7fd07680;0a997a7b-4735-44c9-9b8c-1aa493c70d43;111ad6f9-170d-4a14-a4e2-ff86f60521cd;139f86a4-75c5-4304-894c-8f8b8a396c78;15a80e60-5d8b-4085-ba4c-7616af1ac96b;1a5eff69-0c4c-4e20-9e04-05db3ebbd589;1fa2c0d2-f22d-4f63-89c3-26e0a4216bfc;27c6c38e-e933-4fe7-8748-397686177036;312e65cb-897f-4c24-b17b-be7e8ce469bb;34704c52-b71c-4a6d-9335-00cce4ec7302;398348ed-1b65-4109-9d0f-f9d8a7175d61;40a96527-f89e-4177-9224-5c79167f3e60;4438fed2-7ef5-488f-baa8-39bc65768d1d;449ddc89-6dff-4e3e-a480-66b68389c73d;4be13bd5-0c39-43c3-9232-b1226ccd4dbc;529ac72c-c4a0-4001-8cf9-b94f5bf7265c;533260c1-3d9f-4414-a097-068a215876d5;5552141a-82cf-4eb6-a07d-025fea0de716;5dd1f9bb-acbf-4deb-9b02-992d52239a6b;699fbdb8-a6fd-476a-9b80-08197d869534;6ee54fdc-efe6-4411-a711-8154ceee20b6;71d4bca8-0b51-8f0a-ebab-a67c52fff3b7;9b59428a-a23a-b2d9-982f-98f8a1ed381f;9f852453-5d49-4a83-bba9-54aa454d0c2b;a1f01e8e-97e9-11de-b91d-553856d89593;a23a1cca-bc3e-48c5-abd9-82eddb52e91b;a3b199d0-4ed4-4392-8db6-3ed9fc48db07;b124dded-a848-4a7e-b5cd-05797774b6ad;b95172dd-ff18-4323-a605-ed5ae58a69ed;bb5e3b54-4dd8-478d-9d88-786114be9ce2;be2a14b5-8dc0-473e-8672-96297e20e199;c6c7322b-6a89-4d23-90d1-bf9327bd6d91;d334f6d6-f6a6-4a5e-a5d6-92bf450c0f5b;d85c5ab8-a3d8-42a3-ac0b-799ea5a6369e;dd902513-1411-4746-8f45-f7f3fb68f130;e4bf3611-c2b6-4397-a786-ea022f86d7f8;e680c759-16c5-4532-9c9c-f42c8c3df74a;ea29921d-ae91-4a1b-a8e5-5c00a16be127;eb5c26fc-4201-4b1a-a359-bc9bb3985522;ec61dd9d-a016-4740-b9b8-20754e50be98;fa7ddbd9-29e2-4a36-af46-00c96a77ac85;
5275|7977516c-15bf-4fa5-8772-59c6efbe3dc5| TRENTAL is indicated for the treatment of patients with <annotation cui="C0021775">intermittent claudication</annotation> on the basis of chronic <annotation cui="C0003838">occlusive arterial disease</annotation> of the limbs. TRENTAL can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. <br> <br> |24eb2c70-ca20-490c-837c-9de4f5914225;40ae2d9a-0d95-640d-0640-f76e7e1a13cb;4963034a-3667-472e-97e9-5e07db32b68f;4b6435e3-d102-449f-b21b-ac53130b3c78;59c9a583-1f93-480f-879c-457a574374da;6b902d5e-1526-4f80-bb31-57c1b4e5a4f5;7096593b-0054-4d51-83df-0208ccdcc147;73f8cef4-39f3-4f71-b3cc-8da07b8fd65f;74a51821-8d41-47a6-88e9-6ed3c20df7db;7977516c-15bf-4fa5-8772-59c6efbe3dc5;81a0e173-0dc6-4d46-a699-37d2ac5b4df1;83d5ef4b-8b46-48b6-ae5a-9a0e493350a0;a2363acb-717f-4401-ad5d-ea068e971410;a6c39757-4551-4493-b27f-5b311fd1fc77;af8bf978-45e7-4548-a314-beb205f36749;b218b02c-e6a1-410c-95fa-f798260c51ab;edd4dbbc-04ed-4741-9cd9-42e9b744f99e;ff7c9b1c-4192-4d09-a2ab-b80ec14cd424;
8414|65AFA805-603A-43DE-9651-D04E49BD2AA7| <div> Treatment of <annotation cui="C0020443">Hypercholesterolemia</annotation> </div> Triglide is indicated as adjunctive therapy to diet for the reduction of LDL C, Total C, Triglycerides and Apo B in adult patients with <annotation cui="C0342879">primary hypercholesterolemia</annotation> or mixed <annotation cui="C0242339">dyslipidemia</annotation> (Frederickson Types IIa and IIb). <br> <br> Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines , below). <br> <br> <div> Treatment of <annotation cui="C0020557">Hypertriglyceridemia</annotation> </div> TRIGLIDE is indicated as adjunctive therapy to diet for treatment of adult patients with <annotation cui="C0020557">Hypertriglyceridemia</annotation> (Fredrickson <annotation cui="C0020480;C0020473">Types IV and V hyperlipidemia</annotation>). <br> <br> Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides ( <i> e.g. </i> > 2,000 mg dL) may increase the risk of developing pancreatitis. The effect of TRIGLIDE therapy on reducing this risk has not been studied. <br> <br> Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia (Nikkila, 1983). <br> <br> The initial treatment for <annotation cui="C0242339">dyslipidemia</annotation> is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in <annotation cui="C0020557">Hypertriglyceridemia</annotation> and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. <br> <br> Diseases contributory to <annotation cui="C0020473">hyperlipidemia</annotation>, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. <br> <br> Estrogen therapy, like thiazide diuretics and beta blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. <br> <br> In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of <annotation cui="C0020557">Hypertriglyceridemia</annotation>. <br> <br> The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS ). <br> <br> |04cbb126-4357-42f6-9c89-6fa9ff475b34;194cd14a-d952-4507-91be-3f1d5371d3b8;1ecb628e-8bdf-4dbc-b5be-9f40eec183e6;24790a18-0291-4b88-a724-acac43b616ce;2e51aa89-684d-451e-b513-12b00bf9aea0;65AFA805-603A-43DE-9651-D04E49BD2AA7;680a6740-8ea8-4a06-b659-41c2e5b1a4fd;77e40fef-78a7-4f60-9632-1cc9b66acd71;806969c4-7702-484a-811d-fe01baa163c6;ACCA05AB-185B-41A6-9CE2-783FC3C3CF96;a7f3a0c2-1444-4178-9d8d-20c2ea2e45b7;a9c5062d-e8ad-44e7-a709-af0092f73d52;bfc6668c-3f69-4dd3-bc19-0d26c23dd04c;c3afa988-d258-4e83-89ed-d674743109c4;c53c20ed-a944-4b35-b5db-91d9f67240e8;c850d4e4-2dce-4a03-964f-b9397ec20514;d5dba7f7-fbd6-47c0-a945-4f1ed5b410b8;dc03eb20-7a97-4e82-a060-7b8062474f4f;e55be390-e4e5-4c45-a21b-7c0198d92d35;e5e78bfc-1b18-46fa-aebd-f8ae313960c1;fa08cf6a-d306-4979-9b23-ac7febf4fd12;
8709|ffcaa218-ed6a-4557-9645-b9a91128a214| <div> <b> Parenteral </b> </div> <ol><li> Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are <annotation cui="C0003469">anxiety</annotation> tension states, <annotation cui="C0020550">hyperthyroidism</annotation>, <annotation cui="C0085580">essential hypertension</annotation>, <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation> of functional origin, <annotation cui="C0026603">motion sickness</annotation>, acute <annotation cui="C0022893">labyrinthitis</annotation>, <annotation cui="C0152163">pylorospasm</annotation> in infants, <annotation cui="C0008489">chorea</annotation> and <annotation cui="C0018801">cardiac failure</annotation>. Phenobarbital is also a useful adjunct in treatment of <annotation cui="C0019080">hemorrhage</annotation> from the respiratory or gastrointestinal tract. Phenobarbital controls <annotation cui="C0003469">anxiety</annotation>, <annotation cui="C0086439">decreases muscular activity</annotation> and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. </li><li> Hypnotic, for the short term treatment of <annotation cui="C0917801">insomnia</annotation>, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). </li><li> Preanesthetic. </li><li> Long term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of <annotation cui="C0751495;C0494475">generalized tonic clonic and cortical focal seizures</annotation>. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate induced depression. </li><li> Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. </li></ol> |ffcaa218-ed6a-4557-9645-b9a91128a214;
9359|c46c4f31-121c-43a8-9538-53ae1288812e| Propylthiouracil is indicated in the medical treatment of <annotation cui="C0020550">hyperthyroidism</annotation>. Long term therapy may lead to remission of the disease. Propylthiouracil may also be used to ameliorate <annotation cui="C0020550">hyperthyroidism</annotation> in preparation for subtotal thyroidectomy or radioactive iodine therapy. Propylthiouracil is also used when thyroidectomy is contraindicated or not advisable. <br> <br> |c46c4f31-121c-43a8-9538-53ae1288812e;
10005|632c566c-39fb-4321-ac56-aea83780fa02| CODRIX is indicated for the relief of <annotation cui="C0278138;C0278140">mild to moderately severe pain</annotation>. <br> <br>|18315a6f-9e89-46d7-81d3-905b8a51aa79;31d4cf3e-a903-4a43-bd44-73fbffc424b3;453f8966-f89c-4ab2-b91e-c7bb50304028;632c566c-39fb-4321-ac56-aea83780fa02;9b3f274c-e7d8-4c67-aa22-bf5aa62064cc;a2ca6210-578d-496c-9a0e-6eb716f87ae6;b7c4c175-d3f9-4ed8-abb8-cfb33b9dc2b3;
10013|a6182855-6287-45e9-b6b4-7b57efc9c76e| <br> To reduce the development of drug resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. <b> <br> <br> <annotation cui="C0042029">Urinary Tract Infections</annotation> </b> <br> <br> For the treatment of <annotation cui="C0042029">Urinary Tract Infections</annotation> due to susceptible strains of the following organisms: <i> Escherichia coli, Klebsiella </i> species, <i> Enterobacter </i> species, <i> Morganella morganii, Proteus mirabilis </i> and <i> Proteus vulgaris. </i> It is recommended that initial episodes of uncomplicated <annotation cui="C0042029">Urinary Tract Infections</annotation> be treated with a single effective antibacterial agent rather than the combination. <b> <br> <br> <annotation cui="C0271429">Acute Otitis Media</annotation> </b> <br> <br> For the treatment of <annotation cui="C0271429">Acute Otitis Media</annotation> in pediatric patients due to susceptible strains of <i> Streptococcus pneumoniae </i> or <i> Haemophilus influenzae </i> when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim oral suspension, USP in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim oral suspension, USP is not indicated for prophylactic or prolonged administration in otitis media at any age. <b> <br> <br> Acute Exacerbations of <annotation cui="C0008677">Chronic Bronchitis</annotation> in Adults </b> <br> <br> For the treatment of acute exacerbations of <annotation cui="C0008677">Chronic Bronchitis</annotation> due to susceptible strains of <i> Streptococcus pneumoniae </i> or <i> Haemophilus influenzae </i> when in the judgment of the physician sulfamethoxazole and trimethoprim oral suspension, USP offers some advantage over the use of a single antimicrobial agent. <b> <br> <br> <annotation cui="C0013371">Shigellosis</annotation> </b> <br> <br> For the treatment of enteritis caused by susceptible strains of <i> Shigella flexneri </i> and <i> Shigella sonnei </i> when antibacterial therapy is indicated. <b> <br> <br> <annotation cui="C0042029">Pneumocystis Carinii Pneumonia</annotation> </b> <br> <br> For the treatment of documented <annotation cui="C0042029"><i> Pneumocystis carinii </i> pneumonia</annotation> and for prophylaxis against <annotation cui="C0042029"><i> Pneumocystis carinii </i> pneumonia</annotation> in individuals who are immunosuppressed and considered to be at an increased risk of developing <annotation cui="C0042029"><i> Pneumocystis carinii </i> pneumonia</annotation>. <br> <br><b> <annotation cui="C0277528">Traveler's Diarrhea</annotation> in Adults <br> </b> <br> For the treatment of <annotation cui="C0277528">Traveler's Diarrhea</annotation> due to susceptible strains of enterotoxigenic <i> coli. </i>|002e3d65-894e-4778-8945-01e71e29e288;00add4a1-377c-4971-8924-65bb1aa25f2a;0138a156-859a-48a3-bf5a-e2db0cc7f2f9;050b2f4e-d653-46ef-8235-4361598888c4;06e3d76b-8f16-4d53-bb9f-201cb6a72fb8;09086798-2dc3-4a0d-a02a-304baec56b72;094071bc-c445-4d09-b8d7-d1517c3a8946;0c3ab79b-cdf4-4a67-b6d9-6c89d7cd4fc1;12c87ae8-0fa2-4c3f-92c4-7d0042ac23b1;1d3e46c4-6652-44c9-8aa6-2bae30d4b246;24b0946d-25dd-457b-b1bf-7fbc7521a84b;27ca999f-2678-4c7d-8f7d-895d0fe77a9f;284b5dac-2b8d-46bf-95fe-80ce03fa178a;2bc4adb5-cac5-4b8b-bc92-35bcc0321e82;3233c54d-484d-4550-b172-db8af47d1b7f;32e2b197-e171-444d-86ca-198d4c84d7a5;38f42bad-6b2a-423d-af66-0e526ba03da1;3e568a2e-421d-4456-a8bf-d983ecee7ad6;4833319a-a7b3-4bf4-bec4-6531b43182d4;52742743-e657-42a6-bd8f-b53c112ef317;5e9d036b-1c69-4cf0-9b8e-ebc1c7f2a954;78581094-bd77-4276-8416-246293907165;84d78cde-110a-448b-b7ee-cfa69cdc4f32;897e4438-ba93-4d47-9d33-6ad1afcd7c25;8fa9225f-dd1a-4225-a2b3-34535451b473;93374337-1499-4225-9585-3b3d20371d84;97617d50-3193-4548-8c38-7ff029d0b0a4;A8DF90D8-78B3-48C3-B42E-1E651D81454B;a03f40f5-068e-41f2-826d-6ed627dd8776;a174991a-53e7-c791-3cee-b706a48e0ec5;a2978977-8ae3-438e-9059-ea8bda49741d;a349e15a-f29b-42b6-5699-77156e198f32;a6182855-6287-45e9-b6b4-7b57efc9c76e;a6f10209-1b12-43dc-bf18-00124d89e27d;aa547448-26c1-4482-8d5d-3cf7d6b1a28a;abe0d2d5-4879-4b4e-9b57-47ea83a17ba0;afb1693a-63d4-4356-976a-51a2d8dcde68;b1645c68-9dfc-4079-8bf0-e61e9b2e4ed0;bcbdbb65-3d82-42e8-9564-630748549954;bf3bab33-55c3-4738-9ea2-b687f640ca39;c12366c1-2e7f-426d-b5ca-bba7b460fbe8;c135323a-33dd-49d5-b55a-33e1ff1b78fd;c62ad12d-a7c1-4846-9dbf-6e11884000bc;c8833d0d-9e8e-40cf-b6df-d559ea83b7b2;c9676c8a-4597-4dcf-8944-18ecc96004e2;cbf74e0d-3254-4ed4-b5bd-d6eeaa1efec0;d9f571b7-0933-4efa-9c0f-402b83c060cf;dc9e3ad3-9599-420a-9697-95bb5a452652;dff887ee-43c7-40fc-9c5f-76014616c461;e0cd17c8-0e88-4a72-baef-969fefa5efe6;f1a64637-6143-4543-a785-12e006cba849;f8f30cc7-94e3-49f4-84c5-1f43ccdabc35;fad287b4-8294-40ce-b49d-1b4adc58942a;fea44910-400c-4688-bedc-bbb1615cd8f5;ff0b3cd5-c9cd-42df-b72f-4c69e76c7bd9;
10071|a6cbc17f-5c60-489c-8029-84b0add556d8|<b> INDICATIONS AND USAGE </b> Butalbital, Acetaminophen, and Caffeine Tablets USP is indicated for the relief of the symptom complex of <annotation cui="C0033893">tension (or muscle contraction) headache</annotation>. <br> <br> Evidence supporting the efficacy and safety of Butalbital, Acetaminophen, and Caffeine Tablets USP in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit forming and potentially abusable. <br> <br>|09eacd24-d327-4a39-8449-646cd56644ae;0a753f12-26f2-8870-00ef-810c0f3e0045;2a23956c-23b1-4ac7-b83c-5487577563e5;2af36469-aeb0-4d48-92c3-5c11e11fab79;338b9f27-7097-4675-9ec5-e1eea6898cd5;3F0F6064-CC9F-491C-A940-3F087ABBC774;418054c3-d8c8-49b0-93a5-a53fd0c5018f;41fbd224-1239-4d89-8e19-0a300cd66f38;469779cc-9a1b-470b-b54e-cf30191b97a4;611356c6-9cf6-4316-a9cb-e7756955755b;692a38bd-4588-4f9c-8def-59484c4ce425;6dd09be6-a345-4a42-9b64-51b7808ff45f;6e574306-b1a3-49a2-a949-aade065ebe70;7F56F5C9-32FE-40FE-8151-F7EA9DA1A0C1;856d0894-e840-4b87-95aa-3085d5aed5be;86ba6ede-c033-423c-9d3f-045f5efe5bbe;8aa576ac-c870-4ac0-a9a5-5539b38f653d;8c330933-ee51-4261-917e-155fddf1b711;8e99c982-50ca-49d7-b80a-b60aa18401cb;917f576b-ead7-442d-bf90-7fb981210805;919456fe-71e7-4edc-ad4f-2320fb07712e;947D5617-4E91-4507-AC80-977824D2B50B;97768690-6a7f-4690-8684-371c89bea71c;9835ae60-e115-4720-ac7e-b8f14b012988;9d319a0b-ee17-4326-8c00-cf98e5dfef14;B151E4EB-BB9A-41B9-98A4-2E12BB4E2E5F;a03276eb-d435-4159-9cc8-70c2ed132882;a04406b8-08fc-4d44-8b3c-63da3d7fb55b;a26775c2-cafb-4b13-99ac-d4e8248265fb;a44a62f0-0bcf-411c-94e2-d1a848028fa4;a6cbc17f-5c60-489c-8029-84b0add556d8;ab17d24a-57af-4d8d-ae01-7e6846107373;ab907b70-5cdc-49b4-a702-1b14e1351a96;aedc5167-cc3c-4044-87fa-4ed648c9f23f;b1f56c61-1a51-48e2-a2f1-f15926284871;b2afd18b-02a2-49dc-b059-e551acccdd4a;c8328545-437a-4591-8cdc-66d275938024;c8e51a2a-17c9-473a-aff1-dd776006c0a9;cfa14b4b-94c6-4403-8ff8-0ecdb8c6ff81;d3c69436-a681-4e00-8db0-8cbfaac9627e;d63959d5-b1dc-4422-8f69-7599f8b11f4a;e8982243-5634-400a-8b23-8029fb4e5e92;e98984a9-a06f-47e7-aff1-a757edf9e2be;eb1f2e22-5120-449f-9efb-7ac5a7c06bed;ed8079a1-670c-48fb-92ff-6e6ad51e6ad3;f3a37ce1-5082-4ac4-88a2-c8fadbd0b7b3;f988e6f2-1e5b-416b-8f2a-aa45a3207945;fa88f437-830b-48bc-a44c-fd142963a150;faf741c4-bfc5-4f52-8773-c50f7b15dd08;fef4844c-2b44-4e5c-9da3-e5b2214c9e8d;fffd3c9b-d7c8-4ba0-8527-3fdd742c69e6;
10238|a2a9f459-e692-4e85-83b0-a35fbf35e91b| VIAGRA is indicated for the treatment of <annotation cui="C0242350">erectile dysfunction</annotation>. <br> <br>|03bdf36c-0cae-4d4f-b85d-99078bc12d11;0b0be196-0c62-461c-94f4-9a35339b4501;1da7847b-16e4-4bf1-957f-3894d023b339;40fa9a7d-749a-46c5-931c-4e187f7a00df;442a09ee-e7de-4d53-a32e-07c7530cdede;4d60822d-1c9b-494d-adb3-20fe921d9c58;a2a9f459-e692-4e85-83b0-a35fbf35e91b;c6c048ec-0b99-4fa4-9df7-9926db93749b;fe24cae8-fb13-4f01-aa72-0ea929a432ef;
10491|966d728e-87ca-4491-9411-2ec253eca632| <br> <b> <annotation cui="C1269683">Major Depressive Disorder</annotation> </b> <br> <br> Sertraline hydrochloride tablets are indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> in adults. <br> <br> The efficacy of sertraline hydrochloride tablets in the treatment of a <annotation cui="C0024517">major depressive episode</annotation> was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM III category of <annotation cui="C1269683">Major Depressive Disorder</annotation> (see <b> Clinical Trials under CLINICAL PHARMACOLOGY </b> ). <br> <br> A <annotation cui="C0024517">major depressive episode</annotation> implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. <br> <br> The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. <br> <br> The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open label acute treatment (52 weeks total) was demonstrated in a placebo controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see <b> Clinical Trials under CLINICAL PHARMACOLOGY </b> ). <br> <br> <b> <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> </b> <br> <br> Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with <annotation cui="C0028768">obsessive compulsive disorder</annotation> (<annotation cui="C0028768">OCD</annotation>), as defined in the DSM III R; i.e., the obsessions or compulsions cause marked distress, are time consuming, or significantly interfere with social or occupational functioning. <br> <br> The efficacy of sertraline hydrochloride tablets were established in 12 week trials with obsessive compulsive outpatients having diagnoses of <annotation cui="C0028768">obsessive compulsive disorder</annotation> as defined according to DSM III or DSM III R criteria (see <b> Clinical Trials under CLINICAL PHARMACOLOGY </b> ). <br> <br> <annotation cui="C0028768">Obsessive compulsive disorder</annotation> is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego dystonic and or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. <br> <br> The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with <annotation cui="C0028768">OCD</annotation> who responded during a 52 week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo controlled trial (see <b> Clinical Trials under CLINICAL PHARMACOLOGY </b> ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <b> <annotation cui="C0030319">Panic Disorder</annotation> </b> <br> <br> Sertraline hydrochloride tablets are indicated for the treatment of <annotation cui="C0030319">Panic Disorder</annotation> in adults, with or without agoraphobia, as defined in DSM IV. <annotation cui="C0030319">Panic Disorder</annotation> is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and or a significant change in behavior related to the attacks. <br> <br> The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult <annotation cui="C0030319">Panic Disorder</annotation> patients whose diagnoses corresponded to the DSM III R category of <annotation cui="C0030319">Panic Disorder</annotation>. <br> <br> <annotation cui="C0030319">Panic Disorder</annotation> (DSM IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. <br> <br> The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with <annotation cui="C0030319">Panic Disorder</annotation> who responded during a 52 week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient. <br> <br> <b> <annotation cui="C0038436">Posttraumatic Stress Disorder</annotation> (<annotation cui="C0038436">PTSD</annotation>) </b> <br> <br> Sertraline hydrochloride tablets are indicated for the treatment of <annotation cui="C0038436">Posttraumatic Stress Disorder</annotation> in adults. <br> <br> The efficacy of sertraline hydrochloride tablets in the treatment of <annotation cui="C0038436">PTSD</annotation> was established in two 12 week placebo controlled trials of adult outpatients whose diagnosis met criteria for the DSM III R category of <annotation cui="C0038436">PTSD</annotation>). <br> <br> <annotation cui="C0038436">PTSD</annotation>, as defined by DSM III R IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A <annotation cui="C0038436">PTSD</annotation> diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. <br> <br> The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with <annotation cui="C0038436">PTSD</annotation> for up to 28 weeks following 24 weeks of open label treatment was demonstrated in a placebo controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient.<b> <annotation cui="C0520676">Premenstrual Dysphoric Disorder</annotation> (<annotation cui="C0520676">PMDD</annotation>) </b> <br> <br> Sertraline hydrochloride tablets are indicated for the treatment of <annotation cui="C0520676">Premenstrual Dysphoric Disorder</annotation> (<annotation cui="C0520676">PMDD</annotation>) in adults. <br> <br> The efficacy of sertraline hydrochloride tablets in the treatment of <annotation cui="C0520676">PMDD</annotation> was established in 2 placebo controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM III R IV category of <annotation cui="C0520676">PMDD</annotation> (see <b> Clinical Trials under CLINICAL PHARMACOLOGY </b> ). <br> <br> The essential features of <annotation cui="C0520676">PMDD</annotation> include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with <annotation cui="C0520676">PMDD</annotation> include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. <br> <br> The effectiveness of sertraline hydrochloride tablets in long term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <b> <annotation cui="C0031572">Social Anxiety Disorder</annotation> </b> <br> <br> Sertraline hydrochloride tablets are indicated for the treatment of <annotation cui="C0031572">Social Anxiety Disorder</annotation>, also known as social phobia in adults. <br> <br> The efficacy of sertraline hydrochloride tablets in the treatment of <annotation cui="C0031572">Social Anxiety Disorder</annotation> was established in two placebo controlled trials of adult outpatients with a diagnosis of <annotation cui="C0031572">Social Anxiety Disorder</annotation> as defined by DSM IV criteria (see <b> Clinical Trials under CLINICAL PHARMACOLOGY </b> ). <br> <br> <annotation cui="C0031572">Social Anxiety Disorder</annotation>, as defined by DSM IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. <br> <br> The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with <annotation cui="C0031572">Social Anxiety Disorder</annotation> for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <b> Clinical Trials under CLINICAL PHARMACOLOGY </b> ). <br> <br>|966d728e-87ca-4491-9411-2ec253eca632;
10540|994b3117-b83e-44d9-910c-1c3a26ef838e| THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. <br> <br> Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). <br> <br> Allopurinol is indicated in <br> <br> <ol><li> 1)the management of patients with signs and symptoms of <annotation cui="C0149896;C0409908">primary or secondary gout</annotation> (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). </li><li> 2)the management of patients with <annotation cui="C0042018">leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels</annotation>. Treatment with allopurinol should be discontinued when the potential for over production of uric acid is no longer present. </li><li> 3)the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. </li></ol>|0b7f42cf-e71d-465c-ba81-23b2ff37fbdc;19a138b8-d225-03e6-f762-abe71560204b;1ce96b87-323d-40b6-a40b-32821e00d94c;2298ed2a-e01b-4f7c-9902-7c58a6e06b7a;29ad13a3-206e-4bb1-b0bf-327e576dee64;30140d33-3a41-40b0-9877-a5d62d6c0e12;342832b5-1a32-4bea-bc49-ab0fd152154e;35707dc4-4897-2452-74c0-0704a80c5036;3df46df4-8b14-459f-949b-dc1f94a07330;40f39058-bfff-4d16-b448-9bbf1c3ebeb0;548f6fbb-155f-45ff-ab44-0a70adad4424;5e8b13b7-ce34-4641-a7f2-d64b7baf31c4;5f9f30a2-085f-473e-9195-500a2068b836;6bbb8947-4f93-4f2a-b205-f4594908aecc;7003e410-b4ff-da07-5571-07e7e13f67e0;72c1078a-55aa-4f81-9c3c-bb086575138e;73cd79c1-6bab-4d7b-ae8b-0176efbaf5b9;7a072f02-05ac-4ce0-8fa4-04a2ad8986fb;81167e87-b1d5-44df-99aa-a033825634dd;8357fbc6-9a5b-4d06-bb99-0bc21ddbdc7d;8afe0c86-00c5-452f-b7b4-7ae81b7da131;939ebead-a5b1-4c3b-a1f5-5225fb60fd38;994b3117-b83e-44d9-910c-1c3a26ef838e;a4595942-a75a-4ac1-b70e-4829edecf1c8;a80fe56f-8d03-423f-8e2a-7ec8c9e5045b;b777d814-8892-43b8-8c4a-6fd11bc97666;bdbf5ad4-86f2-4e9c-a51a-fb0c7220c480;c4cbe7cc-c160-4d46-aad3-61aefe90b3d8;c58b2502-67fa-4535-97a0-4c6b4043a38f;c65e6179-1ee0-4e35-9b12-0a8a55ab9503;c87fceaa-0e56-4042-95a2-08e7c0d6bc47;da5833e4-1a6a-4978-bc9e-3045f774922a;e054ec39-06e2-43ec-88cc-28095f76c6f5;e1f42971-8169-4053-9857-585cef2ba7b0;f213bf75-f514-4bd7-9c64-5f425214134c;fbac3b4f-dc23-4359-ac3f-2b3fdde41af2;fd8f8b8b-f25e-46e9-969a-65363b66e09b;
10560|9c6ec419-5d3b-4053-9970-42a30458b92a| The total management of <annotation cui="C0003469">anxiety</annotation>, <annotation cui="C0233494">tension</annotation>, and <annotation cui="C0085631">psychomotor agitation</annotation> in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of <annotation cui="C0003469">anxiety</annotation> and <annotation cui="C0233494">tension</annotation> as in the preparation for dental procedures and in acute <annotation cui="C0677660">emotional problems</annotation>. It has also been recommended for the management of <annotation cui="C0003469">anxiety</annotation> associated with organic disturbances and as adjunctive therapy in <annotation cui="C0001973">alcoholism</annotation> and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. <br> Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: <br> 1. The acutely disturbed or hysterical patient. <br> 2. The acute or chronic alcoholic with <annotation cui="C0003469">anxiety</annotation> <annotation cui="C0087169">withdrawal symptoms</annotation> or <annotation cui="C0001957">delirium tremens</annotation>. <br> 3. As pre and postoperative and pre  and postpartum adjunctive medication to permit reduction in narcotic dosage, allay <annotation cui="C0003469">anxiety</annotation> and control <annotation cui="C0042963">emesis</annotation>. <br> Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling <annotation cui="C0027497">nausea</annotation> and <annotation cui="C0042963">vomiting</annotation>, excluding <annotation cui="C0027497">nausea</annotation> and vomiting of pregnancy. (See <b> CONTRAINDICATIONS </b> ). <br> In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated <annotation cui="C0003469">anxiety</annotation> and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.|5209ce5b-c14f-44d8-add5-e4de41dc6684;7def1daa-c800-4263-9526-eac8d53e4636;8af7e5ce-d9d9-44cc-9f2f-4ddbc89e758a;9c6ec419-5d3b-4053-9970-42a30458b92a;aed7d120-5f3d-4276-b341-737244d4f8a5;ba605c0d-7185-4195-965d-379990eb4b4e;d834dad1-aedc-48d8-941d-3de56ce04069;
10730|e498b80d-7177-4f9d-8471-2e8f913196af| <br> 1.1 <annotation cui="C0020473">Hyperlipidemia</annotation> and Mixed <annotation cui="C0242339">dyslipidemia</annotation> <br> CRESTOR is indicated as adjunctive therapy to diet to reduce elevated Total C, LDL C, ApoB, nonHDL C, and triglycerides and to increase HDL C in adult patients with primary <annotation cui="C0020473">Hyperlipidemia</annotation> or mixed <annotation cui="C0242339">dyslipidemia</annotation>. Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate. <br> <br> <b> Pediatric Patients 10 to 17 years of age with <annotation cui="C0342882">Heterozygous Familial Hypercholesterolemia</annotation> (HeFH) </b> <br> <br> Adjunct to diet to reduce Total C, LDL C and ApoB levels in adolescent boys and girls, who are at least one year post menarche, 10 17 years of age with <annotation cui="C0342882">heterozygous Familial Hypercholesterolemia</annotation> if after an adequate trial of diet therapy the following findings are present: LDL C > 190 mg/dL or > 160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors. <br> <br> 1.2 <annotation cui="C0020557">Hypertriglyceridemia</annotation> CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with <annotation cui="C0020557">Hypertriglyceridemia</annotation>. <br> <br> 1.3 <annotation cui="C0020479">Primary Dysbetalipoproteinemia</annotation> (<annotation cui="C0020479">Type III Hyperlipoproteinemia</annotation>) CRESTOR is indicated as an adjunct to diet for the treatment of patients with <annotation cui="C0020479">Primary Dysbetalipoproteinemia</annotation> (<annotation cui="C0020479">Type III Hyperlipoproteinemia</annotation>). <br> <br> <br> 1.4 <annotation cui="C0342881">Homozygous Familial Hypercholesterolemia</annotation> CRESTOR is indicated as adjunctive therapy to other lipid lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL C, Total C, and ApoB in adult patients with <annotation cui="C0342881">homozygous Familial Hypercholesterolemia</annotation>. <br> <br> 1.5 Slowing of the Progression of <annotation cui="C0004153">Atherosclerosis</annotation> CRESTOR is indicated as adjunctive therapy to diet to slow the progression of <annotation cui="C0004153">Atherosclerosis</annotation> in adult patients as part of a treatment strategy to lower Total C and LDL C to target levels. <br> <br> 1.6 Primary Prevention of Cardiovascular Disease In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age 50 years old in men and 60 years old in women, hsCRP 2 mg L, and the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL C, smoking, or a family history of premature coronary heart disease, CRESTOR is indicated to <br> <br> <ol><li> reduce the risk of <annotation cui="C0038454">stroke</annotation> <br> </li><li> reduce the risk of <annotation cui="C0027051">myocardial infarction</annotation> <br> </li><li> reduce the risk of arterial revascularization procedures <br> </li></ol> <br> 1.7 Limitations of Use CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. <br> <br> <b> <br> </b> <br> <br> <br> <br> <br>|e498b80d-7177-4f9d-8471-2e8f913196af;
10731|c4ccf549-4324-49b1-8b68-550f8ee2d2e4| <br> <br> 1.1 <annotation cui="C0338831">Mania</annotation> Divalproex sodium extended release tablets are a valproate and are indicated for the treatment of acute <annotation cui="C0349208;C0338831">manic or mixed episodes</annotation> associated with <annotation cui="C0005586">bipolar disorder</annotation>, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of <annotation cui="C0338831">Mania</annotation> include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. A mixed episode is characterized by the criteria for a manic episode in conjunction with those for a major depressive episode (depressed mood, loss of interest or pleasure in nearly all activities). <br> <br> The efficacy of divalproex sodium extended release tablets is based in part on studies of divalproex sodium delayed release tablets in this indication, and was confirmed in a 3 week trial with patients meeting DSM IV TR criteria for <annotation cui="C0853193">bipolar I disorder</annotation>, <annotation cui="C0338831">manic</annotation> or mixed type, who were hospitalized for acute <annotation cui="C0338831">mania</annotation> <i> [see Clinical Studies (14.1) ] </i> . <br> <br> The safety and effectiveness of valproate for long term use in <annotation cui="C0338831">Mania</annotation>, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium extended release tablets for extended periods should continually reevaluate the long term risk benefits of the drug for the individual patient. <br> <br> 1.2 <annotation cui="C0014544">Epilepsy</annotation> Divalproex sodium extended release tablets are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with <annotation cui="C0149958">complex partial seizures</annotation> that occur either in isolation or in association with other types of <annotation cui="C0036572">seizures</annotation>. Divalproex sodium extended release tablets are also indicated for use as sole and adjunctive therapy in the treatment of <annotation cui="C0014553;C0014553">simple and complex absence</annotation> <annotation cui="C0036572">seizures</annotation> in adults and children 10 years of age or older, and adjunctively in adults and children 10 years of age or older with multiple <annotation cui="C0036572">seizure</annotation> types that include <annotation cui="C0014553">absence seizures</annotation>. <br> <br> Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. <br> <br> 1.3 <annotation cui="C0149931">Migraine</annotation> Divalproex sodium extended release tablets are indicated for prophylaxis of <annotation cui="C0149931">migraine headaches</annotation>. There is no evidence that divalproex sodium extended release tablets are useful in the acute treatment of <annotation cui="C0149931">migraine headaches</annotation>. Because it may be a hazard to the fetus, divalproex sodium extended release tablets should be considered for women of childbearing potential only after this risk has been thoroughly discussed with the patient and weighed against the potential benefits of treatment <i> [see Warnings and Precautions (5.2) , Patient Counseling Information (17.3) ] </i> . <br> <br> <br>|c4ccf549-4324-49b1-8b68-550f8ee2d2e4;
10811|2425f944-15d7-4b84-95a0-6538e843f130| Adjunctive therapy and palliative treatment of inoperable, recurrent, and <annotation cui="C1384494;C0476089">metastatic endometrial or renal carcinoma</annotation>. <br> <br>|0ceb4952-5af3-4b80-b8b5-cea4e9a5486d;2425f944-15d7-4b84-95a0-6538e843f130;
11252|5cd02f3a-f953-4513-a63a-9c7e84d49f53| Sulfasalazine tablets are indicated: <br> b. for the prolongation of the remission period between acute attacks of <annotation cui="C0009324">ulcerative colitis</annotation>. <br> <br>|5cd02f3a-f953-4513-a63a-9c7e84d49f53;
11329|9485cc30-15e8-4b53-876d-db317145474b| Sumatriptan succinate tablets are indicated for the acute treatment of <annotation cui="C0149931">migraine</annotation> attacks with or without aura in adults. <br> <br> Sumatriptan succinate tablets are not intended for the prophylactic therapy of <annotation cui="C0149931">migraine</annotation> or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan succinate tablets have not been established for cluster headache, which is present in an older, predominantly male population. <br> <br>|040abcc1-cc1c-4f00-b302-36070611f7b2;1d2cd01c-05e7-44cf-a71d-0f474e826b7e;24bc527e-c682-4c66-964e-c21d31eca5dd;2e5048c1-735f-434d-ae4c-5e822a95a2c4;2fbc01fb-b787-4ff1-bb9f-280dfe975531;5388055e-ca76-4c80-b047-14eccb95ed24;558a2e6f-fbc0-4bac-abcb-7117018bc919;584abe73-8290-4484-ff8e-5890831c095e;7624d1f1-5c03-4a34-a69a-402ae3c49ee8;77523882-3a1e-48ea-9bbb-9fffdd7aa415;7c960eb1-839d-4d96-ba70-a5068a7b6a67;9485cc30-15e8-4b53-876d-db317145474b;94d644b9-9ad1-4c21-9c88-c39796b3e3e6;a169b0c0-600f-4072-8ab7-fafc386eab80;a3735b57-ecc7-43e2-859a-c43e2502779b;ac80d018-6abf-2e41-ddea-90b4ff9e9013;b2503fff-c978-4efa-b1b4-d7740b6b26f2;b56f236d-fbf8-48e3-ad42-8abe4aafcbfc;c4b40689-96e9-4140-a9f9-0c73d4c1d825;c87cf537-9f7f-400e-ac4b-86e6f7e78775;cc11b09d-e6cc-4cf8-1495-5ac64d5aae5f;cd288b01-b95c-6398-fdff-b9ead9f324fa;d82b4065-418d-44a4-8e44-9d73c1360942;e2a3548f-3e3e-4899-a22d-59e6b03d9a26;e94c15f7-7115-4c9e-b5e5-6b8f275882a1;e9f89260-97fb-484a-af52-5d1be77fee76;fc8a8367-d2e2-43ba-a3d6-12436e50a183;
11608|49860a2f-92f2-4da8-b78f-0efc005d725a| Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with <annotation cui="C0032460">polycystic ovary syndrome</annotation> (see <b> WARNINGS </b> <b> Ovarian Hyperstimulation Syndrome </b> ), amenorrhea galactorrhea syndrome, psychogenic <annotation cui="C0002453">amenorrhea</annotation>, post oral contraceptive <annotation cui="C0002453">amenorrhea</annotation>, and certain cases of <annotation cui="C0232940">secondary amenorrhea</annotation> of undetermined etiology. <br> <br> Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See <b> DOSAGE AND ADMINISTRATION </b> and <b> PRECAUTIONS </b> .) <br> <br> Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see <b> CONTRAINDICATIONS </b> ) <br> <br> <ol><li> Patients who are not pregnant. </li><li> Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with <annotation cui="C0032460">polycystic ovary syndrome</annotation>. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. </li><li> Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. </li><li> Patients with normal liver function. </li></ol> In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following <br> <br> <ol><li> Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. </li><li> Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. </li><li> Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. </li><li> Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. </li><li> Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. </li></ol> There are no adequate or well controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. <br> <br> Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. <br> <br>|49860a2f-92f2-4da8-b78f-0efc005d725a;5d544453-f6d4-45a4-9ece-2f705b32011f;DF518802-0EFD-4DA4-816D-65A7E92CECD2;aa0690af-2cb2-48fb-8f12-d81f13d83378;b2f33ee6-0c57-45d9-b8fc-a8daf2a2185c;be399623-6400-475d-93d3-1dedd4d43017;e9950303-9322-4f27-9e28-f1cedaf87b20;
11647|c55cf30f-6d98-4212-86bd-f7f9f08bbce3| <annotation cui="C1269683">Major Depressive Disorder</annotation> <br> <br> Paroxetine tablets, USP are indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation>. <br> <br> The efficacy of paroxetine in the treatment of a <annotation cui="C0024517">major depressive episode</annotation> was established in 6 week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM III category of <annotation cui="C1269683">Major Depressive Disorder</annotation> (see <u> CLINICAL PHARMACOLOGY Clinical Trials <br> <br> The effects of paroxetine in hospitalized depressed patients have not been adequately studied. <br> <br> The efficacy of paroxetine in maintaining a response in <annotation cui="C1269683">Major Depressive Disorder</annotation> for up to 1 year was demonstrated in a placebo controlled trial (see <u> CLINICAL PHARMACOLOGY Clinical Trials </u> ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient. <br> <br> <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> <br> <br> Paroxetine tablets, USP are indicated for the treatment of obsessions and compulsions in patients with <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> (<annotation cui="C0028768">OCD</annotation>) as defined in the DSM IV. The obsessions or compulsions cause marked distress, are time consuming, or significantly interfere with social or occupational functioning. <br> <br> The efficacy of paroxetine was established in two 12 week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM IIIR category of <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> (see <u> CLINICAL PHARMACOLOGY Clinical Trials </u> ). <br> <br> <annotation cui="C0028768">Obsessive Compulsive Disorder</annotation> is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego dystonic and or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. <br> <br> Long term maintenance of efficacy was demonstrated in a 6 month relapse prevention trial. In this trial, patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo (see <u> CLINICAL PHARMACOLOGY Clinical Trials </u> ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <u> DOSAGE AND ADMINISTRATION </u> ). <br> <br> <annotation cui="C0030319">Panic Disorder</annotation> <br> <br> Paroxetine tablets, USP are indicated for the treatment of <annotation cui="C0030319">Panic Disorder</annotation>, with or without agoraphobia, as defined in DSM IV. <annotation cui="C0030319">Panic Disorder</annotation> is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and or a significant change in behavior related to the attacks. <br> <br> The efficacy of paroxetine was established in three 10  to 12 week trials in <annotation cui="C0030319">Panic Disorder</annotation> patients whose diagnoses corresponded to the DSM IIIR category of <annotation cui="C0030319">Panic Disorder</annotation> (see <u> CLINICAL PHARMACOLOGY Clinical Trials </u> ). <br> <br> <br> Long term maintenance of efficacy was demonstrated in a 3 month relapse prevention trial. In this trial, patients with <annotation cui="C0030319">Panic Disorder</annotation> assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see <u> CLINICAL PHARMACOLOGY Clinical Trials </u> ). Nevertheless, the physician who prescribes paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <u> DOSAGE AND ADMINISTRATION </u> ). <br> <br> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> <br> <br> Paroxetine tablets, USP are indicated for the treatment of <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (<annotation cui="C0270549">GAD</annotation>), as defined in DSM IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <br> The efficacy of paroxetine in the treatment of <annotation cui="C0270549">GAD</annotation> was established in two 8 week placebo controlled trials in adults with <annotation cui="C0270549">GAD</annotation>. Paroxetine has not been studied in children or adolescents with <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (see <u> CLINICAL PHARMACOLOGY Clinical Trials </u> ). <br> <br> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (DSM IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms Restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. <br> <br> The efficacy of paroxetine in maintaining a response in patients with <annotation cui="C0270549">Generalized Anxiety Disorder</annotation>, who responded during an 8 week acute treatment phase while taking paroxetine and were then observed for relapse during a period of up to 24 weeks, was demonstrated in a placebo controlled trial (see <u> CLINICAL PHARMACOLOGY Clinical Trials </u> ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <u> DOSAGE AND ADMINISTRATION </u> ). <br> <br> </u>|0ae5f19b-e8d5-4ec7-bcf1-697e88c0e66c;3ef42b6a-42d3-468d-afb5-68aaf8dd3f3f;c55cf30f-6d98-4212-86bd-f7f9f08bbce3;
11804|f2f03495-12b6-457a-901f-958b9c844bfd|<b> INDICATIONS AND USAGE </b> <br> <annotation cui="C1269683">Major Depressive Disorder</annotation> Effexor XR (venlafaxine hydrochloride) extended release capsules is indicated for the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation>. <br> <br> The efficacy of Effexor XR in the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> was established in 8  and 12 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM III R or DSM IV category of <annotation cui="C1269683">Major Depressive Disorder</annotation> (see <b> Clinical Trials </b> ). <br> <br> A major depressive episode (DSM IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two week period depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. <br> <br> The efficacy of Effexor (immediate release) in the treatment of <annotation cui="C1269683">Major Depressive Disorder</annotation> in adult inpatients meeting diagnostic criteria for <annotation cui="C1269683">Major Depressive Disorder</annotation> with melancholia was established in a 4 week controlled trial (see <b> Clinical Trials </b> ). The safety and efficacy of Effexor XR in hospitalized depressed patients have not been adequately studied. <br> <br> The efficacy of Effexor XR in maintaining a response in <annotation cui="C1269683">Major Depressive Disorder</annotation> for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo controlled trial. The efficacy of Effexor (immediate release) in maintaining a response in patients with recurrent <annotation cui="C1269683">Major Depressive Disorder</annotation> who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo controlled trial (see <b> Clinical Trials </b> ). Nevertheless, the physician who elects to use Effexor Effexor XR for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> Effexor XR is indicated for the treatment of <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (<annotation cui="C0270549">GAD</annotation>) as defined in DSM IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <br> The efficacy of Effexor XR in the treatment of <annotation cui="C0270549">GAD</annotation> was established in 8 week and 6 month placebo controlled trials in adult outpatients diagnosed with <annotation cui="C0270549">GAD</annotation> according to DSM IV criteria (see <b> Clinical Trials </b> ). <br> <br> <annotation cui="C0270549">Generalized Anxiety Disorder</annotation> (DSM IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. <br> <br> Although the effectiveness of Effexor XR has been demonstrated in 6 month clinical trials in patients with <annotation cui="C0270549">GAD</annotation>, the physician who elects to use Effexor XR for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br><annotation cui="C0031572">Social Anxiety Disorder</annotation> Effexor XR is indicated for the treatment of <annotation cui="C0031572">Social Anxiety Disorder</annotation>, also known as Social Phobia, as defined in DSM IV (300.23). <br> <br> <annotation cui="C0031572">Social Anxiety Disorder</annotation> (DSM IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. <br> <br> The efficacy of Effexor XR in the treatment of <annotation cui="C0031572">Social Anxiety Disorder</annotation> was established in four 12 week and one 6 month placebo controlled trials in adult outpatients with <annotation cui="C0031572">Social Anxiety Disorder</annotation> (DSM IV) (see <b> Clinical Trials </b> ). <br> <br> Although the effectiveness of Effexor XR has been demonstrated in a 6 month clinical trial in patients with <annotation cui="C0031572">Social Anxiety Disorder</annotation>, the physician who elects to use Effexor XR for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br> <annotation cui="C0030319">Panic Disorder</annotation> Effexor XR is indicated for the treatment of <annotation cui="C0030319">Panic Disorder</annotation>, with or without agoraphobia, as defined in DSM IV. <annotation cui="C0030319">Panic Disorder</annotation> is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and or a significant change in behavior related to the attacks. <br> <br> <annotation cui="C0030319">Panic Disorder</annotation> (DSM IV) is characterized by recurrent, unexpected panic attacks, ie, a discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) derealization (feelings of unreality) or depersonalization (being detached from oneself); 10) fear of losing control; 11) fear of dying; 12) paresthesias (numbness or tingling sensations); 13) chills or hot flushes. <br> <br> The efficacy of Effexor XR in the treatment of <annotation cui="C0030319">Panic Disorder</annotation> was established in two 12 week placebo controlled trials in adult outpatients with <annotation cui="C0030319">Panic Disorder</annotation> (DSM IV). The efficacy of Effexor XR in prolonging time to relapse in <annotation cui="C0030319">Panic Disorder</annotation> among responders following 12 weeks of open label acute treatment was demonstrated in a placebo controlled study (see <b> CLINICAL PHARMACOLOGY, Clinical Trials </b> ). Nevertheless, the physician who elects to use Effexor XR for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient (see <b> DOSAGE AND ADMINISTRATION </b> ). <br> <br>|f2f03495-12b6-457a-901f-958b9c844bfd;
12130|cc5fed6e-37b5-415c-af2c-31e2bfb83c7c| Sumatriptan succinate injection is indicated for 1) the acute treatment of <annotation cui="C0149931">migraine</annotation> attacks with or without aura and 2) the acute treatment of <annotation cui="C0009088">cluster headache</annotation> episodes. <br> <br> Sumatriptan succinate injection is not for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). <br> <br>|05adc16c-4c2b-46f0-b810-bb18d4106dc5;07b2c0f1-ac7e-4232-b2d0-5f5aa67a4551;13c8efc3-709a-495b-af93-fec52a864661;24259865-233b-4258-a01b-e895a873f2c4;2a169bec-aa08-44e8-b6fa-f412f5be3b07;413cb899-509f-40cb-b898-c44af9611ce7;55f21004-9ce6-4648-94d9-73ab2c7873e8;6a4c0c2f-497d-4c5c-84c4-9ab42780cbde;b183c7ba-2cc6-4854-a9a6-71ccd3592586;b1b5b1b2-d947-4c5d-afbf-9f5b43a19bc9;cc5fed6e-37b5-415c-af2c-31e2bfb83c7c;e0917960-87bf-4650-b60b-64bef2ccc4d6;e6058c90-eae2-4207-ba7d-563fe4a51112;ea65cd03-171f-4da3-9c2c-432413bb29de;f235152e-dd8d-4679-9d9f-404fe5ff4fba;fee7d073-0b99-48f2-7985-0d8cf970894b;
12150|40caec0c-902c-424c-8c87-63878134641e| Alprazolam tablets are indicated for the management of <annotation cui="C0003469">anxiety disorder</annotation> (a condition corresponding most closely to the APA Diagnostic and Statistical Manual (DSM III R) diagnosis of generalized anxiety disorder) or the short term relief of symptoms of <annotation cui="C0003469">Anxiety</annotation>. <annotation cui="C0003469">Anxiety</annotation> or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <annotation cui="C0003469">Anxiety</annotation> associated with <annotation cui="C0011581">depression</annotation> is responsive to alprazolam. <br> Alprazolam tablets are also indicated for the treatment of <annotation cui="C0030319">Panic disorder</annotation>, with or without <annotation cui="C0001818">agoraphobia</annotation>. <br> Studies supporting this claim were conducted in patients whose diagnoses corresponded closely to the DSM III R criteria for <annotation cui="C0030319">Panic disorder</annotation> (see <u> CLINICAL STUDIES </u> ). <br> <annotation cui="C0030319">Panic disorder</annotation> is an illness characterized by recurrent panic attacks. The panic attacks, at least initially, are unexpected. Later in the course of this disturbance certain situations, eg, driving a car or being in a crowded place, may become associated with having a panic attack. These panic attacks are not triggered by situations in which the person is the focus of others <br> <br>|40caec0c-902c-424c-8c87-63878134641e;
12299|3e41c92a-826d-40af-b2c5-b7720dd32657| Lorazepam is indicated for the management of <annotation cui="C0003469">anxiety disorders</annotation> or for the short term relief of the symptoms of <annotation cui="C0003469">Anxiety</annotation> or <annotation cui="C0003469">Anxiety</annotation> associated with <annotation cui="C0086132">depressive symptoms</annotation>. <annotation cui="C0003469">Anxiety</annotation> or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. <br> <br> The effectiveness of lorazepam in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. <br> <br>|3e41c92a-826d-40af-b2c5-b7720dd32657;
13323|b9e7c593-9499-49c7-8775-1e7761176857| <br> <br> Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of <annotation cui="C0751495">partial seizures</annotation> in adults and as monotherapy in the treatment of <annotation cui="C0751495">partial seizures</annotation> in children aged 4 years and above with <annotation cui="C0014544">epilepsy</annotation>, and as adjunctive therapy in children aged 4 years and above with <annotation cui="C0014544">epilepsy</annotation>. <br> <br> Additional pediatric use information in patients ages 2 to 4 years is approved for Novartis Pharmaceuticals corporation's oxcarbazepine tablets and oral suspension. However due to Novartis' marketing exclusivity rights, this drug product is not labeled for this pediatric age group. <br> <br> <br>|b9e7c593-9499-49c7-8775-1e7761176857;
15530|c17aa1e0-8b69-4c46-8502-9e3e07d461b3| <br> <br> 1.1 <annotation cui="C0036341">Schizophrenia</annotation> <br> <br> SEROQUEL is indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation>. The efficacy of SEROQUEL in <annotation cui="C0036341">Schizophrenia</annotation> was established in three 6 week trials in adults and one 6 week trial in adolescents (13 17 years). The effectiveness of SEROQUEL for the maintenance treatment of <annotation cui="C0036341">Schizophrenia</annotation> has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.1)] <br> <br> 1.2 <annotation cui="C0005586">Bipolar Disorder</annotation> <br> <br> SEROQUEL is indicated for the acute treatment of <annotation cui="C0338831">manic</annotation> episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12 week monotherapy trials in adults, in one 3 week adjunctive trial in adults, and in one 3 week monotherapy trial in pediatric patients (10 17 years) [ <i> see Clinical Studies </i> (14.2)] <br> <br> SEROQUEL is indicated as monotherapy for the acute treatment of depressive episodes associated with <annotation cui="C0005586">Bipolar Disorder</annotation>. Efficacy was established in two 8 week monotherapy trials in adult patients with <annotation cui="C0853193;C0236788">bipolar I and bipolar II disorder</annotation> [ <i> see Clinical Studies </i> (14.2)]. <br> <br> SEROQUEL is indicated for the maintenance treatment of <annotation cui="C0853193">Bipolar I Disorder</annotation>, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of SEROQUEL as monotherapy for the maintenance treatment of <annotation cui="C0005586">Bipolar Disorder</annotation> has not been systematically evaluated in controlled clinical trials [ <i> see Clinical Studies </i> (14.2)]. <br> <br> 1.3 Special Considerations in Treating Pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> <br> <br> Pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> are serious mental disorders, however, diagnosis can be challenging. For pediatric <annotation cui="C0036341">Schizophrenia</annotation>, symptom profiles can be variable, and for <annotation cui="C0853193">Bipolar I Disorder</annotation>, patients may have variable patterns of periodicity of <annotation cui="C0338831">manic</annotation> or mixed symptoms. It is recommended that medication therapy for pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> is indicated as part of a total treatment program that often includes psychological, educational and social interventions. <br> <br> <br>|c17aa1e0-8b69-4c46-8502-9e3e07d461b3;
15707|d5a26c5e-9c3e-4781-8c08-62b91d21a68d| <div> Severe Recalcitrant <annotation cui="C1274727">Nodular Acne</annotation> </div> Sotret is indicated for the treatment of severe recalcitrant <annotation cui="C1274727">nodular acne</annotation>. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. Severe, by definition, 2 means many as opposed to few or several nodules. <u> Because of significant adverse effects associated with its use, Sotret should be reserved for patients with severe <annotation cui="C1274727">nodular acne</annotation> who are unresponsive to conventional therapy, including systemic antibiotics. </u> In addition, Sotret is indicated only for those female patients who are not pregnant, because Sotret can cause severe birth defects (see <b> Boxed CONTRAINDICATIONS AND WARNINGS </b> ). <br> <br> A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients. 1,3,4 If a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off isotretinoin capsules. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see <b> WARNINGS Skeletal Bone Mineral Density, Hyperostosis </b> , and <b> Premature Epiphyseal Closure </b> ). <br> <br>|0018861f-1b9b-431b-84ee-9d34aab615c3;51ff6346-9256-4c01-9f52-417d13f2df05;8d54aab5-3349-4a41-8533-0a566fd7bbaa;a31fd109-d0fd-4ab9-ba98-a3d64333c18d;b2cb63c9-f825-4991-9a2c-6260f1bbcc2c;d5a26c5e-9c3e-4781-8c08-62b91d21a68d;d8429009-c317-4618-a971-b0c6f1280d1a;ee862463-77c0-4694-bba8-97274f13963f;
16190|d63a086a-32e2-49e2-949e-64e4c922775a| Tablets of Mixed Salts of a Single Entity Amphetamine Product are indicated for the treatment of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>) and Narcolepsy. <br> <br> <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>) A diagnosis of <annotation cui="C1263846">Attention Deficit Hyperactivity Disorder</annotation> (<annotation cui="C1263846">ADHD</annotation>; DSM IV ) implies the presence of hyperactive impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months lack of attention to details careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months fidgeting squirming; leaving seat; inappropriate running climbing; difficulty with quiet activities; on the go; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive impulsive criteria to be met. <br> <br> <b> Special Diagnostic Considerations </b> Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM IV characteristics. <br> <br> <b> Need for Comprehensive Treatment Program </b> Tablets of Mixed Salts of a Single Entity Amphetamine Product are indicated as an integral part of a total treatment program for <annotation cui="C1263846">ADHD</annotation> that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms. <br> <br> <b> Long Term Use </b> The effectiveness of Tablets of Mixed Salts of a Single Entity Amphetamine Product for long term use has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Tablets of Mixed Salts of a Single Entity Amphetamine Product for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient. <br> <br>|08f9eb0a-3797-49f6-90e4-9b8732bfc63f;1714de28-482e-463f-e91f-eeaaaa83d17f;24af5ced-ed01-4188-95f0-b6b8e4f70aab;34726042-2386-4c19-abec-440769fff99a;35744538-1704-4ee0-954d-52710cf3456d;3F7F39A5-D5F9-40B3-B20B-55E2C2D4EF3E;4cc84b5d-9b56-4b80-a201-6e4075727d44;72ddd1c9-ddbd-4c95-acd9-003189a353a3;F0FC4960-8262-48E1-805C-DAE63FD045B0;a200fc5e-faab-4471-af77-64da407fa131;afdedf03-f393-454d-9158-99e36071fa93;aff45863-ffe1-4d4f-8acf-c7081512a6c0;c5c2d060-452c-4f76-ad93-2e41fd8f06c2;cffbbb15-d776-41ae-a8a6-687f2c07bfa4;d63a086a-32e2-49e2-949e-64e4c922775a;f55aba1f-9404-4a49-8e3b-7a66ce538c60;f6c30ba1-53d0-4f85-a515-81acfb922e73;
17754|8fe59c4d-c80b-4668-a04e-0dfd2b441f29| DILAUDID ORAL LIQUID and DILAUDID TABLETS are indicated for the management of <annotation cui="C0030193">pain</annotation> in patients where an opioid analgesic is appropriate. <br> <br>|8fe59c4d-c80b-4668-a04e-0dfd2b441f29;
17808|1c993365-1b62-4524-e781-d307f28f63bc| Verapamil Hydrochloride Injection, USP is indicated for the following <br> <br> Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff Parkinson White [W P W] and Lown Ganong  Levine [L G L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. <br> <br> Temporary control of rapid ventricular rate in <annotation cui="C0004239">atrial flutter</annotation> or <annotation cui="C0004238">atrial fibrillation</annotation> except when the <annotation cui="C0004239">atrial flutter</annotation> and or <annotation cui="C0004238">atrial fibrillation</annotation> are associated with accessory bypass tracts (Wolff Parkinson White (W P W) and Lown Ganong Levine (L G L) syndromes). <br> <br> In controlled studies in the United States, about 60% of patients with <annotation cui="C0039240">supraventricular tachycardia</annotation> converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with <annotation cui="C0004239">atrial flutter</annotation> and or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of <annotation cui="C0004239">atrial flutter</annotation> or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation flutter lasts 30 to 60 minutes after a single injection. <br> <br> Because a small fraction (<1%) of patients treated with verapamil hydrochloride respond with life threatening adverse responses (rapid ventricular rate in atrial flutter fibrillation, and an accessory bypass tract, marked hypotension, or extreme bradycardia asystole see CONTRAINDICATIONS and WARNINGS ), the initial use of verapamil hydrochloride injection should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including D.C. cardioversion capability (see ADVERSE REACTIONS , Suggested Treatment of Acute Cardiovascular Adverse Reactions). As familiarity with the patient s response is gained, use in an office setting may be acceptable. <br> <br> Cardioversion has been used safely and effectively after verapamil hydrochloride injection. <br> <br>|0644a3a3-1f7e-4e77-b469-7f4b41625baf;1c993365-1b62-4524-e781-d307f28f63bc;9ca35e18-c823-4e4c-bd69-09d333a7f851;c4415ef0-6e41-4fe0-9627-61f283db8a52;
18112|a136e22d-ad97-4f4d-b28b-347a3d2a994b| ONMEL is indicated for the treatment of <annotation cui="C0040261">onychomycosis</annotation> of the toenail due to <i> Trichophyton rubrum </i> or <i> mentagrophytes </i> in non immunocompromised patients. Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of <annotation cui="C0040261">onychomycosis</annotation>. [ <i> See Contraindications ( 4 ), Warnings and Precautions ( 5 ), Drug Interactions ( 7 ), and Clinical Pharmacology ( 12 ) </i> .] <br> <br>|a136e22d-ad97-4f4d-b28b-347a3d2a994b;
22|4a50cc68-af58-44e7-a278-728e781f0d4e| Hydrochlorothiazide Capsules are indicated in the management of <annotation cui="C0020538">hypertension</annotation> either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, Hydrochlorothiazide Capsules may be used in those patients in whom the development of <annotation cui="C0020461">hyperkalemia</annotation> cannot be risked, including patients taking ACE inhibitors. <br> <br> Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. <br> <br>|4a50cc68-af58-44e7-a278-728e781f0d4e;
2296|2ba50fa9-b349-40cb-9a4b-1af8faa4ec09| Endometrin is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for <annotation cui="C0021359">infertile</annotation> women. <br> <br>|2ba50fa9-b349-40cb-9a4b-1af8faa4ec09;
2406|a4d555fa-787c-40fb-bb7d-b0d4f7318fd0| SPORANOX (itraconazole) Capsules are indicated for the treatment of the following fungal infections in <u> immunocompromised and non immunocompromised </u> patients <br> <br> <ol><li> <annotation cui="C0339964">Blastomycosis, pulmonary</annotation> and extrapulmonary </li><li> <annotation cui="C0019655">Histoplasmosis</annotation>, including chronic cavitary <annotation cui="C0024115">pulmonary disease</annotation> and disseminated, non meningeal <annotation cui="C0019655">histoplasmosis</annotation>, and </li><li> <annotation cui="C2350529">Aspergillosis, pulmonary</annotation> and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. </li></ol> Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. <br> <br> SPORANOX Capsules are also indicated for the treatment of the following fungal infections in <u> non immunocompromised </u> patients <br> <br> <ol><li> <annotation cui="C1274470">Onychomycosis of the toenail</annotation>, with or without fingernail involvement, due to dermatophytes (tinea unguium), and </li><li> <annotation cui="C0040261">Onychomycosis</annotation> of the fingernail due to dermatophytes (tinea unguium). </li></ol> Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of <annotation cui="C0040261">onychomycosis</annotation>. <br> <br> (See CLINICAL PHARMACOLOGY Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS Post marketing Experience for more information.) <br> <br> <div> Description of Clinical Studies </div> <div> <annotation cui="C0005716">Blastomycosis</annotation> </div> Analyses were conducted on data from two open label, non concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of <annotation cui="C0005716">Blastomycosis</annotation> compared with the natural history of untreated cases. <div> <annotation cui="C0019655">Histoplasmosis</annotation> </div> Analyses were conducted on data from two open label, non concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV infected patients). The median dose was 200 mg day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of <annotation cui="C0019655">Histoplasmosis</annotation>, compared with the natural history of untreated cases. <div> <annotation cui="C0019655">Histoplasmosis</annotation> in HIV infected patients </div> Data from a small number of HIV infected patients suggested that the response rate of <annotation cui="C0019655">Histoplasmosis</annotation> in HIV infected patients is similar to that of non HIV infected patients. The clinical course of <annotation cui="C0019655">Histoplasmosis</annotation> in HIV infected patients is more severe and usually requires maintenance therapy to prevent relapse. <div> <annotation cui="C0004030">Aspergillosis</annotation> </div> Analyses were conducted on data from an open label, "single patient use" protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second line therapy for the treatment of <annotation cui="C0004030">Aspergillosis</annotation> compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy. <div> <annotation cui="C1274470">Onychomycosis of the toenail</annotation> </div> Analyses were conducted on data from three double blind, placebo controlled studies (N=214 total; 110 given SPORANOX Capsules) in which patients with <annotation cui="C1274470">Onychomycosis of the toenails</annotation> received 200 mg of SPORANOX Capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). The mean time to overall success was approximately 10 months. Twenty one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive). <div> <annotation cui="C0040261">Onychomycosis</annotation> of the fingernail </div> Analyses were conducted on data from a double blind, placebo controlled study (N=73 total; 37 given SPORANOX Capsules) in which patients with <annotation cui="C0040261">Onychomycosis</annotation> of the fingernails received a 1 week course (pulse) of 200 mg of SPORANOX Capsules b.i.d., followed by a 3 week period without SPORANOX , which was followed by a second 1 week pulse of 200 mg of SPORANOX Capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success.|599dcdd0-df9b-41e2-a767-b1f44f466fbd;6242b7ad-eaa0-a524-b6e0-ec33e63407db;a4d555fa-787c-40fb-bb7d-b0d4f7318fd0;d343050e-00bb-440c-a24b-7cd18c97e184;
2648|3605a8c6-13db-409b-9e5c-19936fef9076| 1.1 <annotation cui="C0036341">Schizophrenia</annotation> Oral ZYPREXA is indicated for the treatment of <annotation cui="C0036341">Schizophrenia</annotation>. Efficacy was established in three clinical trials in adult patients with <annotation cui="C0036341">Schizophrenia</annotation> two 6 week trials and one maintenance trial. In adolescent patients with <annotation cui="C0036341">Schizophrenia</annotation> (ages 13 17), efficacy was established in one 6 week trial <i> [see Clinical Studies ( 14.1 )] </i> . <br> <br> When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents <i> [see Warnings and Precautions ( 5.5 , 5.6 )] </i> . <br> <br> 1.2 <annotation cui="C0853193">Bipolar I Disorder</annotation> <annotation cui="C0349208;C0338831">(Manic or Mixed Episodes</annotation>) <u> Monotherapy </u> Oral ZYPREXA is indicated for the acute treatment of <annotation cui="C0349208;C0338831">Manic or Mixed Episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> and maintenance treatment of <annotation cui="C0853193">Bipolar I Disorder</annotation>. Efficacy was established in three clinical trials in adult patients with <annotation cui="C0349208;C0338831">Manic or Mixed Episodes</annotation> of <annotation cui="C0853193">Bipolar I Disorder</annotation> two 3  to 4 week trials and one monotherapy maintenance trial. In adolescent patients with <annotation cui="C0349208;C0338831">Manic or Mixed Episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> (ages 13 17), efficacy was established in one 3 week trial <i> [see Clinical Studies ( 14.2 )]. </i> <br> <br> When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents <i> [see Warnings and Precautions ( 5.5 , 5.6 )] </i> . <br> <br> <u> Adjunctive Therapy to Lithium or Valproate </u> Oral ZYPREXA is indicated for the treatment of <annotation cui="C0349208;C0338831">Manic or Mixed Episodes</annotation> associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> as an adjunct to lithium or valproate. Efficacy was established in two 6 week clinical trials in adults. The effectiveness of adjunctive therapy for longer term use has not been systematically evaluated in controlled trials <i> [see Clinical Studies ( 14.2 )] </i> . <br> <br> 1.3 Special Considerations in Treating Pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> Pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> are serious mental disorders; however, diagnosis can be challenging. For pediatric <annotation cui="C0036341">Schizophrenia</annotation>, symptom profiles can be variable, and for <annotation cui="C0853193">Bipolar I Disorder</annotation>, pediatric patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric <annotation cui="C0036341">Schizophrenia</annotation> and <annotation cui="C0853193">Bipolar I Disorder</annotation> should be part of a total treatment program that often includes psychological, educational and social interventions. <br> <br> 1.4 ZYPREXA IntraMuscular: <annotation cui="C0085631">Agitation</annotation> Associated with <annotation cui="C0036341">Schizophrenia</annotation> and Bipolar I <annotation cui="C0338831">Mania</annotation> ZYPREXA IntraMuscular is indicated for the treatment of acute <annotation cui="C0085631">Agitation</annotation> associated with <annotation cui="C0036341">Schizophrenia</annotation> and bipolar I <annotation cui="C0338831">Mania</annotation>. <br> <br> Efficacy was demonstrated in 3 short term (24 hours of IM treatment) placebo controlled trials in agitated adult inpatients with <annotation cui="C0036341">Schizophrenia</annotation> or <annotation cui="C0853193">Bipolar I Disorder</annotation> <annotation cui="C0349208;C0338831">(manic or mixed episodes</annotation>) <i> [see Clinical Studies ( 14.3 )]. </i> <br> <br> Psychomotor <annotation cui="C0085631">Agitation</annotation> is defined in DSM IV as excessive motor activity associated with a feeling of inner tension. Patients experiencing <annotation cui="C0085631">Agitation</annotation> often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the <annotation cui="C0085631">Agitation</annotation>. <br> <br> 1.5 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with <annotation cui="C0853193">Bipolar I Disorder</annotation> Oral ZYPREXA and fluoxetine in combination is indicated for the treatment of depressive episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>, based on clinical studies in adult patients. When using ZYPREXA and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. <br> <br> ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with <annotation cui="C0853193">Bipolar I Disorder</annotation>. <br> <br> 1.6 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression Oral ZYPREXA and fluoxetine in combination is indicated for the treatment of treatment resistant depression (major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode), based on clinical studies in adult patients. When using ZYPREXA and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. <br> <br> ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression. <br> <br>|3605a8c6-13db-409b-9e5c-19936fef9076;
2817|b89b5502-ce87-45a6-a43c-9891da3cfca4| <div> <annotation cui="C0032305">Pneumocystis Carinii Pneumonia</annotation> </div> Sulfamethoxazole and trimethoprim injection USP is indicated in the treatment of <annotation cui="C0032305"><i> Pneumocystis carinii </i> pneumonia</annotation> in children and adults. <br> <br> <div> <annotation cui="C0013371">Shigellosis</annotation> </div> Sulfamethoxazole and trimethoprim injection USP is indicated in the treatment of enteritis caused by susceptible strains of <i> Shigella flexneri </i> and <i> Shigella sonnei </i> in children and adults. <br> <br> <div> <annotation cui="C0042029">Urinary Tract Infections</annotation> </div> Sulfamethoxazole and trimethoprim injection USP is indicated in the treatment of severe or complicated <annotation cui="C0042029">Urinary Tract Infections</annotation> due to susceptible strains of <i> Escherichia coli </i> , <i> Klebsiella </i> species, <i> Enterobacter </i> species, <i> Morganella morganii </i> and <i> Proteus </i> species when oral administration of sulfamethoxazole and trimethoprim is not feasible and when the organism is not susceptible to single agent antibacterials effective in the urinary tract. <br> <br> Although appropriate culture and susceptibility studies should be performed, therapy may be started while awaiting the results of these studies. <br> <br>|b89b5502-ce87-45a6-a43c-9891da3cfca4;
3091|36780f92-a17f-4133-8f75-7c3769c40584| <br> <br> <div>1.1 <annotation cui="C0029408">Osteoarthritis</annotation> (<annotation cui="C0029408">OA</annotation>) 1.2 <annotation cui="C0003873">Rheumatoid Arthritis</annotation> (<annotation cui="C0003873">RA</annotation>) 1.3 <annotation cui="C0553662">Juvenile Rheumatoid Arthritis</annotation> (<annotation cui="C0553662">JRA</annotation>) Pauciarticular and Polyarticular Course</div>1 INDICATIONS AND USAGE <br> <br> 1.1 <annotation cui="C0029408">Osteoarthritis</annotation> (<annotation cui="C0029408">OA</annotation>) MOBIC is indicated for relief of the signs and symptoms of <annotation cui="C0029408">Osteoarthritis</annotation> [see Clinical Studies (14.1)]. <br> <br> 1.2 <annotation cui="C0003873">Rheumatoid Arthritis</annotation> (<annotation cui="C0003873">RA</annotation>) MOBIC is indicated for relief of the signs and symptoms of <annotation cui="C0003873">Rheumatoid Arthritis</annotation> [see Clinical Studies (14.1)]. <br> <br> 1.3 <annotation cui="C0553662">Juvenile Rheumatoid Arthritis</annotation> (<annotation cui="C0553662">JRA</annotation>) Pauciarticular and Polyarticular Course MOBIC is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course <annotation cui="C0553662">Juvenile Rheumatoid Arthritis</annotation> in patients 2 years of age and older [see Clinical Studies (14.2)]. |36780f92-a17f-4133-8f75-7c3769c40584;
4060|176af20d-d082-47bd-bc56-a21cc1244a33| <br> <br> Colchicine is indicated for prophylaxis of <annotation cui="C0018099">gout</annotation> flares in adults <br> <br> <br>|176af20d-d082-47bd-bc56-a21cc1244a33;
5926|d7013892-0a00-afd3-cc62-99c195f48c7a| SECTION For mydriasis and cycloplegia in diagnostic procedures. For some pre  and postoperative states when a mydriatic and cycloplegic is needed in treatment of <annotation cui="C0022073">iridocyclitis</annotation>. <br> <br>|d7013892-0a00-afd3-cc62-99c195f48c7a;
8787|80F2C1BC-D66E-499C-95E0-0FCB17F09CDA| For the treatment of intestinal and <annotation cui="C0006849">oral cavity infections caused by <i> Candida </i> (Monilia) <i> albicans. </i></annotation> <br> <br>|80F2C1BC-D66E-499C-95E0-0FCB17F09CDA;